# european journal of pharmacology

## an international journal

ejp

ELSEVIER

**Master Author and Key word Indexes, Volumes 229–248, 1993**
**(EJP Molecular Pharmacology Section, Volumes 244–247, and EJP Environmental Toxicology and Pharmacology Section, Volume 248, incorporated)**

EUROPEAN JOURNAL OF PHARMACOLOGY

INDEXES 1993

# european journal of pharmacology

Author and Key word Indexes, 1993
Volumes 229–248
(EJP Molecular Pharmacology Section, Volumes 244–247, and EJP Environmental Toxicology and Pharmacology Section, Volume 248, incorporated)

ELSEVIER

AMSTERDAM — LONDON — NEW YORK — TOKYO

© 1994 Elsevier Science B.V. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science B.V., Copyright and Permissions Department, P.O. Box 521, 1000 AM Amsterdam, The Netherlands.

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. The fee indicated on the first page of an article in this issue will apply retroactively to all articles published in the journal, regardless of the year of publication. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

This journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 839, 1000 AV Amsterdam, The Netherlands.

This journal is printed on acid-free paper.

*US mailing notice - European Journal of Pharmacology* (ISSN 0014-2999) is published 3 times/month by Elsevier Science B.V. (Molenwerf 1, Postbus 211, 1000 AE Amsterdam, The Netherlands). Annual subscription price in the USA is US$ 4222.00 (valid in North, Central and South America only) including air speed delivery. Second class postage rate is paid at Jamaica, NY 11431.
USA POSTMASTERS: Send address changes to *European Journal of Pharmacology*, Publications Expediting, Inc., 200 Meacham Avenue, Elmont, NY 11003.
Airfreight and mailing in the USA by Publications Expediting.

Printed in The Netherlands

ELSEVIER

ejp

# Master author index to volumes 229–248 (1993)

Abacioğlu, N., see Çakici, Í. (236) 97
Abbenante, J., see Kerr, D.I.B. (236) 239
Abe, Y., see Tamaki, T. (236) 15
Abi-Dargham, A., see Laruelle, M. (230) 119
Abiko, Y., see Hoque, A.N.E. (236) 269
Abiru, T., Watanabe, Y., Kamata, K. and Kasuya, Y.
Simultaneous measurement of vasodilation and changes in cyclic nucleotides in the perfused mesenteric arterial bed of the rat (242) 15
Abrahams, T.P., Taveira DaSilva, A.M., Hamosh, P., McManigle, J.E. and Gillis, R.A.
Cardiorespiratory effects produced by blockade of excitatory amino acid receptors in cats (238) 223
Abrahams, Z., Chang, S.D. and Sutter, M.C.
Stimulant effect of human gamma globulin on smooth muscle preparations (238) 435
Abram, T.S., see Gardiner, P.J. (238) 19
Aceto, M.D., Scates, S.M., Ji, Z. and Bowman, E.R.
Nicotine's opioid and anti-opioid interactions: proposed role in smoking behavior (248) 333
Acquas, E., Meloni, M. and Di Chiara, G.
Blockade of δ-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release (230) 239
Adachi, N., see Oishi, R. (237) 155
Adami, M., see Trampus, M. (235) 83
Adams, M.E., see Burke, S.P. (238) 383
Adeyemo, O.M., Youdim, M.B.H., Markey, S.P., Markey, C.J. and Pollard, H.B.
L-Deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish (240) 185
Adler, L., see Huether, G. (238) 249
Adolfo García-Sáinz, J., see Medina-Martínez, O. (244) 145
Advenier, C., see Dumas, M. (239) 141
Advenier, C., see Martin, C.A.E. (239) 119
Advenier, C., see Martin, C.A.E. (243) 309
Agnati, L.F., see Martire, M. (230) 231
Agrotis, A., Little, P.J., Saltis, J. and Bobik, A.
Dihydropyridine $Ca^{2+}$ channel antagonists inhibit the salvage pathway for DNA synthesis in human vascular smooth muscle cells (244) 269
Ahima, R.S., see Osei, S.Y. (234) 35
Ahlborg, U.G., see Hemming, H. (248) 163
Ahlenius, S., see Salmi, P. (236) 395
Ahrén, B., see Gregersen, S. (232) 35
Ahrén, B., see Skoglund, G. (236) 69
Aishita, H., see Nakagawa, N. (235) 211
Aizenman, E., see Reynolds, I.J. (244) 175
Akaike, A., Tamura, Y., Sato, Y. and Yokota, T.
Protective effects of a vitamin $B_{12}$ analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons (241) 1
Akera, T., see Temma, K. (234) 173
Akeson, A.L., see French, J.F. (233) 109
Aki, Y., see Tamaki, T. (236) 15
Akiba, T., see Hikasa, Y. (229) 241
Aktories, K., see Just, I. (246) 293
Al-Tikriti, M.S., see Laruelle, M. (230) 119
Al-Zubaidy, Z., see Chapman, A.G. (231) 301
Ala-Uotila, S., see Marjamäki, A. (246) 219
Alabadí, J.A., see Alborch, E. (229) 83
Alanko, J., see Saareks, V. (248) 345
Alary, C., see Gué, M. (233) 193
Alborch, E., Salom, J.B., Perales, A.J., Torregrosa, G., Miranda, F.J., Alabadí, J.A. and Jover, T.
Comparison of the anticonstrictor action of dihydropyridines (nimodipine and nicardipine) and $Mg^{2+}$ in isolated human cerebral arteries (229) 83
Alcalde, A.I., see Sorribas, V. (248) 137
Alhaider, A.A., see Mustafa, A.A. (237) 147
Allard, B. and Lazdunski, M.
Pharmacological properties of ATP-sensitive $K^+$ channels in mammalian skeletal muscle cells (236) 419
Allen, R.D., see Ong, J. (233) 169
Allerup, P., see Glenthøj, B. (236) 401
Allgeier, A., see Van Sande, J. (247) 177
Allgeier, H., see Benke, D. (246) 179
Allix, M., see Wahl, F. (230) 209
Alm, P., see Panagiotidis, G. (229) 277
Almotrefi, A.A., see Dzimiri, N. (242) 113
Alsip, N.L. and Harris, P.D.
Serotonin-induced dilation of small arterioles is not mediated via endothelium-derived relaxing factor in skeletal muscle (229) 117
Altavilla, D., see Squadrito, F. (230) 125
Altavilla, D., see Squadrito, F. (237) 223
Altmann, L., see Guilarte, T.R. (248) 273
Altura, B.M., Zhang, A., Cheng, T.P.-O. and Altura, B.T.
Cocaine induces rapid loss of intracellular free $Mg^{2+}$ in cerebral vascular smooth muscle cells (246) 299
Altura, B.M., see Zhang, A. (248) 229
Altura, B.T., see Altura, B.M. (246) 299
Altura, B.T., see Zhang, A. (248) 229
Alvarado, F., see Sorribas, V. (248) 137
Alvarez Sanz, M.C., see Levy, A.D. (241) 275
Ambar, I. and Sokolovsky, M.
Endothelin receptors stimulate both phospholipase C and phospholipase D activities in different cell lines (245) 31
Amenta, F., see Ferrante, F. (240) 229
Amenta, F., see Ferreira-de-Almeida, J.A. (234) 209
Amerini, S., see Lodovici, M. (243) 255
Amico-Roxas, M., see Clementi, G. (238) 101
Amore, C., see Iacoviello, L. (229) 39
Amorim, C.Z., Cordeiro, R.S.B. and Vargaftig, B.B.
Involvement of platelet-activating factor in death following anaphylactic shock in boosted and in unboosted mice (235) 17
Amorim, C.Z., Cordeiro, R.S.B. and Vargaftig, B.B.
Interference of PCA 4248, a novel PAF receptor antagonist, with antigen-induced paw edema in mice (236) 301
Amrani, Y., see Trifilieff, A. (239) 227

Anderson, C.M., see Morgan, D.W. (235) 45
Andrews, N. and File, S.E.
Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety (235) 109
Andrews, N., see File, S.E. (237) 127
Andrews, N., see Rattray, M. (245) 193
Anelli, M., see Caccia, S. (233) 71
Angel, I., Grosset, A., Perrault, G., Schoemaker, H. and Langer, S.Z.
In vivo pharmacological profile of SL 84.0418, a new selective, peripherally active $\alpha_2$-adrenoceptor antagonist (234) 137
Angel, I., Schoemaker, H., Prouteau, M., Garreau, M. and Langer, S.Z.
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-$HT_3$ receptor antagonist and antiemetic properties (232) 139
Angst, C., see Benke, D. (246) 179
Angulo, J.A., Watanabe, Y., Cadet, J., Ledoux, M. and McEwen, B.S.
Upregulation of forebrain proenkephalin mRNA subsequent to NMDA receptor blockade (244) 317
Annies, R., see Löscher, W. (242) 263
Annunziato, L., see Canzoniero, L.M.T. (245) 97
Anthony, T.L., see Knoper, S.R. (232) 65
Antunes, E., see Santana, A.C. (231) 237
Aoyagi, T., see Majima, M. (232) 181
Arakawa, H., Kawikova, I., Löfdahl, C.-G. and Lötvall, J.
Bradykinin-induced airway responses in guinea pig: effects of inhibition of cyclooxygenase and thromboxane synthetase (229) 131
Araki, T., see Kanai, Y. (248) 191
Arányi, P., see Horváth, E.J. (236) 151
Arbilla, S., see Faure-Halley, C. (246) 283
Archer, S., see Jiang, Q. (230) 129
Archer, S., see Jiang, Q. (240) 201
Ardaillou, R., see Chansel, D. (247) 193
Arias-Montaño, J.-A. and Young, J.M.
Locus of action of $Ni^{2+}$ on histamine-induced inositol phosphate formation in brain slices and in HeLa cells (245) 221
Arias-Montaño, J.-A. and Young, J.M.
Characteristics of histamine $H_1$ receptors on HeLa cells (245) 291
Arimura, A., Asanuma, F., Yagi, H., Kurosawa, A. and Harada, M.
Involvement of thromboxane $A_2$ in bronchial hyperresponsiveness but not lung inflammation induced by bacterial lipopolysaccharide in guinea pigs (231) 13
Armario, A., see Martí, J. (236) 295
Arnal, J.-F., El Amrani, A.-I. and Michel, J.-B.
Atrial natriuretic factor influences in vivo plasma, lung and aortic wall cGMP concentrations differently (237) 265
Arnold, I.R., Mistry, R. and Barnett, D.B.
Subtype selective regulation of coupling of rat cardiac $\beta$-adrenoceptors to adenylate cyclase (245) 285
Arora, R.C., see Gulati, A. (231) 151
Arruebo, M.P., see Sorribas, V. (248) 137
Artalejo, A.R., see Montiel, C. (230) 77
Artalejo, C.R., see Priego, J. (243) 25
Artigas, F., see Bel, N. (229) 101
Artigas, F., see Bel, N. (232) 326
Asahina, T., see Tanaka, Y. (244) 105
Asai, Y., see Umemura, K. (239) 17
Asano, M., Matsuda, T., Hayakawa, M., Ito, K.M. and Ito, K.
Increased resting $Ca^{2+}$ maintains the myogenic tone and activates $K^+$ channels in arteries from young spontaneously hypertensive rats (247) 295
Asanuma, F., see Arimura, A. (231) 13
Ashford, M.L.J., see Lee, K. (247) 347
Ashida, S.-i., see Watabe, S. (238) 303
Ashino, H., see Oikawa, T. (241) 221
Asin, K.E. and Wirtshafter, D.
Effects of repeated dopamine $D_1$ receptor stimulation on rotation and c-fos expression (235) 167
Assié, M.-B., Sleight, A.J. and Koek, W.
Biphasic displacement of [$^3$H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics (237) 183
Atkinson, J., see Gohar, M. (229) 69
Ator, N.A., Grant, K.A., Purdy, R.H., Paul, S.M. and Griffiths, R.R.
Drug discrimination analysis of endogenous neuroactive steroids in rats (241) 237
Attali, B., see Nah, S.-Y. (244) 67
Attila, M., see Salvadori, S. (230) 357
Audia, J.E., see Johnson, M.P. (239) 111
Aulakh, C.S., Hill, J.L. and Murphy, D.L.
Attenuation of hypercortisolemia in fawn-hooded rats by antidepressant drugs (240) 85
Aulakh, C.S., see Hulihan-Giblin, B.A. (239) 99
Aurell, C.-J., see Vilhardt, H. (232) 223
Awere, S., see Moore, N.A. (237) 1
Azmitia, E.C., see Gu, X.F. (235) 51

Bachetti, T., see Spampinato, S. (244) 139
Bachy, A., Héaulme, M., Giudice, A., Michaud, J.-C., Lefevre, I.A., Souilhac, J., Manara, L., Emerit, M.B., Gozlan, H., Hamon, M., Keane, P.E., Soubrié, P. and Le Fur, G.
SR 57227A: a potent and selective agonist at central and peripheral 5-$HT_3$ receptors in vitro and in vivo (237) 299
Badgery-Parker, T., see Burcher, E. (233) 201
Badia, A., see Vivas, N.M. (245) 9
Baeyens, J.M., see Ocaña, M. (230) 203
Baeyens, J.M., see Ocaña, M. (239) 253
Bagdy, G., Kalogeras, K.T. and Szemeredi, K.
Effect of 5-$HT_{1C}$ and 5-$HT_2$ receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations (229) 9
Bagetta, G., Massoud, R., Rodinò, P., Federici, G. and Nisticò, G.
Systemic administration of lithium chloride and tacrine increases nitric oxide synthase activity in the hippocampus of rats (237) 61
Bagrov, A.Y., Roukoyatkina, N.I., Fedorova, O.V., Pinaev, A.G. and Ukhanova, M.V.
Digitalis-like and vasoconstrictor effects of endogenous digoxin-like factor(s) from the venom of *Bufo marinus* toad (234) 165
Bai, X., see Walker, J.M. (231) 61
Bai, X., see Walker, J.M. (236) 495
Bailey, M.A. and Karbon, E.W.
Haloperidol treatment differentially regulates [$^3$H]DTG and [$^3$H](+)-3-PPP labeled $\sigma$ binding sites (240) 243
Baker, J., see Lummis, S.C.R. (243) 7
Bakhle, Y.S., see Santana, A.C. (231) 237
Bakker, J.M., see Heijna, M.H. (229) 197
Bakthavachalam, V., see Baldessarini, R.J. (239) 269
Balasubramaniam, G., Lee, H.S. and Mah, S.C.
Antihypertensive effect of chronic i.v. administration of 5-carboxamidotryptamine in spontaneously hypertensive rats (237) 207
Balboni, G., see Romualdi, P. (229) 149
Baldessarini, R.J., Kula, N.S., McGrath, C.R., Bakthavachalam, V., Kebabian, J.W. and Neumeyer, J.L.
Isomeric selectivity at dopamine $D_3$ receptors (239) 269
Balduini, W., Cimino, M., Renò, F., Marini, P., Princivalle, A. and Cattabeni, F.
Effects of postnatal or adult chronic acetylcholinesterase inhibition on muscarinic receptors, phosphoinositide turnover and $m_1$ mRNA expression (248) 281
Baldwin, R.M., see Laruelle, M. (230) 119

Ball, S.G., see Hall, A.S. (247) 249
Balloy, V., see Renesto, P. (248) 151
Balmforth, A.J., see Hall, A.S. (247) 249
Balster, R.L., see Gold, L.H. (230) 285
Bangalore, R., see Hawthorn, M.H. (229) 143
Baptista, T., Weiss, S.R.B. and Post, R.M.
Carbamazepine attenuates cocaine-induced increases in dopamine in the nucleus accumbens: an in vivo dialysis study (236) 39
Barber, A.
$\mu$- and $\kappa$-opioid receptor agonists produce peripheral inhibition of neurogenic plasma extravasation in rat skin (236) 113
Barber, P.C., see Barnes, J.M. (230) 251
Barclay, P.L., see Scott, J.M. (242) 91
Bardgett, M.E., Wrona, C.T., Newcomer, J.W. and Csernansky, J.G.
Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics (230) 245
Barnard, E.A., see Fujita, R. (240) 213
Barnes, J.M., Steward, L.J., Barber, P.C. and Barnes, N.M.
Identification and characterisation of angiotensin II receptor subtypes in human brain (230) 251
Barnes, N.M., see Barnes, J.M. (230) 251
Barnes, N.M., see Steward, L.J. (242) 137
Barnes, N.M., see Steward, L.J. (243) 13
Barnes, P.J., see Belvisi, M.G. (231) 97
Barnes, P.J., see Kato, M. (232) 7
Barnes, P.J., see Lei, Y.-H. (239) 257
Barnes, P.J., see Nishikawa, M. (247) 131
Barnes, P.J., see Rabe, K.F. (231) 305
Barnes, P.J., see Sakamoto, T. (231) 31
Barnett, D.B., see Arnold, I.R. (245) 285
Barone, D., see Bianchi, G. (238) 327
Barr, G.A. and Wang, S.
Behavioral effects of chronic cocaine treatment in the week-old rat pup (233) 143
Barrett, J.E., see Gleeson, S. (229) 109
Barry, D.I., see Glenthøj, B. (236) 401
Bartfai, T., see Gregersen, S. (232) 35
Bartfai, T., see Zini, S. (245) 1
Barth, T., see Vilhardt, H. (232) 223
Barthelmebs, M., see Michel, B. (242) 237
Bartrons, R., see Planas, M.E. (237) 251
Bashir, Z.I., Jane, D.E., Sunter, D.C., Watkins, J.C. and Collingridge, G.L.
Metabotropic glutamate receptors contribute to the induction of long-term depression in the CA1 region of the hippocampus (239) 265
Baskys, A., Wang, S., Remington, G. and Wojtowicz, J.M.
Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus (235) 305
Bassi, L., see Cerri, M.A. (232) 291
Bast, A., see Smit, M.J. (247) 223
Bast, A., see Ter Laak, A.M. (232) 199
Batra, S., see Kostrzewska, A. (233) 127
Battistini, B., see Filep, J.G. (239) 231
Battistini, B., see Filep, J.G. (240) 315
Battula, N., see Salonpää, P. (248) 95
Baudrie, V., De Vry, J., Broqua, P., Schmidt, B., Chaouloff, F. and Glaser, T.
Subchronic treatment with anxiolytic doses of the 5-$HT_{1A}$ receptor agonist ipsapirone does not affect 5-$HT_2$ receptor sensitivity in the rat (231) 395
Baudrie, V., see Chaouloff, F. (231) 77
Baudry, M., see Marvizón, J.-C. (244) 103
Baugh, L.E., see Kudlacz, E.M. (241) 17
Bax, W.A., Bos, E. and Saxena, P.R.
Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein (239) 267
Bax, W.A., Renzenbrink, G.J., Van Heuven-Nolsen, D., Thijssen, E.J.M., Bos, E. and Saxena, P.R.
5-HT receptors mediating contractions of the isolated human coronary artery (239) 203
Bax, W.A., see Schoemaker, R.G. (230) 103
Bazan, E., Campbell, A.K. and Rapoport, R.M.
Effects of protein kinase C activation on norepinephrine-induced phosphatidylinositide hydrolysis in intact rat aorta (245) 173
Bazzoni, G., see Cerri, M.A. (232) 291
Beal, M.F., see Nozaki, K. (232) 295
Beani, L., see Tanganelli, S. (230) 159
Beaudet, A., see Pasquini, F. (243) 39
Beaujouan, J.-C., see Petitet, F. (247) 185
Beer, M.S. and Middlemiss, D.N.
Serotonin-5-O-carboxymethyl-glycyl[$^{125}$I]tyrosinamide labels the 5-$HT_{1D\beta}$ receptor subtype in human cortex (242) 195
Beer, M.S., Stanton, J.A., Hawkins, L.M. and Middlemiss, D.N.
5-Carboxamidotryptamine-insensitive 5-$HT_1$-like receptors are concentrated in guinea pig but not rat, claustrum (236) 167
Bel, N. and Artigas, F.
Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study (229) 101
Bel, N. and Artigas, F.
Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. European Journal of Pharmacology, 229 (1992) 101–103 (232) 326
Belcourt, A., see Bennai, F. (246) 45
Bélichard, P., see Pruneau, D. (231) 215
Bélichard, P., see Pruneau, D. (239) 63
Bellan, J.A., Longenecker, L.L., Kadowitz, P.J. and McNamara, D.B.
Selective and complete blockade of acetylcholine-induced relaxation in rabbit aortic rings by $N^{\omega}$-nitro-L-arginine but not by glybenclamide (234) 273
Belogi, L., see Tubaro, E. (248) 175
Beltrán-Nuñez, A., see Cerri, M.A. (232) 291
Belvisi, M.G., Miura, M., Stretton, D. and Barnes, P.J.
Endogenous vasoactive intestinal peptide and nitric oxide modulate cholinergic neurotransmission in guinea-pig trachea (231) 97
Bemelmans, M., see Huijberts, M. (240) 207
Bemis, K.G., see Shannon, H.E. (232) 47
Ben-Ari, Y., see Zini, S. (245) 1
Bendotti, C., see Parolaro, D. (244) 211
Benitah, J.-P., see Le Grand, B. (229) 91
Benke, D., Marti, T., Heckendorn, R., Rehm, H., Künzi, R., Allgeier, H., Angst, C. and Mohler, H.
Photoaffinity labeling of the NMDA receptor (246) 179
Bennai, F., Greney, H., Bricca, G., Belcourt, A., Bousquet, P. and Dontenwill, M.
Polyclonal anti-idazoxan antibodies: characterization and purification (246) 45
Bennardini, F., see Lodovici, M. (243) 255
Bensoussan, M., Mitchell, T., Reilly, T., Timmermans, P.B.M.W.M., Verroust, P.J. and Ronco, P.M.
Immunological reactivity of angiotensin II receptor antagonists: possible implications for receptor binding sites (247) 169
Benthem, L., Scheurink, A.J.W., Van der Leest, J., Leuvenink, H., Zijlstra, W.G. and Steffens, A.B.
Effects of long-term d-fenfluramine treatment on energy metabolism in rats (232) 279

Benvenga, M.J. and Leander, J.D.
Antidepressant-like effect of LY228729 as measured in the rodent forced swim paradigm (239) 249
Beretta, A., see Sandrini, G. (243) 99
Bereznai, B., see Deckert, J. (238) 131
Berg, M., see Johansson-Wallsten, C.E. (243) 149
Bergeron, R., Debonnel, G. and De Montigny, C.
Modification of the N-methyl-D-aspartate response by antidepressant $\sigma$ receptor ligands (240) 319
Bergman, Å., see Hemming, H. (248) 163
Berkenboom, G., see Unger, P. (248) 145
Berkenbosch, A., Rupreht, J., DeGoede, J., Olievier, C.N. and Wolsink, J.G.
Effects of eseroline on the ventilatory response to $CO_2$ (232) 21
Berkenkopf, J.W., see Grimes, D. (236) 217
Berkenkopf, J.W., see Heaslip, R.J. (234) 247
Bernad, N., see Lignon, M.-F. (245) 241
Bernard, J.-F., see Huang, G.-F. (230) 279
Bernard, J.-F., see Huang, G.-F. (236) 449
Bernard, M., see Pontoire, C. (247) 111
Bernasconi. S., see Cerri, M.A. (232) 291
Bernier, S., see Poitras, M. (244) 203
Berning, B., see Rupprecht, R. (247) 145
Bertrand, C., see Huber, O. (239) 103
Bertrand, C., see Yamawaki, I. (243) 1
Bertrand, G., Gross, R., Puech, R., Loubatières-Mariani, M.-M. and Bockaert, J.
Glutamate stimulates glucagon secretion via an excitatory amino acid receptor of the AMPA subtype in rat pancreas (237) 45
Bervoets, K., see Millan, M.J. (230) 99
Berzetei-Gurske, I.P., see Webster, J.L. (231) 251
Besson, J.-M., see Huang, G.-F. (230) 279
Besson, J.-M., see Huang, G.-F. (236) 449
Bethea, C.L., see Levy, A.D. (241) 275
Betito, K., Diorio, J. and Boksa, P.
Brief cortisol exposure elevates adrenal phenylethanolamine N-methyltransferase after a necessary lag period (238) 273
Beubler, E., Schirgi-Degen, A. and Gamse, R.
Inhibition of 5-hydroxytryptamine- and enterotoxin-induced fluid secretion by 5-HT receptor antagonists in the rat jejunum (248) 157
Bhargava, H.N., see Veeranna, (235) 23
Bhatia, A.J., see Zorad, S. (241) 195
Bhave, S.V., see Przywara, D.A. (247) 353
Bianchi, C., see Tanganelli, S. (230) 159
Bianchi, G., Barone, D., Lanzarotti, E., Tettamanti, R., Porta, R., Moltrasio, D., Cedro, A., Salvetti, L., Mantovani, M. and Prino, G.
Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist (238) 327
Bianchi, R., Zhu, X., Fiori, M.G. and Eichberg, J.
Effect of gangliosides on diacylglycerol content and molecular species in nerve from diabetic rats (239) 55
Bianchin, M., see Jerusalinsky, D. (240) 103
Bidlack, J.M., see Jiang, Q. (230) 129
Bidlack, J.M., see Jiang, Q. (240) 201
Bidzseranova, A., Varga, J. and Telegdy, G.
The effects of brain natriuretic peptide-32 on electroconvulsive shock-induced amnesia in rats. The role of neurotransmitters (232) 305
Biegon, A., see Jagust, W.J. (242) 189
Bigg, D.C.H., see Sleight, A.J. (238) 407
Biggio, G., see Imperato, A. (238) 135
Bill, D.J., see Fletcher, A. (237) 283
Bill, S.J., see Fletcher, A. (237) 283
Billaud, G., Costentin, J. and Bonnet, J.-J.
Specific binding of [$^3$H]GBR 12783 to the dopamine neuronal carrier included in polarized membranes (247) 333
Billman, G.E.
Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation (229) 179
Binet, P., see Scamps, F. (244) 119
Bird, J.E. and Waldron, T.L.
Incomplete inhibition of endothelin-1 pressor effects by an endothelin $ET_A$ receptor antagonist (240) 295
Bisaga, A., Krzascik, P., Jankowska, E., Palejko, W., Kostowski, W. and Danysz, W.
Effect of glutamate receptor antagonists on N-methyl-D-aspartate- and (S)-$\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced convulsant effects in mice and rats (242) 213
Bischoff, S., see Bruinink, A. (245) 157
Bitar, K.G., see Cheng, D.Y. (243) 79
Biton, C., see Randle, J.C.R. (247) 257
Bittiger, H., see Olpe, H.-R. (233) 179
Blackman, A., see Moore, N.A. (237) 1
Blankesteijn, W.M., Siero, H.L.M., Rodrigues de Miranda, J.F., Van Megen, Y.J.B. and Russel, F.G.M.
Characterization of muscarinic receptors in rat kidney (244) 21
Bloemers, S.M., see Smit, M.J. (247) 223
Blokland, A., Bothmer, J., Honig, W. and Jolles, J.
Behavioural and biochemical effects of acute central metabolic inhibition: effects of acetyl-l-carnitine (235) 275
Bloom, J.W., see Witt-Enderby, P.A. (241) 121
Bloss, J.L., see Hammond, D.L. (231) 281
Bobik, A., see Agrotis, A. (244) 269
Bockaert, J., see Bertrand, G. (237) 45
Bockaert, J., see Didier, M. (244) 57
Boden, P.R., see Norris, S.K. (234) 223
Boev, K.K., see Gagov, H.S. (243) 19
Boeynaems, J.-M., Heilporn, S., Broeders, F. and Braekman, J.-C.
Enhancement of the endothelial production of prostacyclin by substituted derivatives of BAPTA-AM (233) 13
Boeynaems, J.-M., see Pirotton, S. (241) 55
Bojö, L., Lefebvre, R.A., Nellgård, P. and Cassuto, J.
Involvement of vasoactive intestinal polypeptide in gastric reflex relaxation (236) 443
Boksa, P., see Betito, K. (238) 273
Bolaños-Jiménez, F., Manhães de Castro, R. and Fillion, G.
Antagonism by citalopram and tianeptine of presynaptic 5-$HT_{1B}$ heteroreceptors inhibiting acetylcholine release (242) 1
Boldry, R.C., see Papa, S.M. (232) 247
Bolkenius, F.N., see Lukovic, L. (233) 63
Bolwig, T.G., see Glenthøj, B. (236) 401
Bolwig, T.G., see Glenthøj, B. (242) 283
Bomzon, A., see Pauletzki, J.G. (232) 263
Bon, C., see Tesson, F. (248) 27
Bon, C., see Tesson, F. (248) 351
Bonadonna, A.M., see Levy, A.D. (241) 275
Bonanno, G., see Lanza, M. (237) 191
Bond, A., see Boot, J.R. (231) 83
Bondiolotti, G.P., see Cattaneo, L. (241) 245
Bonini, I., see Sacchetti, G. (236) 171
Boniotti, A., see Mapp, C.E. (248) 67
Boniotti, A., see Mapp, C.E. (248) 277
Bonnafous, C., Martinez, J., Fargeas, M.-J. and Buéno, L.
Clonazepam-induced intestinal motor disturbances are linked to central nervous system release of cholecystokinin in rats (237) 237
Bonnet, J.-J., see Billaud, G. (247) 333
Bonnet, J.-J., see Vaugeois, J.-M. (230) 195
Bonnot-Lours, S., see Tavitian, B. (236) 229
Boot, J.R., Bond, A., Thomas, K.H., O'Brien, A., Gilmore, J. and Todd, A.
The pharmacology of LY290324 in the guinea-pig: an orally active, potent and selective cysteinyl leukotriene receptor antagonist (231) 83
Borelli, G.P., see Tubaro, E. (248) 175

Borges, R.
Ionic mechanisms involved in the secretory effects of histamine in the rat adrenal medulla (241) 189
Boric, M., see Donoso, M.V. (240) 93
Borman, R.A., see Burleigh, D.E. (241) 125
Borsodi, A., see Fürst, Z. (236) 209
Borsodi, A., see Wild, K.D. (246) 25
Borsodi, A., see Wild, K.D. (246) 289
Bos, E., see Bax, W.A. (239) 203
Bos, E., see Bax, W.A. (239) 267
Bos, E., see Schoemaker, R.G. (230) 103
Bot, G. and Chahl, L.A.
Effects of pertussis toxin on behavioural responses of guinea-pigs to centrally administered substance P, quinpirole, carbachol, U-50,488H, morphine and morphine withdrawal (231) 53
Botella, A., Delvaux, M., Fioramonti, J., Frexinos, J. and Bueno, L. Stimulatory ($EP_1$ and $EP_3$) and inhibitory ($EP_2$) prostaglandin $E_2$ receptors in isolated ileal smooth muscle cells (237) 131
Bothmer, J., see Blokland, A. (235) 275
Bouaboula, M., see Rinaldi-Carmona, M. (246) 73
Boucher, S., see Picard, P. (232) 255
Bouhassira, D., Chitour, D., Villanueva, L. and Le Bars, D.
Morphine and diffuse noxious inhibitory controls in the rat: effects of lesions of the rostral ventromedial medulla (232) 207
Boukili, M.A., see Cunha, F.Q. (238) 47
Boulay, G., see Poitras, M. (244) 203
Boulton, A.A., see Zhu, M.-Y. (238) 157
Boulton, C.L., McCrohan, C.R. and O'Shaughnessy, C.T.
Cyclic AMP analogues increase excitability and enhance epileptiform activity in rat neocortex in vitro (236) 131
Boulu, R.G., see Wahl, F. (230) 209
Bourdon, V., see Damas, J. (231) 231
Bourinbaiar, A.S. and Nagorny, R.
Inhibitory effect of natural interferon alpha on human immunodeficiency virus type 1 transmission from epithelial cells to lymphocytes in vitro (230) 15
Bousquet, P., see Bennai, F. (246) 45
Bouysset, F., see Vayssettes-Courchay, C. (236) 121
Bouysset, F., see Vayssettes-Courchay, C. (242) 37
Bowen, J.P., see Lewin, A.H. (247) 1
Bowen, W.D., see Horan, P.J. (233) 53
Bowen, W.D., see Vilner, B.J. (244) 199
Bowen, W.D., see Walker, J.M. (231) 61
Bowen, W.D., see Walker, J.M. (236) 495
Bowlin, T.L., see French, J.F. (233) 109
Bowman, E.R., see Aceto, M.D. (248) 333
Boye, S.M., see Rompré, P.-P. (232) 299
Boyett, M., see Cannings, I. (248) 213
Boyett, M., see Harrison, S. (237) 83
Bozza, P.T., Castro-Faria-Neto, H.C., Martins, M.A., Larangeira, A.P., Perales, J.E., E Silva, P.M.R. and Cordeiro, R.S.B.
Pharmacological modulation of lipopolysaccharide-induced pleural eosinophilia in the rat; a role for a newly generated protein (248) 41
Bozza, P.T., see Martins, M.A. (237) 17
Bradamante, S., Jotti, A., Paracchini, L. and Monti, E.
The hydrophilic spin trap, 5,5-dimethyl-1-pyrroline-1-oxide, does not protect the rat heart from reperfusion injury European Journal of Pharmacology, 234 (1993) 113–116 (239) 275
Bradamante, S., Jotti, A., Paracchini, L. and Morti, E.
The hydrophilic spin trap, 5,5-dimethyl-1-pyrroline-1-oxide, does not protect the rat heart from reperfusion injury (234) 113
Braekman, J.-C., see Boeynaems, J.-M. (233) 13
Braga Da Motta, J.I., see Cunha, F.Q. (238) 47
Brain, S.D., see Lawrence, E. (233) 243
Brandt, S.R., see Webster, J.L. (231) 251
Brasseur, R., see Van Bambeke, F. (247) 155
Breittmayer, J.P., see Vigne, P. (245) 229
Brékine, D., see Unger, P. (248) 145
Brelière, J.-C., see Rinaldi-Carmona, M. (246) 73
Brelière, J.-C., see Santucci, V. (237) 143
Brémont, B., see Langlois, M. (244) 77
Brennan, K.M., see Jagust, W.J. (242) 189
Brent, P.J., Chahl, L.A., Cantarella, P.A. and Kavanagh, C.
The κ-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs (241) 149
Brewster, M., see Gater, P.R. (238) 59
Brewster, W.K., see Kohli, J.D. (235) 31
Bricca, G., see Bennai, F. (246) 45
Briley, M., see Marien, M. (236) 487
Briley, M., see Moret, C. (230) 379
Brioni, J.D., O'Neill, A.B., Kim, D.J.B. and Decker, M.W.
Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test (238) 1
Britton, D.R., see Kebabian, J.W. (229) 203
Britton II, L.W., see Weishaar, R.E. (236) 363
Brocco, M., see Millan, M.J. (230) 99
Brödemann, R., see Krug, M. (231) 355
Broeders, F., see Boeynaems, J.-M. (233) 13
Brooks, D.P., see Wang, Y.-X. (248) 217
Broqua, P., see Baudrie, V. (231) 395
Brouwer, F., see Coppes, R.P. (243) 273
Brown, C.A., see Chan, S.L.F. (230) 375
Brown, C.M., see MacKinnon, A.C. (232) 79
Brown, J.P., see Thurlow, R.J. (247) 341
Brown, P.D., see Garner, C. (239) 31
Brugger, F., Wicki, U., Olpe, H.-R., Froestl, W. and Mickel, S.
The action of new potent $GABA_B$ receptor antagonists in the hemisected spinal cord preparation of the rat (235) 153
Brugger, F., see Olpe, H.-R. (233) 179
Bruhn, T., see Glenthøj, B. (236) 401
Bruinink, A. and Bischoff, S.
Dopamine $D_2$ receptors are unevenly distributed in the rat hippocampus and are modulated differently than in striatum (245) 157
Brun, P., Suaud-Chagny, M.-F., Gonon, F. and Buda, M.
Differential effects of desipramine on direct- and sensory-evoked noradrenaline release in thalamic locus coeruleus terminals (235) 205
Brunkwall, J., see Erlinge, D. (240) 77
Bruttel, K., see Schoeffter, P. (241) 165
Bryant, S.D., see Salvadori, S. (230) 357
Bryson, S.E., see Hall, A.S. (247) 249
Brzozowski, T., see Konturek, S.J. (229) 155
Brzozowski, T., see Konturek, S.J. (239) 215
Bubser, M., Keseberg, U., Notz, P.K. and Schmidt, W.J.
Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats (229) 75
Buchholz, J., see Tsai, H. (237) 311
Buchholz, R.A., see De Garavilla, L. (234) 77
Buczko, W., see Iacoviello, L. (229) 39
Buda, M., see Brun, P. (235) 205
Budihna, M.V. and Strojan, P.
$Ca^{2+}$ channel antagonists inhibit the intestinal absorption of digoxin in the guinea-pig (230) 301
Buéno, L., see Bonnafous, C. (237) 237
Buéno, L., see Botella, A. (237) 131
Buéno, L., see Gué, M. (233) 193
Bufton, K.E., see Steward, L.J. (242) 137
Bundy, D.M., see Salvadori, S. (230) 357
Bungardt, E., see Eltze, M. (238) 343
Bunnett, N.W., see Huber, O. (239) 103
Burakoff, R., see Goldhill, J. (238) 387

Burchell, B., see Hope, A.G. (245) 187
Burcher, E., Badgery-Parker, T., Zeng, X.-P. and Lavielle, S.
Characterisation of a novel, selective radioligand, [$^{125}$I]Lys$^5$, Tyr(I$_2$)$^7$,MeLeu$^9$,Nle$^{10}$]neurokinin A-(4–10), for the tachykinin NK$_2$ receptor in rat fundus (233) 201
Burke, S.P., Adams, M.E. and Taylor, C.P.
Inhibition of endogenous glutamate release from hippocampal tissue by $Ca^{2+}$ channel toxins (238) 383
Burks, T.F., see Horan, P.J. (233) 53
Burleigh, D.E. and Borman, R.A.
Short-circuit current responses to 5-hydroxytryptamine in human ileal mucosa are mediated by a 5-HT$_4$ receptor (241) 125
Burlina, A., see Mapp, C.E. (248) 277
Burnstock, G., see Rennick, R.E. (230) 367
Burres, N.S., see Pollock, D.M. (231) 459
Busik, J., Habara, Y., Maruyama, T. and Kanno, T.
Inhibition by a receptor-mediated $Ca^{2+}$ entry blocker, SK&F 96365, of $Ca^{2+}$ and secretory responses in rat pancreatic acini (247) 273
Butcher, S.P., see Hodgkiss, J.P. (240) 219
Butcher, S.P., see Sherriffs, H.J. (247) 319
Búzás, B., see Fürst, Z. (236) 209
Bylund, D.B., see Pleus, R.C. (244) 181
Bymaster, F.P., see Shannon, H.E. (232) 47

Caccia, S., Anelli, M., Ferrarese, A., Fracasso, C. and Garattini, S.
The role of d-norfenfluramine in the indole-depleting effect of d-fenfluramine in the rat (233) 71
Cadet, J., see Angulo, J.A. (244) 317
Cadet, P., see Ottaviani, E. (248) 319
Cadieux, A., see Dumont, Y. (238) 37
Çakici, Í., Tunçtan, B., Abacioğlu, N. and Kanzik, Í.
Epithelium-dependent responses of serotonin in a co-axial bioassay system (236) 97
Calapai, G., see Squadrito, F. (230) 125
Calapai, G., see Squadrito, F. (237) 223
Calcutt, N.A., see Carrington, A.L. (237) 257
Calignano, A., Persico, P., Mancuso, F. and Sorrentino, L.
Endogenous nitric oxide modulates morphine-induced changes in locomotion and food intake in mice (231) 415
Calignano, A., Whittle, B.J.R., Di Rosa, M. and Moncada, S.
Involvement of endogenous nitric oxide in the regulation of rat intestinal motility in vivo (229) 273
Calignano, A., see Persico, P. (238) 105
Calignano, A., see Persico, P. (241) 71
Calixto, J.B., see Medeiros, Y.S. (241) 157
Calixto, J.B., see Neves, P.C.A. (243) 213
Calixto, J.B., see Rae, G.A. (240) 113
Callahan, P.E., see Ratz, P.H. (236) 433
Calvo, M.A., see Cejalvo, D. (234) 23
Cambarrat, C., see Iliou, J.-P. (248) 263
Cameron, N.E. and Cotter, M.A.
Contraction and relaxation of aortas from galactosaemic rats and the effects of aldose reductase inhibition (243) 47
Campbell, A.K., see Bazan, E. (245) 173
Campbell, P.M., see Forster, C. (242) 119
Campo, G.M., see Squadrito, F. (230) 125
Campo, G.M., see Squadrito, F. (237) 223
Candura, S.M., see Coccini, T. (248) 1
Cannings, I., Harrison, S., White, E. and Boyett, M.
The effect of a range of alcohols on the contraction of guinea-pig ventricular myocytes (248) 213
Cano, J., see Santiago, M. (239) 83
Cantarella, P.A., see Brent, P.J. (241) 149
Canton, H., see Lejeune, F. (240) 307
Canton, H., see Millan, M.J. (230) 99
Canton, T., see Debono, M.-W. (235) 283
Canzoniero, L.M.T., Taglialatela, M., Di Renzo, G. and Annunziato, L.
Gadolinium and neomycin block voltage-sensitive $Ca^{2+}$ channels without interfering with the $Na^+$-$Ca^{2+}$ antiporter in brain nerve endings (245) 97
Cao, B.-J. and Peng, N.-A.
Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents (237) 177
Capararo, M., see Sandrini, G. (243) 99
Capasso, F., see Izzo, A.A. (243) 87
Capogna, M., see Zeise, M.L. (231) 47
Cappendijk, S.L.T. and Dzoljic, M.R.
Inhibitory effects of ibogaine on cocaine self-administration in rats (241) 261
Caputi, A.P., see Squadrito, F. (230) 125
Caputi, A.P., see Squadrito, F. (237) 223
Carboni, L., see Spampinato, S. (244) 139
Cardinali, D.P., see Golombek, D.A. (237) 231
Carli, M., Tatarczynska, E., Cervo, L. and Samanin, R.
Stimulation of hippocampal 5-HT$_{1A}$ receptors causes amnesia and anxiolytic-like but not antidepressant-like effects in the rat (234) 215
Carlson, R.P., see Grimes, D. (236) 217
Carlsson, A., see Waters, N. (242) 151
Carnuccio, R., see Iuvone, T. (243) 163
Carnuccio, R., see Zingarelli, B. (243) 107
Carrington, A.L., Calcutt, N.A., Ettlinger, C.B., Gustafsson, T. and Tomlinson, D.R.
Effects of treatment with myo-inositol or its 1,2,6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes (237) 257
Carroll, F.I., see Walker, J.M. (231) 61
Carroll, F.I., see Walker, J.M. (236) 495
Carroll, G.C., see Cheng, D.Y. (243) 79
Carrón, R., see Pérez-Vizcaíno, F. (232) 105
Carter, D.A.
Differential intracellular mechanisms mediate the co-ordinate induction of c-*fos* and *jun*-B in the rat pineal gland (244) 285
Carter, D.A.
Noradrenergic regulation of c-*jun* expression in the rat pineal gland in culture: positive and negative components (247) 97
Caruso, A., see Clementi, G. (238) 101
Carvalho, A.P., see Duarte, C.B. (244) 259
Carvalho, C.A.M., see Duarte, C.B. (244) 259
Casabona, G., see Nicoletti, F. (245) 297
Casalotti, S.O., Kozikowski, A.P., Fauq, A., Tückemantel, W. and Krueger, K.E.
Monoclonal antibodies against a phencyclidine derivative are used to investigate protein–ligand interactions (247) 209
Casellas, P., see Rinaldi-Carmona, M. (246) 73
Cassel, G.E., Mjörndal, T., Persson, S.-Å. and Söderström, E.
Effects of cyanide on the striatal dopamine receptor binding in the rat (248) 297
Cassuto, J., see Bojö, L. (236) 443
Castillo, C., Ibarra, M., Márquez, J.A., Villalobos-Molina, R. and Hong, E.
Pharmacological evidence for interactions between 5-HT$_{1A}$ receptor agonists and subtypes of $\alpha_1$-adrenoceptors on rabbit aorta (241) 141
Castle, N.A., Haylett, D.G., Morgan, J.M. and Jenkinson, D.H.
Dequalinium: a potent inhibitor of apamin-sensitive $K^+$ channels in hepatocytes and of nicotinic responses in skeletal muscle (236) 201
Castro Faria Neto, H.C., see Bozza, P.T. (248) 41
Castro Faria Neto, H.C., see Martins, M.A. (237) 17

Cattabeni, F., see Balduini, W. (248) 281
Cattaneo, L., Bondiolotti, G.P., Muller, E.E. and Cocchi, D.
Effect of acute and short-term administration of cholinomimetic drugs on corticosterone secretion in the rat (241) 245
Cattaneo, M.G., Gullo, M. and Vicentini, L.M.
$Ca^{2+}$ and $Ca^{2+}$ channel antagonists in the control of human small cell lung carcinoma cell proliferation (247) 325
Cauley, R.K., see Chang, Y.-F. (233) 209
Cavallo, G., see Tubaro, E. (248) 175
Cavallotti, C., see Ferreira-de-Almeida, J.A. (234) 209
Cazaubon, C., see Delisée, C. (247) 139
Ceccaldi, P.-E., Fillion, M.-P., Ermine, A., Tsiang, H. and Fillion, G.
Rabies virus selectively alters 5-$HT_1$ receptor subtypes in rat brain (245) 129
Cedro, A., see Bianchi, G. (238) 327
Cejalvo, D., Calvo, M.A., Lloris, J.M., Cortijo, J. and Morcillo, E.J.
Effects of $Ca^{2+}$ channel antagonists in guinea-pig normal and skinned gall bladder (234) 23
Cerletti, C., see Rotondo, S. (232) 41
Cerri, M.A., Beltrán-Nuñez, A., Bernasconi, S., Dejana, E., Bassi, L. and Bazzoni, G.
Inhibition of cytokine production and endothelial expression of adhesion antigens by 5′-methylthioadenosine (232) 291
Cerveñansky, C., see Jerusalinsky, D. (240) 103
Cervo, L., Rossi, C. and Samanin, R.
Clonidine-induced place preference is mediated by $\alpha_2$-adrenoceptors outside the locus coeruleus (238) 201
Cervo, L., see Carli, M. (234) 215
Chahl, L.A., see Bot, G. (231) 53
Chahl, L.A., see Brent, P.J. (241) 149
Chaki, S., see Tanaka, M. (238) 89
Chakrabarti, A., Chugh, Y. and Sharma, P.L.
Search for an antidote to electroconvulsion and lethality in aminophylline-sensitized mice (235) 133
Chakrabarti, M.K., see Wang, C. (243) 113
Chan, P., Li, Y., Zheng, Z., Hu, P., Sarbach, S.D. and Guez, D.
Neurologic and histologic evaluation of almitrine + raubasine (Duxil®) in middle cerebral artery occlusion in cats (231) 175
Chan, S.L.F., Brown, C.A. and Morgan, N.G.
Stimulation of insulin secretion by the imidazoline $\alpha_2$-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site (230) 375
Chang, A.S.-S., Chang, S.M. and Starnes, D.M.
Structure-activity relationships of serotonin transport: relevance to nontricyclic antidepressant interactions (247) 239
Chang, C.-H., see Song, D.-L. (247) 283
Chang, C.C., see Chiou, L.C. (248) 185
Chang, G.-D., see Song, D.-L. (247) 283
Chang, K.-J., see Wild, K.D. (246) 289
Chang, K.C., Ko, H.J., Cho, S.D., Yoon, Y.J. and Kim, J.H.
Pharmacological characterization of effects of verapamil and GS 283 on isolated guinea pig and rat trachealis (236) 51
Chang, L.-R., see Tao, P.-L. (246) 233
Chang, S.D., see Abrahams, Z. (238) 435
Chang, S.M., see Chang, A.S.-S. (247) 239
Chang, Y.-F., Wang, Y., Cauley, R.K. and Gao, X.-M.
Chronic L-lysine develops anti-pentylenetetrazol tolerance and reduces synaptic GABAergic sensitivity (233) 209
Chansel, D., Vandermeersch, S., Pham, P. and Ardaillou, R.
Characterization of [$^3$H]losartan receptors in isolated rat glomeruli (247) 193
Chanussot, F., see Clerc, T. (235) 59
Chaouloff, F., Layeillon, C. and Baudrie, V.
5-$HT_{1C}$/5-$HT_2$ receptor blockade prevents 1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane-, but not stress-induced increases in brain tryptophan (231) 77
Chaouloff, F., see Baudrie, V. (231) 395
Chapman, A.G., Al-Zubaidy, Z. and Meldrum, B.S.
Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice (231) 301
Chapman, R.W., see Rizzo, C.A. (234) 109
Chapman, R.W., see Rizzo, C.A. (240) 327
Chaponnier, C., see Just, I. (246) 293
Charney, D.S., see Laruelle, M. (230) 119
Chase, T.N., see Engber, T.M. (236) 385
Chase, T.N., see Marin, C. (231) 191
Chase, T.N., see Papa, S.M. (232) 247
Chatelain, P., Clinet, M., Polster, P., Christophe, B. and Manning, A.S.
In vitro characterization of a novel $Ca^{2+}$ entry blocker: SR 33805 (246) 181
Chatelain, P., see Delisée, C. (247) 139
Chautan, M., see Clerc, T. (235) 59
Cheetham, M.E., see McLaughlin, D.P. (244) 89
Chen, C. and Schofield, G.G.
Nitric oxide modulates $Ca^{2+}$ channel currents in rat sympathetic neurons (243) 83
Chen, C.-C., see Huang, H.-C. (237) 39
Cheng, C.H.K., Costall, B., Naylor, R.J. and Rudd, J.A.
The effect of 5-HT receptor ligands on the uptake of [$^3$H]5-hydroxytryptamine into rat cortical synaptosomes (239) 211
Cheng, D.Y., McMahon, T.J., Dewitt, B.J., Carroll, G.C., Lee, S.S., Murphy, W.A., Bitar, K.G., Coy, D.H. and Kadowitz, P.J.
Comparison of responses to pituitary adenylate cyclase activating peptides 38 and 27 in the pulmonary vascular bed of the cat (243) 79
Cheng, P.Y., Wu, D., Decena, J., Soong, Y., McCabe, S. and Szeto, H.H.
Opioid-induced stimulation of fetal respiratory activity by [D-Ala$^2$]deltorphin I (230) 85
Cheng, T.P.-O., see Altura, B.M. (246) 299
Chern, J.-W., see Tao, P.-L. (243) 135
Chhajlani, V., see Xia, Y. (246) 129
Chiba, S., see Horiuchi, A. (237) 23
Chiba, S., see Noguchi, M. (234) 101
Chiba, S., see Skrbic, R. (230) 131
Chiba, S., see Takayama, S. (231) 315
Chida, Y., see Shibata, M. (235) 245
Chignard, M., see Renesto, P. (248) 151
Chihara, K., see Maeda, K. (233) 227
Childers, S.R., see Davies, H.M.L. (244) 93
Chiodo, L.A., see Zhang, J. (230) 371
Chiou, L.C. and Chang, C.C.
Improvement by diazepam of neuromuscular transmission blocked by anticholinesterase agents in mouse diaphragms (248) 185
Chitano, P., see Mapp, C.E. (248) 67
Chitour, D., see Bouhassira, D. (232) 207
Chiu, S., see Mamelak, M. (233) 175
Chiu, T.H., see Li, M. (247) 313
Chiueh, C.C., see Wu, R.-M. (243) 241
Chłopicki, S. and Gryglewski, R.J.
Nitric oxide is a major mediator in reactive hyperaemia evoked by a brief coronary occlusion in the guinea pig heart (241) 117
Cho, S.D., see Chang, K.C. (236) 51
Choppin, A. and O'Connor, S.E.
Pre-contraction with histamine and U46619 unmasks a 5-$HT_1$-like receptor in rabbit renal artery (231) 469
Chou, H., see Yu, S.-M. (234) 121
Chou, Y.-P., see Tao, P.-L. (246) 233
Chovet, M., see Pascaud, X.B. (231) 389
Chrapusta, S.J., Karoum, F., Egan, M.F. and Wyatt, R.J.
Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not γ-butyrolactone-resistant dopamine release (233) 135

Christians, U., see Hoof, T. (246) 53
Christoffersen, T., see Sandnes, D. (246) 163
Christophe, B., see Chatelain, P. (246) 181
Christopoulos, A., Loiacono, R. and Mitchelson, F.
Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3′-phthalimidopropyl)ammonium bromide at cholinoceptor sites (246) 1
Christopoulos, A., Loiacono, R. and Mitchelson, F.
Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3′-phthalimidopropyl)ammonium bromide at cholinoceptor sites. European Journal of Pharmacology – Molecular Pharmacology Section, 246 (1993) 1–8 (247) 227
Chugh, Y., see Chakrabarti, A. (235) 133
Chugun, A., see Temma, K. (234) 173
Chuliá, S., see Ivorra, M.D. (231) 165
Chulia, T., see Tejerina, T. (239) 75
Chuluyan, H.E., see Saphier, D. (236) 183
Chumpradit, S., see Kung, M.-P. (235) 165
Chung, K.F., see Sakamoto, T. (231) 31
Chung, Y.-L., see Huang, H.-C. (237) 39
Ciaccia, A., see Mapp, C.E. (248) 67
Ciaccia, A., see Mapp, C.E. (248) 277
Cid, M.E. and Ortega, A.
Glutamate stimulates [$^3$H]phorbol 12,13-dibutyrate binding in cultured Bergmann glia cells (245) 51
Cillero, F.J., see Priego, J. (243) 25
Cimino, M., see Balduini, W. (248) 281
Claing, A., see Télémaque, S. (237) 275
Clapham, J. and Kilpatrick, G.J.
Histamine $H_3$ receptor-mediated modulation of water consumption in the rat (232) 99
Clark, A.H. and Garland, C.J.
$Ca^{2+}$ channel antagonists and inhibition of protein kinase C each block contraction but not depolarization to 5-hydroxytryptamine in the rabbit basilar artery (235) 113
Clark, W.A., see Morrow, B.A. (238) 255
Clarke, R.W., see Harris, J. (237) 323
Classen, M., see Schmidtler, J. (246) 59
Clegg, R.A., see MacEwan, D.J. (246) 9
Clementi, G., Amico-Roxas, M., Caruso, A., Cutuli, V.M.C., Maugeri, S. and Prato, A.
Protective effects of calcitonin gene-related peptide in different experimental models of gastric ulcers (238) 101
Clerc, T., Jomier, M., Chautan, M., Portugal, H., Senft, M., Pauli, A.-M., Laruelle, C., Morel, O., Lafont, H. and Chanussot, F.
Mechanisms of action in the liver of crilvastatin, a new hydroxymethylglutaryl-coenzyme A reductase inhibitor (235) 59
Cliffe, I.A., see Fletcher, A. (237) 283
Clinet, M., see Chatelain, P. (246) 181
Cocchi, D., see Cattaneo, L. (241) 245
Coccini, T., Candura, S.M., Manzo, L., Costa, L.G. and Tonini, M.
Interaction of the neurotoxic pesticides ivermectin and lindane with the enteric $GABA_A$ receptor-ionophore complex in the guinea-pig (248) 1
Code, R.A., see Tang, A.H. (236) 1
Codegoni, A., see Mennini, T. (241) 255
Coelho, M.M., Pelá, I.R. and Rothwell, N.J.
Dexamethasone inhibits the pyrogenic activity of prostaglandin $F_{2\alpha}$, but not prostaglandin $E_2$ (238) 391
Coggan, J.S., see Knoper, S.R. (232) 65
Cohen, D.S., see Olson, R.W. (236) 75
Cohen, G., see Evans, J. (232) 241
Collin, J.-P., see Pontoire, C. (247) 111
Collingridge, G.L., see Bashir, Z.I. (239) 265
Collins, D.R. and Davies, S.N.
Co-administration of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid and arachidonic acid potentiates synaptic transmission in rat hippocampal slices (240) 325
Collins, K.A., see Tseng, L.F. (241) 63
Colombo, S., see Revel, L. (229) 45
Colpaert, F., see Marien, M. (236) 487
Comtois, A., Light, P., Renaud, J.M. and Kong, M.
Tolbutamide, but not glyburide, affects the excitability and contractility of unfatigued frog sartorius muscle (242) 65
Congy, C., see Rinaldi-Carmona, M. (246) 73
Connor, H.E., see O'Shaughnessy, C.T. (236) 319
Connor, K., see MacEwan, D.J. (246) 9
Consolo, S., see Garcia Ruiz, A.J. (244) 125
Cools, A.R., see Koene, P. (233) 151
Cools, A.R., see Prinssen, E.P.M. (231) 275
Cools Waeterloos, G., see Sacchetti, G. (236) 171
Coppes, R.P., Smit, J., Khali, N.N., Brouwer, F. and Zaagsma, J.
Strong activation of vascular prejunctional $\beta_2$-adrenoceptors in freely moving rats by adrenaline released as a co-transmitter (243) 273
Coraboeuf, E., see Le Grand, B. (229) 91
Corbett, J.A., see Misko, T.P. (233) 119
Corda, M.G., see Giorgi, O. (245) 139
Cordeiro, R.S.B., see Amorim, C.Z. (235) 17
Cordeiro, R.S.B., see Amorim, C.Z. (236) 301
Cordeiro, R.S.B., see Bozza, P.T. (248) 41
Cordeiro, R.S.B., see Martins, M.A. (237) 17
Cortijo, J., see Cejalvo, D. (234) 23
Coser, E., see Mapp, C.E. (248) 67
Costa, E., see Dučić, I. (244) 29
Costa, E., see Fohrman, E.B. (245) 263
Costa, L.G., see Coccini, T. (248) 1
Costall, B., Domeney, A.M., Kelly, M.E., Tomkins, D.M., Naylor, R.J., Wong, E.H.F., Smith, W.L., Whiting, R.L. and Eglen, R.M.
The effect of the 5-$HT_3$ receptor antagonist, RS-42358-197, in animal models of anxiety (234) 91
Costall, B., see Cheng, C.H.K. (239) 211
Costall, B., see Williams, T.J. (245) 197
Costentin, J., see Billaud, G. (247) 333
Costentin, J., see Vaugeois, J.-M. (230) 195
Cotter, M.A., see Cameron, N.E. (243) 47
Cottrell, D.A., see Hodgkiss, J.P. (240) 219
Courteix, C., Lavarenne, J. and Eschalier, A.
RP-67580, a specific tachykinin $NK_1$ receptor antagonist, relieves chronic hyperalgesia in diabetic rats (241) 267
Couture, R., see Picard, P. (232) 255
Cowan, A., see Wheeler-Aceto, H. (236) 193
Coy, D.H., see Cheng, D.Y. (243) 79
Coy, D.H., see Ladenheim, E.E. (235) 121
Coy, D.H., see Rossowski, W.J. (240) 259
Craft, R.M. and Dykstra, L.A.
Morphine antagonizes U50,488's effects in a squirrel monkey shock titration procedure (234) 199
Crayton, J., see Gulati, A. (231) 151
Cremades, A., see Martínez, F. (248) 199
Crijns, F., see Huijberts, M. (240) 207
Croce, C., see Tubaro, E. (248) 175
Crocker, C., see Ying, S.-W. (246) 89
Croiset, G. and De Wied, D.
ACTH: a structure-activity study on pilocarpine-induced epilepsy (229) 211
Crouzel, C., see Tavitian, B. (236) 229
Cruz, A.B., see Neves, P.C.A. (243) 213

Cruz, J.d.S. and Matsuda, H.
Arenobufagin, a compound in toad venom, blocks $Na^+$-$K^+$ pump current in cardiac myocytes (239) 223
Csernansky, J.G., see Bardgett, M.E. (230) 245
Cucinotta, D., see Squadrito, F. (230) 125
Cumming-Hood, P.A., Strahlendorf, H.K. and Strahlendorf, J.C.
Effects of serotonin and the 5-$HT_{2/1C}$ receptor agonist DOI on neurons of the cerebellar dentate/interpositus nuclei: possible involvement of a GABAergic interneuron (236) 457
Cunha, F.Q., Boukili, M.A., Braga Da Motta, J.I., Vargaftig, B.B. and Ferreira, S.H.
Blockade by fenspiride of endotoxin-induced neutrophil migration in the rat (238) 47
Currie, M.G., see Kato, J. (244) 153
Currie, M.G., see Misko, T.P. (233) 119
Currie, P.J. and Wilson, L.M.
Potentiation of dark onset feeding in obese mice (genotype ob/ob) following central injection of norepinephrine and clonidine (232) 227
Curzon, G., see Gibson, E.L. (242) 83
Cuthbert, N.J., see Gardiner, P.J. (238) 19
Cuthbert, N.J., see Norman, P. (229) 171
Cutting, G.R., see Kusama, T. (245) 83
Cutuli, V.M.C., see Clementi, G. (238) 101
Czechowska, G., Dziki, M., Pietrasiewicz, T., Kleinrok, Z., Turski, W.A. and Czuczwar, S.J.
Competitive antagonists of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice (232) 59
Czernilofsky, A., see Van Sande, J. (247) 177
Członkowski, A., Stein, C. and Herz, A.
Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines (242) 229
Czuczwar, S.J., see Czechowska, G. (232) 59

D'Adamo, M.C., see Iacoviello, L. (229) 39
Daffonchio, L., see Yamawaki, I. (243) 1
Dage, R.C., see French, J.F. (233) 109
Dagerlind, Å., see Meister, B. (247) 229
Dakshinamurti, K., see Lal, K.J. (234) 183
Daleau, P., see Gohar, M. (229) 69
Damas, J., Remacle-Volon, G. and Bourdon, V.
Platelet-activating factor and the vascular effects of zymosan in rats (231) 231
Damm, K., see Rupprecht, R. (247) 145
Daniel, E.E., see Low, A.M. (230) 53
Danilov, A., see Sandrini, G. (243) 99
Danober, L., Depaulis, A., Marescaux, C. and Vergnes, M.
Effects of cholinergic drugs on genetic absence seizures in rats (234) 263
Danysz, W., see Bisaga, A. (242) 213
Darby, P.J., see Low, A.M. (230) 53
Davidson, M., see Matsumoto, I. (247) 289
Davies, A., see Heijink, E. (248) 15
Davies, H.M.L., Saikali, E., Sexton, T. and Childers, S.R.
Novel 2-substituted cocaine analogs: binding properties at dopamine transport sites in rat striatum (244) 93
Davies, J.A., see Dickie, B.G.M. (229) 97
Davies, S.N., see Collins, D.R. (240) 325
Davies, W.E., see Steward, L.J. (242) 137
Davis, B., see Jones, C.A. (242) 183
Davis, J.M., see Javaid, J.I. (238) 425
Davis, J.M., see Pandey, S.C. (247) 81
Davis, T.P., see Horan, P.J. (233) 53
Davison, J.S., see Mathison, R. (240) 163
Davison, J.S., see Pauletzki, J.G. (232) 263
Davisson, R.L., Walton, T.M., Johnson, A.K. and Lewis, S.J.
Cardiovascular effects produced by systemic injections of nitro blue tetrazolium in the rat (241) 135
Dawirs, R.R., Teuchert-Noodt, G. and Molthagen, M.
Indication of methamphetamine-induced reactive synaptogenesis in the prefrontal cortex of gerbils (*Meriones unguiculatus*) (241) 89
Dawson, Jr., R., Felheim, R. and Phillips, M.I.
Dopamine receptor agonists and antagonists both inhibit dopamine secretion in LLC-$PK_1$ cells (240) 277
Daykin, K., Widdop, S. and Hall, I.P.
Control of histamine induced inositol phospholipid hydrolysis in cultured human tracheal smooth muscle cells (246) 135
Dazzi, L., see Imperato, A. (238) 135
Debas, H.T., see Huber, O. (239) 103
Debonnel, G., see Bergeron, R. (240) 319
Debono, M.-W., Le Guern, J., Canton, T., Doble, A. and Pradier, L.
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in *Xenopus* oocytes (235) 283
Decena, J., see Cheng, P.Y. (230) 85
De Chaffoy de Courcelles, D., see Roevens, P. (245) 273
Decker, M.W., see Brioni, J.D. (238) 1
Deckert, J., Bereznai, B., Hennemann, A., Gsell, W., Götz, M., Fritze, J. and Riederer, P.
Nimodipine inhibits [$^3$H]nitrobenzylthioinosine binding to the adenosine transporter in human brain (238) 131
De Clerck, F., see Lu, H.R. (235) 89
De Clerck, F., see Roevens, P. (245) 273
De Costa, B., see Wong, G. (247) 57
De Costa, B.R., see Hudzik, T.J. (236) 279
De Curtis, A., see Iacoviello, L. (229) 39
De Erausquin, G., see Fohrman, E.B. (245) 263
De Gaetano, G., see Iacoviello, L. (229) 39
De Gaetano, G., see Rotondo, S. (232) 41
De Garavilla, L., Volberg, M.L., Pratt, P.F., Silver, P.J. and Buchholz, R.A.
Lack of cross-tolerance between nitroglycerin and endothelium-derived relaxing factor-mediated vasoactive agents in spontaneously hypertensive rats (234) 77
DeGoede, J., see Berkenbosch, A. (232) 21
DeHaven-Hudkins, D.L., see Fritz, P.M. (235) 229
DeHaven-Hudkins, D.L., see Hudkins, R.L. (231) 485
Dehne, K., see Schmidtler, J. (246) 59
Dehring, D.J., see Nelson, S.H. (242) 255
Dejana, E., see Cerri, M.A. (232) 291
De Jong, W., see Lukovic, L. (233) 63
De Kloet, E.R., see Van Erp, A.M.M. (232) 217
De Koster, B.M., see Elferink, J.G.R. (246) 157
De Laat, S.W., see Smit, M.J. (247) 223
De la Fuente, M., see López, M.G. (247) 199
De la Fuente, M.-T., Guantes, J.M., Del Valle, M. and Garcia, A.G.
Mechanism of blockade by flunarizine of bovine adrenal catecholamine release (229) 189
De Lang, H., see De Wildt, D.J. (233) 157
Del Bianco, E., see Santicioli, P. (231) 139
Delbro, D.S., see Gustafsson, B.I. (230) 1
Delisée, C., Schaeffer, P., Cazaubon, C. and Chatelain, P.
Characterization of cardiac angiotensin $AT_1$ receptors by [$^3$H]SR 47436 (247) 139
Delpón, E., see Pérez-Vizcaíno, F. (232) 105
Del Pozo, E., see Ocaña, M. (230) 203
Del Pozo, E., see Ocaña, M. (239) 253
Del Rio-Lacheze, C., see Gué, M. (233) 193
Del Valle, M., see De la Fuente, M.-T. (229) 189
Delvaux, M., see Botella, A. (237) 131
De Matteis, F., see Heijink, E. (248) 15
Demmer, A., see Hoof, T. (246) 53
De Montigny, C., see Bergeron, R. (240) 319
Demontis, M.V., see Imperato, A. (229) 265
Deng, H.-w., see Li, Y.-j. (239) 127
Deng, H.-w., see Yu, X.-j. (241) 35
DeNinno, M.P., see Kebabian, J.W. (229) 203

Dent, G., see Rabe, K.F. (231) 305
De Nucci, G., see Santana, A.C. (231) 237
De Pascual, R., see Priego, J. (243) 25
Depaulis, A., see Danober, L. (234) 263
De Potter, W., see Jimenez Del Rio, M. (247) 11
Deroubaix, E., see Le Grand, B. (229) 91
De Santi, M.M., see Sgaragli, G.P. (248) 121
De Sarro, A., see De Sarro, G. (230) 151
De Sarro, G., Donato Di Paola, E., De Sarro, A. and Vidal, M.J.
L-Arginine potentiates excitatory amino acid-induced seizures elicited in the deep prepiriform cortex (230) 151
Descombes, J.-J., Devys, M., Laubie, M. and Verbeuren, T.J.
Endothelial thromboxane production plays a role in the contraction caused by 5-hydroxytryptamine in rat basilar arteries (243) 193
DeSouza, E.B., see Levant, B. (246) 171
Desquand, S., Ruffié, C., Lefort, J., Hatmi, M., Pina, M., Priego, J.G. and Vargaftig, B.B.
Compound PCA-4248 interferes with bronchopulmonary anaphylaxis and with in vitro hyperresponsiveness to platelet-activating factor (235) 101
Dessy, C., Salomone, S., Morel, N. and Godfraind, T.
Activity of dihydrothienopyridine S312 enantiomers on L-type $Ca^{2+}$ channels in isolated rat aorta and cerebral microvessels (231) 435
Devine, D.P., Leone, P. and Wise, R.A.
Mesolimbic dopamine neurotransmission is increased by administration of $\mu$-opioid receptor antagonists (243) 55
Devlin, T.M., see Von Lubitz, D.K.J.E. (233) 95
De Vries, T.J., see Tjon Tien Ril, H.K.G. (235) 321
De Vry, J., see Baudrie, V. (231) 395
De Vry, J., see Sommermeyer, H. (240) 29
Devynck, M.-A., Le Quan Sang, K.H., Joulin, Y. and Mazeaud, M.
Acute membrane effects of trimetazidine in human platelets (245) 105
Devys, M., see Descombes, J.-J. (243) 193
Dewar, K.M., Grondin, L., Nénonéné, E.K., Ohayon, M. and Reader, T.A.
[$^3$H]Paroxetine binding and serotonin content of rat brain: absence of changes following antidepressant treatments (235) 137
De Wied, D., see Croiset, G. (229) 211
De Wildt, D.J., Krugers, H., Kasbergen, C.M., De Lang, H. and Versteeg, D.H.G.
The hemodynamic effects of $\gamma_2$-melanocyte-stimulating hormone and related melanotropins depend on the arousal potential of the rat (233) 157
Dewitt, B.J., see Cheng, D.Y. (243) 79
De Witte, P., see Nijs, G. (239) 241
Diana, M., Pistis, M., Muntoni, A. and Gessa, G.
Heterogeneous responses of substantia nigra pars reticulata neurons to $\gamma$-hydroxybutyric acid administration (230) 363
Diana, M., see Rossetti, Z.L. (231) 203
Di Chiara, G., see Acquas, E. (230) 239
Dickie, B.G.M. and Davies, J.A.
Calcium channel blocking agents and potassium-stimulated release of glutamate from cerebellar slices (229) 97
Didier, M., Héaulme, M., Gonalons, N., Soubrié, P., Bockaert, J. and Pin, J.-P.
35 mM $K^+$-stimulated $^{45}Ca^{2+}$ uptake in cerebellar granule cell cultures mainly results from NMDA receptor activation (244) 57
Diederen, W., see Van Meel, J.C.A. (233) 295
Diener, M. and Scharrer, E.
The leukotriene $D_4$ receptor blocker, SK&F 104353, inhibits volume regulation in isolated crypts from the rat distal colon (238) 217
Dierssen, M., see Ruiz, F. (240) 155
Dierssen, M., see Vivas, N.M. (245) 9
Di Giamberardino, L., see Tavitian, B. (236) 229
Dinh-Xuan, A.T., see Pepke-Zaba, J. (235) 169
Dini, G., see Lodovici, M. (243) 255
Diorio, J., see Betito, K. (238) 273
Di Renzo, G., see Canzoniero, L.M.T. (245) 97
Di Rosa, M., see Calignano, A. (229) 273
Di Rosa, M., see Iuvone, T. (243) 163
Di Rosa, M., see Zingarelli, B. (243) 107
Di Stefano, A., see Mapp, C.E. (248) 67
Divish, B.J., see Pollock, D.M. (231) 459
Doble, A., see Debono, M.-W. (235) 283
Doble, A., see Malgouris, C. (233) 29
Doble, A., see Malgouris, C. (233) 37
D'Ocon, M.P., see Ivorra, M.D. (231) 165
Dodd, P.R., see Westphalen, R.I. (238) 399
Doehmer, J., see Schmalix, W.A. (248) 251
Dohi, M., Sakata, Y., Seki, J., Namikawa, Y., Fujisaki, J., Tanaka, A., Takasugi, H., Motoyama, Y. and Yoshida, K.
The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor (243) 179
Dolara, P., see Lodovici, M. (243) 255
Dolata, J., see Lindberg, S. (231) 375
Domènech, C., Fierro-Durán, G., Rodríguez, L., Grau-Oliete, M.R. and Rivera-Fillat, M.P.
Vincristine cellular pharmacokinetic changes associated with multidrug resistance (248) 49
Domenech, R., Macho, P., Penna, M., Schwarze, H., Huidobro-Toro, J.P. and Thumala, A.
Role of endothelium-derived relaxing factor on coronary blood flow regulation in the dog (238) 53
Domeney, A.M., see Costall, B. (234) 91
Domenici, M.R., Longo, R., Scotti de Carolis, A., Frank, C. and Sagratella, S.
Protective actions of 21-aminosteroids and MK-801 on hypoxia-induced electrophysiological changes in rat hippocampal slices (233) 291
Donati, M.B., see Iacoviello, L. (229) 39
Donatini, A., see Romualdi, P. (229) 149
Donato Di Paola, E., see De Sarro, G. (230) 151
Donné-Op den Kelder, G.M., see Ter Laak, A.M. (232) 199
Donoso, M.V., Boric, M., Prado, M., Fournier, A., St. Pierre, S., Edvinsson, L. and Huidobro-Toro, J.P.
D-myo-Inositol 1,2,6-trisphosphate blocks neuropeptide Y-induced facilitation of noradrenaline-evoked vasoconstriction of the mesenteric bed (240) 93
Donovan, V., see Goldhill, J. (238) 387
Dontenwill, M., see Bennai, F. (246) 45
Doods, H., Entzeroth, M., Ziegler, H., Schiavi, G., Engel, W., Mihm, G., Rudolf, K. and Eberlein, W.
Characterization of BIBN 99: a lipophilic and selective muscarinic $M_2$ receptor antagonist (242) 23
Doods, H.N., see Van Meel, J.C.A. (233) 295
Doolette, D.J., see Kerr, D.I.B. (236) 239
Doolette, D.J., see Ong, J. (233) 169
D'Orléans-Juste, P., see Filep, J.G. (239) 231
D'Orléans-Juste, P., see Rae, G.A. (240) 113
D'Orléans-Juste, P., see Télémaque, S. (237) 275
Dotson, R., see Olson, R.W. (236) 75
Dourish, C.T., see Routledge, C. (239) 195
Dover, G.M., see Fletcher, A. (237) 283
Dow, J., see Lukovic, L. (233) 63
Downes, R.P. and Waddington, J.L.
Grooming and vacuous chewing induced by SK&F 83959, and agonist of dopamine '$D_1$-like' receptors that *inhibits* dopamine-sensitive adenylyl cyclase (234) 135
Downie, D.L., see Hope, A.G. (245) 187
Drejer, J., see Johansen, T.H. (246) 195

Druhan, J.P., Jakob, A. and Stewart, J.
The development of behavioral sensitization to apomorphine is blocked by MK-801 (243) 73
Drukarch, B., see Vermeulen, R.J. (235) 143
Drummer, C., see Ivanova, K. (244) 37
Drummer, C., see Menshikov, M.Y. (245) 281
Du, F., see Gao, X.-M. (241) 7
Du, X.Y., see Schoemaker, R.G. (230) 103
Duarte, C.B., Tome, A.R., Forsberg, E., Carvalho, C.A.M., Carvalho, A.P., Santos, R.M. and Rosario, L.M.
Neomycin blocks dihydropyridine-insensitive $Ca^{2+}$ influx in bovine adrenal chromaffin cells (244) 259
Duarte, J., Pérez-Vizcaíno, F., Zarzuelo, A., Jiménez, J. and Tamargo, J.
Vasodilator effects of quercetin in isolated rat vascular smooth muscle (239) 1
Duarte, J., see Pérez-Vizcaíno, F. (232) 105
Dubey, M.P., see Pandey, S.C. (247) 81
Dučić, I., Puia, G., Vicini, S. and Costa, E.
Triazolam is more efficacious than diazepam in a broad spectrum of recombinant $GABA_A$ receptors (244) 29
Duckles, S.P., see Li, Y. (236) 373
Duckles, S.P., see Tsai, H. (237) 311
Dufour, M.N., see Gil-Longo, J. (247) 119
Duke, R.K., see Ong, J. (233) 169
Dumas, J.-P., see Dumas, M. (239) 141
Dumas, M., Dumas, J.-P., Advenier, C. and Giudicelli, J.-F.
Effects of three $K^+$ channel openers on airways and pulmonary circulation in the isolated guinea-pig lung (239) 141
Dumont, J.E., see Van Sande, J. (247) 177
Dumont, M., see Lemaire, S. (245) 247
Dumont, P., see Lambert, D.M. (243) 129
Dumont, Y., Satoh, H., Cadieux, A., Taoudi-Benchekroun, M., Pheng, L.-H., St-Pierre, S., Fournier, A. and Quirion, R.
Evaluation of truncated neuropeptide Y analogues with modifications of the tyrosine residue in position 1 on $Y_1$, $Y_2$ and $Y_3$ receptor sub-types (238) 37
Duncalfe, L.L. and Dunn, S.M.J.
Benzodiazepine binding to $GABA_A$ receptors: differential effects of sulfhydryl modification (246) 141
Dunn, P.M.
Ganglion-blocking activity of dequalinium in frog and rat sympathetic ganglia in vitro (230) 335
Dunn, S.M.J., see Duncalfe, L.L. (246) 141
Duridanova, D.B., see Gagov, H.S. (243) 19
Dutar, P., see Potier, B. (231) 427
Duterte-Boucher, D., see Vaugeois, J.-M. (230) 195
Dwoskin, L., see Jewell, A. (243) 249
Dyer, D.C., see Zhang, L. (230) 115
Dykstra, L.A., see Craft, R.M. (234) 199
Dziki, M., see Czechowska, G. (232) 59
Dzimiri, N. and Almotrefi, A.A.
Actions of amiodarone on mitochondrial ATPase and lactate dehydrogenase activities in guinea pig heart preparations (242) 113
Dzoljic, M.R., see Cappendijk, S.L.T. (241) 261

Eaton, S.A., Jane, D.E., Jones, P.L.S.J., Porter, R.H.P., Pook, P.C.-K., Sunter, D.C., Udvarhelyi, P.M., Roberts, P.J., Salt, T.E. and Watkins, J.C.
Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-α-methyl-4-carboxyphenylglycine (244) 195
Eberlein, W., see Doods, H. (242) 23
Eberling, J.L., see Jagust, W.J. (242) 189
Ebert, B., see Madsen, U. (230) 383
Ebinger, G., see Jimenez Del Rio, M. (247) 11
Edvinsson, L., see Donoso, M.V. (240) 93
Edvinsson, L., see Erlinge, D. (240) 77
Edwall, L., see Kerezoudis, N.P. (241) 209
Egan, J.W., see Smith III, E.F. (236) 477
Egan, M.F., see Chrapusta, S.J. (233) 135
Eglen, R.M., Sharif, N.A. and To, Z.P.
Muscarinic $M_3$ receptors mediate total inositol phosphates accumulation in murine HSDM1C1 fibrosarcoma cells (244) 49
Eglen, R.M., see Costall, B. (234) 91
Eichberg, J., see Bianchi, R. (239) 55
Eikenburg, D.C., see Lakhlani, P.P. (230) 107
Ekman, A. and Eriksson, E.
A high dose of EEDQ reduces pituitary dopamine $D_2$ receptor density and the prolactin suppressive potency of agonists (243) 295
Ekonsalo, T., see Riekkinen, Jr., P. (238) 263
Ekonsalo, T., see Riekkinen, Jr., P. (240) 1
El Amrani, A.-I., see Arnal, J.-F. (237) 265
Elferink, J.G.R. and De Koster, B.M.
The effect of cyclic GMP and cyclic AMP on migration by electroporated human neutrophils (246) 157
Ellenbroek, B.A., see Prinssen, E.P.M. (231) 275
Ellinwood, Jr., E.H., see Lee, T.H. (232) 125
Ellis, E.F., see Uphouse, L.A. (242) 53
Eltze, M., Ullrich, B., Mutschler, E., Moser, U., Bungardt, E., Friebe, T., Gubitz, C., Tacke, R. and Lambrecht, G.
Characterization of muscarinic receptors mediating vasodilation in rat perfused kidney (238) 343
Embrey, J.P., see Uphouse, L.A. (242) 53
Emerit, M.B., see Bachy, A. (237) 299
Emonds-Alt, X., see Martin, C.A.E. (243) 309
Emonds-Alt, X., see Santucci, V. (237) 143
Enas, J.D., see Jagust, W.J. (242) 189
Endo, C., see Okawa, T. (230) 341
Endo, T., see Iwata, N. (248) 243
Engber, T.M., Marin, C., Susel, Z. and Chase, T.N.
Differential effects of chronic dopamine $D_1$ and $D_2$ receptor agonists on rotational behavior and dopamine receptor binding (236) 385
Engber, T.M., see Papa, S.M. (232) 247
Engel, J.A., see Heilig, M. (236) 339
Engel, W., see Doods, H. (242) 23
Ennis, C. and Minchin, M.C.W.
The effect of toxin I, a $K^+$ channel inhibitor, on [$^3$H]noradrenaline release from rat cerebral cortex (248) 85
Entzeroth, M., see Doods, H. (242) 23
Epand, R.M., see Nie, S.-Q. (244) 15
Eriksson, E., see Ekman, A. (243) 295
Erlinge, D., Edvinsson, L., Brunkwall, J., Yee, F. and Wahlestedt, C.
Human neuropeptide Y $Y_1$ receptor antisense oligodeoxynucleotide specifically inhibits neuropeptide Y-evoked vasoconstriction (240) 77
Ermine, A., see Ceccaldi, P.-E. (245) 129
Errasfa, M. and Stern, A.
Inhibition of protein tyrosine phosphatase activity in HER14 cells by melittin and $Ca^{2+}$ ionophore A23187 (247) 73
Ertan, A., see Rossowski, W.J. (240) 259
Escalante, B., Omata, K., Sessa, W., Lee, S.-G., Falck, J.R. and Schwartzman, M.L.
20-Hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries (235) 1
Eschalier, A., see Courteix, C. (241) 267
E Silva, P.M.R., see Tesson, F. (248) 27
E Silva, P.M.R., see Bozza, P.T. (248) 41
E Silva, P.M.R., see Tesson, F. (248) 351
Esinhart, J.D., see Makujina, S.R. (243) 35
Essien, E., see Wynn, R.L. (241) 47

Eto, T., see Ishiyama, Y. (241) 271
Ettlinger, C.B., see Carrington, A.L. (237) 257
Evans, D.L., see Lahti, R.A. (236) 483
Evans, J. and Cohen, G.
Catecholamine uptake inhibitors elevate 6-hydroxydopamine in brain after administration of 6-hydroxydopa (232) 241
Evans, P., see Rabe, K.F. (231) 305
Eyssen, H., see Nijs, G. (239) 241
Ezra, D., see Shamiss, A. (233) 113

Fabbri, L., see Mapp, C.E. (248) 277
Fabbri, L.M., see Mapp, C.E. (248) 67
Facci, L., see Skaper, S.D. (243) 91
Fadda, E., see Skaper, S.D. (243) 91
Falch, E., see White, H.S. (236) 147
Falck, J.R., see Escalante, B. (235) 1
Fan, S.-f. and Kao, C.Y.
Difference in the effects of verapamil on $Ca^{2+}$-activated $K^+$ channels of smooth myocytes of aorta and taenia coli (229) 259
Fang, L., see Horan, P.J. (233) 53
Fang, L., see Wild, K.D. (246) 289
Fanger, B.O., see Huggins, J.P. (245) 203
Farb, D.H., see Wu, F.-S. (246) 239
Fardin, V., see Hermans, E. (245) 43
Fargeas, M.-J., see Bonnafous, C. (237) 237
Farrell, A.M., see Kudlacz, E.M. (241) 17
Fassio, A., see Lanza, M. (237) 191
Fau de Casa-Juana, M., see Priego, J. (243) 25
Fauq, A., see Casalotti, S.O. (247) 209
Faure-Halley, C., Graham, D., Arbilla, S. and Langer, S.Z.
Expression and properties of recombinant $\alpha_1\beta_2\gamma_2$ and $\alpha_5\beta_2\gamma_2$ forms of the rat $GABA_A$ receptor (246) 283
Fazi, M., see Lodovici, M. (243) 255
Fedele, E., see Pittaluga, A. (231) 129
Federici, G., see Bagetta, G. (237) 61
Fedorova, O.V., see Bagrov, A.Y. (234) 165
Fekete, I., see Hegedüs, K. (237) 293
Fekete, M.I.K., see Horváth, E.J. (236) 151
Felheim, R., see Dawson, Jr., R. (240) 277
Feniuk, W., see Garner, C. (239) 31
Feolde, E., Vigne, P. and Frelin, C.
Angiotensin $AT_1$ receptors mediate a positive inotropic effect of angiotensin II in guinea pig atria (245) 63
Ferguson, R., see Horan, P.J. (233) 53
Ferrante, F. and Amenta, F.
Autoradiographic localization of [$^3$H]nicardipine binding sites in the human renal artery (240) 229
Ferrante, J.N., see Hawthorn, M.H. (229) 143
Ferrarese, A., see Caccia, S. (233) 71
Ferrari, F., see Revel, L. (229) 45
Ferraris, V.A., see Weishaar, R.E. (236) 363
Ferraro, L., see Tanganelli, S. (230) 159
Ferrat, T., see Olpe, H.-R. (233) 179
Ferré, S., Snaprud, P. and Fuxe, K.
Opposing actions of an adenosine $A_2$ receptor agonist and a GTP analogue on the regulation of dopamine $D_2$ receptors in rat neostriatal membranes (244) 311
Ferreira-de-Almeida, J.A., Pereira-Leite, L., Cavallotti, C., Ricci, A. and Amenta, F.
Pharmacological characterization and autoradiographic localization of dopamine $D_1$ receptors in the human umbilical artery (234) 209
Ferreira, S.H., see Cunha, F.Q. (238) 47
Ferrer, J.M.R., Sabater, R. and Saez, J.A.
Neurotensin participates in self-stimulation of the medial prefrontal cortex in the rat (231) 39
Ferrer, J.M.R., see Sabater, R. (242) 205
Ferri, N., see Trampus, M. (235) 83
Ferri, S., see Romualdi, P. (229) 149
Ferri, S., see Spampinato, S. (244) 139
Feuerstein, G.Z., see Yue, T.-L. (240) 81
Feyen, J.H.M., see Schneider, H. (246) 149
Fibiger, H.C., see Hamamura, T. (237) 65
Fierro-Durán, G., see Domènech, C. (248) 49
Figur, L.M., see Lahti, R.A. (236) 483
File, S.E. and Andrews, N.
Enhanced anxiolytic effect of zacopride enantiomers in diazepam-withdrawn rats (237) 127
File, S.E., see Andrews, N. (235) 109
File, S.E., see Rattray, M. (245) 193
Filep, J.G., Battistini, B., Fournier, A. and Sirois, P.
Relaxation by dexamethasone of isolated guinea-pig airways precontracted with endothelin-1 (240) 315
Filep, J.G., Télémaque, S., Battistini, B., Sirois, P. and D'Orléans-Juste, P.
Increased plasma levels of endothelin during anaphylactic shock in the guinea-pig (239) 231
Filep, J.G., see Hermán, F. (236) 143
Fillion, G., see Bolaños-Jiménez, F. (242) 1
Fillion, G., see Ceccaldi, P.-E. (245) 129
Fillion, M.-P., see Ceccaldi, P.-E. (245) 129
Finiels-Marlier, F., see Weller, M. (248) 303
Finklestein, S.P., see Nozaki, K. (232) 295
Finn, D.A. and Gee, K.W.
A comparison of Ro 16-6028 with benzodiazepine receptor 'full agonists' on $GABA_A$ receptor function (247) 233
Finnman, U.-B., see Li, X.-M. (234) 125
Finta, E.P., see Sevcik, J. (230) 223
Fioramonti, J., see Botella, A. (237) 131
Fiori, M.G., see Bianchi, R. (239) 55
Fischer, S., Wolf, G., Keilhoff, G. and Hass, P.
$Mg^{2+}$ antagonizes $\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced brain damage and convulsions (232) 121
Fisher, A., see Riekkinen, Jr., P. (240) 1
Flamand, F., see Malgouris, C. (233) 29
Flamand, F., see Malgouris, C. (233) 37
Fleck, T., see Ochsner, M. (245) 15
Fleetwood-Walker, S.M., Parker, R.M.C., Munro, F.E., Young, M.R., Hope, P.J. and Mitchell, R.
Evidence for a role of tachykinin $NK_2$ receptors in mediating brief nociceptive inputs to rat dorsal horn (laminae III-V) neurons (242) 173
Fleissner, L.C., see Fritz, P.M. (235) 229
Fletcher, A., Bill, D.J., Bill, S.J., Cliffe, I.A., Dover, G.M., Forster, E.A., Haskins, J.T., Jones, D., Mansell, H.L. and Reilly, Y.
WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-$HT_{1A}$ receptors (237) 283
Fletcher, E.J. and MacDonald, J.F.
Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones (235) 291
Flezar, M., see Pon, D.J. (245) 119
Flodström, S., see Hemming, H. (248) 163
Flood, J.F. and Morley, J.E.
Dose-response differences in the ability of ramipril to improve retention in diabetic mice (240) 311
Flórez, J., see Ruiz, F. (240) 155
Flynn, J.T., see Loick, H.M. (248) 75
Fohrman, E.B., De Erausquin, G., Costa, E. and Wojcik, W.J.
Muscarinic m3 receptors and dynamics of intracellular $Ca^{2+}$ cerebellar granule neurons (245) 263
Folco, G., see Revel, L. (229) 45
Fölsch, U.R., see Höcker, M. (242) 105
Fontaine, J., see Unger, P. (248) 145

Fonteríz, R.I., see López, M.G. (247) 199
Ford-Rice, F.Y., see Fritz, P.M. (235) 229
Forrest, J.M.S., see Müller, W.E.G. (246) 261
Forsberg, E., see Duarte, C.B. (244) 259
Forster, C. and Campbell, P.M.
Nifedipine inhibits responses to α-adrenoceptor stimulation in canine blood vessels: impact of heart failure (242) 119
Forster, E.A., see Fletcher, A. (237) 283
Foulon, C., see Kung, M.-P. (235) 165
Fournié-Zaluski, M.-C., see Noble, F. (230) 139
Fournié-Zaluski, M.-C., see Perrot, S. (241) 129
Fournier, A., see Donoso, M.V. (240) 93
Fournier, A., see Dumont, Y. (238) 37
Fournier, A., see Filep, J.G. (240) 315
Fournier, A., see Poitras, M. (244) 203
Fozard, J.R., see Schoeffter, P. (244) 251
Fracasso, C., see Caccia, S. (233) 71
Francisco, T., see Mendelson, S.D. (236) 177
Franco-Cereceda, A., Källner, G. and Lundberg, J.M.
Capsazepine-sensitive release of calcitonin gene-related peptide from C-fibre afferents in the guinea-pig heart by low pH and lactic acid (238) 311
Frank, C., see Domenici, M.R. (233) 291
Franklin, P.H., see Roth, J.E. (236) 327
Franks, R., see Guard, S. (232) 287
Franks, R., see Guard, S. (236) 496
Fredholm, B.B., see Johansson, B. (247) 103
Fredholm, B.B., see Ljunggren, Ö. (244) 111
Freeman, A.S., see Zhang, J. (230) 371
Fréhel, D., see Gully, D. (232) 13
Frelin, C., see Feolde, E. (245) 63
Frelin, C., see Vigne, P. (245) 229
French, J.F., Schroeder, K.K., Akeson, A.L., Dage, R.C. and Bowlin, T.L.
Identification of a specific receptor for interleukin-1 in vascular smooth muscle cells: regulation by interleukin-1 and interleukin-6 (233) 109
Frew, R., see Lundy, P.M. (231) 197
Frexinos, J., see Botella, A. (237) 131
Frey, E.A., Nicholson, D.W. and Metters, K.M.
Characterization of the leukotriene $D_4$ receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene $D_4$ receptor in human lung and guinea-pig lung (244) 239
Fride, E. and Mechoulam, R.
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent (231) 313
Friebe, T., see Eltze, M. (238) 343
Friedmann, T., see Fürst, Z. (236) 209
Frittoli, E., see Gobbi, M. (238) 9
Fritz, P.M., DeHaven-Hudkins, D.L., Fleissner, L.C., Ford-Rice, F.Y. and Luttinger, D.
σ Receptor binding affinity and inhibition of apomorphine-induced climbing (235) 229
Fritze, J., see Deckert, J. (238) 131
Froestl, W., see Brugger, F. (235) 153
Froestl, W., see Olpe, H.-R. (233) 179
Frost, J.J., see Laruelle, M. (230) 119
Fu, W.-M., see Liu, S.-H. (231) 23
Fuji, K., Hiramatsu, M., Kameyama, T. and Nabeshima, T.
Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats (236) 411
Fujii, T., see Morimoto, H. (240) 121
Fujii, T., see Murai, M. (236) 7
Fujii, W., see Takaki, M. (237) 51
Fujimoto, M., see Itazaki, K. (245) 147
Fujimoto, M., see Mihara, S.-i. (246) 33
Fujimoto, M., see Mihara, S.-i. (247) 219
Fujioka, Y., see Miyake, K. (235) 75
Fujisaki, J., see Dohi, M. (243) 179
Fujisawa, A., see Shimamura, K. (231) 103
Fujisawa, M., Miyamoto, O., Itano, T., Tokuda, M., Matsui, H., Nagao, S., Negi, T. and Hatase, O.
Ceruletide suppresses rotational behavior in lesioned rats via $CCK_A$ receptors (238) 127
Fujishima, M., see Ooboshi, H. (233) 165
Fujita, K., Iijima, N., Suzuki, S. and Nakazawa, K.
Effects of clonidine on desipramine- and desmethylclomipramine-induced 3-methoxy-4-hydroxyphenylglycol levels in rat brain (242) 301
Fujita, K., see Hisaki, K. (241) 75
Fujita, K., see Matsumura, Y. (230) 89
Fujita, R., Tamazawa, Y., Barnard, E.A. and Matsumoto, M.
Blocking effect of serotonin on β-adrenoceptor activity in follicle-enclosed *Xenopus* oocytes (240) 213
Fukuda, T., see Irifune, M. (238) 235
Fukui, T., see Tamaki, T. (236) 15
Fukunaga, Y., Mine, Y., Yoshikawa, S., Takeuchi, T., Hata, F. and Yagasaki, O.
Role of prostacyclin in acetylcholine release from myenteric plexus of guinea-pig ileum (233) 237
Fukunaga, Y., see Yoshikawa, S. (239) 261
Fukushima, H., see Okada, Y. (241) 177
Fukushima, H., see Osada, Y. (241) 183
Fukutake, K., see Mizuguchi, K. (231) 121
Funder, J.W., see Jefferys, D.E. (239) 189
Fung, K.-P., see Zielenski, J. (248) 313
Furman, B.L. and Sneddon, P.
Endothelium-dependent vasodilator responses of the isolated mesenteric bed are preserved in long-term streptozotocin diabetic rats (232) 29
Fürst, Z., Búzás, B., Friedmann, T., Schmidhammer, H. and Borsodi, A.
Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series (236) 209
Furuichi, A., see Isono, T. (246) 205
Furukawa, S., Satoh, K. and Taira, N.
Opening of ATP-sensitive $K^+$ channels responsible for adenosine $A_2$ receptor-mediated vasodepression does not involve a pertussis toxin-sensitive G protein (236) 255
Furukawa, Y., see Takayama, S. (231) 315
Furuya, T., see Nakagawa, N. (235) 211
Fusi, F., see Sgaragli, G.P. (248) 121
Fuxe, K., see Ferré, S. (244) 311
Fuxe, K., see Li, X.-M. (234) 125
Fuxe, K., see Martire, M. (230) 231
Fuxe, K., see Tanganelli, S. (230) 159

Gagnon, R.C., see Smith III, E.F. (236) 477
Gagov, H.S., Duridanova, D.B. and Boev, K.K.
Inhibition of $Ca^{2+}$ current in ileal cells by cyclopiazonic acid and ryanodine (243) 19
Galligan, J.J., see Minocha, A. (230) 187
Gamse, R., see Beubler, E. (248) 157
Gandía, L., see López, M.G. (247) 199
Gao, X.-M., Shirakawa, O., Du, F. and Tamminga, C.A.
Delayed regional metabolic actions of phencyclidine (241) 7
Gao, X.-M., see Chang, Y.-F. (233) 209
Garattini, S., see Caccia, S. (233) 71
Garattini, S., see Mennini, T. (241) 255
Garbay-Jaureguiberry, C., see Pasquini, F. (243) 39
García, A.G., see De la Fuente, M.-T. (229) 189
García, A.G., see López, M.G. (247) 199
García, A.G., see Montiel, C. (230) 77

García, A.G., see Moro, M.A. (246) 213
García, A.G., see Priego, J. (243) 25
García, F., see Martínez, F. (248) 199
Garcia, M.L., see Huang, J.-C. (235) 37
García-Sancho, J., see López, M.G. (247) 199
García-Sevilla, J.A., see Miralles, A. (243) 305
García-Sevilla, J.A., see Olmos, G. (236) 467
García-Sevilla, J.A., see Ugedo, L. (239) 149
Garcia Ruiz, A.J., Zambelli, M., La Porta, C., Ladinsky, H. and Consolo, S.
Differences between rat dorsal and ventral hippocampus in muscarinic receptor agonist binding and interaction with phospholipase C (244) 125
Gardiner, P.J., Norman, P., Cuthbert, N.J., Tudhope, S.R. and Abram, T.S.
Characterisation of the peptido-leukotriene receptor PL2 on the ferret spleen strip (238) 19
Gardiner, P.J., see Norman, P. (229) 171
Garg, U.C. and Hassid, A.
Mechanisms of nitrosothiol-induced antimitogenesis in aortic smooth muscle cells (237) 243
Garges, P.L., see Pucilowski, O. (240) 89
Gargouil, Y.-M., see Gohar, M. (229) 69
Garland, C.J., see Clark, A.H. (235) 113
Garner, C., Feniuk, W. and Brown, P.D.
Serotonin activates $Cl^-$ channels in the apical membrane of rat choroid plexus epithelial cells (239) 31
Garreau, M., see Angel, I. (232) 139
Garret, C., see Hermans, E. (245) 43
Garret, C., see Moussaoui, S.M. (238) 421
Garro, M.A., see Olmos, G. (236) 467
Garro, M.A., see Ugedo, L. (239) 149
Gater, P.R., Paciorek, P.M., McKean, J.C., Wilson, K., Brewster, M. and Waterfall, J.F.
The inhibitory effects of Ro 31-6930 and BRL 38227 on cholinergically mediated bronchoconstriction in the guinea-pig (238) 59
Gaudry-Talarmain, Y.M., see Moulian, N. (231) 407
Gaudy, F., see Langlois, M. (244) 77
Gayet, J., see Ginefri-Gayet, M. (235) 189
Geboes, K., see Nijs, G. (239) 241
Gee, K.W., see Finn, D.A. (247) 233
Gee, N.S., see Thurlow, R.J. (247) 341
Gemignani, A., see Lanza, M. (237) 191
Genazzani, A.A., see Nicoletti, F. (245) 297
Georgiev, V., see Johansson, B. (247) 103
Geppetti, P., see Huber, O. (239) 103
Geppetti, P., see Yamawaki, I. (243) 1
Gerlach, J., see Peacock, L. (237) 329
Gerzer, R., see Ivanova, K. (244) 37
Gerzer, R., see Menshikov, M.Y. (245) 281
Gessa, G.L., see Diana, M. (230) 363
Gessa, G.L., see Imperato, A. (229) 265
Gessa, G.L., see Imperato, A. (238) 135
Gessa, G.L., see Imperato, A. (238) 377
Gessa, G.L., see Rossetti, Z.L. (231) 203
Gessa, G.L., see Rossetti, Z.L. (242) 313
Giachetti, A., see Maggi, C.A. (234) 83
Giagnoni, G., see Massi, P. (243) 65
Gibb, W.R.G., see Rose, S. (230) 177
Gibbs, A.H., see Heijink, E. (248) 15
Gibbs, T.T., see Wu, F.-S. (246) 239
Gibson, E.L., Kennedy, A.J. and Curzon, G.
d-Fenfluramine- and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors (242) 83
Giembycz, M.A., see Rabe, K.F. (231) 305
Gies, J.-P., see Trifilieff, A. (239) 227
Gifford, A.N. and Johnson, K.M.
A pharmacological analysis of the effects of (+)-AJ 76 and (+)-UH 232 at release regulating pre- and postsynaptic dopamine receptors (237) 169
Gil-Longo, J., Dufour, M.N., Guillon, G. and Lugnier, C.
G proteins in aortic endothelial cells and bradykinin-induced formation of nitric oxide (247) 119
Gill, J., see Jeremy, J.Y. (245) 67
Gillis, R.A., see Abrahams, T.P. (238) 223
Gilmore, J., see Boot, J.R. (231) 83
Gilmore, J.H., see Watts, V.J. (242) 165
Ginefri-Gayet, M. and Gayet, J.
Hypothermia induced by infusion of methionine sulfoximine into the dorsal raphe nucleus of the rat: involvement of $5\text{-HT}_{1A}$ and $GABA_B$ receptors (235) 189
Giorgi, O., Pibiri, M.G., Loi, R. and Corda, M.G.
Chronic treatment with SCH 23390 increases the production rate of dopamine $D_1$ receptors in the nigro-striatal system of the rat (245) 139
Giralt, M.T., see Olmos, G. (236) 467
Giralt, M.T., see Ugedo, L. (239) 149
Gispen, W.-H., see Hamers, F.P.T. (233) 177
Gitter, B.D., see Picard, P. (232) 255
Giudice, A., see Bachy, A. (237) 299
Giudicelli, J.-F., see Dumas, M. (239) 141
Giuliani, S., see Maggi, C.A. (234) 83
Giuliani, S., see Maggi, C.A. (235) 309
Giuliani, S., see Maggi, C.A. (240) 45
Glaser, T., see Baudrie, V. (231) 395
Glaser, T., see Sommermeyer, H. (240) 29
Glatt, H., see Schmalix, W.A. (248) 251
Glavin, G.B. and Szabo, S.
Effects of the $Ca^{2+}$ chelators EGTA and EDTA on ethanol- or stress-induced gastric mucosal lesions and gastric secretion (233) 269
Gleeson, S., Weissman, B.A., Seggel, M.R. and Barrett, J.E.
Neurochemical effects of $5\text{-HT}_1$ receptor ligands in pigeons (229) 109
Glenthøj, B., Bolwig, T.G. and Hemmingsen, R.
Effects of chronic discontinuous and continuous treatment of rats with a dopamine $D_1$ receptor antagonist (NNC-756) (242) 283
Glenthøj, B., Hemmingsen, R., Barry, D.I., Allerup, P., Bruhn, T. and Bolwig, T.G.
Electrical kindling of rats treated discontinuously or continuously with haloperidol (236) 401
Glock, D., see Kohli, J.D. (235) 31
Glowinski, J., see Petitet, F. (247) 185
Gobbi, M., Frittoli, E., Uslenghi, A. and Mennini, T.
Evidence of an exocytotic-like release of [$^3$H]5-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes (238) 9
Gobbi, M., see Mennini, T. (241) 255
Gobert, A., see Lejeune, F. (240) 307
Gobert, A., see Millan, M.J. (230) 99
Godfraind, T., see Dessy, C. (231) 435
Goethals, M., see Van Bogaert, P.P. (229) 55
Gohar, M., Daleau, P., Atkinson, J. and Gargouil, Y.-M.
Ultradian variations in sensitivity of rat aorta rings to noradrenaline (229) 69
Gold, L.H. and Balster, R.L.
Effects of NMDA receptor antagonists in squirrel monkeys trained to discriminate the competitive NMDA receptor antagonist NPC 12626 from saline (230) 285
Goldberg, R., see Hilakivi-Clarke, L.A. (237) 101
Goldberg, S.R., see Heidbreder, C. (243) 123

Goldhill, J., Zhao, L., Xu, Y., Donovan, V. and Burakoff, R.
Defective stimulation of cyclic AMP by prostaglandin $E_2$ in colonic epithelial cells in colitis (238) 387
Goldman, D., see Hulihan-Giblin, B.A. (239) 99
Golombek, D.A., Martini, M. and Cardinali, D.P.
Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system (237) 231
Gonalons, N., see Didier, M. (244) 57
Gonon, F., see Brun, P. (235) 205
Gonzalez, F., see Schmalix, W.A. (248) 251
González-Morales, M.A., see Priego, J. (243) 25
González, P., see Planas, M.E. (237) 251
González, P., see Tejerina, T. (239) 75
Goosen, C., see Vermeulen, R.J. (235) 143
Gori, E., see Parolaro, D. (244) 211
Gorostiza, P., see Guarner, V. (237) 139
Gorski, J., see Namiot, Z. (243) 301
Goto, K., see Hayakawa, A. (239) 219
Götz, E., see Mondeh, J.D. (240) 39
Götz, M., see Deckert, J. (238) 131
Gouardères, C., Sutak, M., Zajac, J.-M. and Jhamandas, K.
Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat (237) 73
Gozlan, H., see Bachy, A. (237) 299
Gozlan, H., see Kidd, E.J. (247) 45
Graham, A.M. and Sneddon, P.
Evidence for nitric oxide as an inhibitory neurotransmitter in rabbit isolated anococcygeus muscle (237) 93
Graham, D., see Faure-Halley, C. (246) 283
Grahame-Smith, D., see Grasby, P. (230) 41
Grahame-Smith, D.G., see Pei, Q. (230) 63
Grant, K.A., see Ator, N.A. (241) 237
Grasby, P., Sharp, T., Moorman, J. and Grahame-Smith, D.
Comparison of the effect of buspirone and 1-(2-pyrimidinyl)-piperazine on cerebral glucose utilization in the rat (230) 41
Grassi, F., see Intorre, L. (243) 265
Gratton, J.-P., see Télémaque, S. (237) 275
Grau-Oliete, M.R., see Domènech, C. (248) 49
Gregersen, S., Lindskog, S., Land, T., Langel, Ü., Bartfai, T. and Ahrén, B.
Blockade of galanin-induced inhibition of insulin secretion from isolated mouse islets by the non-methionine containing antagonist M35 (232) 35
Grégoire, L., see Hamel, E. (242) 75
Greim, H., see Schmalix, W.A. (248) 251
Greiner, K., see Olpe, H.-R. (233) 179
Greney, H., see Bennai, F. (246) 45
Grenhoff, J. and Svensson, T.H.
Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area (233) 79
Greuel, J.M., see Sommermeyer, H. (240) 29
Griffiths, R.R., see Ator, N.A. (241) 237
Grigoriadis, D.E., see Levant, B. (246) 171
Grima, M., see Michel, B. (242) 237
Grimes, D., Sturm, R.J., Marinari, L.R., Carlson, R.P., Berkenkopf, J.W., Musser, J.H., Kreft, A.F. and Weichman, B.M.
WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity (236) 217
Grimes, D., see Heaslip, R.J. (234) 247
Grisar, J.M., see Lukovic, L. (233) 63
Griswold, D.E., see Smith III, E.F. (236) 477
Grondin, L., see Dewar, K.M. (235) 137
Groppetti, A., see Massi, P. (243) 65
Gross, R., see Bertrand, G. (237) 45
Gross, R., see Skoglund, G. (236) 69
Grosset, A., see Angel, I. (234) 137
Grosset, A., see Lorrain, J. (229) 105
Gruetter, C.A., see Szarek, J.L. (231) 339
Grundemar, L., Krstenansky, J.L. and Håkanson, R.
Activation of neuropeptide $Y_1$ and neuropeptide $Y_2$ receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes (232) 271
Gryglewski, R.J., see Chłopicki, S. (241) 117
Gryglewski, R.J., see Korbut, R. (234) 17
Gsell, W., see Deckert, J. (238) 131
Gu, J.-L., see Yue, T.-L. (240) 81
Gu, X.F. and Azmitia, E.C.
Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons (235) 51
Gu, Z.-Q., see Wong, G. (247) 57
Guantes, J.M., see De la Fuente, M.-T. (229) 189
Guard, S., Pain, D., Franks, R. and Watling, K.J.
[$^{125}$I]Neurokinin A labels pharmacologically distinct populations of $NK_2$ binding sites in hamster and rabbit urinary bladder (232) 287
Guard, S., Pain, D., Franks, R. and Watling, K.J.
[$^{125}$I]Neurokinin A labels pharmacologically distinct populations of $NK_2$ binding sites in hamster and rabbit urinary bladder. European Journal of Pharmacology, 232 (1993) 287–290 (236) 496
Guard, S., Watling, K.J. and Howson, W.
Structure-activity requirements of bombesin for gastrin-releasing peptide- and neuromedin B-preferring bombesin receptors in rat brain (240) 177
Guarner, V., Hernández, E.H., Huerto, R., Gorostiza, P. and Valenzuela, F.
Trifluoperazine inhibition of insulin-induced increase in skeletal muscle glucose uptake (237) 139
Gubitz, C., see Eltze, M. (238) 343
Gué, M., Alary, C., Del Rio-Lacheze, C., Junien, J.L. and Buéno, L.
Comparative involvement of 5-$HT_1$, 5-$HT_2$ and 5-$HT_3$ receptors in stress-induced colonic motor alterations in rats (233) 193
Gueudet, C., see Santucci, V. (237) 143
Guez, D., see Chan, P. (231) 175
Guggino, W.B., see Kusama, T. (245) 83
Guida, G., see Tubaro, E. (248) 175
Guilarte, T.R., Miceli, R.C., Altmann, L., Weinsberg, F., Winneke, G. and Wiegand, H.
Chronic prenatal and postnatal $Pb^{2+}$ exposure increases [$^3$H]MK801 binding sites in adult rat forebrain (248) 273
Guilbaud, G., see Perrot, S. (241) 129
Guillemette, G., see Poitras, M. (244) 203
Guillén, J., see Luquin, M.R. (235) 297
Guillon, G., see Gil-Longo, J. (247) 119
Guillonneau, C., see Iliou, J.-P. (248) 263
Guirimand, F., see Strimbu-Gozariu, M. (237) 197
Gulati, A. and Srimal, R.C.
Endothelin antagonizes the hypotension and potentiates the hypertension induced by clonidine (230) 293
Gulati, A., Arora, R.C. and Crayton, J.
Central serotonergic uptake mechanisms in hypertensive rats: effects of clonidine and centhaquin (231) 151
Gulati, A., see Rebello, S. (237) 9
Gullo, M., see Cattaneo, M.G. (247) 325
Gully, D., Fréhel, D., Marcy, C., Spinazzé, A., Lespy, L., Neliat, G., Maffrand, J.-P. and Le Fur, G.
Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of $CCK_A$ receptors (232) 13
Guo, J., see Kostrzewa, R.M. (239) 183
Guo, L., see Singewald, N. (240) 21
Guo, X., Ohno, Y. and Takanaka, A.
Inhibition of hepatocyte gap junctional communication by 25-hydroxycholesterol may be mediated through free radicals (248) 337
Gurling, J., see Routledge, C. (239) 195

Gustafsson, B.I. and Delbro, D.S.
Motor effects of indomethacin, morphine or vagal nerve stimulation on the feline small intestine in vivo (230) 1
Gustafsson, L.E., see Wiklund, C.U. (240) 235
Gustafsson, T., see Carrington, A.L. (237) 257
Guth, P.H., see Tanaka, T. (243) 221
Gutkowska, J., Strick, D.M., Pan, L. and McCann, S.M.
Effect of morphine on urine output: possible role of atrial natriuretic factor (242) 7
Gwilt, M., Norton, B. and Henderson, C.G.
Pharmacological studies of $K^+$ loss from ischaemic myocardium in vitro: roles of ATP-dependent $K^+$ channels and lactate-coupled efflux (236) 107

Haaseth, R.C., see Wild, K.D. (246) 25
Habara, Y., see Busik, J. (247) 273
Hacksell, U., see Yu, H. (231) 69
Haefely, W.E., see Jenck, F. (231) 223
Haensel, S.M., Mos, J., Van der Schoot, P. and Slob, A.K.
Testosterone is required for the stimulatory effects of 8-OH-DPAT on sexual behavior in castrated male rats (233) 187
Hagan, R.M., see Suzuki, H. (241) 105
Hagane, K., see Temma, K. (234) 173
Hagino, Y., see Nomura, T. (246) 113
Hagiwara, D., see Murai, M. (236) 7
Hagiwara, S., Mitsui, M. and Karaki, H.
Effects of felodipine, nifedipine and verapamil on cytosolic $Ca^{2+}$ and contraction in vascular smooth muscle (234) 1
Haigh, R.M., see Van Meel, J.C.A. (233) 295
Haigh, R.M., see Van Meel, J.C.A. (247) 357
Håkanson, R., see Grundemar, L. (232) 271
Hakkola, J., see Salonpää, P. (248) 95
Haldeman, B., see Thomsen, C. (244) 187
Hall, A.S., Bryson, S.E., Ball, S.G. and Balmforth, A.J.
Phenoxybenzamine mediated inhibition of the vascular dopamine $D_1$ receptor (247) 249
Hall, I.P., see Daykin, K. (246) 135
Halonen, M., see Witt-Enderby, P.A. (241) 121
Hamada, T., see Shibata, S. (231) 381
Hamamura, T. and Fibiger, H.C.
Enhanced stress-induced dopamine release in the prefrontal cortex of amphetamine-sensitized rats (237) 65
Hamel, E., Grégoire, L. and Lau, B.
5-$HT_1$ receptors mediating contraction in bovine cerebral arteries: a model for human cerebrovascular '5-$HT_{1D\beta}$' receptors (242) 75
Hamers, F.P.T., Pette, C., Neijt, J.P. and Gispen, W.-H.
The ACTH-(4–9) analog, ORG 2766, prevents taxol-induced neuropathy in rats (233) 177
Hamilton, C.A., Jardine, E. and Reid, J.L.
Down-regulation of imidazoline sites in rabbit kidney (243) 95
Hammond, D.L. and Bloss, J.L.
Antinociceptive effects of SC-39566, an opioid dipeptide arylalkylamide, in the Rhesus monkey (231) 281
Hammond, D.L. and Moy, M.L.
Actions of 4-amino-3-(5-methoxybenzo(b)furan-2-yl) butanoic acid and 4-amino-3-benzo(b)furan-2-yl butanoic acid in the rat spinal cord (229) 227
Hammond, D.L. and Washington, J.D.
Antagonism of L-baclofen-induced antinociception by CGP 35348 in the spinal cord of the rat (234) 255
Hammond, J.R., see Jones, K.W. (246) 97
Hamon, M., see Bachy, A. (237) 299
Hamon, M., see Kidd, E.J. (247) 45
Hamosh, P., see Abrahams, T.P. (238) 223
Hamra, M. and Rosen, M.R.
The influence of pH on the use-dependent effects of lidocaine in adult and neonatal canine Purkinje fibers (230) 167
Hamra, M. and Rosen, M.R.
The influence of pH on the use-dependent effects of lidocaine in adult and neonatal canine Purkinje fibers. European Journal of Pharmacology, 230 (1993) 167–175 (236) 497
Han, J.-S., see Zhou, Y. (234) 147
Haneda, M., see Koya, D. (245) 79
Hanrahan, S.M., see Jagust, W.J. (242) 189
Hansen, J.J., see Madsen, U. (230) 383
Hara, S., see Iwata, N. (248) 243
Harada, K., see Ohta, H. (231) 323
Harada, M., see Arimura, A. (231) 13
Harris, J. and Clarke, R.W.
Motor and cardiovascular effects of selective $\alpha_2$-adrenoceptor antagonists in the decerebrated rabbit (237) 323
Harris, P.D., see Alsip, N.L. (229) 117
Harrison, S., Milner, R. and Boyett, M.
Influence of $Ca^{2+}$ channel agonists and antagonists on the post-rest staircase (237) 83
Harrison, S., see Cannings, I. (248) 213
Hartman, J.C., Hullinger, T.G., Wall, T.M. and Shebuski, R.J.
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition (234) 229
Hartnett, K.A., see Reynolds, I.J. (244) 175
Haruno, A. and Hashimoto, K.
Antiarrhythmic effects of bisaramil in canine models of ventricular arrhythmia (233) 1
Haruno, A., see Matsuzaki, T. (231) 363
Hasegawa, M., see Osada, Y. (241) 183
Hasegawa, S., see Nomura, T. (246) 113
Hashimoto, K. and London, E.D.
Further characterization of [$^3$H]ifenprodil binding to $\sigma$ receptors in rat brain (236) 159
Hashimoto, K., see Haruno, A. (233) 1
Hashimoto, K., see Matsuzaki, T. (231) 363
Hashimoto, S., Kigoshi, S. and Muramatsu, I.
Nitric oxide-dependent and -independent neurogenic relaxation of isolated dog urethra (231) 209
Hashimoto, S., see Ukai, M. (239) 237
Hashimoto, T., see Hirouchi, M. (247) 127
Haskins, J.T., see Fletcher, A. (237) 283
Hass, P., see Fischer, S. (232) 121
Hassid, A., see Garg, U.C. (237) 243
Hassinen, I.E., see Uusimaa, P.A. (242) 199
Hata, F., see Fukunaga, Y. (233) 237
Hata, F., see Yoshikawa, S. (239) 261
Hatake, K., Wakabayashi, I. and Hishida, S.
Mechanism of inhibitory action of ethanol on endothelium-dependent relaxation in rat aorta (238) 441
Hatake, K., see Masui, H. (248) 103
Hatase, O., see Fujisawa, M. (238) 127
Hatem, S., see Le Grand, B. (229) 91
Hatmi, M., see Desquand, S. (235) 101
Hauck Newman, A., see Izenwasser, S. (243) 201
Häussinger, D., see Wöll, E. (246) 269
Hawkins, L.M., see Beer, M.S. (236) 167
Hawley, S.B., see Woodward, D.F. (230) 327
Hawthorn, M.H., Ferrante, J.N., Kwon, Y.W., Rutledge, A., Luchowski, E., Bangalore, R. and Triggle, D.J.
Effect of an homologous series of aliphatic alcohols on neuronal and smooth muscle voltage-dependent $Ca^{2+}$ channels (229) 143

Hawthorn, M.H., see Kim, W.-K. (247) 89
Hayakawa, A., Kawanishi, M., Ishikawa, N., Shimada, Y. and Goto, K.
Different mode of action of endothelin-1 in parietal and visceral veins (239) 219
Hayakawa, M., see Asano, M. (247) 295
Hayashi, A., see Oyama, Y. (248) 89
Haylett, D.G., see Castle, N.A. (236) 201
Hayward, N.J., McKnight, A.T. and Woodruff, G.N.
Brain temperature and the neuroprotective action of enadoline and dizocilpine in the gerbil model of global ischaemia (236) 247
He, H., see Tamaki, T. (236) 15
Heaslip, R.J., Grimes, D., Berkenkopf, J.W., Ilsemann, B.A., Sickels, B.D. and Weichman, B.M.
Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues (234) 247
Heath, A.R., see Potter, D.E. (236) 61
Heath, I., see Shannon, H.E. (232) 47
Héaulme, M., see Bachy, A. (237) 299
Héaulme, M., see Didier, M. (244) 57
Heckendorn, R., see Benke, D. (246) 179
Hedlund, P.B., see Li, X.-M. (234) 125
Heffner-Lauc, M., see Müller, W.E.G. (246) 261
Hegedüs, K., Fekete, I. and Molnár, L.
Effects of dipyridamole in spontaneously hypertensive rabbits with diffuse chronic cerebral ischemia (237) 293
Heidbreder, C., Goldberg, S.R. and Shippenberg, T.S.
Inhibition of cocaine-induced sensitization by the δ-opioid receptor antagonist naltrindole (243) 123
Heijink, E., De Matteis, F., Gibbs, A.H., Davies, A. and White, I.N.H.
Metabolic activation of halothane to neoantigens in C57Bl/10 mice: immunochemical studies (248) 15
Heijna, M.H., Bakker, J.M., Hogenboom, F., Mulder, A.H. and Schoffelmeer, A.N.M.
Opioid receptors and inhibition of dopamine-sensitive adenylate cyclase in slices of rat brain regions receiving a dense dopaminergic input (229) 197
Heilig, M., Engel, J.A. and Söderpalm, B.
*C-fos* antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine (236) 339
Heilporn, S., see Boeynaems, J.-M. (233) 13
Heisler, S., see Pon, D.J. (245) 119
Hemming, H., Flodström, S., Wärngård, L., Bergman, Å., Kronevi, T., Nordgren, I. and Ahlborg, U.G.
Relative tumour promoting activity of three polychlorinated biphenyls in rat liver (248) 163
Hemmingsen, R., see Glenthøj, B. (236) 401
Hemmingsen, R., see Glenthøj, B. (242) 283
Henderson, A.K., Roeske, W.R., Smith, T.L. and Yamamura, H.I.
Desensitization of neurokinin A receptors expressed by B82 fibroblasts (245) 75
Henderson, C.G., see Gwilt, M. (236) 107
Henderson, C.G., see Tweedie, D. (240) 251
Hennemann, A., see Deckert, J. (238) 131
Hepner, B.C., see Pomerantz, S.M. (243) 227
Herman, A.G., see Van Diest, M.J. (231) 267
Hermán, F., Yano, M. and Filep, J.G.
The in vivo antiaggregatory action of endothelin-1 is not mediated through the endothelin $ET_A$ receptor (236) 143
Hermans, E., Jeanjean, A.P., Fardin, V., Pradier, L., Garret, C., Laduron, P.M., Octave, J.-N. and Maloteaux, J.-M.
Interaction of the substance P receptor antagonist RP 67580 with the rat brain $NK_1$ receptor expressed in transfected CHO cells (245) 43
Hernández, E.H., see Guarner, V. (237) 139
Hertting, G., see Lauth, D. (236) 165
Herz, A., see Członkowski, A. (242) 229
Hess, M.L., see Okabe, E. (248) 33
Hibbs, M.J., see Smith III, E.F. (236) 477
Hibert, M.F., see Huggins, J.P. (245) 203
Hidi, R., see Tesson, F. (248) 27
Hidi, R., see Tesson, F. (248) 351
Hietala, J., see Kuoppamäki, M. (245) 179
Higa, A., McKnight, G.W. and Wallace, J.L.
Attenuation of epithelial injury in acute experimental colitis by immunomodulators (239) 171
Higenbottam, T.W., see Pepke-Zaba, J. (235) 169
Higuchi, M., Uezu, K. and Sakanashi, M.
Ex vivo effect of insulin on normal and diabetic rat hearts hypoperfused with norepinephrine (242) 293
Hikasa, Y., Akiba, T., Iino, Y., Matsukura, M., Takase, K. and Ogasawara, S.
Central α-adrenoceptor subtypes involved in the emetic pathway in cats (229) 241
Hilakivi-Clarke, L.A. and Goldberg, R.
Effects of tryptophan and serotonin uptake inhibitors on behavior in male transgenic transforming growth factor α mice (237) 101
Hill, D.R., Suman-Chauhan, N. and Woodruff, G.N.
Localization of [$^3$H]gabapentin to a novel site in rat brain: autoradiographic studies (244) 303
Hill, D.R., see Suman-Chauhan, N. (244) 293
Hill, D.R., see Thurlow, R.J. (247) 341
Hill, J.L., see Aulakh, C.S. (240) 85
Hillegass, L.M., see Smith III, E.F. (236) 477
Himes, C.S., see Tang, A.H. (236) 1
Hirai, K., see Miyamoto, M. (238) 181
Hiramatsu, M., see Fuji, K. (236) 411
Hiramatsu, M., see Ishihara, S.-i. (230) 313
Hirano, K., Hirano, M. and Kanaide, H.
Enhancement by captopril of bradykinin-induced calcium transients in cultured endothelial cells of the bovine aorta (244) 133
Hirano, M., see Hirano, K. (244) 133
Hirano, S.-i., see Temma, K. (234) 173
Hirata, Y., Takiguchi, Y., Wada, K., Matsuno, H., Umemura, K., Uematsu, T. and Nakashima, M.
Roles of platelet-activating factor, thromboxane $A_2$, ADP and thrombin in thrombogenesis in the guinea pig (231) 421
Hirobe, M., see Tateyama, M. (240) 51
Hirobe, M., see Watanabe, H. (243) 155
Hirose, H., see Noguchi, K. (233) 47
Hirota, K., see Nagakawa, J.-i. (229) 63
Hirouchi, M., Hashimoto, T. and Kuriyama, K.
Alteration of $GABA_A$ receptor $\alpha_1$-subunit mRNA in mouse brain following continuous ethanol inhalation (247) 127
Hisa, H., see Ogasawara, A. (243) 103
Hisaki, K., Matsumura, Y., Nishiguchi, S., Fujita, K., Takaoka, M. and Morimoto, S.
Endothelium-independent pressor effect of big endothelin-1 and its inhibition by phosphoramidon in rat mesenteric artery (241) 75
Hisamoto, M., see Itoh, K. (237) 215
Hishida, S., see Hatake, K. (238) 441
Hishinuma, I., see Nagakawa, J.-i. (229) 63
Hjorth, S. and Pettersson, G.
5-$HT_{1A}$ autoreceptor-mediated effects of the amperozide congeners, FG5865 and FG5893, on rat brain 5-hydroxytryptamine neurochemistry in vivo (238) 357
Hjorth, S., see Söderpalm, B. (239) 69
Hmaidan, Y., see Rossetti, Z.L. (231) 203
Hmaidan, Y., see Rossetti, Z.L. (242) 313
Ho, C.-L., see Song, D.-L. (247) 283
Ho, I.K., see Jaw, S.P. (239) 133
Ho, I.K., see Jaw, S.P. (240) 67
Ho, I.K., see Tseng, Y.T. (236) 23

Höcker, M., Hughes, J., Fölsch, U.R. and Schmidt, W.E.
PD 135158, a $CCK_B$/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a $CCK_A$ receptor agonist (242) 105
Hodgkiss, J.P., Sherriffs, H.J., Cottrell, D.A., Shirakawa, K., Kelly, J.S., Kuno, A., Ohkubo, M., Butcher, S.P. and Olverman, H.J.
Neurochemical and electrophysiological studies on FR115427, a novel non-competitive NMDA receptor antagonist (240) 219
Hodgson, W.C., see Sikorski, B.W. (242) 275
Hoey, A., Lehmkuhl, A., Sadony, V. and Ravens, U.
Inotropic actions of BDF 9148 and DPI 201-106 and their enantiomers in guinea-pig, rat and human atria (231) 477
Hoffer, P.B., see Laruelle, M. (230) 119
Hoffman, P.L., see Iorio, K.R. (248) 209
Hoflack, J.M., see Huggins, J.P. (245) 203
Hofman, G., see Van Oosterhout, A.J.M. (236) 379
Hofman, G., see Van Oosterhout, A.J.M. (239) 277
Högberg, T., see Mohell, N. (238) 121
Hogenboom, F., see Heijna, M.H. (229) 197
Hogenboom, F., see Tjon Tien Ril, H.K.G. (235) 321
Hökfelt, T., see Meister, B. (247) 229
Holsboer, F., see Rupprecht, R. (247) 145
Holtzman, S.G., see Woolfolk, D.R. (239) 177
Holzer, P., see Lippe, I.T. (232) 113
Hönack, D., see Löscher, W. (232) 147
Hönack, D., see Löscher, W. (234) 237
Hönack, D., see Löscher, W. (238) 191
Hönack, D., see Löscher, W. (242) 99
Hönack, D., see Löscher, W. (242) 263
Honda, A., Mori, Y., Ikekawa, N. and Raz, A.
Manipulation of thromboxane synthesis by novel 26,27-dialkyl analogues of $1\alpha$,25-dihydroxyvitamin $D_3$ in human promyelocytic leukemia (HL-60) cells (229) 217
Hong, E., see Castillo, C. (241) 141
Hong, E., see Villalón, C.M. (240) 9
Hong, K.W., Park, M.G., Shin, Y.W., Rhim, B.Y. and Ko, K.H.
Effect of ouabain on relaxation induced by cromakalim in human and canine mesenteric arteries (231) 1
Honig, W., see Blokland, A. (235) 275
Honoré, T., see Suzdak, P.D. (245) 215
Honscha, W., Schulz, K., Müller, D. and Petzinger, E.
Two different mRNAs from rat liver code for the transport of bumetanide and taurocholate in *Xenopus laevis* oocytes (246) 227
Hoof, T., Demmer, A., Christians, U. and Tümmler, B.
Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin (246) 53
Hope, A.G., Downie, D.L., Sutherland, L., Lambert, J.J., Peters, J.A. and Burchell, B.
Cloning and functional expression of an apparent splice variant of the murine 5-$HT_3$ receptor A subunit (245) 187
Hope, P.J., see Fleetwood-Walker, S.M. (242) 173
Hopkins, P.C., see Steward, L.J. (242) 137
Hoque, A.N.E., Nasa, Y. and Abiko, Y.
Cardioprotective effect of d-propranolol in ischemic-reperfused isolated rat hearts (236) 269
Horan, P.J. and Porreca, F.
Lack of cross-tolerance between U69,593 and bremazocine suggests $\kappa$-opioid receptor multiplicity in mice (239) 93
Horan, P.J., Wild, K.D., Kazmierski, W.M., Ferguson, R., Hruby, V.J., Weber, S.J., Davis, T.P., Fang, L., Knapp, R.J., Yamamura, H.I., Kramer, T.H., Burks, T.F., Bowen, W.D., Takemori, A.E. and Porreca, F.
Unexpected antinociceptive potency of cyclic [D-$Tca^1$]CTAP: potential for a novel mechanism of action (233) 53
Horan, P.J., see Wild, K.D. (246) 25
Hori, M., see Karaki, H. (231) 371
Hori, M., see Sudjarwo, S.A. (229) 137
Horie, S., Yano, S. and Watanabe, K.
Effects of drugs acting on $Cl^-$-$HCO_3^-$ and $Na^+$-$H^+$ exchangers on acid secretion in the rat gastric mucosa sheet preparation (229) 15
Horiuchi, A., Iwatsuki, K., Ren, L.-M., Kuroda, T. and Chiba, S.
Dual actions of glucagon: direct stimulation and indirect inhibition of dog pancreatic secretion (237) 23
Horn, P.T., see Kohli, J.D. (235) 31
Horváth, E.J., Hudák, J., Palkovits, M., Lenkei, Z., Fekete, M.I.K. and Arányi, P.
A novel specific binding site for homophthalazines in the rat brain (236) 151
Hoshi, K., see Okawa, T. (230) 341
Hoskins, B., see Jaw, S.P. (239) 133
Hoskins, B., see Jaw, S.P. (240) 67
Howbert, J.J., see Picard, P. (232) 255
Howson, W., see Guard, S. (240) 177
Hoy, K., see Marley, P.D. (244) 7
Hoyer, D., see Schoeffter, P. (244) 251
Hruby, V.J., see Horan, P.J. (233) 53
Hruby, V.J., see Wild, K.D. (246) 25
Hsieh, L.-M., see Huang, H.-C. (237) 39
Hu, P., see Chan, P. (231) 175
Hu, S. and Kim, H.S.
Activation of $K^+$ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid (230) 215
Huang, G.-F., Besson, J.-M. and Bernard, J.-F.
Morphine depresses the transmission of noxious messages in the spino(trigemino)-ponto-amygdaloid pathway (230) 279
Huang, G.-F., Besson, J.-M. and Bernard, J.-F.
Intravenous morphine depresses the transmission of noxious messages to the nucleus centralis of the amygdala (236) 449
Huang, H.-C., Lai, M.-W., Wang, H.-R., Chung, Y.-L., Hsieh, L.-M. and Chen, C.-C.
Antiproliferative effect of esculetin on vascular smooth muscle cells: possible roles of signal transduction pathways (237) 39
Huang, J.-C., Garcia, M.L., Reuben, J.P. and Kacsorowski, G.J.
Inhibition of $\beta$-adrenoceptor agonist relaxation of airway smooth muscle by $Ca^{2+}$-activated $K^+$ channel blockers (235) 37
Huang, K.-X., see Sun, B.-C. (231) 331
Huang, T.-F., see Teng, C.-M. (233) 7
Huang, X. and Nichols, D.E.
5-$HT_2$ receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits (238) 291
Huang, X., Marona-Lewicka, D. and Nichols, D.E.
p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent (229) 31
Huang, Z.-S., see Yu, S.-M. (248) 289
Huber, O., Bertrand, C., Bunnett, N.W., Pellegrini, C.A., Nadel, J.A., Nakazato, P., Debas, H.T. and Geppetti, P.
Tachykinins mediate contraction of the human lower esophageal sphincter in vitro via activation of $NK_2$ receptors (239) 103
Huber, O., see Yamawaki, I. (243) 1
Huchet, C. and Léoty, C.
Effects of cyclopiazonic acid on $Ca^{2+}$-activated tension production in skinned skeletal muscle fibres of the ferret (241) 41
Hudák, J., see Horváth, E.J. (236) 151
Hudkins, R.L., Stubbins, J.F. and DeHaven-Hudkins, D.L.
Caramiphen, iodocaramiphen and nitrocaramiphen are potent, competitive, muscarinic $M_1$ receptor-selective agents (231) 485
Hudson, G.M., see Young, G.A. (231) 473
Hudzik, T.J., De Costa, B.R. and McMillan, D.E.
$\sigma$ Receptor-mediated emetic response in pigeons: agonists, antagonists and modifiers (236) 279
Huerto, R., see Guarner, V. (237) 139

Huether, G., Poeggeler, B., Adler, L. and Rüther, E.
Effects of indirectly acting 5-HT receptor agonists on circulating melatonin levels in rats (238) 249
Huggins, J.P., Trumpp-Kallmeyer, S., Hibert, M.F., Hoflack, J.M., Fanger, B.O. and Jones, C.R.
Modelling and modification of the binding site of endothelin and other receptors (245) 203
Hughes, J., see Höcker, M. (242) 105
Huidobro-Toro, J.P., see Domenech, R. (238) 53
Huidobro-Toro, J.P., see Donoso, M.V. (240) 93
Huijberts, M., Wolffenbuttel, B., Crijns, F., Nieuwenhuijzen Kruseman, A., Bemelmans, M., Van Essen, H., Smits, J. and Struijker Boudier, H.
Inhibition of angiotensin-converting enzyme reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes (240) 207
Hulihan-Giblin, B.A., Park, Y.D., Goldman, D. and Aulakh, C.S.
Analysis of the 5-$HT_{1C}$ receptor and the serotonin uptake site in Fawn-Hooded rat brain (239) 99
Hullinger, T.G., see Hartman, J.C. (234) 229
Hunt, J., see White, H.S. (236) 147
Hurlé, M.A., see Ruiz, F. (240) 155
Hušek, P., see Šmíd, M. (230) 69
Hutheson, S., see Pucilowski, O. (240) 89
Huupponen, R., see Rouru, J. (234) 191
Huupponen, R., see Rouru, J. (246) 67
Huwiler, A., see Ochsner, M. (245) 15
Hyslop, S., see Santana, A.C. (231) 237

Iacoviello, L., De Curtis, A., Amore, C., D'Adamo, M.C., Buczko, W., De Gaetano, G. and Donati, M.B.
Effect of aspirin on the fibrinolytic response in perfused rat hindquarters (229) 39
Ibarra, M., see Castillo, C. (241) 141
Ibayashi, S., see Ooboshi, H. (233) 165
Ibrahim, I.H., see Lemaire, S. (245) 247
Ichihara, K., Nabeshima, T. and Kameyama, T.
Mediation of dopamine $D_1$ and $D_2$ receptors in the effects of GBR 12909 on latent learning and locomotor activity in mice (234) 155
Ichihara, K., Okumura, K., Mori, H. and Nagasaka, M.
Effects of MPC-1304, a novel $Ca^{2+}$ entry blocker, on $\alpha$-adrenoceptor-mediated pressor responses in pithed rats (238) 283
Ichihara, K., see Miyoshi, K. (238) 139
Ichihara, K., see Okumura, K. (235) 69
Ichiki, Y., see Ishiyama, Y. (241) 271
Iga, Y., Yoshioka, M., Togashi, H. and Saito, H.
Inhibitory action of $N^{\omega}$-nitro-L-arginine methyl ester on in vivo long-term potentiation in the rat dentate gyrus (238) 395
Ihara, M., see Kobayashi, M. (235) 95
Ihara, M., see Noguchi, K. (233) 47
Iijima, N., see Fujita, K. (242) 301
Iino, Y., see Hikasa, Y. (229) 241
Iinuma, K., see Yokoyama, H. (234) 129
Iizuka, Y., see Itoh, K. (239) 159
Iizuka, Y., see Yamaguchi, T. (236) 43
Ikari, N., see Murai, M. (236) 7
Ikeda, M., see Kihara, T. (230) 271
Ikeda, T., see Itoh, K. (237) 215
Ikeda, T., see Yoshioka, M. (236) 491
Ikekawa, N., see Honda, A. (229) 217
Ikemoto, F., see Kobayashi, M. (235) 95
Iliou, J.-P., Thollon, C., Robin, F., Cambarrat, C., Guillonneau, C., Régnier, G., Lenaers, A. and Vilaine, J.-P.
Protective effect of S12340 on cardiac cells exposed to oxidative stress (248) 263
Illes, P., see Sevcik, J. (230) 223
Ilsemann, B.A., see Heaslip, R.J. (234) 247
Im, W.B. and Pregenzer, J.F.
Interaction of $La^{3+}$ with $GABA_A$ receptors in rat cerebrocortical membranes as detected with [$^{35}$S]t-butylbicyclophosphorothionate binding (245) 111
Imagawa, Y., see Tanaka, M. (238) 89
Imai, M., see Shinkawa, T. (238) 317
Imano, K., see Kita, A. (237) 317
Imazumi, K., see Morimoto, H. (240) 121
Imbs, J.-L., see Michel, B. (242) 237
Imperato, A., Dazzi, L., Obinu, M.C., Gessa, G.L. and Biggio, G.
Inhibition of hippocampal acetylcholine release by benzodiazepines: antagonism by flumazenil (238) 135
Imperato, A., Obinu, M.C. and Gessa, G.L.
Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus (238) 377
Imperato, A., Obinu, M.C., Demontis, M.V. and Gessa, G.L.
Cocaine releases limbic acetylcholine through endogenous dopamine action on $D_1$ receptors (229) 265
Inaba, N., see Shibata, M. (235) 245
Innis, R.B., see Laruelle, M. (230) 119
Inoue, N.N.T., see Iwai, J. (248) 341
Inoue, Y., Shimamura, K. and Sperelakis, N.
Forskolin inhibition of $K^+$ current in pregnant rat uterine smooth muscle cells (240) 169
Inoue, Y., see Takayama, S. (231) 315
Insel, T.R., see Winslow, J.T. (233) 101
Intorre, L., Mengozzi, G., Vanni, E., Grassi, F. and Soldani, G.
The role of peripheral opioid receptor subtypes in the modulation of gastric acid secretion and plasma gastrin in dogs (243) 265
Ioculano, M., see Squadrito, F. (230) 125
Ioculano, M., see Squadrito, F. (237) 223
Iorio, K.R., Tabakoff, B. and Hoffman, P.L.
Glutamate-induced neurotoxicity is increased in cerebellar granule cells exposed chronically to ethanol (248) 209
Irifune, M., Nomoto, M. and Fukuda, T.
Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets (238) 235
Isaksson, K., see Rouru, J. (234) 191
Isaksson, K., see Rouru, J. (246) 67
Ishibashi, M., see Mizuguchi, K. (231) 121
Ishibashi, M., see Mizuguchi, K. (235) 221
Ishihara, S.-i., Hiramatsu, M., Kameyama, T. and Nabeshima, T.
Development of tolerance to amnesic effects of chlordiazepoxide in relation to GABAergic and cholinergic neuronal systems (230) 313
Ishikawa, K., see Noguchi, K. (233) 47
Ishikawa, M., Ouchi, Y., Orimo, H.,
Effect of calcitonin gene-related peptide on cytosolic free $Ca^{2+}$ level in vascular smooth muscle (246) 121
Ishikawa, N., see Hayakawa, A. (239) 219
Ishiyama, Y., Kitamura, K., Ichiki, Y., Nakamura, S., Kida, O., Kangawa, K. and Eto, T.
Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats (241) 271
Ishizaki, R., see Kojima, S.-i. (241) 171
Isono, T., Koibuchi, Y., Sato, N., Furuichi, A., Nishii, M., Yamamoto, T., Mori, J., Kohsaka, M. and Ohtsuka, M.
Vasorelaxant mechanism of the new vasodilator, FK409 (246) 205
Israël, M., see Moulian, N. (231) 407
Itano, T., see Fujisawa, M. (238) 127
Itazaki, K., Shigeri, Y. and Fujimoto, M.
Molecular cloning and characterization of the angiotensin receptor subtype in porcine aortic smooth muscle (245) 147
Ito, H., see Kamato, T. (238) 369
Ito, H., see Oikawa, T. (241) 221
Ito, H., see Okabe, E. (248) 33

Ito, K., see Asano, M. (247) 295
Ito, K.M., see Asano, M. (247) 295
Ito, M., see Itoh, H. (240) 57
Ito, M., see Suga, T. (242) 129
Itoh, H., Kusagawa, M., Shimomura, A., Suga, T., Ito, M., Konishi, T. and Nakano, T.
$Ca^{2+}$-dependent and $Ca^{2+}$-independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors (240) 57
Itoh, H., see Suga, T. (242) 129
Itoh, J., Ukai, M. and Kameyama, T.
Dynorphin A-(1–13) potently prevents memory dysfunctions induced by transient cerebral ischemia in mice (234) 9
Itoh, J., Ukai, M. and Kameyama, T.
Dynorphin A-(1–13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice (236) 341
Itoh, J., Ukai, M. and Kameyama, T.
Dopaminergic involvement in the improving effects of dynorphin A-(1–13) on scopolamine-induced impairment of alternation performance (241) 99
Itoh, K., Mukaiyama, O., Satoh, Y., Yamaguchi, T. and Iizuka, Y.
Effects of CS-518, a thromboxane synthase inhibitor, on eosinophil function (239) 159
Itoh, K., Satoh, Y., Hisamoto, M., Yamamura, N., Mukaiyama, O., Yamaguchi, T., Ikeda, T. and Matsuda, K.
Alteration of eicosanoid production in the sensitized guinea pig lung by CS-518 (237) 215
Itoh, K., see Yamaguchi, T. (236) 43
Itoh, N., see Yayama, K. (236) 337
Itoh, Y., see Takeda, Y. (233) 299
Itoshima, T., see Masui, A. (238) 297
Itzhak, Y.
Repeated methamphetamine-treatment alters brain $\sigma$ receptors (230) 243
Iuvone, T., Carnuccio, R. and Di Rosa, M.
Characterization of vasocortin-like proteins induced by dexamethasone in endothelial cells (243) 163
Ivanova, K., Schaefer, M., Drummer, C. and Gerzer, R.
Effects of nitric oxide-containing compounds on increases in cytosolic ionized $Ca^{2+}$ and on aggregation of human platelets (244) 37
Ivanova, K., see Menshikov, M.Y. (245) 281
Ivorra, M.D., Chuliá, S., Lugnier, C. and D'Ocon, M.P.
Selective action of two aporphines at $\alpha_1$-adrenoceptors and potential-operated $Ca^{2+}$ channels (231) 165
Iwai, J., Kanayama, Y., Inoue, N.N.T., Okamura, M. and Takeda, T.
Increased endothelial gene expression of angiotensin $AT_{1A}$ receptor in cyclosporine induced hypertensive rats (248) 341
Iwamoto, Y., see Kamei, J. (233) 251
Iwamoto, Y., see Kamei, J. (234) 117
Iwamoto, Y., see Kamei, J. (240) 99
Iwamoto, Y., see Kamei, J. (242) 209
Iwao, H., see Tamaki, T. (236) 15
Iwata, K., see Toide, K. (233) 21
Iwata, N., Suzuki, K., Minegishi, K.-i., Kawanishi, T., Hara, S., Endo, T. and Takahashi, A.
Induction of cytochrome P450 1A2 by musk analogues and other inducing agents in rat liver (248) 243
Iwatsuki, K., see Horiuchi, A. (237) 23
Izawa, T., see Okada, Y. (241) 177
Izenwasser, S. and Katz, J.L.
Differential efficacies of dopamine $D_1$ receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat (246) 39
Izenwasser, S., Hauck Newman, A. and Katz, J.L.
Cocaine and several $\sigma$ receptor ligands inhibit dopamine uptake in rat caudate-putamen (243) 201
Izquierdo, I., see Jerusalinsky, D. (240) 103
Izzo, A.A., Mascolo, N., Viola, P. and Capasso, F.
Inhibitors of nitric oxide synthase enhance rat ileum contractions induced by ricinoleic acid in vitro (243) 87

Jackisch, R., see Lauth, D. (236) 165
Jackson, D.M., see Mohell, N. (238) 121
Jackson, E.A., see Rose, S. (230) 177
Jacobsen, F.W., see Sandnes, D. (246) 163
Jaehnig, P., see Rose, S. (230) 177
Jagust, W.J., Eberling, J.L., Roberts, J.A., Brennan, K.M., Hanrahan, S.M., VanBrocklin, H., Enas, J.D., Biegon, A. and Mathis, C.A.
In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [$^{123}$I]5-iodo-6-nitroquipazine (242) 189
Jakob, A., see Druhan, J.P. (243) 73
Jane, D.E., see Bashir, Z.I. (239) 265
Jane, D.E., see Eaton, S.A. (244) 195
Jankowska, E., see Bisaga, A. (242) 213
Janowsky, D.S., see Pucilowski, O. (240) 89
Jardine, E., see Hamilton, C.A. (243) 95
Jaroszewicz, W., see Namiot, Z. (243) 301
Javaid, J.I., Sahni, S.K., Pandey, S.C. and Davis, J.M.
Repeated cocaine administration does not affect 5-HT receptor subtypes (5-$HT_{1A}$, 5-$HT_2$) in several rat brain regions (238) 425
Javitch, J., see Parsons, B. (234) 269
Jaw, S.P., Hoskins, B. and Ho, I.K.
Involvement of $\delta$-opioid receptors in physical dependence on butorphanol (240) 67
Jaw, S.P., Makimura, M., Hoskins, B. and Ho, I.K.
Effects of nor-binaltorphimine on butorphanol dependence (239) 133
Jeanjean, A.P., Mestre, M., Maloteaux, J.-M. and Laduron, P.M.
Is the $\sigma_2$ receptor in rat brain related to the $K^+$ channel of class III antiarrhythmic drugs? (241) 111
Jeanjean, A.P., see Hermans, E. (245) 43
Jefferys, D.E. and Funder, J.W.
The thyroadrenal axis, food deprivation and retention of a behavioural response (239) 189
Jenck, F., Moreau, J.-L., Mutel, V., Martin, J.R. and Haefely, W.E.
Evidence for a role of 5-$HT_{1C}$ receptors in the antiserotonergic properties of some antidepressant drugs (231) 223
Jenkinson, D.H., see Castle, N.A. (236) 201
Jenner, P., see Kebabian, J.W. (229) 203
Jenner, P., see Rose, S. (230) 177
Jensen, R.T., see Ladenheim, E.E. (235) 121
Jeremy, J.Y., Gill, J. and Mikhailidis, D.
Effect of milrinone on thromboxane $A_2$ synthesis, cAMP phosphodiesterase and $^{45}Ca^{2+}$ uptake by human platelets (245) 67
Jerusalinsky, D., Cerveñansky, C., Walz, R., Bianchin, M. and Izquierdo, I.
A peptide muscarinic toxin from the Green Mamba venom shows agonist-like action in an inhibitory avoidance learning task (240) 103
Jewell, A., Wedlund, P. and Dwoskin, L.
Strain differences in rat brain and liver $\sigma$ binding: lack of cytochrome P450-2D1 involvement (243) 249
Jhamandas, K., see Gouardères, C. (237) 73
Ji, Z., see Aceto, M.D. (248) 333
Jiang, N.-Y., see Rossowski, W.J. (240) 259
Jiang, Q., Sebastian, A., Archer, S. and Bidlack, J.M.
5$\beta$-Methyl-14$\beta$-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting $\mu$-opioid receptor antagonist devoid of agonist properties (230) 129
Jiang, Q., Seyed-Mozaffari, A., Archer, S. and Bidlack, J.M.
Antinociceptive evaluation of 14$\beta$-(bromoacetamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone in mice (240) 201

Jiménez, J., see Duarte, J. (239) 1
Jimenez, P., see Salmi, P. (236) 395
Jimenez Del Rio, M., Velez Pardo, C., Pinxteren, J., De Potter, W., Ebinger, G. and Vauquelin, G.
Binding of serotonin and dopamine to 'serotonin binding proteins' in bovine frontal cortex: evidence for iron-induced oxidative mechanisms (247) 11
Jin, G.-Z., see Sun, B.-C. (231) 331
Jinnai, Y., see Ozaki, Y. (235) 255
Jinno, Y., see Ohta, H. (231) 323
Jinno, Y., see Okada, Y. (241) 177
Jobert, A., see Tavitian, B. (236) 229
Johansen, T.H., Drejer, J., Wätjen, F. and Nielsen, E.Ø.
A novel non-NMDA receptor antagonist shows selective displacement of low-affinity [$^3$H]kainate binding (246) 195
Johansson, B., Georgiev, V., Parkinson, F.E. and Fredholm, B.B.
The binding of the adenosine $A_2$ receptor selective agonist [$^3$H]CGS 21680 to rat cortex differs from its binding to rat striatum (247) 103
Johansson-Wallsten, C.E., Berg, M. and Meyerson, B.J.
The effects of long-term treatment with the 5-$HT_{1A}$ receptor agonist 8-OH-DPAT and the 5-$HT_{2/1C}$ receptor agonist DOI in the neonatal rat (243) 149
Johns, E.J.
Effect of BRL 38227 on the adrenergic regulation of the kidney vasculature of the rat (230) 47
Johnson, A.K., see Davisson, R.L. (241) 135
Johnson, K.M., see Gifford, A.N. (237) 169
Johnson, M.P., Audia, J.E., Nissen, J.S. and Nelson, D.L.
N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-$HT_2$ receptor (239) 111
Johnson, M.S., see MacEwan, D.J. (246) 9
Johnson, R.L., see Nelson, S.H. (242) 255
Johnston, G.A.R., see Ong, J. (233) 169
Jolkkonen, J., Mazurkiewicz, M., Lahtinen, H. and Riekkinen, P.
Acute effects of γ-vinyl GABA on the GABAergic system in rats as studied by microdialysis (229) 269
Jolles, J., see Blokland, A. (235) 275
Jomary, C., see Pasquini, F. (243) 39
Jomier, M., see Clerc, T. (235) 59
Jones, C.A., Zempléni, É., Davis, B. and Reynolds, G.P.
Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro (242) 183
Jones, C.R., see Huggins, J.P. (245) 203
Jones, D., see Fletcher, A. (237) 283
Jones, K.W. and Hammond, J.R.
Interaction of the mioflazine derivative R75231 with the nucleoside transporter: evidence for positive cooperativity (246) 97
Jones, P.L.S.J., see Eaton, S.A. (244) 195
Jost, B., see Schoeffter, P. (241) 165
Jotti, A., see Bradamante, S. (234) 113
Jotti, A., see Bradamante, S. (239) 275
Joulin, Y., see Devynck, M.-A. (245) 105
Jover, T., see Alborch, E. (229) 83
Junien, J.-L., see Gué, M. (233) 193
Junien, J.-L., see Pascaud, X.B. (231) 389
Junien, J.-L., see Roman, F.J. (242) 305
Jun Liu, G. and Takeuchi, H.
Modulatory effects of achatin-I, an *Achatina* endogenous neuroactive peptide, on responses to 5-hydroxytryptamine (231) 259
Juorio, A.V., see Zhu, M.-Y. (238) 157
Just, I., Wille, M., Chaponnier, C. and Aktories, K.
Gelsolin-actin complex is target for ADP-ribosylation by *Clostridium botulinum* C2 toxin in intact human neutrophils (246) 293

Kacsorowski, G.J., see Huang, J.-C. (235) 37
Kadowitz, P.J., see Bellan, J.A. (234) 273
Kadowitz, P.J., see Cheng, D.Y. (243) 79
Kadowitz, P.J., see Osei, S.Y. (234) 35
Kadowitz, P.J., see Santiago, J.A. (236) 315
Kadowitz, P.J., see Santiago, J.A. (243) 291
Kaehler, C., see Kieselbach, G. (235) 117
Kagami-Ishi, Y., see Shibata, S. (229) 21
Kajiwara, N., see Koya, D. (245) 79
Kakei, M., see Nakashima, H. (233) 219
Kaku, S., see Tanaka, M. (238) 93
Kalan, H., see Wu, P.H. (231) 157
Kalant, H., see Khanna, J.M. (230) 23
Källner, G., see Franco-Cereceda, A. (238) 311
Kalogeras, K.T., see Bagdy, G. (229) 9
Kamata, K., see Abiru, T. (242) 15
Kamato, T., Ito, H., Nagakura, Y., Nishida, A., Yuki, H., Yamano, M. and Miyata, K.
Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets (238) 369
Kamei, H., see Miyoshi, K. (238) 139
Kamei, J., Iwamoto, Y., Misawa, M. and Kasuya, Y.
Effects of rimcazole, a specific antagonist of σ sites, on the antitussive effects of non-narcotic antitussive drugs (242) 209
Kamei, J., Iwamoto, Y., Misawa, M., Nagase, H. and Kasuya, Y.
Antitussive effect of β-endorphin is mediated by μ-opioid receptors, but not by κ- or ε-opioid receptors (233) 251
Kamei, J., Iwamoto, Y., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y.
The role of the $\mu_2$-opioid receptor in the antitussive effect of morphine in $\mu_1$-opioid receptor-deficient CXBK mice (240) 99
Kamei, J., Iwamoto, Y., Suzuki, T., Nagase, H., Misawa, M. and Kasuya, Y.
Differential modulation of μ-opioid receptor-mediated antitussive activity by δ-opioid receptor agonists in mice (234) 117
Kameyama, T., see Fuji, K. (236) 411
Kameyama, T., see Ichihara, K. (234) 155
Kameyama, T., see Ishihara, S.-i. (230) 313
Kameyama, T., see Itoh, J. (234) 9
Kameyama, T., see Itoh, J. (236) 341
Kameyama, T., see Itoh, J. (241) 99
Kameyama, T., see Ukai, M. (231) 143
Kameyama, T., see Ukai, M. (239) 237
Kan, S., see Taniyama, K. (235) 149
Kanai, Y., Araki, T., Murakami, F., Kato, H. and Kogure, K.
Effect of pentobarbital on postischemic SCH 23390 and rolipram binding in gerbil brain (248) 191
Kanaide, H., see Hirano, K. (244) 133
Kanayama, Y., see Iwai, J. (248) 341
Kanda, A., see Miyoshi, K. (238) 139
Kane, K., see Tweedie, D. (240) 251
Kaneko, K. and Sunano, S.
Involvement of α-adrenoceptors in the endothelium-dependent depression of noradrenaline-induced contraction in rat aorta (240) 195
Kangawa, K., see Ishiyama, Y. (241) 271
Kanno, T., see Busik, J. (247) 273
Kanzik, İ., see Çakici, İ. (236) 97
Kao, C.Y., see Fan, S.-f. (229) 259
Karaki, H., Sudjarwo, S.A., Hori, M., Sakata, K., Urade, Y., Takai, M. and Okada, T.
$ET_B$ receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation (231) 371
Karaki, H., see Hagiwara, S. (234) 1
Karaki, H., see Sudjarwo, S.A. (229) 137
Karbon, E.W., see Bailey, M.A. (240) 243
Karoum, F., see Chrapusta, S.J. (233) 135
Kasamatsu, K., see Kawabata, A. (233) 255

Kasbergen, C.M., see De Wildt, D.J. (233) 157
Kashimoto, T., see Tachikawa, E. (236) 355
Kashiwabara, T., see Okada, Y. (241) 177
Kashiwagi, A., see Tanaka, Y. (244) 105
Kasparov, S., see Zeise, M.L. (231) 47
Kasten, T.P., see Misko, T.P. (233) 119
Kasuya, Y., see Abiru, T. (242) 15
Kasuya, Y., see Kamei, J. (233) 251
Kasuya, Y., see Kamei, J. (234) 117
Kasuya, Y., see Kamei, J. (240) 99
Kasuya, Y., see Kamei, J. (242) 209
Katayama, K.-i., see Nagakawa, J.-i. (229) 63
Kato, H., see Kanai, Y. (248) 191
Kato, H., see Kurihara, J. (240) 73
Kato, J., Misko, T.P. and Currie, M.G.
Induction of nitric oxide synthase regulates atrial natriuretic peptide receptors in vascular smooth muscle cells (244) 153
Kato, K., see Miyamoto, M. (238) 181
Kato, M., Tokuyama, K., Morikawa, A., Kuroume, T. and Barnes, P.J.
Platelet-activating factor-induced enhancement of superoxide anion generation in guinea-pigs (232) 7
Kato, N., see Masui, A. (238) 297
Katori, M., see Majima, M. (232) 181
Katsumata, K., see Sakurada, T. (242) 47
Katz, J.L., see Izenwasser, S. (243) 201
Katz, J.L., see Izenwasser, S. (246) 39
Katz, S., see Wong, S. (245) 55
Kavanagh, C., see Brent, P.J. (241) 149
Kawabata, A., Kasamatsu, K. and Takagi, H.
L-Tyrosine-induced antinociception in the mouse: involvement of central $\delta$-opioid receptors and bulbo-spinal noradrenergic system (233) 255
Kawamura, K., see Oka, T. (234) 55
Kawanishi, M., see Hayakawa, A. (239) 219
Kawanishi, T., see Iwata, N. (248) 243
Kawao, M., see Yayama, K. (236) 337
Kawasaki, K., see Murata, S. (239) 9
Kawata, E., see Maeda, K. (233) 227
Kawikova, I., see Arakawa, H. (229) 131
Kayser, V., see Perrot, S. (241) 129
Kazmierski, W.M., see Horan, P.J. (233) 53
Kealey, T., see Pepke-Zaba, J. (235) 169
Keane, P.E., see Bachy, A. (237) 299
Keane, P.E., see Labie, C. (231) 465
Kebabian, J.W., Britton, D.R., DeNinno, M.P., Perner, R., Smith, L., Jenner, P., Schoenleber, R. and Williams, M.
A-77636: a potent and selective dopamine $D_1$ receptor agonist with antiparkinsonian activity in marmosets (229) 203
Kebabian, J.W., see Baldessarini, R.J. (239) 269
Keil, R., see Matias, A. (244) 223
Keilhoff, G., see Fischer, S. (232) 121
Kelly, J.S., see Hodgkiss, J.P. (240) 219
Kelly, J.S., see Sherriffs, H.J. (247) 319
Kelly, M.E., see Costall, B. (234) 91
Kennedy, A.J., see Gibson, E.L. (242) 83
Kerezoudis, N.P., Olgart, L. and Edwall, L.
Differential effects of nitric oxide synthesis inhibition on basal blood flow and antidromic vasodilation in rat oral tissues (241) 209
Kerr, D.I.B., Ong, J., Doolette, D.J., Abbenante, J. and Prager, R.H.
3-Amino-2-(4-chlorophenyl)-nitropropane is a new $GABA_B$ receptor agonist, more active peripherally (236) 239
Kerr, D.I.B., see Ong, J. (233) 169
Kerwin, R.W., see McLaughlin, D.P. (244) 89
Keseberg, U., see Bubser, M. (229) 75
Khali, N.N., see Coppes, R.P. (243) 273
Khanna, J.M., Shah, G., Weiner, J., Wu, P.H. and Kalant, H.
Effect of NMDA receptor antagonists on rapid tolerance to ethanol (230) 23
Khosla, M.C., see Osei, S.Y. (234) 35
Kida, O., see Ishiyama, Y. (241) 271
Kidd, E.J., Levy, J.C., Nielsen, M., Hamon, M. and Gozlan, H.
Characterisation of the non-5-$HT_3$ high-affinity 'R' binding site for (*R*)-zacopride in brain and other tissues (247) 45
Kiefer, F., see Schmalix, W.A. (248) 251
Kieselbach, G., Troger, J., Kaehler, C. and Saria, A.
Indomethacin reduces substance P levels in human ocular aqueous humor (235) 117
Kigoshi, S., see Hashimoto, S. (231) 209
Kigoshi, S., see Noguchi, H. (240) 291
Kihara, T., Ikeda, M., Matsubara, K. and Matsushita, A.
Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat (230) 271
Kikkawa, R., see Koya, D. (245) 79
Kikkawa, R., see Tanaka, Y. (244) 105
Kikuchi de Beltrán, K., Koshikawa, N., Miwa, Y., Kobayashi, M. and Stephenson, J.D.
Further evidence for a functional dorsal-ventral division of the rat striatum: GABAergic involvement in oral movements (239) 47
Kilpatrick, G.J., see Clapham, J. (232) 99
Kilpatrick, G.J., see Lummis, S.C.R. (243) 7
Kilpatrick, G.J., see Steward, L.J. (243) 13
Kim, D.J.B., see Brioni, J.D. (238) 1
Kim, H.S., see Hu, S. (230) 215
Kim, J.H., see Chang, K.C. (236) 51
Kim, W.-K., Hawthorn, M.H. and Rabin, R.A.
Chronic ethanol exposure potentiates muscarinic receptor and $\alpha_2$-adrenoceptor-mediated inhibition of cAMP accumulation in PC 12 cells (247) 89
Kimura, S., see Tamaki, T. (236) 15
King, R.G., see Sikorski, B.W. (242) 275
Kinoshita, M., see Matsumoto, T. (237) 31
Kinugawa, K.-i., Kohmoto, O., Takahashi, T. and Serizawa, T.
Effects of a nonpeptide angiotensin II receptor antagonist (CV-11974) on $[Ca^{2+}]_i$ and cell motion in cultured ventricular myocytes (235) 313
Király, Á., Sütő, G. and Taché, Y.
Role of nitric oxide in the gastric cytoprotection induced by central vagal stimulation (240) 299
Kirker, M.L., see Weishaar, R.E. (236) 363
Kisara, K., see Sakurada, T. (242) 47
Kita, A., Imano, K. and Nakamura, H.
Involvement of corticotropin-releasing factor in the antinociception produced by interleukin-1 in mice (237) 317
Kitamura, K., see Ishiyama, Y. (241) 271
Kitamura, M., see Saigusa, T. (237) 161
Kiviluoma, K.T., see Uusimaa, P.A. (242) 199
Klaus, W., see Rump, A.F.E. (241) 201
Kleinrok, Z., see Czechowska, G. (232) 59
Klitgaard, H., Knutsen, L.J.S. and Thomsen, C.
Contrasting effects of adenosine $A_1$ and $A_2$ receptor ligands in different chemoconvulsive rodent models (242) 221
Knapp, R.J., see Horan, P.J. (233) 53
Knoerzer, T., see Watts, V.J. (239) 271
Knoper, S.R., Meehan, A.G., Purnyn, S., Coggan, J.S., Anthony, T.L. and Kreulen, D.L.
$CCK_A$ receptors mediate slow depolarizations in cultured mammalian sympathetic neurons (232) 65
Knutsen, L.J.S., see Klitgaard, H. (242) 221
Ko, F.-N., see Lin, C.-H. (237) 109
Ko, F.-N., see Teng, C.-M. (233) 7
Ko, H.J., see Chang, K.C. (236) 51
Ko, K.H., see Hong, K.W. (231) 1

Kobayashi, A., see Suzuki, S. (231) 297
Kobayashi, M., Ihara, M., Sato, N., Saeki, T., Ozaki, S., Ikemoto, F. and Yano, M.
A novel ligand, [$^{125}$I]BQ-3020, reveals the localization of endothelin $ET_B$ receptors (235) 95
Kobayashi, M., see Kikuchi de Beltrán, K. (239) 47
Kobayashi, M., see Ohno, M. (238) 117
Kobayashi, M., see Saigusa, T. (237) 161
Kobayashi, T., see Nakagawa, N. (235) 211
Kobayashi, T., see Ukai, M. (239) 237
Kodama, K., see Shibata, S. (229) 21
Koek, W., see Assié, M.-B. (237) 183
Koek, W., see Sleight, A.J. (238) 407
Koene, P., Prinssen, E.P.M. and Cools, A.R.
Involvement of the nucleus accumbens in oral behaviour in the freely moving rat (233) 151
Koga, Y., see Shibata, S. (231) 381
Kogo, H., Takasaki, K., Takeo, S., Watanabe, G., Taya, K. and Sasamoto, S.
A role of prostaglandin in the secretion of inhibin and oestradiol-17$\beta$ in equine chorionic gonadotrophin-primed rats (231) 481
Kogure, K., see Kanai, Y. (248) 191
Kohli, J.D., Horn, P.T., Glock, D., Brewster, W.K. and Nichols, D.E.
Dihydrexidine: a new potent peripheral dopamine $D_1$ receptor agonist (235) 31
Kohmoto, O., see Kinugawa, K.-i. (235) 313
Kohno, Y., see Umemura, K. (239) 17
Kohsaka, M., see Isono, T. (246) 205
Koibuchi, Y., see Isono, T. (246) 205
Koide, T., see Nagafuji, T. (248) 325
Kojima, S.-i., Ishizaki, R. and Shimo, Y.
Investigation of nicotine-induced relaxation of circular smooth muscle of the guinea-pig gastric fundus (241) 171
Koller, M.M., see Scarpace, P.J. (247) 65
Komori, S., see Nagasaki, M. (235) 197
Komoriya, K., see Osada, Y. (241) 183
Kondo, H., see Nomura, T. (246) 113
Kondo, H., see Temma, K. (234) 173
Kondo, S., see Osada, Y. (241) 183
Kong, M., see Comtois, A. (242) 65
Konishi, T., see Itoh, H. (240) 57
Konishi, T., see Suga, T. (242) 129
Konoike, T., see Mihara, S.-i. (247) 219
Konturek, S.J., Brzozowski, T., Majka, J., Pytko-Polonczyk, J. and Stachura, J.
Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers (239) 215
Konturek, S.J., Brzozowski, T., Majka, J., Szlachcic, A., Nauert, C. and Slomiany, B.
Nitric oxide in gastroprotection by aluminium-containing antacids (229) 155
Kooyman, A.R., Zwart, R. and Vijverberg, H.P.M.
Tetraethylammonium ions block 5-$HT_3$ receptor-mediated ion current at the agonist recognition site and prevent desensitization in cultured mouse neuroblastoma cells (246) 247
Korbut, R. and Gryglewski, R.J.
Nitric oxide from polymorphonuclear leukocytes modulates red blood cell deformability in vitro (234) 17
Koreuber, D., see Rump, A.F.E. (241) 201
Korpi, E.R. and Seeburg, P.H.
Natural mutation of $GABA_A$ receptor $\alpha$6 subunit alters benzodiazepine affinity but not allosteric GABA effects (247) 23
Korpi, E.R., see Taira, T. (230) 307
Koshikawa, N., see Kikuchi de Beltrán, K. (239) 47
Koshikawa, N., see Saigusa, T. (237) 161
Kostowski, W., see Bisaga, A. (242) 213
Kostrzewa, F.P., see Kostrzewa, R.M. (239) 183
Kostrzewa, R.M., Guo, J. and Kostrzewa, F.P.
Ontogenetic quinpirole treatment induces vertical jumping activity in rats (239) 183
Kostrzewska, A., Laudánski, T. and Batra, S.
Effect of ovarian steroids and diethylstilbestrol on the contractile responses of the human myometrium and intramyometrial arteries (233) 127
Koulu, M., see Rouru, J. (234) 191
Koulu, M., see Rouru, J. (246) 67
Kovács, G.L.
$\alpha$-Atrial natriuretic peptide attenuates ethanol withdrawal symptoms (238) 417
Koya, D., Kikkawa, R., Haneda, M., Uzu, T., Sawada, M., Kajiwara, N., Sakamoto, K., Sugimoto, T. and Shigeta, Y.
Nipradilol inhibits rat mesangial cell mitogenesis through the activation of soluble guanylate cyclase (245) 79
Kozikowski, A.P., see Casalotti, S.O. (247) 209
Kramer, T.H., see Horan, P.J. (233) 53
Kreeger, J.S. and Larson, A.A.
Substance P-(1–7), a substance P metabolite, inhibits withdrawal jumping in morphine-dependent mice (238) 111
Kreft, A.F., see Grimes, D. (236) 217
Kreulen, D.L., see Knoper, S.R. (232) 65
Kreutner, W., see Rizzo, C.A. (234) 109
Kreutner, W., see Rizzo, C.A. (240) 327
Krieglstein, J., see Nikolov, R. (248) 205
Kristensen, P., see Thomsen, C. (244) 187
Krogsgaard-Larsen, P., see Madsen, U. (230) 383
Krogsgaard-Larsen, P., see White, H.S. (236) 147
Kromer, W.
Synergistic opioid inhibition of colonic $Cl^-$ secretion by $\kappa$-opioid receptor agonism plus $\mu$-opioid receptor antagonism (230) 235
Kronevi, T., see Hemming, H. (248) 163
Krstenansky, J.L., see Grundemar, L. (232) 271
Krueger, K.E., see Casalotti, S.O. (247) 209
Krug, M., Matthies, R., Wagner, M. and Brödemann, R.
Non-opioid antitussives and methadone differentially influence hippocampal long-term potentiation in freely moving rats (231) 355
Krugers, H., see De Wildt, D.J. (233) 157
Kruk, M.R., see Van Erp, A.M.M. (232) 217
Krzascik, P., see Bisaga, A. (242) 213
Kubes, P., see McCafferty, D.-M. (232) 169
Kubota, J., see Oka, T. (234) 55
Kudlacz, E.M., Logan, D.E., Shatzer, S.A., Farrell, A.M. and Baugh, L.E.
Tachykinin-mediated respiratory effects in conscious guinea pigs: modulation by $NK_1$ and $NK_2$ receptor antagonists (241) 17
Kukreja, R.C., see Okabe, E. (248) 33
Kula, N.S., see Baldessarini, R.J. (239) 269
Kume, S., see Ozaki, Y. (235) 255
Kung, H.F., see Kung, M.-P. (235) 165
Kung, M.-P., Kung, H.F., Chumpradit, S. and Foulon, C.
In vitro binding of a novel dopamine $D_3$ receptor ligand: [$^{125}$I]trans-7-OH-PIPAT-A (235) 165
Kuno, A., see Hodgkiss, J.P. (240) 219
Kuno, A., see Sherriffs, H.J. (247) 319
Künzi, R., see Benke, D. (246) 179
Kuoppamäki, M., Syvälahti, E. and Hietala, J.
Clozapine and N-desmethylclozapine are potent 5-$HT_{1C}$ receptor antagonists (245) 179
Kuribara, H.
Ceruletide, a cholecystokinin-like decapeptide, differentially reduces the stimulant effect of MK-801 and ketamine: evaluation by discrete shuttle avoidance in mice (231) 7
Kuribayashi, Y., see Majima, M. (232) 181

Kurihara, J., Tamaoki, S. and Kato, H.
Blockade of $\alpha_2$-adrenoceptors protects the vagal baroreflex system from transient global cerebral ischemia in dogs (240) 73
Kuriyama, K., see Hirouchi, M. (247) 127
Kuroda, T., see Horiuchi, A. (237) 23
Kurosawa, A., see Arimura, A. (231) 13
Kurosawa, M., Yodonawa, S. and Tsukagoshi, H.
Inhibition of $9\alpha,11\beta$-prostaglandin $F_2$-induced bronchial hyperresponsiveness by thromboxane $A_2$ receptor antagonists in guinea pigs (238) 335
Kuroume, T., see Kato, M. (232) 7
Kuroume, T., see Yokoyama, T. (236) 427
Kusagawa, M., see Itoh, H. (240) 57
Kusagawa, M., see Suga, T. (242) 129
Kusama, T., Wang, T.-L., Guggino, W.B., Cutting, G.R. and Uhl, G.R.
GABA $\rho_2$ receptor pharmacological profile: GABA recognition site similarities to $\rho_1$ (245) 83
Kuttan, S.C. and Sim, M.K.
Angiotensin II-induced tachyphylaxis in aortas of normo- and hypertensive rats: changes in receptor affinity (232) 173
Kwan, C.-Y. and Wang, Z.-L.
Tetrandrine: a vasodilator of medicinal herb origin with a novel contractile effect on dog saphenous vein (238) 431
Kwan, C.-Y., see Low, A.M. (230) 53
Kwan, C.-Y., see Nie, S.-Q. (244) 15
Kwon, Y.W., see Hawthorn, M.H. (229) 143

Labie, C., Keane, P.E., Soubrié, P. and Le Fur, G.
The $\sigma$ receptor ligand SR 31742A increases neurotensin in the nucleus accumbens but not in the caudate-putamen of the rat (231) 465
Ladenheim, E.E., Jensen, R.T., Mantey, S.A., Taylor, J.E., Coy, D.H. and Moran, T.H.
Bombesin receptor antagonists differentiate receptor subtypes in rat brain (235) 121
Ladenius, A.R.C. and Nijkamp, F.P.
Capsaicin pretreatment of guinea pigs in vivo prevents ovalbumin-induced tracheal hyperreactivity in vitro (235) 127
Ladinsky, H., see Garcia Ruiz, A.J. (244) 125
Laduron, P.M., see Hermans, E. (245) 43
Laduron, P.M., see Jeanjean, A.P. (241) 111
Lafont, H., see Clerc, T. (235) 59
Lagerkvist, S., see Waters, N. (242) 151
Laguna, J., see Luquin, M.R. (235) 297
Lahti, R.A., Evans, D.L., Stratman, N.C. and Figur, L.M.
Dopamine $D_4$ versus $D_2$ receptor selectivity of dopamine receptor antagonists: possible therapeutic implications (236) 483
Lahtinen, H., see Jolkkonen, J. (229) 269
Lai, M., see Rossetti, Z.L. (242) 313
Lai, M.-W., see Huang, H.-C. (237) 39
Lakhlani, P.P. and Eikenburg, D.C.
Dependence of prejunctional $\beta$-adrenoceptor facilitation of sympathetic neurotransmission on stimulus train length and agonist exposure time (230) 107
Lal, K.J. and Dakshinamurti, K.
Hypotensive action of 5-HT receptor agonists in the vitamin $B_6$-deficient hypertensive rat (234) 183
Lamb, F.S., see Watts, S.W. (242) 245
Lambert, D.M., Mergen, F., Poupaert, J.H. and Dumont, P.
Analgesic potency of *S*-acetylthiorphan after intravenous administration to mice (243) 129
Lambert, J.J., see Hope, A.G. (245) 187
Lambrecht, G., see Eltze, M. (238) 343
Lammintausta, R., see Riekkinen, Jr., P. (235) 317
Lammintausta, R., see Riekkinen, Jr., P. (238) 263
Land, S.L., see Woodcock, E.A. (247) 93
Land, T., see Gregersen, S. (232) 35
Land, T., see Ögren, S.O. (242) 59
Landry, Y., see Trifilieff, A. (239) 227
Lang, F., see Wöll, E. (246) 269
Lang, H.-J., see Wöll, E. (246) 269
Langel, Ü., see Zini, S. (245) 1
Langel, Ü., see Gregersen, S. (232) 35
Langel, Ü., see Ögren, S.O. (242) 59
Langer, L., see Witte, K. (247) 215
Langer, S.Z., see Angel, I. (232) 139
Langer, S.Z., see Angel, I. (234) 137
Langer, S.Z., see Faure-Halley, C. (246) 283
Langlois, M., Brémont, B., Rousselle, D. and Gaudy, F.
Structural analysis by the comparative molecular field analysis method of the affinity of $\beta$-adrenoreceptor blocking agents for $5\text{-HT}_{1A}$ and $5\text{-HT}_{1B}$ receptors (244) 77
Lanza, M., Fassio, A., Gemignani, A., Bonanno, G. and Raiteri, M.
CGP 52432: a novel potent and selective $GABA_B$ autoreceptor antagonist in rat cerebral cortex (237) 191
Lanzarotti, E., see Bianchi, G. (238) 327
Lapierre, C., see Lemaire, S. (245) 247
La Porta, C., see Garcia Ruiz, A.J. (244) 125
Larangeira, A.P., see Bozza, P.T. (248) 41
Larson, A.A., see Kreeger, J.S. (238) 111
Laruelle, C., see Clerc, T. (235) 59
Laruelle, M., Abi-Dargham, A., Rattner, Z., Al-Tikriti, M.S., Zea-Ponce, Y., Zoghbi, S.S., Charney, D.S., Price, J., Frost, J.J., Hoffer, P.B., Baldwin, R.M. and Innis, R.B.
Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [$^{123}$I]iomazenil (230) 119
Lathrop, D.A., Nánási, P.P., Schwartz, A. and Varró, A.
Ionic basis for OPC-8212-induced increase in action potential duration in isolated rabbit, guinea pig and human ventricular myocytes (240) 127
Latifpour, J., see Yoshida, M. (232) 159
Lattanzio, Jr., F.A., see Ratz, P.H. (236) 433
Lau, B., see Hamel, E. (242) 75
Laubie, M., see Descombes, J.-J. (243) 193
Laubie, M., see Vayssettes-Courchay, C. (236) 121
Laubie, M., see Vayssettes-Courchay, C. (242) 37
Laudánski, T., see Kostrzewska, A. (233) 127
Lauth, D., Hertting, G. and Jackisch, R.
Involvement of nitric oxide synthase in 3,4-diaminopyridine-evoked noradrenaline release in rat hippocampus (236) 165
Lavarenne, J., see Courteix, C. (241) 267
Lavielle, S., see Burcher, E. (233) 201
Law, P.-Y., see Tao, P.-L. (246) 233
Lawler, C.P., see Watts, V.J. (239) 271
Lawler, C.P., see Watts, V.J. (242) 165
Lawrence, E. and Brain, S.D.
Big endothelin-1 and big endothelin-3 are constrictor agents in the microvasculature: evidence for the local phosphoramidon-sensitive conversion of big endothelin-1 (233) 243
Layeillon, C., see Chaouloff, F. (231) 77
Layer, R.T., see Paul, I.A. (247) 305
Lazarus, L.H., see Salvadori, S. (230) 357
Lazdunski, M., see Allard, B. (236) 419
Lê, A.D., see Wu, P.H. (231) 157
Leander, J.D., see Benvenga, M.J. (239) 249
Leander, J.D., see Moore, N.A. (237) 1
Le Bars, D., see Bouhassira, D. (232) 207
Le Bars, D., see Strimbu-Gozariu, M. (237) 197
Ledda, F., see Lodovici, M. (243) 255
Ledoux, M., see Angulo, J.A. (244) 317
Lee, E.W., see Lee, K.S. (234) 43
Lee, H.S., see Balasubramaniam, G. (237) 207

Lee, K. and Ashford, M.L.J.
$Mg^{2+}$ modulates the binding of [$^3$H]glibenclamide to its receptor in rat cerebral cortical membranes (247) 347
Lee, K.S., Tsai, T.D. and Lee, E.W.
Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide (234) 43
Lee, S.-G., see Escalante, B. (235) 1
Lee, S.-S., see Teng, C.-M. (233) 7
Lee, S.-S., see Yu, S.-M. (234) 121
Lee, S.-S., see Cheng, D.Y. (243) 79
Lee, T.H., Ellinwood, Jr., E.H. and Zhang, H.
In vitro extracellular recording from nigral dopamine neurons following continuous d-amphetamine infusion (232) 125
Lefebvre, R.A., see Bojö, L. (236) 443
Lefevre, I.A., see Bachy, A. (237) 299
Lefort, J., see Desquand, S. (235) 101
Le Fur, G., see Rinaldi-Carmona, M. (246) 73
Le Fur, G., see Bachy, A. (237) 299
Le Fur, G., see Gully, D. (232) 13
Le Fur, G., see Labie, C. (231) 465
Le Fur, G., see Santucci, V. (237) 143
Le Grand, B., Hatem, S., Le Heuzey, J.-Y., Deroubaix, E., Benitah, J.-P. and Coraboeuf, E.
Pro-arrhythmic effect of nicorandil in isolated rabbit atria and its suppression by tolbutamide and quinidine (229) 91
Le Guern, J., see Debono, M.-W. (235) 283
Le Heuzey, J.-Y., see Le Grand, B. (229) 91
Lehmkuhl, A., see Hoey, A. (231) 477
Lei, Y.-H., Barnes, P.J. and Rogers, D.F.
Inhibition of neurogenic plasma exudation and bronchoconstriction by a $K^+$ channel activator, BRL 38227, in guinea pig airways in vivo (239) 257
Leid, M., see Musser, B. (246) 105
Lejeune, F., Rivet, J.-M., Gobert, A., Canton, H. and Millan, M.J.
WAY 100,135 and (−)-tertatolol act as antagonists at both 5-$HT_{1A}$ autoreceptors and postsynaptic 5-$HT_{1A}$ receptors in vivo (240) 307
Lejeune, F., see Millan, M.J. (230) 99
Lemaire, S., Shukla, V.K., Rogers, C., Ibrahim, I.H., Lapierre, C., Parent, P. and Dumont, M.
Isolation and characterization of histogranin, a natural peptide with NMDA receptor antagonist activity (245) 247
Lemaire, S., see Shukla, V.K. (231) 293
Lemmer, B., see Witte, K. (247) 215
Lenaers, A., see Iliou, J.-P. (248) 263
Lenkei, Z., see Horváth, E.J. (236) 151
Leone, P., see Devine, D.P. (243) 55
Léoty, C., see Huchet, C. (241) 41
Lepagnol, J.M., see Randle, J.C.R. (247) 257
L'Episcopo, M.R., see Nicoletti, F. (245) 297
Le Prado, N., see Moussaoui, S.M. (238) 421
Le Quan Sang, K.H., see Devynck, M.-A. (245) 105
Lerner, U.H., see Ljunggren, Ö. (244) 111
Lesa, G., see Romualdi, P. (229) 149
Leslie, R.A., see Pei, Q. (230) 63
Lespy, L., see Gully, D. (232) 13
Leurs, R., see Smit, M.J. (247) 223
Leuvenink, H., see Benthem, L. (232) 279
Levant, B., Grigoriadis, D.E. and DeSouza, E.B.
Monoamine oxidase inhibitors inhibit [$^3$H]quinpirole binding in rat striatal membranes (246) 171
Levy, A.D., Rittenhouse, P.A., Bonadonna, A.M., Alvarez Sanz, M.C., Bethea, C.L. and Van de Kar, L.D.
Repeated exposure to cocaine produces long-lasting deficits in the serotonergic stimulation of prolactin and renin, but not adrenocorticotropin secretion (241) 275
Levy, J.C., see Kidd, E.J. (247) 45
Lewander, T., see Yu, H. (231) 69
Lewin, A.H., Skolnick, P., Marvizon, J.C., Paul, I.A. and Bowen, J.P.
Requirements for high affinity binding of glycine analogs to the glycine site of the NMDA receptor complex (247) 1
Lewis, M.J., see Siney, L. (229) 223
Lewis, S.J., see Davisson, R.L. (241) 135
Li, C.G., see Rand, M.J. (241) 249
Li, M., Rosenberg, H.C. and Chiu, T.H.
Tolerance to the effects of diazepam, clonazepam and bretazenil on GABA-stimulated $Cl^-$ influx in flurazepam tolerant rats (247) 313
Li, R.-K., see Zielenski, J. (248) 313
Li, X.-M., Von Euler, G., Hedlund, P.B., Finnman, U.-B. and Fuxe, K.
The C-terminal neurotensin-(8–13) fragment potently modulates rat neostriatal dopamine $D_2$ receptors (234) 125
Li, X.-M., see Tanganelli, S. (230) 159
Li, Y. and Duckles, S.P.
Effect of age on vascular content of calcitonin gene-related peptide and mesenteric vasodilator nerve activity in the rat (236) 373
Li, Y., see Chan, P. (231) 175
Li, Y.-j., Yu, X.-j. and Deng, H.-w.
Nitric oxide modulates responses to sensory nerve activation of the perfused rat mesentery (239) 127
Li, Y.-j., see Yu, X.-j. (241) 35
Liebmann, C., Nawrath, S., Ludwig, B. and Paegelow, I.
Pharmacological and molecular actions of the bradykinin $B_2$ receptor antagonist, Hoe 140, in the rat uterus (235) 183
Light, P., see Comtois, A. (242) 65
Lignon, M.-F., Bernad, N. and Martinez, J.
Cholecystokinin increases intracellular $Ca^{2+}$ concentration in the Human JURKAT T Lymphocyte Cell Line (245) 241
Lima, M.C.R., see Martins, M.A. (237) 17
Liminga, U.
Selective neurokinin $NK_1$ and $NK_2$ receptor agonists infused in the substantia nigra of the rat increase vacuous chewing (235) 177
Lin, C.-H., Ko, F.-N., Wu, Y.-C., Lu, S.-T. and Teng, C.-M.
The relaxant actions on guinea-pig trachealis of atherosperminine isolated from *Fissistigma glaucescens* (237) 109
Lin, J.J., see Tseng, L.F. (241) 63
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (233) 95
Lin-Shiau, S.-Y., see Liu, S.-H. (231) 23
Linares, H.A., see Loick, H.M. (248) 75
Lindberg, S. and Dolata, J.
$NK_1$ receptors mediate the increase in mucociliary activity produced by tachykinins (231) 375
Linden, J., see Musser, B. (246) 105
Lindskog, S., see Gregersen, S. (232) 35
Lipkowski, A., see Wild, K.D. (246) 25
Lippe, I.T., Stabentheiner, A. and Holzer, P.
Participation of nitric oxide in the mustard oil-induced neurogenic inflammation of the rat paw skin (232) 113
Litster, D.L., see Pon, D.J. (245) 119
Little, P.J., see Agrotis, A. (244) 269
Liu, G.J. and Takeuchi, H.
AJ-2615, a long-acting $Ca^{2+}$ channel antagonist with a novel structure (231) 91
Liu, G.J. and Takeuchi, H.
Modulation of neuropeptide effects by achatin-I, an *Achatina* endogenous tetrapeptide (240) 139
Liu, J.-F., see Wu, P.H. (231) 157
Liu, S.-H., Fu, W.-M. and Lin-Shiau, S.-Y.
Studies on the inhibition by chlorpromazine of myotonia induced by ion channel modulators in mouse skeletal muscle (231) 23
Liu, Y., see Von Euler, G. (245) 233

Liu, Y., see Yu, H. (231) 69
Liu, Y.J.
Evidence that [Sar$^1$]angiotensin II behaves differently from angiotensin II at angiotensin $AT_1$ receptors in rabbit aorta (235) 9
Liu, Yu.J.
Antagonist effect of losartan on angiotensin II induced contraction in five isolated smooth muscle assays (240) 147
Ljunggren, Ö., Fredholm, B.B., Nordstedt, C., Ljunghall, S. and Lerner, U.H.
Role of protein kinase C in bradykinin-induced prostaglandin formation in osteoblasts (244) 111
Ljunghall, S., see Ljunggren, Ö. (244) 111
Lloris, J.M., see Cejalvo, D. (234) 23
Lockwood, M., see Patrick, S.L. (231) 243
Lodge, D., see Palmer, A.J. (244) 193
Lodovici, M., Dolara, P., Amerini, S., Mantelli, L., Ledda, F., Bennardini, F., Fazi, M., Montereggi, A. and Dini, G.
Effects of GM1 ganglioside on cardiac function following experimental hypoxia-reoxygenation (243) 255
Löfberg, L., see Waters, N. (242) 151
Löfdahl, C.-G., see Arakawa, H. (229) 131
Logan, D.E., see Kudlacz, E.M. (241) 17
Loh, H.H., see Tao, P.-L. (231) 145
Loh, H.H., see Tao, P.-L. (246) 233
Loi, R., see Giorgi, O. (245) 139
Loiacono, R., see Christopoulos, A. (246) 1
Loiacono, R., see Christopoulos, A. (247) 227
Loick, H.M., Traber, L.D., Tokyay, R., Linares, H.A., Rogers, S., Flynn, J.T. and Traber, D.L.
Thromboxane receptor blockade with BM 13,177 following toxic airway damage by smoke inhalation in sheep (248) 75
London, E.D., see Hashimoto, K. (236) 159
Longenecker, L.L., see Bellan, J.A. (234) 273
Longo, R., see Domenici, M.R. (233) 291
López, M.G., Fonteríz, R.I., Gandía, L., De la Fuente, M., Villarroya, M., García-Sancho, J. and García, A.G.
The nicotinic acetylcholine receptor of the bovine chromaffin cell, a new target for dihydropyridines (247) 199
López, M.G., see Priego, J. (243) 25
López-Novoa, J.M., see Montero, A. (243) 235
Lorenzen, A., see Matias, A. (244) 223
Lorenzini, L., see Sgaragli, G.P. (248) 121
Lorrain, J., Grosset, A. and O'Connor, S.E.
$5\text{-}HT_4$ receptors, present in piglet atria and sensitive to SDZ 205-557, are absent in papillary muscle (229) 105
Löscher, W. and Hönack, D.
Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats (232) 147
Löscher, W. and Hönack, D.
Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats (234) 237
Löscher, W. and Hönack, D.
Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats (238) 191
Löscher, W. and Hönack, D.
Effects of the novel $5\text{-}HT_{1A}$ receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats (242) 99
Löscher, W. and Richter, A.
The glycine/NMDA receptor ligand (+)-HA-966 but not D-cycloserine has potent antidystonic efficacy in a genetic animal model of dystonia (239) 245
Löscher, W., Annies, R. and Hönack, D.
Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats (242) 263
Löscher, W., see Richter, A. (231) 111
Löscher, W., see Richter, A. (231) 287
Löscher, W., see Richter, A. (236) 289
Löscher, W., see Richter, A. (242) 309
Löschmann, P.-A., see Richter, A. (231) 287
Lötvall, J., see Arakawa, H. (229) 131
Lou, Y.-P., see Satoh, H. (236) 367
Loubatières-Mariani, M.-M., see Bertrand, G. (237) 45
Loubatières-Mariani, M.-M., see Skoglund, G. (236) 69
Low, A.M., Darby, P.J., Kwan, C.-Y. and Daniel, E.E.
Effects of thapsigargin and ryanodine on vascular contractility: cross-talk between sarcoplasmic reticulum and plasmalemma (230) 53
Lu, H.R., Remeysen, P. and De Clerck, F.
Inhibition of $Na^+/Ca^{2+}$ overload with R 56 865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs (235) 89
Lu, S.-T., see Lin, C.-H. (237) 109
Luchowski, E., see Hawthorn, M.H. (229) 143
Ludwig, B., see Liebmann, C. (235) 183
Lugnier, C., see Gil-Longo, J. (247) 119
Lugnier, C., see Ivorra, M.D. (231) 165
Lukovic, L., Petty, M.A., Bolkenius, F.N., Grisar, J.M., Dow, J. and De Jong, W.
Protection of infarcted, chronically reperfused hearts by an $\alpha$-tocopherol analogue (233) 63
Lummis, S.C.R., Sepúlveda, M.-I., Kilpatrick, G.J. and Baker, J.
Characterization of [$^3$H]meta-chlorophenylbiguanide binding to $5\text{-}HT_3$ receptors in N1E-115 neuroblastoma cells (243) 7
Lundberg, J.M., see Franco-Cereceda, A. (238) 311
Lundberg, J.M., see Satoh, H. (236) 367
Lundberg, J.M., see Weitzberg, E. (233) 85
Lundin, B., see Söderpalm, B. (239) 69
Lundquist, I., see Panagiotidis, G. (229) 277
Lundquist, I., see Panagiotidis, G. (233) 285
Lundquist, I., see Salehi, A. (243) 185
Lundy, P.M. and Frew, R.
Pharmacological characterization of voltage-sensitive $Ca^{2+}$ channels in autonomic nerves (231) 197
Luo, L. and Wiesenfeld-Hallin, Z.
Low-dose intrathecal clonidine releases tachykinins in rat spinal cord (235) 157
Luomala, K., see Marjamäki, A. (246) 219
Luquin, M.R., Obeso, J.A., Laguna, J., Guillén, J. and Martínez-Lage, J.M.
The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys (235) 297
Luttinger, D., see Fritz, P.M. (235) 229
Lutz, E.M., see MacEwan, D.J. (246) 9

Maccarone, P., see Marley, P.D. (244) 7
MacDonald, E., see McDonald, A. (240) 303
MacDonald, J.F., see Fletcher, E.J. (235) 291
MacEwan, D.J., Mitchell, R., Johnson, M.S., Thomson, F.J., Lutz, E.M., Clegg, R.A. and Connor, K.
Evidence that protein kinase $C\alpha$ has reduced affinity towards 1,2-dioctanoyl-sn-glycerol: the effects of lipid activators on phorbol ester binding and kinase activity (246) 9
Machado, A., see Ruano, D. (246) 81
Machado, A., see Santiago, M. (239) 83
Macho, P., see Domenech, R. (238) 53
MacKinnon, A.C., Stewart, M., Olverman, H.J., Spedding, M. and Brown, C.M.

[$^3$H]p-Aminoclonidine and [$^3$H]idazoxan label different populations of imidazoline sites on rat kidney (232) 79
Madsen, U., Ebert, B., Hansen, J.J. and Krogsgaard-Larsen, P.
The non-depolarizing D-form of bromohomoibotenic acid enhances depolarizations evoked by the L-form or quisqualate (230) 383
Maeda, K., Kawata, E., Sakai, K. and Chihara, K.
Effects of putative cognitive function-enhancing drugs and dopaminergic agents on somatostatin and neuropeptide Y in rat brain (233) 227
Maeda, Y., see Murai, M. (236) 7
Maehara, T., see Suzuki, H. (241) 105
Maenhaut, C., see Van Sande, J. (247) 177
Maestrelli, P., see Mapp, C.E. (248) 277
Maffrand, J.-P., see Gully, D. (232) 13
Maggi, C.A., Patacchini, R., Giuliani, S. and Giachetti, A.
In vivo and in vitro pharmacology of SR 48,968, a non-peptide tachykinin $NK_2$ receptor antagonist (234) 83
Maggi, C.A., Patacchini, R., Meini, S. and Giuliani, S.
Evidence for the presence of a septide-sensitive tachykinin receptor in the circular muscle of the guinea-pig ileum (235) 309
Maggi, C.A., Patacchini, R., Meini, S. and Giuliani, S.
Nitric oxide is the mediator of tachykinin $NK_3$ receptor-induced relaxation in the circular muscle of the guinea-pig ileum (240) 45
Maggi, C.A., see Patacchini, R. (236) 31
Maggi, C.A., see Santicioli, P. (231) 139
Mah, S.C., see Balasubramaniam, G. (237) 207
Mailman, R.B., see Watts, V.J. (239) 271
Mailman, R.B., see Watts, V.J. (242) 165
Maixner, W., see Suarez-Roca, H. (229) 1
Majima, M., Shima, C., Saito, M., Kuribayashi, Y., Katori, M. and Aoyagi, T.
Poststatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine (232) 181
Majka, J., see Konturek, S.J. (229) 155
Majka, J., see Konturek, S.J. (239) 215
Mak, J.C.W., see Nishikawa, M. (247) 131
Makimura, M., see Jaw, S.P. (239) 133
Makovec, F., see Revel, L. (229) 45
Maksay, G.
Kinetic cooperative effect of glycine receptor agonists and antagonists on the dissociation of strychnine binding (245) 183
Maksay, G.
Partial and full agonists/inverse agonists affect [$^{35}$S]TBPS binding at different occupancies of central benzodiazepine receptors (246) 255
Makujina, S.R., Olsson, R.A., Esinhart, J.D. and Mustafa, S.J.
Structure-activity relationship of 2-(ar)alkoxyadenosines at the adenosine $A_2$ receptor in coronary artery (243) 35
Malgouris, C., Flamand, F. and Doble, A.
Autoradiographic studies of RP 62203, a potent 5-$HT_2$ receptor antagonist. In vitro and ex vivo selectivity profile (233) 29
Malgouris, C., Flamand, F. and Doble, A.
Autoradiographic studies of RP 62203, a potent 5-$HT_2$ receptor antagonist. Pharmacological characterization of [$^3$H]RP 62203 binding in the rat brain (233) 37
Malmberg, Å., see Mohell, N. (238) 121
Maloteaux, J.-M., see Hermans, E. (245) 43
Maloteaux, J.-M., see Jeanjean, A.P. (241) 111
Mamelak, M., Chiu, S. and Mishra, R.K.
High- and low-affinity states of dopamine $D_1$ receptors in schizophrenia (233) 175
Manara, L., see Bachy, A. (237) 299
Mancuso, F., see Calignano, A. (231) 415
Mancuso, F., see Persico, P. (238) 105
Mancuso, F., see Persico, P. (241) 71
Manev, H., see Skaper, S.D. (243) 91
Manhães de Castro, R., see Bolaños-Jiménez, F. (242) 1
Manning, A.S., see Chatelain, P. (246) 181
Männistö, P.T., see Törnwall, M. (239) 39
Manome, Y., see Sakurada, T. (242) 47
Mansell, H.L., see Fletcher, A. (237) 283
Manson, N.H., see Okabe, E. (248) 33
Mantelli, L., see Lodovici, M. (243) 255
Mantey, S.A., see Ladenheim, E.E. (235) 121
Mantovani, M., see Bianchi, G. (238) 327
Mantovani, P., see Sgaragli, G.P. (248) 121
Manzini, S., see Riccio, M.M. (232) 89
Manzo, L., see Coccini, T. (248) 1
Mapp, C.E., Boniotti, A., Masiero, M., Plebani, M., Burlina, A., Papi, A., Maestrelli, P., Saetta, M., Ciaccia, A. and Fabbri, L.
Toluene diisocyanate-stimulated release of arachidonic acid metabolites in the organ bath from guinea-pig airways (248) 277
Mapp, C.E., Boniotti, A., Papi, A., Chitano, P., Coser, E., Di Stefano, A., Saetta, M., Ciaccia, A. and Fabbri, L.M.
The effect of compound 48/80 on contractions induced by toluene diisocyanate in isolated guinea-pig bronchus (248) 67
March, D. and Shaw, C.A.
Fetal, neonatal and adult expression of benzodiazepine receptor subtypes in human visual cortex (236) 333
Marcinkiewicz, M., see Namiot, Z. (243) 301
Marcozzi, C., see Parolaro, D. (244) 211
Marcy, C., see Gully, D. (232) 13
Marescaux, C., see Danober, L. (234) 263
Marien, M., Briley, M. and Colpaert, F.
Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice (236) 487
Marin, C. and Chase, T.N.
Dopamine $D_1$ receptor stimulation but not dopamine $D_2$ receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation (231) 191
Marin, C., see Engber, T.M. (236) 385
Marinari, L.R., see Grimes, D. (236) 217
Marini, A.M., see Weller, M. (248) 303
Marini, P., see Balduini, W. (248) 281
Mariniello, L., see Persico, P. (241) 71
Marjamäki, A., Luomala, K., Ala-Uotila, S. and Scheinin, M.
Use of recombinant human $\alpha_2$-adrenoceptors to characterize subtype selectivity of antagonist binding (246) 219
Markey, C.J., see Adeyemo, O.M. (240) 185
Markey, S.P., see Adeyemo, O.M. (240) 185
Marley, P.D., Thomson, K.A., Hoy, K. and Maccarone, P.
Regulation of cyclic AMP levels by phorbol esters in bovine adrenal medullary cells (244) 7
Màrmol, F., see Vivas, N.M. (245) 9
Marona-Lewicka, D., see Huang, X. (229) 31
Márquez, J.A., see Castillo, C. (241) 141
Marsden, C.D., see Rose, S. (230) 177
Martí, J. and Armario, A.
Effects of diazepam and desipramine in the forced swimming test: influence of previous experience with the situation (236) 295
Marti, T., see Benke, D. (246) 179
Martin, B., see Roman, F.J. (242) 305
Martin, B., see Weller, M. (248) 303
Martin, C.A.E. and Advenier, C.
Effects of cromakalim on bradykinin-, histamine- and substance P-induced airway microvascular leakage in the guinea-pig (239) 119
Martin, C.A.E., Emonds-Alt, X. and Advenier, C.
Inhibition of cholinergic neurotransmission in isolated guinea-pig main bronchi by SR 48968 (243) 309
Martin, J.R., see Jenck, F. (231) 223

Martínez, F., Vicente, I., García, F., Peñafiel, R. and Cremades, A.
Effects of different factors in lead- and cadmium-induced hypothermia in mice (248) 199
Martinez, J., see Bonnafous, C. (237) 237
Martinez, J., see Lignon, M.-F. (245) 241
Martínez-Lage, J.M., see Luquin, M.R. (235) 297
Martinez-Piñero, M.G., Vargas, M.L. and Milanés, M.V.
L-type $Ca^{2+}$ channel ligands modulate morphine effects on the hypothalamus-pituitary-adrenocortical axis in rats (232) 191
Martini, M., see Golombek, D.A. (237) 231
Martins, M.A., Lima, M.C.R., Bozza, P.T., Castro Faria Neto, H.C., Silva, P.M.R., Sunkel, C.E. and Cordeiro, R.S.B.
Interference of the PAF receptor antagonist, PCA 4248, with the rat pleurisy evoked by inflammatory mediators or allergen (237) 17
Martins, M.A., see Bozza, P.T. (248) 41
Martire, M., Pistritto, G., Mores, N., Agnati, L.F. and Fuxe, K.
Region-specific inhibition of potassium-evoked [$^3$H]noradrenaline release from rat brain synaptosomes by neuropeptide Y-(13–36). Involvement of NPY receptors of the $Y_2$ type (230) 231
Maruyama, T., see Busik, J. (247) 273
Marvizón, J.-C. and Baudry, M.
NMDA receptor activation by spermine requires glutamate but not glycine (244) 103
Marvizón, J.-C., see Lewin, A.H. (247) 1
Masada, A., see Mizuguchi, K. (231) 121
Masada, A., see Mizuguchi, K. (235) 221
Mascarella, S.W., see Walker, J.M. (231) 61
Mascarella, S.W., see Walker, J.M. (236) 495
Mascolo, N., see Izzo, A.A. (243) 87
Mäser, H., see Schmalix, W.A. (248) 251
Mashalkar, V., see Przywara, D.A. (247) 353
Masiero, M., see Mapp, C.E. (248) 277
Massart, C., see Van Sande, J. (247) 177
Massi, P., Rubino, T., Parenti, M., Giagnoni, G., Groppetti, A. and Parolaro, D.
Cholera toxin antagonizes morphine-induced catalepsy through a cyclic AMP-independent mechanism (243) 65
Massi, P., see Parolaro, D. (244) 211
Massoud, R., see Bagetta, G. (237) 61
Masui, A., Kato, N., Itoshima, T., Tsunashima, K., Nakajima, T. and Yanaihara, N.
Scratching behavior induced by bombesin-related peptides. Comparison of bombesin, gastrin-releasing peptide and phyllolitorins (238) 297
Masui, H., Wakabayashi, I., Hatake, K., Yoshimoto, S. and Sakamoto, K.
Effects of ethanol on contractile response of gall bladder isolated from guinea pig (248) 103
Mathis, C.A., see Jagust, W.J. (242) 189
Mathis, J., see Olson, R.W. (236) 75
Mathison, R. and Davison, J.S.
Altered vascular permeability responses to substance P in diabetic rats: interactions with a nitric oxide synthesis inhibitor (240) 163
Matias, A., Zimmer, F.J., Lorenzen, A., Keil, R. and Schwabe, U.
Affinity of central adenosine $A_1$ receptors is decreased in spontaneously hypertensive rats (244) 223
Matsubara, K., see Kihara, T. (230) 271
Matsuda, A., see Morimoto, H. (240) 121
Matsuda, H., see Cruz, J.d.S. (239) 223
Matsuda, K., see Itoh, K. (237) 215
Matsuda, T., see Asano, M. (247) 295
Matsuda, Y., see Nozawa, M. (236) 263
Matsui, H., see Fujisawa, M. (238) 127
Matsui, T., see Nagafuji, T. (248) 325
Matsuki, N., Torii, Y. and Saito, H.
Effects of iron and deferoxamine on cisplatin-induced emesis: further evidence for the role of free radicals (248) 329
Matsuki, N., see Torii, Y. (248) 131
Matsukura, M., see Hikasa, Y. (229) 241
Matsumoto, I., Davidson, M. and Wilce, P.A.
Polyamine-enhanced NMDA receptor activity: effect of ethanol (247) 289
Matsumoto, M., see Fujita, R. (240) 213
Matsumoto, T., Okamura, T., Kinoshita, M. and Toda, N.
Interactions of nitrovasodilators and atrial natriuretic peptide in isolated dog coronary arteries (237) 31
Matsumura, Y., Fujita, K., Takaoka, M. and Morimoto, S.
Big endothelin-3-induced hypertension and its inhibition by phosphoramidon in anaesthetized rats (230) 89
Matsumura, Y., see Hisaki, K. (241) 75
Matsunaga, T.O., see Wild, K.D. (246) 25
Matsuno, H., see Hirata, Y. (231) 421
Matsuno, K., Senda, T. and Mita, S.
Correlation between potentiation of neurogenic twitch contraction and benzomorphan $\sigma$ receptor binding potency in the mouse vas deferens (231) 451
Matsuo, M., see Murai, M. (236) 7
Matsuoka, N., Yamaguchi, I. and Satoh, M.
Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer (241) 27
Matsushita, A., see Kihara, T. (230) 271
Matsuzaki, T., Haruno, A. and Hashimoto, K.
Effects of gallopamil, a $Ca^{2+}$ channel blocker in models of ventricular arrhythmia in dogs (231) 363
Matthies, R., see Krug, M. (231) 355
Maugeri, S., see Clementi, G. (238) 101
Mayhan, W.G.
In vivo reactivity of resistance arterioles to activation of ATP-sensitive $K^+$ channels (242) 109
Mayleben, M.A., see Watts, V.J. (239) 271
Mazeaud, M., see Devynck, M.-A. (245) 105
Mazurkiewicz, M., see Jolkkonen, J. (229) 269
McAllister, K.H.
Antagonism of non-NMDA receptors inhibits handling-induced, strychnine-potentiated convulsions (231) 309
McCabe, S., see Cheng, P.Y. (230) 85
McCafferty, D.-M., Kubes, P. and Wallace, J.L.
Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin (232) 169
McCann, S.M., see Gutkowska, J. (242) 7
McCrohan, C.R., see Boulton, C.L. (236) 131
McDaniel, M.L., see Misko, T.P. (233) 119
McDonald, A., MacDonald, E., Wadsworth, R.M. and Scott, P.J.W.
Vasodilator action of cromakalim on human mesenteric artery (240) 303
McEwen, B.S., see Angulo, J.A. (244) 317
McGrath, C.R., see Baldessarini, R.J. (239) 269
McKean, J.C., see Gater, P.R. (238) 59
Mckenna, P.J., see Yue, T.-L. (240) 81
McKenniff, M.G., see Norman, P. (229) 171
McKenzie, R.J., see Von Lubitz, D.K.J.E. (233) 95
McKnight, A.T., see Hayward, N.J. (236) 247
McKnight, G.W., see Higa, A. (239) 171
McLaughlin, D.P., Cheetham, M.E. and Kerwin, R.W.
Expression of alternatively-spliced glutamate receptors in human hippocampus (244) 89
McLean, M.J., see Wamil, A.W. (230) 263
McMahon, T.J., see Cheng, D.Y. (243) 79
McManigle, J.E., see Abrahams, T.P. (238) 223

McMillan, D.E., see Hudzik, T.J. (236) 279
McNamara, D.B., see Bellan, J.A. (234) 273
McNutt, R.W., see Wild, K.D. (246) 289
Mechoulam, R., see Fride, E. (231) 313
Medeiros, Y.S. and Calixto, J.B.
Analysis of the mechanisms underlying the biphasic responses to bradykinin in circular muscle from guinea pig ileum (241) 157
Medina-Martínez, O. and Adolfo García-Sáinz, J.
Hepatocyte homologous $\beta_2$-adrenergic desensitization is associated with a decrease in number of plasma membrane $\beta_2$-adrenoceptors (244) 145
Meehan, A.G., see Knoper, S.R. (232) 65
Meehan, S.M., see Schechter, M.D. (232) 135
Meini, S., see Maggi, C.A. (235) 309
Meini, S., see Maggi, C.A. (240) 45
Meister, B., Dagerlind, Å., Nicholas, A.P. and Hökfelt, T.
Increased $\alpha_{1B}$-adrenoreceptor mRNA levels in the rat kidney after thyroidectomy (247) 229
Meldrum, B.S., see Chapman, A.G. (231) 301
Melin, P., see Vilhardt, H. (232) 223
Meloni, M., see Acquas, E. (230) 239
Meltzer, H.Y., see Pehek, E.A. (240) 107
Menargues, A., see Olmos, G. (236) 467
Menargues, A., see Ugedo, L. (239) 149
Mendelson, S.D., Quartermain, D., Francisco, T. and Shemer, A.
5-$HT_{1A}$ receptor agonists induce anterograde amnesia in mice through a postsynaptic mechanism (236) 177
Mengozzi, G., see Intorre, L. (243) 265
Mennini, T., Taddei, C., Codegoni, A., Gobbi, M. and Garattini, S.
Acute noise stress reduces [$^3$H]5-hydroxytryptamine uptake in rat brain synaptosomes: protective effects of buspirone and tianeptine (241) 255
Mennini, T., see Gobbi, M. (238) 9
Menshikov, M.Y., Ivanova, K., Schaefer, M., Drummer, C. and Gerzer, R.
Influence of the cGMP analog 8-PCPT-cGMP on agonist-induced increases in cytosolic ionized $Ca^{2+}$ and on aggregation of human platelets (245) 281
Mergen, F., see Lambert, D.M. (243) 129
Mertens, J., see Nijs, G. (239) 241
Mesnil, M., Piccoli, C. and Yamasaki, H.
An improved long-term culture of rat hepatocytes to detect liver tumour-promoting agents: results with phenobarbital (248) 59
Mestre, M., see Jeanjean, A.P. (241) 111
Metafora, S., see Persico, P. (241) 71
Metters, K.M., see Frey, E.A. (244) 239
Metters, K.M., see Slipetz, D.M. (244) 161
Mewett, K.N., see Ong, J. (233) 169
Meyer, D.K., see Mondeh, J.D. (240) 39
Meyers, K.P., see Morgan, D.W. (235) 45
Meyerson, B.J., see Johansson-Wallsten, C.E. (243) 149
Miceli, A., see Squadrito, F. (237) 223
Miceli, R.C., see Guilarte, T.R. (248) 273
Michaud, J.-C., see Bachy, A. (237) 299
Michel, B., Stephan, D., Grima, M., Barthelmebs, M. and Imbs, J.-L.
Effects of one-hour and one-week treatment with ramipril on plasma and renal brush border angiotensin converting enzyme in the rat (242) 237
Michel, J.-B., see Arnal, J.-F. (237) 265
Michelena, P., see Moro, M.A. (246) 213
Mickel, S.J., see Brugger, F. (235) 153
Mickel, S.J., see Oipe, H.-R. (233) 179
Mickle, D.A.G., see Zielenski, J. (248) 313
Middlemiss, D.N., see Beer, M.S. (236) 167
Middlemiss, D.N., see Beer, M.S. (242) 195
Mihara, S.-i. and Fujimoto, M.
The endothelin $ET_A$ receptor-specific effect of 50-235, a nonpeptide endothelin antagonist (246) 33
Mihara, S.-i., Sakurai, K., Nakamura, M., Konoike, T. and Fujimoto, M.
Structure-activity relationships of an endothelin $ET_A$ receptor antagonist, 50-235, and its derivatives (247) 219
Mihic, S.J., see Wu, P.H. (231) 157
Mihm, G., see Doods, H. (242) 23
Mikhailidis, D., see Jeremy, J.Y. (245) 67
Milanés, M.V., see Martinez-Piñero, M.G. (232) 191
Milicic, I., see Pollock, D.M. (231) 459
Millan, M.J. and Seguin, L.
(+)-HA 966, a partial agonist at the glycine site coupled to NMDA receptors, blocks formalin-induced pain in mice (238) 445
Millan, M.J., Rivet, J.-M., Canton, H., Lejeune, F., Gobert, A., Widdowson, P., Bervoets, K., Brocco, M. and Peglion, J.-L.
S 15535: a highly selective benzodioxopiperazine 5-$HT_{1A}$ receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively (230) 99
Millan, M.J., see Lejeune, F. (240) 307
Mills, M., see Rossowski, W.J. (240) 259
Milner, P., see Rennick, R.E. (230) 367
Milner, R., see Harrison, S. (237) 83
Minchin, M.C.W., see Ennis, C. (248) 85
Mine, Y., see Fukunaga, Y. (233) 237
Minegishi, K.-i., see Iwata, N. (248) 243
Mingeot-Leclercq, M.-P., see Van Bambeke, F. (247) 155
Minkes, R.K., see Osei, S.Y. (234) 35
Minocha, A. and Galligan, J.J.
Excitatory and inhibitory responses mediated by $GABA_A$ and $GABA_B$ receptors in guinea pig distal colon (230) 187
Miocque, M., see Scamps, F. (244) 119
Miralles, A., Ribas, C., Olmos, G. and García-Sevilla, J.A.
No effect of genetic obesity and mazindol on imidazoline $I_2$ binding sites in the brain of Zucker rats (243) 305
Miralles, A., see Olmos, G. (236) 467
Miralles, A., see Ugedo, L. (239) 149
Miranda, F.J., see Alborch, E. (229) 83
Mironneau, C., see Sayet, I. (246) 275
Mironneau, J., see Sayet, I. (246) 275
Misawa, M., see Kamei, J. (233) 251
Misawa, M., see Kamei, J. (234) 117
Misawa, M., see Kamei, J. (240) 99
Misawa, M., see Kamei, J. (242) 209
Mishra, R.K., see Mamelak, M. (233) 175
Misicka, A., see Wild, K.D. (246) 25
Misko, T.P., Moore, W.M., Kasten, T.P., Nickols, G.A., Corbett, J.A., Tilton, R.G., McDaniel, M.L., Williamson, J.R. and Currie, M.G.
Selective inhibition of the inducible nitric oxide synthase by aminoguanidine (233) 119
Misko, T.P., see Kato, J. (244) 153
Mistry, R., see Arnold, I.R. (245) 285
Mita, S., see Matsuno, K. (231) 451
Mitch, C.H., see Shannon, H.E. (232) 47
Mitchell, R., see Fleetwood-Walker, S.M. (242) 173
Mitchell, R., see MacEwan, D.J. (246) 9
Mitchell, T., see Bensoussan, M. (247) 169
Mitchelson, F., see Christopoulos, A. (246) 1
Mitchelson, F., see Christopoulos, A. (247) 227
Mitsui, M., see Hagiwara, S. (234) 1
Miura, M., see Belvisi, M.G. (231) 97
Miwa, A., see Ohta, H. (231) 323
Miwa, Y., see Kikuchi de Beltrán, K. (239) 47

Miyake, H., see Miyoshi, K. (238) 139
Miyake, H., see Murai, M. (236) 7
Miyake, H., see Takeuchi, K. (231) 135
Miyake, K., Tanonaka, K., Nasa, Y., Takagi, N., Tsuchiya, T., Yoshizawa, M., Fujioka, Y. and Takeo, S.
Effects of naftidrofuryl oxalate on microsphere embolism-induced changes in tricarboxylic acid cycle intermediates of rats (235) 75
Miyamori, I., see Takeda, Y. (233) 299
Miyamoto, K., see Nagakawa, J.-i. (229) 63
Miyamoto, M., Hirai, K., Takahashi, H., Kato, K., Nishiyama, M., Okada, H. and Nagaoka, A.
Effects of sustained release formulation of thyrotropin-releasing hormone on learning impairments caused by scopolamine and AF64A in rodents (238) 181
Miyamoto, O., see Fujisawa, M. (238) 127
Miyaoka, T., see Tseng, Y.T. (236) 23
Miyata, K., see Kamato, T. (238) 369
Miyatake, A., see Tamaki, T. (236) 15
Miyoshi, K., Kanda, A., Miyake, H., Ichihara, K., Kamei, H. and Nagasaka, M.
MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action (238) 139
Mizota, M., see Mizuguchi, K. (231) 121
Mizota, M., see Mizuguchi, K. (235) 221
Mizuguchi, K., Yano, T., Ishibashi, M., Masada, A., Mizota, M. and Saito, Y.
Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein (235) 221
Mizuguchi, K., Yano, T., Tanaka, Y., Ishibashi, M., Masada, A., Mizota, M., Fukutake, K. and Saito, Y.
Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate (231) 121
Mizuhara, H., see Morimoto, H. (240) 121
Mizuma, K., see Tachikawa, E. (236) 355
Mjörndal, T., see Cassel, G.E. (248) 297
Modin, A., see Pernow, J. (243) 281
Mohell, N., Sällemark, M., Rosqvist, S., Malmberg, Å., Högberg, T. and Jackson, D.M.
Binding characteristics of remoxipride and its metabolites to dopamine $D_2$ and $D_3$ receptors (238) 121
Mohler, H., see Benke, D. (246) 179
Mok, W., see Wong, S. (245) 55
Molnár, L., see Hegedüs, K. (237) 293
Molthagen, M., see Dawirs, R.R. (241) 89
Moltrasio, D., see Bianchi, G. (238) 327
Moncada, S., see Calignano, A. (229) 273
Moncada, S., see Moro, M.A. (246) 213
Mondeh, J.D., Olenik, C., Götz, E., Uhl, A. and Meyer, D.K.
Cerebral cortex injury: effect of blockers of re-uptake of catecholamines (240) 39
Montereggi, A., see Lodovici, M. (243) 255
Montero, A., Rodriguez-Barbero, A. and López-Novoa, J.M.
A role for platelet-activating factor in endothelin-1-induced rat mesangial cell proliferation (243) 235
Monti, E., see Bradamante, S. (239) 275
Montiel, C., Artalejo, A.R., Sánchez-García, P. and García, A.G.
Two components in the adrenal nicotinic secretory response revealed by cobalt ramps (230) 77
Montuschi, P., Preziosi, P. and Navarra, P.
Interleukin-1$\alpha$ and tumour necrosis factor inhibit rat gastric fundus motility in vitro (233) 303
Moore, N.A., Blackman, A., Awere, S. and Leander, J.D.
NMDA receptor antagonists inhibit catalepsy induced by either dopamine $D_1$ or $D_2$ receptor antagonists (237) 1
Moore, W.M., see Misko, T.P. (233) 119
Moorman, J., see Grasby, P. (230) 41
Morales-Aguilera, A. and Sampayo-Reyes, A.
Molecular changes in erythrocyte membranes induced by long-term administration of clofibrate (245) 89
Moran, T.H., see Ladenheim, E.E. (235) 121
Morcillo, E.J., see Cejalvo, D. (234) 23
Moreau, J.-L., see Jenck, F. (231) 223
Morel, N., see Dessy, C. (231) 435
Morel, O., see Clerc, T. (235) 59
Mores, N., see Martire, M. (230) 231
Moret, C. and Briley, M.
Does 5-carboxamidotryptamine-induced turning in guinea-pigs involve 5-$HT_{1D}$ autoreceptors? (230) 379
Morgan, D.W., Anderson, C.M. and Meyers, K.P.
Recombinant human type II phospholipase $A_2$ lacks edema producing activity in rat (235) 45
Morgan, J.M., see Castle, N.A. (236) 201
Morgan, M.E., see Musser, B. (246) 105
Morgan, N.G., see Chan, S.L.F. (230) 375
Mori, E., see Ukai, M. (231) 143
Mori, H., see Ichihara, K. (238) 283
Mori, J., see Isono, T. (246) 205
Mori, K., see Ukai, M. (239) 237
Mori, Y., see Honda, A. (229) 217
Morikawa, A., see Kato, M. (232) 7
Morikawa, A., see Yokoyama, T. (236) 427
Morikawa, M., Sekizawa, K. and Sasaki, H.
Inhibitory actions of cyclic AMP on neurogenic plasma extravasation in rat airways (241) 83
Morimoto, H., Yamashita, M., Imazumi, K., Matsuda, A., Ochi, T., Seki, N., Mizuhara, H., Fujii, T. and Senoh, H.
Effects of adenosine $A_2$ receptor agonists on the excitation of capsaicin-sensitive afferent sensory nerves in airway tissues (240) 121
Morimoto, S., see Hisaki, K. (241) 75
Morimoto, S., see Matsumura, Y. (230) 89
Morita, I., see Oikawa, T. (241) 221
Morley, J.E., see Flood, J.F. (240) 311
Moro, M.A., Michelena, P., Sánchez-García, P., Palmer, R., Moncada, S. and García, A.G.
Activation of adrenal medullary L-arginine : nitric oxide pathway by stimuli which induce the release of catecholamines (246) 213
Morrow, B.A., Clark, W.A. and Roth, R.H.
Stress activation of mesocorticolimbic dopamine neurons: effects of a glycine/NMDA receptor antagonist (238) 255
Morti, E., see Bradamante, S. (234) 113
Mos, J., Olivier, B., Poth, M., Van Oorschot, R. and Van Aken, H.
The effects of dorsal raphe administration of eltoprazine, TFMPP and 8-OH-DPAT on resident intruder aggression in the rat (238) 411
Mos, J., see Haensel, S.M. (233) 187
Mosberg, H.I., see Raffa, R.B. (244) 231
Moser, U., see Eltze, M. (238) 343
Motoyama, Y., see Dohi, M. (243) 179
Moulian, N., Gaudry-Talarmain, Y.M. and Israël, M.
The effect of MR16728, a cetiedil analogue, on acetylcholine release in *Torpedo* synaptosomes (231) 407
Moussaoui, S.M., Philippe, L., Le Prado, N. and Garret, C.
Inhibition of neurogenic inflammation in the meninges by a non-peptide $NK_1$ receptor antagonist, RP 67580 (238) 421
Movva, N.R., see Schneider, H. (246) 149
Moy, M.L., see Hammond, D.L. (229) 227
Mucha, I., see Saareks, V. (248) 345
Mukaiyama, O., see Itoh, K. (237) 215
Mukaiyama, O., see Itoh, K. (239) 159
Mukaiyama, O., see Yamaguchi, T. (236) 43
Mukherjee, J., Yang, Z.-Y. and Perry, B.D.
Fluorine-18 labelled substituted benzazepines as potential radio-

tracers for imaging dopamine $D_1$ receptors by positron emission tomography (243) 287
Mulder, A.H., see Heijna, M.H. (229) 197
Mulder, A.H., see Ronken, E. (230) 349
Mulder, A.H., see Tjon Tien Ril, H.K.G. (235) 321
Mulder, A.H., see Van Vliet, B.J. (245) 23
Müller, D., see Honscha, W. (246) 227
Muller, E.E., see Cattaneo, L. (241) 245
Müller, W.E.G., Ushijima, H., Schröder, H.C., Forrest, J.M.S., Schatton, W.F.H., Rytik, P.G. and Heffner-Lauc, M.
Cytoprotective effect of NMDA receptor antagonists on prion protein ($Prion^{Sc}$)-induced toxicity in rat cortical cell cultures (246) 261
Mulvany, M.J., see Prieto, D. (238) 27
Mulvihill, E., see Thomsen, C. (244) 187
Mungan, Z., see Rossowski, W.J. (240) 259
Munro, F.E., see Fleetwood-Walker, S.M. (242) 173
Muntoni, A., see Diana, M. (230) 363
Murai, M., Maeda, Y., Hagiwara, D., Miyake, H., Ikari, N., Matsuo, M. and Fujii, T.
Effects of an $NK_1$ receptor antagonist, FK888, on constriction and plasma extravasation induced in guinea pig airway by neurokinins and capsaicin (236) 7
Murakami, F., see Kanai, Y. (248) 191
Muramatsu, I., see Hashimoto, S. (231) 209
Muramatsu, I., see Noguchi, H. (240) 291
Muramatsu, M., see Tanaka, M. (238) 89
Muramatsu, M., see Tanaka, M. (238) 93
Muraoka, R., see Noguchi, H. (240) 291
Murata, S. and Kawasaki, K.
Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor/channel complex (239) 9
Murota, S.-i., see Oikawa, T. (241) 221
Murphy, D.L., see Aulakh, C.S. (240) 85
Murphy, D.L., see Wu, R.-M. (243) 241
Murphy, W.A., see Cheng, D.Y. (243) 79
Murray, T.F., see Musser, B. (246) 105
Murray, T.F., see Roth, J.E. (236) 327
Murthy, J.N., see Pranzatelli, M.R. (244) 1
Muryobayashi, K., see Nakagawa, N. (235) 211
Musser, B., Morgan, M.E., Leid, M., Murray, T.F., Linden, J. and Vestal, R.E.
Species comparison of adenosine and $\beta$-adrenoceptors in mammalian atrial and ventricular myocardium (246) 105
Musser, J.H., see Grimes, D. (236) 217
Mustafa, A.A. and Alhaider, A.A.
Differential effects of fluoxetine on isoprenaline-stimulated water intake in ethanol-treated rats: a role for $\beta$-adrenoceptors (237) 147
Mustafa, S.J., see Makujina, S.R. (243) 35
Mutabagani, K., see Tamura, K. (232) 235
Mutel, V., see Jenck, F. (231) 223
Mutoh, M., see Torii, Y. (248) 131
Mutschler, E., see Eltze, M. (238) 343
Myers, J.H., see Watts, S.W. (242) 245

Nabeshima, T., see Fuji, K. (236) 411
Nabeshima, T., see Ichihara, K. (234) 155
Nabeshima, T., see Ishihara, S.-i. (230) 313
Nadel, J.A., see Huber, O. (239) 103
Nadel, J.A., see Yamawaki, I. (243) 1
Nagafuji, T., Sugiyama, M., Matsui, T. and Koide, T.
A narrow therapeutical window of a nitric oxide synthase inhibitor against transient ischemic brain injury (248) 325
Nagakawa, J.-i., Hishinuma, I., Hirota, K., Miyamoto, K., Yamanaka, T., Yamatsu, I. and Katayama, K.-i.
Protective effects of E3330, a novel quinone derivative, on galactosamine/tumor necrosis factor-$\alpha$-induced hepatitis in mice (229) 63
Nagakura, Y., see Kamato, T. (238) 369
Nagao, S., see Fujisawa, M. (238) 127
Nagao, T., see Tateyama, M. (240) 51
Nagao, T., see Watanabe, H. (243) 155
Nagaoka, A., see Miyamoto, M. (238) 181
Nagasaka, M., see Ichihara, K. (238) 283
Nagasaka, M., see Miyoshi, K. (238) 139
Nagasaka, M., see Okumura, K. (235) 69
Nagasaki, M., Komori, S., Tamaki, H. and Ohashi, H.
Effect of trimebutine on $K^+$ current in rabbit ileal smooth muscle cells (235) 197
Nagase, H., see Kamei, J. (233) 251
Nagase, H., see Kamei, J. (234) 117
Nagase, H., see Kamei, J. (240) 99
Nagorny, R., see Bourinbaiar, A.S. (230) 15
Nah, S.-Y., Attali, B. and Vogel, Z.
Heterologous desensitization and reduced G protein ADP-ribosylation following exposure to $\alpha_2$-adrenoceptor and muscarinic receptor agonists (244) 67
Nah, S.-Y., Saya, D. and Vogel, Z.
Cannabinoids inhibit agonist-stimulated formation of inositol phosphates in rat hippocampal cultures (246) 19
Nakagawa, N., Obata, T., Kobayashi, T., Okada, Y., Nambu, F., Terawaki, T., Furuya, T., Muryobayashi, K., Sawada, M. and Aishita, H.
Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma (235) 211
Nakajima, T., see Masui, A. (238) 297
Nakakuki, M., see Shinkawa, T. (238) 317
Nakamura, H., see Kita, A. (237) 317
Nakamura, M., see Mihara, S.-i. (247) 219
Nakamura, S., see Ishiyama, Y. (241) 271
Nakane, T., see Noguchi, M. (234) 101
Nakanishi, H., see Okawa, T. (230) 341
Nakanishi, S., see Suzuki, H. (241) 105
Nakano, T., see Itoh, H. (240) 57
Nakano, T., see Suga, T. (242) 129
Nakashima, H., Kakei, M. and Tanaka, H.
Activation of the ATP-sensitive $K^+$ channel by decavanadate in guinea-pig ventricular myocytes (233) 219
Nakashima, M., see Hirata, Y. (231) 421
Nakashima, M., see Umemura, K. (239) 17
Nakashio, A., see Shibata, S. (245) 257
Nakazato, P., see Huber, O. (239) 103
Nakazawa, H., see Ohta, H. (231) 323
Nakazawa, K., see Fujita, K. (242) 301
Nakazawa, K., see Suzuki, S. (231) 297
Namba, T., see Takaki, M. (237) 51
Nambu, F., see Nakagawa, N. (235) 211
Namikawa, Y., see Dohi, M. (243) 179
Namiot, Z., Marcinkiewicz, M., Jaroszewicz, W., Stasiewicz, J. and Gorski, J.
Mucosal adenosine deaminase activity and gastric ulcer healing (243) 301
Nánási, P.P., see Lathrop, D.A. (240) 127
Nappi, G., see Sandrini, G. (243) 99
Nasa, Y., see Hoque, A.N.E. (236) 269
Nasa, Y., see Miyake, K. (235) 75
Nauert, C., see Konturek, S.J. (229) 155
Navarra, P., see Montuschi, P. (233) 303
Nawrath, S., see Liebmann, C. (235) 183
Naylor, R.J., see Cheng, C.H.K. (239) 211
Naylor, R.J., see Costall, B. (234) 91
Naylor, R.J., see Williams, T.J. (245) 197

Negi, T., see Fujisawa, M. (238) 127
Neijt, J.P., see Hamers, F.P.T. (233) 177
Neliat, G., see Gully, D. (232) 13
Nellgård, P., see Bojö, L. (236) 443
Nelson, D.L., see Johnson, M.P. (239) 111
Nelson, S.H., Suresh, M.S., Dehring, D.J. and Johnson, R.L.
Relaxation by calcitonin gene-related peptide may involve activation of $K^+$ channels in the human uterine artery (242) 255
Nénonéné, E.K., see Dewar, K.M. (235) 137
Netzer, R., Pflimlin, P. and Trube, G.
Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons (238) 209
Neuilly, G., see Sayet, I. (246) 275
Neuman, R.S., see Rahman, S. (231) 347
Neuman, R.S., see Rahman, S. (238) 173
Neumeyer, J.L., see Baldessarini, R.J. (239) 269
Neve, K.A., see Watts, V.J. (239) 271
Neves, M.C.A., see Neves, P.C.A. (243) 213
Neves, P.C.A., Neves, M.C.A., Cruz, A.B., Sant'Ana, A.E.G., Yunes, R.A. and Calixto, J.B.
Differential effects of *Mandevilla velutina* compounds on paw oedema induced by phospholipase $A_2$ and phospholipase C (243) 213
Newcomer, J.W., see Bardgett, M.E. (230) 245
Nicholas, A.P., see Meister, B. (247) 229
Nichols, D.E., see Huang, X. (229) 31
Nichols, D.E., see Huang, X. (238) 291
Nichols, D.E., see Kohli, J.D. (235) 31
Nichols, D.E., see Watts, V.J. (239) 271
Nichols, D.E., see Watts, V.J. (242) 165
Nicholson, D.W., see Frey, E.A. (244) 239
Nicholson, D.W., see Slipetz, D.M. (244) 161
Nickols, G.A., see Misko, T.P. (233) 119
Nicoletti, F., Casabona, G., Genazzani, A.A., L'Episcopo, M.R. and Shinozaki, H.
($2_S$,$1'_R$,$2'_R$,$3'_R$)-2-(2,3-Dicarboxycyclopropyl)glycine enhances quisqualate-stimulated inositol phospholipid hydrolysis in hippocampal slices (245) 297
Nie, S.-Q., Kwan, C.-Y. and Epand, R.M.
Pyrazine derivatives affect membrane fluidity of vascular smooth muscle microsomes in relation to their biological activity (244) 15
Nielsen, E.Ø., see Johansen, T.H. (246) 195
Nielsen-Kudsk, J.E., see Pedersen, C.M. (238) 75
Nielsen, M., see Kidd, E.J. (247) 45
Nieuwenhuijzen Kruseman, A., see Huijberts, M. (240) 207
Nieves, A.L., see Woodward, D.F. (230) 327
Nihonyanagi, K. and Oba, T.
Gold ion induces contraction in frog skeletal muscle fibers (238) 149
Nijkamp, F.P., see Ladenius, A.R.C. (235) 127
Nijkamp, F.P., see Van Oosterhout, A.J.M. (236) 379
Nijkamp, F.P., see Van Oosterhout, A.J.M. (239) 277
Nijs, G., De Witte, P., Geboes, K., Mertens, J. and Eyssen, H.
Conventionalization of germ-free rats reverses the disability of rhein anthrone to induce laxation (239) 241
Niki, S., see Takeuchi, K. (231) 135
Nikolov, R., Rami, A. and Krieglstein, J.
Endothelin-1 exacerbates focal cerebral ischemia without exerting neurotoxic action in vitro (248) 205
Niles, L.P., see Ying, S.-W. (246) 89
Nishi, S., see Yamada, S. (232) 1
Nishida, A., see Kamato, T. (238) 369
Nishiguchi, S., see Hisaki, K. (241) 75
Nishii, M., see Isono, T. (246) 205
Nishijima, K., see Shinkawa, T. (238) 317
Nishikawa, M., Mak, J.C.W., Shirasaki, H. and Barnes, P.J.
Differential down-regulation of pulmonary $\beta_1$- and $\beta_2$-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline (247) 131
Nishikawa, T., see Shirayama, Y. (237) 117
Nishikibe, M., see Noguchi, K. (233) 47
Nishikori, K., see Ohta, H. (231) 323
Nishimura, H., see Oka, T. (234) 55
Nishio, H., see Yoshikawa, S. (239) 261
Nishiyama, A., see Tamaki, T. (236) 15
Nishiyama, M., see Miyamoto, M. (238) 181
Nissen, J.S., see Johnson, M.P. (239) 111
Nisticò, G., see Bagetta, G. (237) 61
Niwa, M., see Taniyama, K. (235) 149
Noble, F., Fournié-Zaluski, M.-C. and Roques, B.P.
Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice (230) 139
Noguchi, H., Muraoka, R., Kigoshi, S. and Muramatsu, I.
$\alpha_1$-Adrenoceptor subtype involved in the positive inotropic response to phenylephrine in rat atria (240) 291
Noguchi, K., Noguchi, Y., Hirose, H., Nishikibe, M., Ihara, M., Ishikawa, K. and Yano, M.
Role of endothelin $ET_B$ receptors in bronchoconstrictor and vasoconstrictor responses in guinea-pigs (233) 47
Noguchi, M., Nakane, T. and Chiba, S.
Characterization of 5-HT receptors in simian isolated gastroepiploic artery (234) 101
Noguchi, Y., see Noguchi, K. (233) 47
Nomoto, M., see Irifune, M. (238) 235
Nomoto, M., see Rose, S. (230) 177
Nomura, H., see Nomura, T. (246) 113
Nomura, T., Kondo, H., Hasegawa, S., Watanabe, T., Yokoyama, R., Ukai, K., Tachibana, M., Sumi-Ichinose, C., Nomura, H. and Hagino, Y.
$\alpha_{1B}$-Adrenoceptor-mediated stimulation of $Ca^{2+}$ mobilization and cAMP accumulation in isolated rat hepatocytes (246) 113
Nordgren, I., see Hemming, H. (248) 163
Nordholm, L., see Sheardown, M.J. (236) 347
Nordstedt, C., see Ljunggren, Ö. (244) 111
Norisue, M., see Okabe, E. (248) 33
Norman, P., Cuthbert, N.J., McKenniff, M.G. and Gardiner, P.J.
The thromboxane receptors of rat and guinea-pig lung (229) 171
Norman, P., see Gardiner, P.J. (238) 19
Norris, S.K., Boden, P.R. and Woodruff, G.N.
Agonists selective for tachykinin $NK_1$ and $NK_3$ receptors excite subpopulations of neurons in the rat medial habenula nucleus in vitro (234) 223
Norton, B., see Gwilt, M. (236) 107
Notsu, T., see Shinkawa, T. (238) 317
Notz, P.K., see Bubser, M. (229) 75
Nouso, K., see Salonpää, P. (248) 95
Novosad, E.I., see Pollock, D.M. (231) 459
Nowak, G., Paul, I.A., Popik, P., Young, A. and Skolnick, P.
$Ca^{2+}$ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex (247) 101
Nowak, G., see Paul, I.A. (247) 305
Nozaki, K., Finklestein, S.P. and Beal, M.F.
Delayed administration of basic fibroblast growth factor protects against N-methyl-D-aspartate neurotoxicity in neonatal rats (232) 295
Nozawa, M., Toki, S. and Matsuda, Y.
The neuroprotective properties of ES-242s, novel NMDA receptor antagonists, in neuronal cell culture toxicity studies (236) 263
Nyborg, N.C.B., see Prieto, D. (238) 27

Oba, T., see Nihonyanagi, K. (238) 149
Obach, R., see Olmos, G. (236) 467
Obach, R., see Ugedo, L. (239) 149
Obata, T., see Nakagawa, N. (235) 211
Obeso, J.A., see Luquin, M.R. (235) 297
Obinu, M.C., see Imperato, A. (229) 265
Obinu, M.C., see Imperato, A. (238) 135
Obinu, M.C., see Imperato, A. (238) 377
O'Brien, A., see Boot, J.R. (231) 83
Ocaña, M., Del Pozo, E. and Baeyens, J.M.
ATP-dependent $K^+$ channel blockers antagonize morphine- but not U-504,88H-induced antinociception (230) 203
Ocaña, M., Del Pozo, E. and Baeyens, J.M.
Gliquidone, an ATP-dependent $K^+$ channel antagonist, antagonizes morphine-induced hypermotility (239) 253
Ochi, T., see Morimoto, H. (240) 121
Ochsner, M., Huwiler, A., Fleck, T. and Pfeilschifter, J.
Protein kinase C inhibitors potentiate angiotensin II-induced phosphoinositide hydrolysis and intracellular $Ca^{2+}$ mobilization in renal mesangial cells (245) 15
O'Connor, B., see Pagani, E.D. (243) 141
O'Connor, S.E., see Choppin, A. (231) 469
O'Connor, S.E., see Lorrain, J. (229) 105
O'Connor, W.T., see Tanganelli, S. (230) 159
Octave, J.-N., see Hermans, E. (245) 43
Oda, N., see Okumura, K. (235) 69
Offner, F., see Wöll, E. (246) 269
Ogasawara, A., Hisa, H. and Satoh, S.
Effects of nifedipine and TMB-8 on renal vasoconstriction induced by hypertonic saline in dogs (243) 103
Ogasawara, S., see Hikasa, Y. (229) 241
Ogawa, N., see Ohta, H. (231) 323
Ogawa, N., see Okada, Y. (241) 177
Ogidigben, M.J., see Potter, D.E. (236) 61
Ögren, S.O., Pramanik, A., Land, T. and Langel, Ü.
Differential effects of the putative galanin receptor antagonists M15 and M35 on striatal acetylcholine release (242) 59
Ogura, H., see Ohya, K. (248) 111
Ohashi, H., see Nagasaki, M. (235) 197
Ohayon, M., see Dewar, K.M. (235) 137
Ohba, M., see Sakurada, T. (242) 47
Ohkubo, M., see Hodgkiss, J.P. (240) 219
Ohnishi, H., see Shibata, M. (235) 245
Ohno, M., Yamamoto, T. and Watanabe, S.
Working memory deficits induced by intrahippocampal administration of 8-OH-DPAT, a 5-$HT_{1A}$ receptor agonist, in the rat (234) 29
Ohno, M., Yamamoto, T., Kobayashi, M. and Watanabe, S.
Impairment of working memory induced by scopolamine in rats with noradrenergic DSP-4 lesions (238) 117
Ohno, Y., see Guo, X. (248) 337
Ohta, H., Nakazawa, H., Jinno, Y., Harada, K., Ogawa, N., Miwa, A. and Nishikori, K.
Effects of $K^+$ channel openers on ischemic dysfunction and metabolic disturbance in isolated perfused rat heart (231) 323
Ohta, S., see Tateyama, M. (240) 51
Ohta, S., see Watanabe, H. (243) 155
Ohtsuka, M., see Isono, T. (246) 205
Ohuchi, T., see Takeuchi, K. (231) 135
Ohya, K. and Ogura, H.
The effects of colchicine or vinblastine on the blood calcium level in rats (248) 111
Oikawa, T., Ito, H., Ashino, H., Toi, M., Tominaga, T., Morita, I. and Murota, S.-i.
Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis (241) 221
Oishi, R., Adachi, N. and Saeki, K.
$N^{\alpha}$-Methylhistamine inhibits intestinal transit in mice by central histamine $H_1$ receptor activation (237) 155
Oka, T., Nishimura, H., Ueyama, M., Kubota, J. and Kawamura, K.
Lisinopril reduces cardiac hypertrophy and mortality in rats with aortocaval fistula (234) 55
Okabe, E., Takahashi, S.-s., Norisue, M., Manson, N.H., Kukreja, R.C., Hess, M.L. and Ito, H.
The effect of hypochlorous acid and hydrogen peroxide on coronary flow and arrhythmogenesis in myocardial ischemia and reperfusion (248) 33
Okabe, S., see Takeuchi, K. (231) 135
Okada, H., see Miyamoto, M. (238) 181
Okada, T., see Karaki, H. (231) 371
Okada, Y., Yokoyama, T., Jinno, Y., Kashiwabara, T., Izawa, T., Fukushima, H. and Ogawa, N.
Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery (241) 177
Okada, Y., see Nakagawa, N. (235) 211
Okamoto, H., see Yayama, K. (236) 337
Okamoto, K., see Sakuta, H. (244) 277
Okamoto, K., see Yoneda, I. (247) 267
Okamura, M., see Iwai, J. (248) 341
Okamura, T., see Matsumoto, T. (237) 31
Okawa, T., Suzuki, Y., Endo, C., Hoshi, K., Sato, A. and Nakanishi, H.
The influence of prostaglandins on the contractile response to electrical field stimulation in rabbit myometrial and cervical smooth muscles (230) 341
Okubo, M., see Sherriffs, H.J. (247) 319
Okumura, K., Ichihara, K., Nagasaka, M., Oda, N. and Tajima, K.
Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites (235) 69
Okumura, K., see Ichihara, K. (238) 283
Okuyama, S., see Tanaka, M. (238) 89
Olbrich, H.-G., see Witte, K. (247) 215
Olenik, C., see Mondeh, J.D. (240) 39
Olgart, L., see Kerezoudis, N.P. (241) 209
Olievier, C.N., see Berkenbosch, A. (232) 21
Olivier, B., see Mos, J. (238) 411
Olmos, G., Miralles, A., García-Sevilla, J.A., Giralt, M.T., Pineda, J., Garro, M.A., Ugedo, L., Menargues, A. and Obach, R.
Acute and chronic effects of cholinesterase inhibitors and pilocarpine on the density and sensitivity of central and peripheral $\alpha_2$-adrenoceptors (236) 467
Olmos, G., see Miralles, A. (243) 305
Olmos, G., see Ugedo, L. (239) 149
Olpe, H.-R., Steinmann, M.W., Ferrat, T., Pozza, M.F., Greiner, K., Brugger, F., Froestl, W., Mickel, S.J. and Bittiger, H.
The actions of orally active $GABA_B$ receptor antagonists on GABAergic transmission in vivo and in vitro (233) 179
Olpe, H.-R., see Brugger, F. (235) 153
Olson, R.W., Dotson, R., Mathis, J., Cohen, D.S. and Webb, R.L.
Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis (236) 75
Olsson, R.A., see Makujina, S.R. (243) 35
Olverman, H.J., see Hodgkiss, J.P. (240) 219
Olverman, H.J., see MacKinnon, A.C. (232) 79
Olverman, H.J., see Sherriffs, H.J. (247) 319
Omata, K., see Escalante, B. (235) 1
Omini, C., see Yamawaki, I. (243) 1
O'Neill, A.B., see Brioni, J.D. (238) 1
Ong, J., Kerr, D.I.S., Doolette, D.J., Duke, R.K., Mewett, K.N., Allen, R.D. and Johnston, G.A.R.

R-(−)-β-phenyl-GABA is a full agonist at $GABA_B$ receptors in brain slices but a partial agonist in the ileum (233) 169
Ong, J., see Kerr, D.I.B. (236) 239
Ongini, E., see Trampus, M. (235) 83
Ono, H., see Tateyama, M. (240) 51
Ono, H., see Watanabe, H. (243) 155
Onodera, K., see Yokoyama, H. (234) 129
Onodera, S., see Shibata, M. (235) 245
Ooboshi, H., Sadoshima, S., Ibayashi, S., Yao, H., Uchimura, H. and Fujishima, M.
Isradipine attenuates the ischemia-induced release of dopamine in the striatum of the rat (233) 165
Opgenorth, T.J., see Pollock, D.M. (231) 459
Orimo, H., see Ishikawa, M. (246) 121
Orito, K., Satoh, K. and Taira, N.
Involvement of ATP-sensitive $K^+$ channels in the sustained coronary vasodilator response to adenosine in dogs (231) 183
Ormandy, G.C.
Increased cyclic AMP reduces $5\text{-}HT_{1D}$ receptor-mediated inhibition of [$^3$H]5-hydroxytryptamine release from guinea-pig cortical slices (244) 189
Ortega, A., see Cid, M.E. (245) 51
Osada, Y., Tsuchimoto, M., Fukushima, H., Takahashi, K., Kondo, S., Hasegawa, M. and Komoriya, K.
Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents (241) 183
Osei, S.Y., Ahima, R.S., Minkes, R.K., Weaver, J.P., Khosla, M.C. and Kadowitz, P.J.
Differential responses to angiotensin-(1–7) in the feline mesenteric and hindquarters vascular beds (234) 35
Osei, S.Y., see Santiago, J.A. (236) 315
O'Shaughnessy, C.T. and Connor, H.E.
Neurokinin $NK_1$ receptors mediate plasma protein extravasation in guinea-pig dura (236) 319
O'Shaughnessy, C.T., see Boulton, C.L. (236) 131
Otomo, S., see Tanaka, M. (238) 89
Otomo, S., see Tanaka, M. (238) 93
Otsuka, M., see Suzuki, H. (241) 105
Ottaviani, E., Paemen, L.R., Cadet, P. and Stefano, G.B.
Evidence for nitric oxide production and utilization as a bacteriocidal agent by invertebrate immunocytes (248) 319
Ouchi, Y., see Ishikawa, M. (246) 121
Oury-Donat, F., see Rinaldi-Carmona, M. (246) 73
Oyama, Y., Ueha, T. and Hayashi, A.
Effect of tri-n-butyltin on intracellular $Ca^{2+}$ concentration of rat cerebellar neurons (248) 89
Ozaki, S., see Kobayashi, M. (235) 95
Ozaki, Y., Jinnai, Y., Yatomi, Y. and Kume, S.
Protein kinase C inhibitors suppress disc-sphere changes of human platelets, as assessed with the shape-change parameter (235) 255

Paciorek, P.M., see Gater, P.R. (238) 59
Paegelow, I., see Liebmann, C. (235) 183
Paemen, L.R., see Ottaviani, E. (248) 319
Pagani, E.D., VanAller, G.S., O'Connor, B. and Silver, P.J.
Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast (243) 141
Page, C.P., see Riccio, M.M. (232) 89
Pain, D., see Guard, S. (232) 287
Pain, D., see Guard, S. (236) 496
Pairet, M., see Van Meel, J.C.A. (233) 295
Palejko, W., see Bisaga, A. (242) 213
Palkovits, M., see Horváth, E.J. (236) 151
Palmer, A.J. and Lodge, D.
Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655 (244) 193
Palmer, J.D., see Witt-Enderby, P.A. (241) 121
Palmer, R., see Moro, M.A. (246) 213
Palmi, M., see Sgaragli, G.P. (248) 121
Pan, L., see Gutkowska, J. (242) 7
Panagiotidis, G., Alm, P. and Lundquist, I.
Inhibition of islet nitric oxide synthase increases arginine-induced insulin release (229) 277
Panagiotidis, G., Stenström, A. and Lundquist, I.
Effects of adrenergic and cholinergic stimulation on islet monoamine oxidase activity and insulin secretion in the mouse (233) 285
Pandey, G.N., see Pandey, S.C. (247) 81
Pandey, S.C., Dubey, M.P., Piano, M.R., Schwertz, D.W., Davis, J.M. and Pandey, G.N.
Modulation of $5\text{-}HT_{1C}$ receptors and phosphoinositide system by ethanol consumption in rat brain and choroid plexus (247) 81
Pandey, S.C., see Javaid, J.I. (238) 425
Pang, C.C.Y., see Wang, Y.-X. (233) 275
Panizzon, K.L., see Wallis, R.A. (238) 165
Papa, S.M., Engber, T.M., Boldry, R.C. and Chase, T.N.
Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists (232) 247
Papi, A., see Mapp, C.E. (248) 67
Papi, A., see Mapp, C.E. (248) 277
Pappata, S., see Tavitian, B. (236) 229
Paracchini, L., see Bradamante, S. (234) 113
Paracchini, L., see Bradamante, S. (239) 275
Parent, P., see Lemaire, S. (245) 247
Parenti, M., see Massi, P. (243) 65
Parenti, M., see Parolaro, D. (244) 211
Park, K.S., Sohn, D.H., Veech, R.L. and Song, B.J.
Translational activation of ethanol-inducible cytochrome P450 (*CYP*2E1) by isoniazid (248) 7
Park, M.G., see Hong, K.W. (231) 1
Park, Y.D., see Hulihan-Giblin, B.A. (239) 99
Parker, R.M.C., see Fleetwood-Walker, S.M. (242) 173
Parkinson, F.E., see Johansson, B. (247) 103
Parolaro, D., Rubino, T., Gori, E., Massi, P., Bendotti, C., Patrini, G., Marcozzi, C. and Parenti, M.
In situ hybridization reveals specific increases in $G\alpha_s$ and $G\alpha_o$ mRNA in discrete brain regions of morphine-tolerant rats (244) 211
Parolaro, D., see Massi, P. (243) 65
Parsons, B., Stanley, M. and Javitch, J.
Differential visualization of dopamine $D_2$ and $D_3$ receptors in rat brain (234) 269
Pasanen, M., see Salonpää, P. (248) 95
Pascaud, X.B., Chovet, M., Roze, C. and Junien, J.-L.
Neuropeptide Y and σ receptor agonists act through a common pathway to stimulate duodenal alkaline secretion in rats (231) 389
Pasquini, F., Jomary, C., Garbay-Jaureguiberry, C., Roques, B.P. and Beaudet, A.
[$^{125}$I]Azido-DTLET as a tool for selective covalent labeling of δ-opioid receptors in rat brain sections (243) 39
Patacchini, R. and Maggi, C.A.
Amastatin interferes with the antagonist properties of MEN 10,208 in the rabbit pulmonary artery but not in the hamster trachea (236) 31
Patacchini, R., see Maggi, C.A. (234) 83
Patacchini, R., see Maggi, C.A. (235) 309
Patacchini, R., see Maggi, C.A. (240) 45
Paterson, I.A., see Zhu, M.-Y. (238) 157
Patrick, R.L., see Patrick, S.L. (231) 243
Patrick, S.L., Walker, J.M., Perkel, J.M., Lockwood, M. and Patrick, R.L.
Increases in rat striatal extracellular dopamine and vacuous chewing produced by two σ receptor ligands (231) 243

Patrick, S.L., see Walker, J.M. (231) 61
Patrick, S.L., see Walker, J.M. (236) 495
Patrini, G., see Parolaro, D. (244) 211
Patsalos, P.N., see Semba, J. (230) 321
Paul, I.A., Layer, R.T., Skolnick, P. and Nowak, G.
Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine (247) 305
Paul, I.A., see Lewin, A.H. (247) 1
Paul, I.A., see Nowak, G. (247) 101
Paul, S.M., see Ator, N.A. (241) 237
Paul, S.M., see Weller, M. (248) 223
Paul, S.M., see Weller, M. (248) 303
Pauletzki, J.G., Sharkey, K.A., Davison, J.S., Bomzon, A. and Shaffer, E.A.
Involvement of L-arginine-nitric oxide pathways in neural relaxation of the sphincter of Oddi (232) 263
Pauli, A.-M., see Clerc, T. (235) 59
Pazzagli, M., Pedata, F. and Pepeu, G.
Effect of $K^+$ depolarization, tetrodotoxin, and NMDA receptor inhibition on extracellular adenosine levels in rat striatum (234) 61
Peacock, L. and Gerlach, J.
Effects of several partial dopamine $D_2$ receptor agonists in *Cebus apella* monkeys previously treated with haloperidol (237) 329
Pearson, H.A. and Wray, D.
Non-competitive antagonism of calcium by magnesium ions at the $K^+$-depolarised mouse neuromuscular junction (236) 323
Pedata, F., see Pazzagli, M. (234) 61
Pedersen, C.M., Thirstrup, S. and Nielsen-Kudsk, J.E.
Smooth muscle relaxant effects of propofol and ketamine in isolated guinea-pig trachea (238) 75
Peglion, J.-L., see Millan, M.J. (230) 99
Pehek, E.A., Meltzer, H.Y. and Yamamoto, B.K.
The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux (240) 107
Pei, Q., Zetterström, T., Leslie, R.A. and Grahame-Smith, D.G.
5-$HT_3$ receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat (230) 63
Pelá, I.R., see Coelho, M.M. (238) 391
Peleg, E., see Shamiss, A. (233) 113
Pelkonen, O., see Salonpää, P. (248) 95
Pellegrini, C.A., see Huber, O. (239) 103
Peñafiel, R., see Martínez, F. (248) 199
Peng, N.-A., see Cao, B.-J. (237) 177
Penna, M., see Domenech, R. (238) 53
Pepeu, G., see Pazzagli, M. (234) 61
Pepke-Zaba, J., Higenbottam, T.W., Dinh-Xuan, A.T., Ridden, C. and Kealey, T.
$\alpha$-Adrenoceptor stimulation of porcine pulmonary arteries (235) 169
Perales, A.J., see Alborch, E. (229) 83
Perales, J.E., see Bozza, P.T. (248) 41
Pereira-Leite, L., see Ferreira-de-Almeida, J.A. (234) 209
Pérez-Vizcaíno, F., Carrón, R., Delpón, E., Duarte, J. and Tamargo, J.
Effects of (S)-nafenodone on $^{45}Ca^{2+}$ fluxes and contractions in rat isolated vascular smooth muscle (232) 105
Pérez-Vizcaíno, F., see Duarte, J. (239) 1
Peričić, D. and Tvrdeić, A.
Dihydroergosine: anticonflict effect in rats and enhancing effects on [$^3$H]muscimol binding in the human brain post mortem (235) 267
Perkel, J.M., see Patrick, S.L. (231) 243
Perkins, R.S., see Rabe, K.F. (231) 305
Perner, R., see Kebabian, J.W. (229) 203
Pernow, J. and Modin, A.
Endothelial regulation of coronary vascular tone in vitro: contribution of endothelin receptor subtypes and nitric oxide (243) 281
Perrault, G., see Angel, I. (234) 137
Perrot, S., Kayser, V., Fournié-Zaluski, M.-C., Roques, B.P. and Guilbaud, G.
Antinociceptive effect of systemic PC 12, a prodrug mixed inhibitor of enkephalin-degrading enzymes, in normal and arthritic rats (241) 129
Perry, B.D., see Mukherjee, J. (243) 287
Persico, P., Calignano, A., Mancuso, F. and Sorrentino, L.
Involvement of NK receptors and $\beta$-adrenoceptors in nitric oxide-dependent relaxation of rabbit aorta rings following electrical-field stimulation (238) 105
Persico, P., Metafora, S., Mancuso, F., Calignano, A., Venturelli, A., Mariniello, L. and Porta, R.
Protective effect of SV-IV on platelet-activating factor-induced hypotension, bronchoconstriction and gastric mucosal injury (241) 71
Persico, P., see Calignano, A. (231) 415
Persson, S.-Å., see Cassel, G.E. (248) 297
Pert, A., see Wu, R.-M. (243) 241
Pesonen, U., see Rouru, J. (234) 191
Peters, J.A., see Hope, A.G. (245) 187
Petitet, F., Saffroy, M., Torrens, Y., Glowinski, J. and Beaujouan, J.-C.
A new selective bioassay for tachykinin $NK_3$ receptors based on inositol monophosphate accumulation in the guinea pig ileum (247) 185
Pette, C., see Hamers, F.P.T. (233) 177
Pettersson, G., see Hjorth, S. (238) 357
Petty, M.A., see Lukovic, L. (233) 63
Petzinger, E., see Honscha, W. (246) 227
Peuhkurinen, K.J., see Uusimaa, P.A. (242) 199
Pewnim, T. and Seifert, J.
Structural requirements for altering the L-tryptophan metabolism in mice by organophosphorous and methylcarbamate insecticides (248) 237
Pfaffendorf, M., see Zhang, J. (230) 95
Pfeilschifter, J., see Ochsner, M. (245) 15
Pflimlin, P., see Netzer, R. (238) 209
Pham, P., see Chansel, D. (247) 193
Phaneuf, S., see Wong, S. (245) 55
Pheng, L.-H., see Dumont, Y. (238) 37
Philippe, L., see Moussaoui, S.M. (238) 421
Philippu, A., see Singewald, N. (240) 21
Phillips, M.I., see Dawson, Jr., R. (240) 277
Piano, M.R., see Pandey, S.C. (247) 81
Pibiri, M.G., see Giorgi, O. (245) 139
Picard, P., Boucher, S., Regoli, D., Gitter, B.D., Howbert, J.J. and Couture, R.
Use of non-peptide tachykinin receptor antagonists to substantiate the involvement of $NK_1$ and $NK_2$ receptors in a spinal nociceptive reflex in the rat (232) 255
Piccoli, C., see Mesnil, M. (248) 59
Piercey, M., see Waters, N. (242) 151
Pietrasiewicz, T., see Czechowska, G. (232) 59
Pin, J.-P., see Didier, M. (244) 57
Pina, M., see Desquand, S. (235) 101
Pinaev, A.G., see Bagrov, A.Y. (234) 165
Pineda, J., see Olmos, G. (236) 467
Pineda, J., see Ugedo, L. (239) 149
Pinxteren, J., see Jimenez Del Rio, M. (247) 11

Pirotton, S. and Boeynaems, J.-M.
Evidence that ATP, ADP and AMP are not ligands of the striatal adenosine $A_{2A}$ receptors (241) 55
Pistis, M., see Diana, M. (230) 363
Pistritto, G., see Martire, M. (230) 231
Pittaluga, A., Fedele, E., Risiglione, C. and Raiteri, M.
Age-related decrease of the NMDA receptor-mediated noradrenaline release in rat hippocampus and partial restoration by D-cycloserine (231) 129
Planas, M.E., Sánchez, S., González, P., Rodrigues de Oliveira, J. and Bartrons, R.
Protective effect of fructose 1,6-bisphosphate against carrageenan-induced inflammation (237) 251
Plebani, M., see Mapp, C.E. (248) 277
Pleus, R.C., Shreve, P.E., Toews, M.L. and Bylund, D.B.
Down-regulation of $\alpha_2$-adrenoceptor subtypes (244) 181
Plotkine, M., see Wahl, F. (230) 209
Poeggeler, B., see Huether, G. (238) 249
Poitras, M., Bernier, S., Boulay, G., Fournier, A. and Guillemette, G.
Interaction of benzene 1,2,4-trisphosphate with inositol 1,4,5-trisphosphate receptor and metabolizing enzymes (244) 203
Polgar, W.E., see Webster, J.L. (231) 251
Pollard, H.B., see Adeyemo, O.M. (240) 185
Pollock, D.M., Divish, B.J., Milicic, I., Novosad, E.I., Burres, N.S. and Opgenorth, T.J.
In vivo characterization of a phosphoramidon-sensitive endothelin-converting enzyme in the rat (231) 459
Polster, P., see Chatelain, P. (246) 181
Pomerantz, S.M., Hepner, B.C. and Wertz, J.M.
$5\text{-HT}_{1A}$ and $5\text{-HT}_{1C/1D}$ receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys (243) 227
Pon, D.J., Flezar, M., Litster, D.L. and Heisler, S.
Diphenylamine-2-carboxylate analogues block $Cl^-$ conductances in A7r5 cells by affecting cellular $Ca^{2+}$ homeostasis (245) 119
Pons, F., Williams, T.J. and Warren, J.B.
Nitric oxide, but not interleukin-1, mediates the local blood flow response to lipopolysaccharide in rabbit skin (239) 23
Pontoire, C., Bernard, M., Silvain, C., Collin, J.-P. and Voisin, P.
Characterization of melatonin binding sites in chicken and human intestines (247) 111
Pook, P.C.-K., see Eaton, S.A. (244) 195
Popik, P., see Nowak, G. (247) 101
Porkka-Heiskanen, T., see Stenberg, D. (238) 241
Porreca, F., see Horan, P.J. (233) 53
Porreca, F., see Horan, P.J. (239) 93
Porreca, F., see Raffa, R.B. (244) 231
Porreca, F., see Wild, K.D. (246) 25
Porreca, F., see Wild, K.D. (246) 289
Porta, R., see Bianchi, G. (238) 327
Porta, R., see Persico, P. (241) 71
Porter, R.H.P., see Eaton, S.A. (244) 195
Portoghese, P.S., see Takemori, A.E. (242) 145
Portugal, H., see Clerc, T. (235) 59
Post, R.M., see Baptista, T. (236) 39
Poth, M., see Mos, J. (238) 411
Potier, B. and Dutar, P.
Presynaptic inhibitory effect of baclofen on hippocampal inhibitory synaptic transmission involves a pertussis toxin-sensitive G-protein (231) 427
Potter, D.E., Ogidigben, M.J. and Heath, A.R.
Ocular actions of an octahydrobenzo[f]quinoline: Ha117 (236) 61
Poupaert, J.H., see Lambert, D.M. (243) 129
Pozza, M.F., see Olpe, H.-R. (233) 179
Pradier, L., see Debono, M.-W. (235) 283
Pradier, L., see Hermans, E. (245) 43
Prado, M., see Donoso, M.V. (240) 93
Prager, R.H., see Kerr, D.I.B. (236) 239
Pramanik, A., see Ögren, S.O. (242) 59
Pranzatelli, M.R., Murthy, J.N. and Tailor, P.T.
Novel regulation of $5\text{-HT}_{1C}$ receptors: down-regulation induced both by $5\text{-HT}_{1C/2}$ receptor agonists and antagonists (244) 1
Prato, A., see Clementi, G. (238) 101
Pratt, P.F., see De Garavilla, L. (234) 77
Pregenzer, J.F., see Im, W.B. (245) 111
Prenant, C., see Tavitian, B. (236) 229
Preziosi, P., see Montuschi, P. (233) 303
Price, J., see Laruelle, M. (230) 119
Priego, J.G., González-Morales, M.A., Cillero, F.J., Villarroya, M., Sunkel, C., Fau de Casa-Juana, M., López, M.G., Artalejo, C.R., De Pascual, R. and García, A.G.
PCA 50941, a novel $Ca^{2+}$ channel agonist (243) 25
Priego, J.G., see Desquand, S. (235) 101
Prieto, D., Mulvany, M.J. and Nyborg, N.C.B.
Effects of (+)-S-12967 and (−)-S-12968, two enantiomers of a new slow-acting 1,4-dihydropyridine, on rat coronary resistance arteries (238) 27
Principalle, A., see Balduini, W. (248) 281
Prino, G., see Bianchi, G. (238) 327
Prinssen, E.P.M., Ellenbroek, B.A., Stamatovic, B. and Cools, A.R.
The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166 (231) 275
Prinssen, E.P.M., see Koene, P. (233) 151
Protzman, C.E., see Woodward, D.F. (230) 327
Prouteau, M., see Angel, I. (232) 139
Pruneau, D. and Bélichard, P.
Endothelium-dependent control of vascular tone in the rabbit kidney after ischemia and reperfusion (231) 215
Pruneau, D. and Bélichard, P.
Induction of bradykinin $B_1$ receptor-mediated relaxation in the isolated rabbit carotid artery (239) 63
Przywara, D.A., Mashalkar, V., Bhave, S.V., Wakade, T.D. and Wakade, A.R.
Tetraethylammonium facilitation of single-pulse mediated action potential, $[Ca^{2+}]_i$ and transmitter release in sympathetic neurons (247) 353
Pucilowski, O., Garges, P.L., Rezvani, A.H., Hutheson, S. and Janowsky, D.S.
Verapamil suppresses d-amphetamine-induced place preference conditioning (240) 89
Puech, R., see Bertrand, G. (237) 45
Puia, G., see Dučić, I. (244) 29
Purdy, R.H., see Ator, N.A. (241) 237
Purnyn, S., see Knoper, S.R. (232) 65
Pytko-Polonczyk, J., see Konturek, S.J. (239) 215

Quartermain, D., see Mendelson, S.D. (236) 177
Quast, U. and Villhauer, E.B.
The individual enantiomers of cis-cromakalim possess $K^+$ channel opening activity (245) 165
Quirion, R., see Dumont, Y. (238) 37

Rabe, K.F., Giembycz, M.A., Dent, G., Perkins, R.S., Evans, P. and Barnes, P.J.
Salmeterol is a competitive antagonist at $\beta$-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils (231) 305
Raberger, G., see Schwarzacher, S. (229) 253
Rabin, R.A. and Winter, J.C.
Studies of the biochemical basis for the discriminative properties of 8-hydroxy-2-(di-n-propylamino)tetralin (235) 237
Rabin, R.A., see Kim, W.-K. (247) 89

Rabkin, S.W.
Lisinopril increases the recovery during reoxygenation and resistance to oxidative damage in cardiomyocytes (238) 81
Rae, G.A., Calixto, J.B. and D'Orléans-Juste, P.
Big-endothelin-1 contracts rat isolated uterus via a phosphoramidon-sensitive endothelin $ET_A$ receptor-mediated mechanism (240) 113
Raffa, R.B., Wild, K.D., Mosberg, H.I. and Porreca, F.
Thermodynamic parameters for [D-Pen$^{2,5}$]enkephalin at δ-opioid receptors in the mouse isolated vas deferens (244) 231
Rahman, S. and Neuman, R.S.
Activation of 5-$HT_2$ receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate (231) 347
Rahman, S. and Neuman, R.S.
Multiple mechanisms of serotonin 5-$HT_2$ receptor desensitization (238) 173
Raiteri, M., see Lanza, M. (237) 191
Raiteri, M., see Pittaluga, A. (231) 129
Rajakumar, G., see Scarpace, P.J. (247) 65
Rakotoarisoa, L., see Sayet, I. (246) 275
Rami, A., see Nikolov, R. (248) 205
Rand, M.J. and Li, C.G.
Differential effects of hydroxocobalamin on relaxations induced by nitrosothiols in rat aorta and anococcygeus muscle (241) 249
Randle, J.C.R., Biton, C. and Lepagnol, J.M.
Allosteric potentiation by diazoxide of AMPA receptor currents and synaptic potentials (247) 257
Randriantsoa, A., see Schoeffter, P. (241) 165
Rapoport, R.M.
Potentiation of norepinephrine-induced contraction by primary prostaglandin receptor activation in rat aorta (243) 207
Rapoport, R.M., see Bazan, E. (245) 173
Ratti, E., see Spampinato, S. (244) 139
Rattner, Z., see Laruelle, M. (230) 119
Rattray, M., Singhvi, S., Wu, P.-Y., Andrews, N. and File, S.E.
Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain (245) 193
Ratz, P.H., Callahan, P.E. and Lattanzio, Jr., F.A.
Ketamine relaxes rabbit femoral arteries by reducing $[Ca^{2+}]_i$ and phospholipase C activity (236) 433
Raunio, H., see Salonpää, P. (248) 95
Ravens, U., see Hoey, A. (231) 477
Raz, A., see Honda, A. (229) 217
Reader, T.A., see Dewar, K.M. (235) 137
Rebello, S., Thompson, E.B. and Gulati, A.
Endothelin mechanisms in altered thyroid states in the rat (237) 9
Reddy, P.L., see Veeranna, (235) 23
Reen, R., see Schmalix, W.A. (248) 251
Refsnes, M., see Sandnes, D. (246) 163
Régnier, G., see Iliou, J.-P. (248) 263
Regoli, D., see Picard, P. (232) 255
Rehm, H., see Benke, D. (246) 179
Reid, J.L., see Hamilton, C.A. (243) 95
Reilly, T., see Bensoussan, M. (247) 169
Reilly, Y., see Fletcher, A. (237) 283
Reis, D.J., see Sun, M.-K. (236) 305
Remacle-Volon, G., see Damas, J. (231) 231
Remeysen, P., see Lu, H.R. (235) 89
Remington, G., see Baskys, A. (235) 305
Ren, L.-M., see Horiuchi, A. (237) 23
Ren, L.-M., see Takayama, S. (231) 315
Renaud, J.M., see Comtois, A. (242) 65
Renesto, P., Balloy, V. and Chignard, M.
Inhibition by human leukocyte elastase of neutrophil-mediated platelet activation (248) 151
Rennick, R.E., Milner, P. and Burnstock, G.
Thrombin stimulates release of endothelin and vasopressin, but not substance P, from isolated rabbit tracheal epithelial cells (230) 367
Renò, F., see Balduini, W. (248) 281
Renzenbrink, G.J., see Bax, W.A. (239) 203
Reuben, J.P., see Huang, J.-C. (235) 37
Reul, J.M.H.M., see Rupprecht, R. (247) 145
Revel, L., Colombo, S., Ferrari, F., Folco, G., Rovati, L.C. and Makovec, F.
CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma (229) 45
Reynolds, G.P., see Jones, C.A. (242) 183
Reynolds, I.J., Zeleski, D.M., Rothermund, K.D., Hartnett, K.A., Tidwell, R. and Aizenman, E.
Studies on the effects of several pentamidine analogues on the NMDA receptor (244) 175
Rezvani, A.H., see Pucilowski, O. (240) 89
Rhim, B.Y., see Hong, K.W. (231) 1
Ribas, C., see Miralles, A. (243) 305
Ricci, A., see Ferreira-de-Almeida, J.A. (234) 209
Riccio, M.M., Manzini, S. and Page, C.P.
The effect of neonatal capsaicin on the development of bronchial hyperresponsiveness in allergic rabbits (232) 89
Richelson, E., see Yamada, M. (244) 99
Richter, A. and Löscher, W.
Alterations in pharmacological sensitivity of GABAergic but not dopaminergic and glutamatergic systems during ontogenesis in dystonic mutant hamsters (231) 111
Richter, A. and Löscher, W.
The κ-opioid receptor agonist, U50,488H, exerts antidystonic activity in a mutant hamster model of generalized dystonia (236) 289
Richter, A. and Löscher, W.
The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model. Comparison with haloperidol (242) 309
Richter, A., Löscher, W. and Löschmann, P.-A.
The AMPA receptor antagonist NBQX exerts antidystonic effects in an animal model of idiopathic dystonia (231) 287
Richter, A., see Löscher, W. (239) 245
Ridden, C., see Pepke-Zaba, J. (235) 169
Riederer, P., see Deckert, J. (238) 131
Riekkinen, Jr., P., Lammintausta, R., Ekonsalo, T. and Sirviö, J.
The effects of $\alpha_2$-adrenoceptor stimulation on neocortical EEG activity in control and 6-hydroxydopamine dorsal noradrenergic bundle-lesioned rats (238) 263
Riekkinen, Jr., P., Riekkinen, M., Fisher, A., Ekonsalo, T. and Sirviö, J.
Effects of muscarinic receptor agonists and anticholinesterase drugs on high voltage spindles and slow waves (240) 1
Riekkinen, Jr., P., Sirviö, J., Toivanen, L., Riekkinen, M., Lammintausta, R. and Riekkinen, Sr., P.
$\alpha_1$-Adrenoceptor antagonist decreases $\alpha_2$-adrenoceptor antagonist-induced high voltage spindle suppression in adult and aged rats (235) 317
Riekkinen, M., see Riekkinen, Jr., P. (235) 317
Riekkinen, M., see Riekkinen, Jr., P. (240) 1
Riekkinen, P., see Jolkkonen, J. (229) 269
Riekkinen, Sr., P., see Riekkinen, Jr., P. (235) 317
Rinaldi-Carmona, M., Bouaboula, M., Congy, C., Oury-Donat, F., Simiand, J., Shire, D., Casellas, P., Soubrié, P., Brelière, J.-C. and Le Fur, G.
Up-regulation of 5-$HT_2$ receptors in the rat brain by repeated administration of SR 46349B, a selective 5-$HT_2$ receptor antagonist (246) 73
Rinjard, P., see Scamps, F. (244) 119
Risiglione, C., see Pittaluga, A. (231) 129
Rittenhouse, P.A., see Levy, A.D. (241) 275
Ritter, M., see Wöll, E. (246) 269

Riutta, A., see Saareks, V. (248) 345
Rivera-Fillat, M.P., see Domènech, C. (248) 49
Rivet, J.-M., see Lejeune, F. (240) 307
Rivet, J.-M., see Millan, M.J. (230) 99
Rizzo, C.A., Kreutner, W. and Chapman, R.W.
5-$HT_3$ receptors augment neuronal, cholinergic contractions in guinea pig trachea (234) 109
Rizzo, C.A., Kreutner, W. and Chapman, R.W.
5-$HT_3$ receptors augment neuronal, cholinergic contractions in guinea pig trachea. European Journal of Pharmacology, 234 (1993) 109–112 (240) 327
Roberts, J.A., see Jagust, W.J. (242) 189
Roberts, P.J., see Eaton, S.A. (244) 195
Robin, F., see Iliou, J.-P. (248) 263
Rodinò, P., see Bagetta, G. (237) 61
Rodrigues de Miranda, J.F., see Blankesteijn, W.M. (244) 21
Rodrigues de Oliveira, J., see Planas, M.E. (237) 251
Rodriguez-Barbero, A., see Montero, A. (243) 235
Rodríguez, L., see Domènech, C. (248) 49
Røed, A.
Excitation-contraction uncoupling in the rat diaphragm by 2,3-butanedione monoxime (241) 229
Roeske, W.R., see Henderson, A.K. (245) 75
Roevens, P., De Clerck, F. and De Chaffoy de Courcelles, D.
The synergistic effect of 5-hydroxytryptamine and epinephrine on the human platelet is related to the activation of phospholipase C (245) 273
Roffel, A.F., see Ten Berge, R.E.J. (233) 279
Rogers, C., see Lemaire, S. (245) 247
Rogers, D.F., see Lei, Y.-H. (239) 257
Rogers, S., see Loick, H.M. (248) 75
Roisin, M.-P., see Zini, S. (245) 1
Roman, F.J., Martin, B. and Junien, J.-L.
In vivo interaction of neuropeptide Y and peptide YY with $\sigma$ receptor sites in the mouse brain (242) 305
Rompré, P.-P. and Boye, S.M.
Opposite effects of mesencephalic microinjections of cholecystokinin octapeptide and neurotensin-(1–13) on brain stimulation reward (232) 299
Romualdi, P., Lesa, G., Donatini, A., Balboni, G., Tomatis, R. and Ferri, S.
Alterations in vasoactive intestinal polypeptide-related peptides after pentylenetetrazole-induced seizures in rat brain (229) 149
Ronco, P.M., see Bensoussan, M. (247) 169
Ronken, E., Van Muiswinkel, F.L., Mulder, A.H. and Schoffelmeer, A.N.M.
Opioid receptor-mediated inhibition of evoked catecholamine release from cultured neurons of rat ventral mesencephalon and locus coeruleus (230) 349
Roques, B.P., see Noble, F. (230) 139
Roques, B.P., see Pasquini, F. (243) 39
Roques, B.P., see Perrot, S. (241) 129
Rosario, L.M., see Duarte, C.B. (244) 259
Rose, S., Nomoto, M., Jackson, E.A., Gibb, W.R.G., Jaehnig, P., Jenner, P. and Marsden, C.D.
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets (230) 177
Rosen, M.R., see Hamra, M. (230) 167
Rosen, M.R., see Hamra, M. (236) 497
Rösen, R., see Rump, A.F.E. (241) 201
Rosenberg, H.C., see Li, M. (247) 313
Rosenthal, T., see Shamiss, A. (233) 113
Rosqvist, S., see Mohell, N. (238) 121
Rossetti, Z.L., Hmaidan, Y., Diana, M. and Gessa, G.L.
Lack of tolerance to ethanol-induced dopamine release in the rat ventral striatum (231) 203
Rossetti, Z.L., Lai, M., Hmaidan, Y. and Gessa, G.L.
Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine (242) 313
Rossi, C., see Cervo, L. (238) 201
Rossowski, W.J., Zacharia, S., Jiang, N.-Y., Mungan, Z., Mills, M., Ertan, A. and Coy, D.H.
Galanin: structure-dependent effect on pancreatic amylase secretion and jejunal strip contraction (240) 259
Roth, J.E., Franklin, P.H. and Murray, T.F.
The $\sigma$ receptor ligand 1,3-di(2-tolyl)guanidine is anticonvulsant in the rat prepiriform cortex (236) 327
Roth, R.H., see Morrow, B.A. (238) 255
Rothermund, K.D., see Reynolds, I.J. (244) 175
Rothwell, N.J., see Coelho, M.M. (238) 391
Rotondo, S., De Gaetano, G. and Cerletti, C.
Antiplatelet activity of 2-(6-carboxyhexyl)-3-n-hexylcyclohexylamine (IBI P-05006), a thromboxane receptor antagonist (232) 41
Roukoyatkina, N.I., see Bagrov, A.Y. (234) 165
Rouru, J., Isaksson, K., Santti, E., Huupponen, R. and Koulu, M.
Metformin and brown adipose tissue thermogenetic activity in genetically obese Zucker rats (246) 67
Rouru, J., Pesonen, U., Isaksson, K., Huupponen, R. and Koulu, M.
Effect of chronic treatment with TFMPP, a 5-$HT_1$ receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide mRNA expression in obese Zucker rats (234) 191
Rousselle, D., see Langlois, M. (244) 77
Routledge, C., Gurling, J., Wright, I.K. and Dourish, C.T.
Neurochemical profile of the selective and silent 5-$HT_{1A}$ receptor antagonist WAY100135: an in vivo microdialysis study (239) 195
Rovati, L.C., see Revel, L. (229) 45
Roze, C., see Pascaud, X.B. (231) 389
Ruano, D., Machado, A. and Vitorica, J.
Absence of modifications of the pharmacological properties of the $GABA_A$ receptor complex during aging, as assessed in 3- and 24-month-old rat cerebral cortex (246) 81
Rubino, T., see Massi, P. (243) 65
Rubino, T., see Parolaro, D. (244) 211
Rückert, N.G.H. and Schmidt, W.J.
The $\sigma$ receptor ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia (233) 261
Rudd, J.A., see Cheng, C.H.K. (239) 211
Rudehill, A., see Weitzberg, E. (233) 85
Rudolf, G. and Wioland, N.
Acute blockade of dopamine receptors with haloperidol: a retinal model to study impairments of dopaminergic transmission (230) 259
Rudolf, K., see Doods, H. (242) 23
Ruffié, C., see Desquand, S. (235) 101
Ruffié, C., see Tesson, F. (248) 27
Ruffié, C., see Tesson, F. (248) 351
Ruiz, F., Dierssen, M., Flórez, J. and Hurlé, M.A.
The $Ca^{2+}$ channel agonist Bay K 8644 induces central respiratory depression in cats, an effect blocked by naloxone (240) 155
Ruiz, L., see Sandrini, G. (243) 99
Rump, A.F.E., Koreuber, D., Rösen, R. and Klaus, W.
Cardioprotection by ramiprilat in isolated rabbit hearts (241) 201
Rupprecht, R., Reul, J.M.H.M., Van Steensel, B., Spengler, D., Söder, M., Berning, B., Holsboer, F. and Damm, K.
Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands (247) 145
Rupreht, J., see Berkenbosch, A. (232) 21
Ruskoaho, H., see Uusimaa, P.A. (242) 199
Russel, F.G.M., see Blankesteijn, W.M. (244) 21
Rüther, E., see Huether, G. (238) 249
Rutledge, A., see Hawthorn, M.H. (229) 143
Rytik, P.G., see Müller, W.E.G. (246) 261

Saareks, V., Riutta, A., Mucha, I., Alanko, J. and Vapaatalo, H.
Nicotine and cotinine modulate eicosanoid production in human leukocytes and platelet rich plasma (248) 345
Saavedra, J.M., Viswanathan, M. and Shigematsu, K.
Localization of angiotensin $AT_1$ receptors in the rat heart conduction system (235) 301
Saavedra, J.M., see Zorad, S. (241) 195
Sabater, R., Saez, J.A. and Ferrer, J.M.R.
SCH 23390 decreases self-stimulation of the medial prefrontal cortex in the rat (242) 205
Sabater, R., see Ferrer, J.M.R. (231) 39
Sacchetti, G., Bonini, I., Cools Waeterloos, G. and Samanin, R.
Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortex (236) 171
Sadony, V., see Hoey, A. (231) 477
Sadoshima, S., see Ooboshi, H. (233) 165
Saeki, K., see Oishi, R. (237) 155
Saeki, T., see Kobayashi, M. (235) 95
Saeki, Y., see Tanaka, Y. (244) 105
Saetta, M., see Mapp, C.E. (248) 277
Saetta, M., see Mapp, C.E. (248) 67
Saez, J.A., see Ferrer, J.M.R. (231) 39
Saez, J.A., see Sabater, R. (242) 205
Saffroy, M., see Petitet, F. (247) 185
Sagratella, S., see Domenici, M.R. (233) 291
Sahadat, M.C.R., see Vermeulen, R.J. (235) 143
Sahni, S.K., see Javaid, J.I. (238) 425
Saigusa, T., Koshikawa, N., Kitamura, M. and Kobayashi, M.
Reevaluation of the two-component hypothesis for turning behaviour by manipulating activities in the striatum and the nucleus accumbens of intact rats (237) 161
Saikali, E., see Davies, H.M.L. (244) 93
Saito, H., see Iga, Y. (238) 395
Saito, H., see Matsuki, N. (248) 329
Saito, H., see Torii, Y. (248) 131
Saito, H., see Yoshioka, M. (236) 491
Saito, M., see Majima, M. (232) 181
Saito, T., see Shimosato, K. (234) 67
Saito, Y., see Mizuguchi, K. (231) 121
Saito, Y., see Mizuguchi, K. (235) 221
Sakai, K., see Maeda, K. (233) 227
Sakamoto, K., see Koya, D. (245) 79
Sakamoto, K., see Masui, H. (248) 103
Sakamoto, T., Barnes, P.J. and Chung, K.F.
Effect of CP-96,345, a non-peptide $NK_1$ receptor antagonist, against substance P-, bradykinin- and allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig (231) 31
Sakanashi, M., see Higuchi, M. (242) 293
Sakata, K., see Karaki, H. (231) 371
Sakata, Y., see Dohi, M. (243) 179
Sakurada, S., see Sakurada, T. (242) 47
Sakurada, T., Katsumata, K., Manome, Y., Tan-No, K., Sakurada, S., Kisara, K. and Ohba, M.
Antinociceptive effects in the formalin and capsaicin tests after intrathecal administration of substance P analogues in mice (242) 47
Sakurai, K., see Mihara, S.-i. (247) 219
Sakuta, H. and Okamoto, K.
Activation by KRN2391 and nicorandil of glibenclamide-sensitive $K^+$ channels in *Xenopus* oocytes (244) 277
Sakuta, H., see Yoneda, I. (247) 267
Salari, H., see Wong, S. (245) 55
Salehi, A. and Lundquist, I.
Changes in islet glucan-1,4-$\alpha$-glucosidase activity modulate sulphonylurea-induced but not cholinergic insulin secretion (243) 185
Sällemark, M., see Mohell, N. (238) 121
Salmi, P., Jimenez, P. and Ahlenius, S.
Evidence for specific involvement of dopamine $D_1$ and $D_2$ receptors in the regulation of body temperature in the rat (236) 395
Salom, J.B., see Alborch, E. (229) 83
Salomone, S., see Dessy, C. (231) 435
Salonpää, P., Hakkola, J., Pasanen, M., Pelkonen, O., Vähäkangas, K., Battula, N., Nouso, K. and Raunio, H.
Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells (248) 95
Salt, T.E., see Eaton, S.A. (244) 195
Saltis, J., see Agrotis, A. (244) 269
Salvadori, S., Bryant, S.D., Temussi, P.A., Bundy, D.M., Attila, M., Tomatis, R. and Lazarus, L.H.
Relationship between receptor affinity and topography of N-terminally extended and bridged [$Tyr^1 \rightarrow Asp^4$]deltorphin C analogues: novel probes for the $\delta$-opioid receptor (230) 357
Salvetti, L., see Bianchi, G. (238) 327
Samanin, R., see Carli, M. (234) 215
Samanin, R., see Cervo, L. (238) 201
Samanin, R., see Sacchetti, G. (236) 171
Sampayo-Reyes, A., see Morales-Aguilera, A. (245) 89
Sanchez-Chapula, J.
Caffeine inhibits depolarization-activated outward currents in rat ventricular myocytes (229) 163
Sánchez-García, P., see Montiel, C. (230) 77
Sánchez-García, P., see Moro, M.A. (246) 213
Sánchez, S., see Planas, M.E. (237) 251
Sandnes, D., Jacobsen, F.W., Refsnes, M. and Christoffersen, T.
Long-term inhibitory effect of cAMP on $\beta$-adrenoceptor acquisition and nonselective attenuation of adenylyl cyclase in hepatocytes (246) 163
Sandrini, G., Ruiz, L., Capararo, M., Danilov, A., Beretta, A. and Nappi, G.
Effects of dothiepin on nociceptive flexion reflex and diffuse noxious inhibitory controls in humans (243) 99
Sandström, P.-E. and Sehlin, J.
Evidence for separate $Na^+$, $K^+$, $Cl^-$ and $K^+$, $Cl^-$ co-transport systems in mouse pancreatic $\beta$-cells (238) 403
Santana, A.C., Hyslop, S., Antunes, E., De Nucci, G. and Bakhle, Y.S.
Anti-inflammatory activities of Ph CL28A in rats in vivo (231) 237
Sant'Ana, A.E.G., see Neves, P.C.A. (243) 213
Santiago, J.A. and Kadowitz, P.J.
Analysis of responses to pituitary adenylate cyclase activating polypeptide-38 in the feline hindquarters vascular bed (243) 291
Santiago, J.A., Osei, S.Y. and Kadowitz, P.J.
Inhibitory effects of Hoe 140 on vasodilator responses to bradykinin in the mesenteric vascular bed of the cat (236) 315
Santiago, M., Machado, A. and Cano, J.
Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists (239) 83
Santicioli, P., Del Bianco, E. and Maggi, C.A.
Adenosine $A_1$ receptors mediate the presynaptic inhibition of calcitonin gene-related peptide release by adenosine in the rat spinal cord (231) 139
Santos, R.M., see Duarte, C.B. (244) 259
Santti, E., see Rouru, J. (246) 67
Santucci, V., Gueudet, C., Emonds-Alt, X., Brelière, J.-C., Soubrié, P. and Le Fur, G.
The $NK_2$ receptor antagonist SR48968 inhibits thalamic responses evoked by thermal but not mechanical nociception (237) 143
Saphier, D., Welch, J.E. and Chuluyan, H.E.
$\alpha$-Interferon inhibits adrenocortical secretion via $\mu_1$-opioid receptors in the rat (236) 183
Sarbach, S.D., see Chan, P. (231) 175

Sardella, A., see Squadrito, F. (230) 125
Saria, A., see Kieselbach, G. (235) 117
Sasaki, H., see Morikawa, M. (241) 83
Sasaki, Y., see Ukai, M. (239) 237
Sasamoto, S., see Kogo, H. (231) 481
Sato, A., see Okawa, T. (230) 341
Sato, N., see Isono, T. (246) 205
Sato, N., see Kobayashi, M. (235) 95
Sato, Y., see Akaike, A. (241) 1
Satoh, H. and Sperelakis, N.
Effects of taurine on $Ca^{2+}$ currents in young embryonic chick cardiomyocytes (231) 443
Satoh, H. and Sperelakis, N.
Hyperpolarization-activated inward current in embryonic chick cardiac myocytes: developmental changes and modulation by isoproterenol and carbachol (240) 283
Satoh, H., Lou, Y.-P. and Lundberg, J.M.
Inhibitory effects of capsazepine and SR 48968 on citric acid-induced bronchoconstriction in guinea-pigs (236) 367
Satoh, H., see Dumont, Y. (238) 37
Satoh, K., see Furukawa, S. (236) 255
Satoh, K., see Orito, K. (231) 183
Satoh, M., see Matsuoka, N. (241) 27
Satoh, S., see Ogasawara, A. (243) 103
Satoh, Y., see Itoh, K. (237) 215
Satoh, Y., see Itoh, K. (239) 159
Satoh, Y., see Yamaguchi, T. (236) 43
Savelkoul, H.F.J., see Van Oosterhout, A.J.M. (236) 379
Savelkoul, H.F.J., see Van Oosterhout, A.J.M. (239) 277
Sawada, M., see Koya, D. (245) 79
Sawada, M., see Nakagawa, N. (235) 211
Sawaki, S., see Takayama, S. (231) 315
Sawyer, B.D., see Shannon, H.E. (232) 47
Saxena, P.R., see Bax, W.A. (239) 203
Saxena, P.R., see Bax, W.A. (239) 267
Saxena, P.R., see Schoemaker, R.G. (230) 103
Saya, D., see Nah, S.-Y. (246) 19
Sayet, I., Neuilly, G., Rakotoarisoa, L., Mironneau, J. and Mironneau, C.
Rat vena cava $\alpha_{1D}$-adrenoceptors: characterization by [$^3$H]prazosin binding and contraction experiments (246) 275
Scamps, F., Tran, G., Rinjard, P., Binet, P., Miocque, M. and Vassort, G.
Effect of an antihypertensive hydrazine derivative on $Ca^{2+}$ current of single frog cardiac cells (244) 119
Scarpace, P.J., Koller, M.M. and Rajakumar, G.
Desipramine desensitizes $\beta$-adrenergic signal transduction in salivary glands: differential regulation with age (247) 65
Scates, S.M., see Aceto, M.D. (248) 333
Schade, F.U. and Schudt, C.
The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages (230) 9
Schaefer, M., see Ivanova, K. (244) 37
Schaefer, M., see Menshikov, M.Y. (245) 281
Schaeffer, P., see Delisée, C. (247) 139
Schanck, A., see Van Bambeke, F. (247) 155
Scharrer, E., see Diener, M. (238) 217
Schatton, W.F.H., see Müller, W.E.G. (246) 261
Schechter, M.D. and Meehan, S.M.
Conditioned place preference produced by the psychostimulant cathinone (232) 135
Scheinin, M., see Marjamäki, A. (246) 219
Schemper, M., see Schwarzacher, S. (229) 253
Schepp, W., see Schmidtler, J. (246) 59
Scheurink, A.J.W., see Benthem, L. (232) 279
Schiavi, G., see Doods, H. (242) 23
Schirgi-Degen, A., see Beubler, E. (248) 157
Schmalix, W.A., Mäser, H., Kiefer, F., Reen, R., Wiebel, F.J., Gonzalez, F., Seidel, A., Glatt, H., Greim, H. and Doehmer, J.
Stable expression of human cytochrome P450 1A1 cDNA in V79 Chinese hamster cells and metabolic activation of benzo[a]pyrene (248) 251
Schmidhammer, H., see Fürst, Z. (236) 209
Schmidt, B., see Baudrie, V. (231) 395
Schmidt, W.E., see Höcker, M. (242) 105
Schmidt, W.J., see Bubser, M. (229) 75
Schmidt, W.J., see Rückert, N.G.H. (233) 261
Schmidtler, J., Dehne, K., Schusdziarra, V., Classen, M. and Schepp, W.
Pertussis toxin-sensitive inhibition of glucagon-like peptide 1-stimulated acid production by epidermal growth factor and transforming growth factor $\alpha$ in rat parietal cells (246) 59
Schneider, H., Feyen, J.H.M., Seuwen, K. and Movva, N.R.
Cloning and functional expression of a human parathyroid hormone receptor (246) 149
Schoeffter, P., Fozard, J.R., Stoll, A., Siegl, H., Seiler, M.P. and Hoyer, D.
SDZ 216-525, a selective and potent 5-$HT_{1A}$ receptor antagonist (244) 251
Schoeffter, P., Randriantsoa, A., Jost, B. and Bruttel, K.
Comparative effects of the two endothelin $ET_A$ receptor antagonists, BQ-123 and FR139317, on endothelin-1-induced contraction in guinea-pig iliac artery (241) 165
Schoemaker, H.
[$^3$H]7-OH-DPAT labels both dopamine $D_3$ receptors and $\sigma$ sites in the bovine caudate nucleus (242) R1
Schoemaker, H., see Angel, I. (232) 139
Schoemaker, H., see Angel, I. (234) 137
Schoemaker, R.G., Du, X.Y., Bax, W.A., Bos, E. and Saxena, P.R.
5-Hydroxytryptamine stimulates human isolated atrium but not ventricle (230) 103
Schoenleber, R., see Kebabian, J.W. (229) 203
Schoffelmeer, A.N.M., see Heijna, M.H. (229) 197
Schoffelmeer, A.N.M., see Ronken, E. (230) 349
Schoffelmeer, A.N.M., see Tjon Tien Ril, H.K.G. (235) 321
Schoffelmeer, A.N.M., see Van Vliet, B.J. (245) 23
Schofield, G.G., see Chen, C. (243) 83
Schölkens, B., see Wöll, E. (246) 269
Schott, C.A., Vetrovsky, P. and Stoclet, J.-C.
Cationic amino acids inhibit the effects of L-arginine in rat aorta exposed to lipopolysaccharide (236) 155
Schousboe, A., see White, H.S. (236) 147
Schreiber, R., see Sommermeyer, H. (240) 29
Schröder, H.C., see Müller, W.E.G. (246) 261
Schroeder, K.K., see French, J.F. (233) 109
Schrör, K., see Weber, A.-A. (247) 29
Schudt, C., see Schade, F.U. (230) 9
Schulz, K., see Honscha, W. (246) 227
Schusdziarra, V., see Schmidtler, J. (246) 59
Schwabe, U., see Matias, A. (244) 223
Schwartz, A., see Lathrop, D.A. (240) 127
Schwartzman, M.L., see Escalante, B. (235) 1
Schwarzacher, S., Weidinger, F., Schemper, M. and Raberger, G.
Blockade of endothelium-derived relaxing factor synthesis with $N^G$-nitro-L-arginine methyl ester leads to enhanced venous reactivity in vivo (229) 253
Schwarze, H., see Domenech, R. (238) 53
Schwertz, D.W., see Pandey, S.C. (247) 81
Scoggan, K.A., see Slipetz, D.M. (244) 161
Scott, J.M., Barclay, P.L. and Shepperson, N.B.
Renal effects of neutral endopeptidase inhibition in euvolemic and hypervolemic rats (242) 91
Scott, P.J.W., see McDonald, A. (240) 303

Scotti de Carolis, A., see Domenici, M.R. (233) 291
Sebastian, A., see Jiang, Q. (230) 129
Seeburg, P.H., see Korpi, E.R. (247) 23
Seeman, P. and Van Tol, H.H.M.
Dopamine $D_4$ receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective (233) 173
Seggel, M.R., see Gleeson, S. (229) 109
Seguin, L., see Millan, M.J. (238) 445
Sehlin, J., see Sandström, P.-E. (238) 403
Seidel, A., see Schmalix, W.A. (248) 251
Seifert, J., see Pewnim, T. (248) 237
Seiler, M.P., see Schoeffter, P. (244) 251
Seki, J., see Dohi, M. (243) 179
Seki, N., see Morimoto, H. (240) 121
Sekizawa, K., see Morikawa, M. (241) 83
Semba, J. and Patsalos, P.N.
Milacemide effects on the temporal inter-relationship of amino acids and monoamine metabolites in rat cerebrospinal fluid (230) 321
Senda, T., see Matsuno, K. (231) 451
Senft, M., see Clerc, T. (235) 59
Senoh, H., see Morimoto, H. (240) 121
Sepúlveda, M.-I., see Lummis, S.C.R. (243) 7
Serizawa, T., see Kinugawa, K.-i. (235) 313
Sessa, W., see Escalante, B. (235) 1
Seuwen, K., see Schneider, H. (246) 149
Sevcik, J., Finta, E.P. and Illes, P.
Galanin receptors inhibit the spontaneous firing of locus coeruleus neurones and interact with $\mu$-opioid receptors (230) 223
Sexton, T., see Davies, H.M.L. (244) 93
Seybold, V.S., see Tao, P.-L. (231) 145
Seyed-Mozaffari, A., see Jiang, Q. (240) 201
Sgaragli, G.P., Valoti, M., Fusi, F., Palmi, M., Mantovani, P., De Santi, M.M., Lorenzini, L. and Tosi, P.
Toxic injury to rat gut musculature following intraperitoneal administration of 2-t-butyl-4-methoxyphenol (248) 121
Shaffer, E.A., see Pauletzki, J.G. (232) 263
Shah, G., see Khanna, J.M. (230) 23
Shalmi, M. and Thomsen, K.
Inhibition of tubular lithium reabsorption by amiloride in the conscious sodium-restricted rat (230) 33
Shamiss, A., Peleg, E., Rosenthal, T. and Ezra, D.
The role of atrial natriuretic peptide in the diuretic effect of $Ca^{2+}$ entry blockers (233) 113
Shannon, H.E., Sawyer, B.D., Bemis, K.G., Bymaster, F.P., Heath, I., Mitch, C.H. and Ward, J.S.
Muscarinic $M_1$ receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens (232) 47
Sharif, N.A., see Eglen, R.M. (244) 49
Sharkey, K.A., see Pauletzki, J.G. (232) 263
Sharma, P.L., see Chakrabarti, A. (235) 133
Sharp, T., see Grasby, P. (230) 41
Shatzer, S.A., see Kudlacz, E.M. (241) 17
Shaw, C.A., see March, D. (236) 333
Sheardown, M.J., Suzdak, P.D. and Nordholm, L.
AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h (236) 347
Sheardown, M.J., see Suzdak, P.D. (245) 215
Shebuski, R.J., see Hartman, J.C. (234) 229
Shemer, A., see Mendelson, S.D. (236) 177
Shepperson, N.B., see Scott, J.M. (242) 91
Sherriffs, H.J., Shirakawa, K., Kelly, J.S., Olverman, H.J., Kuno, A., Okubo, M. and Butcher, S.P.
Characterisation of the binding of [$^3$H]FR115427, a novel non-competitive NMDA receptor antagonist, to rat brain membranes (247) 319
Sherriffs, H.J., see Hodgkiss, J.P. (240) 219
Shibata, M., Yamaura, T., Inaba, N., Onodera, S., Chida, Y. and Ohnishi, H.
Gastric antisecretory effect of FRG-8813, a new histamine $H_2$ receptor antagonist, in rats and dogs (235) 245
Shibata, S., Kagami-Ishi, Y., Tominaga, K., Kodama, K., Ueki, S. and Watanabe, S.
Ischemia-induced impairment of 2-deoxyglucose uptake and CA1 field potentials in rat hippocampal slices: protection by 5-$HT_{1A}$ receptor agonists and 5-$HT_2$ receptor antagonists (229) 21
Shibata, S., Koga, Y., Hamada, T. and Watanabe, S.
Facilitation of 2-deoxyglucose uptake in rat cortex and hippocampus slices by somatostatin is independent of cholinergic activity (231) 381
Shibata, S., Nakashio, A., Ueki, S. and Watanabe, S.
Facilitatory effect of phorbol ester on 2-deoxyglucose uptake in rat hippocampal slices (245) 257
Shigematsu, K., see Saavedra, J.M. (235) 301
Shigeri, Y., see Itazaki, K. (245) 147
Shigeta, Y., see Koya, D. (245) 79
Shigeta, Y., see Tanaka, Y. (244) 105
Shima, C., see Majima, M. (232) 181
Shimada, Y., see Hayakawa, A. (239) 219
Shimamura, K., Fujisawa, A., Toda, N. and Sunano, S.
Effects of $N^G$-nitro-L-arginine on electrical and mechanical responses to stimulation of non-adrenergic, non-cholinergic inhibitory nerves in circular muscle of the rat gastric fundus (231) 103
Shimamura, K., see Inoue, Y. (240) 169
Shimo, Y., see Kojima, S.-i. (241) 171
Shimomura, A., see Itoh, H. (240) 57
Shimomura, A., see Suga, T. (242) 129
Shimosato, K. and Saito, T.
Suppressive effect of cycloheximide on behavioral sensitization to methamphetamine in mice (234) 67
Shin, Y.W., see Hong, K.W. (231) 1
Shinkawa, T., Yamasaki, F., Notsu, T., Nakakuki, M., Nishijima, K., Yoshitomi, K. and Imai, M.
Loop and distal actions of a novel diuretic, M17055 (238) 317
Shinoda, M., see Toide, K. (233) 21
Shinozaki, H., see Nicoletti, F. (245) 297
Shippenberg, T.S., see Heidbreder, C. (243) 123
Shirakawa, K., see Hodgkiss, J.P. (240) 219
Shirakawa, K., see Sherriffs, H.J. (247) 319
Shirakawa, O., see Gao, X.-M. (241) 7
Shirakawa, O., see Tarazi, F.I. (232) 71
Shirasaki, H., see Nishikawa, M. (247) 131
Shirayama, Y., Nishikawa, T., Umino, A. and Takahashi, K.
p-Chlorophenylalanine-reversible reduction of $\sigma$ binding sites by chronic imipramine treatment in rat brain (237) 117
Shire, D., see Rinaldi-Carmona, M. (246) 73
Short, K.R. and Tabakoff, B.
Chronic barbiturate treatment increases NMDA receptors but decreases kainate receptors in mouse cortex (230) 111
Shreve, P.E., see Pleus, R.C. (244) 181
Shukla, V.K. and Lemaire, S.
Norbinaltorphimine protection against N-methyl-D-aspartic acid-induced convulsions and mortality (231) 293
Shukla, V.K., see Lemaire, S. (245) 247
Shyu, W.-S., see Tao, P.-L. (243) 135
Sickels, B.D., see Heaslip, R.J. (234) 247
Siegl, H., see Schoeffter, P. (244) 251
Siero, H.L.M., see Blankesteijn, W.M. (244) 21
Sikorski, B.W., Hodgson, W.C. and King, R.G.
Effects of haemoglobin and N-nitro-L-arginine on constrictor and dilator responses of aortic rings from streptozotocin diabetic rats (242) 275
Silva, P.M.R., see Martins, M.A. (237) 17

Silvain, C., see Pontoire, C. (247) 111
Silver, P.J., see De Garavilla, L. (234) 77
Silver, P.J., see Pagani, E.D. (243) 141
Silverman, P.B.
Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat (229) 235
Silverman, P.B.
On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat (242) 31
Sim, M.F., see Weishaar, R.E. (236) 363
Sim, M.K., see Kuttan, S.C. (232) 173
Simiand, J., see Rinaldi-Carmona, M. (246) 73
Siney, L. and Lewis, M.J.
Endothelium-derived relaxing factor inhibits platelet adhesion to cultured porcine endocardial endothelium (229) 223
Singewald, N., Guo, L. and Philippu, A.
Taurine release in the hypothalamus is altered by blood pressure changes and neuroactive drugs (240) 21
Singhvi, S., see Rattray, M. (245) 193
Sirois, P., see Filep, J.G. (239) 231
Sirois, P., see Filep, J.G. (240) 315
Sirviö, J., see Riekkinen, Jr., P. (235) 317
Sirviö, J., see Riekkinen, Jr., P. (238) 263
Sirviö, J., see Riekkinen, Jr., P. (240) 1
Skaper, S.D., Fadda, E., Facci, L. and Manev, H.
A semisynthetic glycosphingolipid (LIGA20) reduces 2,4,5-trihydroxyphenylalanine neurotoxicity in primary neuronal cultures (243) 91
Skarsfeldt, T.
Comparison of the effect of substituted benzamides on midbrain dopamine neurones after treatment of rats for 21 days (240) 269
Skoglund, G., Gross, R., Ahrén, B. and Loubatières-Mariani, M.-M.
Different mechanisms are involved in neuropeptide Y-induced pancreatic vasoconstriction and inhibition of insulin secretion (236) 69
Skolnick, P., see Lewin, A.H. (247) 1
Skolnick, P., see Nowak, G. (247) 101
Skolnick, P., see Paul, I.A. (247) 305
Skolnick, P., see Von Lubitz, D.K.J.E. (233) 95
Skolnick, P., see Wong, G. (247) 57
Skrbic, R. and Chiba, S.
Dominant antagonistic action of $\alpha_2$-adrenoceptor agonists on $\alpha_1$-agonist-induced vasoconstriction (230) 131
Sleight, A.J., Koek, W. and Bigg, D.C.H.
Binding of antipsychotic drugs at $\alpha_{1A}$- and $\alpha_{1B}$-adrenoceptors: risperidone is selective for the $\alpha_{1B}$-adrenoceptors (238) 407
Sleight, A.J., see Assié, M.-B. (237) 183
Slipetz, D.M., Scoggan, K.A., Nicholson, D.W. and Metters, K.M.
Photoaffinity labelling and radiation inactivation of the leukotriene $B_4$ receptor in human myeloid cells (244) 161
Slob, A.K., see Haensel, S.M. (233) 187
Slomiany, B., see Konturek, S.J. (229) 155
Šmíd, M. and Hušek, P.
Vasoconstrictor reaction to prostaglandins $E_1$ and $E_2$ in the isolated rat hindlimb mediated through serotonin release (230) 69
Smit, J., see Coppes, R.P. (243) 273
Smit, M.J., Leurs, R., Bloemers, S.M., Tertoolen, L.G.J., Bast, A., De Laat, S.W. and Timmerman, H.
Extracellular ATP elevates cytoplasmatic free $Ca^{2+}$ in HeLa cells by the interaction with a 5′-nucleotide receptor (247) 223
Smith, L., see Kebabian, J.W. (229) 203
Smith, R.A.G., see Smith III, E.F. (236) 477
Smith, T.L., see Henderson, A.K. (245) 75
Smith, W.L., see Costall, B. (234) 91
Smith III, E.F., Griswold, D.E., Egan, J.W., Hillegass, L.M., Smith, R.A.G., Hibbs, M.J. and Gagnon, R.C.
Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730) (236) 477
Smits, J., see Huijberts, M. (240) 207
Snaprud, P., see Ferré, S. (244) 311
Sneddon, P., see Furman, B.L. (232) 29
Sneddon, P., see Graham, A.M. (237) 93
Söder, M., see Rupprecht, R. (247) 145
Söderpalm, B., Lundin, B. and Hjorth, S.
Sustained 5-hydroxytryptamine release-inhibitory and anxiolytic-like action of the partial 5-$HT_{1A}$ receptor agonist, buspirone, after prolonged chronic administration (239) 69
Söderpalm, B., see Heilig, M. (236) 339
Söderström, E., see Cassel, G.E. (248) 297
Sohn, D.H., see Park, K.S. (248) 7
Sokolovsky, M., see Ambar, I. (245) 31
Soldani, G., see Intorre, L. (243) 265
Sommermeyer, H., Schreiber, R., Greuel, J.M., De Vry, J. and Glaser, T.
Anxiolytic effects of the 5-$HT_{1A}$ receptor agonist ipsapirone in the rat: neurobiological correlates (240) 29
Song, B.J., see Park, K.S. (248) 7
Song, D.-L., Chang, G.-D., Ho, C.-L. and Chang, C.-H.
Structural requirements of mastoparan for activation of membrane-bound guanylate cyclase (247) 283
Soong, Y., see Cheng, P.Y. (230) 85
Sorrentino, L., see Calignano, A. (231) 415
Sorrentino, L., see Persico, P. (238) 105
Sorribas, V., Arruebo, M.P., Alvarado, F. and Alcalde, A.I.
Action of robenidine on the intestinal transport and digestion of nutrients in rabbit (248) 137
Soubrié, P., see Bachy, A. (237) 299
Soubrié, P., see Didier, M. (244) 57
Soubrié, P., see Labie, C. (231) 465
Soubrié, P., see Rinaldi-Carmona, M. (246) 73
Soubrié, P., see Santucci, V. (237) 143
Souilhac, J., see Bachy, A. (237) 299
Southerland, S.B., see Watts, V.J. (242) 165
Spada, C.S., see Woodward, D.F. (230) 327
Spampinato, S., Bachetti, T., Carboni, L., Ratti, E., Van Amsterdam, F.T.M. and Ferri, S.
$Ca^{2+}$ channel blocking activity of lacidipine and amlodipine in $A_7r_5$ vascular smooth muscle cells (244) 139
Spedding, M., see MacKinnon, A.C. (232) 79
Spengler, D., see Rupprecht, R. (247) 145
Sperelakis, N., see Inoue, Y. (240) 169
Sperelakis, N., see Satoh, H. (231) 443
Sperelakis, N., see Satoh, H. (240) 283
Spinazzé, A., see Gully, D. (232) 13
Squadrito, F., Altavilla, D., Zingarelli, B., Ioculano, M., Calapai, G., Campo, G.M., Miceli, A. and Caputi, A.P.
Tumor necrosis factor involvement in myocardial ischaemia-reperfusion injury (237) 223
Squadrito, F., Calapai, G., Cucinotta, D., Altavilla, D., Zingarelli, B., Ioculano, M., Urna, G., Sardella, A., Campo, G.M. and Caputi, A.P.
Anorectic activity of $N^G$-nitro-L-arginine, an inhibitor of brain nitric oxide synthase, in obese Zucker rats (230) 125
Srimal, R.C., see Gulati, A. (230) 293
St-Pierre, S., see Dumont, Y. (238) 37
Stabentheiner, A., see Lippe, I.T. (232) 113
Stachura, J., see Konturek, S.J. (239) 215
Stamatovic, B., see Prinssen, E.P.M. (231) 275
Stamidis, H., see Young, G.A. (231) 473
Stanley, M., see Parsons, B. (234) 269
Stanton, J.A., see Beer, M.S. (236) 167
Starnes, D.M., see Chang, A.S.-S. (247) 239

Stasiewicz, J., see Namiot, Z. (243) 301
Stefano, G.B., see Ottaviani, E. (248) 319
Steffens, A.B., see Benthem, L. (232) 279
Stein, C., see Członkowski, A. (242) 229
Steinfels, G.F., see Young, G.A. (231) 473
Steinmann, M.W., see Olpe, H.-R. (233) 179
Stenberg, D., Porkka-Heiskanen, T. and Toppila, J.
$\alpha_2$-Adrenoceptors and vigilance in cats: antagonism of medetomidine sedation by atipamezole (238) 241
Stenström, A., see Panagiotidis, G. (233) 285
Stephan, D., see Michel, B. (242) 237
Stephenson, J.D., see Kikuchi de Beltrán, K. (239) 47
Stern, A., see Errasfa, M. (247) 73
Steward, L.J., Bufton, K.E., Hopkins, P.C., Davies, W.E. and Barnes, N.M.
Reduced levels of 5-$HT_3$ receptor recognition sites in the putamen of patients with Huntington's disease (242) 137
Steward, L.J., West, K.E., Kilpatrick, G.J. and Barnes, N.M.
Labelling of 5-$HT_3$ receptor recognition sites in the rat brain using the agonist radioligand [$^3$H]meta-chlorophenylbiguanide (243) 13
Steward, L.J., see Barnes, J.M. (230) 251
Stewart, J., see Druhan, J.P. (243) 73
Stewart, M., see MacKinnon, A.C. (232) 79
Stoclet, J.-C., see Schott, C.A. (236) 155
Stoll, A., see Schoeffter, P. (244) 251
Stoof, J.C., see Vermeulen, R.J. (235) 143
St. Pierre, S., see Donoso, M.V. (240) 93
Strahlendorf, H.K., see Cumming-Hood, P.A. (236) 457
Strahlendorf, J.C., see Cumming-Hood, P.A. (236) 457
Stratman, N.C., see Lahti, R.A. (236) 483
Stretton, D., see Belvisi, M.G. (231) 97
Strick, D.M., see Gutkowska, J. (242) 7
Strimbu-Gozariu, M., Guirimand, F., Willer, J.-C. and Le Bars, D.
A sensitive test for studying the effects of opioids on a C-fibre reflex elicited by a wide range of stimulus intensities in the rat (237) 197
Strobach, H., see Weber, A.-A. (247) 29
Strojan, P., see Budihna, M.V. (230) 301
Struijker Boudier, H., see Huijberts, M. (240) 207
Stubbins, J.F., see Hudkins, R.L. (231) 485
Sturm, R.J., see Grimes, D. (236) 217
Su, M.-J., see Teng, C.-M. (233) 7
Suarez-Roca, H. and Maixner, W.
$\delta$-Opioid-receptor activation by [D-Pen$^2$,D-Pen$^5$]enkephalin and morphine inhibits substance P release from trigeminal nucleus slices (229) 1
Suaud-Chagny, M.-F., see Brun, P. (235) 205
Sudjarwo, S.A., Hori, M. and Karaki, H.
Effect of endothelin-3 on cytosolic calcium level in vascular endothelium and on smooth muscle contraction (229) 137
Sudjarwo, S.A., see Karaki, H. (231) 371
Suga, H., see Takaki, M. (237) 51
Suga, T., Itoh, H., Shimomura, A., Kusagawa, M., Ito, M., Takase, K., Konishi, T. and Nakano, T.
Comparison of the effects of various vasodilators on the rat portal vein and mesenteric artery (242) 129
Suga, T., see Itoh, H. (240) 57
Sugawa, M.
Alterations of inositol phosphate turnover in striatum of aged rats (247) 39
Sugimoto, T., see Koya, D. (245) 79
Sugita, S., see Suzuki, S. (231) 297
Sugiyama, M., see Nagafuji, T. (248) 325
Suman-Chauhan, N., Webdale, L., Hill, D.R. and Woodruff, G.N.
Characterisation of [$^3$H]gabapentin binding to a novel site in rat brain: homogenate binding studies (244) 293
Suman-Chauhan, N., see Hill, D.R. (244) 303
Sumi-Ichinose, C., see Nomura, T. (246) 113
Sun, B.-C., Huang, K.-X. and Jin, G.-Z.
Repeated reserpine treatment alters firing pattern and responses of substantia nigral dopamine neurons (231) 331
Sun, M.-K. and Reis, D.J.
Extracellular $H^+$ iontophoresis modifies responses to γ-aminobutyric acid and cyanide of reticulospinal vasomotor neurons in rats (236) 305
Sun, Y.-H., see Zhou, Y. (234) 147
Sunano, S., see Kaneko, K. (240) 195
Sunano, S., see Shimamura, K. (231) 103
Sunkel, C., see Priego, J. (243) 25
Sunkel, C.E., see Martins, M.A. (237) 17
Sunter, D.C., see Bashir, Z.I. (239) 265
Sunter, D.C., see Eaton, S.A. (244) 195
Suresh, M.S., see Nelson, S.H. (242) 255
Susel, Z., see Engber, T.M. (236) 385
Sutak, M., see Gouardères, C. (237) 73
Sutherland, L., see Hope, A.G. (245) 187
Sütő, G., see Király, Á. (240) 299
Sutter, M.C., see Abrahams, Z. (238) 435
Suzdak, P.D., Sheardown, M.J. and Honoré, T.
Characterization of the metabotropic glutamate receptor in mouse cerebellar granule cells: lack of effect of 2,3-dihydroxy-6-nitro-7-sulphamoylbenzo(F)-quinoxaline (NBQX) (245) 215
Suzdak, P.D., see Sheardown, M.J. (236) 347
Suzdak, P.D., see Thomsen, C. (244) 187
Suzdak, P.D., see Thomsen, C. (245) 299
Suzuki, H., Yoshioka, K., Maehara, T., Hagan, R.M., Nakanishi, S. and Otsuka, M.
Pharmacological characteristics of tachykinin receptors mediating acetylcholine release from neonatal rat spinal cord (241) 105
Suzuki, K., see Iwata, N. (248) 243
Suzuki, S., Yoshida, T., Sugita, S., Kobayashi, A. and Nakazawa, K.
Triiodothyronine increases desipramine with changing the concentrations of monoamines, in the brain of rat given imipramine (231) 297
Suzuki, S., see Fujita, K. (242) 301
Suzuki, T., see Kamei, J. (234) 117
Suzuki, T., see Kamei, J. (240) 99
Suzuki, Y., see Okawa, T. (230) 341
Svensson, T.H., see Grenhoff, J. (233) 79
Swinyard, E.A., see White, H.S. (236) 147
Syvälahti, E., see Kuoppamäki, M. (245) 179
Szabo, S., see Glavin, G.B. (233) 269
Szarek, J.L., Zhang, J.Z. and Gruetter, C.A.
5-$HT_2$ receptors augment cholinergic nerve-mediated contraction of rat bronchi (231) 339
Szemeredi, K., see Bagdy, G. (229) 9
Szeto, H.H., see Cheng, P.Y. (230) 85
Szlachcic, A., see Konturek, S.J. (229) 155

Tabakoff, B., see Iorio, K.R. (248) 209
Tabakoff, B., see Short, K.R. (230) 111
Taché, Y., see Király, Á. (240) 299
Taché, Y., see Tanaka, T. (243) 221
Tachibana, M., see Nomura, T. (246) 113
Tachikawa, E., Yoshinari, H., Takahashi, S., Kashimoto, T., Mizuma, K. and Takahashi, E.
Cisplatin, an antineoplastic drug, inhibits catecholamine secretion from bovine adrenal chromaffin cells (236) 355
Tacke, R., see Eltze, M. (238) 343
Taddei, C., see Mennini, T. (241) 255
Taglialatela, M., see Canzoniero, L.M.T. (245) 97
Tailor, P.T., see Pranzatelli, M.R. (244) 1
Taira, N., see Furukawa, S. (236) 255

Taira, N., see Orito, K. (231) 183
Taira, T., Uusi-Oukari, M. and Korpi, E.R.
Early postnatal treatment with muscimol transiently alters brain $GABA_A$ receptors and open-field behavior in rat (230) 307
Tajima, K., see Okumura, K. (235) 69
Takagi, H., see Kawabata, A. (233) 255
Takagi, N., see Miyake, K. (235) 75
Takagi, Y., see Tanaka, Y. (244) 105
Takahashi, A., see Iwata, N. (248) 243
Takahashi, E., see Tachikawa, E. (236) 355
Takahashi, H., see Miyamoto, M. (238) 181
Takahashi, K., see Osada, Y. (241) 183
Takahashi, K., see Shirayama, Y. (237) 117
Takahashi, S., see Tachikawa, E. (236) 355
Takahashi, S.-s., see Okabe, E. (248) 33
Takahashi, T., see Kinugawa, K.-i. (235) 313
Takai, M., see Karaki, H. (231) 371
Takaki, M., Namba, T., Fujii, W. and Suga, H.
Adenosine inhibits efferent function of extrinsic capsaicin-sensitive sensory nerves in the enteric nervous system (237) 51
Takanaka, A., see Guo, X. (248) 337
Takaoka, M., see Hisaki, K. (241) 75
Takaoka, M., see Matsumura, Y. (230) 89
Takasaki, K., see Kogo, H. (231) 481
Takase, K., see Hikasa, Y. (229) 241
Takase, K., see Suga, T. (242) 129
Takase, M., see Toide, K. (233) 21
Takasugi, H., see Dohi, M. (243) 179
Takayama, S., Furukawa, Y., Ren, L.-M., Inoue, Y., Sawaki, S. and Chiba, S.
Positive chronotropic and inotropic responses to BRL 37344, a $\beta_3$-adrenoceptor agonist in isolated, blood-perfused dog atria (231) 315
Takeda, R., see Takeda, Y. (233) 299
Takeda, T., see Iwai, J. (248) 341
Takeda, Y., Itoh, Y., Yoneda, T., Miyamori, I. and Takeda, R.
Cyclosporine A induces endothelin-1 release from cultured rat vascular smooth muscle cells (233) 299
Takemori, A.E. and Portoghese, P.S.
Enkephalin antinociception in mice is mediated by $\delta_1$-and $\delta_2$-opioid receptors in the brain and spinal cord, respectively (242) 145
Takemori, A.E., see Horan, P.J. (233) 53
Takeo, S., see Kogo, H. (231) 481
Takeo, S., see Miyake, K. (235) 75
Takeuchi, H., see Jun Liu, G. (231) 259
Takeuchi, H., see Liu, G.J. (231) 91
Takeuchi, H., see Liu, G.J. (240) 139
Takeuchi, K., Ohuchi, T., Miyake, H., Niki, S. and Okabe, S.
Effects of nitric oxide synthase inhibitors on duodenal alkaline secretion in anesthetized rats (231) 135
Takeuchi, T., see Fukunaga, Y. (233) 237
Takeuchi, T., see Yoshikawa, S. (239) 261
Takiguchi, Y., see Hirata, Y. (231) 421
Tamaki, H., see Nagasaki, M. (235) 197
Tamaki, T., Nishiyama, A., Yoshida, H., He, H., Fukui, T., Yamamoto, A., Aki, Y., Kimura, S., Iwao, H., Miyatake, A. and Abe, Y.
Effects of EXP3174, a non-peptide angiotensin II receptor antagonist, on renal hemodynamics and renal function in dogs (236) 15
Tamaoki, S., see Kurihara, J. (240) 73
Tamargo, J., see Duarte, J. (239) 1
Tamargo, J., see Pérez-Vizcaíno, F. (232) 105
Tamazawa, Y., see Fujita, R. (240) 213
Tamminga, C.A., see Gao, X.-M. (241) 7
Tamminga, C.A., see Tarazi, F.I. (232) 71
Tamura, K., Mutabagani, K. and Wood, J.D.
Analysis of a nonpeptide antagonist for substance P on myenteric neurons of guinea-pig small intestine (232) 235
Tamura, Y., see Akaike, A. (241) 1
Tan-No, K., see Sakurada, T. (242) 47
Tanaka, A., see Dohi, M. (243) 179
Tanaka, H., see Nakashima, H. (233) 219
Tanaka, M., Chaki, S., Imagawa, Y., Okuyama, S., Muramatsu, M. and Otomo, S.
FH-510, a potent and selective ligand for rat brain $\sigma$ recognition sites (238) 89
Tanaka, M., Kaku, S., Muramatsu, M. and Otomo, S.
Binding of [$^3$H]FH-510 to $\sigma$ ligand recognition sites in guinea-pig brain membranes (238) 93
Tanaka, T., Taché, Y. and Guth, P.H.
Involvement of vagal pathway in the anti-secretory effect of a novel xanthine derivative (243) 221
Tanaka, Y., Kashiwagi, A., Saeki, Y., Takagi, Y., Asahina, T., Kikkawa, R. and Shigeta, Y.
Effects of verapamil on the cardiac $\alpha_1$-adrenoceptor signalling system in diabetic rats (244) 105
Tanaka, Y., see Mizuguchi, K. (231) 121
Tang, A.H., Code, R.A. and Himes, C.S.
Antagonism of hypothermia produced by benzodiazepine-related compounds by U-78875 in mice (236) 1
Tanganelli, S., Li, X.-M., Ferraro, L., Von Euler, G., O'Connor, W.T., Bianchi, C., Beani, L. and Fuxe, K.
Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine $D_2$ receptor affinity in rat neostriatum (230) 159
Taniyama, K., Kan, S., Yoshimura, M. and Niwa, M.
Involvement of cholinergic neurons in intestinal contraction caused by vasoactive intestinal contractor (235) 149
Tanonaka, K., see Miyake, K. (235) 75
Tao, P.-L., Chang, L.-R., Chou, Y.-P., Law, P.-Y. and Loh, H.H.
Chronic opioid treatment may uncouple opioid receptors and G-proteins: evidence from radiation inactivation analysis (246) 233
Tao, P.-L., Seybold, V.S. and Loh, H.H.
Autoradiographic evidence for decrease in binding of $\mu$- and $\delta$-opioid receptors after subchronic [D-Ala$^2$,D-Leu$^5$]enkephalin treatment in rats (231) 145
Tao, P.-L., Yen, M.-H., Shyu, W.-S. and Chern, J.-W.
Doridosine derivatives: binding at adenosine receptors and in vivo effects (243) 135
Taoudi-Benchekroun, M., see Dumont, Y. (238) 37
Tarazi, F.I., Shirakawa, O. and Tamminga, C.A.
Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects (232) 71
Tatarczynska, E., see Carli, M. (234) 215
Tateyama, M., Nagao, T., Ohta, S., Hirobe, M. and Ono, H.
4-Phenyltetrahydroisoquinoline, but not nomifensine or cocaine, inhibits methamphetamine-induced dopamine release (240) 51
Tateyama, M., see Watanabe, H. (243) 155
Taveira DaSilva, A.M., see Abrahams, T.P. (238) 223
Tavitian, B., Pappata, S., Bonnot-Lours, S., Prenant, C., Jobert, A., Crouzel, C. and Di Giamberardino, L.
Positron emission tomography study of [$^{11}$C]methyl-tetrahydroaminoacridine (methyl-tacrine) in baboon brain (236) 229
Taya, K., see Kogo, H. (231) 481
Taylor, C.P., see Burke, S.P. (238) 383
Taylor, J.E., see Ladenheim, E.E. (235) 121
Tejerina, T., Chulia, T. and Gonzalez, P.
Effects of dotarizine on $^{45}Ca^{2+}$ movements and contractile responses in vascular smooth muscle (239) 75
Telegdy, G., see Bidzseranova, A. (232) 305

Télémaque, S., Gratton, J.-P., Claing, A. and D'Orléans-Juste, P.
Endothelin-1 induces vasoconstriction and prostacyclin release via the activation of endothelin $ET_A$ receptors in the perfused rabbit kidney (237) 275
Télémaque, S., see Filep, J.G. (239) 231
Temma, K., Akera, T., Chugun, A., Kondo, H., Hagane, K. and Hirano, S.-i.
Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart (234) 173
Temussi, P.A., see Salvadori, S. (230) 357
Ten Berge, R.E.J., Roffel, A.F. and Zaagsma, J.
The interaction of selective and non-selective antagonists with pre- and postjunctional muscarinic receptor subtypes in the guinea pig trachea (233) 279
Teng, C.-M., Yu, S.-M., Lee, S.-S., Ko, F.-N., Su, M.-J. and Huang, T.-F.
Vasoconstricting effect in rat aorta caused by thaliporphine isolated from the plant *Neolitsea konishii* K (233) 7
Teng, C.-M., see Lin, C.-H. (237) 109
Teng, C.-M., see Yu, S.-M. (234) 121
Teng, C.-M., see Yu, S.-M. (248) 289
Terada, A., see Yamaguchi, T. (236) 43
Terawaki, T., see Nakagawa, N. (235) 211
Ter Laak, A.M., Donné-Op den Kelder, G.M., Bast, A. and Timmerman, H.
Is there a difference in the affinity of histamine $H_1$ receptor antagonists for CNS and peripheral receptors? An in vitro study (232) 199
Terrón, J.A., see Villalón, C.M. (240) 9
Tertoolen, L.G.J., see Smit, M.J. (247) 223
Tesson, F., Ruffié, C., Hidi, R., E Silva, P.M.R., Vazeux, G., Vargaftig, B.B. and Bon, C.
Cell-associated and soluble phospholipases $A_2$ increase during carrageenan and zymosan-induced pleurisy in rat (248) 27
Tesson, F., Ruffié, C., Hidi, R., E Silva, P.M.R., Vazeux, G., Vargaftig, B.B. and Bon, C.
Cell-associated and soluble phospholipases $A_2$ increase during carrageenan and zymosan-induced pleurisy in rat (Eur. J. Pharmacol. Environ. Toxicol. Pharmacol. 248 (1993) 27–32) (248) 351
Tettamanti, R., see Bianchi, G. (238) 327
Teuchert-Noodt, G., see Dawirs, R.R. (241) 89
Thalody, G.P., see Wiener, H.L. (238) 65
Theobald, Jr., R.J.
Subclasses of purinoceptors in feline bladder (229) 125
Thijssen, E.J.M., see Bax, W.A. (239) 203
Thirstrup, S., see Pedersen, C.M. (238) 75
Thollon, C., see Iliou, J.-P. (248) 263
Thomas, K.H., see Boot, J.R. (231) 83
Thompson, E.B., see Rebello, S. (237) 9
Thomsen, C. and Suzdak, P.D.
4-Carboxy-3-hydroxyphenylglycine, an antagonist at type I metabotropic glutamate receptors (245) 299
Thomsen, C., Kristensen, P., Mulvihill, E., Haldeman, B. and Suzdak, P.D.
L-2-Amino-4-phosphonobutyrate (L-AP4) is an agonist at the type IV metabotropic glutamate receptor which is negatively coupled to adenylate cyclase. European Journal of Pharmacology – Molecular Pharmacology Section, 227 (1992) 361–362 (244) 187
Thomsen, C., see Klitgaard, H. (242) 221
Thomsen, K., see Shalmi, M. (230) 33
Thomson, F.J., see MacEwan, D.J. (246) 9
Thomson, K.A., see Marley, P.D. (244) 7
Thumala, A., see Domenech, R. (238) 53
Thurlow, R.J., Brown, J.P., Gee, N.S., Hill, D.R. and Woodruff, G.N.
[$^3$H]Gabapentin may label a system-L-like neutral amino acid carrier in brain (247) 341
Thut, P.D., see Wynn, R.L. (241) 47
Tidwell, R., see Reynolds, I.J. (244) 175
Tilton, R.G., see Misko, T.P. (233) 119
Timmerman, H., see Smit, M.J. (247) 223
Timmerman, H., see Ter Laak, A.M. (232) 199
Timmermans, P.B.M.W.M., see Bensoussan, M. (247) 169
Tiseo, P.J. and Yaksh, T.L.
Dose-dependent antagonism of spinal opioid receptor agonists by naloxone and naltrindole: additional evidence for $\delta$-opioid receptor subtypes in the rat (236) 89
Tjon Tien Ril, H.K.G., De Vries, T.J., Wardeh, G., Hogenboom, F., Mulder, A.H. and Schoffelmeer, A.N.M.
Long-lasting reciprocal changes in striatal dopamine and acetylcholine release upon morphine withdrawal (235) 321
To, Z.P., see Eglen, R.M. (244) 49
Toda, N., see Matsumoto, T. (237) 31
Toda, N., see Shimamura, K. (231) 103
Todd, A., see Boot, J.R. (231) 83
Toews, M.L., see Pleus, R.C. (244) 181
Togashi, H., see Iga, Y. (238) 395
Togashi, H., see Yoshioka, M. (236) 491
Toi, M., see Oikawa, T. (241) 221
Toide, K., Shinoda, M., Takase, M., Iwata, K. and Yoshida, H.
Effects of a novel thyrotropin-releasing hormone analogue, JTP-2942, on extracellular acetylcholine and choline levels in the rat frontal cortex and hippocampus (233) 21
Toivanen, L., see Riekkinen, Jr., P. (235) 317
Toki, S., see Nozawa, M. (236) 263
Tokuda, M., see Fujisawa, M. (238) 127
Tokuyama, K., see Kato, M. (232) 7
Tokuyama, K., see Yokoyama, T. (236) 427
Tokyay, R., see Loick, H.M. (248) 75
Toll, L., see Webster, J.L. (231) 251
Tomatis, R., see Romualdi, P. (229) 149
Tomatis, R., see Salvadori, S. (230) 357
Tome, A.R., see Duarte, C.B. (244) 259
Tominaga, K., see Shibata, S. (229) 21
Tominaga, T., see Oikawa, T. (241) 221
Tomkins, D.M., see Costall, B. (234) 91
Tomlinson, D.R., see Carrington, A.L. (237) 257
Tonini, M., see Coccini, T. (248) 1
Toppila, J., see Stenberg, D. (238) 241
Torii, Y., Mutoh, M., Saito, H. and Matsuki, N.
Involvement of free radicals in cisplatin-induced emesis in *Suncus murinus* (248) 131
Torii, Y., see Matsuki, N. (248) 329
Törnwall, M., Tuomainen, P. and Männistö, P.T.
Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase (239) 39
Torregrosa, G., see Alborch, E. (229) 83
Torrens, Y., see Petitet, F. (247) 185
Tosi, P., see Sgaragli, G.P. (248) 121
Toth, G., see Wild, K.D. (246) 25
Toth, G., see Wild, K.D. (246) 289
Tóth, M., see Uusimaa, P.A. (242) 199
Traber, D.L., see Loick, H.M. (248) 75
Traber, L.D., see Loick, H.M. (248) 75
Trampus, M., Ferri, N., Adami, M. and Ongini, E.
The dopamine $D_1$ receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat (235) 83
Tran, G., see Scamps, F. (244) 119
Traub, O., see Watts, S.W. (242) 245
Trifilieff, A., Amrani, Y., Landry, Y. and Gies, J.-P.
Comparative action of new highly potent bradykinin receptor antagonists in the guinea-pig trachea (239) 227
Triggle, D.J., see Hawthorn, M.H. (229) 143
Troger, J., see Kieselbach, G. (235) 117

Trube, G., see Netzer, R. (238) 209
Trumpp-Kallmeyer, S., see Huggins, J.P. (245) 203
Tsai, H., Buchholz, J. and Duckles, S.P.
Postjunctional $\alpha_2$-adrenoceptors in blood vessels: effect of age (237) 311
Tsai, T.D., see Lee, K.S. (234) 43
Tseng, L.F., Lin, J.J. and Collins, K.A.
Partial antinociceptive cross-tolerance to intracerebroventricular $\beta$-endorphin in mice tolerant to systemic morphine (241) 63
Tseng, L.F., see Xu, J.Y. (236) 137
Tseng, Y.T., Miyaoka, T. and Ho, I.K.
Region-specific changes of $GABA_A$ receptors by tolerance to and dependence upon pentobarbital (236) 23
Tsiang, H., see Ceccaldi, P.-E. (245) 129
Tsuchimoto, M., see Osada, Y. (241) 183
Tsuchiya, T., see Miyake, K. (235) 75
Tsukagoshi, H., see Kurosawa, M. (238) 335
Tsunashima, K., see Masui, A. (238) 297
Tsutsumi, K., see Zorad, S. (241) 195
Tubaro, E., Belogi, L., Croce, C., Cavallo, G., Guida, G. and Borelli, G.P.
Antiplatelet effects of a new de-N-acetyl-lyso-glycosphingolipid (248) 175
Tückemantel, W., see Casalotti, S.O. (247) 209
Tudhope, S.R., see Gardiner, P.J. (238) 19
Tujii, H., see Yayama, K. (236) 337
Tulkens, P.M., see Van Bambeke, F. (247) 155
Tümmler, B., see Hoof, T. (246) 53
Tunçtan, B., see Çakici, İ. (236) 97
Tuomainen, P., see Törnwall, M. (239) 39
Turconi, M., see Van Meel, J.C.A. (233) 295
Turski, W.A., see Czechowska, G. (232) 59
Tvrdeić, A., see Peričić, D. (235) 267
Tweedie, D., Henderson, C. and Kane, K.
Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts (240) 251

Uchimura, H., see Ooboshi, H. (233) 165
Udvarhelyi, P.M., see Eaton, S.A. (244) 195
Ueha, T., see Oyama, Y. (248) 89
Ueki, S., see Shibata, S. (229) 21
Ueki, S., see Shibata, S. (245) 257
Uematsu, T., see Hirata, Y. (231) 421
Uematsu, T., see Umemura, K. (239) 17
Ueyama, M., see Oka, T. (234) 55
Uezu, K., see Higuchi, M. (242) 293
Ugedo, L., Garro, M.A., Pineda, J., Giralt, M.T., Miralles, A., Olmos, G., García-Sevilla, J.A., Menargues, A. and Obach, R.
Acute and chronic effects of reserpine on biochemical and functional parameters of central and peripheral $\alpha_2$-adrenoceptors (239) 149
Ugedo, L., see Olmos, G. (236) 467
Uhl, A., see Mondeh, J.D. (240) 39
Uhl, G.R., see Kusama, T. (245) 83
Ukai, K., see Nomura, T. (246) 113
Ukai, M., Mori, E. and Kameyama, T.
Cocaine-like discriminative stimulus properties of the $\delta$-selective opioid receptor agonist, [D-Pen$^2$,L-Pen$^5$]enkephalin, in the rat (231) 143
Ukai, M., Mori, K., Hashimoto, S., Kobayashi, T., Sasaki, Y. and Kameyama, T.
Tyr-D-Arg-Phe-$\beta$-Ala-$NH_2$, a novel dermorphin analog, impairs memory consolidation in mice (239) 237
Ukai, M., see Itoh, J. (234) 9
Ukai, M., see Itoh, J. (236) 341
Ukai, M., see Itoh, J. (241) 99
Ukhanova, M.V., see Bagrov, A.Y. (234) 165
Ullrich, B., see Eltze, M. (238) 343
Umemura, K., Kohno, Y., Asai, Y., Uematsu, T. and Nakashima, M.
Effect of a $Ca^{2+}$ entry blocker, nilvadipine, on hearing disturbances and equilibrium dysfunction caused by microcirculatory disorders of the rat inner ear (239) 17
Umemura, K., see Hirata, Y. (231) 421
Umino, A., see Shirayama, Y. (237) 117
Unger, P., Berkenboom, G., Brékine, D. and Fontaine, J.
Nitrate tolerance and aging in isolated rat aorta (248) 145
Uphouse, L.A., Welch, S.P., Ward, C.R., Ellis, E.F. and Embrey, J.P.
Antinociceptive activity of intrathecal ketorolac is blocked by the $\kappa$-opioid receptor antagonist, nor-binaltorphimine (242) 53
Urade, Y., see Karaki, H. (231) 371
Urna, G., see Squadrito, F. (230) 125
Ushijima, H., see Müller, W.E.G. (246) 261
Uslenghi, A., see Gobbi, M. (238) 9
Uusi-Oukari, M., see Taira, T. (230) 307
Uusimaa, P.A., Kiviluoma, K.T., Tóth, M., Hassinen, I.E., Peuhkurinen, K.J. and Ruskoaho, H.
Adenosine inhibits the release of atrial natriuretic peptide from the perfused rat heart (242) 199
Uzu, T., see Koya, D. (245) 79

Vähäkangas, K., see Salonpää, P. (248) 95
Valenzuela, F., see Guarner, V. (237) 139
Valoti, M., see Sgaragli, G.P. (248) 121
Van Aken, H., see Mos, J. (238) 411
VanAller, G.S., see Pagani, E.D. (243) 141
Van Amsterdam, F.T.M., see Spampinato, S. (244) 139
Van Ark, I., see Van Oosterhout, A.J.M. (236) 379
Van Ark, I., see Van Oosterhout, A.J.M. (239) 277
Van Bambeke, F., Mingeot-Leclercq, M.-P., Schanck, A., Brasseur, R. and Tulkens, P.M.
Alterations in membrane permeability induced by aminoglycoside antibiotics: studies on liposomes and cultured cells (247) 155
Van Bogaert, P.P. and Goethals, M.
Blockade of the pacemaker current by intracellular application of UL-FS 49 and UL-AH 99 in sheep cardiac Purkinje fibers (229) 55
VanBrocklin, H., see Jagust, W.J. (242) 189
Van de Kar, L.D., see Levy, A.D. (241) 275
Van den Buuse, M.
Effects of 7-hydroxy-*N*,*N*-di-*n*-propylaminotetralin on behaviour and blood pressure of spontaneously hypertensive rats (243) 169
Van der Leest, J., see Benthem, L. (232) 279
Vandermeersch, S., see Chansel, D. (247) 193
Van der Schoot, P., see Haensel, S.M. (233) 187
Van der Valk, J.B.F. and Vijverberg, H.P.M.
Chronic sabeluzole treatment of cultured rat cerebellar granule cells reduces N-methyl-D-aspartate-induced inward current (232) 131
Van Diest, M.J., Verbeuren, T.J. and Herman, A.G.
Vascular interaction between 5-hydroxytryptamine and 15-lipoxygenase metabolites of arachidonic acid (231) 267
Van Erp, A.M.M., Kruk, M.R. and De Kloet, E.R.
Induction of grooming in resting rats by intracerebroventricular oxytocin but not by adrenocorticotropic hormone-(1–24) and $\alpha$-melanocyte-stimulating hormone (232) 217
Van Essen, H., see Huijberts, M. (240) 207
Van Heuven-Nolsen, D., see Bax, W.A. (239) 203
Van Meel, J.C.A. and Haigh, R.M.
Unexpected contractile response from the G-protein activator mastoparan in cardiac myocytes (247) 357
Van Meel, J.C.A., Diederen, W., Haigh, R., Wienen, W., Pairet, M., Turconi, M. and Doods, H.N.
The novel 5-$HT_4$ receptor antagonist DAU 6285 antagonizes 5-hydroxytryptamine-induced tachycardia in pigs (233) 295

Van Meel, J.C.A., see Zhang, J. (230) 95
Van Megen, Y.J.B., see Blankesteijn, W.M. (244) 21
Van Muiswinkel, F.L., see Ronken, E. (230) 349
Vanni, E., see Intorre, L. (243) 265
Van Oorschot, R., see Mos, J. (238) 411
Van Oosterhout, A.J.M., Van Ark, I., Hofman, G., Savelkoul, H.F.J. and Nijkamp, F.P.
Recombinant interleukin-5 induces in vivo airway hyperresponsiveness to histamine in guinea pigs (236) 379
Van Oosterhout, A.J.M., Van Ark, I., Hofman, G., Savelkoul, H.F.J. and Nijkamp, F.P.
Recombinant interleukin-5 induces in vivo airway hyperresponsiveness to histamine in guinea pigs European Journal of Pharmacology, 236 (1993) 379–383 (239) 277
Van Rijswijk, A.L.C.T., see Van Vliet, B.J. (245) 23
Van Sande, J., Allgeier, A., Massart, C., Czernilofsky, A., Vassart, G., Dumont, J.E. and Maenhaut, C.
The human and dog 5-$HT_{1D}$ receptors can both activate and inhibit adenylate cyclase in transfected cells (247) 177
Van Steensel, B., see Rupprecht, R. (247) 145
Van Tol, H.H.M., see Seeman, P. (233) 173
Van Vliet, B.J., Van Rijswijk, A.L.C.T., Wardeh, G., Mulder, A.H. and Schoffelmeer, A.N.M.
Adaptive changes in the number of $G_s$- and $G_i$-proteins underlie adenylyl cyclase sensitization in morphine-treated rat striatal neurons (245) 23
Van Zwieten, P.A., see Zhang, J. (230) 95
Vapaatalo, H., see Saareks, V. (248) 345
Varga, J., see Bidzseranova, A. (232) 305
Vargaftig, B.B., see Amorim, C.Z. (235) 17
Vargaftig, B.B., see Amorim, C.Z. (236) 301
Vargaftig, B.B., see Cunha, F.Q. (238) 47
Vargaftig, B.B., see Desquand, S. (235) 101
Vargaftig, B.B., see Tesson, F. (248) 27
Vargaftig, B.B., see Tesson, F. (248) 351
Vargas, M.L., see Martinez-Piñero, M.G. (232) 191
Varró, A., see Lathrop, D.A. (240) 127
Vassart, G., see Van Sande, J. (247) 177
Vassort, G., see Scamps, F. (244) 119
Vaugeois, J.-M., Bonnet, J.-J., Duterte-Boucher, D. and Costentin, J.
In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion (230) 195
Vauquelin, G., see Jimenez Del Rio, M. (247) 11
Vayssettes-Courchay, C., Bouysset, F., Verbeuren, T.J. and Laubie, M.
Role of the lateral tegmental field in the central sympatho-inhibitory effect of 8-hydroxy-2-(di-n-propylamino)tetralin in the cat (236) 121
Vayssettes-Courchay, C., Bouysset, F., Verbeuren, T.J. and Laubie, M.
Role of the nucleus tractus solitarii and the rostral depressive area in the sympatholytic effect of 8-hydroxy-2-(di-n-propylamino)tetralin in the cat (242) 37
Vazeux, G., see Tesson, F. (248) 27
Vazeux, G., see Tesson, F. (248) 351
Veech, R.L., see Park, K.S. (248) 7
Veeranna, , Reddy, P.L. and Bhargava, H.N.
Effect of chronic administration of U-50,488H, a $\kappa$-opioid receptor agonist, on central dopamine $D_2$ receptors of the rat (235) 23
Velez Pardo, C., see Jimenez Del Rio, M. (247) 11
Venturelli, A., see Persico, P. (241) 71
Verbeuren, T.J., see Descombes, J.-J. (243) 193
Verbeuren, T.J., see Van Diest, M.J. (231) 267
Verbeuren, T.J., see Vayssettes-Courchay, C. (236) 121
Verbeuren, T.J., see Vayssettes-Courchay, C. (242) 37
Vergnes, M., see Danober, L. (234) 263
Vermeulen, R.J., Drukarch, B., Sahadat, M.C.R., Goosen, C., Wolters, E.C. and Stoof, J.C.
The selective dopamine $D_1$ receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys (235) 143
Verroust, P.J., see Bensoussan, M. (247) 169
Versteeg, D.H.G., see De Wildt, D.J. (233) 157
Vestal, R.E., see Musser, B. (246) 105
Vetrovsky, P., see Schott, C.A. (236) 155
Vicente, I., see Martínez, F. (248) 199
Vicentini, L.M., see Cattaneo, M.G. (247) 325
Vicini, S., see Dučić, I. (244) 29
Vidal, M.J., see De Sarro, G. (230) 151
Vigne, P., Breittmayer, J.P. and Frelin, C.
Competitive and non competitive interactions of BQ-123 with endothelin $ET_A$ receptors (245) 229
Vigne, P., see Feolde, E. (245) 63
Vijverberg, H.P.M., see Kooyman, A.R. (246) 247
Vijverberg, H.P.M., see Van der Valk, J.B.F. (232) 131
Vilaine, J.-P., see Iliou, J.-P. (248) 263
Vilhardt, H., Barth, T., Melin, P. and Aurell, C.-J.
Antidiuretic activity and release of Factor VIII by vasopressin analogues (232) 223
Villalobos-Molina, R., see Castillo, C. (241) 141
Villalón, C.M., Terrón, J.A. and Hong, E.
Role of 5-$HT_1$-like receptors in the increase in external carotid blood flow induced by 5-hydroxytryptamine in the dog (240) 9
Villanueva, L., see Bouhassira, D. (232) 207
Villarroya, M., see López, M.G. (247) 199
Villarroya, M., see Priego, J. (243) 25
Villhauer, E.B., see Quast, U. (245) 165
Vilner, B.J. and Bowen, W.D.
$\sigma$ Receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture (244) 199
Viola, P., see Izzo, A.A. (243) 87
Viswanathan, M., see Saavedra, J.M. (235) 301
Vitorica, J., see Ruano, D. (246) 81
Vivas, N.M., Badia, A., Màrmol, F. and Dierssen, M.
Differential effects of physostigmine and 1,2,3,4-tetrahydro-9-aminoacridine on the $\beta$-adrenoceptor transduction system (245) 9
Vogel, Z., see Nah, S.-Y. (244) 67
Vogel, Z., see Nah, S.-Y. (246) 19
Voisin, P., see Pontoire, C. (247) 111
Volberg, M.L., see De Garavilla, L. (234) 77
Von Euler, G. and Liu, Y.
Glutamate and glycine decrease the affinity of [$^3$H]MK-801 binding in the presence of $Mg^{2+}$ (245) 233
Von Euler, G., see Li, X.-M. (234) 125
Von Euler, G., see Tanganelli, S. (230) 159
Von Lubitz, D.K.J.E., McKenzie, R.J., Lin, R.C.-S., Devlin, T.M. and Skolnick, P.
MK-801 is neuroprotective but does not improve survival in severe forebrain ischemia (233) 95

Wada, K., see Hirata, Y. (231) 421
Waddington, J.L., see Downes, R.P. (234) 135
Wadsworth, R.M., see McDonald, A. (240) 303
Wagner, M., see Krug, M. (231) 355
Wahl, F., Allix, M., Plotkine, M. and Boulu, R.G.
Effect of riluzole on focal cerebral ischemia in rats (230) 209
Wahlestedt, C., see Erlinge, D. (240) 77
Wakabayashi, I., see Hatake, K. (238) 441
Wakabayashi, I., see Masui, H. (248) 103
Wakade, A.R., see Przywara, D.A. (247) 353
Wakade, T.D., see Przywara, D.A. (247) 353
Waldron, T.L., see Bird, J.E. (240) 295
Walker, J.M., Bowen, W.D., Patrick, S.L., Williams, W.E., Mascarella, S.W., Bai, X. and Carroll, F.I.

A comparison of (−)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests role of $\sigma_2$ receptors in motor function (231) 61
Walker, J.M., Bowen, W.D., Patrick, S.L., Williams, W.E., Mascarella, S.W., Bai, X. and Carroll, F.I.
A comparison of (−)-deoxybenzomorphans devoid of opiate activity with their dextrorotatory phenolic counterparts suggests role of $\sigma_2$ receptors in motor function. European Journal of Pharmacology, 231 (1993) 61–68 (236) 495
Walker, J.M., see Patrick, S.L. (231) 243
Wall, T.M., see Hartman, J.C. (234) 229
Wallace, A.M., see Weishaar, R.E. (236) 363
Wallace, J.L., see Higa, A. (239) 171
Wallace, J.L., see McCafferty, D.-M. (232) 169
Wallis, R.A. and Panizzon, K.L.
Protection from hypoxic and N-methyl-D-aspartate injury with azelastine, a leukotriene inhibitor (238) 165
Walton, T.M., see Davisson, R.L. (241) 135
Walz, R., see Jerusalinsky, D. (240) 103
Wamil, A.W. and McLean, M.J.
Effect of temperature on limitation by MK-801 of firing of action potentials by spinal cord neurons in cell culture (230) 263
Wang, C., Chakrabarti, M.K. and Whitwam, J.G.
Effect of ICI197067, a $\kappa$-opioid receptor agonist, spinally on A$\delta$ and C reflexes and intracerebrally on respiration (243) 113
Wang, C.-Y., see Yu, S.-M. (248) 289
Wang, H.-R., see Huang, H.-C. (237) 39
Wang, S., see Barr, G.A. (233) 143
Wang, S., see Baskys, A. (235) 305
Wang, T.-L., see Kusama, T. (245) 83
Wang, Y., see Chang, Y.-F. (233) 209
Wang, Y.-X. and Brooks, D.P.
Effect of dietary protein on the renal response to fenoldopam in diabetic rats (248) 217
Wang, Y.-X. and Pang, C.C.Y.
Suppression by ethanol of pressor response caused by the inhibition of nitric oxide synthesis (233) 275
Wang, Z.-L., see Kwan, C.-Y. (238) 431
Ward, C.R., see Uphouse, L.A. (242) 53
Ward, J.S., see Shannon, H.E. (232) 47
Wardeh, G., see Tjon Tien Ril, H.K.G. (235) 321
Wardeh, G., see Van Vliet, B.J. (245) 23
Wärngård, L., see Hemming, H. (248) 163
Warren, J.B., see Pons, F. (239) 23
Washington, J.D., see Hammond, D.L. (234) 255
Watabe, S., Yamaguchi, H. and Ashida, S.-i.
DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex (238) 303
Watanabe, G., see Kogo, H. (231) 481
Watanabe, H., Tateyama, M., Nagao, T., Ohta, S., Hirobe, M. and Ono, H.
Methamphetamine antagonistic property of (+)- and (−)-4-phenyltetrahydroisoquinoline in rat anococcygeus muscle (243) 155
Watanabe, K., see Horie, S. (229) 15
Watanabe, S., see Ohno, M. (234) 29
Watanabe, S., see Ohno, M. (238) 117
Watanabe, S., see Shibata, S. (229) 21
Watanabe, S., see Shibata, S. (231) 381
Watanabe, S., see Shibata, S. (245) 257
Watanabe, T., see Nomura, T. (246) 113
Watanabe, T., see Yokoyama, H. (234) 129
Watanabe, Y., see Abiru, T. (242) 15
Watanabe, Y., see Angulo, J.A. (244) 317
Watanabe, Y., see Yoneda, I. (247) 267
Waterfall, J.F., see Gater, P.R. (238) 59
Waters, N., Lagerkvist, S., Löfberg, L., Piercey, M. and Carlsson, A.
The dopamine $D_3$ receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study (242) 151
Wätjen, F., see Johansen, T.H. (246) 195
Watkins, J.C., see Bashir, Z.I. (239) 265
Watkins, J.C., see Eaton, S.A. (244) 195
Watling, K.J., see Guard, S. (232) 287
Watling, K.J., see Guard, S. (236) 496
Watling, K.J., see Guard, S. (240) 177
Watson, M.A., see Yamada, M. (244) 99
Watts, S.W., Traub, O., Lamb, F.S., Myers, J.H. and Webb, R.C.
Effect of ramipril on $\alpha$-adrenoceptor-mediated oscillatory contractions in tail artery of hypertensive rats (242) 245
Watts, V.J., Lawler, C.P., Gilmore, J.H., Southerland, S.B., Nichols, D.E. and Mailman, R.B.
Dopamine $D_1$ receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents (242) 165
Watts, V.J., Lawler, C.P., Knoerzer, T., Mayleben, M.A., Neve, K.A., Nichols, D.E. and Mailman, R.B.
Hexahydrobenzo[a]phenanthridines: novel dopamine $D_3$ receptor ligands (239) 271
Weaver, J.P., see Osei, S.Y. (234) 35
Webb, R.C., see Watts, S.W. (242) 245
Webb, R.L., see Olson, R.W. (236) 75
Webdale, L., see Suman-Chauhan, N. (244) 293
Weber, A.-A., Strobach, H. and Schrör, K.
Direct inhibition of platelet function by organic nitrates via nitric oxide formation (247) 29
Weber, S.J., see Horan, P.J. (233) 53
Webster, J.L., Polgar, W.E., Brandt, S.R., Berzetei-Gurske, I.P. and Toll, L.
Comparison of $\kappa_2$-opioid receptors in guinea pig brain and guinea pig ileum membranes (231) 251
Wedlund, P., see Jewell, A. (243) 249
Weichman, B.M., see Grimes, D. (236) 217
Weichman, B.M., see Heaslip, R.J. (234) 247
Weidinger, F., see Schwarzacher, S. (229) 253
Weiner, J., see Khanna, J.M. (230) 23
Weinsberg, F., see Guilarte, T.R. (248) 273
Weishaar, R.E., Kirker, M.L., Wallace, A.M., Ferraris, V.A., Britton II, L.W. and Sim, M.F.
Relationship between inotropic activity and phosphodiesterase inhibition for flosequinan and milrinone (236) 363
Weiss, R.M., see Yoshida, M. (232) 159
Weiss, S.R.B., see Baptista, T. (236) 39
Weissman, B.A., see Gleeson, S. (229) 109
Weitzberg, E., Rudehill, A. and Lundberg, J.M.
Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxin shock (233) 85
Welch, J.E., see Saphier, D. (236) 183
Welch, S.P., see Uphouse, L.A. (242) 53
Weller, M. and Paul, S.M.
3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons (248) 223
Weller, M., Marini, A.M., Finiels-Marlier, F., Martin, B. and Paul, S.M.
MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate (248) 303
Wertz, J.M., see Pomerantz, S.M. (243) 227
West, K.E., see Steward, L.J. (243) 13
Westphalen, R.I. and Dodd, P.R.
The regeneration of d,l-fenfluramine-destroyed serotonergic nerve terminals (238) 399
Wheeler-Aceto, H. and Cowan, A.
Naloxone causes apparent antinociception and pronociception simultaneously in the rat paw formalin test (236) 193

White, E., see Cannings, I. (248) 213
White, H.S., Hunt, J., Wolf, H.H., Swinyard, E.A., Falch, E., Krogsgaard-Larsen, P. and Schousboe, A.
Anticonvulsant activity of the γ-aminobutyric acid uptake inhibitor N-4,4-diphenyl-3-butenyl-4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol (236) 147
White, I.N.H., see Heijink, E. (248) 15
Whiting, R.L., see Costall, B. (234) 91
Whittle, B.J.R., see Calignano, A. (229) 273
Whitwam, J.G., see Wang, C. (243) 113
Wicki, U., see Brugger, F. (235) 153
Widdop, S., see Daykin, K. (246) 135
Widdowson, P., see Millan, M.J. (230) 99
Wiebel, F.J., see Schmalix, W.A. (248) 251
Wiegand, H., see Guilarte, T.R. (248) 273
Wienen, W., see Van Meel, J.C.A. (233) 295
Wiener, H.L. and Thalody, G.P.
Kinetic characterization of adenosine $A_2$ receptor-mediated relaxation in isolated rabbit aorta (238) 65
Wiesenfeld-Hallin, Z., see Luo, L. (235) 157
Wiesenfeld-Hallin, Z., see Xu, X.-J. (235) 161
Wikberg, J.E.S., see Xia, Y. (246) 129
Wikberg, J.E.S., see Xu, X.-J. (235) 161
Wiklund, C.U., Wiklund, N.P. and Gustafsson, L.E.
Modulation of neuroeffector transmission by endogenous nitric oxide: a role for acetylcholine receptor-activated nitric oxide formation, as indicated by measurements of nitric oxide/nitrite release (240) 235
Wiklund, N.P., see Wiklund, C.U. (240) 235
Wilce, P.A., see Matsumoto, I. (247) 289
Wild, K.D., Fang, L., McNutt, R.W., Chang, K.-J., Toth, G., Borsodi, A., Yamamura, H.I. and Porreca, F.
Binding of BW 373U86, a non-peptidic δ opioid receptor agonist, is not regulated by guanine nucleotides and sodium (246) 289
Wild, K.D., Horan, P.J., Misicka, A., Lipkowski, A., Haaseth, R.C., Matsunaga, T.O., Hruby, V.J., Toth, G., Borsodi, A., Yamamura, H.I. and Porreca, F.
Pseudoirreversible binding characteristics of [D-Ala$^2$,Glu$^4$]deltorphin and its Cys$^4$ substituted derivative to δ-opioid receptors (246) 25
Wild, K.D., see Horan, P.J. (233) 53
Wild, K.D., see Raffa, R.B. (244) 231
Wille, M., see Just, I. (246) 293
Willer, J.-C., see Strimbu-Gozariu, M. (237) 197
Williams, L.S., see Woodward, D.F. (230) 327
Williams, M., see Kebabian, J.W. (229) 203
Williams, T.J., Costall, B. and Naylor, R.J.
Problematical binding of [$^3$H]5-hydroxytryptamine to rat gut myenteric membranes (245) 197
Williams, T.J., see Pons, F. (239) 23
Williams, W.E., see Walker, J.M. (231) 61
Williams, W.E., see Walker, J.M. (236) 495
Williamson, J.R., see Misko, T.P. (233) 119
Wilson, K., see Gater, P.R. (238) 59
Wilson, L.M., see Currie, P.J. (232) 227
Winneke, G., see Guilarte, T.R. (248) 273
Winslow, J.T. and Insel, T.R.
Effects of central vasopressin administration to infant rats (233) 101
Winter, J.C., see Rabin, R.A. (235) 237
Wioland, N., see Rudolf, G. (230) 259
Wirtshafter, D., see Asin, K.E. (235) 167
Wise, R.A., see Devine, D.P. (243) 55
Witt-Enderby, P.A., Yamamura, H.I., Halonen, M., Palmer, J.D. and Bloom, J.W.
Chronic exposure to a $\beta_2$-adrenoceptor agonist increases the airway response to methacholine (241) 121
Witte, K., Olbrich, H.-G., Langer, L. and Lemmer, B.
Uncoupling of $\beta_1$-adrenoceptors from cardiac adenylyl cyclase in cardiomyopathic and control hamsters (247) 215
Wojcik, W.J., see Fohrman, E.B. (245) 263
Wojtowicz, J.M., see Baskys, A. (235) 305
Wolf, G., see Fischer, S. (232) 121
Wolf, H.H., see White, H.S. (236) 147
Wolffenbuttel, B., see Huijberts, M. (240) 207
Wöll, E., Ritter, M., Offner, F., Lang, H.-J., Schölkens, B., Häussinger, D. and Lang, F.
Effects of HOE 694 – a novel inhibitor of $Na^+/H^+$ exchange – on NIH 3T3 fibroblasts expressing the *RAS* oncogene (246) 269
Wolsink, J.G., see Berkenbosch, A. (232) 21
Wolters, E.C., see Vermeulen, R.J. (235) 143
Wong, E.H.F., see Costall, B. (234) 91
Wong, G., Gu, Z.-Q., De Costa, B. and Skolnick, P.
Labelling of diazepam-sensitive and -insensitive benzodiazepine receptors with [$^3$H]*tert*-butyl-8-chloro-5,6-dihydro-5-methyl-6-oxo-4*H*-imidazo[1,5-*a*][1,4]benzodiazepine 3-carboxylate (ZG-63) (247) 57
Wong, S., Mok, W., Phaneuf, S., Katz, S. and Salari, H.
Forskolin inhibits platelet-activating factor binding to platelet receptors independently of adenylyl cyclase activation (245) 55
Wood, J.D., see Tamura, K. (232) 235
Woodcock, E.A. and Land, S.L.
Functional endothelin $ET_B$ receptors on renal papillary tubules (247) 93
Woodruff, G.N., see Hayward, N.J. (236) 247
Woodruff, G.N., see Hill, D.R. (244) 303
Woodruff, G.N., see Norris, S.K. (234) 223
Woodruff, G.N., see Suman-Chauhan, N. (244) 293
Woodruff, G.N., see Thurlow, R.J. (247) 341
Woodward, D.F., Spada, C.S., Hawley, S.B., Williams, L.S., Protzman, C.E. and Nieves, A.L.
Further studies on ocular responses to DP receptor stimulation (230) 327
Woolfolk, D.R. and Holtzman, S.G.
Restraint stress potentiates analgesia induced by 5′-N-ethylcarboxamidoadenosine: comparison with morphine (239) 177
Wray, D., see Pearson, H.A. (236) 323
Wright, I.K., see Routledge, C. (239) 195
Wrona, C.T., see Bardgett, M.E. (230) 245
Wu, D., see Cheng, P.Y. (230) 85
Wu, F.-S., Gibbs, T.T. and Farb, D.H.
Dual activation of $GABA_A$ and glycine receptors by β-alanine: inverse modulation by progesterone and 5α-pregnan-3α-ol-20-one (246) 239
Wu, J., see Zielenski, J. (248) 313
Wu, P.-Y., see Rattray, M. (245) 193
Wu, P.H., Mihic, S.J., Liu, J.-F., Lê, A.D. and Kalan, H.
Blockade of chronic tolerance to ethanol by the NMDA antagonist, (+)-MK-801 (231) 157
Wu, P.H., see Khanna, J.M. (230) 23
Wu, R.-M., Chiueh, C.C., Pert, A. and Murphy, D.L.
Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by $MPP^+$ in vivo (243) 241
Wu, T.-W., see Zielenski, J. (248) 313
Wu, Y.-C., see Lin, C.-H. (237) 109
Wyatt, R.J., see Chrapusta, S.J. (233) 135
Wynn, R.L., Essien, E. and Thut, P.D.
The effects of different antiemetic agents on morphine-induced emesis in ferrets (241) 47

Xia, Y., Chhajlani, V. and Wikberg, J.E.S.
Functional expression of rat $\alpha_{2B}$-adrenoceptor in *Escherichia coli* (246) 129

Xu, J.Y. and Tseng, L.F.
Increase of nitric oxide by L-arginine potentiates β-endorphin- but not μ-, δ- or κ-opioid agonist-induced antinociception in the mouse (236) 137
Xu, X.-J., Wikberg, J.E.S. and Wiesenfeld-Hallin, Z.
The effect of intrathecal guanfacine and clonidine on the flexor reflex in rats with intact and sectioned sciatic nerves (235) 161
Xu, Y., see Goldhill, J. (238) 387

Yagasaki, O., see Fukunaga, Y. (233) 237
Yagi, H., see Arimura, A. (231) 13
Yaksh, T.L., see Tiseo, P.J. (236) 89
Yamada, M., Yamada, M., Watson, M.A. and Richelson, E.
Neurotensin stimulates cyclic AMP formation in CHO-rNTR-10 cells expressing the cloned rat neurotensin receptor (244) 99
Yamada, M., see Yamada, M. (244) 99
Yamada, S., Yokoo, H. and Nishi, S.
Chronic treatment with haloperidol modifies the sensitivity of autoreceptors that modulate dopamine release in rat striatum (232) 1
Yamaguchi, H., see Watabe, S. (238) 303
Yamaguchi, I., see Matsuoka, N. (241) 27
Yamaguchi, T., Mukaiyama, O., Itoh, K., Satoh, Y., Terada, A. and Iizuka, Y.
Effects of CS-518, a thromboxane synthase inhibitor, on the asthmatic response (236) 43
Yamaguchi, T., see Itoh, K. (237) 215
Yamaguchi, T., see Itoh, K. (239) 159
Yamamoto, A., see Tamaki, T. (236) 15
Yamamoto, B.K., see Pehek, E.A. (240) 107
Yamamoto, T., see Isono, T. (246) 205
Yamamoto, T., see Ohno, M. (234) 29
Yamamoto, T., see Ohno, M. (238) 117
Yamamura, H.I., see Henderson, A.K. (245) 75
Yamamura, H.I., see Horan, P.J. (233) 53
Yamamura, H.I., see Wild, K.D. (246) 25
Yamamura, H.I., see Wild, K.D. (246) 289
Yamamura, H.I., see Witt-Enderby, P.A. (241) 121
Yamamura, N., see Itoh, K. (237) 215
Yamanaka, T., see Nagakawa, J.-i. (229) 63
Yamano, M., see Kamato, T. (238) 369
Yamasaki, F., see Shinkawa, T. (238) 317
Yamasaki, H., see Mesnil, M. (248) 59
Yamashita, M., see Morimoto, H. (240) 121
Yamatsu, I., see Nagakawa, J.-i. (229) 63
Yamaura, T., see Shibata, M. (235) 245
Yamawaki, I., Geppetti, P., Bertrand, C., Huber, O., Daffonchio, L., Omini, C. and Nadel, J.A.
Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea (243) 1
Yanaihara, N., see Masui, A. (238) 297
Yang, Z.-Y., see Mukherjee, J. (243) 287
Yano, M., see Hermán, F. (236) 143
Yano, M., see Kobayashi, M. (235) 95
Yano, M., see Noguchi, K. (233) 47
Yano, S., see Horie, S. (229) 15
Yano, T., see Mizuguchi, K. (231) 121
Yano, T., see Mizuguchi, K. (235) 221
Yao, H., see Ooboshi, H. (233) 165
Yatomi, Y., see Ozaki, Y. (235) 255
Yayama, K., Kawao, M., Tujii, H., Itoh, N. and Okamoto, H.
Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis (236) 337
Yee, F., see Erlinge, D. (240) 77
Yen, M.-H., see Tao, P.-L. (243) 135
Ying, S.-W., Niles, L.P. and Crocker, C.
Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin (246) 89
Yodonawa, S., see Kurosawa, M. (238) 335
Yokoo, H., see Yamada, S. (232) 1
Yokota, T., see Akaike, A. (241) 1
Yokoyama, H., Onodera, K., Iinuma, K. and Watanabe, T.
Effect of thioperamide, a histamine $H_3$ receptor antagonist, on electrically induced convulsions in mice (234) 129
Yokoyama, R., see Nomura, T. (246) 113
Yokoyama, T., Tokuyama, K., Morikawa, A. and Kuroume, T.
Bradykinin is less potent in causing airway microvascular leakage in immature than in adult guinea-pigs. Role of neutral endopeptidase (236) 427
Yokoyama, T., see Okada, Y. (241) 177
Yoneda, I., Sakuta, H., Okamoto, K. and Watanabe, Y.
Effects of local anesthetics and related drugs on endogenous glibenclamide-sensitive $K^+$ channels in *Xenopus* oocytes (247) 267
Yoneda, T., see Takeda, Y. (233) 299
Yoon, Y.J., see Chang, K.C. (236) 51
Yoshida, H., see Tamaki, T. (236) 15
Yoshida, H., see Toide, K. (233) 21
Yoshida, K., see Dohi, M. (243) 179
Yoshida, M., Latifpour, J. and Weiss, R.M.
Age-related changes in $Ca^{2+}$ channel antagonist receptors in rabbit lower urinary tract (232) 159
Yoshida, T., see Suzuki, S. (231) 297
Yoshikawa, S., Fukunaga, Y., Takeuchi, T., Nishio, H. and Hata, F.
Modulation of acetylcholine release from the myenteric plexus of guinea-pig ileum by 5-lipoxygenase metabolites of arachidonic acid (239) 261
Yoshikawa, S., see Fukunaga, Y. (233) 237
Yoshimoto, S., see Masui, H. (248) 103
Yoshimura, M., see Taniyama, K. (235) 149
Yoshinari, H., see Tachikawa, E. (236) 355
Yoshioka, K., see Suzuki, H. (241) 105
Yoshioka, M., Ikeda, T., Togashi, H. and Saito, H.
Effect of 5-hydroxytryptamine on glossopharyngeal afferent nerve activity in anesthetized rats (236) 491
Yoshioka, M., see Iga, Y. (238) 395
Yoshitomi, K., see Shinkawa, T. (238) 317
Yoshizawa, M., see Miyake, K. (235) 75
Youdim, M.B.H., see Adeyemo, O.M. (240) 185
Young, A., see Nowak, G. (247) 101
Young, G.A., Hudson, G.M., Stamidis, H. and Steinfels, G.F.
Interactions between U-50,488H and σ receptor antagonists: EEG, EEG power spectral and behavioral correlates (231) 473
Young, J.M., see Arias-Montaño, J.-A. (245) 221
Young, J.M., see Arias-Montaño, J.-A. (245) 291
Young, M.R., see Fleetwood-Walker, S.M. (242) 173
Yu, H., Liu, Y., Hacksell, U. and Lewander, T.
(R)- and (S)-8-acetyl-2-(dipropylamino)tetralin (LY-41): two novel 5-$HT_{1A}$ receptor agonists (231) 69
Yu, S.-M., Huang, Z.-S., Wang, C.-Y. and Teng, C.-M.
Effects of hyperlipidemia on the vascular reactivity in the Wistar-Kyoto and spontaneously hypertensive rats (248) 289
Yu, S.-M., Lee, S.-S., Chou, H. and Teng, C.-M.
Contractile effects caused by thaliporphine in the guinea-pig ileum (234) 121
Yu, S.-M., see Teng, C.-M. (233) 7
Yu, X.-j., Li, Y.-j. and Deng, H.-w.
The regulatory effect of bradykinin on the actions of sensory

nerves in the perfused rat mesentery is mediated by nitric oxide (241) 35
Yu, X.-j., see Li, Y.-j. (239) 127
Yue, T.-L., Mckenna, P.J., Gu, J.-L. and Feuerstein, G.Z.
Interleukin-8 is chemotactic for vascular smooth muscle cells (240) 81
Yuki, H., see Kamato, T. (238) 369
Yunes, R.A., see Neves, P.C.A. (243) 213

Zaagsma, J., see Coppes, R.P. (243) 273
Zaagsma, J., see Ten Berge, R.E.J. (233) 279
Zacharia, S., see Rossowski, W.J. (240) 259
Zajac, J.-M., see Gouardères, C. (237) 73
Zambelli, M., see Garcia Ruiz, A.J. (244) 125
Zarzuelo, A., see Duarte, J. (239) 1
Zea-Ponce, Y., see Laruelle, M. (230) 119
Zeise, M.L., Kasparov, S., Capogna, M. and Zieglgänsberger, W.
Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors (231) 47
Zeleski, D.M., see Reynolds, I.J. (244) 175
Zempléni, É., see Jones, C.A. (242) 183
Zeng, L.-H., see Zielenski, J. (248) 313
Zeng, X.-P., see Burcher, E. (233) 201
Zetterström, T., see Pei, Q. (230) 63
Zhang, A., Altura, B.T. and Altura, B.M.
Ethanol-induced contraction of cerebral arteries in diverse mammals and its mechanism of action (248) 229
Zhang, A., see Altura, B.M. (246) 299
Zhang, H., see Lee, T.H. (232) 125
Zhang, J., Chiodo, L.A. and Freeman, A.S.
Effects of phencyclidine, MK-801 and 1,3-di(2-tolyl)guanidine on non-dopaminergic midbrain neurons (230) 371
Zhang, J., Van Meel, J.C.A., Pfaffendorf, M. and Van Zwieten, P.A.
Cholera toxin but not pertussis toxin inhibits angiotensin II-enhanced contractions in the rat portal vein (230) 95
Zhang, J.Z., see Szarek, J.L. (231) 339
Zhang, L. and Dyer, D.C.
Lysergic acid diethylamide is a partial agonist at 5-$HT_2$ receptors in ovine uterine artery of late pregnancy (230) 115
Zhang, Z.-W., see Zhou, Y. (234) 147
Zhao, L., see Goldhill, J. (238) 387
Zheng, Z., see Chan, P. (231) 175
Zhou, Y., Sun, Y.-H., Zhang, Z.-W. and Han, J.-S.
Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of $\mu$-opioid analgesia by $CCK_B$ receptor antagonist L-365,260 in rat spinal cord (234) 147
Zhu, M.-Y., Juorio, A.V., Paterson, I.A. and Boulton, A.A.
Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors (238) 157
Zhu, X., see Bianchi, R. (239) 55
Ziegler, H., see Doods, H. (242) 23
Zieglgänsberger, W., see Zeise, M.L. (231) 47
Zielenski, J., Wu, T.-W., Fung, K.-P., Zeng, L.-H., Li, R.-K., Mickle, D.A.G. and Wu, J.
Chemical syntheses of Trolox conjugates which protect human ventricular myocytes against in situ-generated oxyradicals (248) 313
Zijlstra, W.G., see Benthem, L. (232) 279
Zimmer, F.J., see Matias, A. (244) 223
Zingarelli, B., Carnuccio, R. and Di Rosa, M.
Cloricromene inhibits the induction of nitric oxide synthase (243) 107
Zingarelli, B., see Squadrito, F. (230) 125
Zingarelli, B., see Squadrito, F. (237) 223
Zini, S., Roisin, M.-P., Langel, U., Bartfai, T. and Ben-Ari, Y.
Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus (245) 1
Zoghbi, S.S., see Laruelle, M. (230) 119
Zorad, S., Tsutsumi, K., Bhatia, A.J. and Saavedra, J.M.
Localization and characteristics of atrial natriuretic peptide receptors in prenatal and postnatal rat brain (241) 195
Zwart, R., see Kooyman, A.R. (246) 247

ELSEVIER

ejp

# Master key word index to volumes 229–248 (1993)

**A-68930**
Dopamine $D_1$ receptor agonists; SK&F 38393; Grooming behaviour; REM (rapid eye movement) sleep; (Rat) (Trampus, M. (235) 83)

**A-77636**
Dopamine $D_1$ receptors; Parkinsonism; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); A-77636 ((1R,3S)-3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride); (Marmoset) (Kebabian, J.W. (229) 203)

**A-77636 ((1R,3S)-3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride)**
Dopamine $D_1$ receptors; A-77636; Parkinsonism; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); (Marmoset) (Kebabian, J.W. (229) 203)

**Abdominal aorta**
Hyperlipidemia; Vascular reactivity; Wistar-Kyoto rats (WKY); Endothelium-derived relaxing factor (EDRF); Spontaneously hypertensive rats (SHR); Aortic arch (Yu, S.-M. (248) 289)

**Absence seizures**
Epilepsy; Cholinergic drugs; Electroencephalography; (Rat) (Danober, L. (234) 263)

**Abstinence**
U-50,488H; Tolerance; Dopamine $D_2$ receptors; 2-Bromo-α-ergocryptine; Behavioural activity (Veeranna, (235) 23)

**Acamprosate (calciumacetylhomotaurinate)**
Excitatory amino acids; GABA (γ-aminobutyric acid); Neocortex; Postsynaptic potentials; Neurotransmission (Zeise, M.L. (231) 47)

**Acarbose**
Insulin secretion; Islet acid glucan-1,4-α-glucosidase; α-Glucosidehydrolase inhibition; Emiglitate; Glibenclamide; Carbachol (Salehi, A. (243) 185)

**Acetorphan**
Acetylthiorphan; Thiorphan; Neutral endopeptidase; Hot-plate test; Analgesia (Lambert, D.M. (243) 129)

**Acetylcholine**
Dopamine; Microdialysis; Cocaine; α-Methyltyrosine + reserpine; (−)-Sulpiride; SCH 23390 (Imperato, A. (229) 265)

Somatostatin; 2-Deoxyglucose; Cerebral cortex; Hippocampus; Acetylcholine receptors (Shibata, S. (231) 381)

JTP-2942 ($N^{\alpha}$-[(1S,2R)-2-methyl-4-oxycyclopentanecarbonyl]-L-histidyl-L-prolinamide); TRH (thyrotropin-releasing hormone); Choline; Frontal cortex; Hippocampus; Microdialysis (Toide, K. (233) 21)

Nitrate vasodilators; Phosphodiesterase inhibitors; Zaprinast; $N^{\omega}$-Nitro-L-arginine; L-Arginine; Bradykinin; Blood pressure (De Garavilla, L. (234) 77)

Cisplatin; Catecholamine secretion; Adrenal chromaffin cells; $Ca^{2+}$ influx (Tachikawa, E. (236) 355)

DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Scopolamine; Working memory; Reference memory (Ohno, M. (238) 117)

Cocaine; d-Amphetamine; Hippocampus; Caudate nucleus; Dopamine (Imperato, A. (238) 377)

Ethanol; Endothelium; Vasorelaxation; Aorta; (Rat) (Hatake, K. (238) 441)

Hyperpolarization-activated inward current; Pacemaker current; Automaticity; Myocytes (embryonic chick heart); Autonomic agents; Isoproterenol (Satoh, H. (240) 283)

Hippocampus; Long-term potentiation; Cognitive enhancer; Somatostatin; Mossy fiber-CA3 pathway; FR121196; (Guinea-pig) (Matsuoka, N. (241) 27)

Mesenteric arterial bed; Nitric oxide (NO); cAMP; cGMP; Endothelium-dependent relaxation (Abiru, T. (242) 15)

**Acetylcholine receptors**
Chlordiazepoxide; Passive avoidance response; $GABA_A$/benzodiazepine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

Somatostatin; 2-Deoxyglucose; Cerebral cortex; Hippocampus; Acetylcholine (Shibata, S. (231) 381)

Muscarine receptor antagonist; Cerebral cortex (Christopoulos, A. (246) 1)

Muscarine receptor antagonist; Cerebral cortex (Christopoulos, A. (247) 227)

**Acetylcholine release**
$Ca^{2+}$; Cetiedil; Cholinergic synapses; Mediatophore; (*Torpedo marmorata* synaptosomes) (Moulian, N. (231) 407)

OP-41483 (prostacyclin analog); Prostaglandin release; Myenteric plexus (Fukunaga, Y. (233) 237)

Vasoactive intestinal contractor; Endothelin; Ileum (guinea-pig) (Taniyama, K. (235) 149)

AJ 76; UH 232; Dopamine receptors; Striatum; Antipsychotics (Gifford, A.N. (237) 169)

Hippocampus; Benzodiazepines (Imperato, A. (238) 135)

5-Lipoxygenase; Leukotriene $D_4$; Myenteric plexus (Yoshikawa, S. (239) 261)

Spinal cord; Substance P; Neurokinin A; Tachykinin receptors; Polymerase chain reaction (Suzuki, H. (241) 105)

Citalopram; Tianeptine; 5-$HT_{1B}$ receptors; Antidepressants (Bolaños-Jiménez, F. (242) 1)

**Acetylcholine release (striatal)**
Morphine withdrawal; Dopamine release (striatal) (Tjon Tien Ril, H.K.G. (235) 321)

**Acetylcholinesterase**
Alzheimer's disease; Tetrahydroaminoacridine (THA, tacrine); PET (positron emission tomography); (Baboon); (Rat) (Tavitian, B. (236) 229)

**$N^{\alpha}$-Acetyl-galanin-(9–29) (porcine, rat)**
Galanin (porcine, rat); Galanin fragments; Pancreatic amylase secretion; Jejunal strip contraction (rat) (Rossowski, W.J. (240) 259)

**Acetylthiorphan**
Acetorphan; Thiorphan; Neutral endopeptidase; Hot-plate test; Analgesia (Lambert, D.M. (243) 129)

**Achatin-I**
D-Amino acid residue; Molluscan peptide; 5-HT (5-hydroxytryptamine, serotonin); Modulatory effects; Voltage clamp; Neurons; (Snail) (Jun Liu, G. (231) 259)

D-Amino acid residue; Oxytocin, APGW-amide (Ala-Pro-Gly-Trp-$NH_2$), FMRFamide (Phe-Met-Arg-Phe-$NH_2$); [$Ser^2$]MIP (Gly-Ser-Pro-Met-Phe-Val-$NH_2$); Modulatory effects; Voltage clamp; Neurons; (Snail) (Liu, G.J. (240) 139)

**Acidosis**
Lidocaine; Use dependence; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (230) 167)

Lidocaine; Use dependence; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (236) 497)

**Acid production**
Parietal cell rat; Glucagon-like peptide 1-(7–36) amide; Epidermal growth factor; Transforming growth factor-$\alpha$; GTP-binding proteins (Schmidtler, J. (246) 59)

**Aclarubicin**
Doxorubicin; Pirarubicin; Heart (guinea-pig); Antimuscarinic action; Positive inotropic effect; Potentiated postrest contraction; Time to peak twitch tension (Temma, K. (234) 173)

**ACPD ((1S,3R)-1-aminocyclopentane-1,3-dicarboxylate) antagonists**
Metabotropic glutamate receptors; Phenylglycine derivatives (Eaton, S.A. (244) 195)

**ACTH-(4–10)**
$\gamma_2$-MSH ($\gamma_2$-melanocyte-stimulating hormone); Melanotropins; Hemodynamics; Urethane anesthesia; Pentobarbital anesthesia; Excitability; (Conscious rat) (De Wildt, D.J. (233) 157)

**ACTH (adrenocorticotrophic hormone)**
Seizures (chemically induced); Pilocarpine; Epilepsy; Anticonvulsants (Croiset, G. (229) 211)

$\alpha$-MSH ($\alpha$-melanocyte-stimulating hormone); Behavioural state; Grooming; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

Imipramine; Clomipramine; Clorgyline; Corticosterone; Fawn-hooded rat (Aulakh, C.S. (240) 85)

Cocaine (neuroendocrine); 5-HT (5-hydroxytryptamine, serotonin); Prolactin; Renin (Levy, A.D. (241) 275)

**Action potential duration**
OPC-8212; Cardiac ventricular myocytes; $K^+$ currents; Secondary inward current; Veratrine (Lathrop, D.A. (240) 127)

**Action potentials**
Class III antiarrhythmics; Ionic currents; Single ventricular cells (Lee, K.S. (234) 43)

**Active avoidance**
Angiotensin; Angiotensin-converting enzyme inhibitor; Bradykinin; Diabetes mellitus; Memory; (Mouse) (Flood, J.F. (240) 311)

**Actyl-l-carnitine**
Histotoxic hypoxia; Cyanide; Spatial learning; Phosphoinositide metabolism (Blokland, A. (235) 275)

**Adamantanes**
Scrapie; Cortical cells; Memantine; NMDA receptor; Neurons; Prion; MK-801 (Müller, W.E.G. (246) 261)

**Addiction**
RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Conditioned place preference; Naloxone; (Mouse) (Noble, F. (230) 139)

**Adenine nucleotides**
Adenosine $A_2$ receptors; Adenosine deaminase; APCP (5′-O-($\alpha,\beta$-methylene)diphosphate); Striatum (Pirotton, S. (241) 55)

**Adenosine**
Antinociception; Adenosine receptors; Sensory neuropeptides; Capsaicin (Santicioli, P. (231) 139)

Adenosine $A_2$ receptor-mediated vasodilatation; $K^+$ channels (ATP-sensitive); 8-Phenyltheophylline; Glibenclamide (Orito, K. (231) 183)

Glibenclamide-sensitive $K^+$ channels; Levcromakalim; YT-146 (2-(1-octynyl)-adenosine); G-protein (pertussis toxin-sensitive) (Furukawa, S. (236) 255)

Capsaicin; Extrinsic sensory nerves; Myenteric neurons (Takaki, M. (237) 51)

Anococcygeus (rabbit); Nitric oxide (NO); Nitric oxide synthase inhibitors; Purinoceptors; ATP; 8-(p-Sulfophenyl)theophylline; Suramin (Graham, A.M. (237) 93)

Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

ANP (atrial natriuretic peptide); Beating frequency; Hormone secretion (Uusimaa, P.A. (242) 199)

Seizure; GABA ($\gamma$-aminobutyric acid); GABA/benzodiazepine receptor; Glutamate; Mouse (Klitgaard, H. (242) 221)

**Adenosine analogs**
TNF (tumor necrosis factor); Endothelium; Polymorphonuclear leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291)

**Adenosine deaminase**
Adenine nucleotides; Adenosine $A_2$ receptors; APCP (5′-O-($\alpha$,$\beta$-methylene)diphosphate); Striatum (Pirotton, S. (241) 55)

Gastric ulcer; Ranitidine (Namiot, Z. (243) 301)

**Adenosine (extracellular)**
Brain microdialysis; Striatum; Anaesthesia; Tetrodotoxin; NMDA receptors (Pazzagli, M. (234) 61)

**Adenosine $A_2$ receptor-mediated vasodilatation**
Adenosine; $K^+$ channels (ATP-sensitive); 8-Phenyltheophylline; Glibenclamide (Orito, K. (231) 183)

**Adenosine receptors**
Adenosine; Antinociception; Sensory neuropeptides; Capsaicin (Santicioli, P. (231) 139)

Purinoceptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

Coronary artery (porcine); 2-(ar)Alkoxyadenosines; (Binding domains) (Makujina, S.R. (243) 35)

Heart; $\beta$-Adrenoceptors; Species differences (Guinea Pig, Pig, Rabbit, Rat) (Musser, B. (246) 105)

Autoradiography; (Cat); (Rat) (Johansson, B. (247) 103)

**Adenosine $A_1$ receptors**
Doridosine (1-methylisoguanosine) derivatives; Competition binding studies; Adenosine $A_2$ receptors; Bradycardia; (Rat) (Tao, P.-L. (243) 135)

Hypertension; G proteins (Matias, A. (244) 223)

**Adenosine $A_2$ receptors**
Kinetics; Antagonism, functional; $\alpha_1$-Adrenoceptor; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

Substance P release; Sensory nerves; Airways (Morimoto, H. (240) 121)

Adenine nucleotides; Adenosine deaminase; APCP (5′-O-($\alpha$,$\beta$-methylene)diphosphate); Striatum (Pirotton, S. (241) 55)

Doridosine (1-methylisoguanosine) derivatives; Competition binding studies; Adenosine $A_1$ receptors; Bradycardia; (Rat) (Tao, P.-L. (243) 135)

Dopamine $D_2$ receptors; CGS 21680; Gpp(NH)p; GDP-$\beta$-S; $Mg^{2+}$; Neostriatum; (Rat) (Ferré, S. (244) 311)

**Adenosine transporters**
Nimodipine; [$^3$H]Nitrobenzylthioinosine binding; Parietal cortex (human) (Deckert, J. (238) 131)

**Adenylate cyclase**
Opioid receptors; Dopamine receptors; Brain slices (rat) (Heijna, M.H. (229) 197)

5-$HT_{1A}$ receptors; Drug discrimination; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Rabin, R.A. (235) 237)

Dopamine $D_1$ receptors; Dihydrexidine; SCH23390; SKF38393; Parkinson's disease; (Rhesus monkey); (Rat) (Watts, V.J. (242) 165)

cAMP; Protein kinase C; Adrenal chromaffin cells; Second messengers; Adrenal medulla (Marley, P.D. (244) 7)

Tetrahydroaminoacridine; Physostigmine; $\beta$-Adrenoceptors; Hippocampus; Cortex; cAMP (Vivas, N.M. (245) 9)

$\beta$-Adrenoceptors; Desensitisation; Xamoterol; Atenolol (Arnold, I.R. (245) 285)

**Adenylate cyclase (activation)**
5-$HT_{1D}$ receptor (human); (Inhibition) (Van Sande, J. (247) 177)

**Adenylyl cyclase**
PAF (platelet activating factor); Forskolin; G-protein; PAF receptor (Wong, S. (245) 55)

Dopamine $D_1$ receptor (Izenwasser, S. (246) 39)

Hepatocytes; cAMP; $\beta$-Adrenoceptors; Desensitization (Sandnes, D. (246) 163)

G-protein; Cerebral cortex; $\beta$-Adrenoceptors; F-344 rats; Tricyclic antidepressants; Down-regulation (Scarpace, P.J. (247) 65)

Cardiomyopathy; Adrenoceptor subtypes; CGP 20712A (Witte, K. (247) 215)

**Adenylyl cyclase activity**
Morphine exposure (chronic); Tolerance; Dependence; G-proteins; Striatal neurons (Van Vliet, B.J. (245) 23)

**Adherence**
Inflammation; Microcirculation; Neutrophils; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

**ADP**
Thrombosis; Thromboxane $A_2$; PAF (platelet-activating factor, PAF-acether); Thrombin; (Guinea-pig) (Hirata, Y. (231) 421)

**ADP ribosylation**
$\alpha_2$-Adrenoceptors; Muscarinic receptors; $Ca^{2+}$ channels; Heterologous desensitization; GTP-binding proteins (Nah, S.-Y. (244) 67)

**ADP-ribosylation actin**
Gelsolin; *Clostridium botulinum* C2 toxin (Just, I. (246) 293)

**Adrenal chromaffin cells**
Cisplatin; Catecholamine secretion; Acetylcholine; $Ca^{2+}$ influx (Tachikawa, E. (236) 355)

cAMP; Protein kinase C; Adenylate cyclase; Second messengers; Adrenal medulla (Marley, P.D. (244) 7)

**Adrenalectomy**
Immobility; Porsolt swimming test; Hypothyroidism; Food deprivation (Jefferys, D.E. (239) 189)

**Adrenaline**
Noradrenaline; $\beta_2$-Adrenoceptors (prejunctional); Catecholamine overflow (evoked); Portal vein; (Freely moving rats) (Coppes, R.P. (243) 273)

**Adrenal medulla**
Flunarizine; $Ca^{2+}$ channel antagonists; Voltage dependence; Catecholamine secretion (De la Fuente, M.-T. (229) 189)

Cobalt ramps; Nicotinic receptors; Catecholamine secretion (Montiel, C. (230) 77)

Glucocorticoid receptors; Phenylethanolamine N-methyltransferase; Nicotine; Catecholamines (Betito, K. (238) 273)

Chromaffin cell; Histamine; Catecholamine release; $Ca^{2+}$ channels; $Ca^{2+}$ (intracellular) (Borges, R. (241) 189)

cAMP; Protein kinase C; Adenylate cyclase; Adrenal chromaffin cells; Second messengers (Marley, P.D. (244) 7)

Neomycin; Dihydropyridine drugs; $Ca^{2+}$ influx; $Ca^{2+}$ (intracellular); Catecholamine release (Duarte, C.B. (244) 259)

Histogranin; Endogenous peptide; NMDA receptors; Anticonvulsant (Lemaire, S. (245) 247)

Nitric oxide (NO) synthase; cGMP; Catecholamine release; Chromaffin cells (Moro, M.A. (246) 213)

**Adrenergic reactivity**
Postjunctional $\alpha_2$-adrenoceptors; $\alpha_2$-Adrenoceptor antagonists; $\alpha_2$-Adrenoceptor agonists; Tail artery (rat); Aging (Tsai, H. (237) 311)

**$\alpha_1$-Adrenoceptor activation pathways**
Congestive heart failure; $Ca^{2+}$ channel antagonists; Dorsal pedal artery; Saphenous vein (Forster, C. (242) 119)

**Adrenoceptor agonists**
$K^+$ channel activators; Renal haemodynamics; Renal nerve stimulation (Johns, E.J. (230) 47)

**$\alpha_2$-Adrenoceptor agonists**
Postjunctional $\alpha_2$-adrenoceptors; Adrenergic reactivity; $\alpha_2$-Adrenoceptor antagonists; Tail artery (rat); Aging (Tsai, H. (237) 311)

Locus coeruleus; $\alpha_2$-Adrenoceptor antagonists; High voltage spindle; Slow wave (Riekkinen, Jr., P. (238) 263)

**$\beta$-Adrenoceptor agonists**
Down-regulation; $\beta$-Adrenoceptors; Lung; Transcription factor; (rat) (Nishikawa, M. (247) 131)

**$\beta_2$-Adrenoceptor agonists**
$K^+$ channel antagonists; Smooth muscle (airway); Trachea (guinea-pig) (Huang, J.-C. (235) 37)

Albuterol; Asthma; Methacholine; (Rabbit) (Witt-Enderby, P.A. (241) 121)

**$\alpha$-Adrenoceptor antagonists**
Pancreatic vessels; Insulin secretion; Verapamil; Pancreas (isolated); cAMP analogues; (Rat) (Skoglund, G. (236) 69)

**$\alpha_1$-Adrenoceptor antagonists**
$Ca^{2+}$ channel antagonists; Aorta (rat); Aporphines; Phosphodiesterase inhibitors (Ivorra, M.D. (231) 165)

**$\alpha_2$-Adrenoceptor antagonists**
Postjunctional $\alpha_2$-adrenoceptors; Adrenergic reactivity; $\alpha_2$-Adrenoceptor agonists; Tail artery (rat); Aging (Tsai, H. (237) 311)

Locus coeruleus; $\alpha_2$-Adrenoceptor agonists; High voltage spindle; Slow wave (Riekkinen, Jr., P. (238) 263)

**$\beta$-Adrenoceptor antagonists**
5-HT (serotonin); $5\text{-HT}_{1A}$ receptors; $5\text{-HT}_{1B}$ receptors; Computer graphics; Comparative molecular field analysis method (Langlois, M. (244) 77)

**$\alpha_2$-Adrenoceptor blockade**
Cerebral ischemia; Baroreflex (vagal) (Kurihara, J. (240) 73)

**Adrenoceptors**
Diurnal rhythm; Noradrenaline; Aorta; (Rat) (Gohar, M. (229) 69)

Substance P; Neurokinin A (Luo, L. (235) 157)

Ramipril; Genetic hypertension; Oscillation (Watts, S.W. (242) 245)

c-*fos*; *jun*-B; Pineal gland; Second messengers; Protein kinase (Carter, D.A. (244) 285)

Pineal gland; Immediate-early genes; c-*jun*; cAMP (Carter, D.A. (247) 97)

Noradrenaline; Proximal tubule; Thyroid hormone; In situ hybridization (Meister, B. (247) 229)

**$\alpha$-Adrenoceptors**
MPC-1304; $Ca^{2+}$ entry blockers; (Pithed rat) (Ichihara, K. (238) 283)

Noradrenaline-induced contraction; Endothelium; Nitric oxide (NO) (Kaneko, K. (240) 195)

**$\alpha_1$-Adrenoceptors**
$\alpha_2$-Adrenoceptors; Vomiting; Reserpine; 6-Hydroxydopamine (6-OHDA); Area postrema (Hikasa, Y. (229) 241)

Lingual arteries (isolated); $\alpha_2$-Adrenoceptors; Phenylephrine; (Partial agonist) (Skrbic, R. (230) 131)

Burst firing; Idazoxan; Noradrenaline; Reserpine (Grenhoff, J. (233) 79)

$\alpha_2$-Adrenoceptors; cGMP; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Pulmonary artery (pig) (Pepke-Zaba, J. (235) 169)

$\alpha_2$-Adrenoceptors; High voltage spindle promoter; (Adult and aged rats) (Riekkinen, Jr., P. (235) 317)

Kinetics; Antagonism, functional; Adenosine $A_2$ receptors; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

$\alpha_{1B}$-Adrenoceptors; Noradrenaline; Chloroethylclonidine; $Ca^{2+}$; cAMP; Hepatocyte (Rat) (Nomura, T. (246) 113)

Prazosin binding; Contraction; Smooth muscle (vascular) (Sayet, I. (246) 275)

**$\alpha_{1A}$-Adrenoceptors**
$\alpha_{1B}$-Adrenoceptors; Risperidone; Antipsychotics; Receptor binding (Sleight, A.J. (238) 407)

**$\alpha_{1B}$-Adrenoceptors**
$\alpha_{1A}$-Adrenoceptors; Risperidone; Antipsychotics; Receptor binding (Sleight, A.J. (238) 407)

$\alpha_1$-Adrenoceptors; Noradrenaline; Chloroethylclonidine; $Ca^{2+}$; cAMP; Hepatocyte (Rat) (Nomura, T. (246) 113)

**$\alpha_2$-Adrenoceptors**
$\alpha_1$-Adrenoceptors; Vomiting; Reserpine; 6-Hydroxydopamine (6-OHDA); Area postrema (Hikasa, Y. (229) 241)

Lingual arteries (isolated); $\alpha_1$-Adrenoceptors; Phenylephrine; (Partial agonist) (Skrbic, R. (230) 131)

Islets of Langerhans; $K^+$ channels; Imidazoline; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

Feeding; Obese mice; Norepinephrine; Clonidine; Yohimbine (Currie, P.J. (232) 227)

SL 84.0418; (Peripheral activity) (Angel, I. (234) 137)

$\alpha_1$-Adrenoceptors; cGMP; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Pulmonary artery (pig) (Pepke-Zaba, J. (235) 169)

$\alpha_1$-Adrenoceptors; High voltage spindle promoter; (Adult and aged rats) (Riekkinen, Jr., P. (235) 317)

[$^3$H]Clonidine; [$^3$H]UK 14,304 (bromoxidine); [$^3$H]RX 821002 (2-methoxy idazoxan); Neostigmine; Physostigmine; Diisopropylfluorophosphate; Pilocarpine (Olmos, G. (236) 467)

Spinal reflexes; Descending inhibition; Imidazoline binding sites; Blood pressure (Harris, J. (237) 323)

Clonidine; Place preference; (Rat) (Cervo, L. (238) 201)

Sedation; Anaesthesia; Medetomidine; Atipamezole; (Cat) (Stenberg, D. (238) 241)

Brain (rat); Vas deferens (rat); [$^3$H]UK 14304; [$^3$H]RX 821002; Reserpine (Ugedo, L. (239) 149)

Zucker rat; Imidazoline $I_2$ binding sites; Brain; [$^3$H]Idazoxan; [$^3$H]Clonidine; [$^3$H]RX821002; Mazindol (Miralles, A. (243) 305)

Muscarinic receptors; $Ca^{2+}$ channels; Heterologous desensitization; GTP-binding proteins; ADP ribosylation (Nah, S.-Y. (244) 67)

Kidney cells (opossum); Transfected CHO cells (Pleus, R.C. (244) 181)

cAMP; Ethanol; Muscarinic acetylcholine receptor (Kim, W.-K. (247) 89)

**$\alpha_{2B}$-Adrenoceptors**
Expression; Radioligand binding; (*E. coli*) (Xia, Y. (246) 129)

**$\beta$-Adrenoceptors**
Desensitization; Facilitation; Prejunctional; Stimulus train length (Lakhlani, P.P. (230) 107)

Eosinophils; Respiratory burst; Salmeterol; Eformoterol; Salbutamol (Rabe, K.F. (231) 305)

Fluoxetine; Ethanol; Isoprenaline-induced drinking (Mustafa, A.A. (237) 147)

Substance P; Nitric oxide (NO); Morphine; Substance P receptor antagonists (Persico, P. (238) 105)

Noradrenaline; 5-HT (5-hydroxytryptamine, serotonin); Competitive inhibition (Fujita, R. (240) 213)

Tetrahydroaminoacridine; Physostigmine; Adenylate cyclase; Hippocampus; Cortex; cAMP (Vivas, N.M. (245) 9)

Adenylate cyclase; Desensitisation; Xamoterol; Atenolol (Arnold, I.R. (245) 285)

Heart; Adenosine receptors; Species differences (Guinea Pig, Pig, Rabbit, Rat) (Musser, B. (246) 105)

Hepatocytes; cAMP; Adenylyl cyclase; Desensitization (Sandnes, D. (246) 163)

G-protein; Cerebral cortex; Adenylyl cyclase; F-344 rats; Tricyclic antidepressants; Down-regulation (Scarpace, P.J. (247) 65)

Down-regulation; $\beta$-Adrenoceptor agonist; Lung; Transcription factor; (rat) (Nishikawa, M. (247) 131)

**$\beta_2$-Adrenoceptors**
Hepatocytes; Desensitization (Medina-Martínez, O. (244) 145)

**$\beta_3$-Adrenoceptors**
BRL 37344; Chronotropism; Inotropism; Heart (dog) (Takayama, S. (231) 315)

**$\alpha_1$-Adrenoceptors (cardiac)**
Verapamil; Inositol 1,4,5-trisphosphate (cardiac); Protein kinase C (cardiac); Diabetic cardiomyopathy; (Rat) (Tanaka, Y. (244) 105)

**$\beta_2$-Adrenoceptors (prejunctional)**
Noradrenaline; Adrenaline; Catecholamine overflow (evoked); Portal vein; (Freely moving rats) (Coppes, R.P. (243) 273)

**$\alpha$-Adrenoceptor stimulation**
Islets of Langerhans; Monoamine oxidase activity; $\beta$-Adrenoceptor stimulation; Cholinergic stimulation; Insulin; Glucose; (Mouse) (Panagiotidis, G. (233) 285)

**$\beta$-Adrenoceptor stimulation**
Islets of Langerhans; Monoamine oxidase activity; $\alpha$-Adrenoceptor stimulation; Cholinergic stimulation; Insulin; Glucose; (Mouse) (Panagiotidis, G. (233) 285)

**$\alpha_1$-Adrenoceptor subtype**
Positive inotropic response; Heart (rat) (Noguchi, H. (240) 291)

**$\alpha_2$-Adrenoceptor subtype**
Stable transfection; Cell line; [$^3$H]Rauwolscine binding; (Antagonist) (Marjamäki, A. (246) 219)

**Adrenoceptor subtypes**
Cardiomyopathy; Adenylyl cyclase; CGP 20712A (Witte, K. (247) 215)

**$\alpha_1$-Adrenoceptor subtypes**
5-$HT_{1A}$ receptor agonists; 8-OH-DPAT; Buspirone; Aorta (rabbit); (8-hydroxy-2(di-N-propylamino)tetralin) (Castillo, C. (241) 141)

**Adrenocortical axis**
Cholinergic drugs; Corticosterone; Tolerance (Cattaneo, L. (241) 245)

**Adrenomedullin**
cAMP; Blood pressure (rat); Vasodilation (Ishiyama, Y. (241) 271)

**Adult respiratory distress syndrome (ARDS)**
Nitric oxide (NO); Endotoxin shock; Pulmonary hypertension; Endothelin; Noradrenaline; Neuropeptide Y (Weitzberg, E. (233) 85)

**AF64A (ethylcholine aziridinium ion)**
TRH (thyrotropin-releasing hormone); Sustained release formulation; Scopolamine; Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

**AF102B**
High voltage spindles; Slow wave; Muscarinic $M_1$ receptor; Muscarinic $M_2$ receptor; Physostigmine; Tetrahydroaminoacridine; Pilocarpine; Oxotremorine (Riekkinen, Jr., P. (240) 1)

**AF-DX 116**
BIBN 99; Muscarinic $M_2$ receptor antagonist; Muscarinic receptors ($M_1$–$M_3$, m1–m5) (Doods, H. (242) 23)

**Afferent nerves**
Nitric oxide (NO); Blood flow; Pulp; Oral mucosa; Lip; Submandibular gland (Kerezoudis, N.P. (241) 209)

**Affiliation**
Vasopressin; Ultrasonic vocalization; Anxiety; Thermoregulation; Vasotocin (Winslow, J.T. (233) 101)

**Affinity states**
Schizophrenia; Dopamine $D_1$ receptors (Mamelak, M. (233) 175)

[$^3$H]Spiperone; Dopamine $D_2$ receptors; Dorsal hippocampus; Ventral hippocampus; Striatum; $Mg^{2+}$; GTP; Iron-chelator (Bruinink, A. (245) 157)

**ω-Agatoxin IVA**
$Ca^{2+}$; $Ca^{2+}$ channels; $Ca^{2+}$ channel antagonists; ω-Conotoxin; Small cell lung carcinoma cells; Proliferation (Cattaneo, M.G. (247) 325)

**Age**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Substantia nigra; Motor deficits; Dopamine; (Common marmoset) (Rose, S. (230) 177)

**Aggregation**
Platelets; Trimetazidine; Membrane fluidity; cAMP (Devynck, M.-A. (245) 105)

**Aggression**
$TGF_\alpha$ (transforming growth factor α); Tryptophan; 5-HT (5-hydroxytryptamine, serotonin); Antidepressant drugs; Depression; Transgenic mice (Hilakivi-Clarke, L.A. (237) 101)

TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Dorsal raphe (rat) (Mos, J. (238) 411)

**Aging**
NMDA receptors; Glycine; D-Cycloserine; Noradrenaline release; Glycine uptake (Pittaluga, A. (231) 129)

CGRP (calcitonin gene-related peptide); Fischer 344 rats; Mesenteric vasculature; Sensory nerves (capsaicin-sensitive) (Li, Y. (236) 373)

Postjunctional $\alpha_2$-adrenoceptors; Adrenergic reactivity; $\alpha_2$-Adrenoceptor antagonists; $\alpha_2$-Adrenoceptor agonists; Tail artery (rat) (Tsai, H. (237) 311)

$GABA_A$ receptor complex (Type I and Type II benzodiazepine binding sites); [$^3$H]Zolpidem binding; [$^3$H]Flunitrazepam binding; γ-Aminobutyric acid; Cortex (Ruano, D. (246) 81)

Phospholipase C; Phosphatidylinositol 4,5-bisphosphate; Inositol 1,4,5-trisphosphate; Dopamine; Striatum (rat) (Sugawa, M. (247) 39)

Aorta (rat); Nitrate tolerance; Nitroglycerin; Sin-1 (3-morpholinosydnonimine) (Unger, P. (248) 145)

**Agonists/inverse agonists (partial and full)**
$GABA_A$ receptor-ionophore complex; Benzodiazepine receptors; [$^{35}$S]TBPS binding (t-butylbicyclophosphoro[$^{35}$S]thionate); Allosteric regulation of efficacy (Maksay, G. (246) 255)

**AIDS**
Cytokine; T lymphocytes; Mucosa; Virus infection (Bourinbaiar, A.S. (230) 15)

**Airway constriction**
Substance P; Neurokinin A; Capsaicin; Plasma extravasation (Murai, M. (236) 7)

**Airway hyperreactivity**
ONO-1078; Peptide leukotriene receptor antagonists; Asthmatic responses; Eosinophil accumulation (Nakagawa, N. (235) 211)

**Airway microvascular leakage**
Allergen; Bradykinin; CP-96,345; $NK_1$ receptors; Substance P (Sakamoto, T. (231) 31)

**Airway obstruction**
Asthma; Edema; Plasma exudation; Bradykinin; Vascular permeability; OKY-046; Indomethacin (Arakawa, H. (229) 131)

Asthma; Development; Maturation; Plasma exudation; Vascular permeability (Yokoyama, T. (236) 427)

**Airway receptors**
Inositol phosphates; Smooth muscle (human airway); Cell culture (Daykin, K. (246) 135)

**Airways**
Bradykinin; Histamine; Substance P; Cromakalim; Vascular permeability; Plasma exudation (Martin, C.A.E. (239) 119)

$K^+$ channel openers; Smooth muscle (vascular) (Dumas, M. (239) 141)

Adenosine $A_2$ receptors; Substance P release; Sensory nerves (Morimoto, H. (240) 121)

**AJ-76**
UH 232; Dopamine receptors; Striatum; Acetylcholine release; Antipsychotics (Gifford, A.N. (237) 169)

**AJ-2615**
$Ca^{2+}$ channel antagonists; Ion channels; (Neurons); (Snail) (Liu, G.J. (231) 91)

**β-Alanine**
Glycine receptor; $GABA_A$ receptor; Progesterone; 5α-Pregnan-3α-ol-20-one (5α3α); Neuromodulation (Wu, F.-S. (246) 239)

**Albuminuria**
Angiotensin-converting enzyme inhibition; Vascular permeability; Diabetes; (Rat) (Huijberts, M. (240) 207)

**Albuterol**
$\beta_2$-Adrenoceptor agonists; Asthma; Methacholine; (Rabbit) (Witt-Enderby, P.A. (241) 121)

**Alcohol dependence**
$GABA_A$ receptor $\alpha_1$-subunit; mRNA; Ethanol inhalation (Hirouchi, M. (247) 127)

**Alcohols**
Calcium channels; Synaptosomes; Longitudinal muscle; [$^3$H]Nitrendipine; [$^{125}$I]ω-Conotoxin (Hawthorn, M.H. (229) 143)

Heart; Cardiac myocytes; Contractions (Cannings, I. (248) 213)

**Aldose reductase**
Aorta; EDRF (endothelium-derived relaxing factor); Galactosaemia; Nitric oxide (NO); Polyol pathway (Cameron, N.E. (243) 47)

**2-(ar)Alkoxyadenosines**
Adenosine receptors; Coronary artery (porcine); (Binding domains) (Makujina, S.R. (243) 35)

**14-Alkoxymetopons**
Opioid receptors; Analgesia; Physical dependence; (Binding) (Fürst, Z. (236) 209)

**Allergen**
Bradykinin; CP-96,345; Airway microvascular leakage; $NK_1$ receptors; Substance P (Sakamoto, T. (231) 31)

Capsaicin; Bronchial hyperresponsiveness; Neonatal treatment (Riccio, M.M. (232) 89)

**Allergic inflammation**
PCA 4248; PAF (platelet-activating factor, PAF-acether) (Martins, M.A. (237) 17)

**Allopurinol**
TEI-6720; Xanthine oxidase/xanthine dehydrogenase; Uric acid; Hyperuricemia (Osada, Y. (241) 183)

**Allosteric regulation of efficacy**
$GABA_A$ receptor-ionophore complex; Benzodiazepine receptors; Agonists/inverse agonists (Partial and full); [$^{35}$S]TBPS binding (t-butylbicyclophosphoro[$^{35}$S]thionate) (Maksay, G. (246) 255)

**Almitrine**
Raubasine; Middle cerebral artery; Ischemia; Penumbra; (Cat) (Chan, P. (231) 175)

**Alpidem**
$GABA_A$ receptors; ω modulatory site; [$^3$H]Flumazenil; Zolpidem (Faure-Halley, C. (246) 283)

**Alprazolam**
BN-52021; Endothelin; Mesangial cells; Proliferation; PAF (platelet-activating factor, PAF-acether) (Montero, A. (243) 235)

**Alveolar macrophages**
Superoxide anion; PAF (platelet-activating factor, PAF-acether); Polymorphonuclear leukocytes; Thromboxane $A_2$; (Guinea-pig) (Kato, M. (232) 7)

**Alzheimer's disease**
Tetrahydroaminoacridine (THA, tacrine); PET (positron emission tomography); Acetylcholinesterase; (Baboon); (Rat) (Tavitian, B. (236) 229)

**Amantadine**
Somatostatin; Neuropeptide Y; l-DOPA (l-dihydroxyphenylalanine); 6-Hydroxydopamine; Bifemelane (Maeda, K. (233) 227)

**Amastatin**
Aminopeptidases; Tachykinin receptor antagonists; Tachykinin receptors (Patacchini, R. (236) 31)

**Amesergide**
$5\text{-}HT_2$ receptors; Ergolines; Tryptamines, [$^{125}$I]DOI ([$^{125}$I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); LY53857 (Johnson, M.P. (239) 111)

**[$^{125}$I]AMIK ([$^{125}$I]7-amino-8-iodo-ketanserin)**
RP 62203; $5\text{-}HT_2$ receptor antagonists; 5-HT (5-hydroxytryptamine, serotonin); Autoradiography; [$^3$H]Mesulergine (Malgouris, C. (233) 29)

**Amiloride**
Gastric acid secretion; DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid); $Cl^- \text{-} HCO_3^-$ exchanger; $Na^+ \text{-} H^+$ exchanger; Stomach (isolated); (Rat) (Horie, S. (229) 15)

$Li^+$ reabsorption; $Na^+$ restriction; $Li^+$ clearance (Shalmi, M. (230) 33)

M17055; Loop diuretics; Thiazide diuretics; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

Kidney (rat); Muscarinic receptor subtypes (agonist binding) (Blankesteijn, W.M. (244) 21)

**Amino acid release**
ATP-sensitive $K^+$ channels; Galanin; Glibenclamide; Hippocampus (rat) (Zini, S. (245) 1)

**D-Amino acid residue**
Achatin-I; Molluscan peptide; 5-HT (5-hydroxytryptamine, serotonin); Modulatory effects; Voltage clamp; Neurons; (Snail) (Jun Liu, G. (231) 259)

Achatin-I; Oxytocin, APGW-amide (Ala-Pro-Gly-Trp-$NH_2$), FMRFamide (Phe-Met-Arg-Phe-$NH_2$); [Ser$^2$]MIP (Gly-Ser-Pro-Met-Phe-Val-$NH_2$); Modulatory effects; Voltage clamp; Neurons; (Snail) (Liu, G.J. (240) 139)

**Amino acids**
Milacemide; Monoamine metabolites; Taurine; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

**L-Amino acids**
Gabapentin; Anticonvulsant; System-L; Transporter; Brain (Thurlow, R.J. (247) 341)

**[$^3$H]p-Aminoclonidine**
[$^3$H]Idazoxan; Imidazoline binding sites; RS-15385-197; Kidney (rat) (MacKinnon, A.C. (232) 79)

**Aminoglycoside**
Membrane permeability; Calcein; $Mn^{2+}$; $Ca^{2+}$; Conformational analysis (Van Bambeke, F. (247) 155)

**Aminoguanidine**
Nitric oxide synthase; Selective inhibitor inducible (Misko, T.P. (233) 119)

**Aminopeptidase**
Robenidine; Coccidiosis; D-Galactose; L-Leucine; Intestinal transport; Jejunum (rabbit); Drug-nutrient interaction; Sucrase (Sorribas, V. (248) 137)

**Aminopeptidases**
Amastatin; Tachykinin receptor antagonists; Tachykinin receptors (Patacchini, R. (236) 31)

**L-2-Amino-4-phosphonobutyric acid (L-AP4)**
Excitatory amino acids; Sensitization; Quisqualate priming; Cortical wedge (Madsen, U. (230) 383)

Metabotropic glutamate receptors; cAMP (Thomsen, C. (244) 187)

**Aminophylline**
Neurosensitization; Electroconvulsion; Diazepam; MK-801; $Na^+$ valproate (Chakrabarti, A. (235) 133)

**21-Aminosteroids**
NMDA (N-methyl-D-aspartate); Lipid peroxidation; Hypoxia (Domenici, M.R. (233) 291)

**Aminotetralins**
Dopamine $D_3$ receptors; 7-OH-DPAT (7-hydroxy-2-(N,N-di-n-propylamino)tetralin) (Baldessarini, R.J. (239) 269)

**Amiodarone**
Antiarrhythmic agents; Lactate dehydrogenase; Mitochondrial ATPase (Dzimiri, N. (242) 113)

**Amlodipine**
Smooth muscle (vascular); $Ca^{2+}$ influx; $A_7r_5$ cells; Lacidipine; 1,4-Dihydropyridines (Spampinato, S. (244) 139)

**Amnesia**
pBNP-32 (porcine brain natriuretic peptide-32); Electroconvulsive shock; (Receptor blockers) (Bidzseranova, A. (232) 305)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-HT}_{1A}$ receptors (Mendelson, S.D. (236) 177)

**cAMP**
Cytokines; Leukotrienes; Endotoxin (Schade, F.U. (230) 9)

Epileptiform activity; Forskolin; Neocortex (Boulton, C.L. (236) 131)

$Cl^-$ secretion; Colitis; Inflammatory bowel disease; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

Cardiotonic agent; Phosphodiesterase inhibitor; $Ca^{2+}$; Thoracic aorta (rat) (Itoh, H. (240) 57)

Forskolin action; Uterus (pregnant); Smooth muscle cells (myometrial); $K^+$ currents; Tetraethylammonium (Inoue, Y. (240) 169)

Adrenomedullin; Blood pressure (rat); Vasodilation (Ishiyama, Y. (241) 271)

Acetylcholine; Mesenteric arterial bed; Nitric oxide (NO); cGMP; Endothelium-dependent relaxation (Abiru, T. (242) 15)

Protein kinase C; Adenylate cyclase; Adrenal chromaffin cells; Second messengers; Adrenal medulla (Marley, P.D. (244) 7)

Metabotropic glutamate receptors; L-2-Amino-4-phosphonobutyrate (L-AP4) (Thomsen, C. (244) 187)

$5\text{-HT}_{1D}$ receptors; 5-HT release; 5-HT (5-hydroxytryptamine, serotonin) (Ormandy, G.C. (244) 189)

Tetrahydroaminoacridine; Physostigmine; $\beta$-Adrenoceptors; Adenylate cyclase; Hippocampus; Cortex (Vivas, N.M. (245) 9)

Platelets; Trimetazidine; Membrane fluidity; Aggregation (Devynck, M.-A. (245) 105)

Melatonin; 6-Chloromelatonin; 2-Iodomelatonin; Melatonin receptors; Melanoma cells (human); Cytostatic activity (Ying, S.-W. (246) 89)

$\alpha_1$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Noradrenaline; Chloroethylclonidine; $Ca^{2+}$; Hepatocyte (Rat) (Nomura, T. (246) 113)

CGRP (Calcitonin gene-related peptide); Cytosolic free $Ca^{2+}$; Fura 2; Aortic spiral preparation (rat) (Michiro Ishikawa, (246) 121)

Neutrophils (electroporated); Migration; cGMP; Chemokinesis (Elferink, J.G.R. (246) 157)

Hepatocytes; $\beta$-Adrenoceptors; Adenylyl cyclase; Desensitization (Sandnes, D. (246) 163)

Ethanol; Muscarinic acetylcholine receptor; $\alpha_2$-Adrenoceptor (Kim, W.-K. (247) 89)

Pineal gland; Immediate-early genes; c-*jun*; Adrenoceptors (Carter, D.A. (247) 97)

Mesenteric artery; Dopamine receptor; Smooth muscle (vascular); Phenoxybenzamine (Hall, A.S. (247) 249)

**AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)**
Norbinaltorphimine; NMDA (N-methyl-D-aspartate); Convulsion; Mortality (Shukla, V.K. (231) 293)

Excitotoxicity; $Mg^{2+}$; Hippocampus; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

NMDA (N-methyl-D-aspartate); Convulsions; (Screening); (Neonatal rat); (Mouse); (Rat) (Bisaga, A. (242) 213)

Glutamate receptors; Cyclothiazide; GYKI 53655 (Palmer, A.J. (244) 193)

**[$^3$H]AMPA binding**
Hippocampal slices; *Xenopus* oocytes (rat cortex mRNA-injected); Glutamate receptors; GABA receptor; ATP-sensitive potassium channel activators; [$^3$H]Kainate binding (Randle, J.C.R. (247) 257)

**AMPA/kainate receptors**
Bergmann glia; Glutamate (Cid, M.E. (245) 51)

**cAMP analogues**
Pancreatic vessels; Insulin secretion; $\alpha$-Adrenoceptor antagonists; Verapamil; Pancreas (isolated); (Rat) (Skoglund, G. (236) 69)

**AMPA receptor antagonists**
DBA/2 mice; Aniracetam; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline); GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine · HCl); CPPene (D(−)-(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid) (Chapman, A.G. (231) 301)

**AMPA receptors**
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline(1H, 4H)dione sodium salt); Parkinsonism; Dyskinesia; Dopamine receptor agonists (Luquin, M.R. (235) 297)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline); Cerebral ischaemia; NMDA receptors; NMDA receptor antagonists; Glutamate (Sheardown, M.J. (236) 347)

Glutamate; Glucagon release; Pancreas (rat) (Bertrand, G. (237) 45)

**Amperozide**
Prefrontal cortex; Microdialysis; Dopamine; Schizophrenia; Clozapine (Pehek, E.A. (240) 107)

**AMP formation**
Transfection; Promiscuous coupling; Neurotensin (Yamada, M. (244) 99)

**Amphetamine**
Ceruletide; Hyperlocomotion; Stereotypy; Microdialysis; (Rat) (Kihara, T. (230) 271)

Dopamine; Prefrontal cortex; Stress; Sensitization (Hamamura, T. (237) 65)

Dopamine autoreceptors; Dopamine $D_2$ receptor agonists; Dopamine $D_2$ receptor antagonists; Side-effects; (Monkey) (Peacock, L. (237) 329)

Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; 5-$HT_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

**d-Amphetamine**
Dopamine; Substantia nigra; Autoreceptors; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

Cocaine; Hippocampus; Caudate nucleus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

Verapamil; Reinforcement; Place preference conditioning; $Ca^{2+}$ channel inhibitors (Pucilowski, O. (240) 89)

**d,l-Amphetamine**
$\sigma$ Binding sites; DTG (1,3-di-(2-tolyl)guanidine); Antipsychotics; Dizocilpine; Animal models; (Rat) (Rückert, N.G.H. (233) 261)

**cAMP levels**
Morphine; Catalepsy; Pertussis toxin; Cholera toxin (Massi, P. (243) 65)

**Amygdala**
Opioid; Central nucleus; Parabrachial area; Nociception; Pain pathway; (Rat) (Huang, G.-F. (236) 449)

**Amygdala kindling**
Oral dyskinesia; Haloperidol (intermittent); Sensitization (pharmacological); Drug holidays (rats) (Glenthøj, B. (236) 401)

**Amylase secretion**
SR 27897; $CCK_A$ receptors; Gastric emptying; Gall bladder emptying (Gully, D. (232) 13)

SK&F 96365; $Ca^{2+}$ dynamics; Pancreatic acini (Busik, J. (247) 273)

**Anaesthesia**
Adenosine (extracellular); Brain microdialysis; Striatum; Tetrodotoxin; NMDA receptors (Pazzagli, M. (234) 61)

$\alpha_2$-Adrenoceptors; Sedation; Medetomidine; Atipamezole; (Cat) (Stenberg, D. (238) 241)

**Anaesthetics**
Asthma; Ketamine; Propofol; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

**Analgesia**
Opioids; Parabrachial; Noxious; Thermal stimuli; Pain pathway; (Rat) (Huang, G.-F. (230) 279)

$\kappa$-Opioid receptor antagonists; Morphine; U50,488; Shock titration; Squirrel monkeys (Craft, R.M. (234) 199)

Nociception; Noradrenaline; Neuropathic pain; Axotomy; Nerve injury (Xu, X.-J. (235) 161)

Opioid receptors; Physical dependence; 14-Alkoxymetopons; (Binding) (Fürst, Z. (236) 209)

Restraint stress; Morphine; NECA (5'-(N-ethyl)carboxamido-adenosine); Caffeine; Opioids (Woolfolk, D.R. (239) 177)

Endorphin receptors; $\mu$-Opioid receptor antagonists; $\kappa$-Opioid receptor agonists; N-CPM-$H_2$BAMO (14$\beta$-(bromoacetamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone); (Mouse) (Jiang, Q. (240) 201)

Tachykinins; Neurokinins; Pain; Spinal cord (Fleetwood-Walker, S.M. (242) 173)

Acetylthiorphan; Acetorphan; Thiorphan; Neutral endopeptidase; Hot-plate test (Lambert, D.M. (243) 129)

**Anaphylactic shock**
PAF receptor antagonists; WEB 2170 (Amorim, C.Z. (235) 17)

Endothelin; Hemorrhagic shock; Hypotension; Hypovolemia; Hypoxia (Filep, J.G. (239) 231)

**Anaphylaxis**
Hyperresponsiveness; PAF (platelet-activating factor, PAF-acether); PCA-4248 (Desquand, S. (235) 101)

PAF (platelet-activating factor, PAF-acether); PCA 4248; Paw edema (mouse) (Amorim, C.Z. (236) 301)

**ANF (atrial natriuretic factor)**
EDRF (endothelium-derived relaxing factor); cGMP; Heart failure (Arnal, J.-F. (237) 265)

Morphine; Diuresis (Gutkowska, J. (242) 7)

Candoxatrilat; Neutral endopeptidase inhibition; Volume expansion; cGMP (Scott, J.M. (242) 91)

Mastoparan; Guanylate cyclase; cGMP; ATP (Song, D.-L. (247) 283)

**Angiotensin-(1–7)**
Peptides; Angiotensin receptors; DuP 753; Nitric oxide synthase; L-NAME ($N^G$-nitro-L-arginine methyl ester) (Osei, S.Y. (234) 35)

Angiotensin-converting enzyme inhibition; Myocardial ischemia; Myocardial infarction (Hartman, J.C. (234) 229)

Active avoidance; Angiotensin-converting enzyme inhibitor; Bradykinin; Diabetes mellitus; Memory; (Mouse) (Flood, J.F. (240) 311)

NADH fluorescence; Angiotensin-converting enzyme; Myocardial ischemia; Angiotensin-converting enzyme inhibitors; Ramiprilat; Cardioprotection (Rump, A.F.E. (241) 201)

**Angiotensin II**
Cholera toxin; Pertussis toxin; Portal vein (rat); Dibutyryl cAMP (Zhang, J. (230) 95)

Receptor affinity; Smooth muscle (vascular) (Kuttan, S.C. (232) 173)

$N^G$-Nitro-L-arginine; Ethanol; Noradrenaline; Vasopressor; Bradycardia; Baroreflex (Wang, Y.-X. (233) 275)

[Sar$^1$]angiotensin II; Angiotensin $AT_1$ receptors; Aorta; (Agonists) (Liu, Y.J. (235) 9)

Angiotensin $AT_1$ receptor antagonists; CV-11974; $[Ca^{2+}]_i$ transient; Cardiac myocytes; (Neonatal rat) (Kinugawa, K.-i. (235) 313)

EXP3174; $Li^+$ clearance; Renal blood flow; Glomerular filtration rate (Tamaki, T. (236) 15)

Losartan; Angiotensin receptor (antagonism); Stomach; Trachea (Liu, Yu.J. (240) 147)

Protein kinase C; Isoenzymes; Inositol 1,4,5-trisphosphate ($InsP_3$); $Ca^{2+}$; Diacylglycerol; Mesangial cells (Ochsner, M. (245) 15)

Angiotensin $AT_1$ receptors; Losartan; Inotropy; Atria (guinea pig) (Feolde, E. (245) 63)

SR 47436; Cardiomyocytes (neonatal rat); $Ca^{2+}$ (intracellular free); Angiotensin $AT_1$ receptors (Delisée, C. (247) 139)

Angiotensin receptors; Angiotensin receptor antagonists; Monoclonal antibodies (Bensoussan, M. (247) 169)

**[$^{125}$I]Angiotensin II**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); Brain (human); Losartan; PD123177 (Barnes, J.M. (230) 251)

**[Sar$^1$]angiotensin II**
Angiotensin II; Angiotensin $AT_1$ receptors; Aorta; (Agonists) (Liu, Y.J. (235) 9)

**Angiotensin-converting enzyme**
NADH fluorescence; Angiotensin; Myocardial ischemia; Angiotensin-converting enzyme inhibitors; Ramiprilat; Cardioprotection (Rump, A.F.E. (241) 201)

Ramipril; Plasma; Renal brush border membrane; Induction (Michel, B. (242) 237)

**Angiotensin-converting enzyme inhibition**
Angiotensin; Myocardial ischemia; Myocardial infarction (Hartman, J.C. (234) 229)

Albuminuria; Vascular permeability; Diabetes; (Rat) (Huijberts, M. (240) 207)

**Angiotensin-converting enzyme inhibitors**
Lisinopril; Hypoxia; Reoxygenation; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

Active avoidance; Angiotensin; Bradykinin; Diabetes mellitus; Memory; (Mouse) (Flood, J.F. (240) 311)

NADH fluorescence; Angiotensin; Angiotensin-converting enzyme; Myocardial ischemia; Ramiprilat; Cardioprotection (Rump, A.F.E. (241) 201)

Endothelial cells; Bradykinin; Fura-2 (Hirano, K. (244) 133)

**Angiotensin receptor (antagonism)**
Angiotensin II; Losartan; Stomach; Trachea (Liu, Yu.J. (240) 147)

**Angiotensin receptor antagonists**
Angiotensin II; Angiotensin receptors; Monoclonal antibodies (Bensoussan, M. (247) 169)

**Angiotensin $AT_1$ receptor antagonists**
Angiotensin II; CV-11974; $[Ca^{2+}]_i$ transient; Cardiac myocytes; (Neonatal rat) (Kinugawa, K.-i. (235) 313)

**Angiotensin receptors**
Peptides; Angiotensin-(1–7); DuP 753; Nitric oxide synthase; L-NAME ($N^G$-nitro-L-arginine methyl ester) (Osei, S.Y. (234) 35)

Sinoatrial node; Atrioventricular node; Angiotensin system; Losartan (Saavedra, J.M. (235) 301)

cDNA sequence; Aorta (porcine); COS cell expression; *Xenopus* oocyte expression (Itazaki, K. (245) 147)

Angiotensin II; Angiotensin receptor antagonists; Monoclonal antibodies (Bensoussan, M. (247) 169)

**Angiotensin $AT_1$ receptors**
Angiotensin II; Losartan; Inotropy; Atria (guinea pig) (Feolde, E. (245) 63)

SR 47436; Cardiomyocytes (neonatal rat); Angiotensin II; $Ca^{2+}$ (intracellular free) (Delisée, C. (247) 139)

Losartan; Glomerulus (Chansel, D. (247) 193)

[Sar$^1$]angiotensin II; Angiotensin II; Aorta; (Agonists) (Liu, Y.J. (235) 9)

**Angiotensin $AT_{1A}$ receptors**
Cyclosporine; Hypertension; Endothelium; Gene expression (Iwai, J. (248) 341)

**Angiotensin II receptor subtypes**
Cerebellum (human); Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Angiotensin system**
Sinoatrial node; Atrioventricular node; Angiotensin receptors; Losartan (Saavedra, J.M. (235) 301)

**Animal models**
$\sigma$ Binding sites; DTG (1,3-di-(2-tolyl)guanidine); Antipsychotics; d,l-Amphetamine; Dizocilpine; (Rat) (Rückert, N.G.H. (233) 261)

**Aniracetam**
DBA/2 mice; AMPA receptor antagonists; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline); GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine·HCl); CPPene (D(−)-(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid) (Chapman, A.G. (231) 301)

**Anococcygeus muscle (rat)**
Co-axial bioassay; EpDRF (epithelium-derived relaxing factor); Ovalbumin challenge; Trachea (guinea-pig); 5-HT (5-hydroxytryptamine, serotonin) (Çakici, İ. (236) 97)

Aortic rings (rat); Hydroxocobalamin; Nitric oxide (NO); S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitroso-coenzyme A; S-Nitrosocysteine; S-Nitrosoglutathione; Nitrosothiols (Rand, M.J. (241) 249)

(+)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; (−)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; Methamphetamine; Cocaine; Nomifensine (Watanabe, H. (243) 155)

**Anococcygeus (rabbit)**
Nitric oxide (NO); Nitric oxide synthase inhibitors; Purinoceptors; ATP; Adenosine; 8-(p-Sulfophenyl)theophylline; Suramin (Graham, A.M. (237) 93)

**α-ANP (α-atrial natriuretic peptide)**
Ethanol withdrawal; Anti-ANP serum (Kovács, G.L. (238) 417)

**ANP (atrial natriuretic polypeptide)**
$Ca^{2+}$ entry blockers; Verapamil; Felodipine; Nifedipine; Diuretic effects (Shamiss, A. (233) 113)

Coronary artery; Nitroglycerin; Nitric oxide (NO); Cyclic GMP (Matsumoto, T. (237) 31)

Adenosine; Beating frequency; Hormone secretion (Uusimaa, P.A. (242) 199)

**Antagonism, functional**
Kinetics; Adenosine $A_2$ receptors; $\alpha_1$-Adrenoceptor; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

**Anteroventral thalamic nucleus**
Desipramine; Noradrenaline; Electrochemistry (in vivo); Brain (rat); Locus coeruleus (Brun, P. (235) 205)

**Anthraquinones**
Cathartics; Germ-free life; Bacteria (Nijs, G. (239) 241)

**Antiallergic activity**
WY-50,295 tromethamine; 5-Lipoxygenase inhibitors; Leukotriene biosynthesis inhibitors (Grimes, D. (236) 217)

**Antiallergic compounds**
CR 2039; Passive cutaneous anaphylaxis; Bronchial anaphylaxis; Lung phosphodiesterase; (Guinea-pig) (Revel, L. (229) 45)

**Antiangiogenic action**
Radicicol; Cell differentiation modulator; Embryonic angiogenesis; Chorioallantoic membrane (Oikawa, T. (241) 221)

**AntiANP serum**
Ethanol withdrawal; α-ANP (α-atrial natriuretic peptide) (Kovács, G.L. (238) 417)

**Antiarrhythmics**
$K^+$ channels; Cardiac ischaemia; Ventricular fibrillation (Gwilt, M. (236) 107)

Refractory period (effective); Ischaemia; (Guinea-pig) (Tweedie, D. (240) 251)

Amiodarone; Lactate dehydrogenase; Mitochondrial ATPase (Dzimiri, N. (242) 113)

**Antiarrhythmics (class I)**
Bisaramil; Arrhythmia (ventricular) (Haruno, A. (233) 1)

**Antiarrhythmics class III**
σ Receptors; [$^3$H](+)-3-PPP ([$^3$H](+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); $K^+$ channels (Jeanjean, A.P. (241) 111)

**Anticholinesterase**
Diazepam; Neostigmine; Neuromuscular transmission; Muscle paralysis (Chiou, L.C. (248) 185)

**Anticonflict activity**
Ergot alkaloids; [$^3$H]Muscimol binding; Brain (human, post-mortem); (Rat) (Peričić, D. (235) 267)

**Anticonvulsants**
Seizures (chemically induced); Pilocarpine; Epilepsy; ACTH (adrenocorticotrophic hormone) (Croiset, G. (229) 211)

Ucb L059; Seizures; Epilepsy; Piracetam; Valproate (Löscher, W. (232) 147)

DTG (1,3-di(2-tolyl)guanidine); σ Receptor ligands; Haloperidol; Prepiriform cortex (Roth, J.E. (236) 327)

Gabapentin; GABA (γ-aminobutyric acid); Baclofen; $GABA_A$ receptors; $GABA_B$ receptors; NMDA (N-methyl-D-aspartate); Glycine; Polyamines (Suman-Chauhan, N. (244) 293)

Gabapentin; Autoradiography; GABA (γ-aminobutyric acid); NMDA (N-methyl-D-aspartate); Glycine; Hippocampus; Excitatory amino acids (Hill, D.R. (244) 303)

Histogranin; Endogenous peptide; Adrenal medulla; NMDA receptors (Lemaire, S. (245) 247)

Gabapentin; L-Amino acids; System-L; Transporter; Brain (Thurlow, R.J. (247) 341)

**Antidepressant effects**
$5\text{-}HT_{1A}$ receptors; Dorsal hippocampus; Passive avoidance; Memory; Anxiolytic effects (Carli, M. (234) 215)

**Antidepressants**
5-HT uptake; Fluvoxamine; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (229) 101)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1C}$ receptors; $5\text{-}HT_{1A}$ receptors; (Rat) (Jenck, F. (231) 223)

(S)-Nafenodone; Aorta (rat); $^{45}Ca^{2+}$ movements (Pérez-Vizcaíno, F. (232) 105)

Litoxetine; Emesis; 5-HT (5-hydroxytryptamine, serotonin) (Angel, I. (232) 139)

5-HT uptake; Fluvoxamine; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

$TGF_\alpha$ (transforming growth factor α); Tryptophan; 5-HT (5-hydroxytryptamine, serotonin); Depression; Aggression; Transgenic mice (Hilakivi-Clarke, L.A. (237) 101)

Forced swim test; $5\text{-}HT_{1A}$ receptor agonists; LY228729 (Benvenga, M.J. (239) 249)

$\sigma$ Receptors; NMDA (N-methyl-D-aspartate); 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor (selective); Monoamine oxidase inhibitors (Bergeron, R. (240) 319)

Citalopram; Tianeptine; $5\text{-HT}_{1B}$ receptors; Acetylcholine release (Bolaños-Jiménez, F. (242) 1)

**Antidiuretic activity**
Factor VIII; Vasopressin analogues; Monkey (Vilhardt, H. (232) 223)

**Antiinflammatory action**
Fructose 1,6-bisphosphate; Carrageenan; Liposome (Planas, M.E. (237) 251)

**Anti-inflammatory drugs**
Adenosine analogs; TNF (tumor necrosis factor); Endothelium; Polymorphonuclear leukocytes (Cerri, M.A. (232) 291)

Paw oedema (rat); *M. velutina* compounds; Phospholipase $A_2$; Phospholipase C (Neves, P.C.A. (243) 213)

**Antimuscarinic action**
Doxorubicin; Pirarubicin; Aclarubicin; Heart (guinea-pig); Positive inotropic effect; Potentiated postrest contraction; Time to peak twitch tension (Temma, K. (234) 173)

**Antinociception**
GABA ($\gamma$-aminobutyric acid); Baclofen; MBFG (4-amino-3-(5-methoxybenzo(b)furan-2-yl) butanoic acid); Spinal cord; BFG (4-amino-3-benzo(b)furan-2-yl-butanoic acid) (Hammond, D.L. (229) 227)

Opioid receptor antagonists; $\mu$-Opioid receptors (Jiang, Q. (230) 129)

Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Opiates (Ocaña, M. (230) 203)

Adenosine; Adenosine receptors; Sensory neuropeptides; Capsaicin (Santicioli, P. (231) 139)

Shock titration; Opioid peptides; Rhesus monkey; SC-39566 (Hammond, D.L. (231) 281)

$\mu$-Opioid receptors; $\delta$-Opioid receptors; Opioid receptor antagonists; Metabolism (Horan, P.J. (233) 53)

L-Tyrosine (methyl ester); $\delta$-Opioid receptors; Bulbo-spinal noradrenergic system (Kawabata, A. (233) 255)

Baclofen; CGP 35348; Spinal cord; $GABA_B$ receptors (Hammond, D.L. (234) 255)

L-Arginine; Nitric oxide (NO); $\beta$-Endorphin; Pain controls (descending) (Xu, J.Y. (236) 137)

Naloxone; Morphine; Formalin; Pronociception; (Rat) (Wheeler-Aceto, H. (236) 193)

$\kappa$-Opioid receptors; Arylacetamides; Benzomorphans; (Mouse) (Horan, P.J. (239) 93)

$\beta$-Endorphin; Morphine; Tolerance; Cross-tolerance; Tail-flick inhibition; Hot-plate inhibition (Tseng, L.F. (241) 63)

Paw pressure; Arthritic rat; Enkephalin degradation; (Normal rat); (Mixed inhibitor) (Perrot, S. (241) 129)

Ketorolac; $\kappa$-Opioid receptors; Intrathecal administration (Uphouse, L.A. (242) 53)

[Leu$^5$]enkephalin; [Met$^5$]enkephalin; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Spinal cord; Brain; $\beta$-Endorphin (Takemori, A.E. (242) 145)

$\kappa$-Opioid receptor agonist; Fentanyl; Respiration; (Intrathecal); (Intraventricular) (Wang, C. (243) 113)

Nicotine; Opioid and anti-opioid interactions; Smoking behaviour; (Mice) (Aceto, M.D. (248) 333)

**Antinociception (mouse)**
Interleukin-1; CRF (corticotropin-releasing factor); Opioids; $\alpha$-Helical CRF-(9–41) (Kita, A. (237) 317)

**Antinociception (peripheral)**
Opioids; Inflammation; Cytokines (Członkowski, A. (242) 229)

**Antioxidants**
[$^3$H]5-HT (5-[$^3$H]Hydroxtryptamine); Enteric membranes (rat); Indoles; (Spurious binding sites) (Williams, T.J. (245) 197)

**Antiplatelet compound**
IBI P-05006; Platelets; Thromboxane $A_2$/prostaglandin endoperoxides receptor antagonists (Rotondo, S. (232) 41)

**Antiproliferative effect**
Esculetin; Coumarins; Smooth muscle cells (vascular); Lipoxygenase inhibitors (Huang, H.-C. (237) 39)

**Antipsychotic effects**
Homophthalazine binding (specific); Anxiolytic drugs (Horváth, E.J. (236) 151)

**Antipsychotics**
SR 31742A; Neurotensin; $\sigma$ Receptor ligands (Labie, C. (231) 465)

$\sigma$ Binding sites; DTG (1,3-di-(2-tolyl)guanidine); d,l-Amphetamine; Dizocilpine; Animal models; (Rat) (Rückert, N.G.H. (233) 261)

Dopamine $D_4$ receptors; Dopamine $D_2$ receptors; Schizophrenia; Extrapyramidal side effects; Tardive dyskinesia (Lahti, R.A. (236) 483)

AJ 76; UH 232; Dopamine receptors; Striatum; Acetylcholine release (Gifford, A.N. (237) 169)

Dopamine $D_2$ receptors; Neuroleptics; [$^3$H]YM-09151-2; Dopamine $D_2$ receptor binding; Biphasic displacement (Assié, M.-B. (237) 183)

Remoxipride; Remoxipride metabolites; Dopamine receptors; [$^3$H]Raclopride binding (Mohell, N. (238) 121)

$\alpha_{1A}$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Risperidone; Receptor binding (Sleight, A.J. (238) 407)

$\sigma$ Receptors; Cytotoxicity (Vilner, B.J. (244) 199)

**Antisense**
Neuropeptide Y; Blood vessel (human); Neuropeptide Y $Y_1$ receptor (Erlinge, D. (240) 77)

**Anti-tumor necrosis factor-α antibodies**
TNFα (tumor necrosis factor-α); Ischaemia-reperfusion injury (Squadrito, F. (237) 223)

**Antitussive activity**
δ-Opioid receptor subtypes; [D-Ala$^2$]deltorphin II; [D-Pen$^2$,D-Pen$^5$]enkephalin; Naltrindole; Benzofuran analogue of naltrindole (Kamei, J. (234) 117)

**Antitussive effects**
Cough; β-Endorphin; Opioid receptors (Kamei, J. (233) 251)

CXBK mouse; Morphine; Naltrexonazine; μ-Opioid receptor subtypes (Kamei, J. (240) 99)

σ Sites; Dextromethorphan; Noscapine; Rimcazole (Kamei, J. (242) 209)

**Anxiety**
Vasopressin; Ultrasonic vocalization; Thermoregulation; Affiliation; Vasotocin (Winslow, J.T. (233) 101)

5-HT$_3$ receptors; Benzodiazepine withdrawal (File, S.E. (237) 127)

Nicotine; Lobeline; Cytisine; Mecamylamine; Chlorisondamine (Brioni, J.D. (238) 1)

Buspirone; Chronic treatment; 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; 5-HT$_{1A}$ receptors; Microdialysis (in vivo); (Rat) (Söderpalm, B. (239) 69)

**Anxiolysis**
Ipsapirone; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT$_{1A}$ receptors; 5-HT$_2$ receptors; Glucose; Corticosterone; Prolactin; Behaviour (Baudrie, V. (231) 395)

Melatonin; Diazepam; Exploratory behaviour; Benzodiazepine antagonism; (Time-dependent effects) (Golombek, D.A. (237) 231)

**Anxiolytic effects**
5-HT$_{1A}$ receptors; Dorsal hippocampus; Passive avoidance; Memory; Antidepressant effects (Carli, M. (234) 215)

**Anxiolytics**
Handling; Stress; 5-HT$_{1A}$ receptors; 5-HT$_3$ receptors; GABA$_B$ receptors (Andrews, N. (235) 109)

Homophthalazine binding (specific); Antipsychotic effects (Horváth, E.J. (236) 151)

Dorsal raphe nucleus; Electrophysiology; Hippocampus; Ipsapirone; Microdialysis; Serotonergic neurotransmission; 5-HT$_{1A}$ receptors; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

**Aorta**
Diurnal rhythm; Adrenoceptors; Noradrenaline; (Rat) (Gohar, M. (229) 69)

[Sar$^1$]angiotensin II; Angiotensin II; Angiotensin AT$_1$ receptors; (Agonists) (Liu, Y.J. (235) 9)

Ethanol; Acetylcholine; Endothelium; Vasorelaxation; (Rat) (Hatake, K. (238) 441)

Dotarizine; $^{45}Ca^{2+}$ movements; Basilar smooth muscle; (Rabbit) (Tejerina, T. (239) 75)

Aldose reductase; EDRF (endothelium-derived relaxing factor); Galactosaemia; Nitric oxide (NO); Polyol pathway (Cameron, N.E. (243) 47)

**Aorta (bovine)**
Endothelial cells; Prostacyclin; $Ca^{2+}$ indicators; Arachidonate metabolism (Boeynaems, J.-M. (233) 13)

**Aorta (porcine)**
Angiotensin receptor; cDNA sequence; COS cell expression; *Xenopus* oocyte expression (Itazaki, K. (245) 147)

**Aorta (rabbit)**
Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); EDHF (endothelium-derived hyperpolarizing factor); N$^{\omega}$-Nitro-L-arginine; Glybenclamide (Bellan, J.A. (234) 273)

5-HT$_{1A}$ receptor agonists; 8-OH-DPAT; Buspirone; α$_1$-Adrenoceptor subtypes; (8-hydroxy-2(di-N-propylamino)tetralin) (Castillo, C. (241) 141)

**Aorta (rat)**
$Ca^{2+}$ channel antagonists; α$_1$-Adrenoceptor antagonists; Aporphines; Phosphodiesterase inhibitors (Ivorra, M.D. (231) 165)

Smooth muscle (vascular); Endothelium (vascular); EDRF (endothelium-derived relaxing factor); Endothelins; ET$_B$ receptors; ET$_B$ receptor antagonists; IRL 1038 (Karaki, H. (231) 371)

S312; Dihydrothienopyridine; Cerebral microvessels (rat); Dihydropyridine binding site; Phenylalkylamine binding site (Dessy, C. (231) 435)

(S)-Nafenodone; $^{45}Ca^{2+}$ movements; Antidepressants (Pérez-Vizcaíno, F. (232) 105)

$Ca^{2+}$ channel blockers; Cytosolic $Ca^{2+}$ levels; Felodipine; Nifedipine; Verapamil; Smooth muscle; (Relaxation) (Hagiwara, S. (234) 1)

Quercetin; Portal vein (Duarte, J. (239) 1)

Diabetes mellitus; N$^G$-Nitro-L-arginine; Haemoglobin; Endothelium-dependent relaxation; Tachyphylaxis (Sikorski, B.W. (242) 275)

Aging; Nitrate tolerance; Nitroglycerin; Sin-1 (3-morpholinosydnonimine) (Unger, P. (248) 145)

**Aortic arch**
Hyperlipidemia; Vascular reactivity; Wistar-Kyoto rats (WKY); Endothelium-derived relaxing factor (EDRF); Spontaneously hypertensive rats (SHR); Abdominal aorta (Yu, S.-M. (248) 289)

**Aortic myocytes**
Taenia coli myocytes; Verapamil (Fan, S.-f. (229) 259)

**Aortic rings (rat)**
Anococcygeus muscle (rat); Hydroxocobalamin; Nitric oxide (NO); S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitroso-coenzyme A; S-Nitrosocysteine; S-Nitrosoglutathione; Nitrosothiols (Rand, M.J. (241) 249)

**Aortic spiral preparation (rat)**
CGRP (Calcitonin gene-related peptide); Cytosolic free $Ca^{2+}$; Fura 2; Cyclic AMP (Michiro Ishikawa, (246) 121)

**Apamin**
Hepatocytes; Nicotinic receptors; $Ca^{2+}$-activated $K^+$ channels; Dequalinium; Vecuronium (Castle, N.A. (236) 201)

Tachykinins; Ileum (guinea-pig); Circular muscle; ω-Conotoxin; Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic); NANC relaxation (Maggi, C.A. (240) 45)

**APCP (5′-O-(α,β-methylene)diphosphate)**
Adenine nucleotides; Adenosine $A_2$ receptors; Adenosine deaminase; Striatum (Pirotton, S. (241) 55)

**Apneustic breathing**
Kynurenic acid; Apnoea; Dizocilpine; Arterial blood pressure; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

**Apnoea**
Kynurenic acid; Dizocilpine; Arterial blood pressure; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

**Apomorphine**
Dopamine release; Striatum; Haloperidol; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

Sensitization; NMDA receptors; Dopamine receptor agonists; MK-801 (Druhan, J.P. (243) 73)

**Apomorphine-induced climbing**
σ Receptor ligands; Apomorphine-induced stereotypy; (Mouse) (Fritz, P.M. (235) 229)

**Apomorphine-induced stereotypy**
σ Receptor ligands; Apomorphine-induced climbing; (Mouse) (Fritz, P.M. (235) 229)

**Aporphines**
$Ca^{2+}$ channel antagonists; $\alpha_1$-Adrenoceptor antagonists; Aorta (rat); Phosphodiesterase inhibitors (Ivorra, M.D. (231) 165)

Dopamine $D_4$ receptors; Sulpiride (Seeman, P. (233) 173)

**Aprikalim**
Cheek pouch arterioles; Vasodilatation, BRL 38227; Nitric oxide (NO); L-NMMA ($N^G$-monomethyl-L-arginine); (Hamster) (Mayhan, W.G. (242) 109)

**Aqueous humor**
Substance P; Prostaglandins; Indomethacin; Timolol; Surgical miosis (Kieselbach, G. (235) 117)

**Aqueous humor flow rate**
Intraocular pressure; Dopamine $D_2$ receptors; (Rabbit) (Potter, D.E. (236) 61)

**Arachidonate metabolism**
Endothelial cells; Prostacyclin; $Ca^{2+}$ indicators; Aorta (bovine) (Boeynaems, J.-M. (233) 13)

**Arachidonic acid**
Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

Cytochrome P450; 20-HETE (20-hydroxy-5,8,11,14-eicosatetraenoic acid); Endothelium-dependent vasoconstrictor (Escalante, B. (235) 1)

Long-term potentiation; Metabotropic receptor (Collins, D.R. (240) 325)

Diacylglycerol; Phorbol ester binding; Protein kinase C isoforms (MacEwan, D.J. (246) 9)

Phosphotyrosine phosphatase; Melittin; EGF (epidermal growth factor); Phospholipase $A_2$; Fibroblasts (Errasfa, M. (247) 73)

**Arachidonoyl-containing molecular species**
Brain gangliosides (bovine); 1,2-Diacylglycerol; Diacylglycerolipids; Phosphatidic acid; Diabetic neuropathy (Bianchi, R. (239) 55)

**$A_7r_3$ cells**
Smooth muscle (vascular); $Ca^{2+}$ influx; Lacidipine; Amlodipine; 1,4-Dihydropyridines (Spampinato, S. (244) 139)

**Area postrema**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; Vomiting; Reserpine; 6-Hydroxydopamine (6-OHDA) (Hikasa, Y. (229) 241)

**Arenobufagin**
Toad venom; Bufadienolide; $Na^+/K^+$ pump current (Cruz, J.d.S. (239) 223)

**Arginine**
Insulin release; NO synthase inhibition; NADPH diaphorase (Panagiotidis, G. (229) 277)

**L-Arginine**
Stomach; Nitric oxide (NO); Indomethacin; Prostaglandins (Konturek, S.J. (229) 155)

Seizures; Nitric oxide (NO); Prepiriform cortex (deep); Excitatory amino acid; Sodium nitroprusside (De Sarro, G. (230) 151)

Nitrate vasodilators; Phosphodiesterase inhibitors; Zaprinast; $N^\omega$-Nitro-L-arginine; Acetylcholine; Bradykinin; Blood pressure (De Garavilla, L. (234) 77)

Nitric oxide (NO); β-Endorphin; Antinociception; Pain controls (descending) (Xu, J.Y. (236) 137)

Mesentery (rat); L-NAME ($N^\omega$-nitro-L-arginine methyl ester); Methylene blue; Diethyldithiocarbamate; CGRP (calcitonin gene-related peptide) (Li, Y.-j. (239) 127)

Peptic ulcers; Nitric oxide (NO); Glyceryl trinitrate healing; Blood flow (Konturek, S.J. (239) 215)

Gastric cytoprotection; L-NAME ($N^G$-nitro-L-arginine methyl ester); Nitric oxide (NO); RX 77368; Vagus (Király, Á. (240) 299)

Mesentery (rat); Bradykinin; L-NAME ($N^\omega$-nitro-L-arginine methyl ester); Methylene blue; Capsaicin-sensitive sensory nerves (Yu, X.-j. (241) 35)

Ricinoleic acid; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester); $N^G$-Monomethyl-L-arginine; Tetrodotoxin; Ileum; (Rat) (Izzo, A.A. (243) 87)

**Aromatic L-amino acid decarboxylase**
Dopamine receptors; Striatum; Neuroleptics (Zhu, M.-Y. (238) 157)

**Arrhythmias**
$Na^+/Ca^{2+}$ overload blockade; Ouabain; (Guinea-pig) (Lu, H.R. (235) 89)

Ischemia; Reperfusion; Hypochlorous acid; Hydrogen peroxide (Okabe, E. (248) 33)

**Arrhythmia (ventricular)**
Bisaramil; Antiarrhythmic agents (class I) (Haruno, A. (233) 1)

**Arterial blood pressure**
Kynurenic acid; Apnoea; Dizocilpine; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

**Arterial myogenic tone**
Voltage-dependent $Ca^{2+}$ channels; Transmembrane $Ca^{2+}$ influx; $Ca^{2+}$-activated $K^+$ channels; Spontaneously hypertensive rats (SHR); (Early hypertensive stages) (Asano, M. (247) 295)

**Arterioles**
5-HT (5-hydroxytryptamine, serotonin); EDRF (endothelium-derived relaxing factor); Microcirculation; Nitric oxide (NO); $N^G$-Nitro-L-arginine (Alsip, N.L. (229) 117)

**Arterioles (submucosal)**
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

**Arthritic rat**
Antinociception; Paw pressure; Enkephalin degradation; (Normal rat); (Mixed inhibitor) (Perrot, S. (241) 129)

**Arylacetamides**
κ-Opioid receptors; Antinociception; Benzomorphans; (Mouse) (Horan, P.J. (239) 93)

**Aspartate**
$Ca^{2+}$ channels; Exocytosis; Glutamate; GABA (γ-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

**Aspirin**
Venous stasis; Fibrinolytic activity (Iacoviello, L. (229) 39)

FR122047; Platelet aggregation; Cyclooxygenase (Dohi, M. (243) 179)

**Asthma**
Edema; Plasma exudation; Bradykinin; Airway obstruction; Vascular permeability; OKY-046; Indomethacin (Arakawa, H. (229) 131)

5-Lipoxygenase; Leukotriene; Bronchoconstriction; Trachea; (Guinea-pig) (Heaslip, R.J. (234) 247)

Hyperresponsiveness; Respiratory airways; Interleukin-5; Eosinophils (Van Oosterhout, A.J.M. (236) 379)

Airway obstruction; Development; Maturation; Plasma exudation; Vascular permeability (Yokoyama, T. (236) 427)

Anaesthetics; Ketamine; Propofol; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

Hyperresponsiveness; Respiratory airways; Interleukin-5; Eosinophils (Van Oosterhout, A.J.M. (239) 277)

$\beta_2$-Adrenoceptor agonists; Albuterol; Methacholine; (Rabbit) (Witt-Enderby, P.A. (241) 121)

**Asthmatic model**
CS-518; Thromboxane synthase inhibitors; Bronchoconstriction; Hyperresponsiveness (Yamaguchi, T. (236) 43)

CS-518; Thromboxane synthase inhibitors; Eicosanoid production (Itoh, K. (237) 215)

CS-518; Thromboxane $A_2$ synthase inhibitors; Eosinophil function (Itoh, K. (239) 159)

**Asthmatic responses**
ONO-1078; Peptide leukotriene receptor antagonists; Airway hyperreactivity; Eosinophil accumulation (Nakagawa, N. (235) 211)

**Atenolol**
β-Adrenoceptors; Adenylate cyclase; Desensitisation; Xamoterol (Arnold, I.R. (245) 285)

**Atherosclerosis**
Contractions; 5-HT (5-hydroxytryptamine, serotonin); Lipoxygenase products; Blood vessels; (Interaction) (Van Diest, M.J. (231) 267)

Interleukin-8; Chemotaxis; Migration; Smooth muscle cell (Yue, T.-L. (240) 81)

**Atherosperminine**
Smooth muscle (trachealis, guinea-pig); Phosphodiesterase inhibition; Cyclic nucleotides; *Fissistigma glaucescens* (Lin, C.-H. (237) 109)

**Atipamezole**
$\alpha_2$-Adrenoceptors; Sedation; Anaesthesia; Medetomidine; (Cat) (Stenberg, D. (238) 241)

**ATP**
Urinary bladder; Purine receptors; Nucleotides (Theobald, Jr., R.J. (229) 125)

Anococcygeus (rabbit); Nitric oxide (NO); Nitric oxide synthase inhibitors; Purinoceptors; Adenosine; 8-(p-Sulfophenyl)theophylline; Suramin (Graham, A.M. (237) 93)

Diabetic heart; Hypoperfusion; Norepinephrine; Left ventricular stiffness; Lactate; Insulin (ex vivo) (Higuchi, M. (242) 293)

5′-Nucleotide receptor; HeLa cells; $Ca^{2+}$; fura-2 (Smit, M.J. (247) 223)

Mastoparan; Guanylate cyclase; ANF (Atrial natriuretic factor); cGMP (Song, D.-L. (247) 283)

**ATP-dependent $K^+$ channels**
Morphine; Gliquidone; Locomotor activity (Ocaña, M. (239) 253)

**ATP-sensitive $K^+$ channels**
Amino acid release; Galanin; Glibenclamide; Hippocampus (rat) (Zini, S. (245) 1)

**ATP-sensitive $K^+$ channel activators**
Hippocampal slices; *Xenopus* oocytes (rat cortex mRNA-injected); Glutamate receptors; GABA receptor; [$^3$H]AMPA (*R,S*)-α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) binding; [$^3$H]Kainate binding (Randle, J.C.R. (247) 257)

**ATP transmission**
σ Receptor ligands; Neurogenic twitch contraction; Benzomorphan-type σ receptor; Vas deferens (mouse); Brain (guinea-pig); SK&F 10,047 (N-allylnormetazocine); Rimcazole; Haloperidol (Matsuno, K. (231) 451)

**Atria (guinea pig)**
Angiotensin II; Angiotensin $AT_1$ receptors; Losartan; Inotropy (Feolde, E. (245) 63)

**Atrial natriuretic peptides (ANP)**
cGMP; EDRF (endothelium-derived relaxing factor; (Receptor down-regulation) (Kato, J. (244) 153)

**Atria (piglet)**
5-$HT_4$ receptors; Papillary muscle (piglet); SDZ 205-557 (Lorrain, J. (229) 105)

**Atria (rabbit)**
Nicorandil; Cardiac arrhythmias; Tolbutamide; Quinidine (Le Grand, B. (229) 91)

**Atrioventricular node**
Sinoatrial node; Angiotensin system; Angiotensin receptors; Losartan (Saavedra, J.M. (235) 301)

**Atrium**
Contractile force; Heart; 5-HT (5-hydroxytryptamine, serotonin); Ventricle; (Human) (Schoemaker, R.G. (230) 103)

Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

**Atropine**
Endothelin; Vein; Cholinergic innervation; Neostigmine; Embryology (Hayakawa, A. (239) 219)

**Automaticity**
Hyperpolarization-activated inward current; Pacemaker current; Myocytes (embryonic chick heart); Autonomic agents; Acetylcholine; Isoproterenol (Satoh, H. (240) 283)

**Autonomic agents**
Hyperpolarization-activated inward current; Pacemaker current; Automaticity; Myocytes (embryonic chick heart); Acetylcholine; Isoproterenol (Satoh, H. (240) 283)

**Autonomic nerves**
$\omega$-Conotoxin GVIA; $Ca^{2+}$ channels (voltage-sensitive); *Hololena curta* venom; Funnel web spider toxin; Neurotransmitter release (Lundy, P.M. (231) 197)

**Autoradiography**
Chlordiazepoxide; Passive avoidance response; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Tolerance (Ishihara, S.-i. (230) 313)

Tolerance; DADLE ([D-$Ala^2$,D-$Leu^5$]enkephalin); Opioid receptors; (Rat) (Tao, P.-L. (231) 145)

Dopamine receptors; Stereotypies; Behavioral supersensitivity (Marin, C. (231) 191)

RP 62203; 5-$HT_2$ receptor antagonists; 5-HT (5-hydroxytryptamine, serotonin); [$^{125}$I]AMIK ([$^{125}$I]7-amino-8-iodo-ketanserin); [$^3$H]Mesulergine (Malgouris, C. (233) 29)

Dopamine $D_1$ receptors; Radioligand binding; Umbilical artery; (Human) (Ferreira-de-Almeida, J.A. (234) 209)

Endothelin; Endothelin $ET_B$ receptors; [$^{125}$I]BQ-3020; Lung (porcine) (Kobayashi, M. (235) 95)

5-$HT_{1E}$/5-$HT_{1F}$ recognition sites; Brain (guinea-pig); Brain (rat) (Beer, M.S. (236) 167)

Benzodiazepine receptors; Visual cortex (human); CL218872 (March, D. (236) 333)

6-Hydroxydopamine; SK & F 38393; Quinpirole; Basal ganglia (Engber, T.M. (236) 385)

Renal artery; Dihydropyridine channels; Nicardipine; (Human) (Ferrante, F. (240) 229)

Cerebral cortex; Development; Natriuretic peptide receptors (Zorad, S. (241) 195)

Opioid receptors; Opioid; Enkephalins; Photoaffinity probe (Pasquini, F. (243) 39)

Gabapentin; GABA ($\gamma$-aminobutyric acid); NMDA (N-methyl-D-aspartate); Glycine; Hippocampus; Anticonvulsants; Excitatory amino acids (Hill, D.R. (244) 303)

Adenosine receptors; (Cat); (Rat) (Johansson, B. (247) 103)

Dopamine $D_1$ receptors; Rolipram receptor; Cerebral ischemia; SCH 23390; Pentobarbital; $Ca^{2+}$/calmodulin independent cyclic adenosine monophosphate selective phosphodiesterase; (Gerbil) (Kanai, Y. (248) 191)

**Autoreceptors**
d-Amphetamine; Dopamine; Substantia nigra; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

**Aversive behaviour**
RS-42358-197; 5-$HT_3$ receptor antagonists; (Mouse); (Rat); (Marmoset) (Costall, B. (234) 91)

**Avoidance behaviour**
MK-801; Ketamine; Methamphetamine; Ceruletide; Cholecystokinin-like decapeptide; Dopamine release (Kuribara, H. (231) 7)

**Axotomy**
Nociception; Noradrenaline; Analgesia; Neuropathic pain; Nerve injury (Xu, X.-J. (235) 161)

**Azelastine**
Cerebral vascular disease; Ischaemia; Leukotriene; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

**Baclofen**
GABA ($\gamma$-aminobutyric acid); MBFG (4-amino-3-(5-methoxybenzo(b)furan-2-yl) butanoic acid); Spinal cord; Antinociception; BFG (4-amino-3-benzo(b)furan-2-yl-butanoic acid) (Hammond, D.L. (229) 227)

$\beta$-Phenyl-GABA; $GABA_B$ receptors; Brain slices (rat); Ileum (guinea-pig); (Agonist/partial agonist) (Ong, J. (233) 169)

CGP 35348; Antinociception; Spinal cord; $GABA_B$ receptors (Hammond, D.L. (234) 255)

$GABA_B$ receptor antagonists; Spinal cord; Monosynaptic reflex; (In vitro) (Brugger, F. (235) 153)

Nitropropane analog of baclofen; $GABA_B$ receptor agonists; Ileum (guinea-pig, isolated); Vas deferens (guinea pig); Brain slices (rat) (Kerr, D.I.B. (236) 239)

Gabapentin; GABA ($\gamma$-aminobutyric acid); $GABA_A$ receptors; $GABA_B$ receptors; NMDA (N-methyl-D-aspartate); Glycine; Anticonvulsants; Polyamines (Suman-Chauhan, N. (244) 293)

**Bacteria**
Anthraquinones; Cathartics; Germ-free life (Nijs, G. (239) 241)

**Baroreflex**
$N^G$-Nitro-L-arginine; Ethanol; Angiotensin II; Noradrenaline; Vasopressor; Bradycardia (Wang, Y.-X. (233) 275)

**Baroreflex sensitivity**
5-Carboxamidotryptamine; 5-$HT_1$ receptor agonists; Spontaneously hypertensive rats (SHR); Blood pressure (systolic); (Chronic infusion) (Balasubramaniam, G. (237) 207)

**Baroreflex (vagal)**
Cerebral ischemia; $\alpha_2$-Adrenoceptor blockade (Kurihara, J. (240) 73)

**Basal forebrain**
Propentofylline; Ibotenic acid; Choline acetyltransferase; Learning and memory; Nerve growth factor (Fuji, K. (236) 411)

**Basal ganglia**
Autoradiography; 6-Hydroxydopamine; SK&F 38393; Quinpirole (Engber, T.M. (236) 385)

**Basilar artery (rat)**
Endothelium; 5-HT receptors; Thromboxane $A_2$ (Descombes, J.-J. (243) 193)

**Basilar smooth muscle**
Dotarizine; Aorta; $^{45}Ca^{2+}$ movements; (Rabbit) (Tejerina, T. (239) 75)

**BAY k 8644**
$Ca^{2+}$ channels; Verapamil; Nimodipine; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

PCA 50941; Dihydropyridines; $Ca^{2+}$ channel agonists (Priego, J. (243) 25)

Nimodipine; Strychnine-insensitive glycine receptors (Nowak, G. (247) 101)

1,4-Dihydropyridines; Nicotinic acetylcholine receptors; Chromaffin cells; Nimodipine; PCA50938; Nifedipine; Nitrendipine; Furnidipine (López, M.G. (247) 199)

**BAY u3405**
Thromboxane receptors; Thromboxane receptor antagonists; Lung strip; I-BOP (1S-(1$\alpha$,2$\alpha$(Z),3$\beta$(1(E),3S),4$\alpha$)-7-(3-(3-hydroxy-4-(4-iodophenoxy)-1-butenyl)-7-oxabicyclo(2,2,1)hept-2-yl-5-heptenoic acid); U46619 (Norman, P. (229) 171)

**BDF 9148**
DPI 201-106; Positive inotropy; (Enantiomers) (Hoey, A. (231) 477)

**Beating frequency**
Adenosine; ANP (atrial natriuretic peptide); Hormone secretion (Uusimaa, P.A. (242) 199)

**Behaviour**
Ipsapirone; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-$HT_{1A}$ receptors; 5-$HT_2$ receptors; Anxiolysis; Glucose; Corticosterone; Prolactin (Baudrie, V. (231) 395)

Epilepsy; NMDA (N-methyl-D-aspartate); Valproate; MK-801; CGP 37849 (Löscher, W. (234) 237)

Neuroactive steroids; Drug discrimination; Benzodiazepines; Pentobarbital; Ethanol (Ator, N.A. (241) 237)

**Behavioural activity**
U-50,488H; Tolerance; Abstinence; Dopamine $D_2$ receptors; 2-Bromo-$\alpha$-ergocryptine (Veeranna, (235) 23)

**Behavioural despair**
Imipramine; Microdialysis; Depression (Rossetti, Z.L. (242) 313)

**Behavioural response**
5-$HT_2$ receptor regulation; Phosphoinositide turnover; mRNA levels; Gene transcription (Rinaldi-Carmona, M. (246) 73)

**Behavioural state**
ACTH (adrenocorticotropic hormone); $\alpha$-MSH ($\alpha$-melanocyte-stimulating hormone); Grooming; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

**Behavioural supersensitivity**
Dopamine receptors; Stereotypies; Autoradiography (Marin, C. (231) 191)

**Benzamides**
Raclopride; Cerebral glucose metabolism (regional); Neuroleptics (Tarazi, F.I. (232) 71)

**Benzamides (substituted)**
Ventral tegmental area; Substantia nigra pars compacta; (Repeated treatment) (Skarsfeldt, T. (240) 269)

**Benzene 1,2,4-trisphosphate**
Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate receptors; Inositol 1,4,5-trisphosphate phosphatase; Inositol 1,4,5-trisphosphate kinase; $Ca^{2+}$ mobilization (Poitras, M. (244) 203)

**Benzo[a]pyrene**
Cytochrome P450 1A1 (human); Cytochrome P450 1A1 recombinant expression vector; V79 Chinese hamster cells; Polycyclic aromatic hydrocarbons (Schmalix, W.A. (248) 251)

**Benzodiazepine antagonism**
Melatonin; Diazepam; Anxiolysis; Exploratory behaviour; (Time-dependent effects) (Golombek, D.A. (237) 231)

**Benzodiazepine receptor agonists**
Benzodiazepine receptor antagonists; Inverse agonists; Hypothermia (Tang, A.H. (236) 1)

**Benzodiazepine receptor antagonists**
Benzodiazepine receptor agonists; Inverse agonists; Hypothermia (Tang, A.H. (236) 1)

**Benzodiazepine receptors**
SPECT (single photon emission tomography); [$^{123}$I]Iomazenil (Laruelle, M. (230) 119)

Visual cortex (human); Autoradiography; CL218872 (March, D. (236) 333)

DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA release; GABA turnover; $GABA_A$ receptors; (Rat) (Watabe, S. (238) 303)

$GABA_A$ receptor-ionophore complex; Agonists/inverse agonists (Partial and full); [$^{35}$S]TBPS binding (t-butylbicyclophosphoro[$^{35}$S]thionate); Allosteric regulation of efficacy (Maksay, G. (246) 255)

**Benzodiazepines**
GABA (γ-aminobutyric acid); CNS (central nervous system) depressants; Seizure tolerance; Receptor coupling; $Cl^-$ channels (Chang, Y.-F. (233) 209)

Acetylcholine release; Hippocampus (Imperato, A. (238) 135)

Neuroactive steroids; Behaviour; Drug discrimination; Pentobarbital; Ethanol (Ator, N.A. (241) 237)

$GABA_A$ receptor; Ro15-4513; Flunitrazepam (Duncalfe, L.L. (246) 141)

$GABA_A$ receptor complex; TBPS (*t*-butylbicyclophosphorothionate) binding; $Cl^-$ uptake (Finn, D.A. (247) 233)

Tolerance; $Cl^-$ flux; Flurazepam; Bretazenil; Clonazepam; Diazepam (Li, M. (247) 313)

**Benzodiazepine withdrawal**
$5\text{-}HT_3$ receptors; Anxiety (File, S.E. (237) 127)

**Benzofuran analogue of naltrindole**
δ-Opioid receptor subtypes; [D-$Ala^2$]deltorphin II; [D-$Pen^2$,D-$Pen^5$]enkephalin; Naltrindole; Antitussive activity (Kamei, J. (234) 117)

**Benzomorphans**
κ-Opioid receptors; Antinociception; Arylacetamides; (Mouse) (Horan, P.J. (239) 93)

**Benzomorphan-type σ receptor**
σ Receptor ligands; Neurogenic twitch contraction; ATP transmission; Vas deferens (mouse); Brain (guinea-pig); SK&F 10,047 (N-allylnormetazocine); Rimcazole; Haloperidol (Matsuno, K. (231) 451)

**Bergmann glia**
AMPA/kainate receptors; Glutamate (Cid, M.E. (245) 51)

**Bezold-Jarisch reflex**
$5\text{-}HT_3$ receptors; [$^3$H]Zacopride; [$^3$H]Granisetron; [$^{14}$C]Guanidinium; Ileum; Turning behaviour; Cortical firing rate; (Ex vivo binding) (Bachy, A. (237) 299)

**BFG (4-amino-3-benzo(b)furan-2-yl-butanoic acid)**
GABA (γ-aminobutyric acid); Baclofen; MBFG (4-amino-3-(5-methoxybenzo(b)furan-2-yl) butanoic acid); Spinal cord; Antinociception (Hammond, D.L. (229) 227)

**BIBN 99**
Muscarinic $M_2$ receptor antagonist; Muscarinic receptors ($M_1$–$M_3$, m1–m5); AF-DX 116 (Doods, H. (242) 23)

**Bicarbonate secretion**
Neuropeptide Y (NPY); σ Receptors; CCK (cholecystokinin); Duodenum; (Rat) (Pascaud, X.B. (231) 389)

**Bifemelane**
Somatostatin; Neuropeptide Y; l-DOPA (l-dihydroxyphenylalanine); Amantadine; 6-Hydroxydopamine (Maeda, K. (233) 227)

**Big endothelin-1**
Endothelin-converting enzyme; Big endothelin-3; Phosphoramidon; Endothelin; Hemodynamics; (Rat) (Pollock, D.M. (231) 459)

Big endothelin-3; Phosphoramidon; Microcirculation; Cheek pouch (hamster); Skin blood flow (rat) (Lawrence, E. (233) 243)

Endothelin-1; Endothelin-3; Endothelin $ET_A$ receptor; BQ-123; Phosphoramidon; Endothelin-converting enzyme; Uterus (rat) (Rae, G.A. (240) 113)

Endothelin-1; Conversion; Mesentery (Hisaki, K. (241) 75)

**Big endothelin-3**
Endothelin-3; Hypertensive effect; Phosphoramidon; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

Endothelin-converting enzyme; Big endothelin-1; Phosphoramidon; Endothelin; Hemodynamics; (Rat) (Pollock, D.M. (231) 459)

Big endothelin-1; Phosphoramidon; Microcirculation; Cheek pouch (hamster); Skin blood flow (rat) (Lawrence, E. (233) 243)

**Bile**
Hypocholesterolemic drugs; Liver; Cholesterol; Lipoproteins (Clerc, T. (235) 59)

**Bile acid**
Cloning; Loop diuretics; Bumetanide (transport); Organic anions; Sinusoidal plasma membrane; Liver (rat) (Honscha, W. (246) 227)

**σ Binding**
Cytochrome P450; Brain; Liver; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); (Dark Agouti rat) (Jewell, A. (243) 249)

**Binding assays**
Neuropeptide Y; Neuropeptide Y receptor sub-types; Truncated analogues; Structure-activity relationships; Bioassays (Dumont, Y. (238) 37)

**Binding (in vitro)**
Dopamine neuronal carrier; Membrane polarity; [$^3$H]GBR 12783; Striatum (rat) (Billaud, G. (247) 333)

**σ Binding sites**
DTG (1,3-di-(2-tolyl)guanidine); Antipsychotics; d,l-Amphetamine; Dizocilpine; Animal models; (Rat) (Rückert, N.G.H. (233) 261)

DTG (1,3-di-o-tolylguanidine); Imipramine; Striatum; Hippocampus; 5-HT (5-hydroxytryptamine, serotonin) (Shirayama, Y. (237) 117)

FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol); Radiolabeled ligand binding; (+)-SKF10,047; Stereotyped behaviour (Tanaka, M. (238) 89)

FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride); Radiolabeled ligand binding; Brain (guinea-pig) (Tanaka, M. (238) 93)

Haloperidol; Dextromethorphan; Phenytoin; DTG (1,3-di-o-tolylguanidine); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl) piperidine) (Bailey, M.A. (240) 243)

**Bioassays**
Neuropeptide Y; Neuropeptide Y receptor sub-types; Truncated analogues; Structure-activity relationships; Binding assays (Dumont, Y. (238) 37)

**Biphasic displacement**
Dopamine $D_2$ receptors; Antipsychotics; Neuroleptics; [$^3$H]YM-09151-2; Dopamine $D_2$ receptor binding (Assié, M.-B. (237) 183)

**Bisaramil**
Antiarrhythmic agents (class I); Arrhythmia (ventricular) (Haruno, A. (233) 1)

**Bladder**
Ontogeny; $Ca^{2+}$ channel antagonists; Dihydropyridine; Urethra (Yoshida, M. (232) 159)

**Bladder (rabbit, hamster)**
Tachykinin; Neurokinin A; Neurokinin receptor subtypes; Tachykinin receptor antagonists (Guard, S. (232) 287)

Tachykinin; Neurokinin A; Neurokinin receptor subtypes; Tachykinin receptor antagonists (Guard, S. (236) 496)

**Bleeding**
Glycosphingolipids; Lysogangliosides; Platelet aggregation; Thrombin; 5-HT (5-hydroxytryptamine, serotonin); Tromboxane $B_2$; Coagulation; Fibrinolysis (Tubaro, E. (248) 175)

**Blood-brain barrier**
Tryptophan; $5\text{-HT}_{1C}$ /$5\text{-HT}_2$ receptors; Sympathetic nervous system; Immobilization stress (Chaouloff, F. (231) 77)

**Blood flow**
Peptic ulcers; Nitric oxide (NO); L-Arginine; Glyceryl trinitrate healing (Konturek, S.J. (239) 215)

Nitric oxide (NO); Afferent nerves; Pulp; Oral mucosa; Lip; Submandibular gland (Kerezoudis, N.P. (241) 209)

**Blood pressure**
Endothelin; Clonidine; Heart rate; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

Spontaneously hypertensive rat (SHR); Imipramine; Clonidine; Centhaquin; Central nervous system (CNS); 5-HT uptake sites (Gulati, A. (231) 151)

Nitrate vasodilators; Phosphodiesterase inhibitors; Zaprinast; $N^{\omega}$-Nitro-L-arginine; L-Arginine; Acetylcholine; Bradykinin (De Garavilla, L. (234) 77)

Spinal reflexes; Descending inhibition; $\alpha_2$-Adrenoceptors; Imidazoline binding sites (Harris, J. (237) 323)

Taurine release; Posterior hypothalamus; Veratridine; Tetrodotoxin; Push-pull cannula (Singewald, N. (240) 21)

Dopamine receptors; Locomotor activity; Turning behaviour; Yawning; Pressor response; Body temperature; Spontaneously hypertensive rats (SHR) (Van den Buuse, M. (243) 169)

**Blood pressure (rat)**
Adrenomedullin; cAMP; Vasodilation (Ishiyama, Y. (241) 271)

**Blood pressure (systolic)**
5-Carboxamidotryptamine; $5\text{-HT}_1$ receptor agonists; Spontaneously hypertensive rats (SHR); Baroreflex sensitivity; (Chronic infusion) (Balasubramaniam, G. (237) 207)

**Blood vessel (human)**
Neuropeptide Y; Antisense; Neuropeptide Y $Y_1$ receptor (Erlinge, D. (240) 77)

**Blood vessels**
Contractions; 5-HT (5-hydroxytryptamine, serotonin); Lipoxygenase products; Atherosclerosis; (Interaction) (Van Diest, M.J. (231) 267)

Neuropeptide Y; Neuropeptide $Y_1$ receptors; Neuropeptide $Y_2$ receptors; Vascular neuropeptide Y receptors; Vas deferens (Grundemar, L. (232) 271)

**BMY 7378**
5-HT (5-hydroxytryptamine, serotonin); $5\text{-HT}_{1A}$ receptors; Raphe; S 15535; NAN-190; Spiperone (Millan, M.J. (230) 99)

**BN-52021**
Alprazolam; Endothelin; Mesangial cells; Proliferation; PAF (platelet-activating factor, PAF-acether) (Montero, A. (243) 235)

**pBNP-32 (porcine brain natriuretic peptide-32)**
Electroconvulsive shock; Amnesia; (Receptor blockers) (Bidzseranova, A. (232) 305)

**BNTX (7-benzylidenenaltrexone)**
[$Leu^5$]enkephalin; [$Met^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; Naltriben; Spinal cord; Brain; $\beta$-Endorphin (Takemori, A.E. (242) 145)

**Body temperature**
Dynorphin A-(1–13); Nor-binaltorphimine; Memory; Ischemia; (Mouse) (Itoh, J. (234) 9)

Dopamine receptors; Locomotor activity; Turning behaviour; Yawning; Blood pressure; Pressor response; Spontaneously hypertensive rats (SHR) (Van den Buuse, M. (243) 169)

**Bombesin**
Gastrin-releasing peptide; Neuromedin B (Ladenheim, E.E. (235) 121)

Gastrin-releasing peptide (GRP); Phyllolitorin; Scratching behaviour; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

Gastrin-releasing peptide; Neuromedin B; Bombesin receptors (Guard, S. (240) 177)

Endothelin receptor model; Diethylpyrocarbonate; Chemical modification (Huggins, J.P. (245) 203)

**Bombesin receptors**
Bombesin; Gastrin-releasing peptide; Neuromedin B (Guard, S. (240) 177)

**Bone cells**
Colchicine; Vinblastine; Blood $Ca^{2+}$; Microtubules (Ohya, K. (248) 111)

**I-BOP (1S-(1α,2α(Z),3β(1(E),3S),4α)-7-(3-(3-hydroxy-4-(4-iodophenoxy)-1-butenyl)-7-oxabicyclo(2,2,1)hept-2-yl-5-heptenoic acid)**
Thromboxane receptors; Thromboxane receptor antagonists; BAY u3405; Lung strip; U46619 (Norman, P. (229) 171)

**BQ-123**
Endothelin; [$Ala^{1,3,11,15}$]endothelin-1; Bronchoconstriction; Hypertension; (Receptor subtype) (Noguchi, K. (233) 47)

Endothelin-1; Endothelin $ET_A$ receptors; Prostacyclin; Platelet aggregation (Hermán, F. (236) 143)

Endothelin-1; Sarafotoxin S6b; Endothelin $ET_A$ receptor; Saphenous vein (human) (Bax, W.A. (239) 267)

Big-endothelin-1; Endothelin-1; Endothelin-3; Endothelin $ET_A$ receptor; Phosphoramidon; Endothelin-converting enzyme; Uterus (rat) (Rae, G.A. (240) 113)

FR139317; Endothelins; Sarafotoxins; Endothelin receptors; Iliac artery (guinea-pig) (Schoeffter, P. (241) 165)

Coronary arteries; Endothelin; Neuropeptide Y; Nitric oxide (NO); $ET_A$ receptor; $ET_B$ receptor (Pernow, J. (243) 281)

Endothelin; Endothelin $ET_A$ receptor; Brain capillary; Endothelial cell (Vigne, P. (245) 229)

**[$^{125}$I]BQ-3020**
Autoradiography; Endothelin; Endothelin $ET_B$ receptors; Lung (porcine) (Kobayashi, M. (235) 95)

**Bradycardia**
$N^G$-Nitro-L-arginine; Ethanol; Angiotensin II; Noradrenaline; Vasopressor; Baroreflex (Wang, Y.-X. (233) 275)

Doridosine (1-methylisoguanosine) derivatives; Competition binding studies; Adenosine $A_1$ receptors; Adenosine $A_2$ receptors; (Rat) (Tao, P.-L. (243) 135)

**Bradycardiac agents**
Sinus node inhibitors; Zatebradine; Pacemaker currents; Purkinje fibres; Iontophoresis; Use-dependent blockade; (Electrophysiology) (Van Bogaert, P.P. (229) 55)

**Bradykinin**
Asthma; Edema; Plasma exudation; Airway obstruction; Vascular permeability; OKY-046; Indomethacin (Arakawa, H. (229) 131)

Allergen; CP-96,345; Airway microvascular leakage; $NK_1$ receptors; Substance P (Sakamoto, T. (231) 31)

Poststatin; Degradation pathway; Urine; Kininase (Majima, M. (232) 181)

Nitrate vasodilators; Phosphodiesterase inhibitors; Zaprinast; $N^{\omega}$-Nitro-L-arginine; L-Arginine; Acetylcholine; Blood pressure (De Garavilla, L. (234) 77)

Hoe 140; Uterus (rat); G-protein activation; Functional antagonism; (Binding sites) (Liebmann, C. (235) 183)

Hoe 140; Mesenteric vascular bed; Vasodilatation; (Cat) (Santiago, J.A. (236) 315)

Bradykinin $B_1$ receptor; Carotid artery; Endothelium; Nitric oxide (NO) (Pruneau, D. (239) 63)

Histamine; Substance P; Cromakalim; Vascular permeability; Plasma exudation; Airways (Martin, C.A.E. (239) 119)

Bradykinin receptor antagonists; Trachea; Bradykinin binding; (Guinea-pig) (Trifilieff, A. (239) 227)

Active avoidance; Angiotensin; Angiotensin-converting enzyme inhibitor; Diabetes mellitus; Memory; (Mouse) (Flood, J.F. (240) 311)

Mesentery (rat); L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Methylene blue; Capsaicin-sensitive sensory nerves (Yu, X.-j. (241) 35)

HOE 140; Circular muscle; Longitudinal muscle; Ileum (guinea-pig) (Medeiros, Y.S. (241) 157)

Protein kinase C; Prostaglandins; Osteoblasts (Ljunggren, Ö. (244) 111)

Endothelial cells; Fura-2; Angiotensin converting enzyme inhibitor (Hirano, K. (244) 133)

G-protein; Endothelial cells; Nitric oxide (NO); cyclic GMP (Gil-Longo, J. (247) 119)

**Bradykinin binding**
Bradykinin; Bradykinin receptor antagonists; Trachea; (Guinea-pig) (Trifilieff, A. (239) 227)

**Bradykinin $B_1$ receptor**
Bradykinin; Carotid artery; Endothelium; Nitric oxide (NO) (Pruneau, D. (239) 63)

**Bradykinin receptor antagonists**
Bradykinin; Trachea; Bradykinin binding; (Guinea-pig) (Trifilieff, A. (239) 227)

**Brain**
Phenobarbital; Dependence; Glutamate receptors (Short, K.R. (230) 111)

Nitric oxide (NO); Food intake; Zucker rat (Squadrito, F. (230) 125)

NPY receptors; Terminals; [$^3$H]noradrenaline release; (Rat) (Martire, M. (230) 231)

Catechol O-methyltransferase (COMT) inhibition; $Uptake_2$ (central); Dopamine; Dopamine metabolism (Törnwall, M. (239) 39)

[Leu$^5$]enkephalin; [Met$^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Spinal cord; $\beta$-Endorphin (Takemori, A.E. (242) 145)

$\sigma$ Binding; Cytochrome P450; Liver; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); (Dark Agouti rat) (Jewell, A. (243) 249)

Zucker rat; Imidazoline $I_2$ binding sites; $\alpha_2$-Adrenoceptors; [$^3$H]Idazoxan; [$^3$H]Clonidine; [$^3$H]RX821002; Mazindol (Miralles, A. (243) 305)

[$^3$H]Kainate binding; Excitatory amino acid receptors; $Ca^{2+}$; Domoate (Johansen, T.H. (246) 195)

5-HT (serotonin 5-hydroxytryptamine binding proteins); 5-HT (serotonin 5-hydroxytryptamine); Dopamine; Superoxide radicals; Iron ions (Jimenez Del Rio, M. (247) 11)

Gabapentin; Anticonvulsant; L-Amino acids; System-L; Transporter (Thurlow, R.J. (247) 341)

**Brain autoradiography**
[$^3$H]RP 62203 binding sites; $5\text{-}HT_2$ receptor antagonists (Malgouris, C. (233) 37)

**Brain capillary**
Endothelin; BQ-123; Endothelin $ET_A$ receptor; Endothelial cell (Vigne, P. (245) 229)

**Brain gangliosides (bovine)**
1,2-Diacylglycerol; Diacylglycerolipids; Phosphatidic acid; Arachidonoyl-containing molecular species; Diabetic neuropathy (Bianchi, R. (239) 55)

**Brain (guinea-pig)**
$\sigma$ Receptor ligands; Neurogenic twitch contraction; Benzomorphan-type $\sigma$ receptor; ATP transmission; Vas deferens (mouse); SK&F 10,047 (N-allylnormetazocine); Rimcazole; Haloperidol (Matsuno, K. (231) 451)

Autoradiography; 5-$HT_{1E}$/5-$HT_{1F}$ recognition sites; Brain (rat) (Beer, M.S. (236) 167)

$\sigma$ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylamino-ethyl)carbazol monohydrochloride); Radiolabeled ligand binding (Tanaka, M. (238) 93)

**Brain (human)**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Brain (human, post-mortem)**
Ergot alkaloids; Anticonflict activity; [$^3$H]Muscimol binding; (Rat) (Peričić, D. (235) 267)

**Brain, in vitro (rat)**
Dopamine release; Glutamate receptors; Olfactory tubercle; Frontal cortex; Striatum (Jones, C.A. (242) 183)

**Brain metal levels**
Lead acetate; Cadmium chloride; Hypothermia; Environmental temperature (Martínez, F. (248) 199)

**Brain microdialysis**
Adenosine (extracellular); Striatum; Anaesthesia; Tetrodotoxin; NMDA receptors (Pazzagli, M. (234) 61)

**Brain neurons**
Tributyltin; Triethyltin; Trimethyltin; Intracellular $Ca^{2+}$; Cytotoxicity (Oyama, Y. (248) 89)

**Brain (primate)**
SPECT (single photon emission computed tomography); 5-HT (5-hydroxytryptamine, serotonin) (Jagust, W.J. (242) 189)

**Brain (rat)**
VIP (vasoactive intestinal polypeptide); VIP-(22–28); Pentylenetetrazole; Seizures (Romualdi, P. (229) 149)

Desipramine; Noradrenaline; Electrochemistry (in vivo); Anteroventral thalamic nucleus; Locus coeruleus (Brun, P. (235) 205)

Ifenprodil; $\sigma$ Receptors; (Subtypes) (Hashimoto, K. (236) 159)

Autoradiography; 5-$HT_{1E}$/5-$HT_{1F}$ recognition sites; Brain (guinea-pig) (Beer, M.S. (236) 167)

[$^3$H]Mesulergine; [$^3$H]Paroxetine; 5-$HT_{1C}$ receptor; 5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake site (Hulihan-Giblin, B.A. (239) 99)

$\alpha_2$-Adrenoceptors; Vas deferens (rat); [$^3$H]UK 14304; [$^3$H]RX 821002; Reserpine (Ugedo, L. (239) 149)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-$HT_{1A}$ autoreceptors (Hjorth, S. (238) 357)

5-$HT_3$ receptor agonists; [$^3$H]meta-Chlorophenylbiguanide; [$^3$H](S)-Zacopride (Steward, L.J. (243) 13)

Dopamine $D_1$ receptors; Dopamine $D_1$ receptor turnover; SCH 23390; N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); Striatum; Substantia nigra (Giorgi, O. (245) 139)

Ethanol; Choroid plexus; 5-$HT_{1C}$ receptors; Phosphoinositide hydrolysis (Pandey, S.C. (247) 81)

NMDA receptor; $Pb^{2+}$; Neurotoxicity; (Age) (Guilarte, T.R. (248) 273)

**Brain (rat and human)**
High-affinity 'R' sites; 5-$HT_3$ receptors; (*R*)-[$^3$H]Zacopride; (*S*)-[$^3$H]Zacopride; Periphery (rat) (Kidd, E.J. (247) 45)

**Brain regions**
Morphine tolerance; G protein expression; In situ hybridization histochemistry; Immunoblot analysis (Parolaro, D. (244) 211)

**Brain regions (rat)**
Cocaine; 5-$HT_{1A}$ receptors; 5-$HT_2$ receptors (Javaid, J.I. (238) 425)

**Brain slices**
p-Chloroamphetamine; p-Methylthioamphetamine; Drug discrimination; Uptake inhibition; Superfusion; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity (Huang, X. (229) 31)

Histamine $H_1$ receptor; Inositol phosphates; $Ni^{2+}$; HeLa cell (Arias-Montaño, J.-A. (245) 221)

**Brain slices (rat)**
Adenylate cyclase; Opioid receptors; Dopamine receptors (Heijna, M.H. (229) 197)

Baclofen; $\beta$-Phenyl-GABA; $GABA_B$ receptors; Ileum (guinea-pig); (Agonist/partial agonist) (Ong, J. (233) 169)

Nitropropane analog of baclofen; Baclofen; $GABA_B$ receptor agonists; Ileum (guinea-pig, isolated); Vas deferens (guinea pig) (Kerr, D.I.B. (236) 239)

**Brain synaptosomes**
Gadolinium; Neomycin; Nimodipine; Verapamil; Voltage-sensitive $Ca^{2+}$ channels (Canzoniero, L.M.T. (245) 97)

**Breathing**
Ventilatory response; $CO_2$; Chemoreflex (central); Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

**Bremazocine**
$\kappa$-Opioid receptors; Dynorphin; Ileum (guinea-pig) (Webster, J.L. (231) 251)

**Bretazenil**
Benzodiazepine; Tolerance; $Cl^-$ flux; Flurazepam; Clonazepam; Diazepam (Li, M. (247) 313)

**BRL 37344**
$\beta_3$-Adrenoceptors; Chronotropism; Inotropism; Heart (dog) (Takayama, S. (231) 315)

**BRL 38227**
Ro 31-6930; Bronchoconstriction; Cholinergic; Neurotransmission (Gater, P.R. (238) 59)

**2-Bromo-α-ergocryptine**
U-50,488H; Tolerance; Abstinence; Dopamine $D_2$ receptors; Behavioural activity (Veeranna, (235) 23)

**Bromocriptine**
Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Dopamine $D_2$ receptor agonists; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

Parkinsonism; Rotational behaviour; 6-Hydroxydopamine; SK&F-77434; Cocaine (Silverman, P.B. (242) 31)

**Bronchial anaphylaxis**
CR 2039; Antiallergic compounds; Passive cutaneous anaphylaxis; Lung phosphodiesterase; (Guinea-pig) (Revel, L. (229) 45)

**Bronchial hyperresponsiveness**
S-1452 (calcium (1R,2S,3S,4S)-(5Z)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate); Thromboxane $A_2$; Lipopolysaccharide; TNF (tumor necrosis factor) (Arimura, A. (231) 13)

Capsaicin; Neonatal treatment; Allergen (Riccio, M.M. (232) 89)

9α,11β-Prostaglandin $F_2$; Thromboxane $A_2$ receptor antagonists (Kurosawa, M. (238) 335)

**Bronchi (rat)**
5-HT (5-hydroxytryptamine, serotonin); α-Methyl-5-hydroxytryptamine; 5-$HT_2$ receptors; Ketanserin; Mianserin; Spiperone; Electrical field stimulation; Cholinergic nerves (Szarek, J.L. (231) 339)

**Bronchoconstriction**
Endothelin; [$Ala^{1,3,11,15}$]endothelin-1; BQ-123; Hypertension; (Receptor subtype) (Noguchi, K. (233) 47)

5-Lipoxygenase; Leukotriene; Trachea; Asthma; (Guinea-pig) (Heaslip, R.J. (234) 247)

CS-518; Thromboxane synthase inhibitors; Asthmatic model; Hyperresponsiveness (Yamaguchi, T. (236) 43)

Capsazepine; Citric acid; Capsaicin; Histamine; pH (low) (Satoh, H. (236) 367)

Ro 31-6930; BRL 38227; Cholinergic; Neurotransmission (Gater, P.R. (238) 59)

Dexamethasone; Endothelin-1; Bronchorelaxation (Filep, J.G. (240) 315)

PAF (platelet-activating factor); Seminal vesicle protein; Hypotension; Gastric mucosal injury (Persico, P. (241) 71)

**Bronchorelaxation**
Dexamethasone; Endothelin-1; Bronchoconstriction (Filep, J.G. (240) 315)

**Brown adipose tissue**
Metformin; Zucker rat; Genetic obesity; Thermogenesis; Uncoupling protein (Rouru, J. (246) 67)

**Bufodienolides**
$Na^+$,$K^+$-ATPase inhibition; Vasoconstriction (Bagrov, A.Y. (234) 165)

Toad venom; Arenobufagin; $Na^+/K^+$ pump current (Cruz, J.d.S. (239) 223)

**Bulbo-spinal noradrenergic system**
L-Tyrosine (methyl ester); Antinociception; δ-Opioid receptors (Kawabata, A. (233) 255)

**Bumetanide (transport)**
Cloning; Loop diuretics; Organic anions; Sinusoidal plasma membrane; Liver (rat); Bile acid (Honscha, W. (246) 227)

**Bupivacaine**
Local anesthetics; $K^+$ channel; Glibenclamide; *Xenopus laevis* oocyte; Calmodulin (Yoneda, I. (247) 267)

**Burst firing**
$α_1$-Adrenoceptors; Idazoxan; Noradrenaline; Reserpine (Grenhoff, J. (233) 79)

**Buspirone**
Glucose utilization; Hippocampus; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

Anxiety; Chronic treatment; 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; 5-$HT_{1A}$ receptors; Microdialysis (in vivo); (Rat) (Söderpalm, B. (239) 69)

5-$HT_{1A}$ receptor agonists; 8-OH-DPAT; $α_1$-Adrenoceptor subtypes; Aorta (rabbit); (8-hydroxy-2(di-N-propylamino)tetralin) (Castillo, C. (241) 141)

5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake; Stress; Tianeptine; Diazepam (Mennini, T. (241) 255)

**2,3-Butanedione monoxime**
Excitation-contraction uncoupling; Sarcolemma hyperexcitability; Dantrolene; Depolarization contractures; Caffeine contracture; Diaphragm (rat) (Røed, A. (241) 229)

**Butorphanol dependence**
Nor-binaltorphimine; κ-Opioid receptors; Naloxone-precipitated withdrawal (Jaw, S.P. (239) 133)

Naltrindole; δ-Opioid receptor; Supraspinal δ-opioid receptor; Naloxone-precipitated withdrawal (Jaw, S.P. (240) 67)

**Butylated hydroxyanisole**
Gut musculature toxicity; (Intraperitoneal administration) (Sgaragli, G.P. (248) 121)

**BW 373U86**
Opioids; δ-Opioid receptors; Guanine nucleotides; Radioligand binding (Wild, K.D. (246) 289)

**$Ca^{2+}$**
Acetylcholine release; Cetiedil; Cholinergic synapses; Mediatophore; (*Torpedo marmorata* synaptosomes) (Moulian, N. (231) 407)

Femoral artery; Fura-2/AM; Inositol phosphates; Isometric contraction; Ketamine; (Rabbit) (Ratz, P.H. (236) 433)

1,4-Dihydropyridine (enantiomers); $K^+$; pH; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

Tetrandrine; Smooth muscle (vascular); Saphenous vein (dog); Excitation-contraction (Kwan, C.-Y. (238) 431)

Cardiotonic agent; Phosphodiesterase inhibitor; Thoracic aorta (rat); cAMP (Itoh, H. (240) 57)

Nitric oxide (NO); Platelet aggregation (Ivanova, K. (244) 37)

Angiotensin II; Protein kinase C; Isoenzymes; Inositol 1,4,5-trisphosphate ($InsP_3$); Diacylglycerol; Mesangial cells (Ochsner, M. (245) 15)

cGMP analog; Platelet aggregation; Nitric oxide (NO) (Menshikov, M.Y. (245) 281)

$\alpha_1$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Noradrenaline; Chloroethylclonidine; cAMP; Hepatocyte (Rat) (Nomura, T. (246) 113)

[$^3$H]Kainate binding; Excitatory amino acid receptors; Domoate; Brain (Johansen, T.H. (246) 195)

Aminoglycoside; Membrane permeability; Calcein; $Mn^{2+}$; Conformational analysis (Van Bambeke, F. (247) 155)

ATP; 5′-Nucleotide receptor; HeLa cells; fura-2 (Smit, M.J. (247) 223)

$Ca^{2+}$ channels; $Ca^{2+}$ channel antagonists; ω-Conotoxin; ω-Agatoxin IVA; Small cell lung carcinoma cells; Proliferation (Cattaneo, M.G. (247) 325)

Ethanol; Gall bladder; Smooth muscle; Tolerance (Masui, H. (248) 103)

Ethanol; Cerebral arteries; $Mg^{2+}$; (Dog); (Sheep); (Piglet); (Baboon) (Zhang, A. (248) 229)

**$Ca^{2+}$-activated chloride conductance**
NPPB (5-nitro-2-(3-phenylpropylamino)-benzoic acid); Fluorescence microscopy (single cell); Vasopressin; Phosphatidylinositol metabolism; Smooth muscle (Pon, D.J. (245) 119)

**$Ca^{2+}$-activated $K^+$ channels**
Hepatocytes; Nicotinic receptors; Dequalinium; Vecuronium; Apamin (Castle, N.A. (236) 201)

Voltage-dependent $Ca^{2+}$ channels; Transmembrane $Ca^{2+}$ influx; Arterial myogenic tone; Spontaneously hypertensive rats (SHR); (Early hypertensive stages) (Asano, M. (247) 295)

**$Ca^{2+}$ (blood)**
Colchicine; Vinblastine; Bone cells; Microtubules (Ohya, K. (248) 111)

**$Ca^{2+}$/calmodulin independent cyclic adenosine monophosphate selective phosphodiesterase**
Autoradiography; Dopamine $D_1$ receptors; Rolipram receptor; Cerebral ischemia; SCH 23390; Pentobarbital; (Gerbil) (Kanai, Y. (248) 191)

**$Ca^{2+}$ channel activators**
Dihydropyridines; $Ca^{2+}$ channels; Ventral medullary surface; Respiration; Opioids (endogenous) (Ruiz, F. (240) 155)

**$Ca^{2+}$ channel agonists**
Thaliporphine; Vasoconstrictors; Thoracic aorta (rat) (Teng, C.-M. (233) 7)

PCA 50941; Bay k 8644; Dihydropyridines (Priego, J. (243) 25)

**$Ca^{2+}$ channel antagonists**
Ventricular fibrillation; Myocardial ischemia; Myocardial infarction; Cardiac arrhythmias (Billman, G.E. (229) 179)

Flunarizine; Voltage dependence; Adrenal medulla; Catecholamine secretion (De la Fuente, M.-T. (229) 189)

AJ-2615; Ion channels; (Neurons); (Snail) (Liu, G.J. (231) 91)

$\alpha_1$-Adrenoceptor antagonists; Aorta (rat); Aporphines; Phosphodiesterase inhibitors (Ivorra, M.D. (231) 165)

Ontogeny; Dihydropyridine; Urethra; Bladder (Yoshida, M. (232) 159)

Gall-bladder (guinea-pig); (Skinned gall bladder) (Cejalvo, D. (234) 23)

Smooth muscle (arterial); 5-HT (5-hydroxytryptamine, serotonin); Cerebral arteries (Clark, A.H. (235) 113)

Carbachol; Histamine; Verapamil; GS 283; Trachealis (Chang, K.C. (236) 51)

MPC-1304; 1,4-Dihydropyridines; Vasodilating action (Miyoshi, K. (238) 139)

Congestive heart failure; $\alpha_1$-Adrenoceptor activation pathways; Dorsal pedal artery; Saphenous vein (Forster, C. (242) 119)

Smooth muscle (vascular); Proliferation (Agrotis, A. (244) 269)

Voltage-operated channel; Smooth muscle; Heart; SR 33805 (Chatelain, P. (246) 181)

$Ca^{2+}$; $Ca^{2+}$ channels; ω-Conotoxin; ω-Agatoxin IVA; Small cell lung carcinoma cells; Proliferation (Cattaneo, M.G. (247) 325)

**$Ca^{2+}$ channel blockers**
Glutamate; Cerebellar slices (Dickie, B.G.M. (229) 97)

Digoxin; Intestinal absorption; (Guinea-pig) (Budihna, M.V. (230) 301)

Cytosolic $Ca^{2+}$ levels; Felodipine; Nifedipine; Verapamil; Smooth muscle; Aorta (rat); (Relaxation) (Hagiwara, S. (234) 1)

**$Ca^{2+}$ channel blocking agents**
Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; $Na^+$ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

**$Ca^{2+}$ channel inhibitors**
Verapamil; d-Amphetamine; Reinforcement; Place preference conditioning (Pucilowski, O. (240) 89)

**$Ca^{2+}$ channels**
Alcohols; Synaptosomes; Longitudinal muscle; [$^3$H]Nitrendipine; [$^{125}$I]ω-Conotoxin (Hawthorn, M.H. (229) 143)

Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Contraction; Thaliporphine; Ileum (guinea-pig) (Yu, S.-M. (234) 121)

5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Synaptosomes; d-Fenfluramine (Gobbi, M. (238) 9)

Exocytosis; Glutamate; Aspartate; GABA (γ-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

Dihydropyridines; $Ca^{2+}$ channel activators; Ventral medullary surface; Respiration; Opioids (endogenous) (Ruiz, F. (240) 155)

Adrenal medulla; Chromaffin cell; Histamine; Catecholamine release; $Ca^{2+}$ (intracellular) (Borges, R. (241) 189)

Vasorelaxation; Portal hypertension; Portal vein; Mesenteric artery; (Rat) (Suga, T. (242) 129)

Cyclopiazonic acid; Ryanodine; Smooth muscle; $Ca^{2+}$ stores; Whole-cell voltage clamp (Gagov, H.S. (243) 19)

Sympathetic ganglion; Nitric oxide (NO); Norepinephrine; Voltage-clamp; Patch-clamp (Chen, C. (243) 83)

Smooth muscle (vascular); Prostaglandins; Protein kinase C; Norepinephrine; Dihydropyridine (Rapoport, R.M. (243) 207)

$\alpha_2$-Adrenoceptors; Muscarinic receptors; Heterologous desensitization; GTP-binding proteins; ADP ribosylation (Nah, S.-Y. (244) 67)

$Ca^{2+}$; $Ca^{2+}$ channel antagonists; ω-Conotoxin; ω-Agatoxin IVA; Small cell lung carcinoma cells; Proliferation (Cattaneo, M.G. (247) 325)

**$Ca^{2+}$ channels (L-type)**
Taurine; $Ca^{2+}$ channels (T-type); Cardiac myocytes; Heart cells (embryonic chick); Voltage clamp (whole cell); Electrophysiology (Satoh, H. (231) 443)

Gold ion; Perchlorate; Skeletal muscle contraction; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

**$Ca^{2+}$ channels (T-type)**
Taurine; $Ca^{2+}$ channels (L-type); Cardiac myocytes; Heart cells (embryonic chick); Voltage clamp (whole cell); Electrophysiology (Satoh, H. (231) 443)

**$Ca^{2+}$ channels (voltage-sensitive)**
ω-Conotoxin GVIA; *Hololena curta* venom; Funnel web spider toxin; Neurotransmitter release; Autonomic nerves (Lundy, P.M. (231) 197)

Isradipine; Cerebral ischemia; Dopamine; Microdialysis (Ooboshi, H. (233) 165)

**$Ca^{2+}$ currents**
Heart; Contraction (Harrison, S. (237) 83)

**$Ca^{2+}$ currents (heart)**
Hypertension; Phosphodiesterase inhibitors; Voltage clamp (Scamps, F. (244) 119)

**Cadmium chloride**
Lead acetate; Hypothermia; Environmental temperature; Brain metal levels (Martínez, F. (248) 199)

**$Ca^{2+}$ dynamics**
SK&F 96365; Amylase secretion; Pancreatic acini (Busik, J. (247) 273)

**$Ca^{2+}$ entry blockers**
ANP (atrial natriuretic peptide); Verapamil; Felodipine; Nifedipine; Diuretic effects (Shamiss, A. (233) 113)

MPC-1304; α-Adrenoceptors; (Pithed rat) (Ichihara, K. (238) 283)

**$Ca^{2+}$ entry blocking activity**
MPC-1304; Stereoselectivity; (Metabolites) (Okumura, K. (235) 69)

**Caffeine**
Myocytes (rat ventricular); Whole cell clamping; Depolarization-activated, $Ca^{2+}$-independent outward currents (Sanchez-Chapula, J. (229) 163)

Restraint stress; Analgesia; Morphine; NECA (5′-(N-ethyl)carboxamido-adenosine); Opioids (Woolfolk, D.R. (239) 177)

**Caffeine contracture**
2,3-Butanedione monoxime; Excitation-contraction uncoupling; Sarcolemma hyperexcitability; Dantrolene; Depolarization contractures; Diaphragm (rat) (Røed, A. (241) 229)

**Caffeine-sensitive $Ca^{2+}$ store**
Fluorescence microscopy of intracellular $Ca^{2+}$; Fura-2 fluorescence; Muscarinic receptor; $IP_3$-sensitive $Ca^{2+}$ store; Neurotransmitter receptor desensitization (Fohrman, E.B. (245) 263)

**27-O-Caffeoyl myricerone (50-235)**
Endothelin receptor antagonist; Cytosolic free $Ca^{2+}$; Mitogenesis; Smooth muscle cell (aorta, rat); Girardi heart cell (human) (Mihara, S.-i. (246) 33)

Structure-activity relationship; Endothelin receptor antagonist; [$^{125}$I]Endothelin-1 binding; Cytosolic free $Ca^{2+}$ (Mihara, S.-i. (247) 219)

**$Ca^{2+}$ indicators**
Endothelial cells; Prostacyclin; Aorta (bovine); Arachidonate metabolism (Boeynaems, J.-M. (233) 13)

**$Ca^{2+}$ influx**
Cisplatin; Catecholamine secretion; Adrenal chromaffin cells; Acetylcholine (Tachikawa, E. (236) 355)

Smooth muscle (vascular); $A_7r_5$ cells; Lacidipine; Amlodipine; 1,4-Dihydropyridines (Spampinato, S. (244) 139)

Neomycin; Dihydropyridine drugs; $Ca^{2+}$ (intracellular); Catecholamine release; Adrenal medulla chromaffin cells (Duarte, C.B. (244) 259)

**$Ca^{2+}$ (intracellular)**
Adrenal medulla; Chromaffin cell; Histamine; Catecholamine release; $Ca^{2+}$ channels (Borges, R. (241) 189)

Neomycin; Dihydropyridine drugs; $Ca^{2+}$ influx; Catecholamine release; Adrenal medulla chromaffin cells (Duarte, C.B. (244) 259)

Tributyltin; Triethyltin; Trimethyltin; Brain neurons; Cytotoxicity (Oyama, Y. (248) 89)

**$Ca^{2+}$ (intracellular free)**
SR 47436; Cardiomyocytes (neonatal rat); Angiotensin II; Angiotensin $AT_1$ receptors (Delisée, C. (247) 139)

**$Ca^{2+}$ ion channels**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_1$-like receptors; 5-$HT_2$ receptors; Gastroepiploic artery (simian) (Noguchi, M. (234) 101)

**Calcein**
Aminoglycoside; Membrane permeability; $Mn^{2+}$; $Ca^{2+}$; Conformational analysis (Van Bambeke, F. (247) 155)

**$Ca^{2+}$ levels (cytosolic)**
Endothelin-3; $ET_B$ receptors; Endothelium-dependent relaxation; Vascular (rat aorta); (Relaxation) (Sudjarwo, S.A. (229) 137)

**Calmodulin**
Trifluoperazine; Glucose uptake; Insulin; Skeletal muscle (Guarner, V. (237) 139)

Local anesthetics; Bupivacaine; $K^+$ channel; Glibenclamide; *Xenopus laevis* oocyte (Yoneda, I. (247) 267)

**Calorimetry (indirect)**
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Insulin; Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

**$Ca^{2+}$ mobilization**
Thapsigargin; Ryanodine; Smooth muscle (vascular) (Low, A.M. (230) 53)

Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate receptors; Inositol 1,4,5-trisphosphate phosphatase; Inositol 1,4,5-trisphosphate kinase; Benzene 1,2,4-trisphosphate (Poitras, M. (244) 203)

**$Ca^{2+}$ mobilization (intercellular)**
CCK-8 (cholecystokinin-8); CCK (cholecystokinin) analog; $CCK_B$ receptor; Jurkat T cells (Lignon, M.-F. (245) 241)

**$^{45}Ca^{2+}$ movements**
(S)-Nafenodone; Aorta (rat); Antidepressants (Pérez-Vizcaíno, F. (232) 105)

Dotarizine; Aorta; Basilar smooth muscle; (Rabbit) (Tejerina, T. (239) 75)

**Cancer chemotherapy**
Cyclosporin A; FK506; Multidrug resistance; P-glycoprotein; Rapamycin (Hoof, T. (246) 53)

**Candoxatrilat**
Neutral endopeptidase inhibition; ANF (atrial natriuretic factor); Volume expansion; cGMP (Scott, J.M. (242) 91)

**Cannabinoids**
Tetrahydrocannabinol; Marihuana (Fride, E. (231) 313)

Hippocampus; Inositol phosphates; Phosphatidylinositol (Nah, S.-Y. (246) 19)

**Capsaicin**
Adenosine; Antinociception; Adenosine receptors; Sensory neuropeptides (Santicioli, P. (231) 139)

Bronchial hyperresponsiveness; Neonatal treatment; Allergen (Riccio, M.M. (232) 89)

Sensory nerves; Tracheal hyperreactivity; (Guinea-pig) (Ladenius, A.R.C. (235) 127)

Substance P; Neurokinin A; Airway constriction; Plasma extravasation (Murai, M. (236) 7)

Bronchoconstriction; Capsazepine; Citric acid; Histamine; pH (low) (Satoh, H. (236) 367)

Adenosine; Extrinsic sensory nerves; Myenteric neurons (Takaki, M. (237) 51)

CGRP (calcitonin gene-related peptide); Capsazepine; Cardiac afferents; Lactic acid (Franco-Cereceda, A. (238) 311)

Neurokinin A; $NK_2$ receptor antagonists; Substance P; $NK_1$ receptor antagonists; Lung (guinea-pig) (Kudlacz, E.M. (241) 17)

Substance P; Spantide; Substance P analogues (containing D-His); Formalin; Nociceptive response; Intrathecal injection (Sakurada, T. (242) 47)

Levodropropizine; Substance P; Sensory nerves; Neurogenic inflammation; Plasma extravasation (Yamawaki, I. (243) 1)

**Capsaicin-sensitive afferents**
Isocyanates; Mast cells; Airways (guinea-pig) (Mapp, C.E. (248) 67)

**Capsaicin-sensitive sensory nerves**
Mesentery (rat); Bradykinin; L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Methylene blue (Yu, X.-j. (241) 35)

**Capsazepine**
Bronchoconstriction; Citric acid; Capsaicin; Histamine; pH (low) (Satoh, H. (236) 367)

CGRP (calcitonin gene-related peptide); Capsaicin; Cardiac afferents; Lactic acid (Franco-Cereceda, A. (238) 311)

**Caramiphen**
Iodocaramiphen; Nitrocaramiphen: Muscarinic receptor antagonists; Muscarinic $M_1$ receptors; (Rat) (Hudkins, R.L. (231) 485)

**Carbachol**
Pertussis toxin; Morphine; Substance P; Quinpirole; U-50,488H (Bot, G. (231) 53)

Muscarinic $M_1$ receptors; Muscarinic $M_1$ receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; McN-A-343 (Shannon, H.E. (232) 47)

$Ca^{2+}$ channel antagonists; Histamine; Verapamil; GS 283; Trachealis (Chang, K.C. (236) 51)

Insulin secretion; Islet acid glucan-1,4-$\alpha$-glucosidase; $\alpha$-Glucosidehydrolase inhibition; Emiglitate; Acarbose; Glibenclamide (Salehi, A. (243) 185)

Gastric acid secretion; Xanthine; TRH analog; 2-Deoxy-D-glucose; Vagus; Gastric mucosal blood flow (Tanaka, T. (243) 221)

Muscarinic receptor subtypes; Inositol phosphate turnover (Garcia Ruiz, A.J. (244) 125)

**Carbamazepine**
Cocaine; Dopamine; Nucleus accumbens; Microdialysis; (Rat) (Baptista, T. (236) 39)

**5-Carboxamidotryptamine**
5-$HT_{1D}$ receptors; Turning model; (Autoreceptor) (Moret, C. (230) 379)

Vascular 5-$HT_1$-like receptors; 5-HT (5-hydroxytryptamine, serotonin); (Effect of pre-contraction) (Choppin, A. (231) 469)

5-$HT_1$ receptor agonists; Spontaneously hypertensive rats (SHR); Blood pressure (systolic); Baroreflex sensitivity; (Chronic infusion) (Balasubramaniam, G. (237) 207)

**4-Carboxy-3-hydroxyphenylglycine**
Metabotropic glutamate receptors; (1S,3R)-1-aminocyclopentane-1,3-dicarboxylate (t-ACPD) (Thomsen, C. (245) 299)

**Carboxypeptidase**
Methotrexate; Glutamate; MK-801; Memantine; Neurotoxicity (Weller, M. (248) 303)

**Cardiac afferents**
CGRP (calcitonin gene-related peptide); Capsaicin; Capsazepine; Lactic acid (Franco-Cereceda, A. (238) 311)

**Cardiac arrhythmias**
Nicorandil; Atria (rabbit); Tolbutamide; Quinidine (Le Grand, B. (229) 91)

$Ca^{2+}$ channel antagonists; Ventricular fibrillation; Myocardial ischemia; Myocardial infarction (Billman, G.E. (229) 179)

**Cardiac cells**
Reactive oxygen species; Lipid peroxidation; Reperfusion injury; Electromechanical coupling (Iliou, J.-P. (248) 263)

**Cardiac contractility**
G-protein; Mastoparan (Van Meel, J.C.A. (247) 357)

**Cardiac ischaemia**
$K^+$ channels; Antiarrhythmic drugs; Ventricular fibrillation (Gwilt, M. (236) 107)

**Cardiac muscle**
Flosequinan; Heart failure; Contractility; Phosphodiesterase; (Human) (Weishaar, R.E. (236) 363)

**Cardiac myocytes**
Taurine; $Ca^{2+}$ channels (L-type); $Ca^{2+}$ channels (T-type); Heart cells (embryonic chick); Voltage clamp (whole cell); Electrophysiology (Satoh, H. (231) 443)

Angiotensin II; Angiotensin $AT_1$ receptor antagonists; CV-11974; $[Ca^{2+}]_i$ transient; (Neonatal rat) (Kinugawa, K.-i. (235) 313)

Heart; Contractions; Alcohol (Cannings, I. (248) 213)

**Cardiac ventricular myocytes**
OPC-8212; Action potential duration; $K^+$ currents; Secondary inward current; Veratrine (Lathrop, D.A. (240) 127)

**Cardiomyocytes**
Angiotensin-converting enzyme inhibitors; Lisinopril; Hypoxia; Reoxygenation; Cardioprotection (Rabkin, S.W. (238) 81)

**Cardiomyocytes (neonatal rat)**
SR 47436; Angiotensin II; $Ca^{2+}$ (intracellular free); Angiotensin $AT_1$ receptors (Delisée, C. (247) 139)

**Cardiomyopathy**
Adrenoceptor subtypes; Adenylyl cyclase; CGP 20712A (Witte, K. (247) 215)

**Cardioprotection**
Angiotensin-converting enzyme inhibitors; Lisinopril; Hypoxia; Reoxygenation; Cardiomyocytes (Rabkin, S.W. (238) 81)

NADH fluorescence; Angiotensin; Angiotensin-converting enzyme; Myocardial ischemia; Angiotensin-converting enzyme inhibitors; Ramiprilat (Rump, A.F.E. (241) 201)

**Cardiotonic agent**
Phosphodiesterase inhibitor; $Ca^{2+}$; Thoracic aorta (rat); cAMP (Itoh, H. (240) 57)

**Cardiovascular neurons**
Sympathetic nerve activity; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Lateral tegmental field (Vayssettes-Courchay, C. (236) 121)

Cyanide; Hydrogen ions; GABA (γ-aminobutyric acid); Rostral ventrolateral medulla; (Rat) (Sun, M.-K. (236) 305)

**Carotid artery**
Bradykinin; Bradykinin $B_1$ receptor; Endothelium; Nitric oxide (NO) (Pruneau, D. (239) 63)

**Carotid blood flow**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_1$-like receptors; (Dog) (Villalón, C.M. (240) 9)

**Carrageenan**
Oedema; Ph CL28A; Pleurisy; Prostacyclin; Thromboxane (Santana, A.C. (231) 237)

Fructose 1,6-bisphosphate; Antiinflammatory; Liposome (Planas, M.E. (237) 251)

Phospholipase $A_2$; Pleurisy; Zymosan; Inflammation; Thromboxane $B_2$ (Tesson, F. (248) 27)

**Carrageenin**
Fenspiride; Tumour necrosis factor; Endotoxin; Neutrophil migration (Cunha, F.Q. (238) 47)

**$Ca^{2+}$ sensitivity**
Skinned fibres; Extensor digitorum longus; Soleus; Cyclopiazonic acid (Huchet, C. (241) 41)

**$Ca^{2+}$ stores**
Cyclopiazonic acid; Ryanodine; Smooth muscle; $Ca^{2+}$ channels; Whole-cell voltage clamp (Gagov, H.S. (243) 19)

**Castration**
Sexual behaviour; Ejaculation; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Testosterone; (Wistar rat) (Haensel, S.M. (233) 187)

**Catalepsy**
NMDA (N-methyl-D-aspartate); MK-801; LY274614; SCH23390; Clebopride; Dopamine; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

Morphine; Pertussis toxin; Cholera toxin; cAMP levels (Massi, P. (243) 65)

**Catecholamine overflow (evoked)**
Noradrenaline; Adrenaline; $\beta_2$-Adrenoceptors (prejunctional); Portal vein; (Freely moving rats) (Coppes, R.P. (243) 273)

**Catecholamine release**
Adrenal medulla; Chromaffin cell; Histamine; $Ca^{2+}$ channels; $Ca^{2+}$ (intracellular) (Borges, R. (241) 189)

Neomycin; Dihydropyridine drugs; $Ca^{2+}$ influx; $Ca^{2+}$ (intracellular); Adrenal medulla chromaffin cells (Duarte, C.B. (244) 259)

Nitric oxide (NO) synthase; cGMP; Adrenal medulla; Chromaffin cells (Moro, M.A. (246) 213)

**Catecholamine re-uptake blockers**
Cortex injury; Procholecystokinin mRNA; Sympathetic nervous system (Mondeh, J.D. (240) 39)

**Catecholamines**
Tianeptine; Frontal cortex; Stress; (Rat) (Sacchetti, G. (236) 171)

Glucocorticoid receptors; Adrenal medulla; Phenylethanolamine N-methyltransferase; Nicotine (Betito, K. (238) 273)

**Catecholamine secretion**
Flunarizine; $Ca^{2+}$ channel antagonists; Voltage dependence; Adrenal medulla (De la Fuente, M.-T. (229) 189)

Cobalt ramps; Nicotinic receptors; Adrenal medulla (Montiel, C. (230) 77)

Cisplatin; Adrenal chromaffin cells; Acetylcholine; $Ca^{2+}$ influx (Tachikawa, E. (236) 355)

**Catechol O-methyltransferase inhibition**
$Uptake_2$ (central); Dopamine; Dopamine metabolism; Brain (Törnwall, M. (239) 39)

**Cathartics**
Anthraquinones; Germ-free life; Bacteria (Nijs, G. (239) 241)

**Cathinone**
Conditioned place preference; Dopamine; Locomotion; (Rat) (Schechter, M.D. (232) 135)

**Cationic amino acids**
Lipopolysaccharide; Nitric oxide (NO) (Schott, C.A. (236) 155)

**$Ca^{2+}$ transients**
Trophism; Cultured neurons; Norepinephrine release (Przywara, D.A. (247) 353)

**$[Ca^{2+}]_i$ transient**
Angiotensin II; Angiotensin $AT_1$ receptor antagonists; CV-11974; Cardiac myocytes; (Neonatal rat) (Kinugawa, K.-i. (235) 313)

**Caudate nucleus**
$^{125}$I-Sulpiride; Dopamine $D_2$ receptors; Dopamine $D_3$ receptors; Nucleus accumbens; Olfactory tubercle; (Rat) (Parsons, B. (234) 269)

Cocaine; d-Amphetamine; Hippocampus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

**Caudate-putamen**
Dopamine uptake; Cocaine; $\sigma$ Receptors; Rimcazole; [$^3$H]CFT ([$^3$H]2$\beta$-carbomethoxy-3$\beta$-(4-fluoro-phenyl)-tropane, [$^3$H]WIN 35,428) (Izenwasser, S. (243) 201)

**$^{45}Ca^{2+}$ uptake**
NMDA receptors; Voltage-operated $Ca^{2+}$ channels; Glutamate release; $K^+$ depolarization; Cerebellar granule cells (Didier, M. (244) 57)

**C57Bl/6 mouse**
Parkinson's disease; Locus coeruleus; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatal dopamine; DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) (Marien, M. (236) 487)

**CCK analog**
CCK-8 (cholecystokinin-8); $CCK_B$ receptor; $Ca^{2+}$ mobilization (intercellular); Jurkat T cells (Lignon, M.-F. (245) 241)

**CCK (cholecystokinin)**
Neuropeptide Y (NPY); $\sigma$ Receptors; Bicarbonate secretion; Duodenum; (Rat) (Pascaud, X.B. (231) 389)

$CCK_A$ receptors; Slow depolarization; Sympathetic neurons (mammalian); Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

Nitric oxide (NO); Non-adrenergic, non-cholinergic (NANC) nerves; Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)

Dopamine; Neurotensin; Reward; Ventral tegmental area (Rompré, P.-P. (232) 299)

Clonazepam; Devazepide; L365-260; Duodenum; Jejunum; Motility (Bonnafous, C. (237) 237)

Ceruletide; $CCK_A$ receptors; $CCK_B$ receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

In situ hybridisation; Diazepam; Tolerance; Withdrawal; mRNA (Rattray, M. (245) 193)

**CCK-8 (cholecystokinin-8)**
Neurotensin; Receptor–receptor interaction; Dopamine $D_2$ receptors; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

CCK (cholecystokinin) analog; $CCK_B$ receptor; $Ca^{2+}$ mobilization (intercellular); Jurkat T cells (Lignon, M.-F. (245) 241)

**$CCK_B$/gastrin receptor antagonists**
$CCK_A$ receptor antagonists; Loxiglumide; Pancreatic acini (isolated, rat) (Höcker, M. (242) 105)

**CCK-8 immunoreactivity**
CCK receptor antagonists; $CCK_B$ receptors; Opiate analgesia; Naloxone (Zhou, Y. (234) 147)

**CCK-like decapeptide**
MK-801; Ketamine; Methamphetamine; Ceruletide; Dopamine release; Avoidance behaviour (Kuribara, H. (231) 7)

**CCK receptor antagonists**
CCK-8 immunoreactivity; $CCK_B$ receptors; Opiate analgesia; Naloxone (Zhou, Y. (234) 147)

**$CCK_A$ receptor antagonists**
$CCK_B$/gastrin receptor antagonists; Loxiglumide; Pancreatic acini (isolated, rat) (Höcker, M. (242) 105)

**$CCK_A$ receptors**
SR 27897; Gastric emptying; Gall bladder emptying; Amylase secretion (Gully, D. (232) 13)

Cholecystokinin; Slow depolarization; Sympathetic neurons (mammalian); Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

Ceruletide; CCK (cholecystokinin); $CCK_B$ receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

**$CCK_B$ receptors**
CCK receptor antagonists; CCK-8 immunoreactivity; Opiate analgesia; Naloxone (Zhou, Y. (234) 147)

Ceruletide; CCK (cholecystokinin); $CCK_A$ receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

CCK-8 (cholecystokinin-8); CCK (cholecystokinin) analog; $Ca^{2+}$ mobilization (intercellular); Jurkat T cells (Lignon, M.-F. (245) 241)

**Cell culture**
Hypoxia; Ischemia; Glutamate; Neurotoxicity; ES-242s; MK-801 (Nozawa, M. (236) 263)

Inositol phosphates; Smooth muscle (human airway); Airway receptors (Daykin, K. (246) 135)

**Cell differentiation modulator**
Radicicol; Anti-angiogenic action; Embryonic angiogenesis; Chorioallantoic membrane (Oikawa, T. (241) 221)

**Cell line**
$\alpha_2$-Adrenoceptor subtype; Stable transfection; [$^3$H]Rauwolscine binding; (Antagonist) (Marjamäki, A. (246) 219)

**Cell proliferation**
pH (intracellular); $Na^+/H^+$ exchanger; Cell volume; *Ras* oncogene; HOE 694 (Wöll, E. (246) 269)

**Cellular pharmacokinetics**
Vincristine; Multidrug resistance (Domènech, C. (248) 49)

**Cell volume**
pH (intracellular); $Na^+/H^+$ exchanger; *Ras* oncogene; cell proliferation; HOE 694 (Wöll, E. (246) 269)

**Centhaquin**
Spontaneously hypertensive rat (SHR); Imipramine; Clonidine; Blood pressure; Central nervous system (CNS); 5-HT uptake sites (Gulati, A. (231) 151)

**Central nervous system (CNS)**
Spontaneously hypertensive rat (SHR); Imipramine; Clonidine; Centhaquin; Blood pressure; 5-HT uptake sites (Gulati, A. (231) 151)

[$^3$H]Quinpirole; Monoamine oxidase inhibitor; Receptor binding; Striatum; (Rat) (Levant, B. (246) 171)

**Central nucleus**
Opioid; Amygdala; Parabrachial area; Nociception; Pain pathway; (Rat) (Huang, G.-F. (236) 449)

**Cerebellar granule cells**
NMDA receptors; Voltage-operated $Ca^{2+}$ channels; Glutamate release; $^{45}Ca^{2+}$ uptake; $K^+$ depolarization (Didier, M. (244) 57)

Ethanol; NMDA receptor; Ethanol withdrawal; Glutamate-induced cytotoxicity (Iorio, K.R. (248) 209)

**Cerebellar granule neurons**
3-Nitropropionic acid; Excitotoxicity; NMDA (N-methyl-D-aspartate); Glutamate (Weller, M. (248) 223)

**Cerebellar slices**
$Ca^{2+}$ channel blockers; Glutamate (Dickie, B.G.M. (229) 97)

**Cerebellum**
Sabeluzole; NMDA receptors; Glutamate; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Histamine $H_1$ receptors; Histamine $H_1$ receptor antagonists; [$^3$H]Mepyramine; Lung tissue; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Dentate/interpositus; GABA ($\gamma$-aminobutyric acid); $5\text{-}HT_{2/1C}$ receptors (Cumming-Hood, P.A. (236) 457)

Ro 15-4513; $GABA_A$ receptor subtypes; Recombinant mutant receptors; (Selected rat lines) (Korpi, E.R. (247) 23)

**Cerebellum (human)**
Angiotensin II receptor subtypes; Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Cerebral arteries**
Smooth muscle (arterial); 5-HT (5-hydroxytryptamine, serotonin); $Ca^{2+}$ channel antagonists (Clark, A.H. (235) 113)

Ethanol; $Ca^{2+}$; $Mg^{2+}$; (Dog); (Sheep); (Piglet); (Baboon) (Zhang, A. (248) 229)

**Cerebral blood flow**
Dipyridamole; Hypertension (rabbit); Chronic cerebral ischaemia (Hegedüs, K. (237) 293)

**Cerebral blood vessels**
5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1D}$ receptors; Cerebral vasoconstriction; Migraine; $5\text{-}HT_1$ receptor subtypes (Hamel, E. (242) 75)

**Cerebral cortex**
Somatostatin; 2-Deoxyglucose; Hippocampus; Acetylcholine; Acetylcholine receptors (Shibata, S. (231) 381)

L-Thyroxine administration (repeated); Methimazole administration (repeated); Plasma endothelin concentration; Endothelin mechanisms; Hypothalamus; Pituitary (Rebello, S. (237) 9)

Glutamate; Nitric oxide (NO); NMDA (N-methyl-D-aspartate); Methylcobalamin; Vitamin $B_{12}$ (Akaike, A. (241) 1)

Autoradiography; Development; Natriuretic peptide receptors (Zorad, S. (241) 195)

Muscarine receptor antagonist; Cholinoceptor (Christopoulos, A. (246) 1)

G-protein; Adenylyl cyclase; $\beta$-Adrenoceptors; F-344 rats; Tricyclic antidepressants; Down-regulation (Scarpace, P.J. (247) 65)

Muscarine receptor antagonist; Cholinoceptor (Christopoulos, A. (247) 227)

**Cerebral cortex (human)**
Serotonin-5-O-carboxymethyl-glycyl[$^{125}$I]tyrosinamide ([$^{125}$I]GTI); $5\text{-}HT_{1D\alpha/\beta}$ receptors (Beer, M.S. (242) 195)

**Cerebral glucose metabolism (regional)**
Raclopride; Benzamides; Neuroleptics (Tarazi, F.I. (232) 71)

**Cerebral ischemia**
Isradipine; Dopamine; Microdialysis; $Ca^{2+}$ channels (voltage-sensitive) (Ooboshi, H. (233) 165)

Baroreflex (vagal); $\alpha_2$-Adrenoceptor blockade (Kurihara, J. (240) 73)

Dizocilpine; Enadoline; Hypothermia; Neuroprotection (Hayward, N.J. (236) 247)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline); AMPA receptors; NMDA receptors; NMDA receptor antagonists; Glutamate (Sheardown, M.J. (236) 347)

Autoradiography; Dopamine $D_1$ receptors; Rolipram receptor; SCH 23390; Pentobarbital; $Ca^{2+}$/calmodulin independent cyclic adenosine monophosphate selective phosphodiesterase; (Gerbil) (Kanai, Y. (248) 191)

Nitric oxide (NO); Nitric oxide synthase; $N^{\omega}$-Nitro-L-arginine; Neuronal necrosis (Nagafuji, T. (248) 325)

**Cerebral ischemia (focal)**
Riluzole; Neurological examination; Passive avoidance task; (Rat) (Wahl, F. (230) 209)

**Cerebral microvessels (rat)**
S312; Dihydrothienopyridine; Aorta (rat); Dihydropyridine binding site; Phenylalkylamine binding site (Dessy, C. (231) 435)

**Cerebral vascular disease**
Azelastine; Ischaemia; Leukotriene; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

**Cerebral vasoconstriction**
5-HT (5-hydroxytryptamine, serotonin); $5\text{-HT}_{1D}$ receptors; Migraine; $5\text{-HT}_1$ receptor subtypes; Cerebral blood vessels (Hamel, E. (242) 75)

**Cerebral vasospasm**
Dihydropyridines; $Mg^{2+}$; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin $F_{2\alpha}$; (Human) (Alborch, E. (229) 83)

**Cerebrospinal fluid**
Milacemide; Amino acids; Monoamine metabolites; Taurine; Homovanillic acid (HVA) (Semba, J. (230) 321)

**Ceruletide**
Amphetamine; Hyperlocomotion; Stereotypy; Microdialysis; (Rat) (Kihara, T. (230) 271)

MK-801; Ketamine; Methamphetamine; Cholecystokinin-like decapeptide; Dopamine release; Avoidance behaviour (Kuribara, H. (231) 7)

CCK (cholecystokinin); $CCK_A$ receptors; $CCK_B$ receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

**Cervical smooth muscle**
Myometrium; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Pregnancy; Electrical field stimulation (Okawa, T. (230) 341)

**Cetiedil**
Acetylcholine release; $Ca^{2+}$; Cholinergic synapses; Mediatophore; (*Torpedo marmorata* synaptosomes) (Moulian, N. (231) 407)

**C-fibre**
Neurogenic plasma extravasation; Opiate action (peripheral); Substance P; Inflammation (Barber, A. (236) 113)

**C-fibre reflex**
Morphine; Spinal cord; Nociception (Strimbu-Gozariu, M. (237) 197)

***C-fos***
Cocaine; Psychostimulants; Nucleus accumbens; Reward (Heilig, M. (236) 339)

***c-fos***
Dopamine $D_1$ receptor; Tolerance (Asin, K.E. (235) 167)

*jun*-B; Pineal gland; Adrenoceptors; Second messengers; Protein kinase (Carter, D.A. (244) 285)

*N*-Methyl-D-aspartate receptor; Polyamines; Ethanol; Seizure (Matsumoto, I. (247) 289)

**[$^3$H]CFT ([$^3$H]2$\beta$-carbomethoxy-3$\beta$-(4-fluoro-phenyl)-tropane, [$^3$H]WIN 35,428)**
Dopamine uptake; Cocaine; Caudate-putamen; $\sigma$ Receptors; Rimcazole (Izenwasser, S. (243) 201)

**C6 glioma**
Endothelins; Sarafotoxins; Endothelin receptor subtypes; Phospholipases; Fibroblasts (Rat-1, Swiss 3T3) (Ambar, I. (245) 31)

**CGP 35348**
Baclofen; Antinociception; Spinal cord; $GABA_B$ receptors (Hammond, D.L. (234) 255)

**CGP 37849**
Drug discrimination; NMDA receptor antagonists; NPC 12626; CP-Pene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

Electroshock (maximal); CGP 39551; Valproate; Seizures (Czechowska, G. (232) 59)

Epilepsy; NMDA (N-methyl-D-aspartate); Valproate; MK-801; Behaviour (Löscher, W. (234) 237)

**CGP 39551**
Electroshock (maximal); CGP 37849; Valproate; Seizures (Czechowska, G. (232) 59)

NMDA receptor antagonists; Dizocilpine; Memantine; Dopamine metabolism; Locomotion (Rat) (Bubser, M. (229) 75)

**CGP-39653**
Electroconvulsive shock; Imipramine; NMDA (*N*-methyl-D-aspartate) receptor complex; Strychnine-insensitive glycine receptor; 5,7-Dichlorokynurenic acid (Paul, I.A. (247) 305)

**CGP 52432**
GABA release; GABA autoreceptors; $GABA_B$ receptor subtypes; Glutamate release; Somatostatin release (Lanza, M. (237) 191)

**CGP 20712A**
Cardiomyopathy; Adrenoceptor subtypes; Adenylyl cyclase (Witte, K. (247) 215)

**CGRP (calcitonin gene-related peptide)**
Neurogenic inflammation; Plasma protein extravasation; Dura mater; Tachykinin receptors (O'Shaughnessy, C.T. (236) 319)

Fischer 344 rats; Aging; Mesenteric vasculature; Sensory nerves (capsaicin-sensitive) (Li, Y. (236) 373)

Gastric ulcer; Reserpine; Somatostatin (Clementi, G. (238) 101)

Capsaicin; Capsazepine; Cardiac afferents; Lactic acid (Franco-Cereceda, A. (238) 311)

Mesentery (rat); L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Methylene blue; Diethyldithiocarbamate (Li, Y.-j. (239) 127)

Uterine artery (human); $K^+$ channels; Pregnancy; Glybenclamide; Tetraethylammonium; Pinacidil (Nelson, S.H. (242) 255)

Cytosolic free $Ca^{2+}$; Fura 2; Cyclic AMP; Aortic spiral preparation (rat) (Michiro Ishikawa, (246) 121)

**CGS 21680**
Adenosine $A_2$ receptors; Dopamine $D_2$ receptors; Gpp(NH)p; GDP-$\beta$-S; $Mg^{2+}$; Neostriatum; (Rat) (Ferré, S. (244) 311)

**Cheek pouch arterioles**
Aprikalim; Vasodilatation, BRL 38227; Nitric oxide (NO); L-NMMA ($N^G$-monomethyl-L-arginine); (Hamster) (Mayhan, W.G. (242) 109)

**Cheek pouch (hamster)**
Big endothelin-1; Big endothelin-3; Phosphoramidon; Microcirculation; Skin blood flow (rat) (Lawrence, E. (233) 243)

**Chemical modification**
Endothelin receptor model; Diethylpyrocarbonate; Bombesin (Huggins, J.P. (245) 203)

**Chemiluminescence**
Nitric oxide (NO); Neuroeffector modulation; Cholinergic; Tachykinin; Smooth muscle (Wiklund, C.U. (240) 235)

**Chemokinesis**
Neutrophils (electroporated); Migration; cGMP; cAMP (Elferink, J.G.R. (246) 157)

**Chemoreflex (central)**
Breathing; Ventilatory response; $CO_2$; Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

**Chemoreflex (peripheral)**
Breathing; Ventilatory response; $CO_2$; Chemoreflex (central); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

**Chemotaxis**
Interleukin-8; Migration; Smooth muscle cell; Atherosclerosis (Yue, T.-L. (240) 81)

**Chlordiazepoxide**
Passive avoidance response; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

**Chlorisondamine**
Nicotine; Lobeline; Cytisine; Mecamylamine; Anxiety (Brioni, J.D. (238) 1)

**p-Chloroamphetamine**
p-Methylthioamphetamine; Drug discrimination; Uptake inhibition; Superfusion; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain slices (Huang, X. (229) 31)

**Chloroethylclonidine**
$\alpha_1$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Noradrenaline; $Ca^{2+}$; cAMP; Hepatocyte (Rat) (Nomura, T. (246) 113)

**6-Chloromelatonin**
Melatonin; 2-Iodomelatonin, Melatonin receptors, Melanoma cells (Human); cAMP; Cytostatic activity (Ying, S.-W. (246) 89)

**p-Chlorophenylalanine**
Food intake; d-Fenfluramine; d-Norfenfluramine; 1-(3-Chlorophenyl)piperazine; $5\text{-}HT_{1C}$ receptors (Gibson, E.L. (242) 83)

**m-Chlorophenylbiguanide**
Emesis; $5\text{-}HT_3$ receptor; Cisplatin; YM060 (Kamato, T. (238) 369)

$5\text{-}HT_3$ receptors; Neuroblastoma; Ligand-gated ion channel (Lummis, S.C.R. (243) 7)

**[$^3$H]meta-Chlorophenylbiguanide**
$5\text{-}HT_3$ receptor agonists; [$^3$H](S)-Zacopride; Brain (rat) (Steward, L.J. (243) 13)

**1-(3-Chlorophenyl)piperazine**
Food intake; d-Fenfluramine; d-Norfenfluramine; $5\text{-}HT_{1C}$ receptors; p-Chlorophenylalanine (Gibson, E.L. (242) 83)

**(+)-Chlorpheniramine**
HeLa cell; Histamine $H_1$ receptor; [$^3$H]Mepyramine; Phosphoinositide; Temelastine (Arias-Montaño, J.-A. (245) 291)

**Chlorpromazine**
Soleus muscle; Extensor digitorum longus muscle; Myotonic depression (Liu, S.-H. (231) 23)

**Cholera toxin**
Angiotensin II; Pertussis toxin; Portal vein (rat); Dibutyryl cAMP (Zhang, J. (230) 95)

Morphine; Catalepsy; Pertussis toxin; cAMP levels (Massi, P. (243) 65)

**Cholesterol**
Hypocholesterolemic drugs; Liver; Bile; Lipoproteins (Clerc, T. (235) 59)

**Cholesterol metabolism**
EPA-E (ethyl all-cis-5,8,11,14,17-icosapentaenoate); (Rat) (Mizuguchi, K. (231) 121)

**Choline**
JTP-2942 ($N^{\alpha}$-[(1S,2R)-2-methyl-4-oxycyclopentanecarbonyl]-L-histidyl-L-prolinamide); TRH (thyrotropin-releasing hormone); Acetylcholine; Frontal cortex; Hippocampus; Microdialysis (Toide, K. (233) 21)

**Choline acetyltransferase**
Propentofylline; Basal forebrain; Ibotenic acid; Learning and memory; Nerve growth factor (Fuji, K. (236) 411)

**Cholinergic**
Ro 31-6930; BRL 38227; Bronchoconstriction; Neurotransmission (Gater, P.R. (238) 59)

Nitric oxide (NO); Neuroeffector modulation; Tachykinin; Smooth muscle; Chemiluminescence (Wiklund, C.U. (240) 235)

**Cholinergic airway constriction**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_3$ receptors (Rizzo, C.A. (234) 109)

5-HT (5-hydroxytryptamine, serotonin); 5-$HT_3$ receptors (Rizzo, C.A. (240) 327)

**Cholinergic drugs**
Epilepsy; Absence seizures; Electroencephalography; (Rat) (Danober, L. (234) 263)

Adrenocortical axis; Corticosterone; Tolerance (Cattaneo, L. (241) 245)

**Cholinergic innervation**
Endothelin; Vein; Atropine; Neostigmine; Embryology (Hayakawa, A. (239) 219)

**Cholinergic mechanisms**
Nitric oxide (NO); Intestinal motility; L-NAME ($N^G$-nitro-L-arginine methyl ester) (Calignano, A. (229) 273)

**Cholinergic nerves**
5-HT (5-hydroxytryptamine, serotonin); $\alpha$-Methyl-5-hydroxytryptamine; Bronchi (rat); 5-$HT_2$ receptors; Ketanserin; Mianserin; Spiperone; Electrical field stimulation (Szarek, J.L. (231) 339)

**Cholinergic neurotransmission**
VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); Inhibitory non-adrenergic non-cholinergic (i-NANC); Electrical field stimulation (Belvisi, M.G. (231) 97)

Muscarinic $M_2$ receptors; Muscarinic $M_3$ receptors; Trachea (guinea-pig); Muscarinic receptor antagonists; Electrical field stimulation (Ten Berge, R.E.J. (233) 279)

**Cholinergic stimulation**
Islets of Langerhans; Monoamine oxidase activity; $\alpha$-Adrenoceptor stimulation; $\beta$-Adrenoceptor stimulation; Insulin; Glucose; (Mouse) (Panagiotidis, G. (233) 285)

**Cholinergic synapses**
Acetylcholine release; $Ca^{2+}$; Cetiedil; Mediatophore; (*Torpedo marmorata* synaptosomes) (Moulian, N. (231) 407)

**Chorioallantoic membrane**
Radicicol; Cell differentiation modulator; Anti-angiogenic action; Embryonic angiogenesis (Oikawa, T. (241) 221)

**Choroid plexus**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1C}$ receptor; $Cl^-$ channels (Garner, C. (239) 31)

Clozapine; N-Desmethylclozapine; Clozapine N-oxide; 5-$HT_{1C}$ receptors (Kuoppamäki, M. (245) 179)

Ethanol; Brain (rat); 5-$HT_{1C}$ receptors; Phosphoinositide hydrolysis (Pandey, S.C. (247) 81)

**Chromaffin cells**
Adrenal medulla; Histamine; Catecholamine release; $Ca^{2+}$ channels; $Ca^{2+}$ (intracellular) (Borges, R. (241) 189)

Nitric oxide (NO) synthase; cGMP; Catecholamine release; Adrenal medulla (Moro, M.A. (246) 213)

1,4-Dihydropyridines; Nicotinic acetylcholine receptors; Nimodipine; BAY K 8644; PCA50938; Nifedipine; Nitrendipine; Furnidipine (López, M.G. (247) 199)

**Chronic cerebral ischemia**
Cerebral blood flow; Dipyridamole; Hypertension (rabbit) (Hegedüs, K. (237) 293)

**Chronic treatment**
Anxiety; Buspirone; 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; 5-$HT_{1A}$ receptors; Microdialysis (in vivo); (Rat) (Söderpalm, B. (239) 69)

**Chronotropism**
BRL 37344; $\beta_3$-Adrenoceptors; Inotropism; Heart (dog) (Takayama, S. (231) 315)

**Cigarette smoke**
Plasma exudation; Vagus nerve stimulation; $K^+$ channel opener; Glibenclamide (Lei, Y.-H. (239) 257)

**Cilia**
Maxillary sinus; Mucociliary activity; Phosphoramidon; Tachykinins; Tachykinin receptors; (Rabbit) (Lindberg, S. (231) 375)

**Circling behaviour**
NMDA receptor antagonists; Learning/memory; Muscle relaxation; (Rat) (Murata, S. (239) 9)

**Circular muscle**
Tachykinins; Ileum (guinea-pig); $\omega$-Conotoxin; Nitric oxide (NO); Apamin; NANC (non-adrenergic, non-cholinergic); NANC relaxation (Maggi, C.A. (240) 45)

HOE 140; Bradykinin; Longitudinal muscle; Ileum (guinea-pig) (Medeiros, Y.S. (241) 157)

**Cis-flupentixol**
Dopamine (renal); Fenoldopam; Quinpirole; SCH 23390; LLC-$PK_1$ cells; Organic cations (renal); Dopamine receptors; Quinine (Dawson, Jr., R. (240) 277)

**Cisplatin**
Catecholamine secretion; Adrenal chromaffin cells; Acetylcholine; $Ca^{2+}$ influx (Tachikawa, E. (236) 355)

Emesis; 5-$HT_3$ receptor; m-Chlorophenylbiguanide; YM060 (Kamato, T. (238) 369)

Emesis; Free radicals; (House musk shrew) (Torii, Y. (248) 131)

Emesis; Free radicals; Iron; (*Suncus murinus*) (Matsuki, N. (248) 329)

**Citalopram**
Tianeptine; 5-$HT_{1B}$ receptors; Acetylcholine release; Antidepressants (Bolaños-Jiménez, F. (242) 1)

**Citric acid**
Bronchoconstriction; Capsazepine; Capsaicin; Histamine; pH (low) (Satoh, H. (236) 367)

***c-jun***
Pineal gland; Immediate-early genes; Adrenoceptors; cAMP (Carter, D.A. (247) 97)

**CL218872**
Benzodiazepine receptors; Visual cortex (human); Autoradiography (March, D. (236) 333)

**Class III antiarrhythmics**
Action potentials; Ionic currents; Single ventricular cells (Lee, K.S. (234) 43)

**Classical conditioning**
On-off effects; Rotation; Dopamine receptor agonists; 6-Hydroxydopamine (6-OHDA); Nigrostriatal lesions (Silverman, P.B. (229) 235)

**$Cl^-$ channels**
GABA (γ-aminobutyric acid); Benzodiazepines; CNS (central nervous system) depressants; Seizure tolerance; Receptor coupling (Chang, Y.-F. (233) 209)

Regulatory decrease in volume; Colon (rat); Leukotriene $D_4$ (Diener, M. (238) 217)

Choroid plexus; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1C}$ receptor (Garner, C. (239) 31)

**Clebopride**
NMDA (N-methyl-D-aspartate); MK-801; LY274614; SCH23390; Catalepsy; Dopamine; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

**$Cl^-$ flux**
Benzodiazepine; Tolerance; Flurazepam; Bretazenil; Clonazepam; Diazepam (Li, M. (247) 313)

**$Cl^-$-$HCO_3^-$ exchanger**
Gastric acid secretion; DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid); Amiloride; $Na^+$-$H^+$ exchanger; Stomach (isolated); (Rat) (Horie, S. (229) 15)

**Clofibrate**
Erythrocyte membrane; Clofibric acid; Membrane electrophoresis; $HCO_3^-$-$Cl^-$ exchange inhibition; (Rat) (Morales-Aguilera, A. (245) 89)

**Clofibric acid**
Erythrocyte membrane; Clofibrate; Membrane electrophoresis; $HCO_3^-$-$Cl^-$ exchange inhibition; (Rat) (Morales-Aguilera, A. (245) 89)

**Clomipramine**
Imipramine; Clorgyline; Corticosterone; ACTH (adrenocorticotropin); Fawn-hooded rat (Aulakh, C.S. (240) 85)

**Clonazepam**
CCK (cholecystokinin); Devazepide; L365-260; Duodenum; Jejunum; Motility (Bonnafous, C. (237) 237)

Benzodiazepine; Tolerance; $Cl^-$ flux; Flurazepam; Bretazenil; Diazepam (Li, M. (247) 313)

**Cloned 5-$HT_3$ receptor subunit**
5-$HT_3$ receptor; N1E-115 neuroblastoma cell; *Xenopus* oocyte expression system (Hope, A.G. (245) 187)

**Clonidine**
Endothelin; Blood pressure; Heart rate; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

Spontaneously hypertensive rat (SHR); Imipramine; Centhaquin; Blood pressure; Central nervous system (CNS); 5-HT uptake sites (Gulati, A. (231) 151)

Galanin; M35; Islets of Langerhans (isolated); Insulin secretion; Somatostatin (Gregersen, S. (232) 35)

Feeding; Obese mice; Norepinephrine; Yohimbine; $\alpha_2$-Adrenoceptors (Currie, P.J. (232) 227)

$\alpha_2$-Adrenoceptors; Place preference; (Rat) (Cervo, L. (238) 201)

Desipramine; Desmethylclomipramine; MHPG (3-methoxy-4-hydroxyphenylglycol); Norepinephrine (Fujita, K. (242) 301)

Idazoxan; Imidazoline; Imidazoline receptor; Polyclonal antibody (Bennai, F. (246) 45)

**[$^3$H]Clonidine**
$\alpha_2$-Adrenoceptors; [$^3$H]UK 14,304 (bromoxidine); [$^3$H]RX 821002 (2-methoxy idazoxan); Neostigmine; Physostigmine; Diisopropylfluorophosphate; Pilocarpine (Olmos, G. (236) 467)

Zucker rat; Imidazoline $I_2$ binding sites; $\alpha_2$-Adrenoceptors; Brain; [$^3$H]Idazoxan; [$^3$H]RX821002; Mazindol (Miralles, A. (243) 305)

**Cloning**
Loop diuretics; Bumetanide (transport); Organic anions; Sinusoidal plasma membrane; Liver (rat); Bile acid (Honscha, W. (246) 227)

**Clorgyline**
MDMA (3,4-methylenedioxymethamphetamine); Parachloroamphetamine; Fluoxetine; Deprenyl; Nimodipine; Reserpine (Gu, X.F. (235) 51)

Imipramine; Clomipramine; Corticosterone; ACTH (adrenocorticotropin); Fawn-hooded rat (Aulakh, C.S. (240) 85)

**Cloricromene**
Endotoxin; Vascular reactivity; Murine J774 macrophages; Nitric oxide synthase (Zingarelli, B. (243) 107)

***Clostridium botulinum* C2 toxin**
ADP-ribosylation actin; Gelsolin (Just, I. (246) 293)

**Clozapine**
Haloperidol; Loxapine; Hippocampus; Synaptic excitation (Baskys, A. (235) 305)

Prefrontal cortex; Microdialysis; Dopamine; Schizophrenia; Amperozide (Pehek, E.A. (240) 107)

N-Desmethylclozapine; Clozapine N-oxide; 5-$HT_{1C}$ receptors; Choroid plexus (Kuoppamäki, M. (245) 179)

**Clozapine N-oxide**
Clozapine; N-Desmethylclozapine; 5-$HT_{1C}$ receptors; Choroid plexus (Kuoppamäki, M. (245) 179)

**$Cl^-$ secretion**
Colitis; cAMP; Inflammatory bowel disease; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

**$Cl^-$ secretion (intestinal)**
Opioids; Receptor subtypes (Kromer, W. (230) 235)

**$Cl^-$ uptake**
$GABA_A$ receptor complex; Benzodiazepine; TBPS (*t*-butylbicyclophosphorothionate) binding (Finn, D.A. (247) 233)

**CNS depressants**
GABA (γ-aminobutyric acid); Benzodiazepines; Seizure tolerance; Receptor coupling; $Cl^-$ channels (Chang, Y.-F. (233) 209)

**$CO_2$**
Breathing; Ventilatory response; Chemoreflex (central); Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

**Coagulation**
Glycosphingolipids; Lysogangliosides; Platelet aggregation; Thrombin; 5-HT (5-hydroxytryptamine, serotonin); Tromboxane $B_2$; Bleeding; Fibrinolysis (Tubaro, E. (248) 175)

**Co-axial bioassay**
EpDRF (epithelium-derived relaxing factor); Ovalbumin challenge; Trachea (guinea-pig); Anococcygeus muscle (rat); 5-HT (5-hydroxytryptamine, serotonin) (Çakici, İ. (236) 97)

**Cobalt ramps**
Nicotinic receptors; Adrenal medulla; Catecholamine secretion (Montiel, C. (230) 77)

**Cocaine**
Dopamine; Acetylcholine; Microdialysis; α-Methyltyrosine + reserpine; (−)-Sulpiride; SCH 23390 (Imperato, A. (229) 265)

[D-$Pen^2$,L-$Pen^5$]enkephalin; Naltrindole (Ukai, M. (231) 143)

Development; Ontogeny; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Stimulants (Barr, G.A. (233) 143)

Carbamazepine; Dopamine; Nucleus accumbens; Microdialysis; (Rat) (Baptista, T. (236) 39)

*C-fos*; Psychostimulants; Nucleus accumbens; Reward (Heilig, M. (236) 339)

d-Amphetamine; Hippocampus; Caudate nucleus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

$5\text{-}HT_{1A}$ receptors; $5\text{-}HT_2$ receptors; Brain regions (rat) (Javaid, J.I. (238) 425)

5-HT (5-hydroxytryptamine, serotonin); [$^3$H]5-HT uptake; Cortical synaptosomes (rat); tropisetron; 5-HT receptor ligands (Cheng, C.H.K. (239) 211)

Microdialysis; 4-PTIQ (4-phenyltetrahydroisoquinoline); Nomifensine; Methamphetamine; Dopamine; Nucleus accumbens (Tateyama, M. (240) 51)

Cocaine dependence; Ibogaine; Self-administration; (Rat) (Cappendijk, S.L.T. (241) 261)

Parkinsonism; Rotational behaviour; 6-Hydroxydopamine; Bromocriptine; SK&F-77434 (Silverman, P.B. (242) 31)

Sensitization; Naltrindole; Locomotor activity; Opioids (Heidbreder, C. (243) 123)

(+)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; (−)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; Methamphetamine; Nomifensine; Anococcygeus muscle (rat) (Watanabe, H. (243) 155)

Dopamine uptake; Caudate-putamen; σ Receptors; Rimcazole; [$^3$H]CFT ([$^3$H]2β-carbomethoxy-3β-(4-fluoro-phenyl)-tropane, [$^3$H]WIN 35,428) (Izenwasser, S. (243) 201)

Tropanes; Dopamine transporters; Striatum (Davies, H.M.L. (244) 93)

**Cocaine dependence**
Cocaine; Ibogaine; Self-administration; (Rat) (Cappendijk, S.L.T. (241) 261)

**Cocaine (neuroendocrine)**
5-HT (5-hydroxytryptamine, serotonin); Prolactin; Renin; ACTH (adrenocorticotropic hormone) (Levy, A.D. (241) 275)

**Cocaine strokes**
$Mg^{2+}$ (cytosolic, free) (Altura, B.M. (246) 299)

**Coccidiosis**
Robenidine; D-Galactose; L-Leucine; Intestinal transport; Jejunum (rabbit); Drug-nutrient interaction; Sucrase; Aminopeptidase (Sorribas, V. (248) 137)

**Codeine**
Dentate gyrus; Field potentials; Long-term potentiation; NMDA receptors; Dextromethorphan; Methadone; Normethadone; MK-801 (Krug, M. (231) 355)

**Cognitive enhancer**
Hippocampus; Long-term potentiation; Somatostatin; Acetylcholine; Mossy fiber-CA3 pathway; FR121196; (Guinea-pig) (Matsuoka, N. (241) 27)

**Colchicine**
Vinblastine; Blood $Ca^{2+}$; Bone cells; Microtubules (Ohya, K. (248) 111)

**Cold-pressor test**
Dothiepin; Nociceptive flexion reflex; Diffuse noxious inhibitory controls; (Human) (Sandrini, G. (243) 99)

**Colitis**
$Cl^-$ secretion; cAMP; Inflammatory bowel disease; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

**Colon**
Gastrointestinal motility; Pain; Stomach; VIP (vasoactive intestinal polypeptide); VIP antiserum (Bojö, L. (236) 443)

**Colonic motility**
Stress (emotional); $5\text{-}HT_{1A}$ receptor agonists; $5\text{-}HT_2$ receptor antagonists; $5\text{-}HT_3$ receptor antagonists; (Rat) (Gué, M. (233) 193)

**Colon (rat)**
Regulatory decrease in volume; $Cl^-$ channels; Leukotriene $D_4$ (Diener, M. (238) 217)

**Comparative molecular field analysis method**
5-HT (serotonin); $5\text{-}HT_{1A}$ receptors; $5\text{-}HT_{1B}$ receptors; Computer graphics; β-Adrenoreceptor antagonists (Langlois, M. (244) 77)

**Competition binding studies**
Doridosine (1-methylisoguanosine) derivatives; Adenosine $A_1$ receptors; Adenosine $A_2$ receptors; Bradycardia; (Rat) (Tao, P.-L. (243) 135)

**Competitive inhibition**
$\beta$-Adrenoceptors; Noradrenaline; 5-HT (5-hydroxytryptamine, serotonin) (Fujita, R. (240) 213)

**Complement**
Zymosan; PAF (platelet-activating factor, PAF-acether); WEB 2086; SM-12502; Plasma leakage (Damas, J. (231) 231)

**Complement receptors**
Myocardial infarction; Neutrophils; Myeloperoxidase (Smith III, E.F. (236) 477)

**Computer graphics**
5-HT (serotonin); 5-$HT_{1A}$ receptors; 5-$HT_{1B}$ receptors; $\beta$-Adrenoreceptor antagonists; Comparative molecular field analysis method (Langlois, M. (244) 77)

**Computer modelling**
Deltorphin; Opioid receptors; Peptide synthesis (Salvadori, S. (230) 357)

**Conditioned place preference**
RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Naloxone; Addiction; (Mouse) (Noble, F. (230) 139)

Cathinone; Dopamine; Locomotion; (Rat) (Schechter, M.D. (232) 135)

**Conformational analysis**
Aminoglycoside; Membrane permeability; Calcein; $Mn^{2+}$; $Ca^{2+}$ (Van Bambeke, F. (247) 155)

**Conformational changes in $GABA_A$ receptors**
$GABA_A$ receptors; $La^{3+}$; Lanthanides; [$^{35}$S]TBPS ([$^{35}$S]t-butylbicyclophosphorothionate) binding (Im, W.B. (245) 111)

**Congestive heart failure**
$\alpha_1$-Adrenoceptor activation pathways; $Ca^{2+}$ channel antagonists; Dorsal pedal artery; Saphenous vein (Forster, C. (242) 119)

**$\omega$-Conotoxin**
Tachykinins; Ileum (guinea-pig); Circular muscle; Nitric oxide (NO); Apamin; NANC (non-adrenergic, non-cholinergic); NANC relaxation (Maggi, C.A. (240) 45)

$Ca^{2+}$; $Ca^{2+}$ channels; $Ca^{2+}$ channel antagonists; $\omega$-Agatoxin IVA; Small cell lung carcinoma cells; Proliferation (Cattaneo, M.G. (247) 325)

**[$^{125}$I]$\omega$-Conotoxin**
Calcium channels; Alcohols; Synaptosomes; Longitudinal muscle; [$^3$H]Nitrendipine (Hawthorn, M.H. (229) 143)

**$\omega$-Conotoxin GVIA**
$Ca^{2+}$ channels (voltage-sensitive); *Hololena curta* venom; Funnel web spider toxin; Neurotransmitter release; Autonomic nerves (Lundy, P.M. (231) 197)

**Contractile force**
Atrium; Heart; 5-HT (5-hydroxytryptamine, serotonin); Ventricle; (Human) (Schoemaker, R.G. (230) 103)

**Contractility**
$\alpha$-Tocopherol analogue (MDL 73404); Free radical scavenger; Reperfusion injury; Myocardial ischaemia/reperfusion; Lipid peroxidation (Lukovic, L. (233) 63)

Flosequinan; Heart failure; Cardiac muscle; Phosphodiesterase; (Human) (Weishaar, R.E. (236) 363)

**Contractions**
5-HT (5-hydroxytryptamine, serotonin); Lipoxygenase products; Atherosclerosis; Blood vessels; (Interaction) (Van Diest, M.J. (231) 267)

Thaliporphine; Ileum (guinea-pig); $Ca^{2+}$ channels (Yu, S.-M. (234) 121)

$Ca^{2+}$ currents; Heart (Harrison, S. (237) 83)

$\alpha_1$-Adrenoceptors; Prazosin binding; Smooth muscle (vascular) (Sayet, I. (246) 275)

Heart; Cardiac myocytes; Alcohol (Cannings, I. (248) 213)

**Conversion**
Big endothelin-1; Endothelin-1; Mesentery (Hisaki, K. (241) 75)

**Convulsions**
Norbinaltorphimine; NMDA (N-methyl-D-aspartate); AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazole propionate); Mortality (Shukla, V.K. (231) 293)

NMDA (N-methyl-D-aspartate); AMPA ((S)-$\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); (Screening); (Neonatal rat); (Mouse); (Rat) (Bisaga, A. (242) 213)

**Convulsions (electrically induced)**
Histamine; Histamine $H_3$ receptor antagonists; Thioperamide; (R)-$\alpha$-Methylhistamine (Yokoyama, H. (234) 129)

**Coronary artery**
ANP (atrial natriuretic polypeptide); Nitroglycerin; Nitric oxide (NO); Cyclic GMP (Matsumoto, T. (237) 31)

1,4-Dihydropyridine (enantiomers); $K^+$; pH; $Ca^{2+}$; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Prieto, D. (238) 27)

Endothelin; Neuropeptide Y; Nitric oxide (NO); BQ-123; $ET_A$ receptor; $ET_B$ receptor (Pernow, J. (243) 281)

**Coronary artery (human)**
5-HT (5-hydroxytryptamine, serotonin); Platelets; Sumatriptan; Ergotamine; 5-$HT_{1D}$-like receptors; 5-$HT_2$ receptors (Bax, W.A. (239) 203)

**Coronary artery (pig)**
Ki1769; Ki3315; KRN2391; $K^+$ channel openers (Okada, Y. (241) 177)

**Coronary artery (porcine)**
Adenosine receptors; 2-(ar)Alkoxyadenosines; (Binding domains) (Makujina, S.R. (243) 35)

**Coronary blood flow**
Thrombolysis; Streptokinase; Thromboxane receptor antagonists; Thromboxane synthase inhibitors (Olson, R.W. (236) 75)

**Corpus striatum**
Glutamate; Dopamine; Neuroleptics; Nucleus accumbens; (Rat) (Bardgett, M.E. (230) 245)

**Cortex**
5-HT (5-hydroxytryptamine, serotonin); NMDA (N-methyl-D-aspartate); Transmitter interaction (Rahman, S. (231) 347)

Tetrahydroaminoacridine; Physostigmine; β-Adrenoceptors; Adenylate cyclase; Hippocampus; cAMP (Vivas, N.M. (245) 9)

$GABA_A$ receptor complex (Type I and Type II benzodiazepine binding sites); [$^3$H]Zolpidem binding; [$^3$H]Flunitrazepam binding; γ-Aminobutyric acid; Aging (Ruano, D. (246) 81)

**Cortex injury**
Catecholamine re-uptake blockers; Procholecystokinin mRNA; Sympathetic nervous system (Mondeh, J.D. (240) 39)

**Cortical cells**
Scrapie; Memantine; NMDA receptor; Neurons; Prion; Adamantanes; MK-801 (Müller, W.E.G. (246) 261)

**Cortical firing rate**
$5\text{-HT}_3$ receptors; [$^3$H]Zacopride; [$^3$H]Granisetron; [$^{14}$C]Guanidinium; Ileum; Bezold-Jarisch reflex; Turning behaviour; (Ex vivo binding) (Bachy, A. (237) 299)

**Cortical synaptosomes (rat)**
5-HT (5-hydroxytryptamine, serotonin); [$^3$H]5-HT uptake; Cocaine; tropisetron; 5-HT receptor ligands (Cheng, C.H.K. (239) 211)

**Cortical wedge**
Excitatory amino acids; Sensitization; Quisqualate priming; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

NMDA (N-methyl-D-aspartate); Non-competitive antagonism; Dizocilpine; FR115427; Hippocampus (Hodgkiss, J.P. (240) 219)

**Corticosterone**
Ipsapirone; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); $5\text{-HT}_{1A}$ receptors; $5\text{-HT}_2$ receptors; Anxiolysis; Glucose; Prolactin; Behaviour (Baudrie, V. (231) 395)

$Ca^{2+}$ channels; Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines (Martinez-Piñero, M.G. (232) 191)

α-Interferon; Stress; Paraventricular nucleus; Opioid receptors (Saphier, D. (236) 183)

Imipramine; Clomipramine; Clorgyline; ACTH (adrenocorticotropin); Fawn-hooded rat (Aulakh, C.S. (240) 85)

Dorsal raphe nucleus; WAY 100,135; (−)-Tertatolol; Flat-body posture (Lejeune, F. (240) 307)

Cholinergic drugs; Adrenocortical axis; Tolerance (Cattaneo, L. (241) 245)

**COS cell expression**
Angiotensin receptor; cDNA sequence; Aorta (porcine); *Xenopus* oocyte expression (Itazaki, K. (245) 147)

**Cotinine**
Nicotine; Prostaglandins; Thromboxane; Leukotrienes (Saareks, V. (248) 345)

**Co-transport**
Pancreatic β-cells; H 25; H 74; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

**Cough**
Antitussive effect; β-Endorphin; Opioid receptors (Kamei, J. (233) 251)

**Coumarins**
Esculetin; Antiproliferative effect; Smooth muscle cells (vascular); Lipoxygenase inhibitors (Huang, H.-C. (237) 39)

**Coupling mechanism**
$GABA_B$ receptors; Hippocampus (Potier, B. (231) 427)

**CP-96,345**
Allergen; Bradykinin; Airway microvascular leakage; $NK_1$ receptors; Substance P (Sakamoto, T. (231) 31)

Tachykinin receptors; Tachykinin receptor subtypes; Septide (Maggi, C.A. (235) 309)

**N-CPM-$H_2$BAMO (14β-(bromoacetamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone)**
Endorphin receptors; μ-Opioid receptor antagonists; κ-Opioid receptor agonists; Analgesia; (Mouse) (Jiang, Q. (240) 201)

**m-CPP (1-(3-chlorophenyl)piperazine)**
5-HT (5-hydroxytryptamine, serotonin); Excessive grooming; Penile erection; Oxytocin concentration (plasma); $5\text{-HT}_{1C}$ receptors; $5\text{-HT}_2$ receptors; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (229) 9)

5-HT (5-hydroxytryptamine, serotonin); NAN-190; RU 24969; TFMPP (trifluoromethylphenylpiperazine); 5-HIAA (CSF levels); $5\text{-HT}_1$ receptor binding (in vitro); (Pigeon) (Gleeson, S. (229) 109)

5-HT (5-hydroxytryptamine, serotonin); Male sexual behavior; Penile erection; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Yawning; (Primates); (Rhesus monkey) (Pomerantz, S.M. (243) 227)

**CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid)**
Drug discrimination; NMDA receptor antagonists; NPC 12626; CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

DBA/2 mice; Aniracetam; AMPA receptor antagonists; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline); GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine·HCl) (Chapman, A.G. (231) 301)

**CR 2039**
Antiallergic compounds; Passive cutaneous anaphylaxis; Bronchial anaphylaxis; Lung phosphodiesterase; (Guinea-pig) (Revel, L. (229) 45)

**CRF (corticotropin-releasing factor)**
Feeding behaviour; Genetic obesity; TFMPP (1-[3-(trifluoromethyl) phenyl]piperazine); Insulin; Neuropeptide Y; (Zucker rat) (Rouru, J. (234) 191)

Interleukin-1; Opioids; α-Helical CRF-(9–41); Antinociception (Mouse) (Kita, A. (237) 317)

**Cromakalim**
$Na^+,K^+$ ATPase pump; $K^+$ channels; Smooth muscle (vascular) (Hong, K.W. (231) 1)

KRN2391; Heart (isolated, rat); Myocardial ischemia; Energy metabolism (Ohta, H. (231) 323)

Bradykinin; Histamine; Substance P; Vascular permeability; Plasma exudation; Airways (Martin, C.A.E. (239) 119)

Mesenteric artery; (Human) (McDonald, A. (240) 303)

$K^+$ channel (*Xenopus laevis*); $K^+$ channel opener; KRN2391; Nicorandil; Glibenclamide; Phentolamine; Trifluoperazine (Sakuta, H. (244) 277)

**Cross-tolerance**
$\beta$-Endorphin; Morphine; Tolerance; Antinociception; Tail-flick inhibition; Hot-plate inhibition (Tseng, L.F. (241) 63)

**CS-518**
Thromboxane synthase inhibitors; Asthmatic model; Bronchoconstriction; Hyperresponsiveness (Yamaguchi, T. (236) 43)

Thromboxane synthase inhibitors; Asthmatic model; Eicosanoid production (Itoh, K. (237) 215)

Thromboxane $A_2$ synthase inhibitors; Asthmatic model; Eosinophil function (Itoh, K. (239) 159)

**Cultured neurons**
Trophism; Norepinephrine release; $Ca^{2+}$ transients (Przywara, D.A. (247) 353)

Endothelin-1; Middle cerebral artery occlusion; Ischemia; Hypoxia; (Mouse) (Nikolov, R. (248) 205)

**Cutaneous vasodilatation**
Mustard oil; Neurogenic inflammation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

**CV-11974**
Angiotensin II; Angiotensin $AT_1$ receptor antagonists; $[Ca^{2+}]_i$ transient; Cardiac myocytes; (Neonatal rat) (Kinugawa, K.-i. (235) 313)

**CXBK mouse**
Morphine; Naltrexonazine; $\mu$-Opioid receptor subtypes; Antitussive effect (Kamei, J. (240) 99)

**Cyanide**
Actyl-l-carnitine; Histotoxic hypoxia; Spatial learning; Phosphoinositide metabolism (Blokland, A. (235) 275)

Cardiovascular neurons; Hydrogen ions; GABA ($\gamma$-aminobutyric acid); Rostral ventrolateral medulla; (Rat) (Sun, M.-K. (236) 305)

Thiocyanate; Dopamine receptors; Striatum (Cassel, G.E. (248) 297)

**Cyclic nucleotides**
Atherosperminine; Smooth muscle (trachealis, guinea-pig); Phosphodiesterase inhibition; *Fissistigma glaucescens* (Lin, C.-H. (237) 109)

**Cycloheximide**
Locomotion; Sensitization; Methamphetamine; (Mouse) (Shimosato, K. (234) 67)

**Cyclooxygenase**
FR122047; Platelet aggregation; Aspirin (Dohi, M. (243) 179)

**Cyclopiazonic acid**
Skinned fibres; Extensor digitorum longus; Soleus; $Ca^{2+}$ sensitivity (Huchet, C. (241) 41)

Ryanodine; Smooth muscle; $Ca^{2+}$ channels; $Ca^{2+}$ stores; Whole-cell voltage clamp (Gagov, H.S. (243) 19)

**D-Cycloserine**
Aging; NMDA receptors; Glycine; Noradrenaline release; Glycine uptake (Pittaluga, A. (231) 129)

**Cyclosporin**
Inflammatory bowel disease; Prostaglandin; Epithelium; Permeability (Higa, A. (239) 171)

Angiotensin $AT_{1A}$ receptors; Hypertension; Endothelium; Gene expression (Iwai, J. (248) 341)

Cancer chemotherapy; FK506; Multidrug resistance; P-glycoprotein; Rapamycin (Hoof, T. (246) 53)

**Cyclosporin A**
Endothelin; Smooth muscle cell (vascular); (Rat) (Takeda, Y. (233) 299)

**Cyclothiazide**
Glutamate receptors; AMPA ($\alpha$-amino-3-hydroxy-5-methylisoxazole-4-propionate); GYKI 53655 (Palmer, A.J. (244) 193)

**CYP2A6 recombinant expression vector**
Cytochrome P4502A6 (human); Heterologous expression; NIH 3T3 cells (Salonpää, P. (248) 95)

**Cytisine**
Nicotine; Lobeline; Mecamylamine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

**Cytochrome P450**
Dopamine uptake inhibitors; [$^3$H]GBR 12783 binding site occupancy; Locomotor activity; (Mouse) (Vaugeois, J.-M. (230) 195)

Arachidonic acid; 20-HETE (20-hydroxy-5,8,11,14-eicosatetraenoic acid); Endothelium-dependent vasoconstrictor (Escalante, B. (235) 1)

$\sigma$ Binding; Brain; Liver; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); (Dark Agouti rat) (Jewell, A. (243) 249)

**Cytochrome P450 1A2**
Musk xylene; Musk ambrette; Liver (rat); Enzyme induction (Iwata, N. (248) 243)

**Cytochrome P450 2A6 (human)**
Heterologous expression; CYP2A6 recombinant expression vector; NIH 3T3 cells (Salonpää, P. (248) 95)

**Cytochrome P450 1A1 (human)**
Cytochrome P450 1A1 recombinant expression vector; V79 Chinese hamster cells; Polycyclic aromatic hydrocarbons; Benzo[a]pyrene (Schmalix, W.A. (248) 251)

**Cytochrome P450 1A1 recombinant expression vector**
Cytochrome P450 1A1 (human); V79 Chinese hamster cells; Polycyclic aromatic hydrocarbons; Benzo[a]pyrene (Schmalix, W.A. (248) 251)

**Cytochrome P450 epoxygenase**
Arachidonic acid; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

**Cytokines**
Leukotrienes; Endotoxin; cAMP (Schade, F.U. (230) 9)

AIDS; T lymphocytes; Mucosa; Virus infection (Bourinbaiar, A.S. (230) 15)

Opioids; Antinociception (peripheral); Inflammation (Członkowski, A. (242) 229)

**Cytosolic $Ca^{2+}$ levels**
$Ca^{2+}$ channel blockers; Felodipine; Nifedipine; Verapamil; Smooth muscle; Aorta (rat); (Relaxation) (Hagiwara, S. (234) 1)

**Cytosolic free $Ca^{2+}$**
27-O-Caffeoyl myricerone (50-235); Endothelin receptor antagonist; Mitogenesis; Smooth muscle cell (aorta, rat); Girardi heart cell (human) (Mihara, S.-i. (246) 33)

CGRP (Calcitonin gene-related peptide); Fura 2; Cyclic AMP; Aortic spiral preparation (rat) (Michiro Ishikawa, (246) 121)

27-*O*-Caffeoyl myricerone (50-235); Structure-activity relationship; Endothelin receptor antagonist; [$^{125}$I]Endothelin-1 binding (Mihara, S.-i. (247) 219)

**Cytostatic activity**
Melatonin; 6-Chloromelatonin; 2-Iodomelatonin; Melatonin receptors; Melanoma cells (human); cAMP (Ying, S.-W. (246) 89)

**Cytotoxicity**
$\sigma$ Receptors; Antipsychotic drugs (Vilner, B.J. (244) 199)

Tributyltin; Triethyltin; Trimethyltin; Intracellular $Ca^{2+}$; Brain neurons (Oyama, Y. (248) 89)

**DADLE ([D-Ala$^2$,D-Leu$^5$]enkephalin)**
Tolerance; Opioid receptors; Autoradiography; (Rat) (Tao, P.-L. (231) 145)

Opioid receptors; Naltrindole; Naloxone; DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin) (Tiseo, P.J. (236) 89)

**Dantrolene**
2,3-Butanedione monoxime; Excitation-contraction uncoupling; Sarcolemma hyperexcitability; Depolarization contractures; Caffeine contracture; Diaphragm (rat) (Røed, A. (241) 229)

**DAU 6285**
5-$HT_4$ receptors; (Pig) (Van Meel, J.C.A. (233) 295)

**DBA/2 mice**
Aniracetam; AMPA receptor antagonists; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline); GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine · HCl); CPPene (D(−)-(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid) (Chapman, A.G. (231) 301)

**Decavanadate**
$K^+$ channels (ATP-sensitive); Ventricular cells (single); Patch clamp (Nakashima, H. (233) 219)

**Defibrotide**
Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Trachea (Bianchi, G. (238) 327)

**Degradation pathway**
Poststatin; Bradykinin; Urine; Kininase (Majima, M. (232) 181)

**Deltorphin**
Opioid receptors; Peptide synthesis; Computer modelling (Salvadori, S. (230) 357)

**[D-Ala$^2$]deltorphin**
Fetal breathing; Opiates; δ-Opioid receptors; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

**[D-Ala$^2$]deltorphin II**
δ-Opioid receptor subtypes; [D-Pen$^2$,D-Pen$^5$]enkephalin; Naltrindole; Benzofuran analogue of naltrindole; Antitussive activity (Kamei, J. (234) 117)

**Deltorphin (substituted)**
Opioid; δ-Opioid receptor; Pseudoirreversible binding (Wild, K.D. (246) 25)

**Dendritic spine density**
Methamphetamine; Prefrontal cortex; Reactive synaptogenesis; (Gerbil) (Dawirs, R.R. (241) 89)

**Dentate gyrus**
Field potentials; Long-term potentiation; NMDA receptors; Dextromethorphan; Methadone; Codeine; Normethadone; MK-801 (Krug, M. (231) 355)

Nitric oxide (NO); Hippocampus; (Rat, in vivo) (Iga, Y. (238) 395)

**Dentate/interpositus**
5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Cerebellum; GABA (γ-aminobutyric acid); 5-$HT_{2/1C}$ receptors (Cumming-Hood, P.A. (236) 457)

**2-Deoxyglucose**
Ischemia; 5-$HT_{1A}$ receptors; 5-$HT_2$ receptors; Electrophysiology; Hippocampus (slices) (Shibata, S. (229) 21)

Buspirone; Glucose utilization; Hippocampus; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine) (Grasby, P. (230) 41)

Somatostatin; Cerebral cortex; Hippocampus; Acetylcholine; Acetylcholine receptors (Shibata, S. (231) 381)

Phorbol ester; Protein kinase C; Hippocampus (Shibata, S. (245) 257)

**2-Deoxy-D-glucose**
Gastric acid secretion; Xanthine; TRH analog; Vagus; Gastric mucosal blood flow; Carbachol (Tanaka, T. (243) 221)

**Dependence**
Phenobarbital; Glutamate receptors; Brain (Short, K.R. (230) 111)

Pentobarbital; $GABA_A$ receptors; Tolerance; (Intracerebroventricular) (Tseng, Y.T. (236) 23)

Morphine exposure (chronic); Tolerance; G-proteins; Adenylyl cyclase activity; Striatal neurons (Van Vliet, B.J. (245) 23)

**Depolarization-activated, $Ca^{2+}$-independent outward currents**
Myocytes (rat ventricular); Whole cell clamping; Caffeine (Sanchez-Chapula, J. (229) 163)

**Depolarization block**
Neuroleptics; Dopamine release; Dopamine metabolism; 3-Methoxytyramine; Striatum; Nucleus accumbens; Frontal cortex; (Rat) (Chrapusta, S.J. (233) 135)

**Depolarization contractures**
2,3-Butanedione monoxime; Excitation-contraction uncoupling; Sarcolemma hyperexcitability; Dantrolene; Caffeine contracture; Diaphragm (rat) (Røed, A. (241) 229)

**Deprenyl**
MDMA (3,4-methylenedioxymethamphetamine); Parachloroamphetamine; Fluoxetine; Clorgyline; Nimodipine; Reserpine (Gu, X.F. (235) 51)

**l-Deprenyl (selegiline)**
Hydroxyl radical; Dopamine; MPTP neurotoxin; $MPP^+$ (1-methyl-4-phenylpyridinium ion); Substantia nigra; Parkinson's disease (Wu, R.-M. (243) 241)

**Depression**
$TGF_\alpha$ (transforming growth factor $\alpha$); Tryptophan; 5-HT (5-hydroxytryptamine, serotonin); Antidepressant drugs; Aggression; Transgenic mice (Hilakivi-Clarke, L.A. (237) 101)

Behavioural despair; Imipramine; Microdialysis (Rossetti, Z.L. (242) 313)

**Dequalinium**
Sympathetic ganglia; Ganglion blockers; Muscarinic receptor antagonists; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

Hepatocytes; Nicotinic receptors; $Ca^{2+}$-activated $K^+$ channels; Vecuronium; Apamin (Castle, N.A. (236) 201)

**[D-Arg$^2$]Dermorphin analogue**
$\mu$-Opioid receptors; Memory; $\beta$-Funaltrexamine; Passive avoidance response (Ukai, M. (239) 237)

**Descending inhibition**
Spinal reflexes; $\alpha_2$-Adrenoceptors; Imidazoline binding sites; Blood pressure (Harris, J. (237) 323)

**Descending inhibitory controls**
Pain; Spinal cord; Morphine; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

**Desensitization**
$\beta$-Adrenoceptors; Facilitation; Prejunctional; Stimulus train length (Lakhlani, P.P. (230) 107)

5-HT (5-hydroxytryptamine, serotonin); Transmitter interaction; Receptor internalization; Protein kinase C (Rahman, S. (238) 173)

$\beta_2$-Adrenoceptors; Hepatocytes (Medina-Martínez, O. (244) 145)

Neurokinin A; $NK_2$ receptors (Henderson, A.K. (245) 75)

$\beta$-Adrenoceptors; Adenylate cyclase; Xamoterol; Atenolol (Arnold, I.R. (245) 285)

Hepatocytes; cAMP; $\beta$-Adrenoceptors; Adenylyl cyclase (Sandnes, D. (246) 163)

$5\text{-}HT_3$ receptor; 5-HT (5-hydroxytryptamine, serotonin); Tetraethylammonium; N1E-115 neuroblastoma; Whole-cell voltage clamp; Ion channel (Kooyman, A.R. (246) 247)

**Desipramine**
Imipramine; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Triiodothyronine (Suzuki, S. (231) 297)

6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopamine (6-OHDA); Nomifensine; Neurotoxicity (Evans, J. (232) 241)

Noradrenaline; Electrochemistry (in vivo); Brain (rat); Anteroventral thalamic nucleus; Locus coeruleus (Brun, P. (235) 205)

Forced swimming test; Diazepam (Martí, J. (236) 295)

Desmethylclomipramine; Clonidine; MHPG (3-methoxy-4-hydroxyphenylglycol); Norepinephrine (Fujita, K. (242) 301)

**Desmethylclomipramine**
Desipramine; Clonidine; MHPG (3-methoxy-4-hydroxyphenylglycol); Norepinephrine (Fujita, K. (242) 301)

**N-Desmethylclozapine**
Clozapine; Clozapine N-oxide; $5\text{-}HT_{1C}$ receptors; Choroid plexus (Kuoppamäki, M. (245) 179)

**Devazepide**
Clonazepam; CCK (cholecystokinin); L365-260; Duodenum; Jejunum; Motility (Bonnafous, C. (237) 237)

**Development**
Ethanol; Flunitrazepam; $GABA_A$ receptors; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

Ontogeny; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Cocaine; Stimulants (Barr, G.A. (233) 143)

Airway obstruction; Asthma; Maturation; Plasma exudation; Vascular permeability (Yokoyama, T. (236) 427)

Autoradiography; Cerebral cortex; Natriuretic peptide receptors (Zorad, S. (241) 195)

Muscarinic receptors; Organophosphate pesticides; Phosphoinositide hydrolysis; mRNA (Balduini, W. (248) 281)

**Dexamethasone**
Endothelin-1; Bronchoconstriction; Bronchorelaxation (Filep, J.G. (240) 315)

Endothelial cells; GM 7373 cell line; Vasocortin; Dextran oedema; Histamine release (Iuvone, T. (243) 163)

**Dexamphetamine-chlordiazepoxide mixture**
Valproate; GABA receptor antagonists; Hyperactivity (Cao, B.-J. (237) 177)

**Dextran oedema**
Dexamethasone; Endothelial cells; GM 7373 cell line; Vasocortin; Histamine release (Iuvone, T. (243) 163)

**Dextromethorphan**
Dentate gyrus; Field potentials; Long-term potentiation; NMDA receptors; Methadone; Codeine; Normethadone; MK-801 (Krug, M. (231) 355)

Epilepsy; Dextrorphan; Glutamate; Kindling; (Rat) (Löscher, W. (238) 191)

NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; $Ca^{2+}$ channel blocking agents; $Na^+$ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

Haloperidol; σ Binding sites; Phenytoin; DTG (1,3-di-o-tolylguanidine); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine) (Bailey, M.A. (240) 243)

σ Sites; Antitussive effects; Noscapine; Rimcazole (Kamei, J. (242) 209)

**Dextrorphan**
Epilepsy; Dextromethorphan; Glutamate; Kindling; (Rat) (Löscher, W. (238) 191)

**Diabetes**
Streptozotocin; Endothelium; Mesenteric artery; Vasodilatation (Furman, B.L. (232) 29)

Angiotensin-converting enzyme inhibition; Albuminuria; Vascular permeability; (Rat) (Huijberts, M. (240) 207)

Pain (chronic); Substance P (Courteix, C. (241) 267)

Streptozotocin; Dopamine; Dopamine $D_1$ receptors; Fenoldopam (Wang, Y.-X. (248) 217)

**Diabetes mellitus**
Diabetic neuropathy; Inositol phosphates; myo-Inositol; Nerve conduction; Streptozotocin (Carrington, A.L. (237) 257)

Vascular permeability; Substance P; Neurokinins; Nitric oxide (NO) (Mathison, R. (240) 163)

Active avoidance; Angiotensin; Angiotensin-converting enzyme inhibitor; Bradykinin; Memory; (Mouse) (Flood, J.F. (240) 311)

Aorta (rat); $N^G$-Nitro-L-arginine; Haemoglobin; Endothelium-dependent relaxation; Tachyphylaxis (Sikorski, B.W. (242) 275)

**Diabetic cardiomyopathy**
Verapamil; $\alpha_1$-Adrenoceptors (cardiac); Inositol 1,4,5-trisphosphate (cardiac); Protein kinase C (cardiac); (Rat) (Tanaka, Y. (244) 105)

**Diabetic heart**
Hypoperfusion; Norepinephrine; Left ventricular stiffness; ATP; Lactate; Insulin (ex vivo) (Higuchi, M. (242) 293)

**Diabetic neuropathy**
Diabetes mellitus; Inositol phosphates; myo-Inositol; Nerve conduction; Streptozotocin (Carrington, A.L. (237) 257)

Brain gangliosides (bovine); 1,2-Diacylglycerol; Diacylglycerolipids; Phosphatidic acid; Arachidonoyl-containing molecular species (Bianchi, R. (239) 55)

**Diacylglycerol**
Angiotensin II; Protein kinase C; Isoenzymes; Inositol 1,4,5-trisphosphate ($InsP_3$); $Ca^{2+}$; Mesangial cells (Ochsner, M. (245) 15)

Arachidonic acid; Phorbol ester binding; Protein kinase C isoforms (MacEwan, D.J. (246) 9)

**1,2-Diacylglycerol**
Brain gangliosides (bovine); Diacylglycerolipids; Phosphatidic acid; Arachidonoyl-containing molecular species; Diabetic neuropathy (Bianchi, R. (239) 55)

**Diacylglycerolipids**
Brain gangliosides (bovine); 1,2-Diacylglycerol; Phosphatidic acid; Arachidonoyl-containing molecular species; Diabetic neuropathy (Bianchi, R. (239) 55)

**Diaphragm (rat)**
2,3-Butanedione monoxime; Excitation-contraction uncoupling; Sarcolemma hyperexcitability; Dantrolene; Depolarization contractures; Caffeine contracture (Røed, A. (241) 229)

**Diazepam**
Aminophylline; Neurosensitization; Electroconvulsion; MK-801; $Na^+$ valproate (Chakrabarti, A. (235) 133)

Forced swimming test; Desipramine (Martí, J. (236) 295)

Melatonin; Anxiolysis; Exploratory behaviour; Benzodiazepine antagonism; (Time-dependent effects) (Golombek, D.A. (237) 231)

5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake; Stress; Tianeptine; Buspirone (Mennini, T. (241) 255)

In situ hybridisation; Cholecystokinin (CCK); Tolerance; Withdrawal; mRNA (Rattray, M. (245) 193)

Benzodiazepine; Tolerance; $Cl^-$ flux; Flurazepam; Bretazenil; Clonazepam (Li, M. (247) 313)

Anticholinesterase; Neostigmine; Neuromuscular transmission; Muscle paralysis (Chiou, L.C. (248) 185)

**Diazepam-insensitive benzodiazepine receptor**
$GABA_A$ receptor; GABA (γ-aminobutyric acid); ZG-63 (Wong, G. (247) 57)

**Dibutyryl cAMP**
Angiotensin II; Cholera toxin; Pertussis toxin; Portal vein (rat) (Zhang, J. (230) 95)

**Dicarboxycyclopropylglycine**
Metabotropic glutamate receptors; Quisqualate; (Hippocampal slices) (Nicoletti, F. (245) 297)

**5,7-Dichlorokynurenic acid**
Electroconvulsive shock; Imipramine; NMDA (*N*-methyl-D-aspartate) receptor complex; Strychnine-insensitive glycine receptor; CGP-39653 (Paul, I.A. (247) 305)

**DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid)**
Gastric acid secretion; Amiloride; $Cl^-$-$HCO_3^-$ exchanger; $Na^+$-$H^+$ exchanger; Stomach (isolated); (Rat) (Horie, S. (229) 15)

**Diethyldithiocarbamate**
Mesentery (rat); L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Methylene blue; CGRP (calcitonin gene-related peptide) (Li, Y.-j. (239) 127)

**Diethylpyrocarbonate**
Endothelin receptor model; Chemical modification; Bombesin (Huggins, J.P. (245) 203)

**Diethylstilbestrol**
Steroids; Myometrium; Uterine artery; Estrogen; Progesterone (Kostrzewska, A. (233) 127)

**Diffuse noxious inhibitory controls**
Dothiepin; Nociceptive flexion reflex; Cold-pressor test; (Human) (Sandrini, G. (243) 99)

**Digoxin**
Intestinal absorption; $Ca^{2+}$ channel blockers; (Guinea-pig) (Budihna, M.V. (230) 301)

**Dihydrexidine**
Dopamine receptor ligands; Dopamine receptors (peripheral) (Kohli, J.D. (235) 31)

Dopamine $D_3$ receptors; Dopamine $D_2$ receptors (Watts, V.J. (239) 271)

Dopamine $D_1$ receptors; SCH23390; SKF38393; Adenylate cyclase; Parkinson's disease; (Rhesus monkey); (Rat) (Watts, V.J. (242) 165)

**Dihydropyridine binding site**
S312; Dihydrothienopyridine; Aorta (rat); Cerebral microvessels (rat); Phenylalkylamine binding site (Dessy, C. (231) 435)

**Dihydropyridine channels**
Renal artery; Autoradiography; Nicardipine; (Human) (Ferrante, F. (240) 229)

**Dihydropyridine drugs**
Neomycin; $Ca^{2+}$ influx; $Ca^{2+}$ (intracellular); Catecholamine release; Adrenal medulla; Chromaffin cells (Duarte, C.B. (244) 259)

**1,4-Dihydropyridine (enantiomers)**
$K^+$; pH; $Ca^{2+}$; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

**Dihydropyridines**
$Mg^{2+}$; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin $F_{2\alpha}$; Cerebral vasospasm; (Human) (Alborch, E. (229) 83)

Ontogeny; $Ca^{2+}$ channel antagonists; Urethra; Bladder (Yoshida, M. (232) 159)

$Ca^{2+}$ channels; $Ca^{2+}$ channel activators; Ventral medullary surface; Respiration; Opioids (endogenous) (Ruiz, F. (240) 155)

PCA 50941; Bay k 8644; $Ca^{2+}$ channel agonists (Priego, J. (243) 25)

Smooth muscle (vascular); Prostaglandins; $Ca^{2+}$ channels; Protein kinase C; Norepinephrine (Rapoport, R.M. (243) 207)

**1,4-Dihydropyridines**
MPC-1304; $Ca^{2+}$ channel antagonists; Vasodilating action (Miyoshi, K. (238) 139)

Smooth muscle (vascular); $Ca^{2+}$ influx; $A_7r_5$ cells; Lacidipine; Amlodipine (Spampinato, S. (244) 139)

Nicotinic acetylcholine receptors; Chromaffin cells; Nimodipine; BAY K 8644; PCA50938; Nifedipine; Nitrendipine; Furnidipine (López, M.G. (247) 199)

**Dihydrothienopyridine**
S312; Aorta (rat); Cerebral microvessels (rat); Dihydropyridine binding site; Phenylalkylamine binding site (Dessy, C. (231) 435)

**1$\alpha$,25-Dihydroxyvitamin $D_3$ analogues**
Thromboxane synthesis; HL-60 cells (human); Vitamin D receptors (Honda, A. (229) 217)

**Diisopropylfluorophosphate**
$\alpha_2$-Adrenoceptors; [$^3$H]Clonidine; [$^3$H]UK 14,304 (bromoxidine); [$^3$H]RX 821002 (2-methoxy idazoxan); Neostigmine; Physostigmine; Pilocarpine (Olmos, G. (236) 467)

**Dipyridamole**
Cerebral blood flow; Hypertension (rabbit); Chronic cerebral ischaemia (Hegedüs, K. (237) 293)

**Disc-sphere change**
Platelets (human); Shape-change parameter; Protein kinase C; Thrombin; 1-Oleoyl-2-acetyl-glycerol (Ozaki, Y. (235) 255)

**Dissociation constant**
LSD (d-lysergic acid diethylamide); 5-HT receptors; Uterine artery (sheep) (Zhang, L. (230) 115)

**Distal colon**
Enteric nerves; GABA receptors; Gastrointestinal motility (Minocha, A. (230) 187)

**Distal nephron segments**
M17055; Loop diuretics; Thiazide diuretics; Amiloride; Free water clearance; Microperfusion study (Shinkawa, T. (238) 317)

**Distress vocalization**
Development; Ontogeny; Ultrasonic vocalization; Tolerance; Withdrawal; Cocaine; Stimulants (Barr, G.A. (233) 143)

**Diuresis**
Morphine; ANF (atrial natriuretic factor) (Gutkowska, J. (242) 7)

**Diuretic effects**
ANP (atrial natriuretic peptide); $Ca^{2+}$ entry blockers; Verapamil; Felodipine; Nifedipine (Shamiss, A. (233) 113)

**Diurnal rhythm**
Adrenoceptors; Noradrenaline; Aorta; (Rat) (Gohar, M. (229) 69)

**Dizocilpine**
NMDA receptor antagonists; Memantine; CGP 39551; Dopamine metabolism; Locomotion (Rat) (Bubser, M. (229) 75)

Drug discrimination; NMDA receptor antagonists; NPC 12626; CP-Pene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; (Squirrel monkey) (Gold, L.H. (230) 285)

NMDA receptor antagonists; Phencyclidine; $\sigma$ Receptor ligands; Interneurons (Zhang, J. (230) 371)

$\sigma$ Binding sites; DTG (1,3-di-(2-tolyl)guanidine); Antipsychotics; d,l-Amphetamine; Animal models; (Rat) (Rückert, N.G.H. (233) 261)

Cerebral ischaemia; Enadoline; Hypothermia; Neuroprotection (Hayward, N.J. (236) 247)

Kynurenic acid; Apnoea; Arterial blood pressure; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

NMDA (N-methyl-D-aspartate); Non-competitive antagonism; FR115427; Cortical wedge; Hippocampus (Hodgkiss, J.P. (240) 219)

**Dizocilpine**
NMDA (*N*-methyl-D-aspartate); FR115427; Ligand binding (Sherriffs, H.J. (247) 319)

**DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide)**
GABA uptake; GABA release; GABA turnover; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

**DMPO (5,5-dimethyl-1-pyrroline-1-oxide)**
Ischemia/reperfusion; Heart; Free radicals; Spin traps (Bradamante, S. (234) 113)

Ischemia/reperfusion; Heart; Free radicals; Spin traps (Bradamante, S. (239) 275)

**cDNA**
GABA/benzodiazepine receptors; Triazolam; Patch clamp; Primary culture (Dučić, I. (244) 29)

**cDNA sequence**
Angiotensin receptor; Aorta (porcine); COS cell expression; *Xenopus* oocyte expression (Itazaki, K. (245) 147)

Parathyroid hormone receptor; Functional expression (Schneider, H. (246) 149)

**DNA synthesis**
Thymidine; Uridine; Leucine; RNA synthesis; Protein synthesis; Thymidine kinase activity (Garg, U.C. (237) 243)

**DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)**
5-HT (5-hydroxytryptamine, serotonin); Excessive grooming; Penile erection; Oxytocin concentration (plasma); $5\text{-HT}_{1C}$ receptors; $5\text{-HT}_2$ receptors; m-CPP (1-(3-chlorophenyl)piperazine) (Bagdy, G. (229) 9)

Ipsapirone; $5\text{-HT}_{1A}$ receptors; $5\text{-HT}_2$ receptors; Anxiolysis; Glucose; Corticosterone; Prolactin; Behaviour (Baudrie, V. (231) 395)

5-HT (5-hydroxytryptamine, serotonin); Dentate/interpositus; Cerebellum; GABA (γ-aminobutyric acid); $5\text{-HT}_{2/1C}$ receptors (Cumming-Hood, P.A. (236) 457)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Long-term treatment; Neonatal; Ultrasonic calls; (Rat pup) (Johansson-Wallsten, C.E. (243) 149)

**R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)**
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; $5\text{-HT}_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

**Domoate**
[$^3$H]Kainate binding; Excitatory amino acid receptors; $Ca^{2+}$; Brain (Johansen, T.H. (246) 195)

**DOPAC (3,4-dihydroxyphenylacetic acid)**
HA-966; (+)-MK-801; Excitatory amino acids; Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

**l-DOPA (l-dihydroxyphenylalanine)**
Somatostatin; Neuropeptide Y; Amantadine; 6-Hydroxydopamine; Bifemelane (Maeda, K. (233) 227)

**Dopamine**
Acetylcholine; Microdialysis; Cocaine; α-Methyltyrosine + reserpine; (−)-Sulpiride; SCH 23390 (Imperato, A. (229) 265)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Substantia nigra; Motor deficits; Age; (Common marmoset) (Rose, S. (230) 177)

δ-Opioid receptors; Ethanol (Acquas, E. (230) 239)

Glutamate; Neuroleptics; Nucleus accumbens; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

Electrooculogram; Haloperidol; Light peak; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

Dystonia; Phenobarbital; GABA (γ-aminobutyric acid); Glutamate; Haloperidol (Richter, A. (231) 111)

Microdialysis; Ethanol reinforcement; Tolerance (Rossetti, Z.L. (231) 203)

σ Receptor ligands; Microdialysis; Vacuous chewing; DTG (1,3-di-o-tolylguanidine); (+)-Pentazocine (Patrick, S.L. (231) 243)

d-Amphetamine; Substantia nigra; Autoreceptors; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

Cathinone; Conditioned place preference; Locomotion; (Rat) (Schechter, M.D. (232) 135)

Cholecystokinin; Neurotensin; Reward; Ventral tegmental area (Rompré, P.-P. (232) 299)

Isradipine; Cerebral ischemia; Microdialysis; $Ca^{2+}$ channels (voltage-sensitive) (Ooboshi, H. (233) 165)

Carbamazepine; Cocaine; Nucleus accumbens; Microdialysis; (Rat) (Baptista, T. (236) 39)

Dystonia; κ-Opioid receptors; σ Receptors; Naloxone; Naltrexone; Movement disorders; Glutamate (Richter, A. (236) 289)

Thermoregulation; Dopamine receptors; (Rat) (Salmi, P. (236) 395)

NMDA (N-methyl-D-aspartate); MK-801; LY274614; SCH23390; Clebopride; Catalepsy; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

Amphetamine; Prefrontal cortex; Stress; Sensitization (Hamamura, T. (237) 65)

Cocaine; d-Amphetamine; Hippocampus; Caudate nucleus; Acetylcholine (Imperato, A. (238) 377)

Catechol O-methyltransferase (COMT) inhibition; $Uptake_2$ (central); Dopamine metabolism; Brain (Törnwall, M. (239) 39)

Jumping; Quinpirole; Receptor supersensitivity (Kostrzewa, R.M. (239) 183)

Microdialysis; 4-PTIQ (4-phenyltetrahydroisoquinoline); Cocaine; Nomifensine; Methamphetamine; Nucleus accumbens (Tateyama, M. (240) 51)

Prefrontal cortex; Microdialysis; Schizophrenia; Amperozide; Clozapine (Pehek, E.A. (240) 107)

Glutamate; Phencyclidine; Ipsapirone; 5-HT (5-hydroxytryptamine, serotonin); MK-801 (Löscher, W. (242) 99)

Microdialysis; Dopamine release; Dopamine autoreceptors; Dopamine $D_3$ receptors; (Rat) (Waters, N. (242) 151)

SCH 23390; Dopamine $D_1$ receptors; Self-stimulation (Sabater, R. (242) 205)

Glutamate; 5-HT (5-hydroxytryptamine, serotonin); Phencyclidine (Löscher, W. (242) 263)

Dystonia; Movement disorders; 5-HT (5-hydroxytryptamine, serotonin); Glutamate (Richter, A. (242) 309)

Microdialysis; Opioid; μ-Opioid receptors; GABA (γ-aminobutyric acid); Ventral tegmental area; Nucleus accumbens (Devine, D.P. (243) 55)

l-Deprenyl (selegiline); Hydroxyl radical; MPTP neurotoxin; $MPP^+$ (1-methyl-4-phenylpyridinium ion); Substantia nigra; Parkinson's disease (Wu, R.-M. (243) 241)

5-HT (serotonin 5-hydroxytryptamine binding proteins); Brain; 5-HT (serotonin 5-hydroxytryptamine); Superoxide radicals; Iron ions (Jimenez Del Rio, M. (247) 11)

Phospholipase C; Phosphatidylinositol 4,5-bisphosphate; Inositol 1,4,5-trisphosphate; Striatum (rat); Aging (Sugawa, M. (247) 39)

Diabetes; Streptozotocin; Dopamine $D_1$ receptors; Fenoldopam (Wang, Y.-X. (248) 217)

**Dopamine autoreceptors**
Dopamine $D_2$ receptor agonists; Dopamine $D_2$ receptor antagonists; Amphetamine; Side-effects; (Monkey) (Peacock, L. (237) 329)

Microdialysis; Dopamine; Dopamine release; Dopamine $D_3$ receptors; (Rat) (Waters, N. (242) 151)

**Dopamine $D_1$/$D_2$ receptor interaction**
Turning behaviour; Nucleus accumbens; SKF 38393; Quinpirole; Limb stepping (Saigusa, T. (237) 161)

**Dopamine metabolism**
NMDA receptor antagonists; Dizocilpine; Memantine; CGP 39551; Locomotion (Rat) (Bubser, M. (229) 75)

Neuroleptics; Dopamine release; 3-Methoxytyramine; Striatum; Nucleus accumbens; Frontal cortex; Depolarization block; (Rat) (Chrapusta, S.J. (233) 135)

Catechol O-methyltransferase (COMT) inhibition; $Uptake_2$ (central); Dopamine; Brain (Törnwall, M. (239) 39)

**Dopamine neuronal carrier**
Membrane polarity; [$^3$H]GBR 12783; Binding (in vitro); Striatum (rat) (Billaud, G. (247) 333)

**Dopamine neurons**
Reserpine; Substantia nigra pars compacta; Dopamine receptor agonists; Firing pattern; Single-unit recording; Supersensitivity (Sun, B.-C. (231) 331)

**Dopamine receptor agonists**
On-off effects; Rotation; Classical conditioning; 6-Hydroxydopamine (6-OHDA); Nigrostriatal lesions (Silverman, P.B. (229) 235)

Reserpine; Substantia nigra pars compacta; Dopamine neurons; Firing pattern; Single-unit recording; Supersensitivity (Sun, B.-C. (231) 331)

AMPA receptors; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline(1H,4H)dione sodium salt); Parkinsonism; Dyskinesia (Luquin, M.R. (235) 297)

Sensitization; NMDA receptors; Apomorphine; MK-801 (Druhan, J.P. (243) 73)

**Dopamine $D_1$ receptor agonists**
Dopamine $D_2$ receptor agonists; Nucleus accumbens; Oral behaviour; Principal factor analysis; SK&F 38393; Quinpirole (Koene, P. (233) 151)

A68930; SK&F 38393; Grooming behaviour; REM (rapid eye movement) sleep; (Rat) (Trampus, M. (235) 83)

Dopamine $D_1$ receptors; NNC-756; Dopamine $D_1$ receptor antagonists; Oral movement; Vacuous chewing movement (Glenthøj, B. (242) 283)

**Dopamine $D_2$ receptor agonists**
Dopamine $D_1$ receptor agonists; Nucleus accumbens; Oral behaviour; Principal factor analysis; SK&F 38393; Quinpirole (Koene, P. (233) 151)

Dopamine autoreceptors; Dopamine $D_2$ receptor antagonists; Amphetamine; Side-effects; (Monkey) (Peacock, L. (237) 329)

Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Bromocriptine; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

**Dopamine $D_1$ receptor antagonists**
Dopamine $D_1$ receptors; NNC-756; Dopamine $D_1$ receptor agonists; Oral movement; Vacuous chewing movement (Glenthøj, B. (242) 283)

**Dopamine $D_2$ receptor antagonists**
Dopamine autoreceptors; Dopamine $D_2$ receptor agonists; Amphetamine; Side-effects; (Monkey) (Peacock, L. (237) 329)

**Dopamine $D_2$ receptor binding**
Dopamine $D_2$ receptors; Antipsychotics; Neuroleptics; [$^3$H]YM-09151-2; Biphasic displacement (Assié, M.-B. (237) 183)

**Dopamine receptor ligands**
Dihydrexidine; Dopamine receptors (peripheral) (Kohli, J.D. (235) 31)

**Dopamine receptors**
Adenylate cyclase; Opioid receptors; Brain slices (rat) (Heijna, M.H. (229) 197)

Stereotypies; Behavioral supersensitivity; Autoradiography (Marin, C. (231) 191)

Thermoregulation; Dopamine; (Rat) (Salmi, P. (236) 395)

AJ 76; UH 232; Striatum; Acetylcholine release; Antipsychotics (Gifford, A.N. (237) 169)

Remoxipride; Remoxipride metabolites; Antipsychotics; [$^3$H]Raclopride binding (Mohell, N. (238) 121)

Aromatic L-amino acid decarboxylase; Striatum; Neuroleptics (Zhu, M.-Y. (238) 157)

Dopamine (renal); Fenoldopam; Quinpirole; SCH 23390; Cis-flupentixol; $LLC\text{-}PK_1$ cells; Organic cations (renal); Quinine (Dawson, Jr., R. (240) 277)

Locomotor activity; Turning behaviour; Yawning; Blood pressure; Pressor response; Body temperature; Spontaneously hypertensive rats (SHR) (Van den Buuse, M. (243) 169)

Mesenteric artery; Cyclic AMP; Smooth muscle (vascular); Phenoxybenzamine (Hall, A.S. (247) 249)

Cyanide; Thiocyanate; Striatum (Cassel, G.E. (248) 297)

**Dopamine $D_1$ receptors**
A-77636; Parkinsonism; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); A-77636 ((1R,3S)-3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride); (Marmoset) (Kebabian, J.W. (229) 203)

Paw test; SCH 39166; Raclopride; Haloperidol; Dopamine $D_2$ receptors (Prinssen, E.P.M. (231) 275)

Schizophrenia; Affinity states (Mamelak, M. (233) 175)

Dopamine $D_2$ receptors; GBR 12909; Learning (latent); Locomotor activity (Ichihara, K. (234) 155)

Radioligand binding; Autoradiography; Umbilical artery; (Human) (Ferreira-de-Almeida, J.A. (234) 209)

Dopamine $D_2$ receptors; Motor behaviour; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Monkey) (Vermeulen, R.J. (235) 143)

c-Fos; Tolerance (Asin, K.E. (235) 167)

NMDA (N-methyl-D-aspartate); MK-801; LY274614; SCH23390; Clebopride; Catalepsy; Dopamine; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

Dopamine $D_2$ receptors; Microdialysis; Prefrontal cortex; (Rat) (Santiago, M. (239) 83)

Spontaneous alternation performance; Memory; Dynorphin A-(1–13); Dopamine $D_2$ receptors; (Mouse) (Itoh, J. (241) 99)

Dihydrexidine; SCH23390; SKF38393; Adenylate cyclase; Parkinson's disease; (Rhesus monkey); (Rat) (Watts, V.J. (242) 165)

SCH 23390; Dopamine; Self-stimulation (Sabater, R. (242) 205)

NNC-756; Dopamine $D_1$ receptor antagonists; Dopamine $D_1$ receptor agonists; Oral movement; Vacuous chewing movement (Glenthøj, B. (242) 283)

N-(3-[$^{18}$F]Fluoropropyl)SCH 38548; PET (positron emission tomography) (Mukherjee, J. (243) 287)

Dopamine $D_1$ receptor turnover; SCH 23390; N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); Striatum; Substantia nigra; Brain (Rat) (Giorgi, O. (245) 139)

Adenylyl cyclase (Izenwasser, S. (246) 39)

Autoradiography; Rolipram receptor; Cerebral ischemia; SCH 23390; Pentobarbital; $Ca^{2+}$/calmodulin independent cyclic adenosine monophosphate selective phosphodiesterase; (Gerbil) (Kanai, Y. (248) 191)

Diabetes; Streptozotocin; Dopamine; Fenoldopam (Wang, Y.-X. (248) 217)

**Dopamine $D_2$ receptors**
Neurotensin; CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

Paw test; SCH 39166; Raclopride; Haloperidol; Dopamine $D_1$ receptors (Prinssen, E.P.M. (231) 275)

Neurotensin fragments; Receptor-receptor interactions; Neostriatum; (Rat) (Li, X.-M. (234) 125)

Dopamine $D_1$ receptors; GBR 12909; Learning (latent); Locomotor activity (Ichihara, K. (234) 155)

$^{125}$I-Sulpiride; Dopamine $D_3$ receptors; Nucleus accumbens; Olfactory tubercle; Caudate nucleus; (Rat) (Parsons, B. (234) 269)

U-50,488H; Tolerance; Abstinence; 2-Bromo-$\alpha$-ergocryptine; Behavioural activity (Veeranna, (235) 23)

Dopamine $D_1$ receptors; Motor behaviour; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Monkey) (Vermeulen, R.J. (235) 143)

Intraocular pressure; Aqueous humor flow rate; (Rabbit) (Potter, D.E. (236) 61)

Dopamine $D_4$ receptors; Schizophrenia; Antipsychotics; Extrapyramidal side effects; Tardive dyskinesia (Lahti, R.A. (236) 483)

NMDA (N-methyl-D-aspartate); MK-801; LY274614; SCH23390; Clebopride; Catalepsy; Dopamine; Dopamine $D_1$ receptors; (Rat) (Moore, N.A. (237) 1)

Antipsychotics; Neuroleptics; [$^3$H]YM-09151-2; Dopamine $D_2$ receptor binding; Biphasic displacement (Assié, M.-B. (237) 183)

Dopamine $D_1$ receptors; Microdialysis; Prefrontal cortex; (Rat) (Santiago, M. (239) 83)

Dopamine $D_3$ receptors; Dihydrexidine (Watts, V.J. (239) 271)

Spontaneous alternation performance; Memory; Dynorphin A-(1–13); Dopamine $D_1$ receptors; (Mouse) (Itoh, J. (241) 99)

EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Radioligand binding (in vivo); Pituitary; Prolactin; NPA (*R*-(−)-*N*-*n*-propylnorapomorphine); Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5]azepine); (Receptor reserve); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Ekman, A. (243) 295)

Adenosine $A_2$ receptors; CGS 21680; Gpp(NH)p; GDP-$\beta$-S; $Mg^{2+}$; Neostriatum; (Rat) (Ferré, S. (244) 311)

[$^3$H]Spiperone; Affinity state; Dorsal hippocampus; Ventral hippocampus; Striatum; $Mg^{2+}$; GTP; Iron-chelator (Bruinink, A. (245) 157)

**Dopamine $D_3$ receptors**
$^{125}$I-Sulpiride; Dopamine $D_2$ receptors; Nucleus accumbens; Olfactory tubercle; Caudate nucleus; (Rat) (Parsons, B. (234) 269)

Ligand binding; [$^{125}$I]trans-7-OH-PIPAT-A (Kung, M.-P. (235) 165)

Aminotetralins; 7-OH-DPAT (7-hydroxy-2-(N,N-di-n-propylamino) tetralin) (Baldessarini, R.J. (239) 269)

Dopamine $D_2$ receptors; Dihydrexidine (Watts, V.J. (239) 271)

Microdialysis; Dopamine; Dopamine release; Dopamine autoreceptors; (Rat) (Waters, N. (242) 151)

**Dopamine $D_4$ receptors**
Aporphines; Sulpiride (Seeman, P. (233) 173)

Dopamine $D_2$ receptors; Schizophrenia; Antipsychotics; Extrapyramidal side effects; Tardive dyskinesia (Lahti, R.A. (236) 483)

**Dopamine $D_3$ receptors (bovine caudate)**
7-OH-DPAT (7-hydroxy-N,N-di-n-propyl-2-aminotetralin); $\sigma$ Sites (Schoemaker, H. (242) R1)

**Dopamine receptors (peripheral)**
Dihydrexidine; Dopamine receptor ligands (Kohli, J.D. (235) 31)

**Dopamine $D_1$ receptor subtypes**
Grooming; Vacuous chewing (Downes, R.P. (234) 135)

**Dopamine $D_1$ receptor turnover**
Dopamine $D_1$ receptors; SCH 23390; N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); Striatum; Substantia nigra; Brain (Rat) (Giorgi, O. (245) 139)

**Dopamine release**
MK-801; Ketamine; Methamphetamine; Ceruletide; Cholecystokinin-like decapeptide; Avoidance behaviour (Kuribara, H. (231) 7)

Striatum; Haloperidol; Apomorphine; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

Neuroleptics; Dopamine metabolism; 3-Methoxytyramine; Striatum; Nucleus accumbens; Frontal cortex; Depolarization block; (Rat) (Chrapusta, S.J. (233) 135)

Microdialysis; Dopamine; Dopamine autoreceptors; Dopamine $D_3$ receptors; (Rat) (Waters, N. (242) 151)

Glutamate receptors; Brain, in vitro (rat); Olfactory tubercle; Frontal cortex; Striatum (Jones, C.A. (242) 183)

**Dopamine release (striatal)**
Morphine withdrawal; Acetylcholine release (striatal) (Tjon Tien Ril, H.K.G. (235) 321)

**Dopamine (renal)**
Fenoldopam; Quinpirole; SCH 23390; Cis-flupentixol; LLC-$PK_1$ cells; Organic cations (renal); Dopamine receptors; Quinine (Dawson, Jr., R. (240) 277)

**Dopaminergic neurons**
$\gamma$-Hydroxybutyric acid (GHB); $GABA_A$ receptors; Ethanol; NMDA receptor antagonists (Diana, M. (230) 363)

Ganglioside GM1; Glycosphingolipid derivatives; Excitotoxicity; Neuroprotection; Parkinson's disease (Skaper, S.D. (243) 91)

**Dopamine synthesis**
5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; 5-$HT_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

**Dopamine transporters**
Cocaine; Tropanes; Striatum (Davies, H.M.L. (244) 93)

**Dopamine uptake**
Cocaine; Caudate-putamen; $\sigma$ Receptors; Rimcazole; [$^3$H]CFT ([$^3$H]2$\beta$-carbomethoxy-3$\beta$-(4-fluoro-phenyl)-tropane, [$^3$H]WIN 35,428) (Izenwasser, S. (243) 201)

**Dopamine uptake inhibitors**
[$^3$H]GBR 12783 binding site occupancy; Locomotor activity; Cytochrome P450; (Mouse) (Vaugeois, J.-M. (230) 195)

**Doridosine (1-methylisoguanosine) derivatives**
Competition binding studies; Adenosine $A_1$ receptors; Adenosine $A_2$ receptors; Bradycardia; (Rat) (Tao, P.-L. (243) 135)

**Dorsal hippocampus**
5-$HT_{1A}$ receptors; Passive avoidance; Memory; Anxiolytic effects; Antidepressant effects (Carli, M. (234) 215)

[$^3$H]Spiperone; Dopamine $D_2$ receptors; Affinity state; Ventral hippocampus; Striatum; $Mg^{2+}$; GTP; Iron-chelator (Bruinink, A. (245) 157)

**Dorsal pedal artery**
Congestive heart failure; $\alpha_1$-Adrenoceptor activation pathways; $Ca^{2+}$ channel antagonists; Saphenous vein (Forster, C. (242) 119)

**Dorsal raphe nucleus**
Methionine sulfoximine; Hypothermia; 5-HT receptors; GABA ($\gamma$-aminobutyric acid); GABA receptors (Ginefri-Gayet, M. (235) 189)

Anxiolytics; Electrophysiology; Hippocampus; Ipsapirone; Microdialysis; Serotonergic neurotransmission; 5-$HT_{1A}$ receptors; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

WAY 100,135; (−)-Tertatolol; Flat-body posture; Corticosterone (Lejeune, F. (240) 307)

**Dorsal raphe (rat)**
Aggression; TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Mos, J. (238) 411)

**Dotarizine**
Aorta; $^{45}Ca^{2+}$ movements; Basilar smooth muscle; (Rabbit) (Tejerina, T. (239) 75)

**Dothiepin**
Nociceptive flexion reflex; Diffuse noxious inhibitory controls; Cold-pressor test; (Human) (Sandrini, G. (243) 99)

**Down-regulation**
5-$HT_{1C}$ receptors; Spinal 5-$HT_{1C}$ sites; [$^3$H]Mesulergine; (Rat) (Pranzatelli, M.R. (244) 1)

G-protein; Cerebral cortex; Adenylyl cyclase; $\beta$-Adrenoceptors; F-344 rats; Tricyclic antidepressants (Scarpace, P.J. (247) 65)

$\beta$-Adrenoceptors; $\beta$-Adrenoceptor agonist; Lung; Transcription factor; (rat) (Nishikawa, M. (247) 131)

**Doxorubicin**
Pirarubicin; Aclarubicin; Heart (guinea-pig); Antimuscarinic action; Positive inotropic effect; Potentiated postrest contraction; Time to peak twitch tension (Temma, K. (234) 173)

**DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin)**
Morphine; Naloxone; Naloxonazine, $\beta$-Funaltrexamine; Nor-binaltorphimine; ICI 174,864; Substance P; Trigeminal nucleus caudalis (Suarez-Roca, H. (229) 1)

$\delta$-Opioid receptor subtypes; [D-Ala$^2$]deltorphin II; Naltrindole; Benzofuran analogue of naltrindole; Antitussive activity (Kamei, J. (234) 117)

Opioid receptors; Naltrindole; Naloxone; DADLE ([D-Ala$^2$,D-Leu$^5$]enkephalin) (Tiseo, P.J. (236) 89)

Thermodynamics; δ-Opioid receptors; Mouse vas deferens (Raffa, R.B. (244) 231)

**DPLPE ([D-Pen$^2$,L-Pen$^5$]enkephalin)**
Cocaine; Naltrindole (Ukai, M. (231) 143)

**DPI 201-106**
BDF 9148; Positive inotropy; (Enantiomers) (Hoey, A. (231) 477)

**DP receptors**
Eye; Inflammation; Intraocular pressure; Eosinophils; Prostaglandin $D_2$ (Woodward, D.F. (230) 327)

**Drug design**
Monoclonal antibodies; NMDA receptors; Phencyclidine (Casalotti, S.O. (247) 209)

**Drug discrimination**
p-Chloroamphetamine; p-Methylthioamphetamine; Uptake inhibition; Superfusion; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain slices (Huang, X. (229) 31)

NMDA receptor antagonists; NPC 12626; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

5-$HT_{1A}$ receptors; Adenylate cyclase; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Rabin, R.A. (235) 237)

Neuroactive steroids; Behaviour; Benzodiazepines; Pentobarbital; Ethanol (Ator, N.A. (241) 237)

**Drug holidays (rats)**
Oral dyskinesia; Haloperidol (intermittent); Sensitization (pharmacological); Amygdala kindling (Glenthøj, B. (236) 401)

**Drug-nutrient interaction**
Robenidine; Coccidiosis; D-Galactose; L-Leucine; Intestinal transport; Jejunum (rabbit); Sucrase; Aminopeptidase (Sorribas, V. (248) 137)

**DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)**
Parkinson's disease; Locus coeruleus; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatal dopamine; C57Bl/6 mouse (Marien, M. (236) 487)

Noradrenaline; Scopolamine; Acetylcholine; Working memory; Reference memory (Ohno, M. (238) 117)

**DTG (1,3-di-(2-tolyl)guanidine)**
σ Receptor ligands; Dopamine; Microdialysis; Vacuous chewing; (+)-Pentazocine (Patrick, S.L. (231) 243)

σ Binding sites; Antipsychotics; d,l-Amphetamine; Dizocilpine; Animal models; (Rat) (Rückert, N.G.H. (233) 261)

σ Receptors; Emesis; (Agonists); (Antagonists); (Modifiers); (Pigeon) (Hudzik, T.J. (236) 279)

σ Receptor ligands; Haloperidol; Anticonvulsants; Prepiriform cortex (Roth, J.E. (236) 327)

σ Binding sites; Imipramine; Striatum; Hippocampus; 5-HT (5-hydroxytryptamine, serotonin) (Shirayama, Y. (237) 117)

Haloperidol; Dextromethorphan; σ Binding sites; Phenytoin; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine) (Bailey, M.A. (240) 243)

**Duodenum**
Neuropeptide Y (NPY); σ Receptors; CCK (cholecystokinin); Bicarbonate secretion; (Rat) (Pascaud, X.B. (231) 389)

Clonazepam; CCK (cholecystokinin); Devazepide; L365-260; Jejunum; Motility (Bonnafous, C. (237) 237)

**Duodenum (rat)**
Nitric oxide (NO); NO synthase inhibitors; L-NAME ($N^G$-nitro-L-arginine methyl ester); $HCO_3^-$ secretion (Takeuchi, K. (231) 135)

**DuP 753**
Peptides; Angiotensin-(1–7); Angiotensin receptors; Nitric oxide synthase; L-NAME ($N^G$-nitro-L-arginine methyl ester) (Osei, S.Y. (234) 35)

Nephrosis; Puromycin aminonucleoside (Yayama, K. (236) 337)

**DuPont Merck S-7389-4**
U-50,488H; Rimcazole; κ-Opioid agonists; σ Receptor antagonists; EEG power spectra (Young, G.A. (231) 473)

**Dura mater**
Neurogenic inflammation; Plasma protein extravasation; CGRP (calcitonin gene-related peptide); Tachykinin receptors (O'Shaughnessy, C.T. (236) 319)

$NK_1$, receptor antagonist (non-peptide); Neurogenic inflammation; Migraine model; Substance P (Moussaoui, S.M. (238) 421)

**Dye transfer**
Liver tumour promotion (rat); Hepatocytes; Gap-junctional intercellular communication; (Long-term coculture) (Mesnil, M. (248) 59)

**Dynorphin**
κ-Opioid receptors; Bremazocine; Ileum (guinea-pig) (Webster, J.L. (231) 251)

**Dynorphin A-(1–13)**
Nor-binaltorphimine; Memory; Ischemia; Body temperature; (Mouse) (Itoh, J. (234) 9)

Spontaneous alternation performance; Nor-binaltorphimine; Memory; (Mouse) (Itoh, J. (236) 341)

Spontaneous alternation performance; Memory; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Mouse) (Itoh, J. (241) 99)

**Dyskinesia**
AMPA receptors; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline(1H,4H)dione sodium salt); Parkinsonism; Dopamine receptor agonists (Luquin, M.R. (235) 297)

**Dystonia**
Phenobarbital; Dopamine; GABA (γ-aminobutyric acid); Glutamate; Haloperidol (Richter, A. (231) 111)

Glutamate; Probenecid (Richter, A. (231) 287)

κ-Opioid receptors; σ Receptors; Naloxone; Naltrexone; Movement disorders; Dopamine; Glutamate (Richter, A. (236) 289)

Movement disorders; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Glutamate (Richter, A. (242) 309)

**E3330**
Liver injury; Galactosamine; TNF-α (tumor necrosis factor-α); Leukotrienes; Prostanoids (Nagakawa, J.-i. (229) 63)

**Edema**
Asthma; Plasma exudation; Bradykinin; Airway obstruction; Vascular permeability; OKY-046; Indomethacin (Arakawa, H. (229) 131)

Phospholipase $A_2$; Inflammation (Morgan, D.W. (235) 45)

**EDHF (endothelium-derived hyperpolarizing factor)**
Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); $N^{\omega}$-Nitro-L-arginine; Glybenclamide; Aorta (rabbit) (Bellan, J.A. (234) 273)

**EDRF (endothelium-derived relaxing factor)**
5-HT (5-hydroxytryptamine, serotonin); Arterioles; Microcirculation; Nitric oxide (NO); $N^{G}$-Nitro-L-arginine (Alsip, N.L. (229) 117)

Porcine endocardial endothelium; Human platelets (washed); NO synthase inhibitors (Siney, L. (229) 223)

L-NAME ($N^{G}$-nitro-L-arginine methyl ester); Intravascular ultrasound; Vasomotion (Schwarzacher, S. (229) 253)

Renal arteries; Ischemia; Renal hemodynamics; (Rabbit) (Pruneau, D. (231) 215)

Smooth muscle (vascular); Endothelium (vascular); Endothelins; $ET_B$ receptors; $ET_B$ receptor antagonists; IRL 1038; Aorta (rat) (Karaki, H. (231) 371)

Nitric oxide (NO); EDHF (endothelium-derived hyperpolarizing factor); $N^{\omega}$-Nitro-L-arginine; Glybenclamide; Aorta (rabbit) (Bellan, J.A. (234) 273)

$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; cGMP; Nitric oxide (NO); Pulmonary artery (pig) (Pepke-Zaba, J. (235) 169)

ANF (atrial natriuretic factor); cGMP; Heart failure (Arnal, J.-F. (237) 265)

Hyperemia (reactive); Nitric oxide (NO), Coronary flow regulation; Endothelium (Domenech, R. (238) 53)

Aldose reductase; Aorta; Galactosaemia; Nitric oxide (NO); Polyol pathway (Cameron, N.E. (243) 47)

Atrial natriuretic peptides (ANP); cGMP; (Receptor down-regulation) (Kato, J. (244) 153)

Hyperlipidemia; Vascular reactivity; Wistar-Kyoto rats (WKY); Spontaneously hypertensive rats (SHR); Aortic arch; Abdominal aorta (Yu, S.-M. (248) 289)

**EDTA**
EGTA; Gastric acid secretion; Ethanol; Gastric ulcer; Pepsin; Stress (Glavin, G.B. (233) 269)

**EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline)**
Radioligand binding (in vivo); Pituitary; Prolactin; Dopamine $D_2$ receptors; NPA (*R*-(−)-*N*-*n*-propylnorapomorphine); Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5]azepine); (Receptor reserve); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Ekman, A. (243) 295)

Dopamine $D_1$ receptors; Dopamine $D_1$ receptor turnover; SCH 23390; Striatum; Substantia nigra; Brain (Rat) (Giorgi, O. (245) 139)

**EEG power spectra**
U-50,488H; Rimcazole; DuPont Merck S-7389-4; κ-Opioid agonists; σ Receptor antagonists (Young, G.A. (231) 473)

**Eformoterol**
Eosinophils; Respiratory burst; Salmeterol; Salbutamol; β-Adrenoceptors (Rabe, K.F. (231) 305)

**EGF (epidermal growth factor)**
Phosphotyrosine phosphatase; Melittin; Arachidonic acid; Phospholipase $A_2$; Fibroblasts (Errasfa, M. (247) 73)

**EGTA**
EDTA; Gastric acid secretion; Ethanol; Gastric ulcer; Pepsin; Stress (Glavin, G.B. (233) 269)

**Eicosanoid production**
CS-518; Thromboxane synthase inhibitors; Asthmatic model (Itoh, K. (237) 215)

**Ejaculation**
Sexual behaviour; Castration; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Testosterone; (Wistar rat) (Haensel, S.M. (233) 187)

**Electrical field stimulation**
Myometrium; Cervical smooth muscle; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Pregnancy (Okawa, T. (230) 341)

VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); Cholinergic neurotransmission; Inhibitory non-adrenergic non-cholinergic (i-NANC) (Belvisi, M.G. (231) 97)

5-HT (5-hydroxytryptamine, serotonin); α-Methyl-5-hydroxytryptamine; Bronchi (rat); $5\text{-}HT_2$ receptors; Ketanserin; Mianserin; Spiperone; Cholinergic nerves (Szarek, J.L. (231) 339)

Cholinergic neurotransmission; Muscarinic $M_2$ receptors; Muscarinic $M_3$ receptors; Trachea (guinea-pig); Muscarinic receptor antagonists (Ten Berge, R.E.J. (233) 279)

**Electrochemistry (in vivo)**
Desipramine; Noradrenaline; Brain (rat); Anteroventral thalamic nucleus; Locus coeruleus (Brun, P. (235) 205)

**Electroconvulsion**
Aminophylline; Neurosensitization; Diazepam; MK-801; $Na^+$ valproate (Chakrabarti, A. (235) 133)

**Electroconvulsive shock**
pBNP-32 (porcine brain natriuretic peptide-32); Amnesia; (Receptor blockers) (Bidzseranova, A. (232) 305)

Imipramine; NMDA (*N*-methyl-D-aspartate) receptor complex; Strychnine-insensitive glycine receptor; 5,7-Dichlorokynurenic acid; CGP-39653 (Paul, I.A. (247) 305)

**Electroencephalography**
Epilepsy; Absence seizures; Cholinergic drugs; (Rat) (Danober, L. (234) 263)

**Electromechanical coupling**
Reactive oxygen species; Lipid peroxidation; Cardiac cells; Reperfusion injury (Iliou, J.-P. (248) 263)

**Electron spin resonance**
Tetramethylpyrazine; Membrane fluidity; Fluorescence polarization; Smooth muscle (vascular) (Nie, S.-Q. (244) 15)

**Electrooculogram**
Dopamine; Haloperidol; Light peak; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Electrophysiology**
Ischemia; 5-$HT_{1A}$ receptors; 5-$HT_2$ receptors; 2-Deoxyglucose; Hippocampus (slices) (Shibata, S. (229) 21)

Taurine; $Ca^{2+}$ channels (L-type); $Ca^{2+}$ channels (T-type); Cardiac myocytes; Heart cells (embryonic chick); Voltage clamp (whole cell) (Satoh, H. (231) 443)

Cholecystokinin; $CCK_A$ receptors; Slow depolarization; Sympathetic neurons (mammalian); Primary cell culture (Knoper, S.R. (232) 65)

Anxiolytics; Dorsal raphe nucleus; Hippocampus; Ipsapirone; Microdialysis; Serotonergic neurotransmission; 5-$HT_{1A}$ receptors; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

**Electrophysiology (developmental)**
Lidocaine; Use dependence; Acidosis; Purkinje fibers (Hamra, M. (230) 167)

Lidocaine; Use dependence; Acidosis; Purkinje fibers (Hamra, M. (236) 497)

**Electroshock (maximal)**
CGP 37849; CGP 39551; Valproate; Seizures (Czechowska, G. (232) 59)

**Eltoprazine**
Aggression; TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Dorsal raphe (rat) (Mos, J. (238) 411)

**Embryology**
Endothelin; Vein; Cholinergic innervation; Atropine; Neostigmine (Hayakawa, A. (239) 219)

**Embryonic angiogenesis**
Radicicol; Cell differentiation modulator; Anti-angiogenic action; Chorioallantoic membrane (Oikawa, T. (241) 221)

**Emesis**
Litoxetine; Antidepressants; 5-HT (5-hydroxytryptamine, serotonin) (Angel, I. (232) 139)

$\sigma$ Receptors; DTG (1,3-di-(2-tolyl)guanidine); (Agonists); (Antagonists); (Modifiers); (Pigeon) (Hudzik, T.J. (236) 279)

5-$HT_3$ receptor; Cisplatin; m-Chlorophenylbiguanide; YM060 (Kamato, T. (238) 369)

Morphine; 5-$HT_3$ receptor antagonists; (Ferret) (Wynn, R.L. (241) 47)

Cisplatin; Free radicals; (House musk shrew) (Torii, Y. (248) 131)

Cisplatin; Free radicals; Iron; (*Suncus murinus*) (Matsuki, N. (248) 329)

**Emiglitate**
Insulin secretion; Islet acid glucan-1,4-$\alpha$-glucosidase; $\alpha$-Glucosidehydrolase inhibition; Acarbose; Glibenclamide; Carbachol (Salehi, A. (243) 185)

**Enadoline**
Cerebral ischaemia; Dizocilpine; Hypothermia; Neuroprotection (Hayward, N.J. (236) 247)

**Endogenous peptide**
Histogranin; Adrenal medulla; NMDA receptors; Anticonvulsant (Lemaire, S. (245) 247)

**$\beta$-Endorphin**
Cough; Antitussive effect; Opioid receptors (Kamei, J. (233) 251)

L-Arginine; Nitric oxide (NO); Antinociception; Pain controls (descending) (Xu, J.Y. (236) 137)

Morphine; Tolerance; Cross-tolerance; Antinociception; Tail-flick inhibition; Hot-plate inhibition (Tseng, L.F. (241) 63)

[$Leu^5$]enkephalin; [$Met^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Spinal cord; Brain (Takemori, A.E. (242) 145)

**Endorphin receptors**
$\mu$-Opioid receptor antagonists; $\kappa$-Opioid receptor agonists; Analgesia; N-CPM-$H_2$BAMO (14$\beta$-(bromoacetamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone); (Mouse) (Jiang, Q. (240) 201)

**Endothelial cells**
Prostacyclin; $Ca^{2+}$ indicators; Aorta (bovine); Arachidonate metabolism (Boeynaems, J.-M. (233) 13)

Dexamethasone; GM 7373 cell line; Vasocortin; Dextran oedema; Histamine release (Iuvone, T. (243) 163)

Bradykinin; Fura-2; Angiotensin converting enzyme inhibitor (Hirano, K. (244) 133)

Endothelin; BQ-123; Endothelin $ET_A$ receptor; Brain capillary (Vigne, P. (245) 229)

G-protein; Bradykinin; Nitric oxide (NO); cyclic GMP (Gil-Longo, J. (247) 119)

**Endothelin-1**
Endothelin $ET_A$ receptors; BQ-123; Prostacyclin; Platelet aggregation (Hermán, F. (236) 143)

Prostacyclin; Pressor effects; Endothelin $ET_A$ receptors; Kidney (rabbit) (Télémaque, S. (237) 275)

Vein; Cholinergic innervation; Atropine; Neostigmine; Embryology (Hayakawa, A. (239) 219)

Anaphylactic shock; Hemorrhagic shock; Hypotension; Hypovolemia; Hypoxia (Filep, J.G. (239) 231)

Sarafotoxin S6b; BQ-123; Endothelin $ET_A$ receptor; Saphenous vein (human) (Bax, W.A. (239) 267)

Big-endothelin-1; Endothelin-3; Endothelin $ET_A$ receptor; BQ-123; Phosphoramidon; Endothelin-converting enzyme; Uterus (rat) (Rae, G.A. (240) 113)

Mean arterial pressure; Endothelin receptor antagonist; Sarafotoxin S6c (Bird, J.E. (240) 295)

Dexamethasone; Bronchoconstriction; Bronchorelaxation (Filep, J.G. (240) 315)

Big endothelin-1; Conversion; Mesentery (Hisaki, K. (241) 75)

Alprazolam; BN-52021; Mesangial cells; Proliferation; PAF (platelet-activating factor, PAF-acether) (Montero, A. (243) 235)

Coronary arteries; Neuropeptide Y; Nitric oxide (NO); BQ-123; $ET_A$ receptor; $ET_B$ receptor (Pernow, J. (243) 281)

BQ-123; Endothelin $ET_A$ receptor; Brain capillary; Endothelial cell (Vigne, P. (245) 229)

Inositol phosphates; Vasopressin; Papillary tubules (Woodcock, E.A. (247) 93)

Middle cerebral artery occlusion; Ischemia; Hypoxia; Cultured neurons; (Mouse) (Nikolov, R. (248) 205)

**Endothelin-3**
$ET_B$ receptors; Endothelium-dependent relaxation; $Ca^{2+}$ levels (cytosolic); Vascular (rat aorta); (Relaxation) (Sudjarwo, S.A. (229) 137)

Big endothelin-3; Hypertensive effect; Phosphoramidon; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

Clonidine; Blood pressure; Heart rate; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

Tracheal epithelium; Thrombin; Vasopressin; Substance P (Rennick, R.E. (230) 367)

Endothelin-converting enzyme; Big endothelin-1; Big endothelin-3; Phosphoramidon; Hemodynamics; (Rat) (Pollock, D.M. (231) 459)

[$Ala^{1,3,11,15}$]endothelin-1; BQ-123; Bronchoconstriction; Hypertension; (Receptor subtype) (Noguchi, K. (233) 47)

Nitric oxide (NO); Endotoxin shock; Pulmonary hypertension; Adult respiratory distress syndrome (ARDS); Noradrenaline; Neuropeptide Y (Weitzberg, E. (233) 85)

Cyclosporine A; Smooth muscle cell (vascular); (Rat) (Takeda, Y. (233) 299)

Autoradiography; Endothelin $ET_B$ receptors; [$^{125}$I]BQ-3020; Lung (porcine) (Kobayashi, M. (235) 95)

Vasoactive intestinal contractor; Acetylcholine release; Ileum (guinea-pig) (Taniyama, K. (235) 149)

Big-endothelin-1; Endothelin-1; Endothelin $ET_A$ receptor; BQ-123; Phosphoramidon; Endothelin-converting enzyme; Uterus (rat) (Rae, G.A. (240) 113)

**[$Ala^{1,3,11,15}$]endothelin-1**
Endothelin; BQ-123; Bronchoconstriction; Hypertension; (Receptor subtype) (Noguchi, K. (233) 47)

**[$^{125}$I]Endothelin-1 binding**
27-*O*-Caffeoyl myricerone (50-235); Structure-activity relationship; Endothelin receptor antagonist; Cytosolic free $Ca^{2+}$ (Mihara, S.-i. (247) 219)

**Endothelin-converting enzyme**
Big endothelin-1; Big endothelin-3; Phosphoramidon; Endothelin; Hemodynamics; (Rat) (Pollock, D.M. (231) 459)

Big-endothelin-1; Endothelin-1; Endothelin-3; Endothelin $ET_A$ receptor; BQ-123; Phosphoramidon; Uterus (rat) (Rae, G.A. (240) 113)

**Endothelin $ET_A$ receptor**
Endothelin-1; Sarafotoxin S6b; BQ-123; Saphenous vein (human) (Bax, W.A. (239) 267)

Big-endothelin-1; Endothelin-1; Endothelin-3; BQ-123; Phosphoramidon; Endothelin-converting enzyme; Uterus (rat) (Rae, G.A. (240) 113)

Endothelin; BQ-123; Brain capillary; Endothelial cell (Vigne, P. (245) 229)

**Endothelin mechanisms**
L-Thyroxine administration (repeated); Methimazole administration (repeated); Plasma endothelin concentration; Cerebral cortex; Hypothalamus; Pituitary (Rebello, S. (237) 9)

**Endothelin receptor antagonist**
Endothelin-1; Mean arterial pressure; Sarafotoxin S6c (Bird, J.E. (240) 295)

27-O-Caffeoyl myricerone (50-235); Cytosolic free $Ca^{2+}$; Mitogenesis; Smooth muscle cell (aorta, rat); Girardi heart cell (human) (Mihara, S.-i. (246) 33)

27-*O*-Caffeoyl myricerone (50-235); Structure-activity relationship; [$^{125}$I]Endothelin-1 binding; Cytosolic free $Ca^{2+}$ (Mihara, S.-i. (247) 219)

**Endothelin receptor model**
Diethylpyrocarbonate; Chemical modification; Bombesin (Huggins, J.P. (245) 203)

**Endothelin receptors**
FR139317; BQ-123; Endothelins; Sarafotoxins; Iliac artery (guinea-pig) (Schoeffter, P. (241) 165)

**Endothelin $ET_A$ receptors**
Endothelin-1; BQ-123; Prostacyclin; Platelet aggregation (Hermán, F. (236) 143)

Endothelin; Prostacyclin; Pressor effects; Kidney (rabbit) (Télémaque, S. (237) 275)

**Endothelin $ET_B$ receptors**
Autoradiography; Endothelin; [$^{125}$I]BQ-3020; Lung (porcine) (Kobayashi, M. (235) 95)

**Endothelin receptor subtypes**
Endothelins; Sarafotoxins; Phospholipases; C6 glioma; Fibroblasts (Rat-1, Swiss 3T3) (Ambar, I. (245) 31)

**Endothelins**
Smooth muscle (vascular); Endothelium (vascular); EDRF (endothelium-derived relaxing factor); $ET_B$ receptors; $ET_B$ receptor antagonists; IRL 1038; Aorta (rat) (Karaki, H. (231) 371)

FR139317; BQ-123; Sarafotoxins; Endothelin receptors; Iliac artery (guinea-pig) (Schoeffter, P. (241) 165)

Sarafotoxins; Endothelin receptor subtypes; Phospholipases; C6 glioma; Fibroblasts (Rat-1, Swiss 3T3) (Ambar, I. (245) 31)

**Endothelium**
Diabetes; Streptozotocin; Mesenteric artery; Vasodilatation (Furman, B.L. (232) 29)

Adenosine analogs; TNF (tumor necrosis factor); Polymorphonuclear leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291)

Hyperemia (reactive); EDRF (endothelium-derived relaxing factor); Nitric oxide (NO), Coronary flow regulation (Domenech, R. (238) 53)

Ethanol; Acetylcholine; Vasorelaxation; Aorta; (Rat) (Hatake, K. (238) 441)

Bradykinin; Bradykinin $B_1$ receptor; Carotid artery; Nitric oxide (NO) (Pruneau, D. (239) 63)

Noradrenaline-induced contraction; Nitric oxide (NO); $\alpha$-Adrenoceptors (Kaneko, K. (240) 195)

Basilar artery (rat); 5-HT receptors; Thromboxane $A_2$ (Descombes, J.-J. (243) 193)

Cyclosporine; Angiotensin $AT_{1A}$ receptors; Hypertension; Gene expression (Iwai, J. (248) 341)

**Endothelium-dependent relaxation**
Endothelin-3; $ET_B$ receptors; $Ca^{2+}$ levels (cytosolic); Vascular (rat aorta); (Relaxation) (Sudjarwo, S.A. (229) 137)

Acetylcholine; Mesenteric arterial bed; Nitric oxide (NO); cAMP; cGMP (Abiru, T. (242) 15)

Diabetes mellitus; Aorta (rat); $N^G$-Nitro-L-arginine; Haemoglobin; Tachyphylaxis (Sikorski, B.W. (242) 275)

**Endothelium-dependent vasoconstrictor**
Cytochrome P450; Arachidonic acid; 20-HETE (20-hydroxy-5,8,11,14-eicosatetraenoic acid) (Escalante, B. (235) 1)

**Endothelium (vascular)**
Smooth muscle (vascular); EDRF (endothelium-derived relaxing factor); Endothelins; $ET_B$ receptors; $ET_B$ receptor antagonists; IRL 1038; Aorta (rat) (Karaki, H. (231) 371)

**Endotoxin**
Cytokines; Leukotrienes; cAMP (Schade, F.U. (230) 9)

Fenspiride; Tumour necrosis factor; Carrageenin; Neutrophil migration (Cunha, F.Q. (238) 47)

Vasodilatation; Nitric oxide (NO); Interleukin-1; Neutrophils; Glucocorticoids (Pons, F. (239) 23)

Cloricromene; Vascular reactivity; Murine J774 macrophages; Nitric oxide synthase (Zingarelli, B. (243) 107)

Lipopolysaccharide; Eosinophils; Pleurisy (Bozza, P.T. (248) 41)

**Endotoxin shock**
Nitric oxide (NO); Pulmonary hypertension; Adult respiratory distress syndrome (ARDS); Endothelin; Noradrenaline; Neuropeptide Y (Weitzberg, E. (233) 85)

**Energy metabolism**
KRN2391; Cromakalim; Heart (isolated, rat); Myocardial ischemia (Ohta, H. (231) 323)

**[Leu$^5$]enkephalin**
[Met$^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Spinal cord; Brain; $\beta$-Endorphin (Takemori, A.E. (242) 145)

**[Met$^5$]enkephalin**
[Leu$^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Spinal cord; Brain; $\beta$-Endorphin (Takemori, A.E. (242) 145)

**Enkephalin degradation**
Antinociception; Paw pressure; Arthritic rat; (Normal rat); (Mixed inhibitor) (Perrot, S. (241) 129)

**Enkephalins**
Opioid receptors; Opioid; Autoradiography; Photoaffinity probe (Pasquini, F. (243) 39)

**Enteric $GABA_A$ receptors**
Small intestine (guinea-pig); GABA ($\gamma$-aminobutyric acid); Ivermectin; Lindane (Coccini, T. (248) 1)

**Enteric membranes (rat)**
[$^3$H]5-HT (5-[$^3$H]Hydroxtryptamine); Indoles; Anti-oxidants; (Spurious binding sites) (Williams, T.J. (245) 197)

**Enteric nerves**
Distal colon; GABA receptors; Gastrointestinal motility (Minocha, A. (230) 187)

**Enteric nervous system**
Intestine; Ganglia; Myenteric plexus; Substance P; Tachykinins (Tamura, K. (232) 235)

**Enterotoxin**
Intestinal secretion; Ketanserin; Tropisetron; Ondansetron; Granisetron (Beubler, E. (248) 157)

**Entropy change of binding**
Glycine receptor; [$^3$H]Strychnine binding, (agonist and antagonist); Kinetic cooperativity of dissociation (Maksay, G. (245) 183)

**Environmental temperature**
Lead acetate; Cadmium chloride; Hypothermia; Brain metal levels (Martínez, F. (248) 199)

**Enzyme induction**
Cytochrome P450 1A2; Musk xylene; Musk ambrette; Liver (rat) (Iwata, N. (248) 243)

**Eosinophil accumulation**
ONO-1078; Peptide leukotriene receptor antagonists; Asthmatic responses; Airway hyperreactivity (Nakagawa, N. (235) 211)

**Eosinophil function**
CS-518; Thromboxane $A_2$ synthase inhibitors; Asthmatic model (Itoh, K. (239) 159)

**Eosinophils**
Eye; Inflammation; Intraocular pressure; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

Respiratory burst; Salmeterol; Eformoterol; Salbutamol; β-Adrenoceptors (Rabe, K.F. (231) 305)

Hyperresponsiveness; Respiratory airways; Interleukin-5; Asthma (Van Oosterhout, A.J.M. (236) 379)

Hyperresponsiveness; Respiratory airways; Interleukin-5; Asthma (Van Oosterhout, A.J.M. (239) 277)

Endotoxin; Lipopolysaccharide; Pleurisy (Bozza, P.T. (248) 41)

**EPA-E (ethyl all-cis-5,8,11,14,17-icosapentaenoate)**
Cholesterol metabolism; (Rat) (Mizuguchi, K. (231) 121)

VLDL (very low-density lipoprotein); (Rat) (Mizuguchi, K. (235) 221)

**EpDRF (epithelium-derived relaxing factor)**
Co-axial bioassay; Ovalbumin challenge; Trachea (guinea-pig); Anococcygeus muscle (rat); 5-HT (5-hydroxytryptamine, serotonin) (Çakici, İ. (236) 97)

**Epidermal growth factor**
Parietal cell rat; Acid production; Glucagon-like peptide 1-(7–36) amide; Transforming growth factor-α; GTP-binding proteins (Schmidtler, J. (246) 59)

**Epilepsy**
Seizures (chemically induced); Pilocarpine; Anticonvulsants; ACTH (adrenocorticotrophic hormone) (Croiset, G. (229) 211)

Ucb L059; Seizures; Piracetam; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

NMDA (N-methyl-D-aspartate); Valproate; MK-801; Behaviour; CGP 37849 (Löscher, W. (234) 237)

Absence seizures; Cholinergic drugs; Electroencephalography; (Rat) (Danober, L. (234) 263)

Frings audiogenic seizure-susceptible mice; GABA uptake inhibitors; GABA uptake (glial) (White, H.S. (236) 147)

Lithium chloride; Tacrine; Nitric oxide (NO); Neurodegeneration (Bagetta, G. (237) 61)

Dextromethorphan; Dextrorphan; Glutamate; Kindling; (Rat) (Löscher, W. (238) 191)

**Epileptiform activity**
cAMP; Forskolin; Neocortex (Boulton, C.L. (236) 131)

**Epithelium**
Inflammatory bowel disease; Cyclosporin; Prostaglandin; Permeability (Higa, A. (239) 171)

**Epoxyeicosatrienoic acid**
Arachidonic acid; Cytochrome P450 epoxygenase; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

**EP receptors**
$PGE_2$; Smooth muscle cells (Botella, A. (237) 131)

**Ergolines**
5-$HT_2$ receptors; Tryptamines, [$^{125}$I]DOI ([$^{125}$I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); LY53857; Amesergide (Johnson, M.P. (239) 111)

**Ergot alkaloids**
Anticonflict activity; [$^3$H]Muscimol binding; Brain (human, post-mortem); (Rat) (Peričić, D. (235) 267)

**Ergotamine**
5-HT (5-hydroxytryptamine, serotonin); Platelets; Coronary artery (human); Sumatriptan; 5-$HT_{1D}$-like receptors; 5-$HT_2$ receptors (Bax, W.A. (239) 203)

**Erythrocyte membrane**
Clofibric acid; Clofibrate; Membrane electrophoresis; $HCO_3^-$-$Cl^-$ exchange inhibition; (Rat) (Morales-Aguilera, A. (245) 89)

**Esculetin**
Coumarins; Antiproliferative effect; Smooth muscle cells (vascular); Lipoxygenase inhibitors (Huang, H.-C. (237) 39)

**ES-242s**
Hypoxia; Ischemia; Glutamate; Neurotoxicity; Cell culture; MK-801 (Nozawa, M. (236) 263)

**Estrogen**
Steroids; Myometrium; Uterine artery; Progesterone; Diethylstilbestrol (Kostrzewska, A. (233) 127)

**Ethanol**
δ-Opioid receptors; Dopamine (Acquas, E. (230) 239)

Development; Flunitrazepam; $GABA_A$ receptors; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

γ-Hydroxybutyric acid (GHB); $GABA_A$ receptors; Dopaminergic neurons; NMDA receptor antagonists (Diana, M. (230) 363)

(+)-MK-801; Tolerance; (Rat) (Wu, P.H. (231) 157)

EGTA; EDTA; Gastric acid secretion; Gastric ulcer; Pepsin; Stress (Glavin, G.B. (233) 269)

$N^G$-Nitro-L-arginine; Angiotensin II; Noradrenaline; Vasopressor; Bradycardia; Baroreflex (Wang, Y.-X. (233) 275)

Fluoxetine; β-Adrenoceptors; Isoprenaline-induced drinking (Mustafa, A.A. (237) 147)

Acetylcholine; Endothelium; Vasorelaxation; Aorta; (Rat) (Hatake, K. (238) 441)

Neuroactive steroids; Behaviour; Drug discrimination; Benzodiazepines; Pentobarbital (Ator, N.A. (241) 237)

Brain (rat); Choroid plexus; 5-$HT_{1C}$ receptors; Phosphoinositide hydrolysis (Pandey, S.C. (247) 81)

cAMP; Muscarinic acetylcholine receptor; $\alpha_2$-Adrenoceptor (Kim, W.-K. (247) 89)

*N*-Methyl-D-aspartate receptor; Polyamines; c-*fos*; Seizure (Matsumoto, I. (247) 289)

Gall bladder; Smooth muscle; Tolerance; $Ca^{2+}$ (Masui, H. (248) 103)

NMDA receptor; Ethanol withdrawal; Cerebellar granule cells; Glutamate-induced cytotoxicity (Iorio, K.R. (248) 209)

Cerebral arteries; $Ca^{2+}$; $Mg^{2+}$; (Dog); (Sheep); (Piglet); (Baboon) (Zhang, A. (248) 229)

**Ethanol-inducible cytochrome P450**
Isoniazid; Translational activation (Park, K.S. (248) 7)

**Ethanol inhalation**
$GABA_A$ receptor $\alpha_1$-subunit; mRNA; Alcohol dependence (Hirouchi, M. (247) 127)

**Ethanol reinforcement**
Dopamine; Microdialysis; Tolerance (Rossetti, Z.L. (231) 203)

**Ethanol tolerance**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

**Ethanol withdrawal**
$\alpha$-ANP ($\alpha$-atrial natriuretic peptide); Anti-ANP serum (Kovács, G.L. (238) 417)

Ethanol; NMDA receptor; Cerebellar granule cells; Glutamate-induced cytotoxicity (Iorio, K.R. (248) 209)

**$ET_A$ receptors**
Coronary arteries; Endothelin; Neuropeptide Y; Nitric oxide (NO); BQ-123; $ET_B$ receptor (Pernow, J. (243) 281)

**$ET_B$ receptor antagonists**
Smooth muscle (vascular); Endothelium (vascular); EDRF (endothelium-derived relaxing factor); Endothelins; $ET_B$ receptors; IRL 1038; Aorta (rat) (Karaki, H. (231) 371)

**$ET_B$ receptors**
Endothelin-3; Endothelium-dependent relaxation; $Ca^{2+}$ levels (cytosolic); Vascular (rat aorta); (Relaxation) (Sudjarwo, S.A. (229) 137)

Smooth muscle (vascular); Endothelium (vascular); EDRF (endothelium-derived relaxing factor); Endothelins; $ET_B$ receptor antagonists; IRL 1038; Aorta (rat) (Karaki, H. (231) 371)

Coronary arteries; Endothelin; Neuropeptide Y; Nitric oxide (NO); BQ-123; $ET_A$ receptor (Pernow, J. (243) 281)

**Excessive grooming**
5-HT (5-hydroxytryptamine, serotonin); Penile erection; Oxytocin concentration (plasma); $5\text{-}HT_{1C}$ receptors; $5\text{-}HT_2$ receptors; m-CPP (1-(3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (229) 9)

**Excitability**
$\gamma_2$-MSH ($\gamma_2$-melanocyte-stimulating hormone); ACTH-(4–10); Melanotropins; Hemodynamics; Urethane anesthesia; Pentobarbital anesthesia; (Conscious rat) (De Wildt, D.J. (233) 157)

**Excitation-contraction**
Tetrandrine; Smooth muscle (vascular); Saphenous vein (dog); $Ca^{2+}$ (Kwan, C.-Y. (238) 431)

**Excitation-contraction uncoupling**
2,3-Butanedione monoxime; Sarcolemma hyperexcitability; Dantrolene; Depolarization contractures; Caffeine contracture; Diaphragm (rat) (Røed, A. (241) 229)

**Excitatory amino acid receptors**
*Xenopus* oocytes (rat brain mRNA-injected); Riluzole; Kainate; NMDA (N-methyl-D-aspartate) (Debono, M.-W. (235) 283)

NMDA receptor antagonist; Photoaffinity ligand (Benke, D. (246) 179)

[$^3$H]Kainate binding; $Ca^{2+}$; Domoate; Brain (Johansen, T.H. (246) 195)

**Excitatory amino acids**
Seizures; Nitric oxide (NO); Prepiriform cortex (deep); L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

Sensitization; Quisqualate priming; Cortical wedge; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

Acamprosate (calciumacetylhomotaurinate); GABA ($\gamma$-aminobutyric acid); Neocortex; Postsynaptic potentials; Neurotransmission (Zeise, M.L. (231) 47)

Glutamate receptors; Parkinson's disease; Neuroleptics (Papa, S.M. (232) 247)

Kynurenic acid; Apnoea; Dizocilpine; Arterial blood pressure; Apneustic breathing; (Cat) (Abrahams, T.P. (238) 223)

HA-966; (+)-MK-801; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

Gabapentin; Autoradiography; GABA ($\gamma$-aminobutyric acid); NMDA (N-methyl-D-aspartate); Glycine; Hippocampus; Anticonvulsants (Hill, D.R. (244) 303)

Glutamate; Metabotropic; Phosphoinositide hydrolysis; NBQX (2,3-dihydroxy-6-nitro-7-sulpha-moylbenzo(F)-quinoxaline) (Suzdak, P.D. (245) 215)

**Excitotoxicity**
AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); $Mg^{2+}$; Hippocampus; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

Ganglioside GM1; Glycosphingolipid derivatives; Neuroprotection; Dopaminergic neurons; Parkinson's disease (Skaper, S.D. (243) 91)

3-Nitropropionic acid; NMDA (N-methyl-D-aspartate); Glutamate; Cerebellar granule neurons (Weller, M. (248) 223)

**Excitotoxicity (neonate)**
bFGF (basic fibroblast growth factor); NMDA (N-methyl-D-aspartate); Neuroprotection (Nozaki, K. (232) 295)

**Exercise**
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Insulin; Calorimetry (indirect); (Rat); (Baseline conditions) (Benthem, L. (232) 279)

**Exocrine secretion**
Pancreas (dog); Glucagon; Somatostatin (Horiuchi, A. (237) 23)

**Exocytosis**
$Ca^{2+}$ channels; Glutamate; Aspartate; GABA ($\gamma$-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

**EXP3174**
$Li^+$ clearance; Angiotensin II; Renal blood flow; Glomerular filtration rate (Tamaki, T. (236) 15)

**Exploratory behaviour**
Melatonin; Diazepam; Anxiolysis; Benzodiazepine antagonism; (Time-dependent effects) (Golombek, D.A. (237) 231)

**Expression**
$\alpha_{2B}$-Adrenoceptors; Radioligand binding; (*E. coli*) (Xia, Y. (246) 129)

**Extensor digitorum longus muscle**
Chlorpromazine; Soleus muscle; Myotonic depression (Liu, S.-H. (231) 23)

Skinned fibres; Soleus; Cyclopiazonic acid; $Ca^{2+}$ sensitivity (Huchet, C. (241) 41)

**Extrapyramidal side effects**
Dopamine $D_4$ receptors; Dopamine $D_2$ receptors; Schizophrenia; Antipsychotics; Tardive dyskinesia (Lahti, R.A. (236) 483)

**Extrinsic sensory nerves**
Adenosine; Capsaicin; Myenteric neurons (Takaki, M. (237) 51)

**Eye**
Inflammation; Intraocular pressure; Eosinophils; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

**Facilitation**
$\beta$-Adrenoceptors; Desensitization; Prejunctional; Stimulus train length (Lakhlani, P.P. (230) 107)

**Factor VIII**
Antidiuretic activity; Vasopressin analogues; Monkey (Vilhardt, H. (232) 223)

**Fatigue**
$K^+$ channels (ATP-sensitive); Skeletal muscle (Comtois, A. (242) 65)

**Fawn-hooded rat**
Imipramine; Clomipramine; Clorgyline; Corticosterone; ACTH (adrenocorticotropin) (Aulakh, C.S. (240) 85)

**Feedback inhibition**
Smooth muscle; Phorbol esters (Bazan, E. (245) 173)

**Feeding**
Obese mice; Norepinephrine; Clonidine; Yohimbine; $\alpha_2$-Adrenoceptors (Currie, P.J. (232) 227)

**Feeding behaviour**
Genetic obesity; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); Insulin; Neuropeptide Y; CRF (corticotropin-releasing factor); (Zucker rat) (Rouru, J. (234) 191)

**Felodipine**
ANP (atrial natriuretic peptide); $Ca^{2+}$ entry blockers; Verapamil; Nifedipine; Diuretic effects (Shamiss, A. (233) 113)

$Ca^{2+}$ channel blockers; Cytosolic $Ca^{2+}$ levels; Nifedipine; Verapamil; Smooth muscle; Aorta (rat); (Relaxation) (Hagiwara, S. (234) 1)

**Femoral artery**
$Ca^{2+}$; Fura-2/AM; Inositol phosphates; Isometric contraction; Ketamine; (Rabbit) (Ratz, P.H. (236) 433)

**Fenfluramine**
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

**d-Fenfluramine**
d-Norfenfluramine; Indole-depleting effect; (Rat) (Caccia, S. (233) 71)

5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Synaptosomes; $Ca^{2+}$ channels (Gobbi, M. (238) 9)

Food intake; d-Norfenfluramine; 1-(3-Chlorophenyl)piperazine; 5-$HT_{1C}$ receptors; p-Chlorophenylalanine (Gibson, E.L. (242) 83)

**Fenoldopam**
Dopamine (renal); Quinpirole; SCH 23390; Cis-flupentixol; LLC-$PK_1$ cells; Organic cations (renal); Dopamine receptors; Quinine (Dawson, Jr., R. (240) 277)

Diabetes; Streptozotocin; Dopamine; Dopamine $D_1$ receptors (Wang, Y.-X. (248) 217)

**Fenspiride**
Tumour necrosis factor; Carrageenin; Endotoxin; Neutrophil migration (Cunha, F.Q. (238) 47)

**Fentanyl**
$\kappa$-Opioid receptor agonist; Antinociception; Respiration; (Intrathecal); (Intraventricular) (Wang, C. (243) 113)

**Fetal breathing**
Opiates; $\delta$-Opioid receptors; [D-$Ala^2$]deltorphin; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

**Fever**
Prostaglandins; Glucocorticoids (Coelho, M.M. (238) 391)

**F8Famide (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-$NH_2$)**
FMRFamide (Phe-Met-Arg-Phe-$NH_2$); Naloxone; Morphine; Spinal antinociception (Gouardères, C. (237) 73)

**FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide)**
FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-$HT_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

**FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)**
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-$HT_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

**bFGF (basic fibroblast growth factor)**
NMDA (N-methyl-D-aspartate); Excitotoxicity (neonate); Neuroprotection (Nozaki, K. (232) 295)

**FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol)**
$\sigma$ Binding sites; Radiolabeled ligand binding; (+)-SKF10,047; Stereotyped behaviour (Tanaka, M. (238) 89)

$\sigma$ Binding sites; Radiolabeled ligand binding; Brain (guinea-pig) (Tanaka, M. (238) 93)

**Fibrinolysis**
Glycosphingolipids; Lysogangliosides; Platelet aggregation; Thrombin; 5-HT (5-hydroxytryptamine, serotonin); Tromboxane $B_2$; Bleeding; Coagulation (Tubaro, E. (248) 175)

**Fibrinolytic activity**
Aspirin; Venous stasis (Iacoviello, L. (229) 39)

**Fibroblasts**
Phosphotyrosine phosphatase; Melittin; Arachidonic acid; EGF (epidermal growth factor); Phospholipase $A_2$ (Errasfa, M. (247) 73)

**Fibroblasts (Rat-1, Swiss 3T3)**
Endothelins; Sarafotoxins; Endothelin receptor subtypes; Phospholipases; C6 glioma (Ambar, I. (245) 31)

**Field potentials**
Dentate gyrus; Long-term potentiation; NMDA receptors; Dextromethorphan; Methadone; Codeine; Normethadone; MK-801 (Krug, M. (231) 355)

**Firing pattern**
Reserpine; Substantia nigra pars compacta; Dopamine neurons; Dopamine receptor agonists; Single-unit recording; Supersensitivity (Sun, B.-C. (231) 331)

**Firing rate**
Galanin; Locus coeruleus neurons; Receptor interaction; Membrane potential (Sevcik, J. (230) 223)

**Fischer 344 rats**
CGRP (calcitonin gene-related peptide); Aging; Mesenteric vasculature; Sensory nerves (capsaicin-sensitive) (Li, Y. (236) 373)

***Fissistigma glaucescens***
Atherosperminine; Smooth muscle (trachealis, guinea-pig); Phosphodiesterase inhibition; Cyclic nucleotides (Lin, C.-H. (237) 109)

**FK409**
Vasorelaxation; cGMP; Soluble guanylate cyclase; Cyclic guanosine monophosphate phosphodiesterase (Isono, T. (246) 205)

**FK506**
Cancer chemotherapy; Cyclosporin A; Multidrug resistance; P-glycoprotein; Rapamycin (Hoof, T. (246) 53)

**Flat-body posture**
Dorsal raphe nucleus; WAY 100,135; (−)-Tertatolol; Corticosterone (Lejeune, F. (240) 307)

**Flosequinan**
Heart failure; Cardiac muscle; Contractility; Phosphodiesterase; (Human) (Weishaar, R.E. (236) 363)

**[$^3$H]Flumazenil**
$GABA_A$ receptors; ω modulatory site; Zolpidem; Alpidem (Faure-Halley, C. (246) 283)

**Flunarizine**
$Ca^{2+}$ channel antagonists; Voltage dependence; Adrenal medulla; Catecholamine secretion (De la Fuente, M.-T. (229) 189)

Nilvadipine; Inner ear microcirculation disorder (Umemura, K. (239) 17)

**Flunitrazepam**
Development; Ethanol; $GABA_A$ receptors; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

$GABA_A$ receptor; Benzodiazepine; Ro15-4513 (Duncalfe, L.L. (246) 141)

**[$^3$H]Flunitrazepam binding**
$GABA_A$ receptor complex (Type I and Type II benzodiazepine binding sites); [$^3$H]Zolpidem binding; γ-Aminobutyric acid; Aging; Cortex (Ruano, D. (246) 81)

**Fluorescence microscopy of intracellular $Ca^{2+}$**
Fura-2 fluorescence; Muscarinic receptor; $IP_3$-sensitive $Ca^{2+}$ store; Caffeine-sensitive $Ca^{2+}$ store; Neurotransmitter receptor desensitization (Fohrman, E.B. (245) 263)

**Fluorescence microscopy (single cell)**
NPPB (5-nitro-2-(3-phenylpropylamino)-benzoic acid); Vasopressin; Phosphatidylinositol metabolism; $Ca^{2+}$-activated chloride conductance; Smooth muscle (Pon, D.J. (245) 119)

**Fluorescence polarization**
Tetramethylpyrazine; Membrane fluidity; Electron spin resonance; Smooth muscle (vascular) (Nie, S.-Q. (244) 15)

**N-(3-[$^{18}$F]Fluoropropyl)SCH 38548**
Dopamine $D_1$ receptors; PET (positron emission tomography) (Mukherjee, J. (243) 287)

**Fluoxetine**
MDMA (3,4-methylenedioxymethamphetamine); Parachloroamphetamine; Deprenyl; Clorgyline; Nimodipine; Reserpine (Gu, X.F. (235) 51)

Imipramine; Trimipramine; 5-HIAA (5-hydroxyindole-3-acetic acid); 5-HT uptake (Dewar, K.M. (235) 137)

Ethanol; β-Adrenoceptors; Isoprenaline-induced drinking (Mustafa, A.A. (237) 147)

**Flurazepam**
Benzodiazepine; Tolerance; $Cl^-$ flux; Bretazenil; Clonazepam; Diazepam (Li, M. (247) 313)

**Fluvoxamine**
5-HT uptake; Antidepressants; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (229) 101)

5-HT uptake; Antidepressants; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

**FMRFamide (Phe-Met-Arg-Phe-$NH_2$)**
F8Famide (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-$NH_2$); Naloxone; Morphine; Spinal antinociception (Gouardères, C. (237) 73)

**Food deprivation**
Adrenalectomy; Immobility; Porsolt swimming test; Hypothyroidism (Jefferys, D.E. (239) 189)

**Food intake**
Nitric oxide (NO); Brain; Zucker rat (Squadrito, F. (230) 125)

Nitric oxide (NO); Morphine-induced locomotion; Morphine (Calignano, A. (231) 415)

d-Fenfluramine; d-Norfenfluramine; 1-(3-Chlorophenyl)piperazine; $5\text{-}HT_{1C}$ receptors; p-Chlorophenylalanine (Gibson, E.L. (242) 83)

**Forced swimming test**
Desipramine; Diazepam (Martí, J. (236) 295)

Antidepressants; 5-$HT_{1A}$ receptor agonists; LY228729 (Benvenga, M.J. (239) 249)

**Formalin**
Naloxone; Morphine; Antinociception; Pronociception; (Rat) (Wheeler-Aceto, H. (236) 193)

Substance P; Spantide; Substance P analogues (containing D-His); Capsaicin; Nociceptive response; Intrathecal injection (Sakurada, T. (242) 47)

**Forskolin**
Epileptiform activity; cAMP; Neocortex (Boulton, C.L. (236) 131)

PAF (platelet activating factor); Adenylyl cyclase; G-protein; PAF receptor (Wong, S. (245) 55)

**Forskolin action**
Uterus (pregnant); Smooth muscle cells (myometrial); $K^+$ currents; cAMP; Tetraethylammonium (Inoue, Y. (240) 169)

**FR115427**
NMDA (N-methyl-D-aspartate); Non-competitive antagonism; Dizocilpine; Cortical wedge; Hippocampus (Hodgkiss, J.P. (240) 219)

NMDA (*N*-methyl-D-aspartate); (Non-competitive), Dizocilpine; Ligand binding (Sherriffs, H.J. (247) 319)

**FR121196**
Hippocampus; Long-term potentiation; Cognitive enhancer; Somatostatin; Acetylcholine; Mossy fiber-CA3 pathway; (Guinea-pig) (Matsuoka, N. (241) 27)

**FR122047**
Platelet aggregation; Cyclooxygenase; Aspirin (Dohi, M. (243) 179)

**FR139317**
BQ-123; Endothelins; Sarafotoxins; Endothelin receptors; Iliac artery (guinea-pig) (Schoeffter, P. (241) 165)

**F-344 rats**
G-protein; Cerebral cortex; Adenylyl cyclase; $\beta$-Adrenoceptors; Tricyclic antidepressants; Down-regulation (Scarpace, P.J. (247) 65)

**Free fatty acids**
Serotonergic mechanisms (peripheral); Glucose; Insulin; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

**Free radicals**
Ischemia/reperfusion; Heart; Spin traps; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (234) 113)

Ischemia/reperfusion; Heart; Spin traps; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (239) 275)

Emesis; Cisplatin; (House musk shrew) (Torii, Y. (248) 131)

Cisplatin; Emesis; Iron; (*Suncus murinus*) (Matsuki, N. (248) 329)

25-Hydroxycholesterol; Gap junction; Hepatocytes (Guo, X. (248) 337)

**Free radical scavenger**
$\alpha$-Tocopherol analogue (MDL 73404); Reperfusion injury; Myocardial ischaemia/reperfusion; Contractility; Lipid peroxidation (Lukovic, L. (233) 63)

**Free water clearance**
M17055; Loop diuretics; Thiazide diuretics; Amiloride; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

**FRG-8813**
Histamine $H_2$ receptor antagonists; Stomach; Gastric acid secretation (Shibata, M. (235) 245)

**Frings audiogenic seizure-susceptible mice**
Epilepsy; GABA uptake inhibitors; GABA uptake (glial) (White, H.S. (236) 147)

**Frontal cortex**
5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Microdialysis (in vivo) (Bel, N. (229) 101)

5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Microdialysis (in vivo) (Bel, N. (232) 326)

JTP-2942 ($N^a$-[(1S,2R)-2-methyl-4-oxycyclopentanecarbonyl]-L-histidyl-L-prolinamide); TRH (thyrotropin-releasing hormone); Acetylcholine; Choline; Hippocampus; Microdialysis (Toide, K. (233) 21)

Neuroleptics; Dopamine release; Dopamine metabolism; 3-Methoxytyramine; Striatum; Nucleus accumbens; Depolarization block; (Rat) (Chrapusta, S.J. (233) 135)

Tianeptine; Catecholamines; Stress; (Rat) (Sacchetti, G. (236) 171)

Dopamine release; Glutamate receptors; Brain, in vitro (rat); Olfactory tubercle; Striatum (Jones, C.A. (242) 183)

**Fructose 1,6-bisphosphate**
Carrageenan; Antiinflammatory; Liposome (Planas, M.E. (237) 251)

**$\beta$-Funaltrexamine**
[D-$Arg^2$]Dermorphin analogue; $\mu$-Opioid receptors; Memory; Passive avoidance response (Ukai, M. (239) 237)

**Functional antagonism**
Bradykinin; Hoe 140; Uterus (rat); G-protein activation; (Binding sites) (Liebmann, C. (235) 183)

**Functional expression**
Parathyroid hormone receptor; cDNA sequence (Schneider, H. (246) 149)

**Funnel web spider toxin**
$\omega$-Conotoxin GVIA; $Ca^{2+}$ channels (voltage-sensitive); *Hololena curta* venom; Neurotransmitter release; Autonomic nerves (Lundy, P.M. (231) 197)

**Fura-2**
Endothelial cells; Bradykinin; Angiotensin converting enzyme inhibitor (Hirano, K. (244) 133)

CGRP (Calcitonin gene-related peptide); Cytosolic free $Ca^{2+}$; Cyclic AMP; Aortic spiral preparation (rat) (Michiro Ishikawa, (246) 121)

ATP; 5′-Nucleotide receptor; HeLa cells; $Ca^{2+}$ (Smit, M.J. (247) 223)

**Fura-2/AM**
$Ca^{2+}$; Femoral artery; Inositol phosphates; Isometric contraction; Ketamine; (Rabbit) (Ratz, P.H. (236) 433)

**Fura-2 fluorescence**
Fluorescence microscopy of intracellular $Ca^{2+}$; Muscarinic receptor; $IP_3$-sensitive $Ca^{2+}$ store; Caffeine-sensitive $Ca^{2+}$ store; Neurotransmitter receptor desensitization (Fohrman, E.B. (245) 263)

**Furnidipine**
1,4-Dihydropyridines; Nicotinic acetylcholine receptors; Chromaffin cells; Nimodipine; BAY K 8644; PCA50938; Nifedipine; Nitrendipine (López, M.G. (247) 199)

**GABA/acetylcholine interaction**
GABA (γ-aminobutyric acid); GABA/dopamine interaction; Striatum (dorsal); Striatum (ventral); Oral movements; (Rat) (Kikuchi de Beltrán, K. (239) 47)

**GABA autoreceptors**
GABA release; CGP 52432; $GABA_B$ receptor subtypes; Glutamate release; Somatostatin release (Lanza, M. (237) 191)

**GABA/benzodiazepine receptors**
Adenosine; Seizure; GABA (γ-aminobutyric acid); Glutamate; Mouse (Klitgaard, H. (242) 221)

Triazolam; Patch clamp; Primary culture; cDNA (Dučić, I. (244) 29)

**$GABA_A$/benzodiazepine receptors**
Chlordiazepoxide; Passive avoidance response; Acetylcholine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

**GABA/dopamine interaction**
GABA (γ-aminobutyric acid); GABA/acetylcholine interaction; Striatum (dorsal); Striatum (ventral); Oral movements; (Rat) (Kikuchi de Beltrán, K. (239) 47)

**GABA (γ-aminobutyric acid)**
Baclofen; MBFG (4-amino-3-(5-methoxybenzo(b)furan-2-yl) butanoic acid); Spinal cord; Antinociception; BFG (4-amino-3-benzo(b)furan-2-yl-butanoic acid) (Hammond, D.L. (229) 227)

Acamprosate (calciumacetylhomotaurinate); Excitatory amino acids; Neocortex; Postsynaptic potentials; Neurotransmission (Zeise, M.L. (231) 47)

Dystonia; Phenobarbital; Dopamine; Glutamate; Haloperidol (Richter, A. (231) 111)

Hippocampus; $GABA_B$ receptors; Inhibitory postsynaptic potential (late); GABA transmission; $GABA_B$ receptor antagonists (Olpe, H.-R. (233) 179)

Benzodiazepines; CNS (central nervous system) depressants; Seizure tolerance; Receptor coupling; $Cl^-$ channels (Chang, Y.-F. (233) 209)

Methionine sulfoximine; Dorsal raphe nucleus; Hypothermia; 5-HT receptors; GABA receptors (Ginefri-Gayet, M. (235) 189)

Cardiovascular neurons; Cyanide; Hydrogen ions; Rostral ventrolateral medulla; (Rat) (Sun, M.-K. (236) 305)

5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Dentate/interpositus; Cerebellum; $5\text{-}HT_{2/1C}$ receptors (Cumming-Hood, P.A. (236) 457)

$Ca^{2+}$ channels; Exocytosis; Glutamate; Aspartate; (Rat) (Burke, S.P. (238) 383)

GABA/dopamine interaction; GABA/acetylcholine interaction; Striatum (dorsal); Striatum (ventral); Oral movements; (Rat) (Kikuchi de Beltrán, K. (239) 47)

Adenosine; Seizure; GABA/benzodiazepine receptor; Glutamate; Mouse (Klitgaard, H. (242) 221)

Microdialysis; Dopamine; Opioid; μ-Opioid receptors; Ventral tegmental area; Nucleus accumbens (Devine, D.P. (243) 55)

Gabapentin; Baclofen; $GABA_A$ receptors; $GABA_B$ receptors; NMDA (N-methyl-D-aspartate); Glycine; Anticonvulsants; Polyamines (Suman-Chauhan, N. (244) 293)

Gabapentin; Autoradiography; NMDA (N-methyl-D-aspartate); Glycine; Hippocampus; Anticonvulsants; Excitatory amino acids (Hill, D.R. (244) 303)

GABA $\rho_2$ receptors; GABA $\rho_1$ receptors; Ligand-gated ion channel; Inhibitory amino acids; Retina (Kusama, T. (245) 83)

$GABA_A$ receptor complex (Type I and Type II benzodiazepine binding sites); [$^3$H]Zolpidem binding; [$^3$H]Flunitrazepam binding; Aging; Cortex (Ruano, D. (246) 81)

$GABA_A$ receptor; Diazepam-insensitive benzodiazepine receptor; ZG-63 (Wong, G. (247) 57)

Small intestine (guinea-pig); Ivermectin; Lindane; Enteric $GABA_A$ receptors (Coccini, T. (248) 1)

**Gabapentin**
GABA (γ-aminobutyric acid); Baclofen; $GABA_A$ receptors; $GABA_B$ receptors; NMDA (N-methyl-D-aspartate); Glycine; Anticonvulsants; Polyamines (Suman-Chauhan, N. (244) 293)

Autoradiography; GABA (γ-aminobutyric acid); NMDA (N-methyl-D-aspartate); Glycine; Hippocampus; Anticonvulsants; Excitatory amino acids (Hill, D.R. (244) 303)

Anticonvulsant; L-Amino acids; System-L; Transporter; Brain (Thurlow, R.J. (247) 341)

**$GABA_B$ receptor agonists**
Nitropropane analog of baclofen; Baclofen; Ileum (guinea-pig, isolated); Vas deferens (guinea pig); Brain slices (rat) (Kerr, D.I.B. (236) 239)

**GABA receptor antagonists**
Dexamphetamine-chlordiazepoxide mixture; Valproate; Hyperactivity (Cao, B.-J. (237) 177)

**$GABA_B$ receptor antagonists**
GABA (γ-aminobutyric acid); Hippocampus; $GABA_B$ receptors; Inhibitory postsynaptic potential (late); GABA transmission (Olpe, H.-R. (233) 179)

Spinal cord; Monosynaptic reflex; Baclofen; (In vitro) (Brugger, F. (235) 153)

**$GABA_A$ receptor complex**
Benzodiazepine; TBPS (*t*-butylbicyclophosphorothionate) binding; $Cl^-$ uptake (Finn, D.A. (247) 233)

**$GABA_A$ receptor complex (Type I and Type II benzodiazepine binding sites)**
[$^3$H]Zolpidem binding; [$^3$H]Flunitrazepam binding; γ-Aminobutyric acid; Aging; Cortex (Ruano, D. (246) 81)

**$GABA_A$ receptor-ionophore complex**
Benzodiazepine receptors; Agonists/inverse agonists (Partial and full); [$^{35}$S]TBPS binding (t-butylbicyclophosphoro[$^{35}$S]thionate); Allosteric regulation of efficacy (Maksay, G. (246) 255)

**GABA receptors**
Distal colon; Enteric nerves; Gastrointestinal motility (Minocha, A. (230) 187)

Methionine sulfoximine; Dorsal raphe nucleus; Hypothermia; 5-HT receptors; GABA (γ-aminobutyric acid) (Ginefri-Gayet, M. (235) 189)

Hippocampal slices; *Xenopus* oocytes (rat cortex mRNA-injected); Glutamate receptors; ATP-sensitive potassium channel activators; [$^3$H]AMPA (*R,S*)-α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) binding; [$^3$H]Kainate binding (Randle, J.C.R. (247) 257)

**$GABA_A$ receptors**
Development; Ethanol; Flunitrazepam; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

γ-Hydroxybutyric acid (GHB); Dopaminergic neurons; Ethanol; NMDA receptor antagonists (Diana, M. (230) 363)

Pentobarbital; Tolerance; Dependence; (Intracerebroventricular) (Tseng, Y.T. (236) 23)

DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA release; GABA turnover; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

Gabapentin; GABA (γ-aminobutyric acid); Baclofen; $GABA_B$ receptors; NMDA (N-methyl-D-aspartate); Glycine; Anticonvulsants; Polyamines (Suman-Chauhan, N. (244) 293)

$La^{3+}$; Lanthanides; [$^{35}$S]TBPS ([$^{35}$S]t-butylbicyclophosphorothionate) binding; Conformational changes in $GABA_A$ receptors (Im, W.B. (245) 111)

Benzodiazepine; Ro15-4513; Flunitrazepam (Duncalfe, L.L. (246) 141)

β-Alanine; Glycine receptor; Progesterone; 5α-Pregnan-3α-ol-20-one (5α3α); Neuromodulation (Wu, F.-S. (246) 239)

ω modulatory site; [$^3$H]Flumazenil; Zolpidem; Alpidem (Faure-Halley, C. (246) 283)

GABA (γ-aminobutyric acid); Diazepam-insensitive benzodiazepine receptor; ZG-63 (Wong, G. (247) 57)

**$GABA_B$ receptors**
Hippocampus; Coupling mechanism (Potier, B. (231) 427)

Baclofen; β-Phenyl-GABA; Brain slices (rat); Ileum (guinea-pig); (Agonist/partial agonist) (Ong, J. (233) 169)

GABA (γ-aminobutyric acid); Hippocampus; Inhibitory postsynaptic potential (late); GABA transmission; $GABA_B$ receptor antagonists (Olpe, H.-R. (233) 179)

Baclofen; CGP 35348; Antinociception; Spinal cord (Hammond, D.L. (234) 255)

Handling; Stress; $5\text{-}HT_{1A}$ receptors; $5\text{-}HT_3$ receptors; Anxiolytics (Andrews, N. (235) 109)

Gabapentin; GABA (γ-aminobutyric acid); Baclofen; $GABA_A$ receptors; NMDA (N-methyl-D-aspartate); Glycine; Anticonvulsants; Polyamines (Suman-Chauhan, N. (244) 293)

**GABA $\rho_1$ receptors**
GABA (γ-aminobutyric acid); GABA $\rho_2$ receptors; Ligand-gated ion channel; Inhibitory amino acids; Retina (Kusama, T. (245) 83)

**GABA $\rho_2$ receptors**
GABA (γ-aminobutyric acid); GABA $\rho_1$ receptors; Ligand-gated ion channel; Inhibitory amino acids; Retina (Kusama, T. (245) 83)

**$GABA_A$ receptor subtypes**
Ro 15-4513; Cerebellum; Recombinant mutant receptors; (Selected rat lines) (Korpi, E.R. (247) 23)

**$GABA_B$ receptor subtypes**
GABA release; GABA autoreceptors; CGP 52432; Glutamate release; Somatostatin release (Lanza, M. (237) 191)

**$GABA_A$ receptor $\alpha_1$-subunit**
mRNA; Ethanol inhalation; Alcohol dependence (Hirouchi, M. (247) 127)

**GABA release**
γ-Vinyl GABA; Microdialysis (Jolkkonen, J. (229) 269)

GABA autoreceptors; CGP 52432; $GABA_B$ receptor subtypes; Glutamate release; Somatostatin release (Lanza, M. (237) 191)

DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA turnover; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

**GABA transmission**
GABA (γ-aminobutyric acid); Hippocampus; $GABA_B$ receptors; Inhibitory postsynaptic potential (late); $GABA_B$ receptor antagonists (Olpe, H.-R. (233) 179)

**GABA turnover**
DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA release; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

**GABA uptake**
DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA release; GABA turnover; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

**GABA uptake (glial)**
Epilepsy; Frings audiogenic seizure-susceptible mice; GABA uptake inhibitors (White, H.S. (236) 147)

**GABA uptake inhibitors**
Epilepsy; Frings audiogenic seizure-susceptible mice; GABA uptake (glial) (White, H.S. (236) 147)

**Gadolinium**
Neomycin; Nimodipine; Verapamil; Voltage-sensitive $Ca^{2+}$ channels; Brain synaptosomes (Canzoniero, L.M.T. (245) 97)

**Galactosaemia**
Aldose reductase; Aorta; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Polyol pathway (Cameron, N.E. (243) 47)

**Galactosamine**
E3330; Liver injury; TNF-α (tumor necrosis factor-α); Leukotrienes; Prostanoids (Nagakawa, J.-i. (229) 63)

**D-Galactose**
Robenidine; Coccidiosis; L-Leucine; Intestinal transport; Jejunum (rabbit); Drug-nutrient interaction; Sucrase; Aminopeptidase (Sorribas, V. (248) 137)

**Galanin**
Locus coeruleus neurons; Receptor interaction; Firing rate; Membrane potential (Sevcik, J. (230) 223)

M35; Islets of Langerhans (isolated); Insulin secretion; Clonidine; Somatostatin (Gregersen, S. (232) 35)

Amino acid release; ATP-sensitive $K^+$ channels; Glibenclamide; Hippocampus (rat) (Zini, S. (245) 1)

**Galanin fragments**
Galanin (porcine, rat); $N^{\alpha}$-Acetyl-galanin-(9–29) (porcine, rat); Pancreatic amylase secretion; Jejunal strip contraction (rat) (Rossowski, W.J. (240) 259)

**Galanin (porcine, rat)**
Galanin fragments; $N^{\alpha}$-Acetyl-galanin-(9–29) (porcine, rat); Pancreatic amylase secretion; Jejunal strip contraction (rat) (Rossowski, W.J. (240) 259)

**Galanin receptor antagonists**
Microdialysis; M15; M35; Receptor binding; Striatum (Ögren, S.O. (242) 59)

**Gall bladder**
Ethanol; Smooth muscle; Tolerance; $Ca^{2+}$ (Masui, H. (248) 103)

**Gall bladder emptying**
SR 27897; $CCK_A$ receptors; Gastric emptying; Amylase secretion (Gully, D. (232) 13)

**Gall-bladder (guinea-pig)**
$Ca^{2+}$ channel antagonists; (Skinned gall bladder) (Cejalvo, D. (234) 23)

**Gallopamil**
Ventricular arrhythmia; (Triggered activity); (Plasma concentration) (Matsuzaki, T. (231) 363)

**Gamma globulin (human)**
Immunoglobulins; Smooth muscle; Immunoglobulin G; Spontaneous contractility (Abrahams, Z. (238) 435)

**Ganglia**
Intestine; Enteric nervous system; Myenteric plexus; Substance P; Tachykinins (Tamura, K. (232) 235)

**Ganglion blockers**
Dequalinium; Sympathetic ganglia; Muscarinic receptor antagonists; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

**Ganglioside GM1**
Glycosphingolipid derivatives; Excitotoxicity; Neuroprotection; Dopaminergic neurons; Parkinson's disease (Skaper, S.D. (243) 91)

**Gap junction**
25-Hydroxycholesterol; Hepatocytes; Free radical (Guo, X. (248) 337)

**Gap-junctional intercellular communication**
Liver tumour promotion (rat); Hepatocytes; Dye transfer; Connexin 32; (Long-term coculture) (Mesnil, M. (248) 59)

**Gastric acid secretion**
DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid); Amiloride; $Cl^-$-$HCO_3^-$ exchanger; $Na^+$-$H^+$ exchanger; Stomach (isolated); (Rat) (Horie, S. (229) 15)

EGTA; EDTA; Ethanol; Gastric ulcer; Pepsin; Stress (Glavin, G.B. (233) 269)

FRG-8813; Histamine $H_2$ receptor antagonists; Stomach (Shibata, M. (235) 245)

Xanthine; TRH analog; 2-Deoxy-D-glucose; Vagus; Gastric mucosal blood flow; Carbachol (Tanaka, T. (243) 221)

Opioid receptor subtypes; Gastrin (plasma); (Dog) (Intorre, L. (243) 265)

**Gastric cytoprotection**
L-Arginine; L-NAME ($N^G$-nitro-L-arginine methyl ester); Nitric oxide (NO); RX 77368; Vagus (Király, Á. (240) 299)

**Gastric emptying**
SR 27897; $CCK_A$ receptors; Gall bladder emptying; Amylase secretion (Gully, D. (232) 13)

**Gastric fundus (guinea-pig)**
Nicotine-induced relaxation; Nitric oxide (NO); Noradrenaline (Kojima, S.-i. (241) 171)

**Gastric fundus (rat)**
Tachykinin; $NK_2$ receptors; Radioligand binding; Neurokinin A; Neuropeptide γ (Burcher, E. (233) 201)

**Gastric mucosal blood flow**
Gastric acid secretion; Xanthine; TRH analog; 2-Deoxy-D-glucose; Vagus; Carbachol (Tanaka, T. (243) 221)

**Gastric mucosal injury**
PAF (platelet-activating factor); Seminal vesicle protein; Hypotension; Bronchoconstriction (Persico, P. (241) 71)

**Gastric ulcer**
EGTA; EDTA; Gastric acid secretion; Ethanol; Pepsin; Stress (Glavin, G.B. (233) 269)

CGRP (calcitonin gene-related peptide); Reserpine; Somatostatin (Clementi, G. (238) 101)

Adenosine deaminase; Ranitidine (Namiot, Z. (243) 301)

**Gastrin (plasma)**
Opioid receptor subtypes; Gastric acid secretion; (Dog) (Intorre, L. (243) 265)

**Gastrin-releasing peptide**
Neuromedin B; Bombesin (Ladenheim, E.E. (235) 121)

Bombesin; Phyllolitorin; Scratching behaviour; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

Bombesin; Neuromedin B; Bombesin receptors (Guard, S. (240) 177)

**Gastroepiploic artery (simian)**
5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_1$-like receptors; $5\text{-}HT_2$ receptors; $Ca^{2+}$ ion channels (Noguchi, M. (234) 101)

**Gastrointestinal motility**
Distal colon; Enteric nerves; GABA receptors (Minocha, A. (230) 187)

Colon; Pain; Stomach; VIP (vasoactive intestinal polypeptide); VIP antiserum (Bojö, L. (236) 443)

**GBR 12909**
Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; Learning (latent); Locomotor activity (Ichihara, K. (234) 155)

**[$^3$H]GBR 12783**
Dopamine neuronal carrier; Membrane polarity; Binding (in vitro); Striatum (rat) (Billaud, G. (247) 333)

**[$^3$H]GBR 12783 binding site occupancy**
Dopamine uptake inhibitors; Locomotor activity; Cytochrome P450; (Mouse) (Vaugeois, J.-M. (230) 195)

**GDP-$\beta$-S**
Adenosine $A_2$ receptors; Dopamine $D_2$ receptors; CGS 21680; Gpp(NH)p; $Mg^{2+}$; Neostriatum; (Rat) (Ferré, S. (244) 311)

**Gelsolin**
ADP-ribosylation actin; *Clostridium botulinum* C2 toxin (Just, I. (246) 293)

**Gene expression**
Glutamate; Glutamate receptors; Splicing (alternative); Hippocampus (human) (McLaughlin, D.P. (244) 89)

Cyclosporine; Angiotensin $AT_{1A}$ receptors; Hypertension; Endothelium (Iwai, J. (248) 341)

**Genetic hypertension**
Ramipril; Adrenoceptors; Oscillation (Watts, S.W. (242) 245)

**Genetic obesity**
Feeding behaviour; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); Insulin; Neuropeptide Y; CRF (corticotropin-releasing factor); (Zucker rat) (Rouru, J. (234) 191)

Metformin; Zucker rat; Brown adipose tissue; Thermogenesis; Uncoupling protein (Rouru, J. (246) 67)

**Gene transcription**
5-$HT_2$ receptor regulation; Behavioural response; Phosphoinositide turnover; mRNA levels (Rinaldi-Carmona, M. (246) 73)

**Germ-free life**
Anthraquinones; Cathartics; Bacteria (Nijs, G. (239) 241)

**Girardi heart cell (human)**
27-O-Caffeoyl myricerone (50-235); Endothelin receptor antagonist; Cytosolic free $Ca^{2+}$; Mitogenesis; Smooth muscle cell (aorta, rat) (Mihara, S.-i. (246) 33)

**Glibenclamide**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

Adenosine; Adenosine $A_2$ receptor-mediated vasodilatation; $K^+$ channels (ATP-sensitive); 8-Phenyltheophylline (Orito, K. (231) 183)

Patch clamp; $K^+$ channel openers; Skeletal muscle $K_{ATP}$ channels (Allard, B. (236) 419)

Plasma exudation; Cigarette smoke; Vagus nerve stimulation; $K^+$ channel opener (Lei, Y.-H. (239) 257)

Insulin secretion; Islet acid glucan-1,4-$\alpha$-glucosidase; $\alpha$-Glucosidehydrolase inhibition; Emiglitate; Acarbose; Carbachol (Salehi, A. (243) 185)

$K^+$ channel (*Xenopus laevis*); $K^+$ channel opener; KRN2391; Nicorandil; Cromakalim; Phentolamine; Trifluoperazine (Sakuta, H. (244) 277)

Amino acid release; ATP-sensitive $K^+$ channels; Galanin; Hippocampus (rat) (Zini, S. (245) 1)

Local anesthetics; Bupivacaine; $K^+$ channel; *Xenopus laevis* oocyte; Calmodulin (Yoneda, I. (247) 267)

**Glibenclamide-sensitive $K^+$ channels**
Adenosine; Levcromakalim; YT-146 (2-(1-octynyl)-adenosine); G-protein (pertussis toxin-sensitive) (Furukawa, S. (236) 255)

**Glipizide**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Antinociception; Opiates (Ocaña, M. (230) 203)

**Gliquidone**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Glipizide; Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

Morphine; ATP-dependent $K^+$ channels; Locomotor activity (Ocaña, M. (239) 253)

**Glomerular filtration rate**
EXP3174; $Li^+$ clearance; Angiotensin II; Renal blood flow (Tamaki, T. (236) 15)

Nifedipine; TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate); Hypertonic saline; Renal blood flow (Ogasawara, A. (243) 103)

**Glomerular mesangial cells**
Nipradilol; Guanylate cyclase (soluble); cGMP; Mitogenesis (Koya, D. (245) 79)

**Glomerulus**
Angiotensin $AT_1$ receptors; Losartan (Chansel, D. (247) 193)

**Glossopharyngeal nerve**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_3$ receptors (Yoshioka, M. (236) 491)

**Glucagon**
Pancreas (dog); Exocrine secretion; Somatostatin (Horiuchi, A. (237) 23)

**Glucagon-like peptide 1-(7–36) amide**
Parietal cell rat; Acid production; Epidermal growth factor; Transforming growth factor-$\alpha$; GTP-binding proteins (Schmidtler, J. (246) 59)

**Glucagon release**
Glutamate; AMPA receptors; Pancreas (rat) (Bertrand, G. (237) 45)

**Glucocorticoid receptors**
Adrenal medulla; Phenylethanolamine N-methyltransferase; Nicotine; Catecholamines (Betito, K. (238) 273)

Mineralocorticoid receptor; Steroid hormones; Receptor binding; Localization; Trans-activation (Rupprecht, R. (247) 145)

**Glucocorticoids**
Fever; Prostaglandins (Coelho, M.M. (238) 391)

Vasodilatation; Endotoxin; Nitric oxide (NO); Interleukin-1; Neutrophils (Pons, F. (239) 23)

**Glucose**
Ipsapirone; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-$HT_{1A}$ receptors; 5-$HT_2$ receptors; Anxiolysis; Corticosterone; Prolactin; Behaviour (Baudrie, V. (231) 395)

Serotonergic mechanisms (peripheral); Free fatty acids; Insulin; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

Islets of Langerhans; Monoamine oxidase activity; $\alpha$-Adrenoceptor stimulation; $\beta$-Adrenoceptor stimulation; Cholinergic stimulation; Insulin; (Mouse) (Panagiotidis, G. (233) 285)

**Glucose metabolism**
Phencyclidine; Psychosis; Schizophrenia; Histopathology; Limbic system (Gao, X.-M. (241) 7)

**Glucose uptake**
Trifluoperazine; Calmodulin; Insulin; Skeletal muscle (Guarner, V. (237) 139)

**Glucose utilization**
Buspirone; Hippocampus; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

**$\alpha$-Glucosidehydrolase inhibition**
Insulin secretion; Islet acid glucan-1,4-$\alpha$-glucosidase; Emiglitate; Acarbose; Glibenclamide; Carbachol (Salehi, A. (243) 185)

**Glutamate**
$Ca^{2+}$ channel blockers; Cerebellar slices (Dickie, B.G.M. (229) 97)

Dopamine; Neuroleptics; Nucleus accumbens; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

Dystonia; Phenobarbital; Dopamine; GABA ($\gamma$-aminobutyric acid); Haloperidol (Richter, A. (231) 111)

Dystonia; Probenecid (Richter, A. (231) 287)

Sabeluzole; NMDA receptors; Cerebellum; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Hypoxia; Ischemia; Neurotoxicity; Cell culture; ES-242s; MK-801 (Nozawa, M. (236) 263)

Dystonia; $\kappa$-Opioid receptors; $\sigma$ Receptors; Naloxone; Naltrexone; Movement disorders; Dopamine (Richter, A. (236) 289)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline); Cerebral ischaemia; AMPA receptors; NMDA receptors; NMDA receptor antagonists (Sheardown, M.J. (236) 347)

AMPA receptors; Glucagon release; Pancreas (rat) (Bertrand, G. (237) 45)

Epilepsy; Dextromethorphan; Dextrorphan; Kindling; (Rat) (Löscher, W. (238) 191)

$Ca^{2+}$ channels; Exocytosis; Aspartate; GABA ($\gamma$-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

Movement disorders; Glycine (Löscher, W. (239) 245)

Cerebral cortex; Nitric oxide (NO); NMDA (N-methyl-D-aspartate); Methylcobalamin; Vitamin $B_{12}$ (Akaike, A. (241) 1)

Dopamine; Phencyclidine; Ipsapirone; 5-HT (5-hydroxytryptamine, serotonin); MK-801 (Löscher, W. (242) 99)

Adenosine; Seizure; GABA ($\gamma$-aminobutyric acid); GABA/benzodiazepine receptor; Mouse (Klitgaard, H. (242) 221)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Phencyclidine (Löscher, W. (242) 263)

Dystonia; Movement disorders; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Richter, A. (242) 309)

Glutamate receptors; Splicing (alternative); Gene expression; Hippocampus (human) (McLaughlin, D.P. (244) 89)

NMDA receptors; Proenkephalin mRNA; Striatum; Accumbens; MK-801 (Angulo, J.A. (244) 317)

Bergmann glia; AMPA/kainate receptors (Cid, M.E. (245) 51)

Excitatory amino acids; Metabotropic; Phosphoinositide hydrolysis; NBQX (2,3-dihydroxy-6-nitro-7-sulpha-moylbenzo(F)-quinoxaline) (Suzdak, P.D. (245) 215)

NMDA receptor coupled ion channel; Glycine; $Mg^{2+}$ MK-801 (5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5,10-imine maleate) (Von Euler, G. (245) 233)

3-Nitropropionic acid; Excitotoxicity; NMDA (N-methyl-D-aspartate); Cerebellar granule neurons (Weller, M. (248) 223)

Methotrexate; MK-801; Memantine; Carboxypeptidase; Neurotoxicity (Weller, M. (248) 303)

**Glutamate-induced cytotoxicity**
Ethanol; NMDA receptor; Ethanol withdrawal; Cerebellar granule cells (Iorio, K.R. (248) 209)

**Glutamate metabotropic receptors**
Long-term depression; Long-term potentiation; $\alpha$-Methyl-4-carboxyphenylglycine (Bashir, Z.I. (239) 265)

**Glutamate receptors**
Phenobarbital; Dependence; Brain (Short, K.R. (230) 111)

Excitatory amino acids; Parkinson's disease; Neuroleptics (Papa, S.M. (232) 247)

Dopamine release; Brain, in vitro (rat); Olfactory tubercle; Frontal cortex; Striatum (Jones, C.A. (242) 183)

Glutamate; Splicing (alternative); Gene expression; Hippocampus (human) (McLaughlin, D.P. (244) 89)

Cyclothiazide; AMPA ($\alpha$-amino-3-hydroxy-5-methylisoxazole-4-propionate); GYKI 53655 (Palmer, A.J. (244) 193)

Hippocampal slices; *Xenopus* oocytes (rat cortex mRNA-injected); GABA receptor; ATP-sensitive potassium channel activators; [$^3$H]AMPA (*R*,*S*)-$\alpha$-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) binding; [$^3$H]Kainate binding (Randle, J.C.R. (247) 257)

$K^+$ channels; Noradrenaline release (Ennis, C. (248) 85)

**Glutamate release**
GABA release; GABA autoreceptors; CGP 52432; $GABA_B$ receptor subtypes; Somatostatin release (Lanza, M. (237) 191)

NMDA receptors; Voltage-operated $Ca^{2+}$ channels; $^{45}Ca^{2+}$ uptake; $K^+$ depolarization; Cerebellar granule cells (Didier, M. (244) 57)

**Glybenclamide**
Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); EDHF (endothelium-derived hyperpolarizing factor); $N^{\omega}$-Nitro-L-arginine; Aorta (rabbit) (Bellan, J.A. (234) 273)

CGRP (calcitonin gene-related peptide); Uterine artery (human); $K^+$ channels; Pregnancy; Tetraethylammonium; Pinacidil (Nelson, S.H. (242) 255)

**Glyceryl trinitrate healing**
Peptic ulcers; Nitric oxide (NO); L-Arginine; Blood flow (Konturek, S.J. (239) 215)

**Glycine**
Aging; NMDA receptors; D-Cycloserine; Noradrenaline release; Glycine uptake (Pittaluga, A. (231) 129)

NMDA (N-methyl-D-aspartate); Haloperidol; Hippocampus (Fletcher, E.J. (235) 291)

NMDA (N-methyl-D-aspartate); Pain (Millan, M.J. (238) 445)

Movement disorders; Glutamate (Löscher, W. (239) 245)

Gabapentin; GABA ($\gamma$-aminobutyric acid); Baclofen; $GABA_A$ receptors; $GABA_B$ receptors; NMDA (N-methyl-D-aspartate); Anticonvulsants; Polyamines (Suman-Chauhan, N. (244) 293)

Gabapentin; Autoradiography; GABA ($\gamma$-aminobutyric acid); NMDA (N-methyl-D-aspartate); Hippocampus; Anticonvulsants; Excitatory amino acids (Hill, D.R. (244) 303)

NMDA receptor coupled ion channel; Glutamate; $Mg^{2+}$ MK-801 (5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5,10-imine maleate) (Von Euler, G. (245) 233)

**Glycine receptor**
[$^3$H]Strychnine binding, (agonist and antagonist); Entropy change of binding; Kinetic cooperativity of dissociation (Maksay, G. (245) 183)

$\beta$-Alanine; $GABA_A$ receptor; Progesterone; 5$\alpha$-Pregnan-3$\alpha$-ol-20-one (5$\alpha$3$\alpha$); Neuromodulation (Wu, F.-S. (246) 239)

**Glycine uptake**
Aging; NMDA receptors; Glycine; D-Cycloserine; Noradrenaline release (Pittaluga, A. (231) 129)

**Glycosphingolipid derivatives**
Ganglioside GM1; Excitotoxicity; Neuroprotection; Dopaminergic neurons; Parkinson's disease (Skaper, S.D. (243) 91)

**Glycosphingolipids**
Lysogangliosides; Platelet aggregation; Thrombin; 5-HT (5-hydroxytryptamine, serotonin); Tromboxane $B_2$; Bleeding; Coagulation; Fibrinolysis (Tubaro, E. (248) 175)

**GM 7373 cell line**
Dexamethasone; Endothelial cells; Vasocortin; Dextran oedema; Histamine release (Iuvone, T. (243) 163)

**GM1 ganglioside**
Hypoxia-reoxygenation; $Na^+$,$K^+$-ATPase; Noradrenaline (Lodovici, M. (243) 255)

**cGMP**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO); Pulmonary artery (pig) (Pepke-Zaba, J. (235) 169)

Coronary artery; ANP (atrial natriuretic polypeptide); Nitroglycerin; Nitric oxide (NO) (Matsumoto, T. (237) 31)

ANF (atrial natriuretic factor); EDRF (endothelium-derived relaxing factor); Heart failure (Arnal, J.-F. (237) 265)

Acetylcholine; Mesenteric arterial bed; Nitric oxide (NO); cAMP; Endothelium-dependent relaxation (Abiru, T. (242) 15)

Candoxatrilat; Neutral endopeptidase inhibition; ANF (atrial natriuretic factor); Volume expansion (Scott, J.M. (242) 91)

Atrial natriuretic peptides (ANP); EDRF (endothelium-derived relaxing factor; (Receptor down-regulation) (Kato, J. (244) 153)

Nipradilol; Guanylate cyclase (soluble); Mitogenesis; Glomerular mesangial cells (Koya, D. (245) 79)

Neutrophils (electroporated); Migration; cAMP; Chemokinesis (Elferink, J.G.R. (246) 157)

FK409; Vasorelaxation; Soluble guanylate cyclase; Cyclic guanosine monophosphate phosphodiesterase (Isono, T. (246) 205)

Nitric oxide (NO) synthase; Catecholamine release; Adrenal medulla; Chromaffin cells (Moro, M.A. (246) 213)

Organic nitroesters; Platelets; Nitric oxide (NO) (Weber, A.-A. (247) 29)

G-protein; Endothelial cells; Bradykinin; Nitric oxide (NO) (Gil-Longo, J. (247) 119)

Mastoparan; Guanylate cyclase; ANF (Atrial natriuretic factor); ATP (Song, D.-L. (247) 283)

**cGMP analog**
$Ca^{2+}$; Platelet aggregation; Nitric oxide (NO) (Menshikov, M.Y. (245) 281)

**cGMP (intracellular)**
Nitroglycerin tolerance; Zaprinast; cGMP-phosphodiesterase inhibitor; (Reversal of tolerance) (Pagani, E.D. (243) 141)

**cGMP phosphodiesterase**
FK409; Vasorelaxation; cGMP; Soluble guanylate cyclase (Isono, T. (246) 205)

**cGMP phosphodiesterase inhibitor**
Nitroglycerin tolerance; Zaprinast; cGMP (intracellular); (Reversal of tolerance) (Pagani, E.D. (243) 141)

**Gold ion**
$Ca^{2+}$ channels (L-type); Perchlorate; Skeletal muscle contraction; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

**Gonadotrophin**
Inhibin; Oestradiol-17$\beta$; Ovarian hormones; Prostaglandin $F_{2\alpha}$; Indomethacin (Kogo, H. (231) 481)

**Gpp(NH)p**
Adenosine $A_2$ receptors; Dopamine $D_2$ receptors; CGS 21680; GDP-$\beta$-S; $Mg^{2+}$; Neostriatum; (Rat) (Ferré, S. (244) 311)

**G-protein activation**
Bradykinin; Hoe 140; Uterus (rat); Functional antagonism; (Binding sites) (Liebmann, C. (235) 183)

**G-protein expression**
Morphine tolerance; In situ hybridization histochemistry; Immunoblot analysis; Brain regions (Parolaro, D. (244) 211)

**G-protein (pertussis toxin-sensitive)**
Adenosine; Glibenclamide-sensitive $K^+$ channels; Levcromakalim; YT-146 (2-(1-octynyl)-adenosine) (Furukawa, S. (236) 255)

**G-proteins**
Adenosine $A_1$ receptors; Hypertension (Matias, A. (244) 223)

Morphine exposure (chronic); Tolerance; Dependence; Adenylyl cyclase activity; Striatal neurons (Van Vliet, B.J. (245) 23)

PAF (platelet activating factor); Adenylyl cyclase; Forskolin; PAF receptor (Wong, S. (245) 55)

Radiation inactivation; Opioid receptor; Tolerance; (Uncoupling) (Tao, P.-L. (246) 233)

Cerebral cortex; Adenylyl cyclase; $\beta$-Adrenoceptors; F-344 rats; Tricyclic antidepressants; Down-regulation (Scarpace, P.J. (247) 65)

Endothelial cells; Bradykinin; Nitric oxide (NO); cyclic GMP (Gil-Longo, J. (247) 119)

Mastoparan; Cardiac contractility (Van Meel, J.C.A. (247) 357)

**Granisetron**
Enterotoxin; Intestinal secretion; Ketanserin; Tropisetron; Ondansetron (Beubler, E. (248) 157)

**[$^3$H]Granisetron**
5-$HT_3$ receptors; [$^3$H]Zacopride; [$^{14}$C]Guanidinium; Ileum; Bezold-Jarisch reflex; Turning behaviour; Cortical firing rate; (Ex vivo binding) (Bachy, A. (237) 299)

5-$HT_3$ receptors; Huntington's disease; Parkinson's disease; Putamen (human) (Steward, L.J. (242) 137)

**Granule cells**
Sabeluzole; NMDA receptors; Glutamate; Cerebellum; Voltage clamp (Van der Valk, J.B.F. (232) 131)

**Grooming**
ACTH (adrenocorticotropic hormone); $\alpha$-MSH ($\alpha$-melanocyte-stimulating hormone); Behavioural state; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

Dopamine $D_1$ receptor subtypes; Vacuous chewing (Downes, R.P. (234) 135)

**Grooming behaviour**
Dopamine $D_1$ receptor agonists; A68930; SK&F 38393; REM (rapid eye movement) sleep; (Rat) (Trampus, M. (235) 83)

**GS 283**
$Ca^{2+}$ channel antagonists; Carbachol; Histamine; Verapamil; Trachealis (Chang, K.C. (236) 51)

**GTP**
[$^3$H]Spiperone; Dopamine $D_2$ receptors; Affinity state; Dorsal hippocampus; Ventral hippocampus; Striatum; $Mg^{2+}$; Iron-chelator (Bruinink, A. (245) 157)

**GTP-binding proteins**
$\alpha_2$-Adrenoceptors; Muscarinic receptors; $Ca^{2+}$ channels; Heterologous desensitization; ADP ribosylation (Nah, S.-Y. (244) 67)

Parietal cell rat; Acid production; Glucagon-like peptide 1-(7–36) amide; Epidermal growth factor; Transforming growth factor-$\alpha$ (Schmidtler, J. (246) 59)

**[$^{14}$C]Guanidinium**
5-$HT_3$ receptors; [$^3$H]Zacopride; [$^3$H]Granisetron; Ileum; Bezold-Jarisch reflex; Turning behaviour; Cortical firing rate; (Ex vivo binding) (Bachy, A. (237) 299)

**Guanine nucleotides**
Opioids; $\delta$-Opioid receptors; BW 373U86; Radioligand binding (Wild, K.D. (246) 289)

**Guanylate cyclase**
Mastoparan; ANF (Atrial natriuretic factor); cGMP; ATP (Song, D.-L. (247) 283)

**Guanylate cyclase (soluble)**
Nipradilol; cGMP; Mitogenesis; Glomerular mesangial cells (Koya, D. (245) 79)

**Gut musculature toxicity**
Butylated hydroxyanisole; (Intraperitoneal administration) (Sgaragli, G.P. (248) 121)

**GYKI 53655**
Glutamate receptors; Cyclothiazide; AMPA ($\alpha$-amino-3-hydroxy-5-methylisoxazole-4-propionate) (Palmer, A.J. (244) 193)

**GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine · HCl)**
DBA/2 mice; Aniracetam; AMPA receptor antagonists; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline); CPPene (D(−)-(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid) (Chapman, A.G. (231) 301)

**H 25**
Pancreatic $\beta$-cells; H 74; Co-transport; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

**H 74**
Pancreatic $\beta$-cells; H 25; Co-transport; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

**HA-966**
(+)-MK-801; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

**Haemodynamics**
NADPH diaphorase; Nitro blue tetrazolium; (Rat) (Davisson, R.L. (241) 135)

**Haemoglobin**
Diabetes mellitus; Aorta (rat); $N^G$-Nitro-L-arginine; Endothelium-dependent relaxation; Tachyphylaxis (Sikorski, B.W. (242) 275)

**Haloperidol**
Dopamine; Electrooculogram; Light peak; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

Dystonia; Phenobarbital; Dopamine; GABA (γ-aminobutyric acid); Glutamate (Richter, A. (231) 111)

Paw test; SCH 39166; Raclopride; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors (Prinssen, E.P.M. (231) 275)

σ Receptor ligands; Neurogenic twitch contraction; Benzomorphan-type σ receptor; ATP transmission; Vas deferens (mouse); Brain (guinea-pig); SK&F 10,047 (N-allylnormetazocine); Rimcazole (Matsuno, K. (231) 451)

Dopamine release; Striatum; Apomorphine; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

NMDA (N-methyl-D-aspartate); Glycine; Hippocampus (Fletcher, E.J. (235) 291)

Clozapine; Loxapine; Hippocampus; Synaptic excitation (Baskys, A. (235) 305)

DTG (1,3-di(2-tolyl)guanidine); σ Receptor ligands; Anticonvulsants; Prepiriform cortex (Roth, J.E. (236) 327)

Dextromethorphan; σ Binding sites; Phenytoin; DTG (1,3-di-o-tolylguanidine); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine) (Bailey, M.A. (240) 243)

**Haloperidol (intermittent)**
Oral dyskinesia; Sensitization (pharmacological); Drug holidays (rats); Amygdala kindling (Glenthøj, B. (236) 401)

**Halothane**
Trifluoroacetylated proteins; Neoantigens (Heijink, E. (248) 15)

**Handling**
Stress; $5\text{-}HT_{1A}$ receptors; $5\text{-}HT_3$ receptors; $GABA_B$ receptors; Anxiolytics (Andrews, N. (235) 109)

**$HCO_3^-$-$Cl^-$ exchange inhibition**
Erythrocyte membrane; Clofibric acid; Clofibrate; Membrane electrophoresis; (Rat) (Morales-Aguilera, A. (245) 89)

**$HCO_3^-$ secretion**
Nitric oxide (NO); NO synthase inhibitors; L-NAME ($N^G$-nitro-L-arginine methyl ester); Duodenum (rat) (Takeuchi, K. (231) 135)

**Heart**
Atrium; Contractile force; 5-HT (5-hydroxytryptamine, serotonin); Ventricle; (Human) (Schoemaker, R.G. (230) 103)

Ischemia/reperfusion; Free radicals; Spin traps; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (234) 113)

$Ca^{2+}$ currents; Contraction (Harrison, S. (237) 83)

Ischemia/reperfusion; Free radicals; Spin traps; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (239) 275)

Adenosine receptors; β-Adrenoceptors; Species differences (Guinea Pig, Pig, Rabbit, Rat) (Musser, B. (246) 105)

$Ca^{2+}$ channel antagonist; Voltage-operated channel; Smooth muscle; SR 33805 (Chatelain, P. (246) 181)

Cardiac myocytes; Contractions; Alcohol (Cannings, I. (248) 213)

**Heart cells (embryonic chick)**
Taurine; $Ca^{2+}$ channels (L-type); $Ca^{2+}$ channels (T-type); Cardiac myocytes; Voltage clamp (whole cell); Electrophysiology (Satoh, H. (231) 443)

**Heart (dog)**
BRL 37344; $\beta_3$-Adrenoceptors; Chronotropism; Inotropism (Takayama, S. (231) 315)

**Heart failure**
Flosequinan; Cardiac muscle; Contractility; Phosphodiesterase; (Human) (Weishaar, R.E. (236) 363)

ANF (atrial natriuretic factor); EDRF (endothelium-derived relaxing factor); cGMP (Arnal, J.-F. (237) 265)

**Heart failure (high-output)**
Laser-Doppler flowmetry; Neurohumoral factors; Renal blood flow; Thermodilution; Wistar rat (Oka, T. (234) 55)

**Heart (guinea-pig)**
Doxorubicin; Pirarubicin; Aclarubicin; Antimuscarinic action; Positive inotropic effect; Potentiated postrest contraction; Time to peak twitch tension (Temma, K. (234) 173)

**Heart (guinea pig)**
Nitric oxide (NO); Reactive hyperaemia (Chłopicki, S. (241) 117)

**Heart (isolated, rat)**
KRN2391; Cromakalim; Myocardial ischemia; Energy metabolism (Ohta, H. (231) 323)

**Heart (rat)**
$\alpha_1$-Adrenoceptor subtype; Positive inotropic response (Noguchi, H. (240) 291)

**Heart rate**
Endothelin; Clonidine; Blood pressure; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

**HeLa cells**
Histamine $H_1$ receptor; Inositol phosphates; $Ni^{2+}$; Brain slice (Arias-Montaño, J.-A. (245) 221)

Histamine $H_1$ receptor; [$^3$H]Mepyramine; Phosphoinositide; (+)-Chlorpheniramine; Temelastine (Arias-Montaño, J.-A. (245) 291)

ATP; 5′-Nucleotide receptor; $Ca^{2+}$; fura-2 (Smit, M.J. (247) 223)

**α-Helical CRF-(9–41)**
Interleukin-1; CRF (corticotropin-releasing factor); Opioids; Antinociception (Mouse) (Kita, A. (237) 317)

**Hemodynamics**
Endothelin-converting enzyme; Big endothelin-1; Big endothelin-3; Phosphoramidon; Endothelin; (Rat) (Pollock, D.M. (231) 459)

$\gamma_2$-MSH ($\gamma_2$-melanocyte-stimulating hormone); ACTH-(4–10); Melanotropins; Urethane anesthesia; Pentobarbital anesthesia; Excitability; (Conscious rat) (De Wildt, D.J. (233) 157)

**Hemorrhagic shock**
Endothelin; Anaphylactic shock; Hypotension; Hypovolemia; Hypoxia (Filep, J.G. (239) 231)

**Hepatic foci (altered)**
Polychlorinated biphenyls; Tumour promotion (Hemming, H. (248) 163)

**Hepatocyte (rat)**
$\alpha_1$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Noradrenaline; Chloroethylclonidine; $Ca^{2+}$; cAMP (Nomura, T. (246) 113)

**Hepatocytes**
Nicotinic receptors; $Ca^{2+}$-activated $K^+$ channels; Dequalinium; Vecuronium; Apamin (Castle, N.A. (236) 201)

$\beta_2$-Adrenoceptors; Desensitization (Medina-Martínez, O. (244) 145)

cAMP; $\beta$-Adrenoceptors; Adenylyl cyclase; Desensitization (Sandnes, D. (246) 163)

Liver tumour promotion (rat); Gap-junctional intercellular communication; Dye transfer, Connexin 32; (Long-term coculture) (Mesnil, M. (248) 59)

25-Hydroxycholesterol; Gap junction; Free radical (Guo, X. (248) 337)

**20-HETE (20-hydroxy-5,8,11,14-eicosatetraenoic acid)**
Cytochrome P450; Arachidonic acid; Endothelium-dependent vasoconstrictor (Escalante, B. (235) 1)

**Heterologous desensitization**
$\alpha_2$-Adrenoceptors; Muscarinic receptors; $Ca^{2+}$ channels; GTP-binding proteins; ADP ribosylation (Nah, S.-Y. (244) 67)

**Heterologous expression**
Cytochrome P4502A6 (human); CYP2A6 recombinant expression vector; NIH 3T3 cells (Salonpää, P. (248) 95)

**5-HIAA (CSF levels)**
5-HT (5-hydroxytryptamine, serotonin); NAN-190; RU 24969; TFMPP (trifluoromethylphenylpiperazine); mCPP (m-chlorophenylpiperazine); 5-$HT_1$ receptor binding (in vitro); (Pigeon) (Gleeson, S. (229) 109)

**5-HIAA (5-hydroxyindole-3-acetic acid)**
Imipramine; Trimipramine; Fluoxetine; 5-HT uptake (Dewar, K.M. (235) 137)

**High-affinity 'R' sites**
5-$HT_3$ receptors; (*R*)-[$^3$H]Zacopride; (*S*)-[$^3$H]Zacopride; Brain (rat and human); Periphery (rat) (Kidd, E.J. (247) 45)

**High voltage spindle promoter**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; (Adult and aged rats) (Riekkinen, Jr., P. (235) 317)

**High voltage spindles**
Locus coeruleus; $\alpha_2$-Adrenoceptor agonists; $\alpha_2$-Adrenoceptor antagonists; Slow wave (Riekkinen, Jr., P. (238) 263)

Slow wave; Muscarinic $M_1$ receptor; Muscarinic $M_2$ receptor; Physostigmine; Tetrahydroaminoacridine; Pilocarpine; AF102B; Oxotremorine (Riekkinen, Jr., P. (240) 1)

**Hindlimb (isolated)**
5-HT (5-hydroxytryptamine, serotonin); Prostaglandins E; Temperature; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

**Hindquarters vascular bed**
PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasodilation; Vasoconstriction (Santiago, J.A. (243) 291)

**Hippocampal 5-HT release**
WAY100135; 5-$HT_{1A}$ receptor antagonists; Microdialysis (Routledge, C. (239) 195)

**Hippocampal slices**
Ischemia; 5-$HT_{1A}$ receptors; 5-$HT_2$ receptors; 2-Deoxyglucose; Electrophysiology (Shibata, S. (229) 21)

*Xenopus* oocytes (rat cortex mRNA-injected); Glutamate receptors; GABA receptor; ATP-sensitive potassium channel activators; [$^3$H]AMPA (*R,S*)-$\alpha$-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) binding; [$^3$H]Kainate binding (Randle, J.C.R. (247) 257)

**Hippocampus**
Buspirone; Glucose utilization; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

Somatostatin; 2-Deoxyglucose; Cerebral cortex; Acetylcholine; Acetylcholine receptors (Shibata, S. (231) 381)

$GABA_B$ receptors; Coupling mechanism (Potier, B. (231) 427)

Excitotoxicity; AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); $Mg^{2+}$; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

JTP-2942 (N$^\alpha$-[(1S,2R)-2-methyl-4-oxycyclopentanecarbonyl]-L-histidyl-L-prolinamide); TRH (thyrotropin-releasing hormone); Acetylcholine; Choline; Frontal cortex; Microdialysis (Toide, K. (233) 21)

GABA ($\gamma$-aminobutyric acid); $GABA_B$ receptors; Inhibitory postsynaptic potential (late); GABA transmission; $GABA_B$ receptor antagonists (Olpe, H.-R. (233) 179)

5-$HT_{1A}$ receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Working memory; Reference memory; (Microinjection) (Ohno, M. (234) 29)

NMDA (N-methyl-D-aspartate); Glycine; Haloperidol (Fletcher, E.J. (235) 291)

Clozapine; Haloperidol; Loxapine; Synaptic excitation (Baskys, A. (235) 305)

Nitric oxide synthase; Noradrenaline release (Lauth, D. (236) 165)

$\sigma$ Binding sites; DTG (1,3-di-o-tolylguanidine); Imipramine; Striatum; 5-HT (5-hydroxytryptamine, serotonin) (Shirayama, Y. (237) 117)

Acetylcholine release; Benzodiazepines (Imperato, A. (238) 135)

Cocaine; d-Amphetamine; Caudate nucleus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

Nitric oxide (NO); Dentate gyrus; (Rat, in vivo) (Iga, Y. (238) 395)

Anxiolytics; Dorsal raphe nucleus; Electrophysiology; Ipsapirone; Microdialysis; Serotonergic neurotransmission; 5-$HT_{1A}$ receptors; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

NMDA (N-methyl-D-aspartate); Non-competitive antagonism; Dizocilpine; FR115427; Cortical wedge (Hodgkiss, J.P. (240) 219)

Long-term potentiation; Cognitive enhancer; Somatostatin; Acetylcholine; Mossy fiber-CA3 pathway; FR121196; (Guinea-pig) (Matsuoka, N. (241) 27)

Gabapentin; Autoradiography; GABA ($\gamma$-aminobutyric acid); NMDA (N-methyl-D-aspartate); Glycine; Anticonvulsants; Excitatory amino acids (Hill, D.R. (244) 303)

Tetrahydroaminoacridine; Physostigmine; $\beta$-Adrenoceptors; Adenylate cyclase; Cortex; cAMP (Vivas, N.M. (245) 9)

Phorbol ester; Protein kinase C; 2-Deoxyglucose (Shibata, S. (245) 257)

Cannabinoid; Inositol phosphates; Phosphatidylinositol (Nah, S.-Y. (246) 19)

**Hippocampus (human)**
Glutamate; Glutamate receptors; Splicing (alternative); Gene expression (McLaughlin, D.P. (244) 89)

**Hippocampus (mouse)**
Neuropeptide Y; Peptide YY; $\sigma$ Receptors (Roman, F.J. (242) 305)

**Hippocampus (rat)**
Muscarinic $M_1$ receptors; Muscarinic $M_1$ receptor agonists; Vas deferens (rabbit); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

Amino acid release; ATP-sensitive $K^+$ channels; Galanin; Glibenclamide (Zini, S. (245) 1)

**Histamine**
Nitric oxide (NO); Cholecystokinin; Non-adrenergic, non-cholinergic (NANC) nerves; Sphincter of Oddi (Pauletzki, J.G. (232) 263)

Histamine $H_3$ receptor antagonists; Thioperamide; (R)-$\alpha$-Methylhistamine; Convulsions (electrically induced) (Yokoyama, H. (234) 129)

$Ca^{2+}$ channel antagonists; Carbachol; Verapamil; GS 283; Trachealis (Chang, K.C. (236) 51)

Bronchoconstriction; Capsazepine; Citric acid; Capsaicin; pH (low) (Satoh, H. (236) 367)

$N^{\alpha}$-Methylhistamine; (R)$\alpha$Methylhistamine; Intestinal transit; Histamine $H_1$ receptors; Histamine $H_3$ receptors (Oishi, R. (237) 155)

Bradykinin; Substance P; Cromakalim; Vascular permeability; Plasma exudation; Airways (Martin, C.A.E. (239) 119)

Adrenal medulla; Chromaffin cell; Catecholamine release; $Ca^{2+}$ channels; $Ca^{2+}$ (intracellular) (Borges, R. (241) 189)

**Histamine $H_1$ receptor antagonists**
Histamine $H_1$ receptors; [$^3$H]Mepyramine; Lung tissue; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

**Histamine $H_2$ receptor antagonists**
FRG-8813; Stomach; Gastric acid secretation (Shibata, M. (235) 245)

**Histamine $H_3$ receptor antagonists**
Histamine; Thioperamide; (R)-$\alpha$-Methylhistamine; Convulsions (electrically induced) (Yokoyama, H. (234) 129)

**Histamine $H_1$ receptors**
Histamine $H_1$ receptor antagonists; [$^3$H]Mepyramine; Lung tissue; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

$N^{\alpha}$-Methylhistamine; (R)$\alpha$Methylhistamine; Histamine; Intestinal transit; Histamine $H_3$ receptors (Oishi, R. (237) 155)

Inositol phosphates; $Ni^{2+}$; HeLa cell; Brain slice (Arias-Montaño, J.-A. (245) 221)

HeLa cell; [$^3$H]Mepyramine; Phosphoinositide; (+)-Chlorpheniramine; Temelastine (Arias-Montaño, J.-A. (245) 291)

**Histamine $H_3$ receptors**
(R)-$\alpha$-Methylhistamine; Thioperamide; Water consumption; (Rat) (Clapham, J. (232) 99)

$N^{\alpha}$-Methylhistamine; (R)$\alpha$Methylhistamine; Histamine; Intestinal transit; Histamine $H_1$ receptors (Oishi, R. (237) 155)

**Histamine release**
Dexamethasone; Endothelial cells; GM 7373 cell line; Vasocortin; Dextran oedema (Iuvone, T. (243) 163)

**Histogranin**
Endogenous peptide; Adrenal medulla; NMDA receptors; Anticonvulsant (Lemaire, S. (245) 247)

**Histopathology**
Phencyclidine; Glucose metabolism; Psychosis; Schizophrenia; Limbic system (Gao, X.-M. (241) 7)

**Histotoxic hypoxia**
Actyl-l-carnitine; Cyanide; Spatial learning; Phosphoinositide metabolism (Blokland, A. (235) 275)

**HL-60 cells (human)**
1$\alpha$,25-Dihydroxyvitamin $D_3$ analogues; Thromboxane synthesis; Vitamin D receptors (Honda, A. (229) 217)

**HOE 140**
Bradykinin; Uterus (rat); G-protein activation; Functional antagonism; (Binding sites) (Liebmann, C. (235) 183)

Bradykinin; Mesenteric vascular bed; Vasodilatation; (Cat) (Santiago, J.A. (236) 315)

Bradykinin; Circular muscle; Longitudinal muscle; Ileum (guinea-pig) (Medeiros, Y.S. (241) 157)

**HOE 694**
pH (intracellular); $Na^+/H^+$ exchanger; Cell volume; *Ras* oncogene; cell proliferation (Wöll, E. (246) 269)

***Hololena curta* venom**
ω-Conotoxin GVIA; $Ca^{2+}$ channels (voltage-sensitive); Funnel web spider toxin; Neurotransmitter release; Autonomic nerves (Lundy, P.M. (231) 197)

**Homophthalazine binding (specific)**
Anxiolytic drugs; Antipsychotic effects (Horváth, E.J. (236) 151)

**Homovanillic acid (HVA)**
Milacemide; Amino acids; Monoamine metabolites; Taurine; Cerebrospinal fluid (Semba, J. (230) 321)

**Hormone secretion**
Adenosine; ANP (atrial natriuretic peptide); Beating frequency (Uusimaa, P.A. (242) 199)

**Hot-plate inhibition**
β-Endorphin; Morphine; Tolerance; Cross-tolerance; Antinociception; Tail-flick inhibition (Tseng, L.F. (241) 63)

**Hot-plate test**
Acetylthiorphan; Acetorphan; Thiorphan; Neutral endopeptidase; Analgesia (Lambert, D.M. (243) 129)

**HSDM1C1 cells**
Muscarinic $M_3$ receptors; [$^3$H]N-Methylscopolamine binding; Phosphoinositide metabolism (Eglen, R.M. (244) 49)

**[$^3$H]5-HT**
Enteric membranes (rat); Indoles; Anti-oxidants; (Spurious binding sites) (Williams, T.J. (245) 197)

**5-$HT_{1A}$ autoreceptors**
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; Brain (rat) (Hjorth, S. (238) 357)

**5-HT binding**
5-HT (5-hydroxytryptamine, serotonin); 5-HT release; 5-HT receptors; Rabies virus (Ceccaldi, P.-E. (245) 129)

**5-HT binding proteins**
Brain; 5-HT (serotonin, 5-hydroxytryptamine); Dopamine; Superoxide radicals; Iron ions (Jimenez Del Rio, M. (247) 11)

**5-$HT_{1C}$/5-$HT_2$ receptors**
Tryptophan; Blood-brain barrier; Sympathetic nervous system; Immobilization stress (Chaouloff, F. (231) 77)

**5-$HT_{1E}$/5-$HT_{1F}$ recognition sites**
Autoradiography; Brain (guinea-pig); Brain (rat) (Beer, M.S. (236) 167)

**5-HT (5-hydroxytryptamine, serotonin)**
Excessive grooming; Penile erection; Oxytocin concentration (plasma); 5-$HT_{1C}$ receptors; 5-$HT_2$ receptors; m-CPP (1-(3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (229) 9)

p-Chloroamphetamine; p-Methylthioamphetamine; Drug discrimination; Uptake inhibition; Superfusion; Neurotoxicity; Brain slices (Huang, X. (229) 31)

Dihydropyridines; $Mg^{2+}$; Prostaglandin $F_{2\alpha}$; Cerebral vasospasm; (Human) (Alborch, E. (229) 83)

NAN-190; RU 24969; TFMPP (trifluoromethylphenylpiperazine); mCPP (m-chlorophenylpiperazine); 5-HIAA (CSF levels); 5-$HT_1$ receptor binding (in vitro); (Pigeon) (Gleeson, S. (229) 109)

EDRF (endothelium-derived relaxing factor); Arterioles; Microcirculation; Nitric oxide (NO); $N^G$-Nitro-L-arginine (Alsip, N.L. (229) 117)

Hindlimb (isolated); Prostaglandins E; Temperature; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

5-$HT_{1A}$ receptors; Raphe; S 15535; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

Atrium; Contractile force; Heart; Ventricle; (Human) (Schoemaker, R.G. (230) 103)

Antidepressants; 5-$HT_{1C}$ receptors; 5-$HT_{1A}$ receptors; (Rat) (Jenck, F. (231) 223)

Achatin-I; D-Amino acid residue; Molluscan peptide; Modulatory effects; Voltage clamp; Neurons; (Snail) (Jun Liu, G. (231) 259)

Contractions; Lipoxygenase products; Atherosclerosis; Blood vessels; (Interaction) (Van Diest, M.J. (231) 267)

Imipramine; Desipramine; Norepinephrine; Triiodothyronine (Suzuki, S. (231) 297)

α-Methyl-5-hydroxytryptamine; Bronchi (rat); 5-$HT_2$ receptors; Ketanserin; Mianserin; Spiperone; Electrical field stimulation; Cholinergic nerves (Szarek, J.L. (231) 339)

NMDA (N-methyl-D-aspartate); Cortex; Transmitter interaction (Rahman, S. (231) 347)

Vascular 5-$HT_1$-like receptors; 5-Carboxamidotryptamine; (Effect of pre-contraction) (Choppin, A. (231) 469)

Litoxetine; Antidepressants; Emesis (Angel, I. (232) 139)

RP 62203; 5-$HT_2$ receptor antagonists; Autoradiography; [$^{125}$I]AMIK ([$^{125}$I]7-amino-8-iodo-ketanserin); [$^3$H]Mesulergine (Malgouris, C. (233) 29)

5-$HT_1$-like receptors; 5-$HT_2$ receptors; $Ca^{2+}$ ion channels; Gastroepiploic artery (simian) (Noguchi, M. (234) 101)

5-$HT_3$ receptors; Cholinergic airway constriction (Rizzo, C.A. (234) 109)

Smooth muscle (arterial); $Ca^{2+}$ channel antagonists; Cerebral arteries (Clark, A.H. (235) 113)

Co-axial bioassay; EpDRF (epithelium-derived relaxing factor); Ovalbumin challenge; Trachea (guinea-pig); Anococcygeus muscle (rat) (Çakici, İ. (236) 97)

Amnesia; 5-$HT_{1A}$ receptors (Mendelson, S.D. (236) 177)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Dentate/interpositus; Cerebellum; GABA (γ-aminobutyric acid); 5-$HT_{2/1C}$ receptors (Cumming-Hood, P.A. (236) 457)

Glossopharyngeal nerve; 5-$HT_3$ receptors (Yoshioka, M. (236) 491)

$TGF_\alpha$ (transforming growth factor $\alpha$); Tryptophan; Antidepressant drugs; Depression; Aggression; Transgenic mice (Hilakivi-Clarke, L.A. (237) 101)

$\sigma$ Binding sites; DTG (1,3-di-o-tolylguanidine); Imipramine; Striatum; Hippocampus (Shirayama, Y. (237) 117)

5-HT release; Synaptosomes; d-Fenfluramine; $Ca^{2+}$ channels (Gobbi, M. (238) 9)

1,4-Dihydropyridine (enantiomers); $K^+$; pH; $Ca^{2+}$; Coronary artery; (Rat) (Prieto, D. (238) 27)

Transmitter interaction; Desensitization; Receptor internalization; Protein kinase C (Rahman, S. (238) 173)

Fenfluramine; 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

Dopamine synthesis; 5-HT neurotoxicity; 5-$HT_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-$HT_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

Fenfluramine; Neurotoxins; Nerve terminal regeneration; Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

Choroid plexus; 5-$HT_{1C}$ receptor; $Cl^-$ channels (Garner, C. (239) 31)

Anxiety; Buspirone; Chronic treatment; 5-HT release; 5-$HT_{1A}$ receptors; Microdialysis (in vivo); (Rat) (Söderpalm, B. (239) 69)

[$^3$H]Mesulergine; [$^3$H]Paroxetine; 5-$HT_{1C}$ receptor; 5-HT uptake site; Brain (rat) (Hulihan-Giblin, B.A. (239) 99)

Platelets; Coronary artery (human); Sumatriptan; Ergotamine; 5-$HT_{1D}$-like receptors; 5-$HT_2$ receptors (Bax, W.A. (239) 203)

[$^3$H]5-HT uptake; Cortical synaptosomes (rat); Cocaine; tropisetron; 5-HT receptor ligands (Cheng, C.H.K. (239) 211)

Carotid blood flow; 5-$HT_1$-like receptors; (Dog) (Villalón, C.M. (240) 9)

$\beta$-Adrenoceptors; Noradrenaline; Competitive inhibition (Fujita, R. (240) 213)

5-$HT_3$ receptors; Cholinergic airway constriction (Rizzo, C.A. (240) 327)

Mucosa; Ion transport; Ileum; (Human) (Burleigh, D.E. (241) 125)

5-HT uptake; Stress; Tianeptine; Buspirone; Diazepam (Mennini, T. (241) 255)

Cocaine (neuroendocrine); Prolactin; Renin; ACTH (adrenocorticotropic hormone) (Levy, A.D. (241) 275)

5-$HT_{1D}$ receptors; Cerebral vasoconstriction; Migraine; 5-$HT_1$ receptor subtypes; Cerebral blood vessels (Hamel, E. (242) 75)

Glutamate; Dopamine; Phencyclidine; Ipsapirone; MK-801 (Löscher, W. (242) 99)

SPECT (single photon emission computed tomography); Brain (primate) (Jagust, W.J. (242) 189)

Glutamate; Dopamine; Phencyclidine (Löscher, W. (242) 263)

Dystonia; Movement disorders; Dopamine; Glutamate (Richter, A. (242) 309)

Male sexual behavior; Penile erection; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Yawning; m-CPP; (Primates); (Rhesus monkey) (Pomerantz, S.M. (243) 227)

5-$HT_{1A}$ receptors; 5-$HT_{1B}$ receptors; Computer graphics; $\beta$-Adrenoreceptor antagonists; Comparative molecular field analysis method (Langlois, M. (244) 77)

cAMP; 5-$HT_{1D}$ receptors; 5-HT release (Ormandy, G.C. (244) 189)

SDZ 216-525; MDL 73005; NAN 190; 5-$HT_{1A}$ receptors; 5-$HT_{1B}$ receptors; 5-$HT_{1C}$ receptors; 5-$HT_{1D}$ receptors (Schoeffter, P. (244) 251)

5-HT binding; 5-HT release; 5-HT receptors; Rabies virus (Ceccaldi, P.-E. (245) 129)

Platelet (human); Synergism (Roevens, P. (245) 273)

5-$HT_3$ receptor; Tetraethylammonium; N1E-115 neuroblastoma; Whole-cell voltage clamp; Ion channel; Desensitization (Kooyman, A.R. (246) 247)

5-HT (serotonin 5-hydroxytryptamine binding proteins); Brain; Dopamine; Superoxide radicals; Iron ions (Jimenez Del Rio, M. (247) 11)

Glycosphingolipids; Lysogangliosides; Platelet aggregation; Thrombin; Tromboxane $B_2$; Bleeding; Coagulation; Fibrinolysis (Tubaro, E. (248) 175)

**5-$HT_1$-like receptors**

5-HT (5-hydroxytryptamine, serotonin); 5-$HT_2$ receptors; $Ca^{2+}$ ion channels; Gastroepiploic artery (simian) (Noguchi, M. (234) 101)

Carotid blood flow; 5-HT (5-hydroxytryptamine, serotonin); (Dog) (Villalón, C.M. (240) 9)

**5-$HT_{1D}$-like receptors**

5-HT (5-hydroxytryptamine, serotonin); Platelets; Coronary artery (human); Sumatriptan; Ergotamine; 5-$HT_2$ receptors (Bax, W.A. (239) 203)

**5-HT metabolism/turnover**

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; Microdialysis (in vivo); 5-HT release; 5-$HT_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

**5-HT motor syndrome**
5-$HT_{1A}$ receptor agonists; 5-$HT_{1A}$ receptor antagonists; 8-OH-DPAT derivatives; (S)-UH-301; LY-41 (Yu, H. (231) 69)

**5-HT neurotoxicity**
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

**5-HT (pool, cytoplasmic)**
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

**5-$HT_1$ receptor agonists**
5-Carboxamidotryptamine; Spontaneously hypertensive rats (SHR); Blood pressure (systolic); Baroreflex sensitivity; (Chronic infusion) (Balasubramaniam, G. (237) 207)

**5-$HT_{1A}$ receptor agonists**
5-$HT_{1A}$ receptor antagonists; 8-OH-DPAT derivatives; (S)-UH-301; LY-41; 5-HT motor syndrome (Yu, H. (231) 69)

Stress (emotional); 5-$HT_2$ receptor antagonists; 5-$HT_3$ receptor antagonists; Colonic motility; (Rat) (Gué, M. (233) 193)

Antidepressants; Forced swim test; LY228729 (Benvenga, M.J. (239) 249)

8-OH-DPAT; Buspirone; $\alpha_1$-Adrenoceptor subtypes; Aorta (rabbit); (8-hydroxy-2(di-N-propylamino)tetralin) (Castillo, C. (241) 141)

**5-$HT_3$ receptor agonists**
[$^3$H]meta-Chlorophenylbiguanide; [$^3$H](S)-Zacopride; Brain (rat) (Steward, L.J. (243) 13)

**5-HT receptor agonists (indirectly acting)**
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

**5-$HT_{1A}$ receptor antagonists**
5-$HT_{1A}$ receptor agonists; 8-OH-DPAT derivatives; (S)-UH-301; LY-41; 5-HT motor syndrome (Yu, H. (231) 69)

5-$HT_{1A}$ receptors; WAY100135 (Fletcher, A. (237) 283)

WAY100135; Microdialysis; Hippocampal 5-HT (5-hydroxytryptamine, serotonin) release (Routledge, C. (239) 195)

**5-$HT_2$ receptor antagonists**
RP 62203; 5-HT (5-hydroxytryptamine, serotonin); Autoradiography; [$^{125}$I]AMIK ([$^{125}$I]7-amino-8-iodo-ketanserin); [$^3$H]Mesulergine (Malgouris, C. (233) 29)

[$^3$H]RP 62203 binding sites; Brain autoradiography (Malgouris, C. (233) 37)

Stress (emotional); 5-$HT_{1A}$ receptor agonists; 5-$HT_3$ receptor antagonists; Colonic motility; (Rat) (Gué, M. (233) 193)

**5-$HT_3$ receptor antagonists**
Morphine; Mesolimbic dopamine; Microdialysis (Pei, Q. (230) 63)

Stress (emotional); 5-$HT_{1A}$ receptor agonists; 5-$HT_2$ receptor antagonists; Colonic motility; (Rat) (Gué, M. (233) 193)

RS-42358-197; Aversive behaviour; (Mouse); (Rat); (Marmoset) (Costall, B. (234) 91)

Morphine; Emesis; (Ferret) (Wynn, R.L. (241) 47)

**5-$HT_1$ receptor binding (in vitro)**
5-HT (5-hydroxytryptamine, serotonin); NAN-190; RU 24969; TFMPP (trifluoromethylphenylpiperazine); mCPP (m-chlorophenylpiperazine); 5-HIAA (CSF levels); (Pigeon) (Gleeson, S. (229) 109)

**5-$HT_{1D}$ receptor (human)**
Adenylate cyclase (activation); (Inhibition) (Van Sande, J. (247) 177)

**5-HT receptor ligands**
5-HT (5-hydroxytryptamine, serotonin); [$^3$H]5-HT uptake; Cortical synaptosomes (rat); Cocaine; tropisetron (Cheng, C.H.K. (239) 211)

**5-$HT_2$ receptor regulation**
Behavioural response; Phosphoinositide turnover; mRNA levels; Gene transcription (Rinaldi-Carmona, M. (246) 73)

**5-HT receptors**
LSD (d-lysergic acid diethylamide); Dissociation constant; Uterine artery (sheep) (Zhang, L. (230) 115)

Methionine sulfoximine; Dorsal raphe nucleus; Hypothermia; GABA ($\gamma$-aminobutyric acid); GABA receptors (Ginefri-Gayet, M. (235) 189)

Basilar artery (rat); Endothelium; Thromboxane $A_2$ (Descombes, J.-J. (243) 193)

5-HT (5-hydroxytryptamine, serotonin); 5-HT binding; 5-HT release; Rabies virus (Ceccaldi, P.-E. (245) 129)

**5-$HT_{1A}$ receptors**
Ischemia; 5-$HT_2$ receptors; 2-Deoxyglucose; Electrophysiology; Hippocampus (slices) (Shibata, S. (229) 21)

5-HT (5-hydroxytryptamine, serotonin); Raphe; S 15535; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

Antidepressants; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1C}$ receptors; (Rat) (Jenck, F. (231) 223)

Ipsapirone; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-$HT_2$ receptors; Anxiolysis; Glucose; Corticosterone; Prolactin; Behaviour (Baudrie, V. (231) 395)

Hippocampus; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Working memory; Reference memory; (Microinjection) (Ohno, M. (234) 29)

Vitamin $B_6$ deficiency; Hypertension; (Rat) (Lal, K.J. (234) 183)

Dorsal hippocampus; Passive avoidance; Memory; Anxiolytic effects; Antidepressant effects (Carli, M. (234) 215)

Handling; Stress; 5-$HT_3$ receptors; $GABA_B$ receptors; Anxiolytics (Andrews, N. (235) 109)

Adenylate cyclase; Drug discrimination; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Rabin, R.A. (235) 237)

5-HT (5-hydroxytryptamine, serotonin); Amnesia (Mendelson, S.D. (236) 177)

5-$HT_{1A}$ receptor antagonists; WAY100135 (Fletcher, A. (237) 283)

Cocaine; 5-$HT_2$ receptors; Brain regions (rat) (Javaid, J.I. (238) 425)

Anxiety; Buspirone; Chronic treatment; 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Microdialysis (in vivo); (Rat) (Söderpalm, B. (239) 69)

Anxiolytics; Dorsal raphe nucleus; Electrophysiology; Hippocampus; Ipsapirone; Microdialysis; Serotonergic neurotransmission; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

5-HT (serotonin); 5-$HT_{1B}$ receptors; Computer graphics; $\beta$-Adrenoreceptor antagonists; Comparative molecular field analysis method (Langlois, M. (244) 77)

SDZ 216-525; MDL 73005; NAN 190; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1B}$ receptors; 5-$HT_{1C}$ receptors; 5-$HT_{1D}$ receptors (Schoeffter, P. (244) 251)

**5-$HT_{1B}$ receptors**
Citalopram; Tianeptine; Acetylcholine release; Antidepressants (Bolaños-Jiménez, F. (242) 1)

5-HT (serotonin); 5-$HT_{1A}$ receptors; Computer graphics; $\beta$-Adrenoreceptor antagonists; Comparative molecular field analysis method (Langlois, M. (244) 77)

SDZ 216-525; MDL 73005; NAN 190; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; 5-$HT_{1C}$ receptors; 5-$HT_{1D}$ receptors (Schoeffter, P. (244) 251)

**5-$HT_{1C}$ receptors**
5-HT (5-hydroxytryptamine, serotonin); Excessive grooming; Penile erection; Oxytocin concentration (plasma); 5-$HT_2$ receptors; m-CPP (1-(3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (229) 9)

Antidepressants; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; (Rat) (Jenck, F. (231) 223)

Choroid plexus; 5-HT (5-hydroxytryptamine, serotonin); $Cl^-$ channels (Garner, C. (239) 31)

[$^3$H]Mesulergine; [$^3$H]Paroxetine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake site; Brain (rat) (Hulihan-Giblin, B.A. (239) 99)

Food intake; d-Fenfluramine; d-Norfenfluramine; 1-(3-Chlorophenyl)piperazine; p-Chlorophenylalanine (Gibson, E.L. (242) 83)

Spinal 5-$HT_{1C}$ sites; [$^3$H]Mesulergine; Down-regulation; (Rat) (Pranzatelli, M.R. (244) 1)

SDZ 216-525; MDL 73005; NAN 190; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; 5-$HT_{1B}$ receptors; 5-$HT_{1D}$ receptors (Schoeffter, P. (244) 251)

Clozapine; N-Desmethylclozapine; Clozapine N-oxide; Choroid plexus (Kuoppamäki, M. (245) 179)

Ethanol; Brain (rat); Choroid plexus; Phosphoinositide hydrolysis (Pandey, S.C. (247) 81)

**5-$HT_{1D}$ receptors**
5-Carboxamidotryptamine; Turning model; (Autoreceptor) (Moret, C. (230) 379)

5-HT (5-hydroxytryptamine, serotonin); Cerebral vasoconstriction; Migraine; 5-$HT_1$ receptor subtypes; Cerebral blood vessels (Hamel, E. (242) 75)

cAMP; 5-HT release; 5-HT (5-hydroxytryptamine, serotonin) (Ormandy, G.C. (244) 189)

SDZ 216-525; MDL 73005; NAN 190; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; 5-$HT_{1B}$ receptors; 5-$HT_{1C}$ receptors (Schoeffter, P. (244) 251)

**5-$HT_{1D\alpha/\beta}$ receptors**
Serotonin-5-O-carboxymethyl-glycyl[$^{125}$I]tyrosinamide ([$^{125}$I]GTI); Cerebral cortex (human) (Beer, M.S. (242) 195)

**5-$HT_2$ receptors**
5-HT (5-hydroxytryptamine, serotonin); Excessive grooming; Penile erection; Oxytocin concentration (plasma); 5-$HT_{1C}$ receptors; m-CPP (1-(3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (229) 9)

Ischemia; 5-$HT_{1A}$ receptors; 2-Deoxyglucose; Electrophysiology; Hippocampus (slices) (Shibata, S. (229) 21)

5-HT (5-hydroxytryptamine, serotonin); $\alpha$-Methyl-5-hydroxytryptamine; Bronchi (rat); Ketanserin; Mianserin; Spiperone; Electrical field stimulation; Cholinergic nerves (Szarek, J.L. (231) 339)

Ipsapirone; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-$HT_{1A}$ receptors; Anxiolysis; Glucose; Corticosterone; Prolactin; Behaviour (Baudrie, V. (231) 395)

5-HT (5-hydroxytryptamine, serotonin); 5-$HT_1$-like receptors; $Ca^{2+}$ ion channels; Gastroepiploic artery (simian) (Noguchi, M. (234) 101)

Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

Cocaine; 5-$HT_{1A}$ receptors; Brain regions (rat) (Javaid, J.I. (238) 425)

Ergolines; Tryptamines, [$^{125}$I]DOI ([$^{125}$I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); LY53857; Amesergide (Johnson, M.P. (239) 111)

5-HT (5-hydroxytryptamine, serotonin); Platelets; Coronary artery (human); Sumatriptan; Ergotamine; 5-$HT_{1D}$-like receptors (Bax, W.A. (239) 203)

**5-$HT_{2/1C}$ receptors**
5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Dentate/interpositus; Cerebellum; GABA ($\gamma$-aminobutyric acid) (Cumming-Hood, P.A. (236) 457)

**5-$HT_3$ receptors**
5-HT (5-hydroxytryptamine, serotonin); Cholinergic airway constriction (Rizzo, C.A. (234) 109)

Handling; Stress; 5-$HT_{1A}$ receptors; $GABA_B$ receptors; Anxiolytics (Andrews, N. (235) 109)

Glossopharyngeal nerve; 5-HT (5-hydroxytryptamine, serotonin) (Yoshioka, M. (236) 491)

Anxiety; Benzodiazepine withdrawal (File, S.E. (237) 127)

[$^3$H]Zacopride; [$^3$H]Granisetron; [$^{14}$C]Guanidinium; Ileum; Bezold-Jarisch reflex; Turning behaviour; Cortical firing rate; (Ex vivo binding) (Bachy, A. (237) 299)

Emesis; Cisplatin; m-Chlorophenylbiguanide; YM060 (Kamato, T. (238) 369)

5-HT (5-hydroxytryptamine, serotonin); Cholinergic airway constriction (Rizzo, C.A. (240) 327)

Huntington's disease; Parkinson's disease; Putamen (human); [$^3$H]Granisetron (Steward, L.J. (242) 137)

m-Chlorophenylbiguanide; Neuroblastoma; Ligand-gated ion channel (Lummis, S.C.R. (243) 7)

Cloned 5-HT$_3$ receptor subunit; N1E-115 neuroblastoma cell; *Xenopus* oocyte expression system (Hope, A.G. (245) 187)

5-HT (5-hydroxytryptamine, serotonin); Tetraethylammonium; N1E-115 neuroblastoma; Whole-cell voltage clamp; Ion channel; Desensitization (Kooyman, A.R. (246) 247)

High-affinity 'R' sites; (*R*)-[$^3$H]Zacopride; (*S*)-[$^3$H]Zacopride; Brain (rat and human); Periphery (rat) (Kidd, E.J. (247) 45)

**5-HT$_4$ receptors**
Atria (piglet); Papillary muscle (piglet); SDZ 205-557 (Lorrain, J. (229) 105)

DAU 6285; (Pig) (Van Meel, J.C.A. (233) 295)

**5-HT$_1$ receptor subtypes**
5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{1D}$ receptors; Cerebral vasoconstriction; Migraine; Cerebral blood vessels (Hamel, E. (242) 75)

**5-HT release**
5-HT (5-hydroxytryptamine, serotonin); Synaptosomes; d-Fenfluramine; $Ca^{2+}$ channels (Gobbi, M. (238) 9)

Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); Melatonin; Tryptophan (Huether, G. (238) 249)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT$_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

Anxiety; Buspirone; Chronic treatment; 5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{1A}$ receptors; Microdialysis (in vivo); (Rat) (Söderpalm, B. (239) 69)

cAMP; 5-HT$_{1D}$ receptors; 5-HT (5-hydroxytryptamine, serotonin) (Ormandy, G.C. (244) 189)

5-HT (5-hydroxytryptamine, serotonin); 5-HT binding; 5-HT receptors; Rabies virus (Ceccaldi, P.-E. (245) 129)

**5-HT reuptake inhibitor (selective)**
$\sigma$ Receptors; NMDA (N-methyl-D-aspartate); Antidepressant; Monoamine oxidase inhibitors (Bergeron, R. (240) 319)

**5-HT synthesis**
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-HT$_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

**5-HT uptake**
Fluvoxamine; Antidepressants; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (229) 101)

Fluvoxamine; Antidepressants; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

Imipramine; Trimipramine; Fluoxetine; 5-HIAA (5-hydroxyindole-3-acetic acid) (Dewar, K.M. (235) 137)

5-HT (5-hydroxytryptamine, serotonin); Stress; Tianeptine; Buspirone; Diazepam (Mennini, T. (241) 255)

**[$^3$H]5-HT uptake**
5-HT (5-hydroxytryptamine, serotonin); Cortical synaptosomes (rat); Cocaine; tropisetron; 5-HT receptor ligands (Cheng, C.H.K. (239) 211)

**5-HT uptake sites**
Spontaneously hypertensive rat (SHR); Imipramine; Clonidine; Centhaquin; Blood pressure; Central nervous system (CNS) (Gulati, A. (231) 151)

[$^3$H]Mesulergine; [$^3$H]Paroxetine; 5-HT$_{1C}$ receptor; 5-HT (5-hydroxytryptamine, serotonin); Brain (rat) (Hulihan-Giblin, B.A. (239) 99)

**Human platelets (washed)**
EDRF (endothelium-derived relaxing factor); Porcine endocardial endothelium; NO synthase inhibitors (Siney, L. (229) 223)

**Human polymorphonuclear leukocytes**
THP-1 cells; Leukotriene B$_4$ receptors; Leukotrienes (Slipetz, D.M. (244) 161)

**Huntington's disease**
5-HT$_3$ receptors; Parkinson's disease; Putamen (human); [$^3$H]-Granisetron (Steward, L.J. (242) 137)

**Hydrogen ions**
Cardiovascular neurons; Cyanide; GABA ($\gamma$-aminobutyric acid); Rostral ventrolateral medulla; (Rat) (Sun, M.-K. (236) 305)

**Hydrogen peroxide**
Ischemia; Reperfusion; Arrhythmia; Hypochlorous acid (Okabe, E. (248) 33)

**Hydroxocobalamin**
Aortic rings (rat); Anococcygeus muscle (rat); Nitric oxide (NO); S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitroso-coenzyme A; S-Nitrosocysteine; S-Nitrosoglutathione; Nitrosothiols (Rand, M.J. (241) 249)

**$\gamma$-Hydroxybutyric acid (GHB)**
GABA$_A$ receptors; Dopaminergic neurons; Ethanol; NMDA receptor antagonists (Diana, M. (230) 363)

**25-Hydroxycholesterol**
Gap junction; Hepatocytes; Free radical (Guo, X. (248) 337)

**6-Hydroxydopamine (6-OHDA)**
On-off effects; Rotation; Classical conditioning; Dopamine receptor agonists; Nigrostriatal lesions (Silverman, P.B. (229) 235)

$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; Vomiting; Reserpine; Area postrema (Hikasa, Y. (229) 241)

6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); Nomifensine; Desipramine; Neurotoxicity (Evans, J. (232) 241)

Somatostatin; Neuropeptide Y; l-DOPA (l-dihydroxyphenylalanine); Amantadine; Bifemelane (Maeda, K. (233) 227)

Autoradiography; SK & F 38393; Quinpirole; Basal ganglia (Engber, T.M. (236) 385)

Parkinsonism; Rotational behaviour; Bromocriptine; SK&F-77434; Cocaine (Silverman, P.B. (242) 31)

**6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine)**
6-Hydroxydopamine (6-OHDA); Nomifensine; Desipramine; Neurotoxicity (Evans, J. (232) 241)

**Hydroxyl radical**
l-Deprenyl (selegiline); Dopamine; MPTP neurotoxin; $MPP^+$ (1-methyl-4-phenylpyridinium ion); Substantia nigra; Parkinson's disease (Wu, R.-M. (243) 241)

**Hyperactivity**
Dexamphetamine-chlordiazepoxide mixture; Valproate; GABA receptor antagonists (Cao, B.-J. (237) 177)

**Hyperemia (reactive)**
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO), Coronary flow regulation; Endothelium (Domenech, R. (238) 53)

**Hyperlipidemia**
Vascular reactivity; Wistar-Kyoto rats (WKY); Endothelium-derived relaxing factor (EDRF); Spontaneously hypertensive rats (SHR); Aortic arch; Abdominal aorta (Yu, S.-M. (248) 289)

**Hyperlocomotion**
Ceruletide; Amphetamine; Stereotypy; Microdialysis; (Rat) (Kihara, T. (230) 271)

**Hyperpolarization-activated inward current**
Pacemaker current; Automaticity; Myocytes (embryonic chick heart); Autonomic agents; Acetylcholine; Isoproterenol (Satoh, H. (240) 283)

**Hyperresponsiveness**
Anaphylaxis; PAF (platelet-activating factor, PAF-acether); PCA-4248 (Desquand, S. (235) 101)

CS-518; Thromboxane synthase inhibitors; Asthmatic model; Bronchoconstriction (Yamaguchi, T. (236) 43)

Respiratory airways; Interleukin-5; Eosinophils; Asthma (Van Oosterhout, A.J.M. (236) 379)

Respiratory airways; Interleukin-5; Eosinophils; Asthma (Van Oosterhout, A.J.M. (239) 277)

**Hypertension**
Endothelin; [$Ala^{1,3,11,15}$]endothelin-1; BQ-123; Bronchoconstriction; (Receptor subtype) (Noguchi, K. (233) 47)

Vitamin $B_6$ deficiency; 5-$HT_{1A}$ receptors; (Rat) (Lal, K.J. (234) 183)

$Ca^{2+}$ currents (heart); Phosphodiesterase inhibitors; Voltage clamp (Scamps, F. (244) 119)

Adenosine $A_1$ receptors; G proteins (Matias, A. (244) 223)

Cyclosporine; Angiotensin $AT_{1A}$ receptors; Endothelium; Gene expression (Iwai, J. (248) 341)

**Hypertension (rabbit)**
Cerebral blood flow; Dipyridamole; Chronic cerebral ischaemia (Hegedüs, K. (237) 293)

**Hypertensive effect**
Endothelin-3; Big endothelin-3; Phosphoramidon; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

**Hypertonic saline**
Nifedipine; TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate); Renal blood flow; Glomerular filtration rate (Ogasawara, A. (243) 103)

**Hyperuricemia**
TEI-6720; Allopurinol; Xanthine oxidase/xanthine dehydrogenase; Uric acid (Osada, Y. (241) 183)

**Hypochlorous acid**
Ischemia; Reperfusion; Arrhythmia; Hydrogen peroxide (Okabe, E. (248) 33)

**Hypocholesterolemic drugs**
Liver; Cholesterol; Bile; Lipoproteins (Clerc, T. (235) 59)

**Hypoperfusion**
Diabetic heart; Norepinephrine; Left ventricular stiffness; ATP; Lactate; Insulin (ex vivo) (Higuchi, M. (242) 293)

**Hypotension**
Endothelin; Anaphylactic shock; Hemorrhagic shock; Hypovolemia; Hypoxia (Filep, J.G. (239) 231)

PAF (platelet-activating factor); Seminal vesicle protein; Bronchoconstriction; Gastric mucosal injury (Persico, P. (241) 71)

**Hypothalamic monoamines**
$Ca^{2+}$ channels; Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Corticosterone (Martinez-Piñero, M.G. (232) 191)

**Hypothalamus**
L-Thyroxine administration (repeated); Methimazole administration (repeated); Plasma endothelin concentration; Endothelin mechanisms; Cerebral cortex; Pituitary (Rebello, S. (237) 9)

**Hypothalamus-pituitary-adrenocortical axis**
$Ca^{2+}$ channels; Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

**Hypothermia**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Learning (Khanna, J.M. (230) 23)

Methionine sulfoximine; Dorsal raphe nucleus; 5-HT receptors; GABA (γ-aminobutyric acid); GABA receptors (Ginefri-Gayet, M. (235) 189)

Benzodiazepine receptor agonists; Benzodiazepine receptor antagonists; Inverse agonists (Tang, A.H. (236) 1)

Cerebral ischaemia; Dizocilpine; Enadoline; Neuroprotection (Hayward, N.J. (236) 247)

Lead acetate; Cadmium chloride; Environmental temperature; Brain metal levels (Martínez, F. (248) 199)

**Hypothyroidism**
Adrenalectomy; Immobility; Porsolt swimming test; Food deprivation (Jefferys, D.E. (239) 189)

**Hypovolemia**
Endothelin; Anaphylactic shock; Hemorrhagic shock; Hypotension; Hypoxia (Filep, J.G. (239) 231)

**Hypoxia**
21-Aminosteroids; NMDA (N-methyl-D-aspartate); Lipid peroxidation (Domenici, M.R. (233) 291)

Ischemia; Glutamate; Neurotoxicity; Cell culture; ES-242s; MK-801 (Nozawa, M. (236) 263)

Angiotensin-converting enzyme inhibitors; Lisinopril; Reoxygenation; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

Endothelin; Anaphylactic shock; Hemorrhagic shock; Hypotension; Hypovolemia (Filep, J.G. (239) 231)

Endothelin-1; Middle cerebral artery occlusion; Ischemia; Cultured neurons; (Mouse) (Nikolov, R. (248) 205)

**Hypoxia-reoxygenation**
GM1 ganglioside; $Na^+$,$K^+$-ATPase; Noradrenaline (Lodovici, M. (243) 255)

**IBI P-05006**
Antiplatelet compound; Platelets; Thromboxane $A_2$/prostaglandin endoperoxides receptor antagonists (Rotondo, S. (232) 41)

**Ibogaine**
Cocaine; Cocaine dependence; Self-administration; (Rat) (Cappendijk, S.L.T. (241) 261)

**Ibotenic acid**
Propentofylline; Basal forebrain; Choline acetyltransferase; Learning and memory; Nerve growth factor (Fuji, K. (236) 411)

**ICI 174,864**
DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); Morphine; Naloxone; Naloxonazine, β-Funaltrexamine; Nor-binaltorphimine; Substance P; Trigeminal nucleus caudalis (Suarez-Roca, H. (229) 1)

**ICI 198615**
Spleen (ferret); Leukotriene receptors; SK&F 104353; MK571 (Gardiner, P.J. (238) 19)

**Idazoxan**
$\alpha_1$-Adrenoceptors; Burst firing; Noradrenaline; Reserpine (Grenhoff, J. (233) 79)

Clonidine; Imidazoline; Imidazoline receptor; Polyclonal antibody (Bennai, F. (246) 45)

**[$^3$H]Idazoxan**
[$^3$H]p-Aminoclonidine; Imidazoline binding sites; RS-15385-197; Kidney (rat) (MacKinnon, A.C. (232) 79)

Zucker rat; Imidazoline $I_2$ binding sites; $\alpha_2$-Adrenoceptors; Brain; [$^3$H]Clonidine; [$^3$H]RX821002; Mazindol (Miralles, A. (243) 305)

**Ifenprodil**
σ Receptors; Brain (rat); (Subtypes) (Hashimoto, K. (236) 159)

**Ileum**
5-$HT_3$ receptors; [$^3$H]Zacopride; [$^3$H]Granisetron; [$^{14}$C]Guanidinium; Bezold-Jarisch reflex; Turning behaviour; Cortical firing rate; (Ex vivo binding) (Bachy, A. (237) 299)

Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

5-HT (5-hydroxytryptamine, serotonin); Mucosa; Ion transport; (Human) (Burleigh, D.E. (241) 125)

Ricinoleic acid; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester); $N^G$-Monomethyl-L-arginine; L-Arginine; Tetrodotoxin; (Rat) (Izzo, A.A. (243) 87)

**Ileum (guinea-pig)**
κ-Opioid receptors; Bremazocine; Dynorphin (Webster, J.L. (231) 251)

Baclofen; β-Phenyl-GABA; $GABA_B$ receptors; Brain slices (rat); (Agonist/partial agonist) (Ong, J. (233) 169)

Contraction; Thaliporphine; $Ca^{2+}$ channels (Yu, S.-M. (234) 121)

Vasoactive intestinal contractor; Endothelin; Acetylcholine release (Taniyama, K. (235) 149)

Tachykinins; Circular muscle; ω-Conotoxin; Nitric oxide (NO); Apamin; NANC (non-adrenergic, non-cholinergic); NANC relaxation (Maggi, C.A. (240) 45)

HOE 140; Bradykinin; Circular muscle; Longitudinal muscle (Medeiros, Y.S. (241) 157)

$NK_3$ receptors; Inositol monophosphate accumulation; Selective agonists (Petitet, F. (247) 185)

**Ileum (guinea-pig, isolated)**
Nitropropane analog of baclofen; Baclofen; $GABA_B$ receptor agonists; Vas deferens (guinea pig); Brain slices (rat) (Kerr, D.I.B. (236) 239)

**Iliac artery (guinea-pig)**
FR139317; BQ-123; Endothelins; Sarafotoxins; Endothelin receptors (Schoeffter, P. (241) 165)

**Imidazoline**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

Idazoxan; Clonidine; Imidazoline receptor; Polyclonal antibody (Bennai, F. (246) 45)

**Imidazoline binding sites**
[$^3$H]p-Aminoclonidine; [$^3$H]Idazoxan; RS-15385-197; Kidney (rat) (MacKinnon, A.C. (232) 79)

Spinal reflexes; Descending inhibition; $\alpha_2$-Adrenoceptors; Blood pressure (Harris, J. (237) 323)

Kidney; (Regulation) (Hamilton, C.A. (243) 95)

**Imidazoline $I_2$ binding sites**
Zucker rat; $\alpha_2$-Adrenoceptors; Brain; [$^3$H]Idazoxan; [$^3$H]Clonidine; [$^3$H]RX821002; Mazindol (Miralles, A. (243) 305)

**Imidazoline receptor**
Idazoxan; Clonidine; Imidazoline; Polyclonal antibody (Bennai, F. (246) 45)

**Imipramine**
Spontaneously hypertensive rat (SHR); Clonidine; Centhaquin; Blood pressure; Central nervous system (CNS); 5-HT uptake sites (Gulati, A. (231) 151)

Desipramine; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Triiodothyronine (Suzuki, S. (231) 297)

Trimipramine; Fluoxetine; 5-HIAA (5-hydroxyindole-3-acetic acid); 5-HT uptake (Dewar, K.M. (235) 137)

$\sigma$ Binding sites; DTG (1,3-di-o-tolylguanidine); Striatum; Hippocampus; 5-HT (5-hydroxytryptamine, serotonin) (Shirayama, Y. (237) 117)

Clomipramine; Clorgyline; Corticosterone; ACTH (adrenocorticotropin); Fawn-hooded rat (Aulakh, C.S. (240) 85)

Behavioural despair; Microdialysis; Depression (Rossetti, Z.L. (242) 313)

Electroconvulsive shock; NMDA (*N*-methyl-D-aspartate) receptor complex; Strychnine-insensitive glycine receptor; 5,7-Dichlorokynurenic acid; CGP-39653 (Paul, I.A. (247) 305)

**Immediate-early genes**
Pineal gland; c-*jun*; Adrenoceptors; cAMP (Carter, D.A. (247) 97)

**Immobility**
Adrenalectomy; Porsolt swimming test; Hypothyroidism; Food deprivation (Jefferys, D.E. (239) 189)

**Immobilization stress**
Tryptophan; 5-$HT_{1C}$/5-$HT_2$ receptors; Blood-brain barrier; Sympathetic nervous system (Chaouloff, F. (231) 77)

**Immunoblot analysis**
Morphine tolerance; G protein expression; In situ hybridization histochemistry; Brain regions (Parolaro, D. (244) 211)

**Immunocyte conformational changes**
Nitric oxide (NO); Phagocytosis; (Molluscs); (Bacteria) (Ottaviani, E. (248) 319)

**Immunoglobulin G**
Gamma globulin (human); Immunoglobulins; Smooth muscle; Spontaneous contractility (Abrahams, Z. (238) 435)

**Immunoglobulins**
Gamma globulin (human); Smooth muscle; Immunoglobulin G; Spontaneous contractility (Abrahams, Z. (238) 435)

**Indole-depleting effect**
d-Fenfluramine; d-Norfenfluramine; (Rat) (Caccia, S. (233) 71)

**Indoles**
[$^3$H]5-HT (5-[$^3$H]Hydroxtryptamine); Enteric membranes (rat); Anti-oxidants; (Spurious binding sites) (Williams, T.J. (245) 197)

**Indomethacin**
Asthma; Edema; Plasma exudation; Bradykinin; Airway obstruction; Vascular permeability; OKY-046 (Arakawa, H. (229) 131)

Stomach; Nitric oxide (NO); L-Arginine; Prostaglandins (Konturek, S.J. (229) 155)

Morphine; Naloxone; NANC (non-adrenergic, non-cholinergic); Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

Inhibin; Oestradiol-17$\beta$; Ovarian hormones; Gonadotrophin; Prostaglandin $F_{2\alpha}$ (Kogo, H. (231) 481)

Substance P; Prostaglandins; Aqueous humor; Timolol; Surgical miosis (Kieselbach, G. (235) 117)

**Induction**
Angiotensin converting enzyme; Ramipril; Plasma; Renal brush border membrane (Michel, B. (242) 237)

**Inflammation**
Eye; Intraocular pressure; Eosinophils; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

Adherence; Microcirculation; Neutrophils; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

Phospholipase $A_2$; Edema (Morgan, D.W. (235) 45)

Neurogenic plasma extravasation; Opiate action (peripheral); C-fibre; Substance P (Barber, A. (236) 113)

Opioids; Antinociception (peripheral); Cytokines (Członkowski, A. (242) 229)

Phospholipase $A_2$; Pleurisy; Carrageenan; Zymosan; Thromboxane $B_2$ (Tesson, F. (248) 27)

**Inflammatory bowel disease**
$Cl^-$ secretion; Colitis; cAMP; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

Cyclosporin; Prostaglandin; Epithelium; Permeability (Higa, A. (239) 171)

**Infrared emission thermography**
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Vascular permeability; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

**Inhalation injury (one lung)**
Thromboxane receptor antagonists; Toxic airway damages; Thromboxane; Pulmonary hemodynamics; (Sheep) (Loick, H.M. (248) 75)

**Inhibin**
Oestradiol-17$\beta$; Ovarian hormones; Gonadotrophin; Prostaglandin $F_{2\alpha}$; Indomethacin (Kogo, H. (231) 481)

**Inhibitory amino acids**
GABA ($\gamma$-aminobutyric acid); GABA $\rho_2$ receptors; GABA $\rho_1$ receptors; Ligand-gated ion channel; Retina (Kusama, T. (245) 83)

**Inhibitory non-adrenergic non-cholinergic (i-NANC)**
VIP (vasoactive intestinal polypeptide); Nitric oxide (NO); Cholinergic neurotransmission; Electrical field stimulation (Belvisi, M.G. (231) 97)

**Inhibitory postsynaptic potential (late)**
GABA (γ-aminobutyric acid); Hippocampus; $GABA_B$ receptors; GABA transmission; $GABA_B$ receptor antagonists (Olpe, H.-R. (233) 179)

**Inner ear microcirculation disorder**
Nilvadipine; Flunarizine (Umemura, K. (239) 17)

**Inosine nucleotides**
Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Adenosine; Defibrotide; Trachea (Bianchi, G. (238) 327)

**myo-Inositol**
Diabetes mellitus; Diabetic neuropathy; Inositol phosphates; Nerve conduction; Streptozotocin (Carrington, A.L. (237) 257)

**Inositol monophosphate accumulation**
Ileum (Guinea pig); $NK_3$ receptors; Selective agonists (Petitet, F. (247) 185)

**Inositol phosphates**
$Ca^{2+}$; Femoral artery; Fura-2/AM; Isometric contraction; Ketamine; (Rabbit) (Ratz, P.H. (236) 433)

Diabetes mellitus; Diabetic neuropathy; myo-Inositol; Nerve conduction; Streptozotocin (Carrington, A.L. (237) 257)

Histamine $H_1$ receptor; $Ni^{2+}$; HeLa cell; Brain slice (Arias-Montaño, J.-A. (245) 221)

Cannabinoid; Hippocampus; Phosphatidylinositol (Nah, S.-Y. (246) 19)

Smooth muscle (human airway); Cell culture; Airway receptors (Daykin, K. (246) 135)

Endothelin; Vasopressin; Papillary tubules (Woodcock, E.A. (247) 93)

**Inositol phosphate turnover**
Muscarinic receptor subtypes; Carbachol (Garcia Ruiz, A.J. (244) 125)

**Inositol 1,4,5-trisphosphate**
Inositol 1,4,5-trisphosphate receptors; Inositol 1,4,5-trisphosphate phosphatase; Inositol 1,4,5-trisphosphate kinase; $Ca^{2+}$ mobilization; Benzene 1,2,4-trisphosphate (Poitras, M. (244) 203)

Angiotensin II; Protein kinase C; Isoenzymes; $Ca^{2+}$; Diacylglycerol; Mesangial cells (Ochsner, M. (245) 15)

Phospholipase C; Phosphatidylinositol 4,5-bisphosphate; Dopamine; Striatum (rat); Aging (Sugawa, M. (247) 39)

**D-myo-Inositol 1,2,6-trisphosphate**
Mesenteric circulation; Neuropeptide Y; Noradrenaline-induced vasoconstriction; α-Trinositol (Donoso, M.V. (240) 93)

**Inositol 1,4,5-trisphosphate (cardiac)**
Verapamil; $\alpha_1$-Adrenoceptors (cardiac); Protein kinase C (cardiac); Diabetic cardiomyopathy; (Rat) (Tanaka, Y. (244) 105)

**Inositol 1,4,5-trisphosphate kinase**
Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate receptors; Inositol 1,4,5-trisphosphate phosphatase; $Ca^{2+}$ mobilization; Benzene 1,2,4-trisphosphate (Poitras, M. (244) 203)

**Inositol 1,4,5-trisphosphate phosphatase**
Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate receptors; Inositol 1,4,5-trisphosphate kinase; $Ca^{2+}$ mobilization; Benzene 1,2,4-trisphosphate (Poitras, M. (244) 203)

**Inositol 1,4,5-trisphosphate receptors**
Inositol 1,4,5-trisphosphate; Inositol 1,4,5-trisphosphate phosphatase; Inositol 1,4,5-trisphosphate kinase; $Ca^{2+}$ mobilization; Benzene 1,2,4-trisphosphate (Poitras, M. (244) 203)

**Inotropism**
BRL 37344; $\beta_3$-Adrenoceptors; Chronotropism; Heart (dog) (Takayama, S. (231) 315)

**Inotropy**
Angiotensin II; Angiotensin $AT_1$ receptors; Losartan; Atria (guinea pig) (Feolde, E. (245) 63)

**In situ hybridization**
Cholecystokinin (CCK); Diazepam; Tolerance; Withdrawal; mRNA (Rattray, M. (245) 193)

Adrenoreceptor; Noradrenaline; Proximal tubule; Thyroid hormone (Meister, B. (247) 229)

**In situ hybridization histochemistry**
Morphine tolerance; G protein expression; Immunoblot analysis; Brain regions (Parolaro, D. (244) 211)

**Insulin**
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

Islets of Langerhans; Monoamine oxidase activity; α-Adrenoceptor stimulation; β-Adrenoceptor stimulation; Cholinergic stimulation; Glucose; (Mouse) (Panagiotidis, G. (233) 285)

Feeding behaviour; Genetic obesity; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); Neuropeptide Y; CRF (corticotropin-releasing factor); (Zucker rat) (Rouru, J. (234) 191)

Trifluoperazine; Calmodulin; Glucose uptake; Skeletal muscle (Guarner, V. (237) 139)

**Insulin (ex vivo)**
Diabetic heart; Hypoperfusion; Norepinephrine; Left ventricular stiffness; ATP; Lactate (Higuchi, M. (242) 293)

**Insulin release**
NO synthase inhibition; Arginine; NADPH diaphorase (Panagiotidis, G. (229) 277)

**Insulin secretion**
Galanin; M35; Islets of Langerhans (isolated); Clonidine; Somatostatin (Gregersen, S. (232) 35)

Pancreatic vessels; α-Adrenoceptor antagonists; Verapamil; Pancreas (isolated); cAMP analogues; (Rat) (Skoglund, G. (236) 69)

Islet acid glucan-1,4-α-glucosidase; α-Glucosidehydrolase inhibition; Emiglitate; Acarbose; Glibenclamide; Carbachol (Salehi, A. (243) 185)

**α-Interferon**
Stress; Corticosterone; Paraventricular nucleus; Opioid receptors (Saphier, D. (236) 183)

**Interleukin-1**
Interleukin-6; Interleukin receptors; Smooth muscle (vascular); Phycoerythrin (French, J.F. (233) 109)

Tumour necrosis factor; Stomach (Montuschi, P. (233) 303)

CRF (corticotropin-releasing factor); Opioids; α-Helical CRF-(9–41); Antinociception (Mouse) (Kita, A. (237) 317)

Vasodilatation; Endotoxin; Nitric oxide (NO); Neutrophils; Glucocorticoids (Pons, F. (239) 23)

**Interleukin-5**
Hyperresponsiveness; Respiratory airways; Eosinophils; Asthma (Van Oosterhout, A.J.M. (236) 379)

Hyperresponsiveness; Respiratory airways; Eosinophils; Asthma (Van Oosterhout, A.J.M. (239) 277)

**Interleukin-6**
Interleukin-1; Interleukin receptors; Smooth muscle (vascular); Phycoerythrin (French, J.F. (233) 109)

**Interleukin-8**
Chemotaxis; Migration; Smooth muscle cell; Atherosclerosis (Yue, T.-L. (240) 81)

**Interleukin receptors**
Interleukin-1; Interleukin-6; Smooth muscle (vascular); Phycoerythrin (French, J.F. (233) 109)

**Interneurons**
NMDA receptor antagonists; Phencyclidine; Dizocilpine; σ Receptor ligands (Zhang, J. (230) 371)

**Intestinal absorption**
Digoxin; $Ca^{2+}$ channel blockers; (Guinea-pig) (Budihna, M.V. (230) 301)

**Intestinal motility**
Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester); Cholinergic mechanisms (Calignano, A. (229) 273)

**Intestinal secretion**
Enterotoxin; Ketanserin; Tropisetron; Ondansetron; Granisetron (Beubler, E. (248) 157)

**Intestinal transit**
$N^{\alpha}$-Methylhistamine; (R)αMethylhistamine; Histamine; Histamine $H_1$ receptors; Histamine $H_3$ receptors (Oishi, R. (237) 155)

**Intestinal transport**
Robenidine; Coccidiosis; D-Galactose; L-Leucine; Jejunum (rabbit); Drug-nutrient interaction; Sucrase; Aminopeptidase (Sorribas, V. (248) 137)

**Intestine**
Ganglia; Enteric nervous system; Myenteric plexus; Substance P; Tachykinins (Tamura, K. (232) 235)

Melatonin receptors; (Chicken); (Human) (Pontoire, C. (247) 111)

**Intranigral infusion**
Neurokinin receptor agonists; Substantia nigra; Oral movements; (Rat) (Liminga, U. (235) 177)

**Intraocular pressure**
Eye; Inflammation; Eosinophils; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

Aqueous humor flow rate; Dopamine $D_2$ receptors; (Rabbit) (Potter, D.E. (236) 61)

**Intrathecal administration**
Ketorolac; κ-Opioid receptors; Antinociception (Uphouse, L.A. (242) 53)

**Intrathecal injection**
Substance P; Spantide; Substance P analogues (containing D-His); Formalin; Capsaicin; Nociceptive response (Sakurada, T. (242) 47)

**Intravascular ultrasound**
L-NAME ($N^G$-nitro-L-arginine methyl ester); EDRF (endothelium-derived relaxing factor); Vasomotion (Schwarzacher, S. (229) 253)

**Inverse agonists**
Benzodiazepine receptor agonists; Benzodiazepine receptor antagonists; Hypothermia (Tang, A.H. (236) 1)

**Iodocaramiphen**
Caramiphen; Nitrocaramiphen: Muscarinic receptor antagonists; Muscarinic $M_1$ receptors; (Rat) (Hudkins, R.L. (231) 485)

**2-Iodomelatonin**
Melatonin; 6-Chloromelatonin; cAMP; Cytostatic activity (Ying, S.-W. (246) 89)

**[$^{123}$I]Iomazenil**
SPECT (single photon emission tomography); Benzodiazepine receptors (Laruelle, M. (230) 119)

**Ion channels**
AJ-2615; $Ca^{2+}$ channel antagonists; (Neurons); (Snail) (Liu, G.J. (231) 91)

5-$HT_3$ receptor; 5-HT (5-hydroxytryptamine, serotonin); Tetraethylammonium; N1E-115 neuroblastoma; Whole-cell voltage clamp; Desensitization (Kooyman, A.R. (246) 247)

**Ionic currents**
Class III antiarrhythmics; Action potentials; Single ventricular cells (Lee, K.S. (234) 43)

**Iontophoresis**
Bradycardiac agents; Sinus node inhibitors; Zatebradine; Pacemaker currents; Purkinje fibres; Use-dependent blockade; (Electrophysiology) (Van Bogaert, P.P. (229) 55)

**Ion transport**
5-HT (5-hydroxytryptamine, serotonin); Mucosa; Ileum; (Human) (Burleigh, D.E. (241) 125)

**Ipsapirone**
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-$HT_{1A}$ receptors; 5-$HT_2$ receptors; Anxiolysis; Glucose; Corticosterone; Prolactin; Behaviour (Baudrie, V. (231) 395)

Anxiolytics; Dorsal raphe nucleus; Electrophysiology; Hippocampus; Microdialysis; Serotonergic neurotransmission; 5-$HT_{1A}$ receptors; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

Glutamate; Dopamine; Phencyclidine; 5-HT (5-hydroxytryptamine, serotonin); MK-801 (Löscher, W. (242) 99)

**$IP_3$-sensitive $Ca^{2+}$ store**
Fluorescence microscopy of intracellular $Ca^{2+}$; Fura-2 fluorescence; Muscarinic receptor; Caffeine-sensitive $Ca^{2+}$ store; Neurotransmitter receptor desensitization (Fohrman, E.B. (245) 263)

**IRL 1038**
Smooth muscle (vascular); Endothelium (vascular); EDRF (endothelium-derived relaxing factor); Endothelins; $ET_B$ receptors; $ET_B$ receptor antagonists; Aorta (rat) (Karaki, H. (231) 371)

**Iron**
Cisplatin; Emesis; Free radicals; (*Suncus murinus*) (Matsuki, N. (248) 329)

**Iron-chelator**
[$^3$H]Spiperone; Dopamine $D_2$ receptors; Affinity state; Dorsal hippocampus; Ventral hippocampus; Striatum; $Mg^{2+}$; GTP (Bruinink, A. (245) 157)

**Iron ions**
5-HT (serotonin 5-hydroxytryptamine binding proteins); Brain; 5-HT (serotonin 5-hydroxytryptamine); Dopamine; Superoxide radicals (Jimenez Del Rio, M. (247) 11)

**Ischemia**
5-$HT_{1A}$ receptors; 5-$HT_2$ receptors; 2-Deoxyglucose; Electrophysiology; Hippocampus (slices) (Shibata, S. (229) 21)

Almitrine; Raubasine; Middle cerebral artery; Penumbra; (Cat) (Chan, P. (231) 175)

Renal arteries; EDRF (endothelium-derived relaxing factor); Renal hemodynamics; (Rabbit) (Pruneau, D. (231) 215)

Dynorphin A-(1–13); Nor-binaltorphimine; Memory; Body temperature; (Mouse) (Itoh, J. (234) 9)

Hypoxia; Glutamate; Neurotoxicity; Cell culture; ES-242s; MK-801 (Nozawa, M. (236) 263)

d-Propranolol; dl-Propranolol; Reperfusion; Metabolism (Hoque, A.N.E. (236) 269)

Azelastine; Cerebral vascular disease; Leukotriene; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

Refractory period (effective); Antiarrhythmic drugs; (Guinea-pig) (Tweedie, D. (240) 251)

Reperfusion; Arrhythmia; Hypochlorous acid; Hydrogen peroxide (Okabe, E. (248) 33)

Endothelin-1; Middle cerebral artery occlusion; Hypoxia; Cultured neurons; (Mouse) (Nikolov, R. (248) 205)

**Ischemia (forebrain)**
MK-801; Postischemic recovery; Postischemic survival; (Mongolian gerbil) (Von Lubitz, D.K.J.E. (233) 95)

**Ischemia-reperfusion**
Heart; Free radicals; Spin traps; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (234) 113)

Heart; Free radicals; Spin traps; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (239) 275)

**Ischemia-reperfusion injury**
TNF$\alpha$ (tumor necrosis factor-$\alpha$); Anti-tumor necrosis factor-$\alpha$ antibodies (Squadrito, F. (237) 223)

**Islet acid glucan-1,4-$\alpha$-glucosidase**
Insulin secretion; $\alpha$-Glucosidehydrolase inhibition; Emiglitate; Acarbose; Glibenclamide; Carbachol (Salehi, A. (243) 185)

**Islets of Langerhans**
$K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

Monoamine oxidase activity; $\alpha$-Adrenoceptor stimulation; $\beta$-Adrenoceptor stimulation; Cholinergic stimulation; Insulin; Glucose; (Mouse) (Panagiotidis, G. (233) 285)

**Islets of Langerhans (isolated)**
Galanin; M35; Insulin secretion; Clonidine; Somatostatin (Gregersen, S. (232) 35)

**Isocyanates**
Capsaicin-sensitive afferents; Mast cells, Airways (guinea-pig) (Mapp, C.E. (248) 67)

**Isoenzymes**
Angiotensin II; Protein kinase C; Inositol 1,4,5-trisphosphate ($InsP_3$); $Ca^{2+}$; Diacylglycerol; Mesangial cells (Ochsner, M. (245) 15)

**Isometric contraction**
$Ca^{2+}$; Femoral artery; Fura-2/AM; Inositol phosphates; Ketamine; (Rabbit) (Ratz, P.H. (236) 433)

**Isoniazid**
Ethanol-inducible cytochrome P450; Translational activation (Park, K.S. (248) 7)

**Isoprenaline-induced drinking**
Fluoxetine; Ethanol; $\beta$-Adrenoceptors (Mustafa, A.A. (237) 147)

**Isoproterenol**
Hyperpolarization-activated inward current; Pacemaker current; Automaticity; Myocytes (embryonic chick heart); Autonomic agents; Acetylcholine (Satoh, H. (240) 283)

**Isradipine**
Cerebral ischemia; Dopamine; Microdialysis; $Ca^{2+}$ channels (voltage-sensitive) (Ooboshi, H. (233) 165)

**Ivermectin**
Small intestine (guinea-pig); GABA ($\gamma$-aminobutyric acid); Lindane; Enteric $GABA_A$ receptors (Coccini, T. (248) 1)

**Jejunal strip contraction (rat)**
Galanin (porcine, rat); Galanin fragments; $N^{\alpha}$-Acetyl-galanin-(9–29) (porcine, rat); Pancreatic amylase secretion (Rossowski, W.J. (240) 259)

**Jejunum**
Clonazepam; CCK (cholecystokinin); Devazepide; L365-260; Duodenum; Motility (Bonnafous, C. (237) 237)

**Jejunum (rabbit)**
Robenidine; Coccidiosis; D-Galactose; L-Leucine; Intestinal transport; Drug-nutrient interaction; Sucrase; Aminopeptidase (Sorribas, V. (248) 137)

**JTP-2942 (N$^{\alpha}$-[(1S,2R)-2-methyl-4-oxycyclopentanecarbonyl]-L-histidyl-L-prolinamide)**
TRH (thyrotropin-releasing hormone); Acetylcholine; Choline; Frontal cortex; Hippocampus; Microdialysis (Toide, K. (233) 21)

**Jumping**
Quinpirole; Dopamine; Receptor supersensitivity (Kostrzewa, R.M. (239) 183)

***jun*-B**
c-*fos*; Pineal gland; Adrenoceptors; Second messengers; Protein kinase (Carter, D.A. (244) 285)

**Jurkat T cells**
CCK-8 (cholecystokinin-8); CCK (cholecystokinin) analog; $CCK_B$ receptor; $Ca^{2+}$ mobilization (intercellular) (Lignon, M.-F. (245) 241)

**$K^+$**
1,4-Dihydropyridine (enantiomers); pH; $Ca^{2+}$; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

**Kainate**
*Xenopus* oocytes (rat brain mRNA-injected); Excitatory amino acid receptors; Riluzole; NMDA (N-methyl-D-aspartate) (Debono, M.-W. (235) 283)

**[$^3$H]Kainate binding**
Excitatory amino acid receptors; $Ca^{2+}$; Domoate; Brain (Johansen, T.H. (246) 195)

Hippocampal slices; *Xenopus* oocytes (rat cortex mRNA-injected); Glutamate receptors; GABA receptor; ATP-sensitive potassium channel activators; [$^3$H]AMPA (*R,S*)-α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) binding (Randle, J.C.R. (247) 257)

**$K^+$ channel activators**
Renal haemodynamics; Adrenoceptor agonists; Renal nerve stimulation (Johns, E.J. (230) 47)

**$K^+$ channel antagonists**
$\beta_2$-Adrenoceptor agonists; Smooth muscle (airway); Trachea (guinea-pig) (Huang, J.-C. (235) 37)

**$K^+$ channel openers**
Arachidonic acid; Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated) (Hu, S. (230) 215)

Patch clamp; Glibenclamide; Skeletal muscle $K_{ATP}$ channels (Allard, B. (236) 419)

Airways; Smooth muscle (vascular) (Dumas, M. (239) 141)

Plasma exudation; Cigarette smoke; Vagus nerve stimulation; Glibenclamide (Lei, Y.-H. (239) 257)

Ki1769; Ki3315; KRN2391; Coronary artery (pig) (Okada, Y. (241) 177)

$K^+$ channel (*Xenopus laevis*); KRN2391; Nicorandil; Cromakalim; Glibenclamide; Phentolamine; Trifluoperazine (Sakuta, H. (244) 277)

**$K^+$ channels**
Islets of Langerhans; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

Cromakalim; $Na^+$,$K^+$ ATPase pump; Smooth muscle (vascular) (Hong, K.W. (231) 1)

Antiarrhythmic drugs; Cardiac ischaemia; Ventricular fibrillation (Gwilt, M. (236) 107)

σ Receptors; [$^3$H](+)-3-PPP ([$^3$H](+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); Antiarrhythmic drugs class III (Jeanjean, A.P. (241) 111)

CGRP (calcitonin gene-related peptide); Uterine artery (human); Pregnancy; Glybenclamide; Tetraethylammonium; Pinacidil (Nelson, S.H. (242) 255)

Local anesthetics; Bupivacaine; Glibenclamide; *Xenopus laevis* oocyte; Calmodulin (Yoneda, I. (247) 267)

Noradrenaline release; Glutamate receptors (Ennis, C. (248) 85)

**$K_{ATP}$ channels**
$Mg^{2+}$; Sulphonylureas (Lee, K. (247) 347)

**$K^+$ channels (ATP-dependent)**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

**$K^+$ channels (ATP-sensitive)**
Adenosine; Adenosine $A_2$ receptor-mediated vasodilatation; 8-Phenyltheophylline; Glibenclamide (Orito, K. (231) 183)

Decavanadate; Ventricular cells (single); Patch clamp (Nakashima, H. (233) 219)

Fatigue; Skeletal muscle (Comtois, A. (242) 65)

**$K^+$ channels ($Ca^{2+}$-activated)**
Arachidonic acid; Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channel openers (Hu, S. (230) 215)

**$K^+$ channel (*Xenopus laevis*)**
$K^+$ channel opener; KRN2391; Nicorandil; Cromakalim; Glibenclamide; Phentolamine; Trifluoperazine (Sakuta, H. (244) 277)

**$K^+$ currents**
Trimebutine; Smooth muscle cells (ileal); Patch-clamp (whole cell) (Nagasaki, M. (235) 197)

OPC-8212; Action potential duration; Cardiac ventricular myocytes; Secondary inward current; Veratrine (Lathrop, D.A. (240) 127)

Forskolin action; Uterus (pregnant); Smooth muscle cells (myometrial); cAMP; Tetraethylammonium (Inoue, Y. (240) 169)

**$K^+$ depolarization**
NMDA receptors; Voltage-operated $Ca^{2+}$ channels; Glutamate release; $^{45}Ca^{2+}$ uptake; Cerebellar granule cells (Didier, M. (244) 57)

**Ketamine**
(+)-MK-801; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

MK-801; Methamphetamine; Ceruletide; Cholecystokinin-like decapeptide; Dopamine release; Avoidance behaviour (Kuribara, H. (231) 7)

$Ca^{2+}$; Femoral artery; Fura-2/AM; Inositol phosphates; Isometric contraction; (Rabbit) (Ratz, P.H. (236) 433)

Asthma; Anaesthetics; Propofol; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

**Ketanserin**
5-HT (5-hydroxytryptamine, serotonin); α-Methyl-5-hydroxytryptamine; Bronchi (rat); $5\text{-HT}_2$ receptors; Mianserin; Spiperone; Electrical field stimulation; Cholinergic nerves (Szarek, J.L. (231) 339)

Enterotoxin; Intestinal secretion; Tropisetron; Ondansetron; Granisetron (Beubler, E. (248) 157)

**Ketorolac**
κ-Opioid receptors; Antinociception; Intrathecal administration (Uphouse, L.A. (242) 53)

**Ki1769**
Ki3315; KRN2391; $K^+$ channel openers; Coronary artery (pig) (Okada, Y. (241) 177)

**Ki3315**
Ki1769; KRN2391; $K^+$ channel openers; Coronary artery (pig) (Okada, Y. (241) 177)

**Kidney**
Imidazoline binding sites; (Regulation) (Hamilton, C.A. (243) 95)

**Kidney cells (opossum)**
$\alpha_2$-Adrenoceptors; Transfected CHO cells (Pleus, R.C. (244) 181)

**Kidney (perfused, rat)**
Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

**Kidney (rabbit)**
Endothelin; Prostacyclin; Pressor effects; Endothelin $ET_A$ receptors (Télémaque, S. (237) 275)

**Kidney (rat)**
[$^3$H]p-Aminoclonidine; [$^3$H]Idazoxan; Imidazoline binding sites; RS-15385-197 (MacKinnon, A.C. (232) 79)

Muscarinic receptor subtypes (agonist binding); Amiloride (Blankesteijn, W.M. (244) 21)

**Kindling**
Epilepsy; Dextromethorphan; Dextrorphan; Glutamate; (Rat) (Löscher, W. (238) 191)

**Kinetic cooperativity of dissociation**
Glycine receptor; [$^3$H]Strychnine binding, (agonist and antagonist); Entropy change of binding (Maksay, G. (245) 183)

**Kinetics**
Antagonism, functional; Adenosine $A_2$ receptors; $\alpha_1$-Adrenoceptor; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

**Kininase**
Poststatin; Bradykinin; Degradation pathway; Urine (Majima, M. (232) 181)

**KRN2391**
Cromakalim; Heart (isolated, rat); Myocardial ischemia; Energy metabolism (Ohta, H. (231) 323)

Ki1769; Ki3315; $K^+$ channel openers; Coronary artery (pig) (Okada, Y. (241) 177)

$K^+$ channel (*Xenopus laevis*); $K^+$ channel opener; Nicorandil; Cromakalim; Glibenclamide; Phentolamine; Trifluoperazine (Sakuta, H. (244) 277)

**Kynurenic acid**
Apnoea; Dizocilpine; Arterial blood pressure; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

**Kynurenine formamidase inhibition**
Noncholinergic actions; Organophosphorous insecticides; Methylcarbamate insecticides; Xanthurenic acid (urinary excretion); Plasma L-kynurenine; (Structural requirements) (Pewnim, T. (248) 237)

**L365-260**
Clonazepam; CCK (cholecystokinin); Devazepide; Duodenum; Jejunum; Motility (Bonnafous, C. (237) 237)

**$La^{3+}$**
$GABA_A$ receptors; Lanthanides; [$^{35}$S]TBPS ([$^{35}$S]t-butylbicyclophosphorothionate) binding; Conformational changes in $GABA_A$ receptors (Im, W.B. (245) 111)

**Lacidipine**
Smooth muscle (vascular); $Ca^{2+}$ influx; $A_7r_5$ cells; Amlodipine; 1,4-Dihydropyridines (Spampinato, S. (244) 139)

**Lactate**
Diabetic heart; Hypoperfusion; Norepinephrine; Left ventricular stiffness; ATP; Insulin (ex vivo) (Higuchi, M. (242) 293)

**Lactate dehydrogenase**
Amiodarone; Antiarrhythmic agents; Mitochondrial ATPase (Dzimiri, N. (242) 113)

**Lactic acid**
CGRP (calcitonin gene-related peptide); Capsaicin; Capsazepine; Cardiac afferents (Franco-Cereceda, A. (238) 311)

**Lanthanides**
$GABA_A$ receptors; $La^{3+}$; [$^{35}$S]TBPS ([$^{35}$S]t-butylbicyclophosphorothionate) binding; Conformational changes in $GABA_A$ receptors (Im, W.B. (245) 111)

**Laser-Doppler flowmetry**
Heart failure (high-output); Neurohumoral factors; Renal blood flow; Thermodilution; Wistar rat (Oka, T. (234) 55)

**Lateral habenular nucleus**
Buspirone; Glucose utilization; Hippocampus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

**Lateral tegmental field**
Sympathetic nerve activity; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Cardiovascular neurons (Vayssettes-Courchay, C. (236) 121)

Nucleus tractus solitarii; Rostral vasodepressive area; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Vayssettes-Courchay, C. (242) 37)

**Lead acetate**
Cadmium chloride; Hypothermia; Environmental temperature; Brain metal levels (Martínez, F. (248) 199)

**Learning**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Hypothermia (Khanna, J.M. (230) 23)

**Learning and memory**
Propentofylline; Basal forebrain; Ibotenic acid; Choline acetyltransferase; Nerve growth factor (Fuji, K. (236) 411)

**Learning (latent)**
Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; GBR 12909; Locomotor activity (Ichihara, K. (234) 155)

**Learning/memory**
NMDA receptor antagonists; Muscle relaxation; Circling behaviour; (Rat) (Murata, S. (239) 9)

**Left ventricular stiffness**
Diabetic heart; Hypoperfusion; Norepinephrine; ATP; Lactate; Insulin (ex vivo) (Higuchi, M. (242) 293)

**Leucine**
Thymidine; Uridine; DNA synthesis; RNA synthesis; Protein synthesis; Thymidine kinase activity (Garg, U.C. (237) 243)

**L-Leucine**
Robenidine; Coccidiosis; D-Galactose; Intestinal transport; Jejunum (rabbit); Drug-nutrient interaction; Sucrase; Aminopeptidase (Sorribas, V. (248) 137)

**Leukocyte elastase (human)**
Neutrophils; Platelets (Renesto, P. (248) 151)

**Leukotriene**
5-Lipoxygenase; Bronchoconstriction; Trachea; Asthma; (Guinea-pig) (Heaslip, R.J. (234) 247)

Azelastine; Cerebral vascular disease; Ischaemia; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

**Leukotriene biosynthesis inhibitors**
WY-50,295 tromethamine; 5-Lipoxygenase inhibitors; Anti-allergic activity (Grimes, D. (236) 217)

**Leukotriene receptor antagonists**
LY290324; (Guinea-pig) (Boot, J.R. (231) 83)

Leukotriene $D_4$; Leukotriene $D_4$ receptors; U937 cell line (Frey, E.A. (244) 239)

**Leukotriene receptors**
Spleen (ferret); ICI 198615; SK&F 104353; MK571 (Gardiner, P.J. (238) 19)

**Leukotriene $B_4$ receptors**
THP-1 cells; Human polymorphonuclear leukocytes; Leukotrienes (Slipetz, D.M. (244) 161)

**Leukotriene $D_4$**
Regulatory decrease in volume; Colon (rat); $Cl^-$ channels (Diener, M. (238) 217)

5-Lipoxygenase; Acetylcholine release; Myenteric plexus (Yoshikawa, S. (239) 261)

Leukotriene $D_4$ receptors; Leukotriene receptor antagonists; U937 cell line (Frey, E.A. (244) 239)

**Leukotriene $D_4$ receptors**
Leukotriene $D_4$; Leukotriene receptor antagonists; U937 cell line (Frey, E.A. (244) 239)

**Leukotrienes**
E3330; Liver injury; Galactosamine; TNF-$\alpha$ (tumor necrosis factor-$\alpha$); Prostanoids (Nagakawa, J.-i. (229) 63)

Cytokines; Endotoxin; cAMP (Schade, F.U. (230) 9)

THP-1 cells; Human polymorphonuclear leukocytes; Leukotriene $B_4$ receptors (Slipetz, D.M. (244) 161)

Nicotine; Cotinine; Prostaglandins; Thromboxane (Saareks, V. (248) 345)

**Levcromakalim**
Adenosine; Glibenclamide-sensitive $K^+$ channels; YT-146 (2-(1-octynyl)-adenosine); G-protein (pertussis toxin-sensitive) (Furukawa, S. (236) 255)

**Levodropropizine**
Capsaicin; Substance P; Sensory nerves; Neurogenic inflammation; Plasma extravasation (Yamawaki, I. (243) 1)

**$Li^+$ clearance**
$Li^+$ reabsorption; $Na^+$ restriction; Amiloride (Shalmi, M. (230) 33)

EXP3174; Angiotensin II; Renal blood flow; Glomerular filtration rate (Tamaki, T. (236) 15)

**Lidocaine**
Use dependence; Acidosis; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (230) 167)

Use dependence; Acidosis; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (236) 497)

**Ligand binding**
Dopamine $D_3$ receptor; [$^{125}$I]trans-7-OH-PIPAT-A (Kung, M.-P. (235) 165)

NMDA (*N*-methyl-D-aspartate); (Non-competitive), Dizocilpine; FR115427 (Sherriffs, H.J. (247) 319)

**Ligand-gated ion channel**
5-$HT_3$ receptors; m-Chlorophenylbiguanide; Neuroblastoma (Lummis, S.C.R. (243) 7)

GABA (γ-aminobutyric acid); GABA $\rho_2$ receptors; GABA $\rho_1$ receptors; Inhibitory amino acids; Retina (Kusama, T. (245) 83)

**Light peak**
Dopamine; Electrooculogram; Haloperidol; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Limbic system**
Phencyclidine; Glucose metabolism; Psychosis; Schizophrenia; Histopathology (Gao, X.-M. (241) 7)

**Limb stepping**
Turning behaviour; Dopamine $D_1/D_2$ receptor interaction; Nucleus accumbens; SKF 38393; Quinpirole (Saigusa, T. (237) 161)

**Lindane**
Small intestine (guinea-pig); GABA (γ-aminobutyric acid); Ivermectin; Enteric $GABA_A$ receptors (Coccini, T. (248) 1)

**Lingual arteries (isolated)**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; Phenylephrine; (Partial agonist) (Skrbic, R. (230) 131)

**Lip**
Nitric oxide (NO); Afferent nerves; Blood flow; Pulp; Oral mucosa; Submandibular gland (Kerezoudis, N.P. (241) 209)

**Lipid peroxidation**
$\alpha$-Tocopherol analogue (MDL 73404); Free radical scavenger; Reperfusion injury; Myocardial ischaemia/reperfusion; Contractility (Lukovic, L. (233) 63)

21-Aminosteroids; NMDA (N-methyl-D-aspartate); Hypoxia (Domenici, M.R. (233) 291)

Reactive oxygen species; Cardiac cells; Reperfusion injury; Electromechanical coupling (Iliou, J.-P. (248) 263)

**Lipopolysaccharide**
S-1452 (calcium (1R,2S,3S,4S)-(5Z)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate); Thromboxane $A_2$; TNF (tumor necrosis factor); Bronchial hyperresponsiveness (Arimura, A. (231) 13)

Cationic amino acids; Nitric oxide (NO) (Schott, C.A. (236) 155)

Endotoxin; Eosinophils; Pleurisy (Bozza, P.T. (248) 41)

**Lipoproteins**
Hypocholesterolemic drugs; Liver; Cholesterol; Bile (Clerc, T. (235) 59)

**Liposome**
Fructose 1,6-bisphosphate; Carrageenan; Antiinflammatory (Planas, M.E. (237) 251)

**5-Lipoxygenase**
Leukotriene; Bronchoconstriction; Trachea; Asthma; (Guinea-pig) (Heaslip, R.J. (234) 247)

Acetylcholine release; Leukotriene $D_4$; Myenteric plexus (Yoshikawa, S. (239) 261)

**Lipoxygenase inhibitors**
Esculetin; Coumarins; Antiproliferative effect; Smooth muscle cells (vascular) (Huang, H.-C. (237) 39)

**5-Lipoxygenase inhibitors**
WY-50,295 tromethamine; Leukotriene biosynthesis inhibitors; Anti-allergic activity (Grimes, D. (236) 217)

**Lipoxygenase products**
Contractions; 5-HT (5-hydroxytryptamine, serotonin); Atherosclerosis; Blood vessels; (Interaction) (Van Diest, M.J. (231) 267)

**$Li^+$ reabsorption**
$Na^+$ restriction; Amiloride; $Li^+$ clearance (Shalmi, M. (230) 33)

**Lisinopril**
Angiotensin-converting enzyme inhibitors; Hypoxia; Reoxygenation; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

**Lithium chloride**
Tacrine; Nitric oxide (NO); Epilepsy; Neurodegeneration (Bagetta, G. (237) 61)

**Litoxetine**
Antidepressants; Emesis; 5-HT (5-hydroxytryptamine, serotonin) (Angel, I. (232) 139)

**Liver**
Hypocholesterolemic drugs; Cholesterol; Bile; Lipoproteins (Clerc, T. (235) 59)

$\sigma$ Binding; Cytochrome P450; Brain; (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); (Dark Agouti rat) (Jewell, A. (243) 249)

**Liver injury**
E3330; Galactosamine; TNF-$\alpha$ (tumor necrosis factor-$\alpha$); Leukotrienes; Prostanoids (Nagakawa, J.-i. (229) 63)

**Liver (rat)**
Cloning; Loop diuretics; Bumetanide (transport); Organic anions; Sinusoidal plasma membrane; Bile acid (Honscha, W. (246) 227)

Cytochrome P450 1A2; Musk xylene; Musk ambrette; Enzyme induction (Iwata, N. (248) 243)

**Liver tumour promotion (rat)**
Hepatocytes; Gap-junctional intercellular communication; Dye transfer; Connexin 32; (Long-term coculture) (Mesnil, M. (248) 59)

**LLC-$PK_1$ cells**
Dopamine (renal); Fenoldopam; Quinpirole; SCH 23390; Cisflupentixol; Organic cations (renal); Dopamine receptors; Quinine (Dawson, Jr., R. (240) 277)

**Lobeline**
Nicotine; Cytisine; Mecamylamine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

**Local anesthetics**
Bupivacaine; $K^+$ channel; Glibenclamide; *Xenopus laevis* oocyte; Calmodulin (Yoneda, I. (247) 267)

**Localization**
Mineralocorticoid receptor; Glucocorticoid receptor; Steroid hormones; Receptor binding; Trans-activation (Rupprecht, R. (247) 145)

**Locomotion**
Cathinone; Conditioned place preference; Dopamine; (Rat) (Schechter, M.D. (232) 135)

Sensitization; Methamphetamine; Cycloheximide; (Mouse) (Shimosato, K. (234) 67)

**Locomotion (rat)**
NMDA receptor antagonists; Dizocilpine; Memantine; CGP 39551; Dopamine metabolism (Bubser, M. (229) 75)

**Locomotor activity**
Dopamine uptake inhibitors; [$^3$H]GBR 12783 binding site occupancy; Cytochrome P450; (Mouse) (Vaugeois, J.-M. (230) 195)

Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; GBR 12909; Learning (latent) (Ichihara, K. (234) 155)

Morphine; Gliquidone; ATP-dependent $K^+$ channels (Ocaña, M. (239) 253)

U50,488H; Nor-binaltorphimine; Naloxone; Opioid withdrawal; (Guinea-pig) (Brent, P.J. (241) 149)

Cocaine; Sensitization; Naltrindole; Opioids (Heidbreder, C. (243) 123)

Dopamine receptors; Turning behaviour; Yawning; Blood pressure; Pressor response; Body temperature; Spontaneously hypertensive rats (SHR) (Van den Buuse, M. (243) 169)

**Locus coeruleus**
Primary neuronal cultures; Substantia nigra; κ-Opioid receptors; μ-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

Desipramine; Noradrenaline; Electrochemistry (in vivo); Brain (rat); Anteroventral thalamic nucleus (Brun, P. (235) 205)

Parkinson's disease; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatal dopamine; DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); C57Bl/6 mouse (Marien, M. (236) 487)

$\alpha_2$-Adrenoceptor agonists; $\alpha_2$-Adrenoceptor antagonists; High voltage spindle; Slow wave (Riekkinen, Jr., P. (238) 263)

**Locus coeruleus neurons**
Galanin; Receptor interaction; Firing rate; Membrane potential (Sevcik, J. (230) 223)

**Longitudinal muscle**
Calcium channels; Alcohols; Synaptosomes; [$^3$H]Nitrendipine; [$^{125}$I]ω-Conotoxin (Hawthorn, M.H. (229) 143)

HOE 140; Bradykinin; Circular muscle; Ileum (guinea-pig) (Medeiros, Y.S. (241) 157)

**Long-term depression**
Long-term potentiation; Glutamate metabotropic receptors; α-Methyl-4-carboxyphenylglycine (Bashir, Z.I. (239) 265)

**Long-term potentiation**
Dentate gyrus; Field potentials; NMDA receptors; Dextromethorphan; Methadone; Codeine; Normethadone; MK-801 (Krug, M. (231) 355)

Long-term depression; Glutamate metabotropic receptors; α-Methyl-4-carboxyphenylglycine (Bashir, Z.I. (239) 265)

Arachidonic acid; Metabotropic receptor (Collins, D.R. (240) 325)

Hippocampus; Cognitive enhancer; Somatostatin; Acetylcholine; Mossy fiber-CA3 pathway; FR121196; (Guinea-pig) (Matsuoka, N. (241) 27)

**Long-term treatment**
8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Neonatal; Ultrasonic calls; (Rat pup) (Johansson-Wallsten, C.E. (243) 149)

**Loop diuretics**
M17055; Thiazide diuretics; Amiloride; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

Cloning; Bumetanide (transport); Organic anions; Sinusoidal plasma membrane; Liver (rat); Bile acid (Honscha, W. (246) 227)

**Losartan**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; PD123177 (Barnes, J.M. (230) 251)

Sinoatrial node; Atrioventricular node; Angiotensin system; Angiotensin receptors (Saavedra, J.M. (235) 301)

Angiotensin II; Angiotensin receptor (antagonism); Stomach; Trachea (Liu, Yu.J. (240) 147)

Angiotensin II; Angiotensin $AT_1$ receptors; Inotropy; Atria (guinea pig) (Feolde, E. (245) 63)

Angiotensin $AT_1$ receptors; Glomerulus (Chansel, D. (247) 193)

**Lower esophageal sphincter**
Tachykinins; Substance P; Neurokinin A; $NK_2$ receptors; (Human) (Huber, O. (239) 103)

**Loxapine**
Clozapine; Haloperidol; Hippocampus; Synaptic excitation (Baskys, A. (235) 305)

**Loxiglumide**
$CCK_B$/gastrin receptor antagonists; $CCK_A$ receptor antagonists; Pancreatic acini (isolated, rat) (Höcker, M. (242) 105)

**LSD (d-lysergic acid diethylamide)**
5-HT receptors; Dissociation constant; Uterine artery (sheep) (Zhang, L. (230) 115)

**Lung**
Down-regulation; β-Adrenoceptors; β-Adrenoceptor agonist; Transcription factor; (rat) (Nishikawa, M. (247) 131)

**Lung (guinea-pig)**
Neurokinin A; $NK_2$ receptor antagonists; Substance P; $NK_1$ receptor antagonists; Capsaicin (Kudlacz, E.M. (241) 17)

**Lung phosphodiesterase**
CR 2039; Antiallergic compounds; Passive cutaneous anaphylaxis; Bronchial anaphylaxis; (Guinea-pig) (Revel, L. (229) 45)

**Lung (porcine)**
Autoradiography; Endothelin; Endothelin $ET_B$ receptors; [$^{125}$I]BQ-3020 (Kobayashi, M. (235) 95)

**Lung strip**
Thromboxane receptors; Thromboxane receptor antagonists; BAY u3405; I-BOP (1S-(1α,2α(Z),3β(1(E),3S),4α)-7-(3-(3-hydroxy-4-(4-iodophenoxy)-1-butenyl)-7-oxabicyclo(2,2,1)hept-2-yl-5-heptenoic acid); U46619 (Norman, P. (229) 171)

**Lung tissue**
Histamine $H_1$ receptors; Histamine $H_1$ receptor antagonists; [$^3$H]Mepyramine; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

**LY-41**
5-$HT_{1A}$ receptor agonists; 5-$HT_{1A}$ receptor antagonists; 8-OH-DPAT derivatives; (S)-UH-301; 5-HT motor syndrome (Yu, H. (231) 69)

**LY53857**
5-$HT_2$ receptors; Ergolines; Tryptamines, [$^{125}$I]DOI ([$^{125}$I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amesergide (Johnson, M.P. (239) 111)

**LY228729**
Antidepressants; Forced swim test; 5-$HT_{1A}$ receptor agonists (Benvenga, M.J. (239) 249)

**LY274614**
NMDA (N-methyl-D-aspartate); MK-801; SCH23390; Clebopride; Catalepsy; Dopamine; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

**LY290324**
Leukotriene receptor antagonists; (Guinea-pig) (Boot, J.R. (231) 83)

**Lysogangliosides**
Glycosphingolipids; Platelet aggregation; Thrombin; 5-HT (5-hydroxytryptamine, serotonin); Tromboxane $B_2$; Bleeding; Coagulation; Fibrinolysis (Tubaro, E. (248) 175)

**M15**
Microdialysis; Galanin receptor antagonists; M35; Receptor binding; Striatum (Ögren, S.O. (242) 59)

**M35**
Galanin; Islets of Langerhans (isolated); Insulin secretion; Clonidine; Somatostatin (Gregersen, S. (232) 35)

Microdialysis; Galanin receptor antagonists; M15; Receptor binding; Striatum (Ögren, S.O. (242) 59)

**M17055**
Loop diuretics; Thiazide diuretics; Amiloride; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

**Male sexual behavior**
5-HT (5-hydroxytryptamine, serotonin); Penile erection; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Yawning; m-CPP; (Primates); (Rhesus monkey) (Pomerantz, S.M. (243) 227)

**Marihuana**
Cannabinoids; Tetrahydrocannabinol (Fride, E. (231) 313)

**Mast cells**
Isocyanates; Capsaicin-sensitive afferents (Mapp, C.E. (248) 67)

**Mastoparan**
Guanylate cyclase; ANF (Atrial natriuretic factor); cGMP; ATP (Song, D.-L. (247) 283)

G-protein; Cardiac contractility (Van Meel, J.C.A. (247) 357)

**Maturation**
Airway obstruction; Asthma; Development; Plasma exudation; Vascular permeability (Yokoyama, T. (236) 427)

**Maxillary sinus**
Cilia; Mucociliary activity; Phosphoramidon; Tachykinins; Tachykinin receptors; (Rabbit) (Lindberg, S. (231) 375)

**Mazindol**
Zucker rat; Imidazoline $I_2$ binding sites; $\alpha_2$-Adrenoceptors; Brain; [$^3$H]Idazoxan; [$^3$H]Clonidine; [$^3$H]RX821002 (Miralles, A. (243) 305)

**MBFG (4-amino-3-(5-methoxybenzo(b)furan-2-yl) butanoic acid)**
GABA ($\gamma$-aminobutyric acid); Baclofen; Spinal cord; Antinociception; BFG (4-amino-3-benzo(b)furan-2-yl-butanoic acid) (Hammond, D.L. (229) 227)

**McN-A-343**
Muscarinic $M_1$ receptors; Muscarinic $M_1$ receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol (Shannon, H.E. (232) 47)

**MDL 73005**
SDZ 216-525; NAN 190; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-HT}_{1A}$ receptors; $5\text{-HT}_{1B}$ receptors; $5\text{-HT}_{1C}$ receptors; $5\text{-HT}_{1D}$ receptors (Schoeffter, P. (244) 251)

**MDMA (3,4-methylenedioxymethamphetamine)**
Parachloroamphetamine; Fluoxetine; Deprenyl; Clorgyline; Nimodipine; Reserpine (Gu, X.F. (235) 51)

Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; $5\text{-HT}_2$ receptors; R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

**Mean arterial pressure**
Endothelin-1; Endothelin receptor antagonist; Sarafotoxin S6c (Bird, J.E. (240) 295)

**Mecamylamine**
Nicotine; Lobeline; Cytisine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

**Medetomidine**
$\alpha_2$-Adrenoceptors; Sedation; Anaesthesia; Atipamezole; (Cat) (Stenberg, D. (238) 241)

**Medial habenula**
Neurokinin; Substance P; Tachykinin (Norris, S.K. (234) 223)

**Mediatophore**
Acetylcholine release; $Ca^{2+}$; Cetiedil; Cholinergic synapses; (*Torpedo marmorata* synaptosomes) (Moulian, N. (231) 407)

**Medulla (ventral surface)**
Endothelin; Clonidine; Blood pressure; Heart rate; (Sprague-Dawley rat) (Gulati, A. (230) 293)

**Melanotropins**
$\gamma_2$-MSH ($\gamma_2$-melanocyte-stimulating hormone); ACTH-(4–10); Hemodynamics; Urethane anesthesia; Pentobarbital anesthesia; Excitability; (Conscious rat) (De Wildt, D.J. (233) 157)

**Melatonin**
Diazepam; Anxiolysis; Exploratory behaviour; Benzodiazepine antagonism; (Time-dependent effects) (Golombek, D.A. (237) 231)

Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Tryptophan (Huether, G. (238) 249)

6-Chloromelatonin; 2-Iodomelatonin; Melatonin receptors; Melanoma cells (human); cAMP; Cytostatic activity (Ying, S.-W. (246) 89)

**Melatonin receptors**
Intestine; (Chicken); (Human) (Pontoire, C. (247) 111)

**Melittin**
Phosphotyrosine phosphatase; Arachidonic acid; EGF (epidermal growth factor); Phospholipase $A_2$; Fibroblasts (Errasfa, M. (247) 73)

**Memantine**
NMDA receptor antagonists; Dizocilpine; CGP 39551; Dopamine metabolism; Locomotion (Rat) (Bubser, M. (229) 75)

Scrapie; Cortical cells; NMDA receptor; Neurons; Prion; Adamantanes; MK-801 (Müller, W.E.G. (246) 261)

Methotrexate; Glutamate; MK-801; Carboxypeptidase; Neurotoxicity (Weller, M. (248) 303)

**Membrane electrophoresis**
Erythrocyte membrane; Clofibric acid; Clofibrate; $HCO_3^-$-$Cl^-$ exchange inhibition; (Rat) (Morales-Aguilera, A. (245) 89)

**Membrane fluidity**
Tetramethylpyrazine; Electron spin resonance; Fluorescence polarization; Smooth muscle (vascular) (Nie, S.-Q. (244) 15)

Platelets; Trimetazidine; Aggregation; cAMP (Devynck, M.-A. (245) 105)

**Membrane permeability**
Aminoglycoside; Calcein; $Mn^{2+}$; $Ca^{2+}$; Conformational analysis (Van Bambeke, F. (247) 155)

**Membrane polarity**
Dopamine neuronal carrier; [$^3$H]GBR 12783; Binding (in vitro); Striatum (rat) (Billaud, G. (247) 333)

**Membrane potential**
Galanin; Locus coeruleus neurons; Receptor interaction; Firing rate (Sevcik, J. (230) 223)

**Memory**
Dynorphin A-(1–13); Nor-binaltorphimine; Ischemia; Body temperature; (Mouse) (Itoh, J. (234) 9)

5-$HT_{1A}$ receptors; Dorsal hippocampus; Passive avoidance; Anxiolytic effects; Antidepressant effects (Carli, M. (234) 215)

Spontaneous alternation performance; Dynorphin A-(1–13); Nor-binaltorphimine; (Mouse) (Itoh, J. (236) 341)

[D-Arg$^2$]Dermorphin analogue; $\mu$-Opioid receptors; $\beta$-Funaltrexamine; Passive avoidance response (Ukai, M. (239) 237)

Muscarinic acetylcholine receptors; Muscarinic receptor agonists; Muscarinic toxins (Jerusalinsky, D. (240) 103)

Active avoidance; Angiotensin; Angiotensin-converting enzyme inhibitor; Bradykinin; Diabetes mellitus; (Mouse) (Flood, J.F. (240) 311)

Spontaneous alternation performance; Dynorphin A-(1–13); Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Mouse) (Itoh, J. (241) 99)

**[$^3$H]Mepyramine**
Histamine $H_1$ receptors; Histamine $H_1$ receptor antagonists; Lung tissue; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

HeLa cell; Histamine $H_1$ receptor; Phosphoinositide; (+)-Chlorpheniramine; Temelastine (Arias-Montaño, J.-A. (245) 291)

**Mesangial cells**
Alprazolam; BN-52021; Endothelin; Proliferation; PAF (platelet-activating factor, PAF-acether) (Montero, A. (243) 235)

Angiotensin II; Protein kinase C; Isoenzymes; Inositol 1,4,5-trisphosphate ($InsP_3$); $Ca^{2+}$; Diacylglycerol (Ochsner, M. (245) 15)

**Mesenteric arterial bed**
Acetylcholine; Nitric oxide (NO); cAMP; cGMP; Endothelium-dependent relaxation (Abiru, T. (242) 15)

**Mesenteric artery**
Diabetes; Streptozotocin; Endothelium; Vasodilatation (Furman, B.L. (232) 29)

Cromakalim; (Human) (McDonald, A. (240) 303)

$Ca^{2+}$ channels; Vasorelaxation; Portal hypertension; Portal vein; (Rat) (Suga, T. (242) 129)

Cyclic AMP; Dopamine receptor; Smooth muscle (vascular); Phenoxybenzamine (Hall, A.S. (247) 249)

**Mesenteric circulation**
D-myo-Inositol 1,2,6-trisphosphate; Neuropeptide Y; Noradrenaline-induced vasoconstriction; $\alpha$-Trinositol (Donoso, M.V. (240) 93)

**Mesenteric vascular bed**
Hoe 140; Bradykinin; Vasodilatation; (Cat) (Santiago, J.A. (236) 315)

**Mesenteric vasculature**
CGRP (calcitonin gene-related peptide); Fischer 344 rats; Aging; Sensory nerves (capsaicin-sensitive) (Li, Y. (236) 373)

**Mesentery**
Big endothelin-1; Endothelin-1; Conversion (Hisaki, K. (241) 75)

**Mesentery (rat)**
L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Methylene blue; Diethyldithiocarbamate; CGRP (calcitonin gene-related peptide) (Li, Y.-j. (239) 127)

Bradykinin; L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Methylene blue; Capsaicin-sensitive sensory nerves (Yu, X.-j. (241) 35)

**Mesolimbic dopamine**
Morphine; 5-$HT_3$ receptor antagonists; Microdialysis (Pei, Q. (230) 63)

**[$^3$H]Mesulergine**
RP 62203; 5-$HT_2$ receptor antagonists; 5-HT (5-hydroxytryptamine, serotonin); Autoradiography; [$^{125}$I]AMIK ([$^{125}$I]7-amino-8-iodoketanserin) (Malgouris, C. (233) 29)

[$^3$H]Paroxetine; 5-$HT_{1C}$ receptor; 5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake site; Brain (rat) (Hulihan-Giblin, B.A. (239) 99)

5-$HT_{1C}$ receptors; Spinal 5-$HT_{1C}$ sites; Down-regulation; (Rat) (Pranzatelli, M.R. (244) 1)

**Metabolism**
$\mu$-Opioid receptors; $\delta$-Opioid receptors; Antinociception; Opioid receptor antagonists (Horan, P.J. (233) 53)

d-Propranolol; dl-Propranolol; Ischaemia; Reperfusion (Hoque, A.N.E. (236) 269)

**Metabotropic**
Excitatory amino acids; Glutamate; Phosphoinositide hydrolysis; NBQX (2,3-dihydroxy-6-nitro-7-sulpha-moylbenzo(F)-quinoxaline) (Suzdak, P.D. (245) 215)

**Metabotropic glutamate receptors**
L-2-Amino-4-phosphonobutyrate (L-AP4); cAMP (Thomsen, C. (244) 187)

ACPD ((1S,3R)-1-aminocyclopentane-1,3-dicarboxylate) antagonists; Phenylglycine derivatives (Eaton, S.A. (244) 195)

Quisqualate; Dicarboxycyclopropylglycine; (Hippocampal slices) (Nicoletti, F. (245) 297)

4-Carboxy-3-hydroxyphenylglycine; (1S,3R)-1-aminocyclopentane-1,3-dicarboxylate (t-ACPD) (Thomsen, C. (245) 299)

**Metabotropic receptor**
Long-term potentiation; Arachidonic acid (Collins, D.R. (240) 325)

**Metalloproteinase**
Endothelin-3; Big endothelin-3; Hypertensive effect; Phosphoramidon; (Conversion) (Matsumura, Y. (230) 89)

**Metformin**
Zucker rat; Genetic obesity; Brown adipose tissue; Thermogenesis; Uncoupling protein (Rouru, J. (246) 67)

**Methacholine**
$\beta_2$-Adrenoceptor agonists; Albuterol; Asthma; (Rabbit) (Witt-Enderby, P.A. (241) 121)

**Methadone**
Dentate gyrus; Field potentials; Long-term potentiation; NMDA receptors; Dextromethorphan; Codeine; Normethadone; MK-801 (Krug, M. (231) 355)

**Methamphetamine**
$\sigma$ Receptors; Psychosis (Itzhak, Y. (230) 243)

MK-801; Ketamine; Ceruletide; Cholecystokinin-like decapeptide; Dopamine release; Avoidance behaviour (Kuribara, H. (231) 7)

Locomotion; Sensitization; Cycloheximide; (Mouse) (Shimosato, K. (234) 67)

Microdialysis; 4-PTIQ (4-phenyltetrahydroisoquinoline); Cocaine; Nomifensine; Dopamine; Nucleus accumbens (Tateyama, M. (240) 51)

Prefrontal cortex; Dendritic spine density; Reactive synaptogenesis; (Gerbil) (Dawirs, R.R. (241) 89)

(+)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; (−)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; Cocaine; Nomifensine; Anococcygeus muscle (rat) (Watanabe, H. (243) 155)

**Methimazole administration (repeated)**
L-Thyroxine administration (repeated); Plasma endothelin concentration; Endothelin mechanisms; Cerebral cortex; Hypothalamus; Pituitary (Rebello, S. (237) 9)

**Methionine sulfoximine**
Dorsal raphe nucleus; Hypothermia; 5-HT receptors; GABA (γ-aminobutyric acid); GABA receptors (Ginefri-Gayet, M. (235) 189)

**Methotrexate**
Glutamate; MK-801; Memantine; Carboxypeptidase; Neurotoxicity (Weller, M. (248) 303)

**3-Methoxytyramine**
Neuroleptics; Dopamine release; Dopamine metabolism; Striatum; Nucleus accumbens; Frontal cortex; Depolarization block; (Rat) (Chrapusta, S.J. (233) 135)

**Methylcarbamate insecticides**
Noncholinergic actions; Organophosphorous insecticides; Kynurenine formamidase inhibition; Xanthurenic acid (urinary excretion); Plasma L-kynurenine; (Structural requirements) (Pewnim, T. (248) 237)

**α-Methyl-4-carboxyphenylglycine**
Long-term depression; Long-term potentiation; Glutamate metabotropic receptors (Bashir, Z.I. (239) 265)

**Methylcobalamin**
Cerebral cortex; Glutamate; Nitric oxide (NO); NMDA (N-methyl-D-aspartate); Vitamin $B_{12}$ (Akaike, A. (241) 1)

**Methylene blue**
Mesentery (rat); L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Diethyldithiocarbamate; CGRP (calcitonin gene-related peptide) (Li, Y.-j. (239) 127)

Mesentery (rat); Bradykinin; L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester); L-Arginine; Capsaicin-sensitive sensory nerves (Yu, X.-j. (241) 35)

**$N^{\alpha}$-Methylhistamine**
(R)αMethylhistamine; Histamine; Intestinal transit; Histamine $H_1$ receptors; Histamine $H_3$ receptors (Oishi, R. (237) 155)

**(R)-α-Methylhistamine**
Histamine $H_3$ receptors; Thioperamide; Water consumption; (Rat) (Clapham, J. (232) 99)

Histamine; Histamine $H_3$ receptor antagonists; Thioperamide; Convulsions (electrically induced) (Yokoyama, H. (234) 129)

$N^{\alpha}$-Methylhistamine; Histamine; Intestinal transit; Histamine $H_1$ receptors; Histamine $H_3$ receptors (Oishi, R. (237) 155)

**α-Methyl-5-hydroxytryptamine**
5-HT (5-hydroxytryptamine, serotonin); Bronchi (rat); 5-$HT_2$ receptors; Ketanserin; Mianserin; Spiperone; Electrical field stimulation; Cholinergic nerves (Szarek, J.L. (231) 339)

**[$^3$H]N-Methylscopolamine binding**
Muscarinic $M_3$ receptors; HSDM1C1 cells; Phosphoinositide metabolism (Eglen, R.M. (244) 49)

**p-Methylthioamphetamine**
p-Chloroamphetamine; Drug discrimination; Uptake inhibition; Superfusion; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain slices (Huang, X. (229) 31)

**α-Methyltyrosine + reserpine**
Dopamine; Acetylcholine; Microdialysis; Cocaine; (−)-Sulpiride; SCH 23390 (Imperato, A. (229) 265)

**$Mg^{2+}$**
Dihydropyridines; 5-HT (5-hydroxytryptamine, serotonin); Prostaglandin $F_{2\alpha}$; Cerebral vasospasm; (Human) (Alborch, E. (229) 83)

Excitotoxicity; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Hippocampus; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

Neuromuscular junction; Transmitter release (Pearson, H.A. (236) 323)

Adenosine $A_2$ receptors; Dopamine $D_2$ receptors; CGS 21680; Gpp(NH)p; GDP-β-S; Neostriatum; (Rat) (Ferré, S. (244) 311)

[$^3$H]Spiperone; Dopamine $D_2$ receptors; Affinity state; Dorsal hippocampus; Ventral hippocampus; Striatum; GTP; Iron-chelator (Bruinink, A. (245) 157)

Sulphonylureas; $K_{ATP}$ channels (Lee, K. (247) 347)

Ethanol; Cerebral arteries; $Ca^{2+}$; (Dog); (Sheep); (Piglet); (Baboon) (Zhang, A. (248) 229)

**$Mg^{2+}$ (cytosolic, free)**
Cocaine strokes; Mag-fura-2 (Altura, B.M. (246) 299)

**$Mg^{2+}$**
NMDA receptor coupled ion channel; Glutamate; Glycine (Von Euler, G. (245) 233)

**MHPG (3-methoxy-4-hydroxyphenylglycol)**
Desipramine; Desmethylclomipramine; Clonidine; Norepinephrine (Fujita, K. (242) 301)

**Mianserin**
5-HT (5-hydroxytryptamine, serotonin); α-Methyl-5-hydroxytryptamine; Bronchi (rat); 5-$HT_2$ receptors; Ketanserin; Spiperone; Electrical field stimulation; Cholinergic nerves (Szarek, J.L. (231) 339)

**Microcirculation**
5-HT (5-hydroxytryptamine, serotonin); EDRF (endothelium-derived relaxing factor); Arterioles; Nitric oxide (NO); $N^G$-Nitro-L-arginine (Alsip, N.L. (229) 117)

Inflammation; Adherence; Neutrophils; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

Big endothelin-1; Big endothelin-3; Phosphoramidon; Cheek pouch (hamster); Skin blood flow (rat) (Lawrence, E. (233) 243)

**Microdialysis**
Dopamine; Acetylcholine; Cocaine; α-Methyltyrosine + reserpine; (−)-Sulpiride; SCH 23390 (Imperato, A. (229) 265)

γ-Vinyl GABA; GABA release (Jolkkonen, J. (229) 269)

Morphine; Mesolimbic dopamine; 5-$HT_3$ receptor antagonists (Pei, Q. (230) 63)

Neurotensin; CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Dopamine $D_2$ receptors; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

Ceruletide; Amphetamine; Hyperlocomotion; Stereotypy; (Rat) (Kihara, T. (230) 271)

Dopamine; Ethanol reinforcement; Tolerance (Rossetti, Z.L. (231) 203)

σ Receptor ligands; Dopamine; Vacuous chewing; DTG (1,3-di-o-tolylguanidine); (+)-Pentazocine (Patrick, S.L. (231) 243)

JTP-2942 ($N^a$-[(1S,2R)-2-methyl-4-oxycyclopentanecarbonyl]-L-histidyl-L-prolinamide); TRH (thyrotropin-releasing hormone); Acetylcholine; Choline; Frontal cortex; Hippocampus (Toide, K. (233) 21)

Isradipine; Cerebral ischemia; Dopamine; $Ca^{2+}$ channels (voltage-sensitive) (Ooboshi, H. (233) 165)

Carbamazepine; Cocaine; Dopamine; Nucleus accumbens; (Rat) (Baptista, T. (236) 39)

Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; Prefrontal cortex; (Rat) (Saṇtiago, M. (239) 83)

WAY100135; 5-$HT_{1A}$ receptor antagonists; Hippocampal 5-HT (5-hydroxytryptamine, serotonin) release (Routledge, C. (239) 195)

Anxiolytics; Dorsal raphe nucleus; Electrophysiology; Hippocampus; Ipsapirone; Serotonergic neurotransmission; 5-$HT_{1A}$ receptors; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

4-PTIQ (4-phenyltetrahydroisoquinoline); Cocaine; Nomifensine; Methamphetamine; Dopamine; Nucleus accumbens (Tateyama, M. (240) 51)

Prefrontal cortex; Dopamine; Schizophrenia; Amperozide; Clozapine (Pehek, E.A. (240) 107)

Galanin receptor antagonists; M15; M35; Receptor binding; Striatum (Ögren, S.O. (242) 59)

Dopamine; Dopamine release; Dopamine autoreceptors; Dopamine $D_3$ receptors; (Rat) (Waters, N. (242) 151)

Behavioural despair; Imipramine; Depression (Rossetti, Z.L. (242) 313)

Dopamine; Opioid; μ-Opioid receptors; GABA (γ-aminobutyric acid); Ventral tegmental area; Nucleus accumbens (Devine, D.P. (243) 55)

**Microdialysis (in vivo)**
5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Frontal cortex (Bel, N. (229) 101)

5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Frontal cortex (Bel, N. (232) 326)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; 5-HT release; 5-$HT_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

Anxiety; Buspirone; Chronic treatment; 5-HT (5-hydroxytryptamine, serotonin); 5-HT release; 5-$HT_{1A}$ receptors; (Rat) (Söderpalm, B. (239) 69)

**Microperfusion study**
M17055; Loop diuretics; Thiazide diuretics; Amiloride; Free water clearance; Distal nephron segments (Shinkawa, T. (238) 317)

**Microsphere embolism**
Naftidrofuryl oxalate; Tricarboxylic acid cycle; Triphenyltetrazolium chloride (Miyake, K. (235) 75)

**Microtubules**
Colchicine; Vinblastine; Blood $Ca^{2+}$; Bone cells (Ohya, K. (248) 111)

**Middle cerebral artery**
Almitrine; Raubasine; Ischemia; Penumbra; (Cat) (Chan, P. (231) 175)

**Middle cerebral artery occlusion**
Endothelin-1; Ischemia; Hypoxia; Cultured neurons; (Mouse) (Nikolov, R. (248) 205)

**Migraine**
5-HT (5-hydroxytryptamine, serotonin); $5\text{-HT}_{1D}$ receptors; Cerebral vasoconstriction; $5\text{-HT}_1$ receptor subtypes; Cerebral blood vessels (Hamel, E. (242) 75)

**Migraine model**
$NK_1$ receptor antagonist (non-peptide); Dura mater; Neurogenic inflammation; Substance P (Moussaoui, S.M. (238) 421)

**Migration**
Interleukin-8; Chemotaxis; Smooth muscle cell; Atherosclerosis (Yue, T.-L. (240) 81)

Neutrophils (electroporated); cGMP; cAMP; Chemokinesis (Elferink, J.G.R. (246) 157)

**Milacemide**
Amino acids; Monoamine metabolites; Taurine; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

**Milrinone**
Platelets; Phosphodiesterase; Thromboxane $A_2$ (Jeremy, J.Y. (245) 67)

**Mineralocorticoid receptor**
Glucocorticoid receptor; Steroid hormones; Receptor binding; Localization; Trans-activation (Rupprecht, R. (247) 145)

**[Ser$^2$]MIP (Gly-Ser-Pro-Met-Phe-Val-$NH_2$)**
Achatin-I; D-Amino acid residue; Oxytocin, APGW-amide (Ala-Pro-Gly-Trp-$NH_2$), FMRFamide (Phe-Met-Arg-Phe-$NH_2$); Modulatory effects; Voltage clamp; Neurons; (Snail) (Liu, G.J. (240) 139)

**Mitochondrial ATPase**
Amiodarone; Antiarrhythmic agents; Lactate dehydrogenase (Dzimiri, N. (242) 113)

**Mitogenesis**
Nipradilol; Guanylate cyclase (soluble); cGMP; Glomerular mesangial cells (Koya, D. (245) 79)

27-O-Caffeoyl myricerone (50-235); Endothelin receptor antagonist; Cytosolic free $Ca^{2+}$; Smooth muscle cell (aorta, rat); Girardi heart cell (human) (Mihara, S.-i. (246) 33)

**MK571**
Spleen (ferret); Leukotriene receptors; ICI 198615; SK&F 104353 (Gardiner, P.J. (238) 19)

**(+)-MK-801**
Ketamine; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

Ethanol; Tolerance; (Rat) (Wu, P.H. (231) 157)

HA-966; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

**MK-801**
Temperature dependence; Repetitive firing (sustained); $Na^+$-dependent action potentials; Neurons (cultured) (Wamil, A.W. (230) 263)

Ketamine; Methamphetamine; Ceruletide; Cholecystokinin-like decapeptide; Dopamine release; Avoidance behaviour (Kuribara, H. (231) 7)

Dentate gyrus; Field potentials; Long-term potentiation; NMDA receptors; Dextromethorphan; Methadone; Codeine; Normethadone (Krug, M. (231) 355)

Postischemic recovery; Postischemic survival; Ischemia (forebrain); (Mongolian gerbil) (Von Lubitz, D.K.J.E. (233) 95)

Epilepsy; NMDA (N-methyl-D-aspartate); Valproate; Behaviour; CGP 37849 (Löscher, W. (234) 237)

Aminophylline; Neurosensitization; Electroconvulsion; Diazepam; $Na^+$ valproate (Chakrabarti, A. (235) 133)

Hypoxia; Ischemia; Glutamate; Neurotoxicity; Cell culture; ES-242s (Nozawa, M. (236) 263)

NMDA (N-methyl-D-aspartate); LY274614; SCH23390; Clebopride; Catalepsy; Dopamine; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

Glutamate; Dopamine; Phencyclidine; Ipsapirone; 5-HT (5-hydroxytryptamine, serotonin) (Löscher, W. (242) 99)

Sensitization; NMDA receptors; Dopamine receptor agonists; Apomorphine (Druhan, J.P. (243) 73)

NMDA (N-methyl-D-aspartate); Polyamines (Marvizón, J.-C. (244) 103)

NMDA receptors; Glutamate; Proenkephalin mRNA; Striatum; Accumbens (Angulo, J.A. (244) 317)

Scrapie; Cortical cells; Memantine; NMDA receptor; Neurons; Prion; Adamantanes (Müller, W.E.G. (246) 261)

Methotrexate; Glutamate; Memantine; Carboxypeptidase; Neurotoxicity (Weller, M. (248) 303)

**MMAI (5-methoxy-6-methyl-2-aminoindan)**
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; $5\text{-HT}_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine (Huang, X. (238) 291)

**$Mn^{2+}$**
Aminoglycoside; Membrane permeability; Calcein; $Ca^{2+}$; Conformational analysis (Van Bambeke, F. (247) 155)

**Modulatory effects**
Achatin-I; D-Amino acid residue; Molluscan peptide; 5-HT (5-hydroxytryptamine, serotonin); Voltage clamp; Neurons; (Snail) (Jun Liu, G. (231) 259)

Achatin-I; D-Amino acid residue; Oxytocin, APGW-amide (Ala-Pro-Gly-Trp-$NH_2$), FMRFamide (Phe-Met-Arg-Phe-$NH_2$); [Ser$^2$]MIP (Gly-Ser-Pro-Met-Phe-Val-$NH_2$); Voltage clamp; Neurons; (Snail) (Liu, G.J. (240) 139)

**ω Modulatory site**
$GABA_A$ receptors; [$^3$H]Flumazenil; Zolpidem; Alpidem (Faure-Halley, C. (246) 283)

**Molecular modelling**
Neurotransmitter transport; Transport pharmacophore; Specific serotonin transport inhibitors (Chang, A.S.-S. (247) 239)

**Molluscan peptide**
Achatin-I; D-Amino acid residue; 5-HT (5-hydroxytryptamine, serotonin); Modulatory effects; Voltage clamp; Neurons; (Snail) (Jun Liu, G. (231) 259)

**Monkey**
Factor VIII; Antidiuretic activity; Vasopressin analogues (Vilhardt, H. (232) 223)

**Monoamine metabolites**
Milacemide; Amino acids; Taurine; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

**Monoamine oxidase activity**
Islets of Langerhans; α-Adrenoceptor stimulation; β-Adrenoceptor stimulation; Cholinergic stimulation; Insulin; Glucose; (Mouse) (Panagiotidis, G. (233) 285)

**Monoamine oxidase inhibitors**
σ Receptors; NMDA (N-methyl-D-aspartate); Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor (selective) (Bergeron, R. (240) 319)

[$^3$H]Quinpirole; Receptor binding; Striatum; CNS (central nervous system); (Rat) (Levant, B. (246) 171)

**Monoclonal antibodies**
Angiotensin II; Angiotensin receptors; Angiotensin receptor antagonists (Bensoussan, M. (247) 169)

NMDA receptors; Phencyclidine; Drug design (Casalotti, S.O. (247) 209)

**$N^G$-Monomethyl-L-arginine**
Aprikalim; Cheek pouch arterioles; Vasodilatation, BRL 38227; Nitric oxide (NO); (Hamster) (Mayhan, W.G. (242) 109)

Ricinoleic acid; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester); L-Arginine; Tetrodotoxin; Ileum; (Rat) (Izzo, A.A. (243) 87)

**Monosynaptic reflex**
$GABA_B$ receptor antagonists; Spinal cord; Baclofen; (In vitro) (Brugger, F. (235) 153)

**Morphine**
DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); Naloxone; Naloxonazine; β-Funaltrexamine; Nor-binaltorphimine; ICI 174,864; Substance P; Trigeminal nucleus caudalis (Suarez-Roca, H. (229) 1)

Indomethacin; Naloxone; NANC (non-adrenergic, non-cholinergic); Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

Mesolimbic dopamine; $5\text{-HT}_3$ receptor antagonists; Microdialysis (Pei, Q. (230) 63)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Conditioned place preference; Naloxone; Addiction; (Mouse) (Noble, F. (230) 139)

U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

Pertussis toxin; Substance P; Quinpirole; Carbachol; U-50,488H (Bot, G. (231) 53)

Nitric oxide (NO); Morphine-induced locomotion; Food intake (Calignano, A. (231) 415)

$Ca^{2+}$ channels; Verapamil; Nimodipine; BAY k 8644; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Pain; Spinal cord; Descending inhibitory controls; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

κ-Opioid receptor antagonists; U50,488; Analgesia; Shock titration; Squirrel monkeys (Craft, R.M. (234) 199)

Naloxone; Formalin; Antinociception; Pronociception; (Rat) (Wheeler-Aceto, H. (236) 193)

F8Famide (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-$NH_2$); FMRFamide (Phe-Met-Arg-Phe-$NH_2$); Naloxone; Spinal antinociception (Gouardères, C. (237) 73)

Spinal cord; Nociception; C-fibre reflex (Strimbu-Gozariu, M. (237) 197)

Substance P; Nitric oxide (NO); Substance P receptor antagonists; β-Adrenoceptors (Persico, P. (238) 105)

Restraint stress; Analgesia; NECA (5′-(N-ethyl)carboxamido-adenosine); Caffeine; Opioids (Woolfolk, D.R. (239) 177)

Gliquidone; ATP-dependent $K^+$ channels; Locomotor activity (Ocaña, M. (239) 253)

CXBK mouse; Naltrexonazine; μ-Opioid receptor subtypes; Antitussive effect (Kamei, J. (240) 99)

Emesis; $5\text{-HT}_3$ receptor antagonists; (Ferret) (Wynn, R.L. (241) 47)

β-Endorphin; Tolerance; Cross-tolerance; Antinociception; Tail-flick inhibition; Hot-plate inhibition (Tseng, L.F. (241) 63)

Diuresis; ANF (atrial natriuretic factor) (Gutkowska, J. (242) 7)

Catalepsy; Pertussis toxin; Cholera toxin; cAMP levels (Massi, P. (243) 65)

**Morphine exposure (chronic)**
Tolerance; Dependence; G-proteins; Adenylyl cyclase activity; Striatal neurons (Van Vliet, B.J. (245) 23)

**Morphine-induced locomotion**
Nitric oxide (NO); Morphine; Food intake (Calignano, A. (231) 415)

**Morphine tolerance**
G protein expression; In situ hybridization histochemistry; Immunoblot analysis; Brain regions (Parolaro, D. (244) 211)

**Morphine withdrawal**
Dopamine release (striatal); Acetylcholine release (striatal) (Tjon Tien Ril, H.K.G. (235) 321)

Substance P; Substance P N-terminus; (Intrathecal) (Kreeger, J.S. (238) 111)

**Mortality**
Norbinaltorphimine; NMDA (N-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate); Convulsion (Shukla, V.K. (231) 293)

**Mossy fiber-CA3 pathway**
Hippocampus; Long-term potentiation; Cognitive enhancer; Somatostatin; Acetylcholine; FR121196; (Guinea-pig) (Matsuoka, N. (241) 27)

**Motility**
Clonazepam; CCK (cholecystokinin); Devazepide; L365-260; Duodenum; Jejunum (Bonnafous, C. (237) 237)

**Motor behaviour**
Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Monkey) (Vermeulen, R.J. (235) 143)

**Motor deficits**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Substantia nigra; Dopamine; Age; (Common marmoset) (Rose, S. (230) 177)

**Motor impairment**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Ethanol tolerance; Hypothermia; Learning (Khanna, J.M. (230) 23)

**Mouse**
Adenosine; Seizure; GABA (γ-aminobutyric acid); GABA/benzodiazepine receptor; Glutamate (Klitgaard, H. (242) 221)

**Mouse vas deferens**
Thermodynamics; δ-Opioid receptors; DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin) (Raffa, R.B. (244) 231)

**Movement**
Normetazocine; σ Receptors; Substantia nigra; Naloxone; Opiates (Walker, J.M. (231) 61)

Normetazocine; σ Receptors; Substantia nigra; Naloxone; Opiates (Walker, J.M. (236) 495)

**Movement disorders**
Dystonia; κ-Opioid receptors; σ Receptors; Naloxone; Naltrexone; Dopamine; Glutamate (Richter, A. (236) 289)

Glutamate; Glycine (Löscher, W. (239) 245)

Dystonia; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Glutamate (Richter, A. (242) 309)

**MPC-1304**
Stereoselectivity; $Ca^{2+}$ entry blocking activity; (Metabolites) (Okumura, K. (235) 69)

$Ca^{2+}$ channel antagonists; 1,4-Dihydropyridines; Vasodilating action (Miyoshi, K. (238) 139)

$Ca^{2+}$ entry blockers; α-Adrenoceptors; (Pithed rat) (Ichihara, K. (238) 283)

**$MPP^+$ (1-methyl-4-phenylpyridinium ion)**
l-Deprenyl (selegiline); Hydroxyl radical; Dopamine; MPTP neurotoxin; Substantia nigra; Parkinson's disease (Wu, R.-M. (243) 241)

**MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)**
Dopamine $D_1$ receptors; A-77636; Parkinsonism; A-77636 ((1R,3S)-3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride); (Marmoset) (Kebabian, J.W. (229) 203)

Substantia nigra; Motor deficits; Dopamine; Age; (Common marmoset) (Rose, S. (230) 177)

Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; Motor behaviour; Parkinson's disease; (Monkey) (Vermeulen, R.J. (235) 143)

Parkinson's disease; Locus coeruleus; Striatal dopamine; DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); C57Bl/6 mouse (Marien, M. (236) 487)

Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Bromocriptine; Dopamine $D_2$ receptor agonists; Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

**MPTP neurotoxin**
l-Deprenyl (selegiline); Hydroxyl radical; Dopamine; $MPP^+$ (1-methyl-4-phenylpyridinium ion); Substantia nigra; Parkinson's disease (Wu, R.-M. (243) 241)

**α-MSH (α-melanocyte-stimulating hormone)**
ACTH (adrenocorticotropic hormone); Behavioural state; Grooming; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

**$\gamma_2$-MSH ($\gamma_2$-melanocyte-stimulating hormone)**
ACTH-(4–10); Melanotropins; Hemodynamics; Urethane anesthesia; Pentobarbital anesthesia; Excitability; (Conscious rat) (De Wildt, D.J. (233) 157)

**Mucociliary activity**
Cilia; Maxillary sinus; Phosphoramidon; Tachykinins; Tachykinin receptors; (Rabbit) (Lindberg, S. (231) 375)

**Mucosa**
AIDS; Cytokine; T lymphocytes; Virus infection (Bourinbaiar, A.S. (230) 15)

5-HT (5-hydroxytryptamine, serotonin); Ion transport; Ileum; (Human) (Burleigh, D.E. (241) 125)

**Multidrug resistance**
Cancer chemotherapy; Cyclosporin A; FK506; P-glycoprotein; Rapamycin (Hoof, T. (246) 53)

Vincristine; Cellular pharmacokinetics (Domènech, C. (248) 49)

**Murine J774 macrophages**
Cloricromene; Endotoxin; Vascular reactivity; Nitric oxide synthase (Zingarelli, B. (243) 107)

**Muscarinic acetylcholine receptors**
Muscarinic receptor agonists; Muscarinic toxins; Memory (Jerusalinsky, D. (240) 103)

cAMP; Ethanol; $\alpha_2$-Adrenoceptor (Kim, W.-K. (247) 89)

**Muscarinic receptor**
Fluorescence microscopy of intracellular $Ca^{2+}$; Fura-2 fluorescence; $IP_3$-sensitive $Ca^{2+}$ store; Caffeine-sensitive $Ca^{2+}$ store; Neurotransmitter receptor desensitization (Fohrman, E.B. (245) 263)

**Muscarinic $M_1$ receptor**
High voltage spindles; Slow wave; Muscarinic $M_2$ receptor; Physostigmine; Tetrahydroaminoacridine; Pilocarpine; AF102B; Oxotremorine (Riekkinen, Jr., P. (240) 1)

**Muscarinic $M_2$ receptor**
High voltage spindles; Slow wave; Muscarinic $M_1$ receptor; Physostigmine; Tetrahydroaminoacridine; Pilocarpine; AF102B; Oxotremorine (Riekkinen, Jr., P. (240) 1)

**Muscarinic receptor agonists**
Kidney (perfused, rat); Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Muscarinic acetylcholine receptors; Muscarinic toxins; Memory (Jerusalinsky, D. (240) 103)

**Muscarinic $M_1$ receptor agonists**
Muscarinic $M_1$ receptors; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

**Muscarinic $M_2$ receptor antagonists**
BIBN 99; Muscarinic receptors ($M_1$–$M_3$, m1–m5); AF-DX 116 (Doods, H. (242) 23)

**Muscarinic receptor antagonists**
Dequalinium; Sympathetic ganglia; Ganglion blockers; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

Cholinergic neurotransmission; Muscarinic $M_2$ receptors; Muscarinic $M_3$ receptors; Trachea (guinea-pig); Electrical field stimulation (Ten Berge, R.E.J. (233) 279)

Kidney (perfused, rat); Muscarinic receptor agonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Cerebral cortex; Cholinoceptor (Christopoulos, A. (246) 1)

Cerebral cortex; Cholinoceptor (Christopoulos, A. (247) 227)

**Muscarinic receptors**
$\alpha_2$-Adrenoceptors; $Ca^{2+}$ channels; Heterologous desensitization; GTP-binding proteins; ADP ribosylation (Nah, S.-Y. (244) 67)

Organophosphate pesticides; Development; Phosphoinositide hydrolysis; mRNA (Balduini, W. (248) 281)

**Muscarinic $M_1$ receptors**
Caramiphen; Iodocaramiphen; Nitrocaramiphen: Muscarinic receptor antagonists; (Rat) (Hudkins, R.L. (231) 485)

Muscarinic $M_1$ receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

**Muscarinic $M_2$ receptors**
Cholinergic neurotransmission; Muscarinic $M_3$ receptors; Trachea (guinea-pig); Muscarinic receptor antagonists; Electrical field stimulation (Ten Berge, R.E.J. (233) 279)

**Muscarinic $M_3$ receptors**
Cholinergic neurotransmission; Muscarinic $M_2$ receptors; Trachea (guinea-pig); Muscarinic receptor antagonists; Electrical field stimulation (Ten Berge, R.E.J. (233) 279)

HSDM1C1 cells; [$^3$H]N-Methylscopolamine binding; Phosphoinositide metabolism (Eglen, R.M. (244) 49)

**Muscarinic receptors ($M_1$–$M_3$, m1–m5)**
BIBN 99; Muscarinic $M_2$ receptor antagonist; AF-DX 116 (Doods, H. (242) 23)

**Muscarinic receptor subtypes**
Inositol phosphate turnover; Carbachol (Garcia Ruiz, A.J. (244) 125)

**Muscarinic receptor subtypes (agonist binding)**
Kidney (rat); Amiloride (Blankesteijn, W.M. (244) 21)

**Muscarinic toxins**
Muscarinic acetylcholine receptors; Muscarinic receptor agonists; Memory (Jerusalinsky, D. (240) 103)

**Muscimol**
Development; Ethanol; Flunitrazepam; $GABA_A$ receptors; Ro 15-4513 (Taira, T. (230) 307)

**[$^3$H]Muscimol binding**
Ergot alkaloids; Anticonflict activity; Brain (human, post-mortem); (Rat) (Peričić, D. (235) 267)

**Muscle paralysis**
Diazepam; Anticholinesterase; Neostigmine; Neuromuscular transmission (Chiou, L.C. (248) 185)

**Muscle relaxation**
NMDA receptor antagonists; Learning/memory; Circling behaviour; (Rat) (Murata, S. (239) 9)

**Musk ambrette**
Cytochrome P450 1A2; Musk xylene; Liver (rat); Enzyme induction (Iwata, N. (248) 243)

**Musk xylene**
Cytochrome P450 1A2; Musk ambrette; Liver (rat); Enzyme induction (Iwata, N. (248) 243)

**Mustard oil**
Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

***M. velutina* compounds**
Paw oedema (rat); Phospholipase $A_2$; Phospholipase C; Anti-inflammatory drugs (Neves, P.C.A. (243) 213)

**Myeloperoxidase**
Myocardial infarction; Complement receptors; Neutrophils (Smith III, E.F. (236) 477)

**Myenteric neurons**
Adenosine; Capsaicin; Extrinsic sensory nerves (Takaki, M. (237) 51)

**Myenteric plexus**
Intestine; Ganglia; Enteric nervous system; Substance P; Tachykinins (Tamura, K. (232) 235)

OP-41483 (prostacyclin analog); Acetylcholine release; Prostaglandin release (Fukunaga, Y. (233) 237)

5-Lipoxygenase; Acetylcholine release; Leukotriene $D_4$ (Yoshikawa, S. (239) 261)

**Myocardial infarction**
$Ca^{2+}$ channel antagonists; Ventricular fibrillation; Myocardial ischemia; Cardiac arrhythmias (Billman, G.E. (229) 179)

Angiotensin-converting enzyme inhibition; Angiotensin; Myocardial ischemia (Hartman, J.C. (234) 229)

Complement receptors; Neutrophils; Myeloperoxidase (Smith III, E.F. (236) 477)

**Myocardial ischemia**
$Ca^{2+}$ channel antagonists; Ventricular fibrillation; Myocardial infarction; Cardiac arrhythmias (Billman, G.E. (229) 179)

KRN2391; Cromakalim; Heart (isolated, rat); Energy metabolism (Ohta, H. (231) 323)

Angiotensin-converting enzyme inhibition; Angiotensin; Myocardial infarction (Hartman, J.C. (234) 229)

NADH fluorescence; Angiotensin; Angiotensin-converting enzyme; Angiotensin-converting enzyme inhibitors; Ramiprilat; Cardioprotection (Rump, A.F.E. (241) 201)

**Myocardial ischemia-reperfusion**
$\alpha$-Tocopherol analogue (MDL 73404); Free radical scavenger; Reperfusion injury; Contractility; Lipid peroxidation (Lukovic, L. (233) 63)

**Myocytes (embryonic chick heart)**
Hyperpolarization-activated inward current; Pacemaker current; Automaticity; Autonomic agents; Acetylcholine; Isoproterenol (Satoh, H. (240) 283)

**Myocytes (rat ventricular)**
Whole cell clamping; Caffeine; Depolarization-activated, $Ca^{2+}$-independent outward currents (Sanchez-Chapula, J. (229) 163)

**Myometrium**
Cervical smooth muscle; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Pregnancy; Electrical field stimulation (Okawa, T. (230) 341)

Steroids; Uterine artery; Estrogen; Progesterone; Diethylstilbestrol (Kostrzewska, A. (233) 127)

**Myotonic depression**
Chlorpromazine; Soleus muscle; Extensor digitorum longus muscle (Liu, S.-H. (231) 23)

**$Na^+/Ca^{2+}$ overload blockade**
Ouabain; Arrhythmias; (Guinea-pig) (Lu, H.R. (235) 89)

**$Na^+$ channel blocking agents**
Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; $Ca^{2+}$ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

**$Na^+$-dependent action potentials**
Temperature dependence; MK-801; Repetitive firing (sustained); Neurons (cultured) (Wamil, A.W. (230) 263)

**NADH fluorescence**
Angiotensin; Angiotensin-converting enzyme; Myocardial ischemia; Angiotensin-converting enzyme inhibitors; Ramiprilat; Cardioprotection (Rump, A.F.E. (241) 201)

**NADPH diaphorase**
Insulin release; NO synthase inhibition; Arginine (Panagiotidis, G. (229) 277)

Nitro blue tetrazolium; Haemodynamics; (Rat) (Davisson, R.L. (241) 135)

**(S)-Nafenodone**
Aorta (rat); $^{45}Ca^{2+}$ movements; Antidepressants (Pérez-Vizcaíno, F. (232) 105)

**Naftidrofuryl oxalate**
Microsphere embolism; Tricarboxylic acid cycle; Triphenyltetrazolium chloride (Miyake, K. (235) 75)

**$Na^+$-$H^+$ exchanger**
Gastric acid secretion; DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid); Amiloride; $Cl^-$-$HCO_3^-$ exchanger; Stomach (isolated); (Rat) (Horie, S. (229) 15)

pH (intracellular); Cell volume; *Ras* oncogene; cell proliferation; HOE 694 (Wöll, E. (246) 269)

**$Na^+$,$K^+$-ATPase**
GM1 ganglioside; Hypoxia-reoxygenation; Noradrenaline (Lodovici, M. (243) 255)

**$Na^+$,$K^+$-ATPase inhibition**
Bufodienolides; Vasoconstriction (Bagrov, A.Y. (234) 165)

**$Na^+$,$K^+$-ATPase pump**
Cromakalim; $K^+$ channels; Smooth muscle (vascular) (Hong, K.W. (231) 1)

**$Na^+$,$K^+$ pump current**
Toad venom; Bufadienolide; Arenobufagin (Cruz, J.d.S. (239) 223)

**Naloxonazine**
DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); Morphine; Naloxone; Norbinaltorphimine; ICI 174,864; Substance P; Trigeminal nucleus caudalis (Suarez-Roca, H. (229) 1)

Fetal breathing; Opiates; $\delta$-Opioid receptors; [D-Ala$^2$]deltorphin; Naltrindole (Cheng, P.Y. (230) 85)

**Naloxone**
DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); Morphine; Naloxonazine, $\beta$-Funaltrexamine; Nor-binaltorphimine; ICI 174,864; Substance P; Trigeminal nucleus caudalis (Suarez-Roca, H. (229) 1)

Indomethacin; Morphine; NANC (non-adrenergic, non-cholinergic); Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Conditioned place preference; Addiction; (Mouse) (Noble, F. (230) 139)

Normetazocine; $\sigma$ Receptors; Substantia nigra; Movement; Opiates (Walker, J.M. (231) 61)

CCK receptor antagonists; CCK-8 immunoreactivity; $CCK_B$ receptors; Opiate analgesia (Zhou, Y. (234) 147)

Opioid receptors; Naltrindole; DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); DADLE ([D-Ala$^2$,D-Leu$^5$]enkephalin) (Tiseo, P.J. (236) 89)

Morphine; Formalin; Antinociception; Pronociception; (Rat) (Wheeler-Aceto, H. (236) 193)

Dystonia; κ-Opioid receptors; σ Receptors; Naltrexone; Movement disorders; Dopamine; Glutamate (Richter, A. (236) 289)

Normetazocine; σ Receptors; Substantia nigra; Movement; Opiates (Walker, J.M. (236) 495)

F8Famide (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-$NH_2$); FMRFamide (Phe-Met-Arg-Phe-$NH_2$); Morphine; Spinal antinociception (Gouardères, C. (237) 73)

U50,488H; Nor-binaltorphimine; Opioid withdrawal; Locomotor activity; (Guinea-pig) (Brent, P.J. (241) 149)

**Naloxone-precipitated withdrawal**
Nor-binaltorphimine; κ-Opioid receptors; Butorphanol dependence (Jaw, S.P. (239) 133)

Naltrindole; δ-Opioid receptor; Supraspinal δ-opioid receptor; Butorphanol dependence (Jaw, S.P. (240) 67)

**Naltrexonazine**
CXBK mouse; Morphine; μ-Opioid receptor subtypes; Antitussive effect (Kamei, J. (240) 99)

**Naltrexone**
Dystonia; κ-Opioid receptors; σ Receptors; Naloxone; Movement disorders; Dopamine; Glutamate (Richter, A. (236) 289)

**Naltriben**
[$Leu^5$]enkephalin; [$Met^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Spinal cord; Brain; β-Endorphin (Takemori, A.E. (242) 145)

**Naltrindole**
Fetal breathing; Opiates; δ-Opioid receptors; [D-$Ala^2$]deltorphin; Naloxonazine (Cheng, P.Y. (230) 85)

Cocaine; [D-$Pen^2$,L-$Pen^5$]enkephalin (Ukai, M. (231) 143)

δ-Opioid receptor subtypes; [D-$Ala^2$]deltorphin II; [D-$Pen^2$,D-$Pen^5$]enkephalin; Benzofuran analogue of naltrindole; Antitussive activity (Kamei, J. (234) 117)

Opioid receptors; Naloxone; DPDPE ([D-$Pen^2$,D-$Pen^5$]enkephalin); DADLE ([D-$Ala^2$,D-$Leu^5$]enkephalin) (Tiseo, P.J. (236) 89)

δ-Opioid receptor; Supraspinal δ-opioid receptor; Naloxone-precipitated withdrawal; Butorphanol dependence (Jaw, S.P. (240) 67)

Cocaine; Sensitization; Locomotor activity; Opioids (Heidbreder, C. (243) 123)

**L-NAME ($N^{\omega}$-nitro-L-arginine methyl ester)**
Mesentery (rat); L-Arginine; Methylene blue; Diethyldithiocarbamate; CGRP (calcitonin gene-related peptide) (Li, Y.-j. (239) 127)

Mesentery (rat); Bradykinin; L-Arginine; Methylene blue; Capsaicin-sensitive sensory nerves (Yu, X.-j. (241) 35)

**L-NAME ($N^G$-nitro-L-arginine methyl ester)**
EDRF (endothelium-derived relaxing factor); Intravascular ultrasound; Vasomotion (Schwarzacher, S. (229) 253)

Nitric oxide (NO); Intestinal motility; Cholinergic mechanisms (Calignano, A. (229) 273)

Nitric oxide (NO); NO synthase inhibitors; $HCO_3^-$ secretion; Duodenum (rat) (Takeuchi, K. (231) 135)

Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO) (Lippe, I.T. (232) 113)

Peptides; Angiotensin-(1–7); Angiotensin receptors; DuP 753; Nitric oxide synthase (Osei, S.Y. (234) 35)

Gastric cytoprotection; L-Arginine; Nitric oxide (NO); RX 77368; Vagus (Király, Á. (240) 299)

Ricinoleic acid; Nitric oxide (NO); $N^G$-Monomethyl-L-arginine; L-Arginine; Tetrodotoxin; Ileum; (Rat) (Izzo, A.A. (243) 87)

**NAN-190**
5-HT (5-hydroxytryptamine, serotonin); RU 24969; TFMPP (trifluoromethylphenylpiperazine); mCPP (m-chlorophenylpiperazine); 5-HIAA (CSF levels); $5\text{-}HT_1$ receptor binding (in vitro); (Pigeon) (Gleeson, S. (229) 109)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptors; Raphe; S 15535; BMY 7378; Spiperone (Millan, M.J. (230) 99)

SDZ 216-525; MDL 73005; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptors; $5\text{-}HT_{1B}$ receptors; $5\text{-}HT_{1C}$ receptors; $5\text{-}HT_{1D}$ receptors (Schoeffter, P. (244) 251)

Nitric oxide (NO); Cholecystokinin; Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)

**NANC (non-adrenergic, non-cholinergic)**
Indomethacin; Morphine; Naloxone; Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

Tachykinins; Ileum (guinea-pig); Circular muscle; ω-Conotoxin; Nitric oxide (NO); Apamin; NANC relaxation (Maggi, C.A. (240) 45)

**NANC relaxation**
Urethra (dog); Nitric oxide (NO) synthase inhibitor; VIP receptor antagonists (Hashimoto, S. (231) 209)

Tachykinins; Ileum (guinea-pig); Circular muscle; ω-Conotoxin; Nitric oxide (NO); Apamin; NANC (non-adrenergic, non-cholinergic) (Maggi, C.A. (240) 45)

**NANC transmission**
Nitric oxide (NO); Stomach (rat) (Shimamura, K. (231) 103)

**$Na^+$ restriction**
$Li^+$ reabsorption; Amiloride; $Li^+$ clearance (Shalmi, M. (230) 33)

**Natriuretic peptide receptors**
Autoradiography; Cerebral cortex; Development (Zorad, S. (241) 195)

**$Na^+$ valproate**
Aminophylline; Neurosensitization; Electroconvulsion; Diazepam; MK-801 (Chakrabarti, A. (235) 133)

**NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline)**
DBA/2 mice; Aniracetam; AMPA receptor antagonists; GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine · HCl); CPPene (D(−)-(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid) (Chapman, A.G. (231) 301)

Cerebral ischaemia; AMPA receptors; NMDA receptors; NMDA receptor antagonists; Glutamate (Sheardown, M.J. (236) 347)

Excitatory amino acids; Glutamate; Metabotropic; Phosphoinositide hydrolysis (Suzdak, P.D. (245) 215)

**NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (1H,4H)dione sodium salt)**
AMPA receptors; Parkinsonism; Dyskinesia; Dopamine receptor agonists (Luquin, M.R. (235) 297)

**NECA (5′-(N-ethyl)carboxamido-adenosine)**
Restraint stress; Analgesia; Morphine; Caffeine; Opioids (Woolfolk, D.R. (239) 177)

**N1E-115 neuroblastoma**
5-$HT_3$ receptor; 5-HT (5-hydroxytryptamine, serotonin); Tetraethylammonium; Whole-cell voltage clamp; Ion channel; Desensitization (Kooyman, A.R. (246) 247)

**N1E-115 neuroblastoma cell**
5-$HT_3$ receptor; Cloned 5-$HT_3$ receptor subunit; *Xenopus* oocyte expression system (Hope, A.G. (245) 187)

**Neoantigens**
Halothane; Trifluoroacetylated proteins (Heijink, E. (248) 15)

**Neocortex**
Acamprosate (calciumacetylhomotaurinate); Excitatory amino acids; GABA (γ-aminobutyric acid); Postsynaptic potentials; Neurotransmission (Zeise, M.L. (231) 47)

Epileptiform activity; cAMP; Forskolin (Boulton, C.L. (236) 131)

**Neomycin**
Dihydropyridine drugs; $Ca^{2+}$ influx; $Ca^{2+}$ (intracellular); Catecholamine release; Adrenal medulla chromaffin cells (Duarte, C.B. (244) 259)

Gadolinium; Nimodipine; Verapamil; Voltage-sensitive $Ca^{2+}$ channels; Brain synaptosomes (Canzoniero, L.M.T. (245) 97)

**Neonatal**
8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Long-term treatment; Ultrasonic calls; (Rat pup) (Johansson-Wallsten, C.E. (243) 149)

**Neonatal treatment**
Capsaicin; Bronchial hyperresponsiveness; Allergen (Riccio, M.M. (232) 89)

**Neostigmine**
$\alpha_2$-Adrenoceptors; [$^3$H]Clonidine; [$^3$H]UK 14,304 (bromoxidine); [$^3$H]RX 821002 (2-methoxy idazoxan); Physostigmine; Diisopropylfluorophosphate; Pilocarpine (Olmos, G. (236) 467)

Endothelin; Vein; Cholinergic innervation; Atropine; Embryology (Hayakawa, A. (239) 219)

Diazepam; Anticholinesterase; Neuromuscular transmission; Muscle paralysis (Chiou, L.C. (248) 185)

**Neostriatum**
Neurotensin; CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Dopamine $D_2$ receptors; Microdialysis; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

Neurotensin fragments; Dopamine $D_2$ receptors; Receptor-receptor interactions; (Rat) (Li, X.-M. (234) 125)

Adenosine $A_2$ receptors; Dopamine $D_2$ receptors; CGS 21680; Gpp(NH)p; GDP-β-S; $Mg^{2+}$; (Rat) (Ferré, S. (244) 311)

**Nephrosis**
Dup 753; Puromycin aminonucleoside (Yayama, K. (236) 337)

**Nerve cell cultures**
Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; $Ca^{2+}$ channel blocking agents; $Na^+$ channel blocking agents; Voltage clamp (Netzer, R. (238) 209)

**Nerve conduction**
Diabetes mellitus; Diabetic neuropathy; Inositol phosphates; myo-Inositol; Streptozotocin (Carrington, A.L. (237) 257)

**Nerve growth factor**
Propentofylline; Basal forebrain; Ibotenic acid; Choline acetyltransferase; Learning and memory (Fuji, K. (236) 411)

**Nerve injury**
Nociception; Noradrenaline; Analgesia; Neuropathic pain; Axotomy (Xu, X.-J. (235) 161)

**Nerve terminal regeneration**
Fenfluramine; Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

**Neuroactive steroids**
Behaviour; Drug discrimination; Benzodiazepines; Pentobarbital; Ethanol (Ator, N.A. (241) 237)

**Neuroblastoma**
5-$HT_3$ receptors; m-Chlorophenylbiguanide; Ligand-gated ion channel (Lummis, S.C.R. (243) 7)

**Neurochemical indices (ex vivo)**
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-$HT_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

**Neurodegeneration**
Excitotoxicity; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); $Mg^{2+}$; Hippocampus; Neuroprotection (Fischer, S. (232) 121)

Lithium chloride; Tacrine; Nitric oxide (NO); Epilepsy (Bagetta, G. (237) 61)

**Neuroeffector modulation**
Nitric oxide (NO); Cholinergic; Tachykinin; Smooth muscle; Chemiluminescence (Wiklund, C.U. (240) 235)

**Neurogenic inflammation**
Mustard oil; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Plasma protein extravasation; Dura mater; CGRP (calcitonin gene-related peptide); Tachykinin receptors (O'Shaughnessy, C.T. (236) 319)

$NK_1$, receptor antagonist (non-peptide); Dura mater; Migraine model; Substance P (Moussaoui, S.M. (238) 421)

Neuropeptides; Plasma extravasation (Morikawa, M. (241) 83)

Levodropropizine; Capsaicin; Substance P; Sensory nerves; Plasma extravasation (Yamawaki, I. (243) 1)

**Neurogenic plasma extravasation**
Opiate action (peripheral); C-fibre; Substance P; Inflammation (Barber, A. (236) 113)

**Neurogenic twitch contraction**
$\sigma$ Receptor ligands; Benzomorphan-type $\sigma$ receptor; ATP transmission; Vas deferens (mouse); Brain (guinea-pig); SK&F 10,047 (N-allylnormetazocine); Rimcazole; Haloperidol (Matsuno, K. (231) 451)

**Neurohumoral factors**
Heart failure (high-output); Laser-Doppler flowmetry; Renal blood flow; Thermodilution; Wistar rat (Oka, T. (234) 55)

**Neurokinin**
Medial habenula; Substance P; Tachykinin (Norris, S.K. (234) 223)

**Neurokinin A**
Tachykinin; Neurokinin receptor subtypes; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (232) 287)

Tachykinin; $NK_2$ receptors; Radioligand binding; Neuropeptide $\gamma$; Gastric fundus (rat) (Burcher, E. (233) 201)

Substance P; Adrenoceptors (Luo, L. (235) 157)

Substance P; Capsaicin; Airway constriction; Plasma extravasation (Murai, M. (236) 7)

Tachykinin; Neurokinin receptor subtypes; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (236) 496)

Lower esophageal sphincter; Tachykinins; Substance P; $NK_2$ receptors; (Human) (Huber, O. (239) 103)

$NK_2$ receptor antagonists; Substance P; $NK_1$ receptor antagonists; Capsaicin; Lung (guinea-pig) (Kudlacz, E.M. (241) 17)

Spinal cord; Substance P; Tachykinin receptors; Acetylcholine release; Polymerase chain reaction (Suzuki, H. (241) 105)

$NK_2$ receptors; Desensitization (Henderson, A.K. (245) 75)

**Neurokinin receptor agonists**
Substantia nigra; Intranigral infusion; Oral movements; (Rat) (Liminga, U. (235) 177)

**Neurokinin receptor antagonists**
$NK_1$ receptors; $NK_2$ receptors; Spinal cord; Nociception (Picard, P. (232) 255)

**Neurokinin receptor subtypes**
Tachykinin; Neurokinin A; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (232) 287)

Tachykinin; Neurokinin A; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (236) 496)

**Neurokinins**
Diabetes mellitus; Vascular permeability; Substance P; Nitric oxide (NO) (Mathison, R. (240) 163)

Tachykinins; Pain; Analgesia; Spinal cord (Fleetwood-Walker, S.M. (242) 173)

**Neuroleptics**
Glutamate; Dopamine; Nucleus accumbens; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

Raclopride; Cerebral glucose metabolism (regional); Benzamides (Tarazi, F.I. (232) 71)

Excitatory amino acids; Glutamate receptors; Parkinson's disease (Papa, S.M. (232) 247)

Dopamine release; Dopamine metabolism; 3-Methoxytyramine; Striatum; Nucleus accumbens; Frontal cortex; Depolarization block; (Rat) (Chrapusta, S.J. (233) 135)

Dopamine $D_2$ receptors; Antipsychotics; [$^3$H]YM-09151-2; Dopamine $D_2$ receptor binding; Biphasic displacement (Assié, M.-B. (237) 183)

Aromatic L-amino acid decarboxylase; Dopamine receptors; Striatum (Zhu, M.-Y. (238) 157)

**Neurological examination**
Cerebral ischemia (focal); Riluzole; Passive avoidance task; (Rat) (Wahl, F. (230) 209)

**Neuromedin B**
Gastrin-releasing peptide; Bombesin (Ladenheim, E.E. (235) 121)

Bombesin; Gastrin-releasing peptide; Bombesin receptors (Guard, S. (240) 177)

**Neuromodulation**
$\beta$-Alanine; Glycine receptor; $GABA_A$ receptor; Progesterone; 5$\alpha$-Pregnan-3$\alpha$-ol-20-one (5$\alpha$3$\alpha$) (Wu, F.-S. (246) 239)

**Neuromuscular junction**
Transmitter release; $Mg^{2+}$ (Pearson, H.A. (236) 323)

**Neuromuscular transmission**
Diazepam; Anticholinesterase; Neostigmine; Muscle paralysis (Chiou, L.C. (248) 185)

**Neuronal necrosis**
Nitric oxide (NO); Nitric oxide synthase; N$^{\omega}$-Nitro-L-arginine; Cerebral ischemia (Nagafuji, T. (248) 325)

**Neuronal uptake**
Fenfluramine; Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Synaptosomes (Westphalen, R.I. (238) 399)

**Neurons**
Achatin-I; D-Amino acid residue; Molluscan peptide; 5-HT (5-hydroxytryptamine, serotonin); Modulatory effects; Voltage clamp; (Snail) (Jun Liu, G. (231) 259)

Achatin-I; D-Amino acid residue; Oxytocin, APGW-amide (Ala-Pro-Gly-Trp-$NH_2$), FMRFamide (Phe-Met-Arg-Phe-$NH_2$); [$Ser^2$]MIP (Gly-Ser-Pro-Met-Phe-Val-$NH_2$); Modulatory effects; Voltage clamp; (Snail) (Liu, G.J. (240) 139)

Scrapie; Cortical cells; Memantine; NMDA receptor; Prion; Adamantanes; MK-801 (Müller, W.E.G. (246) 261)

**Neurons (cultured)**
Temperature dependence; MK-801; Repetitive firing (sustained); $Na^+$-dependent action potentials (Wamil, A.W. (230) 263)

**Neuropathic pain**
Nociception; Noradrenaline; Analgesia; Axotomy; Nerve injury (Xu, X.-J. (235) 161)

**Neuropeptide $\gamma$**
Tachykinin; $NK_2$ receptors; Radioligand binding; Neurokinin A; Gastric fundus (rat) (Burcher, E. (233) 201)

**Neuropeptides**
Neurogenic inflammation; Plasma extravasation (Morikawa, M. (241) 83)

**Neuropeptide Y**
$\sigma$ Receptors; CCK (cholecystokinin); Bicarbonate secretion; Duodenum; (Rat) (Pascaud, X.B. (231) 389)

Neuropeptide $Y_1$ receptors; Neuropeptide $Y_2$ receptors; Vascular neuropeptide Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

Nitric oxide (NO); Endotoxin shock; Pulmonary hypertension; Adult respiratory distress syndrome (ARDS); Endothelin; Noradrenaline (Weitzberg, E. (233) 85)

Somatostatin; l-DOPA (l-dihydroxyphenylalanine); Amantadine; 6-Hydroxydopamine; Bifemelane (Maeda, K. (233) 227)

Feeding behaviour; Genetic obesity; TFMPP (1-[3-(trifluoromethyl) phenyl]piperazine); Insulin; CRF (corticotropin-releasing factor); (Zucker rat) (Rouru, J. (234) 191)

Neuropeptide Y receptor sub-types; Truncated analogues; Structure-activity relationships; Binding assays; Bioassays (Dumont, Y. (238) 37)

Blood vessel (human); Antisense; Neuropeptide Y $Y_1$ receptor (Erlinge, D. (240) 77)

D-myo-Inositol 1,2,6-trisphosphate; Mesenteric circulation; Noradrenaline-induced vasoconstriction; $\alpha$-Trinositol (Donoso, M.V. (240) 93)

Peptide YY; Hippocampus (mouse); $\sigma$ Receptors (Roman, F.J. (242) 305)

Coronary arteries; Endothelin; Nitric oxide (NO); BQ-123; $ET_A$ receptor; $ET_B$ receptor (Pernow, J. (243) 281)

**Neuropeptide Y receptors**
Brain; Terminals; [$^3$H]noradrenaline release; (Rat) (Martire, M. (230) 231)

**Neuropeptide Y receptor subtypes**
Neuropeptide Y; Truncated analogues; Structure-activity relationships; Binding assays; Bioassays (Dumont, Y. (238) 37)

**Neuropeptide Y $Y_1$ receptors**
Neuropeptide Y; Neuropeptide $Y_2$ receptors; Vascular neuropeptide Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

Neuropeptide Y; Blood vessel (human); Antisense (Erlinge, D. (240) 77)

**Neuropeptide Y $Y_2$ receptors**
Neuropeptide Y; Neuropeptide $Y_1$ receptors; Vascular neuropeptide Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

**Neuroprotection**
Excitotoxicity; AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); $Mg^{2+}$; Hippocampus; Neurodegeneration (Fischer, S. (232) 121)

bFGF (basic fibroblast growth factor); NMDA (N-methyl-D-aspartate); Excitotoxicity (neonate) (Nozaki, K. (232) 295)

Taxol neuropathy; ORG 2766 (Hamers, F.P.T. (233) 177)

Cerebral ischaemia; Dizocilpine; Enadoline; Hypothermia (Hayward, N.J. (236) 247)

Ganglioside GM1; Glycosphingolipid derivatives; Excitotoxicity; Dopaminergic neurons; Parkinson's disease (Skaper, S.D. (243) 91)

**Neurosensitization**
Aminophylline; Electroconvulsion; Diazepam; MK-801; $Na^+$ valproate (Chakrabarti, A. (235) 133)

**Neurotensin**
CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Dopamine $D_2$ receptors; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

Xenopsin; Self-stimulation; Prefrontal cortex (Ferrer, J.M.R. (231) 39)

SR 31742A; $\sigma$ Receptor ligands; Antipsychotics (Labie, C. (231) 465)

Cholecystokinin; Dopamine; Reward; Ventral tegmental area (Rompré, P.-P. (232) 299)

Transfection; Promiscuous coupling; AMP formation (Yamada, M. (244) 99)

**Neurotensin fragments**
Dopamine $D_2$ receptors; Receptor-receptor interactions; Neostriatum; (Rat) (Li, X.-M. (234) 125)

**Neurotoxicity**
p-Chloroamphetamine; p-Methylthioamphetamine; Drug discrimination; Uptake inhibition; Superfusion; 5-HT (5-hydroxytryptamine, serotonin); Brain slices (Huang, X. (229) 31)

6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopamine (6-OHDA); Nomifensine; Desipramine (Evans, J. (232) 241)

Hypoxia; Ischemia; Glutamate; Cell culture; ES-242s; MK-801 (Nozawa, M. (236) 263)

Pentamidine; NMDA receptors (Reynolds, I.J. (244) 175)

NMDA receptor; $Pb^{2+}$; Brain (rat); (Age) (Guilarte, T.R. (248) 273)

Methotrexate; Glutamate; MK-801; Memantine; Carboxypeptidase (Weller, M. (248) 303)

**Neurotoxins**
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

**Neurotransmission**
Acamprosate (calciumacetylhomotaurinate); Excitatory amino acids; GABA (γ-aminobutyric acid); Neocortex; Postsynaptic potentials (Zeise, M.L. (231) 47)

Ro 31-6930; BRL 38227; Bronchoconstriction; Cholinergic (Gater, P.R. (238) 59)

**Neurotransmitter receptor desensitization**
Fluorescence microscopy of intracellular $Ca^{2+}$; Fura-2 fluorescence; Muscarinic receptor; $IP_3$-sensitive $Ca^{2+}$ store; Caffeine-sensitive $Ca^{2+}$ store (Fohrman, E.B. (245) 263)

**Neurotransmitter release**
ω-Conotoxin GVIA; $Ca^{2+}$ channels (voltage-sensitive); *Hololena curta* venom; Funnel web spider toxin; Autonomic nerves (Lundy, P.M. (231) 197)

**Neurotransmitter transport**
Molecular modelling; Transport pharmacophore; Specific serotonin transport inhibitors (Chang, A.S.-S. (247) 239)

**Neutral endopeptidase**
Acetylthiorphan; Acetorphan; Thiorphan; Hot-plate test; Analgesia (Lambert, D.M. (243) 129)

**Neutral endopeptidase inhibition**
Candoxatrilat; ANF (atrial natriuretic factor); Volume expansion; cGMP (Scott, J.M. (242) 91)

**Neutrophil migration**
Fenspiride; Tumour necrosis factor; Carrageenin; Endotoxin (Cunha, F.Q. (238) 47)

**Neutrophils**
Inflammation; Adherence; Microcirculation; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

Myocardial infarction; Complement receptors; Myeloperoxidase (Smith III, E.F. (236) 477)

Vasodilatation; Endotoxin; Nitric oxide (NO); Interleukin-1; Glucocorticoids (Pons, F. (239) 23)

Leukocyte elastase (human); Platelets (Renesto, P. (248) 151)

**Neutrophils (electroporated)**
Migration; cGMP; cAMP; Chemokinesis (Elferink, J.G.R. (246) 157)

**$Ni^{2+}$**
Histamine $H_1$ receptor; Inositol phosphates; HeLa cell; Brain slice (Arias-Montaño, J.-A. (245) 221)

**Nicardipine**
Renal artery; Autoradiography; Dihydropyridine channels; (Human) (Ferrante, F. (240) 229)

**Nicorandil**
Cardiac arrhythmias; Atria (rabbit); Tolbutamide; Quinidine (Le Grand, B. (229) 91)

$K^+$ channel (*Xenopus laevis*); $K^+$ channel opener; KRN2391; Cromakalim; Glibenclamide; Phentolamine; Trifluoperazine (Sakuta, H. (244) 277)

**Nicotine**
Lobeline; Cytisine; Mecamylamine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

Glucocorticoid receptors; Adrenal medulla; Phenylethanolamine N-methyltransferase; Catecholamines (Betito, K. (238) 273)

Antinociception; Opioid and anti-opioid interactions; Smoking behaviour; (Mice) (Aceto, M.D. (248) 333)

Cotinine; Prostaglandins; Thromboxane; Leukotrienes (Saareks, V. (248) 345)

**Nicotine-induced relaxation**
Nitric oxide (NO); Noradrenaline; Gastric fundus (guinea-pig) (Kojima, S.-i. (241) 171)

**Nicotinic acetylcholine receptors**
1,4-Dihydropyridines; Chromaffin cells; Nimodipine; BAY K 8644; PCA50938; Nifedipine; Nitrendipine; Furnidipine (López, M.G. (247) 199)

**Nicotinic receptor antagonists**
Dequalinium; Sympathetic ganglia; Ganglion blockers; Muscarinic receptor antagonists (Dunn, P.M. (230) 335)

**Nicotinic receptors**
Cobalt ramps; Adrenal medulla; Catecholamine secretion (Montiel, C. (230) 77)

Hepatocytes; $Ca^{2+}$-activated $K^+$ channels; Dequalinium; Vecuronium; Apamin (Castle, N.A. (236) 201)

**Nifedipine**
ANP (atrial natriuretic peptide); $Ca^{2+}$ entry blockers; Verapamil; Felodipine; Diuretic effects (Shamiss, A. (233) 113)

$Ca^{2+}$ channel blockers; Cytosolic $Ca^{2+}$ levels; Felodipine; Verapamil; Smooth muscle; Aorta (rat); (Relaxation) (Hagiwara, S. (234) 1)

TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate); Hypertonic saline; Renal blood flow; Glomerular filtration rate (Ogasawara, A. (243) 103)

1,4-Dihydropyridines; Nicotinic acetylcholine receptors; Chromaffin cells; Nimodipine; BAY K 8644; PCA50938; Nitrendipine; Furnidipine (López, M.G. (247) 199)

**Nigrostriatal lesions**
On-off effects; Rotation; Classical conditioning; Dopamine receptor agonists; 6-Hydroxydopamine (6-OHDA) (Silverman, P.B. (229) 235)

**NIH 3T3 cells**
Cytochrome P4502A6 (human); Heterologous expression; CYP2A6 recombinant expression vector (Salonpää, P. (248) 95)

**Nilvadipine**
Flunarizine; Inner ear microcirculation disorder (Umemura, K. (239) 17)

**Nimodipine**
$Ca^{2+}$ channels; Verapamil; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

MDMA (3,4-methylenedioxymethamphetamine); Parachloroamphetamine; Fluoxetine; Deprenyl; Clorgyline; Reserpine (Gu, X.F. (235) 51)

[$^3$H]Nitrobenzylthioinosine binding; Adenosine transporters; Parietal cortex (human) (Deckert, J. (238) 131)

Gadolinium; Neomycin; Verapamil; Voltage-sensitive $Ca^{2+}$ channels; Brain synaptosomes (Canzoniero, L.M.T. (245) 97)

BAY K 8644; Strychnine-insensitive glycine receptors (Nowak, G. (247) 101)

1,4-Dihydropyridines; Nicotinic acetylcholine receptors; Chromaffin cells; BAY K 8644; PCA50938; Nifedipine; Nitrendipine; Furnidipine (López, M.G. (247) 199)

**Nipradilol**
Guanylate cyclase (soluble); cGMP; Mitogenesis; Glomerular mesangial cells (Koya, D. (245) 79)

**Nitrate tolerance**
Aorta (rat); Aging; Nitroglycerin; Sin-1 (3-morpholinosydnonimine) (Unger, P. (248) 145)

**Nitrate vasodilators**
Phosphodiesterase inhibitors; Zaprinast; $N^{\omega}$-Nitro-L-arginine; L-Arginine; Acetylcholine; Bradykinin; Blood pressure (De Garavilla, L. (234) 77)

**Nitrendipine**
1,4-Dihydropyridines; Nicotinic acetylcholine receptors; Chromaffin cells; Nimodipine; BAY K 8644; PCA50938; Nifedipine; Furnidipine (López, M.G. (247) 199)

**[$^3$H]Nitrendipine**
Calcium channels; Alcohols; Synaptosomes; Longitudinal muscle; [$^{125}$I]$\omega$-Conotoxin (Hawthorn, M.H. (229) 143)

**Nitric oxide (NO)**
5-HT (5-hydroxytryptamine, serotonin); EDRF (endothelium-derived relaxing factor); Arterioles; Microcirculation; $N^G$-Nitro-L-arginine (Alsip, N.L. (229) 117)

Stomach; L-Arginine; Indomethacin; Prostaglandins (Konturek, S.J. (229) 155)

Intestinal motility; L-NAME ($N^G$-nitro-L-arginine methyl ester); Cholinergic mechanisms (Calignano, A. (229) 273)

Brain; Food intake; Zucker rat (Squadrito, F. (230) 125)

Seizures; Prepiriform cortex (deep); Excitatory amino acid; L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

VIP (vasoactive intestinal polypeptide); Cholinergic neurotransmission; Inhibitory non-adrenergic non-cholinergic (i-NANC); Electrical field stimulation (Belvisi, M.G. (231) 97)

Non-adrenergic, non-cholinergic (NANC) transmission; Stomach (rat) (Shimamura, K. (231) 103)

NO synthase inhibitors; L-NAME ($N^G$-nitro-L-arginine methyl ester); $HCO_3^-$ secretion; Duodenum (rat) (Takeuchi, K. (231) 135)

Morphine-induced locomotion; Morphine; Food intake (Calignano, A. (231) 415)

Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; L-NAME ($N^G$-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Cholecystokinin; Non-adrenergic, non-cholinergic (NANC) nerves; Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)

Endotoxin shock; Pulmonary hypertension; Adult respiratory distress syndrome (ARDS); Endothelin; Noradrenaline; Neuropeptide Y (Weitzberg, E. (233) 85)

Polymorphonuclear leukocytes; Red blood cells deformability (Korbut, R. (234) 17)

EDRF (endothelium-derived relaxing factor); EDHF (endothelium-derived hyperpolarizing factor); $N^{\omega}$-Nitro-L-arginine; Glybenclamide; Aorta (rabbit) (Bellan, J.A. (234) 273)

$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; cGMP; EDRF (endothelium-derived relaxing factor); Pulmonary artery (pig) (Pepke-Zaba, J. (235) 169)

L-Arginine; $\beta$-Endorphin; Antinociception; Pain controls (descending) (Xu, J.Y. (236) 137)

Lipopolysaccharide; Cationic amino acids (Schott, C.A. (236) 155)

Coronary artery; ANP (atrial natriuretic polypeptide); Nitroglycerin; Cyclic GMP (Matsumoto, T. (237) 31)

Lithium chloride; Tacrine; Epilepsy; Neurodegeneration (Bagetta, G. (237) 61)

Anococcygeus (rabbit); Nitric oxide synthase inhibitors; Purinoceptors; ATP; Adenosine; 8-(p-Sulfophenyl)theophylline; Suramin (Graham, A.M. (237) 93)

Hyperemia (reactive); EDRF (endothelium-derived relaxing factor); Endothelium (Domenech, R. (238) 53)

Substance P; Morphine; Substance P receptor antagonists; $\beta$-Adrenoceptors (Persico, P. (238) 105)

Hippocampus; Dentate gyrus; (Rat, in vivo) (Iga, Y. (238) 395)

Vasodilatation; Endotoxin; Interleukin-1; Neutrophils; Glucocorticoids (Pons, F. (239) 23)

Bradykinin; Bradykinin $B_1$ receptor; Carotid artery; Endothelium (Pruneau, D. (239) 63)

Peptic ulcers; L-Arginine; Glyceryl trinitrate healing; Blood flow (Konturek, S.J. (239) 215)

Tachykinins; Ileum (guinea-pig); Circular muscle; $\omega$-Conotoxin; Apamin; NANC (non-adrenergic, non-cholinergic); NANC relaxation (Maggi, C.A. (240) 45)

Diabetes mellitus; Vascular permeability; Substance P; Neurokinins (Mathison, R. (240) 163)

Noradrenaline-induced contraction; Endothelium; $\alpha$-Adrenoceptors (Kaneko, K. (240) 195)

Neuroeffector modulation; Cholinergic; Tachykinin; Smooth muscle; Chemiluminescence (Wiklund, C.U. (240) 235)

Gastric cytoprotection; L-Arginine; L-NAME ($N^G$-nitro-L-arginine methyl ester); RX 77368; Vagus (Király, Á. (240) 299)

Cerebral cortex; Glutamate; NMDA (N-methyl-D-aspartate); Methylcobalamin; Vitamin $B_{12}$ (Akaike, A. (241) 1)

Reactive hyperaemia; Heart (guinea pig) (Chłopicki, S. (241) 117)

Nicotine-induced relaxation; Noradrenaline; Gastric fundus (guinea-pig) (Kojima, S.-i. (241) 171)

Afferent nerves; Blood flow; Pulp; Oral mucosa; Lip; Submandibular gland (Kerezoudis, N.P. (241) 209)

Aortic rings (rat); Anococcygeus muscle (rat); Hydroxocobalamin; S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitroso-coenzyme A; S-Nitrosocysteine; S-Nitrosoglutathione; Nitrosothiols (Rand, M.J. (241) 249)

Acetylcholine; Mesenteric arterial bed; cAMP; cGMP; Endothelium-dependent relaxation (Abiru, T. (242) 15)

Aprikalim; Cheek pouch arterioles; Vasodilatation, BRL 38227; L-NMMA ($N^G$-monomethyl-L-arginine); (Hamster) (Mayhan, W.G. (242) 109)

Aldose reductase; Aorta; EDRF (endothelium-derived relaxing factor); Galactosaemia; Polyol pathway (Cameron, N.E. (243) 47)

Sympathetic ganglion; $Ca^{2+}$ channels; Norepinephrine; Voltage-clamp; Patch-clamp (Chen, C. (243) 83)

Ricinoleic acid; L-NAME ($N^G$-nitro-L-arginine methyl ester); $N^G$-Monomethyl-L-arginine; L-Arginine; Tetrodotoxin; Ileum; (Rat) (Izzo, A.A. (243) 87)

Coronary arteries; Endothelin; Neuropeptide Y; BQ-123; $ET_A$ receptor; $ET_B$ receptor (Pernow, J. (243) 281)

$Ca^{2+}$; Platelet aggregation (Ivanova, K. (244) 37)

cGMP analog; $Ca^{2+}$; Platelet aggregation (Menshikov, M.Y. (245) 281)

Organic nitroesters; Platelets; Cyclic GMP (Weber, A.-A. (247) 29)

G-protein; Endothelial cells; Bradykinin; cyclic GMP (Gil-Longo, J. (247) 119)

Immunocyte conformational changes; Phagocytosis; (Molluscs); (Bacteria) (Ottaviani, E. (248) 319)

Nitric oxide synthase; $N^{\omega}$-Nitro-L-arginine; Cerebral ischemia; Neuronal necrosis (Nagafuji, T. (248) 325)

**$N^{\omega}$-Nitro-L-arginine**
Nitrate vasodilators; Phosphodiesterase inhibitors; Zaprinast; L-Arginine; Acetylcholine; Bradykinin; Blood pressure (De Garavilla, L. (234) 77)

Nitric oxide (NO); EDRF (endothelium-derived relaxing factor); EDHF (endothelium-derived hyperpolarizing factor); Glybenclamide; Aorta (rabbit) (Bellan, J.A. (234) 273)

Nitric oxide (NO); Nitric oxide synthase; Cerebral ischemia; Neuronal necrosis (Nagafuji, T. (248) 325)

**$N^G$-Nitro-L-arginine**
5-HT (5-hydroxytryptamine, serotonin); EDRF (endothelium-derived relaxing factor); Arterioles; Microcirculation; Nitric oxide (NO) (Alsip, N.L. (229) 117)

Ethanol; Angiotensin II; Noradrenaline; Vasopressor; Bradycardia; Baroreflex (Wang, Y.-X. (233) 275)

Diabetes mellitus; Aorta (rat); Haemoglobin; Endothelium-dependent relaxation; Tachyphylaxis (Sikorski, B.W. (242) 275)

**[$^3$H]Nitrobenzylthioinosine binding**
Nimodipine; Adenosine transporters; Parietal cortex (human) (Deckert, J. (238) 131)

**Nitro blue tetrazolium**
NADPH diaphorase; Haemodynamics; (Rat) (Davisson, R.L. (241) 135)

**Nitrocaramiphen**
Caramiphen; Iodocaramiphen; Muscarinic $M_1$ receptors; (Rat) (Hudkins, R.L. (231) 485)

**Nitroglycerin**
Coronary artery; ANP (atrial natriuretic polypeptide); Nitric oxide (NO); Cyclic GMP (Matsumoto, T. (237) 31)

Aorta (rat); Aging; Nitrate tolerance; Sin-1 (3-morpholinosydnonimine) (Unger, P. (248) 145)

**Nitroglycerin tolerance**
Zaprinast; cGMP-phosphodiesterase inhibitor; cGMP (intracellular); (Reversal of tolerance) (Pagani, E.D. (243) 141)

**Nitropropane analog of baclofen**
Baclofen; $GABA_B$ receptor agonists; Ileum (guinea-pig, isolated); Vas deferens (guinea pig); Brain slices (rat) (Kerr, D.I.B. (236) 239)

**3-Nitropropionic acid**
Excitotoxicity; NMDA (N-methyl-D-aspartate); Glutamate; Cerebellar granule neurons (Weller, M. (248) 223)

**S-Nitroso-N-acetylpenicillamine (SNAP)**
Aortic rings (rat); Anococcygeus muscle (rat); Hydroxocobalamin; Nitric oxide (NO); S-Nitroso-coenzyme A; S-Nitrosocysteine; S-Nitrosoglutathione; Nitrosothiols (Rand, M.J. (241) 249)

**S-Nitroso-coenzyme A**
Aortic rings (rat); Anococcygeus muscle (rat); Hydroxocobalamin; Nitric oxide (NO); S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitrosocysteine; S-Nitrosoglutathione; Nitrosothiols (Rand, M.J. (241) 249)

**S-Nitrosocysteine**
Aortic rings (rat); Anococcygeus muscle (rat); Hydroxocobalamin; Nitric oxide (NO); S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitroso-coenzyme A; S-Nitrosoglutathione; Nitrosothiols (Rand, M.J. (241) 249)

**S-Nitrosoglutathione**
Aortic rings (rat); Anococcygeus muscle (rat); Hydroxocobalamin; Nitric oxide (NO); S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitroso-coenzyme A; S-Nitrosocysteine; Nitrosothiols (Rand, M.J. (241) 249)

**Nitrosothiols**
Aortic rings (rat); Anococcygeus muscle (rat); Hydroxocobalamin; Nitric oxide (NO); S-Nitroso-N-acetylpenicillamine (SNAP); S-Nitroso-coenzyme A; S-Nitrosocysteine; S-Nitrosoglutathione (Rand, M.J. (241) 249)

**$NK_1$, receptor antagonist (non-peptide)**
Dura mater; Neurogenic inflammation; Migraine model; Substance P (Moussaoui, S.M. (238) 421)

**$NK_1$ receptor antagonists**
Neurokinin A; $NK_2$ receptor antagonists; Substance P; Capsaicin; Lung (guinea-pig) (Kudlacz, E.M. (241) 17)

**$NK_2$ receptor antagonists**
Thalamic extracellular recording; Thermal nociception (Santucci, V. (237) 143)

Neurokinin A; Substance P; $NK_1$ receptor antagonists; Capsaicin; Lung (guinea-pig) (Kudlacz, E.M. (241) 17)

**$NK_1$ receptors**
Allergen; Bradykinin; CP-96,345; Airway microvascular leakage; Substance P (Sakamoto, T. (231) 31)

Neurokinin receptor antagonists; $NK_2$ receptors; Spinal cord; Nociception (Picard, P. (232) 255)

RP 67580; Substance P; Transfection; Second messenger (binding) (Hermans, E. (245) 43)

**$NK_2$ receptors**
Neurokinin receptor antagonists; $NK_1$ receptors; Spinal cord; Nociception (Picard, P. (232) 255)

Tachykinin; Radioligand binding; Neurokinin A; Neuropeptide $\gamma$; Gastric fundus (rat) (Burcher, E. (233) 201)

Lower esophageal sphincter; Tachykinins; Substance P; Neurokinin A; (Human) (Huber, O. (239) 103)

Neurokinin A; Desensitization (Henderson, A.K. (245) 75)

**$NK_3$ receptors**
Ileum (Guinea pig); Inositol monophosphate accumulation; Selective agonists (Petitet, F. (247) 185)

**NMDA (N-methyl-D-aspartate)**
Primary neuronal cultures; Substantia nigra; Locus coeruleus; $\kappa$-Opioid receptors; $\mu$-Opioid receptors (Ronken, E. (230) 349)

Norbinaltorphimine; AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazole propionate); Convulsion; Mortality (Shukla, V.K. (231) 293)

5-HT (5-hydroxytryptamine, serotonin); Cortex; Transmitter interaction (Rahman, S. (231) 347)

bFGF (basic fibroblast growth factor); Excitotoxicity (neonate); Neuroprotection (Nozaki, K. (232) 295)

21-Aminosteroids; Lipid peroxidation; Hypoxia (Domenici, M.R. (233) 291)

Epilepsy; Valproate; MK-801; Behaviour; CGP 37849 (Löscher, W. (234) 237)

*Xenopus* oocytes (rat brain mRNA-injected); Excitatory amino acid receptors; Riluzole; Kainate (Debono, M.-W. (235) 283)

Glycine; Haloperidol; Hippocampus (Fletcher, E.J. (235) 291)

MK-801; LY274614; SCH23390; Clebopride; Catalepsy; Dopamine; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

Azelastine; Cerebral vascular disease; Ischaemia; Leukotriene (Wallis, R.A. (238) 165)

Dextromethorphan; NMDA receptor blocking agents; $Ca^{2+}$ channel blocking agents; $Na^+$ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

Glycine; Pain (Millan, M.J. (238) 445)

Non-competitive antagonism; Dizocilpine; FR115427; Cortical wedge; Hippocampus (Hodgkiss, J.P. (240) 219)

$\sigma$ Receptors; Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor (selective); Monoamine oxidase inhibitors (Bergeron, R. (240) 319)

Cerebral cortex; Glutamate; Nitric oxide (NO); Methylcobalamin; Vitamin $B_{12}$ (Akaike, A. (241) 1)

AMPA ((S)-$\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Convulsions; (Screening); (Neonatal rat); (Mouse); (Rat) (Bisaga, A. (242) 213)

MK-801; Polyamines (Marvizón, J.-C. (244) 103)

Gabapentin; GABA ($\gamma$-aminobutyric acid); Baclofen; $GABA_A$ receptors; $GABA_B$ receptors; Glycine; Anticonvulsants; Polyamines (Suman-Chauhan, N. (244) 293)

Gabapentin; Autoradiography; GABA ($\gamma$-aminobutyric acid); Glycine; Hippocampus; Anticonvulsants; Excitatory amino acids (Hill, D.R. (244) 303)

(Non-competitive), Dizocilpine; FR115427; Ligand binding (Sherriffs, H.J. (247) 319)

3-Nitropropionic acid; Excitotoxicity; Glutamate; Cerebellar granule neurons (Weller, M. (248) 223)

**non-NMDA receptor antagonism**
Spinal seizures; (Mouse) (McAllister, K.H. (231) 309)

**NMDA receptor antagonists**
Dizocilpine; Memantine; CGP 39551; Dopamine metabolism; Locomotion (Rat) (Bubser, M. (229) 75)

(+)-MK-801; Ketamine; Ethanol tolerance; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

Drug discrimination; NPC 12626; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

$\gamma$-Hydroxybutyric acid (GHB); $GABA_A$ receptors; Dopaminergic neurons; Ethanol (Diana, M. (230) 363)

Phencyclidine; Dizocilpine; $\sigma$ Receptor ligands; Interneurons (Zhang, J. (230) 371)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline); Cerebral ischaemia; AMPA receptors; NMDA receptors; Glutamate (Sheardown, M.J. (236) 347)

Learning/memory; Muscle relaxation; Circling behaviour; (Rat) (Murata, S. (239) 9)

Excitatory amino acid receptors; Photoaffinity ligand (Benke, D. (246) 179)

**NMDA receptor blocking agents**
Dextromethorphan; NMDA (N-methyl-D-aspartate); $Ca^{2+}$ channel blocking agents; $Na^{+}$ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

**NMDA receptor complex**
Strychnine-insensitive glycine site; (High affinity) (Lewin, A.H. (247) 1)

Electroconvulsive shock; Imipramine; Strychnine-insensitive glycine receptor; 5,7-Dichlorokynurenic acid; CGP-39653 (Paul, I.A. (247) 305)

**NMDA receptor coupled ion channel**
Glutamate; Glycine; $Mg^{2+}$; MK-801 (5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5,10-imine maleate) (Von Euler, G. (245) 233)

**NMDA receptors**
Aging; Glycine; D-Cycloserine; Noradrenaline release; Glycine uptake (Pittaluga, A. (231) 129)

Dentate gyrus; Field potentials; Long-term potentiation; Dextromethorphan; Methadone; Codeine; Normethadone; MK-801 (Krug, M. (231) 355)

Sabeluzole; Glutamate; Cerebellum; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Adenosine (extracellular); Brain microdialysis; Striatum; Anaesthesia; Tetrodotoxin (Pazzagli, M. (234) 61)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline); Cerebral ischaemia; AMPA receptors; NMDA receptor antagonists; Glutamate (Sheardown, M.J. (236) 347)

Sensitization; Dopamine receptor agonists; Apomorphine; MK-801 (Druhan, J.P. (243) 73)

Voltage-operated $Ca^{2+}$ channels; Glutamate release; $^{45}Ca^{2+}$ uptake; $K^{+}$ depolarization; Cerebellar granule cells (Didier, M. (244) 57)

Pentamidine; Neurotoxicity (Reynolds, I.J. (244) 175)

Glutamate; Proenkephalin mRNA; Striatum; Accumbens; MK-801 (Angulo, J.A. (244) 317)

Histogranin; Endogenous peptide; Adrenal medulla; Anticonvulsant (Lemaire, S. (245) 247)

Scrapie; Cortical cells; Memantine; Neurons; Prion; Adamantanes; MK-801 (Müller, W.E.G. (246) 261)

Monoclonal antibodies; Phencyclidine; Drug design (Casalotti, S.O. (247) 209)

Polyamines; Ethanol; c-*fos*; Seizure (Matsumoto, I. (247) 289)

Ethanol; Ethanol withdrawal; Cerebellar granule cells; Glutamate-induced cytotoxicity (Iorio, K.R. (248) 209)

$Pb^{2+}$; Neurotoxicity; Brain (rat); (Age) (Guilarte, T.R. (248) 273)

**NNC-756**
Dopamine $D_1$ receptors; Dopamine $D_1$ receptor antagonists; Dopamine $D_1$ receptor agonists; Oral movement; Vacuous chewing movement (Glenthøj, B. (242) 283)

**Nociception**
Neurokinin receptor antagonists; $NK_1$ receptors; $NK_2$ receptors; Spinal cord (Picard, P. (232) 255)

Noradrenaline; Analgesia; Neuropathic pain; Axotomy; Nerve injury (Xu, X.-J. (235) 161)

Opioid; Central nucleus; Amygdala; Parabrachial area; Pain pathway; (Rat) (Huang, G.-F. (236) 449)

Morphine; Spinal cord; C-fibre reflex (Strimbu-Gozariu, M. (237) 197)

**Nociceptive flexion reflex**
Dothiepin; Diffuse noxious inhibitory controls; Cold-pressor test; (Human) (Sandrini, G. (243) 99)

**Nociceptive response**
Substance P; Spantide; Substance P analogues (containing D-His); Formalin; Capsaicin; Intrathecal injection (Sakurada, T. (242) 47)

**Nomifensine**
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopamine (6-OHDA); Desipramine; Neurotoxicity (Evans, J. (232) 241)

Microdialysis; 4-PTIQ (4-phenyltetrahydroisoquinoline); Cocaine; Methamphetamine; Dopamine; Nucleus accumbens (Tateyama, M. (240) 51)

(+)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; (−)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; Methamphetamine; Cocaine; Anococcygeus muscle (rat) (Watanabe, H. (243) 155)

**Non-cholinergic actions**
Organophosphorous insecticides; Methylcarbamate insecticides; Kynurenine formamidase inhibition; Xanthurenic acid (urinary excretion); Plasma L-kynurenine; (Structural requirements) (Pewnim, T. (248) 237)

**Non-competitive antagonism**
NMDA (N-methyl-D-aspartate); Dizocilpine; FR115427; Cortical wedge; Hippocampus (Hodgkiss, J.P. (240) 219)

**Noradrenaline**
Diurnal rhythm; Adrenoceptors; Aorta; (Rat) (Gohar, M. (229) 69)

$\alpha_1$-Adrenoceptors; Burst firing; Idazoxan; Reserpine (Grenhoff, J. (233) 79)

Nitric oxide (NO); Endotoxin shock; Pulmonary hypertension; Adult respiratory distress syndrome (ARDS); Endothelin; Neuropeptide Y (Weitzberg, E. (233) 85)

$N^{G}$-Nitro-L-arginine; Ethanol; Angiotensin II; Vasopressor; Bradycardia; Baroreflex (Wang, Y.-X. (233) 275)

Nociception; Analgesia; Neuropathic pain; Axotomy; Nerve injury (Xu, X.-J. (235) 161)

Desipramine; Electrochemistry (in vivo); Brain (rat); Anteroventral thalamic nucleus; Locus coeruleus (Brun, P. (235) 205)

DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Scopolamine; Acetylcholine; Working memory; Reference memory (Ohno, M. (238) 117)

$\beta$-Adrenoceptors; 5-HT (5-hydroxytryptamine, serotonin); Competitive inhibition (Fujita, R. (240) 213)

Nicotine-induced relaxation; Nitric oxide (NO); Gastric fundus (guinea-pig) (Kojima, S.-i. (241) 171)

GM1 ganglioside; Hypoxia-reoxygenation; $Na^+$,$K^+$-ATPase (Lodovici, M. (243) 255)

Adrenaline; $\beta_2$-Adrenoceptors (prejunctional); Catecholamine overflow (evoked); Portal vein; (Freely moving rats) (Coppes, R.P. (243) 273)

$\alpha_1$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Chloroethylclonidine; $Ca^{2+}$; cAMP; Hepatocyte (Rat) (Nomura, T. (246) 113)

Adrenoreceptor; Proximal tubule; Thyroid hormone; In situ hybridization (Meister, B. (247) 229)

**Noradrenaline-induced contraction**
Endothelium; Nitric oxide (NO); $\alpha$-Adrenoceptors (Kaneko, K. (240) 195)

**Noradrenaline-induced vasoconstriction**
D-myo-Inositol 1,2,6-trisphosphate; Mesenteric circulation; Neuropeptide Y; $\alpha$-Trinositol (Donoso, M.V. (240) 93)

**Noradrenaline release**
Aging; NMDA receptors; Glycine; D-Cycloserine; Glycine uptake (Pittaluga, A. (231) 129)

Nitric oxide synthase; Hippocampus (Lauth, D. (236) 165)

$K^+$ channels; Glutamate receptors (Ennis, C. (248) 85)

**[$^3$H]Noradrenaline release**
NPY receptors; Brain; Terminals; (Rat) (Martire, M. (230) 231)

**Nor-binaltorphimine**
DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); Morphine; Naloxone; Naloxonazine, $\beta$-Funaltrexamine; ICI 174,864; Substance P; Trigeminal nucleus caudalis (Suarez-Roca, H. (229) 1)

NMDA (N-methyl-D-aspartate); AMPA ($\alpha$-amino-3-hydroxy-5-methyl-4-isoxazole propionate); Convulsion; Mortality (Shukla, V.K. (231) 293)

Dynorphin A-(1–13); Memory; Ischemia; Body temperature; (Mouse) (Itoh, J. (234) 9)

Spontaneous alternation performance; Dynorphin A-(1–13); Memory; (Mouse) (Itoh, J. (236) 341)

$\kappa$-Opioid receptors; Butorphanol dependence; Naloxone-precipitated withdrawal (Jaw, S.P. (239) 133)

U50,488H; Naloxone; Opioid withdrawal; Locomotor activity; (Guinea-pig) (Brent, P.J. (241) 149)

**Norepinephrine**
Imipramine; Desipramine; 5-HT (5-hydroxytryptamine, serotonin); Triiodothyronine (Suzuki, S. (231) 297)

Feeding; Obese mice; Clonidine; Yohimbine; $\alpha_2$-Adrenoceptors (Currie, P.J. (232) 227)

Diabetic heart; Hypoperfusion; Left ventricular stiffness; ATP; Lactate; Insulin (ex vivo) (Higuchi, M. (242) 293)

Desipramine; Desmethylclomipramine; Clonidine; MHPG (3-methoxy-4-hydroxyphenylglycol) (Fujita, K. (242) 301)

Sympathetic ganglion; $Ca^{2+}$ channels; Nitric oxide (NO); Voltage-clamp; Patch-clamp (Chen, C. (243) 83)

Smooth muscle (vascular); Prostaglandins; $Ca^{2+}$ channels; Protein kinase C; Dihydropyridine (Rapoport, R.M. (243) 207)

**Norepinephrine release**
Trophism; Cultured neurons; $Ca^{2+}$ transients (Przywara, D.A. (247) 353)

**d-Norfenfluramine**
d-Fenfluramine; Indole-depleting effect; (Rat) (Caccia, S. (233) 71)

Food intake; d-Fenfluramine; 1-(3-Chlorophenyl)piperazine; 5-HT$_{1C}$ receptors; p-Chlorophenylalanine (Gibson, E.L. (242) 83)

**Normetazocine**
$\sigma$ Receptors; Substantia nigra; Movement; Naloxone; Opiates (Walker, J.M. (231) 61)

$\sigma$ Receptors; Substantia nigra; Movement; Naloxone; Opiates (Walker, J.M. (236) 495)

**Normethadone**
Dentate gyrus; Field potentials; Long-term potentiation; NMDA receptors; Dextromethorphan; Methadone; Codeine; MK-801 (Krug, M. (231) 355)

**Noscapine**
$\sigma$ Sites; Antitussive effects; Dextromethorphan; Rimcazole (Kamei, J. (242) 209)

**NO synthase**
Aminoguanidine; Selective inhibitor inducible (Misko, T.P. (233) 119)

Peptides; Angiotensin-(1–7); Angiotensin receptors; DuP 753; L-NAME (N$^G$-nitro-L-arginine methyl ester) (Osei, S.Y. (234) 35)

Noradrenaline release; Hippocampus (Lauth, D. (236) 165)

Cloricromene; Endotoxin; Vascular reactivity; Murine J774 macrophages (Zingarelli, B. (243) 107)

cGMP; Catecholamine release; Adrenal medulla; Chromaffin cells (Moro, M.A. (246) 213)

Nitric oxide (NO); N$^\omega$-Nitro-L-arginine; Cerebral ischemia; Neuronal necrosis (Nagafuji, T. (248) 325)

**NO synthase inhibition**
Insulin release; Arginine; NADPH diaphorase (Panagiotidis, G. (229) 277)

**NO synthase inhibitors**
EDRF (endothelium-derived relaxing factor); Porcine endocardial endothelium; Human platelets (washed) (Siney, L. (229) 223)

Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester); $HCO_3^-$ secretion; Duodenum (rat) (Takeuchi, K. (231) 135)

Urethra (dog); Non-adrenergic, non-cholinergic (NANC) relaxation; VIP receptor antagonists (Hashimoto, S. (231) 209)

Anococcygeus (rabbit); Nitric oxide (NO); Purinoceptors; ATP; Adenosine; 8-(p-Sulfophenyl)theophylline; Suramin (Graham, A.M. (237) 93)

**Noxious**
Opioids; Parabrachial; Thermal stimuli; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**NPA (*R*-(−)-*N*-*n*-propylnorapomorphine)**
EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Radioligand binding (in vivo); Pituitary; Prolactin; Dopamine $D_2$ receptors; Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5]azepine); (Receptor reserve); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Ekman, A. (243) 295)

**NPC 12626**
Drug discrimination; NMDA receptor antagonists; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

**NPPB (5-nitro-2-(3-phenylpropylamino)-benzoic acid)**
Fluorescence microscopy (single cell); Vasopressin; Phosphatidylinositol metabolism; $Ca^{2+}$-activated chloride conductance; Smooth muscle (Pon, D.J. (245) 119)

**Nucleoside transport**
R75231; Synaptosomes, Erythrocytes (human); Positive cooperativity (Jones, K.W. (246) 97)

**5′-Nucleotide receptor**
ATP; HeLa cells; $Ca^{2+}$; fura-2 (Smit, M.J. (247) 223)

**Nucleotides**
Urinary bladder; Purine receptors; ATP (Theobald, Jr., R.J. (229) 125)

**Nucleus accumbens**
Glutamate; Dopamine; Neuroleptics; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

Neuroleptics; Dopamine release; Dopamine metabolism; 3-Methoxytyramine; Striatum; Frontal cortex; Depolarization block; (Rat) (Chrapusta, S.J. (233) 135)

Dopamine $D_1$ receptor agonists; Dopamine $D_2$ receptor agonists; Oral behaviour; Principal factor analysis; SK&F 38393; Quinpirole (Koene, P. (233) 151)

$^{125}$I-Sulpiride; Dopamine $D_2$ receptors; Dopamine $D_3$ receptors; Olfactory tubercle; Caudate nucleus; (Rat) (Parsons, B. (234) 269)

Carbamazepine; Cocaine; Dopamine; Microdialysis; (Rat) (Baptista, T. (236) 39)

Cocaine; *C-fos*; Psychostimulants; Reward (Heilig, M. (236) 339)

Turning behaviour; Dopamine $D_1/D_2$ receptor interaction; SKF 38393; Quinpirole; Limb stepping (Saigusa, T. (237) 161)

HA-966; (+)-MK-801; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex (Morrow, B.A. (238) 255)

Microdialysis; 4-PTIQ (4-phenyltetrahydroisoquinoline); Cocaine; Nomifensine; Methamphetamine; Dopamine (Tateyama, M. (240) 51)

Microdialysis; Dopamine; Opioid; $\mu$-Opioid receptors; GABA ($\gamma$-aminobutyric acid); Ventral tegmental area (Devine, D.P. (243) 55)

NMDA receptors; Glutamate; Proenkephalin mRNA; Striatum; MK-801 (Angulo, J.A. (244) 317)

**Nucleus tractus solitarii**
Rostral vasodepressive area; Lateral tegmental field; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Vayssettes-Courchay, C. (242) 37)

**Obese mice**
Feeding; Norepinephrine; Clonidine; Yohimbine; $\alpha_2$-Adrenoceptors (Currie, P.J. (232) 227)

**Oedema**
Carrageenan; Ph CL28A; Pleurisy; Prostacyclin; Thromboxane (Santana, A.C. (231) 237)

**Oestradiol-17$\beta$**
Inhibin; Ovarian hormones; Gonadotrophin; Prostaglandin $F_{2\alpha}$; Indomethacin (Kogo, H. (231) 481)

**8-OH-DPAT derivatives**
5-$HT_{1A}$ receptor agonists; 5-$HT_{1A}$ receptor antagonists; (S)-UH-301; LY-41; 5-HT motor syndrome (Yu, H. (231) 69)

**8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin)**
Sexual behaviour; Ejaculation; Castration; Testosterone; (Wistar rat) (Haensel, S.M. (233) 187)

Hippocampus; 5-$HT_{1A}$ receptors; Working memory; Reference memory; (Microinjection) (Ohno, M. (234) 29)

5-$HT_{1A}$ receptors; Adenylate cyclase; Drug discrimination (Rabin, R.A. (235) 237)

Sympathetic nerve activity; Cardiovascular neurons; Lateral tegmental field (Vayssettes-Courchay, C. (236) 121)

Aggression; TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); Eltoprazine; Dorsal raphe (rat) (Mos, J. (238) 411)

5-$HT_{1A}$ receptor agonists; Buspirone; $\alpha_1$-Adrenoceptor subtypes; Aorta (rabbit); (8-hydroxy-2(di-N-propylamino)tetralin) (Castillo, C. (241) 141)

Nucleus tractus solitarii; Rostral vasodepressive area; Lateral tegmental field (Vayssettes-Courchay, C. (242) 37)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Long-term treatment; Neonatal; Ultrasonic calls; (Rat pup) (Johansson-Wallsten, C.E. (243) 149)

5-HT (5-hydroxytryptamine, serotonin); Male sexual behavior; Penile erection; Yawning; m-CPP; (Primates); (Rhesus monkey) (Pomerantz, S.M. (243) 227)

**7-OH-DPAT (7-hydroxy-2-(N,N-di-n-propylamino)tetralin)**
Aminotetralins; Dopamine $D_3$ receptors (Baldessarini, R.J. (239) 269)

Dopamine $D_3$ receptors (bovine caudate); $\sigma$ Sites (Schoemaker, H. (242) R1)

**[$^{125}$I]trans-7-OH-PIPAT-A**
Dopamine $D_3$ receptor; Ligand binding (Kung, M.-P. (235) 165)

**OKY-046**
Asthma; Edema; Plasma exudation; Bradykinin; Airway obstruction; Vascular permeability; Indomethacin (Arakawa, H. (229) 131)

**1-Oleoyl-2-acetyl-glycerol**
Platelets (human); Shape-change parameter; Protein kinase C; Discsphere change; Thrombin (Ozaki, Y. (235) 255)

**Olfactory tubercle**
$^{125}$I-Sulpiride; Dopamine $D_2$ receptors; Dopamine $D_3$ receptors; Nucleus accumbens; Caudate nucleus; (Rat) (Parsons, B. (234) 269)

Dopamine release; Glutamate receptors; Brain, in vitro (rat); Frontal cortex; Striatum (Jones, C.A. (242) 183)

**Ondansetron**
Enterotoxin; Intestinal secretion; Ketanserin; Tropisetron; Granisetron (Beubler, E. (248) 157)

**ONO-1078**
Peptide leukotriene receptor antagonists; Asthmatic responses; Airway hyperreactivity; Eosinophil accumulation (Nakagawa, N. (235) 211)

**On-off effects**
Rotation; Classical conditioning; Dopamine receptor agonists; 6-Hydroxydopamine (6-OHDA); Nigrostriatal lesions (Silverman, P.B. (229) 235)

**Ontogeny**
$Ca^{2+}$ channel antagonists; Dihydropyridine; Urethra; Bladder (Yoshida, M. (232) 159)

Development; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Cocaine; Stimulants (Barr, G.A. (233) 143)

**OPC-8212**
Action potential duration; Cardiac ventricular myocytes; $K^+$ currents; Secondary inward current; Veratrine (Lathrop, D.A. (240) 127)

**Opiate action (peripheral)**
Neurogenic plasma extravasation; C-fibre; Substance P; Inflammation (Barber, A. (236) 113)

**Opiate analgesia**
CCK receptor antagonists; CCK-8 immunoreactivity; $CCK_B$ receptors; Naloxone (Zhou, Y. (234) 147)

**Opiates**
Fetal breathing; $\delta$-Opioid receptors; [D-Ala$^2$]deltorphin; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception (Ocaña, M. (230) 203)

Normetazocine; $\sigma$ Receptors; Substantia nigra; Movement; Naloxone (Walker, J.M. (231) 61)

Normetazocine; $\sigma$ Receptors; Substantia nigra; Movement; Naloxone (Walker, J.M. (236) 495)

**Opioid**
Central nucleus; Amygdala; Parabrachial area; Nociception; Pain pathway; (Rat) (Huang, G.-F. (236) 449)

Opioid receptors; Enkephalins; Autoradiography; Photoaffinity probe (Pasquini, F. (243) 39)

Microdialysis; Dopamine; $\mu$-Opioid receptors; GABA ($\gamma$-aminobutyric acid); Ventral tegmental area; Nucleus accumbens (Devine, D.P. (243) 55)

$\delta$-Opioid receptor; Deltorphin (substituted); Pseudoirreversible binding (Wild, K.D. (246) 25)

**Opioid and anti-opioid interactions**
Nicotine; Antinociception; Smoking behaviour; (Mice) (Aceto, M.D. (248) 333)

**Opioid peptides**
Shock titration; Antinociception; Rhesus monkey; SC-39566 (Hammond, D.L. (231) 281)

**$\kappa$-Opioid receptor agonists**
U-50,488H; Rimcazole; DuPont Merck S-7389-4; $\sigma$ Receptor antagonists; EEG power spectra (Young, G.A. (231) 473)

Endorphin receptors; $\mu$-Opioid receptor antagonists; Analgesia; N-CPM-$H_2$BAMO (14$\beta$-(bromoacetamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone); (Mouse) (Jiang, Q. (240) 201)

Fentanyl; Antinociception; Respiration; (Intrathecal); (Intraventricular) (Wang, C. (243) 113)

**Opioid receptor antagonists**
Antinociception; $\mu$-Opioid receptors (Jiang, Q. (230) 129)

$\mu$-Opioid receptors; $\delta$-Opioid receptors; Antinociception; Metabolism (Horan, P.J. (233) 53)

**$\kappa$-Opioid receptor antagonists**
Morphine; U50,488; Analgesia; Shock titration; Squirrel monkeys (Craft, R.M. (234) 199)

**$\mu$-Opioid receptor antagonists**
Endorphin receptors; $\kappa$-Opioid receptor agonists; Analgesia; N-CPM-$H_2$BAMO (14$\beta$-(bromoacetamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone); (Mouse) (Jiang, Q. (240) 201)

**Opioid receptors**
Adenylate cyclase; Dopamine receptors; Brain slices (rat) (Heijna, M.H. (229) 197)

Deltorphin; Peptide synthesis; Computer modelling (Salvadori, S. (230) 357)

Tolerance; DADLE ([D-Ala$^2$,D-Leu$^5$]enkephalin); Autoradiography; (Rat) (Tao, P.-L. (231) 145)

Cough; Antitussive effect; $\beta$-Endorphin (Kamei, J. (233) 251)

Naltrindole; Naloxone; DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); DADLE ([D-Ala$^2$,D-Leu$^5$]enkephalin) (Tiseo, P.J. (236) 89)

$\alpha$-Interferon; Stress; Corticosterone; Paraventricular nucleus (Saphier, D. (236) 183)

Analgesia; Physical dependence; 14-Alkoxymetopons; (Binding) (Fürst, Z. (236) 209)

Opioid; Enkephalins; Autoradiography; Photoaffinity probe (Pasquini, F. (243) 39)

SR 48968; Tachykinin $NK_2$ receptors (Martin, C.A.E. (243) 309)

Radiation inactivation; G-protein; Tolerance; (Uncoupling) (Tao, P.-L. (246) 233)

**$\delta$-Opioid receptors**
Fetal breathing; Opiates; [D-Ala$^2$]deltorphin; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

Dopamine; Ethanol (Acquas, E. (230) 239)

$\mu$-Opioid receptors; Antinociception; Opioid receptor antagonists; Metabolism (Horan, P.J. (233) 53)

L-Tyrosine (methyl ester); Antinociception; Bulbo-spinal noradrenergic system (Kawabata, A. (233) 255)

Naltrindole; Supraspinal $\delta$-opioid receptor; Naloxone-precipitated withdrawal; Butorphanol dependence (Jaw, S.P. (240) 67)

Thermodynamics; Mouse vas deferens; DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin) (Raffa, R.B. (244) 231)

Opioid; Deltorphin (substituted); Pseudoirreversible binding (Wild, K.D. (246) 25)

Opioids; BW 373U86; Guanine nucleotides; Radioligand binding (Wild, K.D. (246) 289)

**$\delta_1$-Opioid receptors**
[Leu$^5$]enkephalin; [Met$^5$]enkephalin; Antinociception; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Spinal cord; Brain; $\beta$-Endorphin (Takemori, A.E. (242) 145)

**$\delta_2$-Opioid receptors**
[Leu$^5$]enkephalin; [Met$^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Spinal cord; Brain; $\beta$-Endorphin (Takemori, A.E. (242) 145)

**$\kappa$-Opioid receptors**
Primary neuronal cultures; Substantia nigra; Locus coeruleus; $\mu$-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

Bremazocine; Dynorphin; Ileum (guinea-pig) (Webster, J.L. (231) 251)

Dystonia; $\sigma$ Receptors; Naloxone; Naltrexone; Movement disorders; Dopamine; Glutamate (Richter, A. (236) 289)

Antinociception; Arylacetamides; Benzomorphans; (Mouse) (Horan, P.J. (239) 93)

Nor-binaltorphimine; Butorphanol dependence; Naloxone-precipitated withdrawal (Jaw, S.P. (239) 133)

Ketorolac; Antinociception; Intrathecal administration (Uphouse, L.A. (242) 53)

**$\mu$-Opioid receptors**
Antinociception; Opioid receptor antagonists (Jiang, Q. (230) 129)

Primary neuronal cultures; Substantia nigra; Locus coeruleus; $\kappa$-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

$\delta$-Opioid receptors; Antinociception; Opioid receptor antagonists; Metabolism (Horan, P.J. (233) 53)

[D-Arg$^2$]Dermorphin analogue; Memory; $\beta$-Funaltrexamine; Passive avoidance response (Ukai, M. (239) 237)

Microdialysis; Dopamine; Opioid; GABA ($\gamma$-aminobutyric acid); Ventral tegmental area; Nucleus accumbens (Devine, D.P. (243) 55)

**Opioid receptor subtypes**
Gastric acid secretion; Gastrin (plasma); (Dog) (Intorre, L. (243) 265)

**$\delta$-Opioid receptor subtypes**
[D-Ala$^2$]deltorphin II; [D-Pen$^2$,D-Pen$^5$]enkephalin; Naltrindole; Benzofuran analogue of naltrindole; Antitussive activity (Kamei, J. (234) 117)

**$\mu$-Opioid receptor subtypes**
CXBK mouse; Morphine; Naltrexonazine; Antitussive effect (Kamei, J. (240) 99)

**Opioids**
Receptor subtypes; $Cl^-$ secretion (intestinal) (Kromer, W. (230) 235)

Parabrachial; Noxious; Thermal stimuli; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

Interleukin-1; CRF (corticotropin-releasing factor); $\alpha$-Helical CRF-(9–41); Antinociception (Mouse) (Kita, A. (237) 317)

Restraint stress; Analgesia; Morphine; NECA (5′-(N-ethyl)carboxamido-adenosine); Caffeine (Woolfolk, D.R. (239) 177)

Antinociception (peripheral); Inflammation; Cytokines (Członkowski, A. (242) 229)

Cocaine; Sensitization; Naltrindole; Locomotor activity (Heidbreder, C. (243) 123)

$\delta$-Opioid receptors; BW 373U86; Guanine nucleotides; Radioligand binding (Wild, K.D. (246) 289)

**Opioids (endogenous)**
Dihydropyridines; $Ca^{2+}$ channels; $Ca^{2+}$ channel activators; Ventral medullary surface; Respiration (Ruiz, F. (240) 155)

**Opioid withdrawal**
U50,488H; Nor-binaltorphimine; Naloxone; Locomotor activity; (Guinea-pig) (Brent, P.J. (241) 149)

**OP-41483 (prostacyclin analog)**
Acetylcholine release; Prostaglandin release; Myenteric plexus (Fukunaga, Y. (233) 237)

**Oral behaviour**
Dopamine $D_1$ receptor agonists; Dopamine $D_2$ receptor agonists; Nucleus accumbens; Principal factor analysis; SK&F 38393; Quinpirole (Koene, P. (233) 151)

**Oral dyskinesia**
Haloperidol (intermittent); Sensitization (pharmacological); Drug holidays (rats); Amygdala kindling (Glenthøj, B. (236) 401)

**Oral movements**
Neurokinin receptor agonists; Substantia nigra; Intranigral infusion; (Rat) (Liminga, U. (235) 177)

GABA (γ-aminobutyric acid); GABA/dopamine interaction; GABA/acetylcholine interaction; Striatum (dorsal); Striatum (ventral); (Rat) (Kikuchi de Beltrán, K. (239) 47)

Dopamine $D_1$ receptors; NNC-756; Dopamine $D_1$ receptor antagonists; Dopamine $D_1$ receptor agonists; Vacuous chewing movement (Glenthøj, B. (242) 283)

**Oral mucosa**
Nitric oxide (NO); Afferent nerves; Blood flow; Pulp; Lip; Submandibular gland (Kerezoudis, N.P. (241) 209)

**ORG 2766**
Taxol neuropathy; Neuroprotection (Hamers, F.P.T. (233) 177)

**Organic anions**
Cloning; Loop diuretics; Bumetanide (transport); Sinusoidal plasma membrane; Liver (rat); Bile acid (Honscha, W. (246) 227)

**Organic cations (renal)**
Dopamine (renal); Fenoldopam; Quinpirole; SCH 23390; Cis-flupentixol; LLC-$PK_1$ cells; Dopamine receptors; Quinine (Dawson, Jr., R. (240) 277)

**Organic nitroesters**
Platelets; Nitric oxide (NO); Cyclic GMP (Weber, A.-A. (247) 29)

**Organophosphate pesticides**
Muscarinic receptors; Development; Phosphoinositide hydrolysis; mRNA (Balduini, W. (248) 281)

**Organophosphorous insecticides**
Noncholinergic actions; Methylcarbamate insecticides; Kynurenine formamidase inhibition; Xanthurenic acid (urinary excretion); Plasma L-kynurenine; (Structural requirements) (Pewnim, T. (248) 237)

**Oscillation**
Ramipril; Adrenoceptors; Genetic hypertension (Watts, S.W. (242) 245)

**Osteoblasts**
Protein kinase C; Prostaglandins; Bradykinin (Ljunggren, Ö. (244) 111)

**Ouabain**
$Na^+/Ca^{2+}$ overload blockade; Arrhythmias; (Guinea-pig) (Lu, H.R. (235) 89)

**Ovalbumin challenge**
Co-axial bioassay; EpDRF (epithelium-derived relaxing factor); Trachea (guinea-pig); Anococcygeus muscle (rat); 5-HT (5-hydroxytryptamine, serotonin) (Çakici, Í. (236) 97)

**Ovarian hormones**
Inhibin; Oestradiol-17β; Gonadotrophin; Prostaglandin $F_{2\alpha}$; Indomethacin (Kogo, H. (231) 481)

**Oxotremorine**
High voltage spindles; Slow wave; Muscarinic $M_1$ receptor; Muscarinic $M_2$ receptor; Physostigmine; Tetrahydroaminoacridine; Pilocarpine; AF102B (Riekkinen, Jr., P. (240) 1)

**Oxotremorine-M**
Muscarinic $M_1$ receptors; Muscarinic $M_1$ receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

**Oxyradicals**
Trolox conjugates; Ventricular myocytes (human) (Zielenski, J. (248) 313)

**Oxytocin**
ACTH (adrenocorticotropic hormone); α-MSH (α-melanocyte-stimulating hormone); Behavioural state; Grooming; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

Achatin-I; D-Amino acid residue; [$Ser^2$]MIP (Gly-Ser-Pro-Met-Phe-Val-$NH_2$); Modulatory effects; Voltage clamp; Neurons; (Snail) (Liu, G.J. (240) 139)

**Oxytocin concentration (plasma)**
5-HT (5-hydroxytryptamine, serotonin); Excessive grooming; Penile erection; 5-$HT_{1C}$ receptors; 5-$HT_2$ receptors; m-CPP (1-(3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (229) 9)

**PACAP-27 (pituitary adenylate cyclase activating polypeptide 27)**
Pulmonary vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasodilation (Cheng, D.Y. (243) 79)

Hindquarters vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasodilation; Vasoconstriction (Santiago, J.A. (243) 291)

**PACAP-38 (pituitary adenylate cyclase activating polypeptide 38)**
Pulmonary vascular bed; PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasodilation (Cheng, D.Y. (243) 79)

Hindquarters vascular bed; PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasodilation; Vasoconstriction (Santiago, J.A. (243) 291)

**Pacemaker currents**
Bradycardiac agents; Sinus node inhibitors; Zatebradine; Purkinje fibres; Iontophoresis; Use-dependent blockade; (Electrophysiology) (Van Bogaert, P.P. (229) 55)

Hyperpolarization-activated inward current; Automaticity; Myocytes (embryonic chick heart); Autonomic agents; Acetylcholine; Isoproterenol (Satoh, H. (240) 283)

**PAF (platelet-activating factor)**
Seminal vesicle protein; Hypotension; Bronchoconstriction; Gastric mucosal injury (Persico, P. (241) 71)

Adenylyl cyclase; Forskolin; G-protein; PAF receptor (Wong, S. (245) 55)

Complement; Zymosan; WEB 2086; SM-12502; Plasma leakage (Damas, J. (231) 231)

Thrombosis; Thromboxane $A_2$; ADP; Thrombin; (Guinea-pig) (Hirata, Y. (231) 421)

Superoxide anion; Alveolar macrophages; Polymorphonuclear leukocytes; Thromboxane $A_2$; (Guinea-pig) (Kato, M. (232) 7)

Inflammation; Adherence; Microcirculation; Neutrophils (McCafferty, D.-M. (232) 169)

Anaphylaxis; Hyperresponsiveness; PCA-4248 (Desquand, S. (235) 101)

PCA 4248; Paw edema (mouse); Anaphylaxis (Amorim, C.Z. (236) 301)

PCA 4248; Allergic inflammation (Martins, M.A. (237) 17)

Alprazolam; BN-52021; Endothelin; Mesangial cells; Proliferation (Montero, A. (243) 235)

**PAF receptor**
PAF (platelet activating factor); Adenylyl cyclase; Forskolin; G-protein (Wong, S. (245) 55)

**PAF receptor antagonists**
WEB 2170; Anaphylactic shock (Amorim, C.Z. (235) 17)

**Pain**
Spinal cord; Morphine; Descending inhibitory controls; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

Colon; Gastrointestinal motility; Stomach; VIP (vasoactive intestinal polypeptide); VIP antiserum (Bojö, L. (236) 443)

Glycine; NMDA (N-methyl-D-aspartate) (Millan, M.J. (238) 445)

Tachykinins; Neurokinins; Analgesia; Spinal cord (Fleetwood-Walker, S.M. (242) 173)

**Pain (chronic)**
Diabetes; Substance P (Courteix, C. (241) 267)

**Pain controls (descending)**
L-Arginine; Nitric oxide (NO); $\beta$-Endorphin; Antinociception (Xu, J.Y. (236) 137)

**Pain pathway**
Opioids; Parabrachial; Noxious; Thermal stimuli; Analgesia; (Rat) (Huang, G.-F. (230) 279)

Opioid; Central nucleus; Amygdala; Parabrachial area; Nociception; (Rat) (Huang, G.-F. (236) 449)

**Pancreas (dog)**
Exocrine secretion; Glucagon; Somatostatin (Horiuchi, A. (237) 23)

**Pancreas (isolated)**
Pancreatic vessels; Insulin secretion; $\alpha$-Adrenoceptor antagonists; Verapamil; cAMP analogues; (Rat) (Skoglund, G. (236) 69)

**Pancreas (rat)**
Glutamate; AMPA receptors; Glucagon release (Bertrand, G. (237) 45)

**Pancreatic acini**
SK&F 96365; $Ca^{2+}$ dynamics; Amylase secretion (Busik, J. (247) 273)

**Pancreatic acini (isolated, rat)**
$CCK_B$/gastrin receptor antagonists; $CCK_A$ receptor antagonists; Loxiglumide (Höcker, M. (242) 105)

**Pancreatic amylase secretion**
Galanin (porcine, rat); Galanin fragments; $N^{\alpha}$-Acetyl-galanin-(9–29) (porcine, rat); Jejunal strip contraction (rat) (Rossowski, W.J. (240) 259)

**Pancreatic $\beta$-cells**
H 25; H 74; Co-transport; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

**Pancreatic vessels**
Insulin secretion; $\alpha$-Adrenoceptor antagonists; Verapamil; Pancreas (isolated); cAMP analogues; (Rat) (Skoglund, G. (236) 69)

**Papillary muscle (piglet)**
5-$HT_4$ receptors; Atria (piglet); SDZ 205-557 (Lorrain, J. (229) 105)

**Papillary tubules**
Endothelin; Inositol phosphates; Vasopressin (Woodcock, E.A. (247) 93)

**Parabrachial**
Opioids; Noxious; Thermal stimuli; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**Parabrachial area**
Opioid; Central nucleus; Amygdala; Nociception; Pain pathway; (Rat) (Huang, G.-F. (236) 449)

**Parachloroamphetamine**
MDMA (3,4-methylenedioxymethamphetamine); Fluoxetine; Deprenyl; Clorgyline; Nimodipine; Reserpine (Gu, X.F. (235) 51)

**Parathyroid hormone receptor**
cDNA sequence; Functional expression (Schneider, H. (246) 149)

**Paraventricular nucleus**
$\alpha$-Interferon; Stress; Corticosterone; Opioid receptors (Saphier, D. (236) 183)

**Parietal cell rat**
Acid production; Glucagon-like peptide 1-(7–36) amide; Epidermal growth factor; Transforming growth factor-$\alpha$; GTP-binding proteins (Schmidtler, J. (246) 59)

**Parietal cortex (human)**
Nimodipine; [$^3$H]Nitrobenzylthioinosine binding; Adenosine transporters (Deckert, J. (238) 131)

**Parkinsonism**
Dopamine $D_1$ receptors; A-77636; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); A-77636 ((1R,3S)-3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride); (Marmoset) (Kebabian, J.W. (229) 203)

AMPA receptors; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f] quinoxaline(1H,4H)dione sodium salt); Dyskinesia; Dopamine receptor agonists (Luquin, M.R. (235) 297)

Rotational behaviour; 6-Hydroxydopamine; Bromocriptine; SK&F-77434; Cocaine (Silverman, P.B. (242) 31)

**Parkinson's disease**
Dopamine; Electrooculogram; Haloperidol; Light peak; Transepithelial potential; Retina; (Chicken) (Rudolf, G. (230) 259)

Excitatory amino acids; Glutamate receptors; Neuroleptics (Papa, S.M. (232) 247)

Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; Motor behaviour; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); (Monkey) (Vermeulen, R.J. (235) 143)

Locus coeruleus; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatal dopamine; DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); C57Bl/6 mouse (Marien, M. (236) 487)

Ceruletide; CCK (cholecystokinin); $CCK_A$ receptors; $CCK_B$ receptors; Rotational behaviour (Fujisawa, M. (238) 127)

Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Bromocriptine; Dopamine $D_2$ receptor agonists; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); (Common marmoset) (Irifune, M. (238) 235)

Pyridines; (Goldfish) (Adeyemo, O.M. (240) 185)

$5\text{-}HT_3$ receptors; Huntington's disease; Putamen (human); [$^3$H] Granisetron (Steward, L.J. (242) 137)

Dopamine $D_1$ receptors; Dihydrexidine; SCH23390; SKF38393; Adenylate cyclase; (Rhesus monkey); (Rat) (Watts, V.J. (242) 165)

Ganglioside GM1; Glycosphingolipid derivatives; Excitotoxicity; Neuroprotection; Dopaminergic neurons (Skaper, S.D. (243) 91)

l-Deprenyl (selegiline); Hydroxyl radical; Dopamine; MPTP neurotoxin; $MPP^+$ (1-methyl-4-phenylpyridinium ion); Substantia nigra (Wu, R.-M. (243) 241)

**[$^3$H]Paroxetine**
[$^3$H]Mesulergine; $5\text{-}HT_{1C}$ receptor; 5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake site; Brain (rat) (Hulihan-Giblin, B.A. (239) 99)

**Passive avoidance**
$5\text{-}HT_{1A}$ receptors; Dorsal hippocampus; Memory; Anxiolytic effects; Antidepressant effects (Carli, M. (234) 215)

**Passive avoidance response**
Chlordiazepoxide; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

[D-Arg$^2$]Dermorphin analogue; $\mu$-Opioid receptors; Memory; $\beta$-Funaltrexamine (Ukai, M. (239) 237)

**Passive avoidance task**
Cerebral ischemia (focal); Riluzole; Neurological examination; (Rat) (Wahl, F. (230) 209)

TRH (thyrotropin-releasing hormone); Sustained release formulation; Scopolamine; AF64A (ethylcholine aziridinium ion); Water maze task (Miyamoto, M. (238) 181)

**Passive cutaneous anaphylaxis**
CR 2039; Antiallergic compounds; Bronchial anaphylaxis; Lung phosphodiesterase; (Guinea-pig) (Revel, L. (229) 45)

**Patch clamp**
Decavanadate; $K^+$ channels (ATP-sensitive); Ventricular cells (single) (Nakashima, H. (233) 219)

Glibenclamide; $K^+$ channel openers; Skeletal muscle $K_{ATP}$ channels (Allard, B. (236) 419)

Sympathetic ganglion; $Ca^{2+}$ channels; Nitric oxide (NO); Norepinephrine; Voltage-clamp (Chen, C. (243) 83)

GABA/benzodiazepine receptors; Triazolam; Primary culture; cDNA (Dučić, I. (244) 29)

**Patch-clamp method**
Arachidonic acid; Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

**Patch clamp (whole cell)**
Trimebutine; $K^+$ currents; Smooth muscle cells (ileal) (Nagasaki, M. (235) 197)

**Paw edema (mouse)**
PAF (platelet-activating factor, PAF-acether); PCA 4248; Anaphylaxis (Amorim, C.Z. (236) 301)

**Paw edema (rat)**
*M. velutina* compounds; Phospholipase $A_2$; Phospholipase C; Anti-inflammatory drugs (Neves, P.C.A. (243) 213)

**Paw pressure**
Antinociception; Arthritic rat; Enkephalin degradation; (Normal rat); (Mixed inhibitor) (Perrot, S. (241) 129)

**Paw test**
SCH 39166; Raclopride; Haloperidol; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors (Prinssen, E.P.M. (231) 275)

**$Pb^{2+}$**
NMDA receptor; Neurotoxicity; Brain (rat); (Age) (Guilarte, T.R. (248) 273)

**PCA 4248**
Anaphylaxis; Hyperresponsiveness; PAF (platelet-activating factor, PAF-acether) (Desquand, S. (235) 101)

PAF (platelet-activating factor, PAF-acether); Paw edema (mouse); Anaphylaxis (Amorim, C.Z. (236) 301)

PAF (platelet-activating factor, PAF-acether); Allergic inflammation (Martins, M.A. (237) 17)

**PCA 50938**
1,4-Dihydropyridines; Nicotinic acetylcholine receptors; Chromaffin cells; Nimodipine; BAY K 8644; Nifedipine; Nitrendipine; Furnidipine (López, M.G. (247) 199)

**PCA 50941**
Bay k 8644; Dihydropyridines; $Ca^{2+}$ channel agonists (Priego, J. (243) 25)

**PD123177**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; Losartan (Barnes, J.M. (230) 251)

**Penile erection**
5-HT (5-hydroxytryptamine, serotonin); Excessive grooming; Oxytocin concentration (plasma); $5\text{-}HT_{1C}$ receptors; $5\text{-}HT_2$ receptors; m-CPP (1-(3-chlorophenyl)piperazine); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Bagdy, G. (229) 9)

5-HT (5-hydroxytryptamine, serotonin); Male sexual behavior; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Yawning; m-CPP; (Primates); (Rhesus monkey) (Pomerantz, S.M. (243) 227)

**Pentamidine**
NMDA receptors; Neurotoxicity (Reynolds, I.J. (244) 175)

**(+)-Pentazocine**
$\sigma$ Receptor ligands; Dopamine; Microdialysis; Vacuous chewing; DTG (1,3-di-o-tolylguanidine) (Patrick, S.L. (231) 243)

**Pentobarbital**
$GABA_A$ receptors; Tolerance; Dependence; (Intracerebroventricular) (Tseng, Y.T. (236) 23)

Neuroactive steroids; Behaviour; Drug discrimination; Benzodiazepines; Ethanol (Ator, N.A. (241) 237)

Autoradiography; Dopamine $D_1$ receptors; Rolipram receptor; Cerebral ischemia; SCH 23390; $Ca^{2+}$/calmodulin independent cyclic adenosine monophosphate selective phosphodiesterase; (Gerbil) (Kanai, Y. (248) 191)

**Pentobarbital anesthesia**
$\gamma_2$-MSH ($\gamma_2$-melanocyte-stimulating hormone); ACTH-(4–10); Melanotropins; Hemodynamics; Urethane anesthesia; Excitability; (Conscious rat) (De Wildt, D.J. (233) 157)

**Pentylenetetrazole**
VIP (vasoactive intestinal polypeptide); VIP-(22–28); Seizures; Brain (rat) (Romualdi, P. (229) 149)

**Penumbra**
Almitrine; Raubasine; Middle cerebral artery; Ischemia; (Cat) (Chan, P. (231) 175)

**Pepsin**
EGTA; EDTA; Gastric acid secretion; Ethanol; Gastric ulcer; Stress (Glavin, G.B. (233) 269)

**Peptic ulcers**
Nitric oxide (NO); L-Arginine; Glyceryl trinitrate healing; Blood flow (Konturek, S.J. (239) 215)

**Peptide leukotriene receptor antagonists**
ONO-1078; Asthmatic responses; Airway hyperreactivity; Eosinophil accumulation (Nakagawa, N. (235) 211)

**Peptides**
Angiotensin-(1–7); Angiotensin receptors; DuP 753; Nitric oxide synthase; L-NAME ($N^G$-nitro-L-arginine methyl ester) (Osei, S.Y. (234) 35)

**Peptide synthesis**
Deltorphin; Opioid receptors; Computer modelling (Salvadori, S. (230) 357)

**Peptide YY**
Neuropeptide Y; Hippocampus (mouse); $\sigma$ Receptors (Roman, F.J. (242) 305)

**Perchlorate**
Gold ion; $Ca^{2+}$ channels (L-type); Skeletal muscle contraction; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

**Periphery (rat)**
High-affinity 'R' sites; $5\text{-}HT_3$ receptors; (*R*)-[$^3$H]Zacopride; (*S*)-[$^3$H]Zacopride; Brain (rat and human) (Kidd, E.J. (247) 45)

**Permeability**
Inflammatory bowel disease; Cyclosporin; Prostaglandin; Epithelium (Higa, A. (239) 171)

**Pertussis toxin**
Angiotensin II; Cholera toxin; Portal vein (rat); Dibutyryl cAMP (Zhang, J. (230) 95)

Morphine; Substance P; Quinpirole; Carbachol; U-50,488H (Bot, G. (231) 53)

Morphine; Catalepsy; Cholera toxin; cAMP levels (Massi, P. (243) 65)

**PET (positron emission tomography)**
Alzheimer's disease; Tetrahydroaminoacridine (THA, tacrine); Acetylcholinesterase; (Baboon); (Rat) (Tavitian, B. (236) 229)

N-(3-[$^{18}$F]Fluoropropyl)SCH 38548; Dopamine $D_1$ receptors (Mukherjee, J. (243) 287)

**P-glycoprotein**
Cancer chemotherapy; Cyclosporin A; FK506; Multidrug resistance; Rapamycin (Hoof, T. (246) 53)

**Phagocytosis**
Nitric oxide (NO); Immunocyte conformational changes; (Molluscs); (Bacteria) (Ottaviani, E. (248) 319)

**Ph CL28A**
Carrageenan; Oedema; Pleurisy; Prostacyclin; Thromboxane (Santana, A.C. (231) 237)

**Phencyclidine**
NMDA receptor antagonists; Dizocilpine; $\sigma$ Receptor ligands; Interneurons (Zhang, J. (230) 371)

Glucose metabolism; Psychosis; Schizophrenia; Histopathology; Limbic system (Gao, X.-M. (241) 7)

Glutamate; Dopamine; Ipsapirone; 5-HT (5-hydroxytryptamine, serotonin); MK-801 (Löscher, W. (242) 99)

Glutamate; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Löscher, W. (242) 263)

Monoclonal antibodies; NMDA receptors; Drug design (Casalotti, S.O. (247) 209)

**Phenobarbital**
Dependence; Glutamate receptors; Brain (Short, K.R. (230) 111)

Dystonia; Dopamine; GABA ($\gamma$-aminobutyric acid); Glutamate; Haloperidol (Richter, A. (231) 111)

**Phenoxybenzamine**
Mesenteric artery; Cyclic AMP; Dopamine receptor; Smooth muscle (vascular) (Hall, A.S. (247) 249)

**Phentolamine**
$K^+$ channel (*Xenopus laevis*); $K^+$ channel opener; KRN2391; Nicorandil; Cromakalim; Glibenclamide; Trifluoperazine (Sakuta, H. (244) 277)

**Phenylalkylamine binding site**
S312; Dihydrothienopyridine; Aorta (rat); Cerebral microvessels (rat); Dihydropyridine binding site (Dessy, C. (231) 435)

**Phenylephrine**
Lingual arteries (isolated); $\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; (Partial agonist) (Skrbic, R. (230) 131)

**Phenylethanolamine N-methyltransferase**
Glucocorticoid receptors; Adrenal medulla; Nicotine; Catecholamines (Betito, K. (238) 273)

**β-Phenyl-GABA**
Baclofen; $GABA_B$ receptors; Brain slices (rat); Ileum (guinea-pig); (Agonist/partial agonist) (Ong, J. (233) 169)

**Phenylglycine derivatives**
Metabotropic glutamate receptors; ACPD ((1S,3R)-1-aminocyclopentane-1,3-dicarboxylate) antagonists (Eaton, S.A. (244) 195)

**(+)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline**
(−)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; Methamphetamine; Cocaine; Nomifensine; Anococcygeus muscle (rat) (Watanabe, H. (243) 155)

**(−)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline**
(+)-4-Phenyl-1,2,3,4-tetrahydroisoquinoline; Methamphetamine; Cocaine; Nomifensine; Anococcygeus muscle (rat) (Watanabe, H. (243) 155)

**8-Phenyltheophylline**
Adenosine; Adenosine $A_2$ receptor-mediated vasodilatation; $K^+$ channels (ATP-sensitive); Glibenclamide (Orito, K. (231) 183)

**Phenytoin**
Haloperidol; Dextromethorphan; σ Binding sites; DTG (1,3-di-o-tolylguanidine); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl) piperidine) (Bailey, M.A. (240) 243)

**pH**
1,4-Dihydropyridine (enantiomers); $K^+$; $Ca^{2+}$; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

**pH (intracellular)**
$Na^+/H^+$ exchanger; Cell volume; *Ras* oncogene; cell proliferation; HOE 694 (Wöll, E. (246) 269)

**pH (low)**
Bronchoconstriction; Capsazepine; Citric acid; Capsaicin; Histamine (Satoh, H. (236) 367)

**Phorbol ester binding**
Diacylglycerol; Arachidonic acid; Protein kinase C isoforms (MacEwan, D.J. (246) 9)

**Phorbol esters**
Smooth muscle; Feedback inhibition (Bazan, E. (245) 173)

Protein kinase C; 2-Deoxyglucose; Hippocampus (Shibata, S. (245) 257)

**Phosphatidic acid**
Brain gangliosides (bovine); 1,2-Diacylglycerol; Diacylglycerolipids; Arachidonoyl-containing molecular species; Diabetic neuropathy (Bianchi, R. (239) 55)

**Phosphatidylinositol**
Cannabinoid; Hippocampus; Inositol phosphates (Nah, S.-Y. (246) 19)

**Phosphatidylinositol 4,5-bisphosphate**
Phospholipase C; Inositol 1,4,5-trisphosphate; Dopamine; Striatum (rat); Aging (Sugawa, M. (247) 39)

**Phosphatidylinositol metabolism**
NPPB (5-nitro-2-(3-phenylpropylamino)-benzoic acid); Fluorescence microscopy (single cell); Vasopressin; $Ca^{2+}$-activated chloride conductance; Smooth muscle (Pon, D.J. (245) 119)

**Phosphodiesterase**
Flosequinan; Heart failure; Cardiac muscle; Contractility; (Human) (Weishaar, R.E. (236) 363)

Platelets; Milrinone; Thromboxane $A_2$ (Jeremy, J.Y. (245) 67)

**Phosphodiesterase inhibition**
Atherosperminine; Smooth muscle (trachealis, guinea-pig); Cyclic nucleotides; *Fissistigma glaucescens* (Lin, C.-H. (237) 109)

**Phosphodiesterase inhibitors**
$Ca^{2+}$ channel antagonists; $\alpha_1$-Adrenoceptor antagonists; Aorta (rat); Aporphines (Ivorra, M.D. (231) 165)

Nitrate vasodilators; Zaprinast; $N^{\omega}$-Nitro-L-arginine; L-Arginine; Acetylcholine; Bradykinin; Blood pressure (De Garavilla, L. (234) 77)

Cardiotonic agent; $Ca^{2+}$; Thoracic aorta (rat); cAMP (Itoh, H. (240) 57)

Hypertension; $Ca^{2+}$ currents (heart); Voltage clamp (Scamps, F. (244) 119)

**Phosphoinositide**
HeLa cell; Histamine $H_1$ receptor; [$^3$H]Mepyramine; (+)-Chlorpheniramine; Temelastine (Arias-Montaño, J.-A. (245) 291)

**Phosphoinositide hydrolysis**
Excitatory amino acids; Glutamate; Metabotropic; NBQX (2,3-dihydroxy-6-nitro-7-sulpha-moylbenzo(F)-quinoxaline) (Suzdak, P.D. (245) 215)

Ethanol; Brain (rat); Choroid plexus; $5\text{-}HT_{1C}$ receptors (Pandey, S.C. (247) 81)

Muscarinic receptors; Organophosphate pesticides; Development; mRNA (Balduini, W. (248) 281)

**Phosphoinositide metabolism**
Actyl-l-carnitine; Histotoxic hypoxia; Cyanide; Spatial learning (Blokland, A. (235) 275)

Muscarinic $M_3$ receptors; HSDM1C1 cells; [$^3$H]N-Methylscopolamine binding (Eglen, R.M. (244) 49)

**Phosphoinositide turnover**
$5\text{-}HT_2$ receptor regulation; Behavioural response; mRNA levels; Gene transcription (Rinaldi-Carmona, M. (246) 73)

**Phospholipase $A_2$**
Inflammation; Edema (Morgan, D.W. (235) 45)

Paw oedema (rat); *M. velutina* compounds; Phospholipase C; Anti-inflammatory drugs (Neves, P.C.A. (243) 213)

Phosphotyrosine phosphatase; Melittin; Arachidonic acid; EGF (epidermal growth factor); Fibroblasts (Errasfa, M. (247) 73)

Pleurisy; Carrageenan; Zymosan; Inflammation; Thromboxane $B_2$ (Tesson, F. (248) 27)

**Phospholipase C**
Paw oedema (rat); *M. velutina* compounds; Phospholipase $A_2$; Anti-inflammatory drugs (Neves, P.C.A. (243) 213)

Phosphatidylinositol 4,5-bisphosphate; Inositol 1,4,5-trisphosphate; Dopamine; Striatum (rat); Aging (Sugawa, M. (247) 39)

**Phospholipases**
Endothelins; Sarafotoxins; Endothelin receptor subtypes; C6 glioma; Fibroblasts (Rat-1, Swiss 3T3) (Ambar, I. (245) 31)

**Phosphoramidon**
Endothelin-3; Big endothelin-3; Hypertensive effect; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

Cilia; Maxillary sinus; Mucociliary activity; Tachykinins; Tachykinin receptors; (Rabbit) (Lindberg, S. (231) 375)

Endothelin-converting enzyme; Big endothelin-1; Big endothelin-3; Endothelin; Hemodynamics; (Rat) (Pollock, D.M. (231) 459)

Big endothelin-1; Big endothelin-3; Microcirculation; Cheek pouch (hamster); Skin blood flow (rat) (Lawrence, E. (233) 243)

Big-endothelin-1; Endothelin-1; Endothelin-3; Endothelin $ET_A$ receptor; BQ-123; Endothelin-converting enzyme; Uterus (rat) (Rae, G.A. (240) 113)

**Phosphotyrosine phosphatase**
Melittin; Arachidonic acid; EGF (epidermal growth factor); Phospholipase $A_2$; Fibroblasts (Errasfa, M. (247) 73)

**Photoaffinity ligand**
Excitatory amino acid receptors; NMDA receptor antagonist (Benke, D. (246) 179)

**Photoaffinity probe**
Opioid receptors; Opioid; Enkephalins; Autoradiography (Pasquini, F. (243) 39)

**Phycoerythrin**
Interleukin-1; Interleukin-6; Interleukin receptors; Smooth muscle (vascular) (French, J.F. (233) 109)

**Phyllolitorin**
Bombesin; Gastrin-releasing peptide (GRP); Scratching behaviour; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

**Physical dependence**
Opioid receptors; Analgesia; 14-Alkoxymetopons; (Binding) (Fürst, Z. (236) 209)

**Physostigmine**
$\alpha_2$-Adrenoceptors; [$^3$H]Clonidine; [$^3$H]UK 14,304 (bromoxidine); [$^3$H]RX 821002 (2-methoxy idazoxan); Neostigmine; Diisopropylfluorophosphate; Pilocarpine (Olmos, G. (236) 467)

High voltage spindles; Slow wave; Muscarinic $M_1$ receptor; Muscarinic $M_2$ receptor; Tetrahydroaminoacridine; Pilocarpine; AF102B; Oxotremorine (Riekkinen, Jr., P. (240) 1)

Tetrahydroaminoacridine; $\beta$-Adrenoceptors; Adenylate cyclase; Hippocampus; Cortex; cAMP (Vivas, N.M. (245) 9)

**Pilocarpine**
Seizures (chemically induced); Epilepsy; Anticonvulsants; ACTH (adrenocorticotrophic hormone) (Croiset, G. (229) 211)

$\alpha_2$-Adrenoceptors; [$^3$H]Clonidine; [$^3$H]UK 14,304 (bromoxidine); [$^3$H]RX 821002 (2-methoxy idazoxan); Neostigmine; Physostigmine; Diisopropylfluorophosphate (Olmos, G. (236) 467)

High voltage spindles; Slow wave; Muscarinic $M_1$ receptor; Muscarinic $M_2$ receptor; Physostigmine; Tetrahydroaminoacridine; AF102B; Oxotremorine (Riekkinen, Jr., P. (240) 1)

**Pinacidil**
CGRP (calcitonin gene-related peptide); Uterine artery (human); $K^+$ channels; Pregnancy; Glybenclamide; Tetraethylammonium (Nelson, S.H. (242) 255)

**Pineal gland**
c-*fos*; *jun*-B; Adrenoceptors; Second messengers; Protein kinase (Carter, D.A. (244) 285)

Immediate-early genes; c-*jun*; Adrenoceptors; cAMP (Carter, D.A. (247) 97)

**Piracetam**
Ucb L059; Seizures; Epilepsy; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

**Pirarubicin**
Doxorubicin; Aclarubicin; Heart (guinea-pig); Antimuscarinic action; Positive inotropic effect; Potentiated postrest contraction; Time to peak twitch tension (Temma, K. (234) 173)

**Pirenzepine**
Muscarinic $M_1$ receptors; Muscarinic $M_1$ receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

**Pituitary**
L-Thyroxine administration (repeated); Methimazole administration (repeated); Plasma endothelin concentration; Endothelin mechanisms; Cerebral cortex; Hypothalamus (Rebello, S. (237) 9)

EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Radioligand binding (in vivo); Prolactin; Dopamine $D_2$ receptors; NPA (*R*-(−)-*N*-*n*-propylnorapomorphine); Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5]azepine); (Receptor reserve); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Ekman, A. (243) 295)

**Place preference**
Clonidine; $\alpha_2$-Adrenoceptors; (Rat) (Cervo, L. (238) 201)

**Place preference conditioning**
Verapamil; d-Amphetamine; Reinforcement; $Ca^{2+}$ channel inhibitors (Pucilowski, O. (240) 89)

**Plasma**
Angiotensin converting enzyme; Ramipril; Renal brush border membrane; Induction (Michel, B. (242) 237)

**Plasma endothelin concentration**
L-Thyroxine administration (repeated); Methimazole administration (repeated); Endothelin mechanisms; Cerebral cortex; Hypothalamus; Pituitary (Rebello, S. (237) 9)

**Plasma extravasation**
Substance P; Neurokinin A; Capsaicin; Airway constriction (Murai, M. (236) 7)

Neurogenic inflammation; Neuropeptides (Morikawa, M. (241) 83)

Levodropropizine; Capsaicin; Substance P; Sensory nerves; Neurogenic inflammation (Yamawaki, I. (243) 1)

**Plasma exudation**
Asthma; Edema; Bradykinin; Airway obstruction; Vascular permeability; OKY-046; Indomethacin (Arakawa, H. (229) 131)

Airway obstruction; Asthma; Development; Maturation; Vascular permeability (Yokoyama, T. (236) 427)

Bradykinin; Histamine; Substance P; Cromakalim; Vascular permeability; Airways (Martin, C.A.E. (239) 119)

Cigarette smoke; Vagus nerve stimulation; $K^+$ channel opener; Glibenclamide (Lei, Y.-H. (239) 257)

**Plasma leakage**
Complement; Zymosan; PAF (platelet-activating factor, PAF-acether); WEB 2086; SM-12502 (Damas, J. (231) 231)

**Plasma L-kynurenine**
Noncholinergic actions; Organophosphorous insecticides; Methylcarbamate insecticides; Kynurenine formamidase inhibition; Xanthurenic acid (urinary excretion); (Structural requirements) (Pewnim, T. (248) 237)

**Plasma protein extravasation**
Neurogenic inflammation; Dura mater; CGRP (calcitonin gene-related peptide); Tachykinin receptors (O'Shaughnessy, C.T. (236) 319)

**Platelet aggregation**
Endothelin-1; Endothelin $ET_A$ receptors; BQ-123; Prostacyclin (Hermán, F. (236) 143)

FR122047; Cyclooxygenase; Aspirin (Dohi, M. (243) 179)

Nitric oxide (NO); $Ca^{2+}$ (Ivanova, K. (244) 37)

cGMP analog; $Ca^{2+}$; Nitric oxide (NO) (Menshikov, M.Y. (245) 281)

Glycosphingolipids; Lysogangliosides; Thrombin; 5-HT (5-hydroxytryptamine, serotonin); Tromboxane $B_2$; Bleeding; Coagulation; Fibrinolysis (Tubaro, E. (248) 175)

**Platelets**
Antiplatelet compound; IBI P-05006; Thromboxane $A_2$/prostaglandin endoperoxides receptor antagonists (Rotondo, S. (232) 41)

5-HT (5-hydroxytryptamine, serotonin); Coronary artery (human); Sumatriptan; Ergotamine; 5-$HT_{1D}$-like receptors; 5-$HT_2$ receptors (Bax, W.A. (239) 203)

Milrinone; Phosphodiesterase; Thromboxane $A_2$ (Jeremy, J.Y. (245) 67)

Trimetazidine; Membrane fluidity; Aggregation; cAMP (Devynck, M.-A. (245) 105)

Organic nitroesters; Nitric oxide (NO); Cyclic GMP (Weber, A.-A. (247) 29)

Leukocyte elastase (human); Neutrophils (Renesto, P. (248) 151)

**Platelets (human)**
Shape-change parameter; Protein kinase C; Disc-sphere change; Thrombin; 1-Oleoyl-2-acetyl-glycerol (Ozaki, Y. (235) 255)

5-HT (5-hydroxytryptamine); Synergism (Roevens, P. (245) 273)

**Pleurisy**
Carrageenan; Oedema; Ph CL28A; Prostacyclin; Thromboxane (Santana, A.C. (231) 237)

Phospholipase $A_2$; Carrageenan; Zymosan; Inflammation; Thromboxane $B_2$ (Tesson, F. (248) 27)

Endotoxin; Lipopolysaccharide; Eosinophils (Bozza, P.T. (248) 41)

**Polyamines**
MK-801; NMDA (N-methyl-D-aspartate) (Marvizón, J.-C. (244) 103)

Gabapentin; GABA (γ-aminobutyric acid); Baclofen; $GABA_A$ receptors; $GABA_B$ receptors; NMDA (N-methyl-D-aspartate); Glycine; Anticonvulsants (Suman-Chauhan, N. (244) 293)

*N*-Methyl-D-aspartate receptor; Ethanol; c-*fos*; Seizure (Matsumoto, I. (247) 289)

**Polychlorinated biphenyls**
Hepatic foci (altered); Tumour promotion (Hemming, H. (248) 163)

**Polyclonal antibody**
Idazoxan; Clonidine; Imidazoline; Imidazoline receptor (Bennai, F. (246) 45)

**Polycyclic aromatic hydrocarbons**
Cytochrome P450 1A1 (human); Cytochrome P450 1A1 recombinant expression vector; V79 Chinese hamster cells; Benzo[a]pyrene (Schmalix, W.A. (248) 251)

**Polydeoxyribonucleotides**
Adenosine receptors; Purinoceptors; Adenosine; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

**Polymerase chain reaction**
Spinal cord; Substance P; Neurokinin A; Tachykinin receptors; Acetylcholine release (Suzuki, H. (241) 105)

**Polymorphonuclear leukocytes**
Superoxide anion; PAF (platelet-activating factor, PAF-acether); Alveolar macrophages; Thromboxane $A_2$; (Guinea-pig) (Kato, M. (232) 7)

Adenosine analogs; TNF (tumor necrosis factor); Endothelium; Anti-inflammatory agents (Cerri, M.A. (232) 291)

Nitric oxide (NO); Red blood cells deformability (Korbut, R. (234) 17)

**Polyol pathway**
Aldose reductase; Aorta; EDRF (endothelium-derived relaxing factor); Galactosaemia; Nitric oxide (NO) (Cameron, N.E. (243) 47)

**Porcine endocardial endothelium**
EDRF (endothelium-derived relaxing factor); Human platelets (washed); NO synthase inhibitors (Siney, L. (229) 223)

**Porsolt swimming test**
Adrenalectomy; Immobility; Hypothyroidism; Food deprivation (Jefferys, D.E. (239) 189)

**Portal hypertension**
$Ca^{2+}$ channels; Vasorelaxation; Portal vein; Mesenteric artery; (Rat) (Suga, T. (242) 129)

**Portal vein**
Quercetin; Aorta (rat) (Duarte, J. (239) 1)

$Ca^{2+}$ channels; Vasorelaxation; Portal hypertension; Mesenteric artery; (Rat) (Suga, T. (242) 129)

Noradrenaline; Adrenaline; $\beta_2$-Adrenoceptors (prejunctional); Catecholamine overflow (evoked); (Freely moving rats) (Coppes, R.P. (243) 273)

**Portal vein (rat)**
Angiotensin II; Cholera toxin; Pertussis toxin; Dibutyryl cAMP (Zhang, J. (230) 95)

**Positive cooperativity**
Nucleoside transport; R75231; Synaptosomes, Erythrocytes (human) (Jones, K.W. (246) 97)

**Positive inotropic effect**
Doxorubicin; Pirarubicin; Aclarubicin; Heart (guinea-pig); Antimuscarinic action; Potentiated postrest contraction; Time to peak twitch tension (Temma, K. (234) 173)

**Positive inotropic response**
$\alpha_1$-Adrenoceptor subtype; Heart (rat) (Noguchi, H. (240) 291)

**Positive inotropy**
DPI 201-106; BDF 9148; (Enantiomers) (Hoey, A. (231) 477)

**Posterior hypothalamus**
Taurine release; Blood pressure; Veratridine; Tetrodotoxin; Push-pull cannula (Singewald, N. (240) 21)

**Postischemic recovery**
MK-801; Postischemic survival; Ischemia (forebrain); (Mongolian gerbil) (Von Lubitz, D.K.J.E. (233) 95)

**Postischemic survival**
MK-801; Postischemic recovery; Ischemia (forebrain); (Mongolian gerbil) (Von Lubitz, D.K.J.E. (233) 95)

**Postjunctional $\alpha_2$-adrenoceptors**
Adrenergic reactivity; $\alpha_2$-Adrenoceptor antagonists; $\alpha_2$-Adrenoceptor agonists; Tail artery (rat); Aging (Tsai, H. (237) 311)

**Poststatin**
Bradykinin; Degradation pathway; Urine; Kininase (Majima, M. (232) 181)

**Postsynaptic potentials**
Acamprosate (calciumacetylhomotaurinate); Excitatory amino acids; GABA ($\gamma$-aminobutyric acid); Neocortex; Neurotransmission (Zeise, M.L. (231) 47)

**Potentiated postrest contraction**
Doxorubicin; Pirarubicin; Aclarubicin; Heart (guinea-pig); Antimuscarinic action; Positive inotropic effect; Time to peak twitch tension (Temma, K. (234) 173)

**[$^3$H](+)-3-PPP ([$^3$H](+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine)**
$\sigma$ Receptors; $K^+$ channels; Antiarrhythmic drugs class III (Jeanjean, A.P. (241) 111)

**1-PP (1-(2-pyrimidinyl)-piperazine)**
Buspirone; Glucose utilization; Hippocampus; Lateral habenular nucleus; 2-Deoxyglucose (Grasby, P. (230) 41)

**Prazosin binding**
$\alpha_1$-Adrenoceptors; Contraction; Smooth muscle (vascular) (Sayet, I. (246) 275)

**Prefrontal cortex**
Neurotensin; Xenopsin; Self-stimulation (Ferrer, J.M.R. (231) 39)

Amphetamine; Dopamine; Stress; Sensitization (Hamamura, T. (237) 65)

HA-966; (+)-MK-801; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Nucleus accumbens (Morrow, B.A. (238) 255)

Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; Microdialysis; (Rat) (Santiago, M. (239) 83)

Microdialysis; Dopamine; Schizophrenia; Amperozide; Clozapine (Pehek, E.A. (240) 107)

Methamphetamine; Dendritic spine density; Reactive synaptogenesis; (Gerbil) (Dawirs, R.R. (241) 89)

**5$\alpha$-Pregnan-3$\alpha$-ol-20-one (5$\alpha$3$\alpha$)**
$\beta$-Alanine; Glycine receptor; $GABA_A$ receptor; Progesterone; Neuromodulation (Wu, F.-S. (246) 239)

**Pregnancy**
Myometrium; Cervical smooth muscle; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Electrical field stimulation (Okawa, T. (230) 341)

CGRP (calcitonin gene-related peptide); Uterine artery (human); $K^+$ channels; Glybenclamide; Tetraethylammonium; Pinacidil (Nelson, S.H. (242) 255)

**Prejunctional**
$\beta$-Adrenoceptors; Desensitization; Facilitation; Stimulus train length (Lakhlani, P.P. (230) 107)

**Prepiriform cortex**
DTG (1,3-di(2-tolyl)guanidine); $\sigma$ Receptor ligands; Haloperidol; Anticonvulsants (Roth, J.E. (236) 327)

**Prepiriform cortex (deep)**
Seizures; Nitric oxide (NO); Excitatory amino acid; L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

**Pressor effects**
Endothelin; Prostacyclin; Endothelin $ET_A$ receptors; Kidney (rabbit) (Télémaque, S. (237) 275)

**Pressor response**
Dopamine receptors; Locomotor activity; Turning behaviour; Yawning; Blood pressure; Body temperature; Spontaneously hypertensive rats (SHR) (Van den Buuse, M. (243) 169)

**Primary cell culture**
Cholecystokinin; $CCK_A$ receptors; Slow depolarization; Sympathetic neurons (mammalian); Electrophysiology (Knoper, S.R. (232) 65)

**Primary culture**
GABA/benzodiazepine receptors; Triazolam; Patch clamp; cDNA (Dučić, I. (244) 29)

**Primary neuronal cultures**
Substantia nigra; Locus coeruleus; κ-Opioid receptors; μ-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

**Principal factor analysis**
Dopamine $D_1$ receptor agonists; Dopamine $D_2$ receptor agonists; Nucleus accumbens; Oral behaviour; SK&F 38393; Quinpirole (Koene, P. (233) 151)

**Prion**
Scrapie; Cortical cells; Memantine; NMDA receptor; Neurons; Adamantanes; MK-801 (Müller, W.E.G. (246) 261)

**Probenecid**
Dystonia; Glutamate (Richter, A. (231) 287)

**Procholecystokinin mRNA**
Catecholamine re-uptake blockers; Cortex injury; Sympathetic nervous system (Mondeh, J.D. (240) 39)

**Proenkephalin mRNA**
NMDA receptors; Glutamate; Striatum; Accumbens; MK-801 (Angulo, J.A. (244) 317)

**Progesterone**
Steroids; Myometrium; Uterine artery; Estrogen; Diethylstilbestrol (Kostrzewska, A. (233) 127)

β-Alanine; Glycine receptor; $GABA_A$ receptor; 5α-Pregnan-3α-ol-20-one (5α3α); Neuromodulation (Wu, F.-S. (246) 239)

**Prolactin**
Ipsapirone; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); $5\text{-}HT_{1A}$ receptors; $5\text{-}HT_2$ receptors; Anxiolysis; Glucose; Corticosterone; Behaviour (Baudrie, V. (231) 395)

Cocaine (neuroendocrine); 5-HT (5-hydroxytryptamine, serotonin); Renin; ACTH (adrenocorticotropic hormone) (Levy, A.D. (241) 275)

EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Radioligand binding (in vivo); Pituitary; Dopamine $D_2$ receptors; NPA (*R*-(−)-*N*-*n*-propylnorapomorphine); Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5]azepine); (Receptor reserve); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Ekman, A. (243) 295)

**Proliferation**
Alprazolam; BN-52021; Endothelin; Mesangial cells; PAF (platelet-activating factor, PAF-acether) (Montero, A. (243) 235)

Smooth muscle (vascular); $Ca^{2+}$ channel antagonists (Agrotis, A. (244) 269)

$Ca^{2+}$; $Ca^{2+}$ channels; $Ca^{2+}$ channel antagonists; ω-Conotoxin; ω-Agatoxin IVA; Small cell lung carcinoma cells (Cattaneo, M.G. (247) 325)

**Promiscuous coupling**
Transfection; AMP formation; Neurotensin (Yamada, M. (244) 99)

**Pronociception**
Naloxone; Morphine; Formalin; Antinociception; (Rat) (Wheeler-Aceto, H. (236) 193)

**Propentofylline**
Basal forebrain; Ibotenic acid; Choline acetyltransferase; Learning and memory; Nerve growth factor (Fuji, K. (236) 411)

**Propofol**
Asthma; Anaesthetics; Ketamine; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

**d-Propranolol**
dl-Propranolol; Ischaemia; Reperfusion; Metabolism (Hoque, A.N.E. (236) 269)

**dl-Propranolol**
d-Propranolol; Ischaemia; Reperfusion; Metabolism (Hoque, A.N.E. (236) 269)

**Prostacyclin**
Carrageenan; Oedema; Ph CL28A; Pleurisy; Thromboxane (Santana, A.C. (231) 237)

Endothelial cells; $Ca^{2+}$ indicators; Aorta (bovine); Arachidonate metabolism (Boeynaems, J.-M. (233) 13)

Endothelin-1; Endothelin $ET_A$ receptors; BQ-123; Platelet aggregation (Hermán, F. (236) 143)

Endothelin; Pressor effects; Endothelin $ET_A$ receptors; Kidney (rabbit) (Télémaque, S. (237) 275)

**Prostaglandin**
$Cl^-$ secretion; Colitis; cAMP; Inflammatory bowel disease; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

Inflammatory bowel disease; Cyclosporin; Epithelium; Permeability (Higa, A. (239) 171)

**Prostaglandin $D_2$**
Eye; Inflammation; Intraocular pressure; Eosinophils; DP receptors (Woodward, D.F. (230) 327)

**Prostaglandin $E_2$**
Smooth muscle cells; EP receptors (Botella, A. (237) 131)

**9α,11β-Prostaglandin $F_2$**
Bronchial hyperresponsiveness; Thromboxane $A_2$ receptor antagonists (Kurosawa, M. (238) 335)

**Prostaglandin $F_{2\alpha}$**
Dihydropyridines; $Mg^{2+}$; 5-HT (5-hydroxytryptamine, serotonin); Cerebral vasospasm; (Human) (Alborch, E. (229) 83)

Inhibin; Oestradiol-17β; Ovarian hormones; Gonadotrophin; Indomethacin (Kogo, H. (231) 481)

**Prostaglandin release**
OP-41483 (prostacyclin analog); Acetylcholine release; Myenteric plexus (Fukunaga, Y. (233) 237)

**Prostaglandins**
Stomach; Nitric oxide (NO); L-Arginine; Indomethacin (Konturek, S.J. (229) 155)

Substance P; Aqueous humor; Indomethacin; Timolol; Surgical miosis (Kieselbach, G. (235) 117)

Fever; Glucocorticoids (Coelho, M.M. (238) 391)

Smooth muscle (vascular); $Ca^{2+}$ channels; Protein kinase C; Norepinephrine; Dihydropyridine (Rapoport, R.M. (243) 207)

Protein kinase C; Osteoblasts; Bradykinin (Ljunggren, Ö. (244) 111)

Nicotine; Cotinine; Thromboxane; Leukotrienes (Saareks, V. (248) 345)

**Prostaglandins E**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Temperature; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

**Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$)**
Myometrium; Cervical smooth muscle; Pregnancy; Electrical field stimulation (Okawa, T. (230) 341)

**Prostanoids**
E3330; Liver injury; Galactosamine; TNF-$\alpha$ (tumor necrosis factor-$\alpha$); Leukotrienes (Nagakawa, J.-i. (229) 63)

Toluene diisocyanate; Sensory nerves (Mapp, C.E. (248) 277)

**Protein kinase**
c-*fos*; *jun*-B; Pineal gland; Adrenoceptors; Second messengers (Carter, D.A. (244) 285)

**Protein kinase C**
Platelets (human); Shape-change parameter; Disc-sphere change; Thrombin; 1-Oleoyl-2-acetyl-glycerol (Ozaki, Y. (235) 255)

5-HT (5-hydroxytryptamine, serotonin); Transmitter interaction; Desensitization; Receptor internalization (Rahman, S. (238) 173)

Smooth muscle (vascular); Prostaglandins; $Ca^{2+}$ channels; Norepinephrine; Dihydropyridine (Rapoport, R.M. (243) 207)

cAMP; Adenylate cyclase; Adrenal chromaffin cells; Second messengers; Adrenal medulla (Marley, P.D. (244) 7)

Prostaglandins; Osteoblasts; Bradykinin (Ljunggren, Ö. (244) 111)

Angiotensin II; Isoenzymes; Inositol 1,4,5-trisphosphate ($InsP_3$); $Ca^{2+}$; Diacylglycerol; Mesangial cells (Ochsner, M. (245) 15)

Phorbol ester; 2-Deoxyglucose; Hippocampus (Shibata, S. (245) 257)

**Protein kinase C (cardiac)**
Verapamil; $\alpha_1$-Adrenoceptors (cardiac); Inositol 1,4,5-trisphosphate (cardiac); Diabetic cardiomyopathy; (Rat) (Tanaka, Y. (244) 105)

**Protein kinase C isoforms**
Diacylglycerol; Arachidonic acid; Phorbol ester binding (MacEwan, D.J. (246) 9)

**Protein synthesis**
Thymidine; Uridine; Leucine; DNA synthesis; RNA synthesis; Thymidine kinase activity (Garg, U.C. (237) 243)

**Proximal tubule**
Adrenoreceptor; Noradrenaline; Thyroid hormone; In situ hybridization (Meister, B. (247) 229)

**Pseudoirreversible binding**
Opioid; $\delta$-Opioid receptor; Deltorphin (substituted) (Wild, K.D. (246) 25)

**Psychosis**
Methamphetamine; $\sigma$ Receptors (Itzhak, Y. (230) 243)

Phencyclidine; Glucose metabolism; Schizophrenia; Histopathology; Limbic system (Gao, X.-M. (241) 7)

**Psychostimulants**
Cocaine; *C-fos*; Nucleus accumbens; Reward (Heilig, M. (236) 339)

**4-PTIQ (4-phenyltetrahydroisoquinoline)**
Microdialysis; Cocaine; Nomifensine; Methamphetamine; Dopamine; Nucleus accumbens (Tateyama, M. (240) 51)

**Pulmonary artery (pig)**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; cGMP; EDRF (endothelium-derived relaxing factor); Nitric oxide (NO) (Pepke-Zaba, J. (235) 169)

**Pulmonary hemodynamics**
Thromboxane receptor antagonists; Inhalation injury (one lung); Toxic airway damages; Thromboxane; (Sheep) (Loick, H.M. (248) 75)

**Pulmonary hypertension**
Nitric oxide (NO); Endotoxin shock; Adult respiratory distress syndrome (ARDS); Endothelin; Noradrenaline; Neuropeptide Y (Weitzberg, E. (233) 85)

**Pulmonary vascular bed**
PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasodilation (Cheng, D.Y. (243) 79)

**Pulp**
Nitric oxide (NO); Afferent nerves; Blood flow; Oral mucosa; Lip; Submandibular gland (Kerezoudis, N.P. (241) 209)

**Purinoceptors**
Urinary bladder; ATP; Nucleotides (Theobald, Jr., R.J. (229) 125)

Anococcygeus (rabbit); Nitric oxide (NO); Nitric oxide synthase inhibitors; ATP; Adenosine; 8-(p-Sulfophenyl)theophylline; Suramin (Graham, A.M. (237) 93)

Adenosine receptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

**Purkinje fibers**
Bradycardiac agents; Sinus node inhibitors; Zatebradine; Pacemaker currents; Iontophoresis; Use-dependent blockade; (Electrophysiology) (Van Bogaert, P.P. (229) 55)

Lidocaine; Use dependence; Acidosis; Electrophysiology (developmental) (Hamra, M. (230) 167)

Lidocaine; Use dependence; Acidosis; Electrophysiology (developmental) (Hamra, M. (236) 497)

**Puromycin aminonucleoside**
Dup 753; Nephrosis (Yayama, K. (236) 337)

**Push-pull cannula**
Taurine release; Posterior hypothalamus; Blood pressure; Veratridine; Tetrodotoxin (Singewald, N. (240) 21)

**Putamen (human)**
5-$HT_3$ receptors; Huntington's disease; Parkinson's disease; [$^3$H] Granisetron (Steward, L.J. (242) 137)

**Pyridines**
Parkinson's disease; (Goldfish) (Adeyemo, O.M. (240) 185)

**Quercetin**
Aorta (rat); Portal vein (Duarte, J. (239) 1)

**Quinidine**
Nicorandil; Cardiac arrhythmias; Atria (rabbit); Tolbutamide (Le Grand, B. (229) 91)

**Quinine**
Dopamine (renal); Fenoldopam; Quinpirole; SCH 23390; Cis-flupentixol; LLC-$PK_1$ cells; Organic cations (renal); Dopamine receptors (Dawson, Jr., R. (240) 277)

**Quinpirole**
Pertussis toxin; Morphine; Substance P; Carbachol; U-50,488H (Bot, G. (231) 53)

Dopamine $D_1$ receptor agonists; Dopamine $D_2$ receptor agonists; Nucleus accumbens; Oral behaviour; Principal factor analysis; SK&F 38393 (Koene, P. (233) 151)

Autoradiography; 6-Hydroxydopamine; SK&F 38393; Basal ganglia (Engber, T.M. (236) 385)

Turning behaviour; Dopamine $D_1/D_2$ receptor interaction; Nucleus accumbens; SKF 38393; Limb stepping (Saigusa, T. (237) 161)

Jumping; Dopamine; Receptor supersensitivity (Kostrzewa, R.M. (239) 183)

Dopamine (renal); Fenoldopam; SCH 23390; Cis-flupentixol; LLC-$PK_1$ cells; Organic cations (renal); Dopamine receptors; Quinine (Dawson, Jr., R. (240) 277)

**[$^3$H]Quinpirole**
Monoamine oxidase inhibitor; Receptor binding; Striatum; CNS (central nervous system); (Rat) (Levant, B. (246) 171)

**Quisqualate**
Metabotropic glutamate receptors; Dicarboxycyclopropylglycine; (Hippocampal slices) (Nicoletti, F. (245) 297)

**Quisqualate priming**
Excitatory amino acids; Sensitization; Cortical wedge; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

**R75231**
Nucleoside transport; Synaptosomes, Erythrocytes (human); Positive cooperativity (Jones, K.W. (246) 97)

**Rabies virus**
5-HT (5-hydroxytryptamine, serotonin); 5-HT binding; 5-HT release; 5-HT receptors (Ceccaldi, P.-E. (245) 129)

**Raclopride**
Paw test; SCH 39166; Haloperidol; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors (Prinssen, E.P.M. (231) 275)

Cerebral glucose metabolism (regional); Benzamides; Neuroleptics (Tarazi, F.I. (232) 71)

**[$^3$H]Raclopride binding**
Remoxipride; Remoxipride metabolites; Antipsychotics; Dopamine receptors (Mohell, N. (238) 121)

**Radiation inactivation**
Opioid receptor; G-protein; Tolerance; (Uncoupling) (Tao, P.-L. (246) 233)

**Radicicol**
Cell differentiation modulator; Anti-angiogenic action; Embryonic angiogenesis; Chorioallantoic membrane (Oikawa, T. (241) 221)

**Radiolabeled ligand binding**
$\sigma$ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl) carbazol); (+)-SKF10,047; Stereotyped behaviour (Tanaka, M. (238) 89)

$\sigma$ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride); Brain (guinea-pig) (Tanaka, M. (238) 93)

**Radioligand binding**
Tachykinin; $NK_2$ receptors; Neurokinin A; Neuropeptide $\gamma$; Gastric fundus (rat) (Burcher, E. (233) 201)

Dopamine $D_1$ receptors; Autoradiography; Umbilical artery; (Human) (Ferreira-de-Almeida, J.A. (234) 209)

$\alpha_{2B}$-Adrenoceptors; Expression; (*E. coli*) (Xia, Y. (246) 129)

Opioids; $\delta$-Opioid receptors; BW 373U86; Guanine nucleotides (Wild, K.D. (246) 289)

**Radioligand binding (in vivo)**
EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Pituitary; Prolactin; Dopamine $D_2$ receptors; NPA (*R*-(−)-*N*-*n*-propyl-norapomorphine); Talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5]azepine); (Receptor reserve); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Ekman, A. (243) 295)

**Ramipril**
Angiotensin converting enzyme; Plasma; Renal brush border membrane; Induction (Michel, B. (242) 237)

Adrenoceptors; Genetic hypertension; Oscillation (Watts, S.W. (242) 245)

**Ramiprilat**
NADH fluorescence; Angiotensin; Angiotensin-converting enzyme; Myocardial ischemia; Angiotensin-converting enzyme inhibitors; Cardioprotection (Rump, A.F.E. (241) 201)

**Ranitidine**
Adenosine deaminase; Gastric ulcer (Namiot, Z. (243) 301)

**Rapamycin**
Cancer chemotherapy; Cyclosporin A; FK506; Multidrug resistance; P-glycoprotein (Hoof, T. (246) 53)

**Raphe**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; S 15535; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

**Raphe nuclei**
5-HT uptake; Fluvoxamine; Antidepressants; Frontal cortex; Microdialysis (in vivo) (Bel, N. (229) 101)

5-HT uptake; Fluvoxamine; Antidepressants; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

***Ras* oncogene**
pH (intracellular); $Na^+/H^+$ exchanger; Cell volume; cell proliferation; HOE 694 (Wöll, E. (246) 269)

**Raubasine**
Almitrine; Middle cerebral artery; Ischemia; Penumbra; (Cat) (Chan, P. (231) 175)

**[$^3$H]Rauwolscine binding**
$\alpha_2$-Adrenoceptor subtype; Stable transfection; Cell line; (Antagonist) (Marjamäki, A. (246) 219)

**$^{86}Rb^+$ flux**
Pancreatic $\beta$-cells; H 25; H 74; Co-transport (Sandström, P.-E. (238) 403)

**RB101 (mixed inhibitor of enkephalin-degrading enzymes)**
Morphine; Conditioned place preference; Naloxone; Addiction; (Mouse) (Noble, F. (230) 139)

**Reactive hyperaemia**
Nitric oxide (NO); Heart (guinea pig) (Chłopicki, S. (241) 117)

**Reactive oxygen species**
Lipid peroxidation; Cardiac cells; Reperfusion injury; Electromechanical coupling (Iliou, J.-P. (248) 263)

**Reactive synaptogenesis**
Methamphetamine; Prefrontal cortex; Dendritic spine density; (Gerbil) (Dawirs, R.R. (241) 89)

**Receptor affinity**
Angiotensin II; Smooth muscle (vascular) (Kuttan, S.C. (232) 173)

**$\sigma$ Receptor antagonists**
U-50,488H; Rimcazole; DuPont Merck S-7389-4; $\kappa$-Opioid agonists; EEG power spectra (Young, G.A. (231) 473)

**Receptor binding**
$\alpha_{1A}$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Risperidone; Antipsychotics (Sleight, A.J. (238) 407)

Microdialysis; Galanin receptor antagonists; M15; M35; Striatum (Ögren, S.O. (242) 59)

[$^3$H]Quinpirole; Monoamine oxidase inhibitor; Striatum; CNS (central nervous system); (Rat) (Levant, B. (246) 171)

Mineralocorticoid receptor; Glucocorticoid receptor; Steroid hormones; Localization; Trans-activation (Rupprecht, R. (247) 145)

**Receptor coupling**
GABA ($\gamma$-aminobutyric acid); Benzodiazepines; CNS (central nervous system) depressants; Seizure tolerance; $Cl^-$ channels (Chang, Y.-F. (233) 209)

**Receptor interaction**
Galanin; Locus coeruleus neurons; Firing rate; Membrane potential (Sevcik, J. (230) 223)

**Receptor internalization**
5-HT (5-hydroxytryptamine, serotonin); Transmitter interaction; Desensitization; Protein kinase C (Rahman, S. (238) 173)

**$\sigma$ Receptor ligands**
NMDA receptor antagonists; Phencyclidine; Dizocilpine; Interneurons (Zhang, J. (230) 371)

Dopamine; Microdialysis; Vacuous chewing; DTG (1,3-di-o-tolylguanidine); (+)-Pentazocine (Patrick, S.L. (231) 243)

Neurogenic twitch contraction; Benzomorphan-type $\sigma$ receptor; ATP transmission; Vas deferens (mouse); Brain (guinea-pig); SK&F 10,047 (N-allylnormetazocine); Rimcazole; Haloperidol (Matsuno, K. (231) 451)

SR 31742A; Neurotensin; Antipsychotics (Labie, C. (231) 465)

Apomorphine-induced climbing; Apomorphine-induced stereotypy; (Mouse) (Fritz, P.M. (235) 229)

DTG (1,3-di(2-tolyl)guanidine); Haloperidol; Anticonvulsants; Prepiriform cortex (Roth, J.E. (236) 327)

**Receptor-receptor interactions**
Neurotensin; CCK-8 (cholecystokinin-8); Dopamine $D_2$ receptors; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

Neurotensin fragments; Dopamine $D_2$ receptors; Neostriatum; (Rat) (Li, X.-M. (234) 125)

**$\sigma$ Receptors**
Methamphetamine; Psychosis (Itzhak, Y. (230) 243)

Normetazocine; Substantia nigra; Movement; Naloxone; Opiates (Walker, J.M. (231) 61)

Neuropeptide Y (NPY); CCK (cholecystokinin); Bicarbonate secretion; Duodenum; (Rat) (Pascaud, X.B. (231) 389)

Ifenprodil; Brain (rat); (Subtypes) (Hashimoto, K. (236) 159)

Emesis; DTG (1,3-di-(2-tolyl)guanidine); (Agonists); (Antagonists); (Modifiers); (Pigeon) (Hudzik, T.J. (236) 279)

Dystonia; $\kappa$-Opioid receptors; Naloxone; Naltrexone; Movement disorders; Dopamine; Glutamate (Richter, A. (236) 289)

Normetazocine; Substantia nigra; Movement; Naloxone; Opiates (Walker, J.M. (236) 495)

NMDA (N-methyl-D-aspartate); Antidepressant; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor (selective); Monoamine oxidase inhibitors (Bergeron, R. (240) 319)

[$^3$H](+)-3-PPP ([$^3$H](+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); $K^+$ channels; Antiarrhythmic drugs class III (Jeanjean, A.P. (241) 111)

Neuropeptide Y; Peptide YY; Hippocampus (mouse) (Roman, F.J. (242) 305)

Dopamine uptake; Cocaine; Caudate-putamen; Rimcazole; [$^3$H]CFT ([$^3$H]2$\beta$-carbomethoxy-3$\beta$-(4-fluoro-phenyl)-tropane, [$^3$H]WIN 35,428) (Izenwasser, S. (243) 201)

Antipsychotic drugs; Cytotoxicity (Vilner, B.J. (244) 199)

**Receptor subtypes**
Opioids; $Cl^-$ secretion (intestinal) (Kromer, W. (230) 235)

**Receptor supersensitivity**
Jumping; Quinpirole; Dopamine (Kostrzewa, R.M. (239) 183)

**Recombinant mutant receptors**
Ro 15-4513; Cerebellum; $GABA_A$ receptor subtypes; (Selected rat lines) (Korpi, E.R. (247) 23)

**Red blood cells deformability**
Nitric oxide (NO); Polymorphonuclear leukocytes (Korbut, R. (234) 17)

**Reference memory**
Hippocampus; $5\text{-}HT_{1A}$ receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Working memory; (Microinjection) (Ohno, M. (234) 29)

DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Scopolamine; Acetylcholine; Working memory (Ohno, M. (238) 117)

**Refractory period (effective)**
Ischaemia; Antiarrhythmic drugs; (Guinea-pig) (Tweedie, D. (240) 251)

**Regulatory decrease in volume**
Colon (rat); $Cl^-$ channels; Leukotriene $D_4$ (Diener, M. (238) 217)

**Reinforcement**
Verapamil; d-Amphetamine; Place preference conditioning; $Ca^{2+}$ channel inhibitors (Pucilowski, O. (240) 89)

**Remoxipride**
Remoxipride metabolites; Antipsychotics; Dopamine receptors; [$^3$H]Raclopride binding (Mohell, N. (238) 121)

**Remoxipride metabolites**
Remoxipride; Antipsychotics; Dopamine receptors; [$^3$H]Raclopride binding (Mohell, N. (238) 121)

**REM (rapid eye movement) sleep**
Dopamine $D_1$ receptor agonists; A68930; SK&F 38393; Grooming behaviour; (Rat) (Trampus, M. (235) 83)

**Renal arteries**
EDRF (endothelium-derived relaxing factor); Ischemia; Renal hemodynamics; (Rabbit) (Pruneau, D. (231) 215)

Autoradiography; Dihydropyridine channels; Nicardipine; (Human) (Ferrante, F. (240) 229)

**Renal blood flow**
Heart failure (high-output); Laser-Doppler flowmetry; Neurohumoral factors; Thermodilution; Wistar rat (Oka, T. (234) 55)

EXP3174; $Li^+$ clearance; Angiotensin II; Glomerular filtration rate (Tamaki, T. (236) 15)

Nifedipine; TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate); Hypertonic saline; Glomerular filtration rate (Ogasawara, A. (243) 103)

**Renal brush border membrane**
Angiotensin converting enzyme; Ramipril; Plasma; Induction (Michel, B. (242) 237)

**Renal haemodynamics**
$K^+$ channel activators; Adrenoceptor agonists; Renal nerve stimulation (Johns, E.J. (230) 47)

Renal arteries; EDRF (endothelium-derived relaxing factor); Ischemia; (Rabbit) (Pruneau, D. (231) 215)

**Renal nerve stimulation**
$K^+$ channel activators; Renal haemodynamics; Adrenoceptor agonists (Johns, E.J. (230) 47)

**Renin**
Cocaine (neuroendocrine); 5-HT (5-hydroxytryptamine, serotonin); Prolactin; ACTH (adrenocorticotropic hormone) (Levy, A.D. (241) 275)

**Reoxygenation**
Angiotensin-converting enzyme inhibitors; Lisinopril; Hypoxia; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

**Reperfusion**
d-Propranolol; dl-Propranolol; Ischaemia; Metabolism (Hoque, A.N.E. (236) 269)

Ischemia; Arrhythmia; Hypochlorous acid; Hydrogen peroxide (Okabe, E. (248) 33)

**Reperfusion injury**
$\alpha$-Tocopherol analogue (MDL 73404); Free radical scavenger; Myocardial ischaemia/reperfusion; Contractility; Lipid peroxidation (Lukovic, L. (233) 63)

Reactive oxygen species; Lipid peroxidation; Cardiac cells; Electromechanical coupling (Iliou, J.-P. (248) 263)

**Repetitive firing (sustained)**
Temperature dependence; MK-801; $Na^+$-dependent action potentials; Neurons (cultured) (Wamil, A.W. (230) 263)

**Reserpine**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; Vomiting; 6-Hydroxydopamine (6-OHDA); Area postrema (Hikasa, Y. (229) 241)

Substantia nigra pars compacta; Dopamine neurons; Dopamine receptor agonists; Firing pattern; Single-unit recording; Supersensitivity (Sun, B.-C. (231) 331)

$\alpha_1$-Adrenoceptors; Burst firing; Idazoxan; Noradrenaline (Grenhoff, J. (233) 79)

MDMA (3,4-methylenedioxymethamphetamine); Parachloroamphetamine; Fluoxetine; Deprenyl; Clorgyline; Nimodipine (Gu, X.F. (235) 51)

CGRP (calcitonin gene-related peptide); Gastric ulcer; Somatostatin (Clementi, G. (238) 101)

$\alpha_2$-Adrenoceptors; Brain (rat); Vas deferens (rat); [$^3$H]UK 14304; [$^3$H]RX 821002 (Ugedo, L. (239) 149)

**Respiration**
Dihydropyridines; $Ca^{2+}$ channels; $Ca^{2+}$ channel activators; Ventral medullary surface; Opioids (endogenous) (Ruiz, F. (240) 155)

$\kappa$-Opioid receptor agonist; Fentanyl; Antinociception; (Intrathecal); (Intraventricular) (Wang, C. (243) 113)

**Respiratory airways**
Hyperresponsiveness; Interleukin-5; Eosinophils; Asthma (Van Oosterhout, A.J.M. (236) 379)

Hyperresponsiveness; Interleukin-5; Eosinophils; Asthma (Van Oosterhout, A.J.M. (239) 277)

**Respiratory burst**
Eosinophils; Salmeterol; Eformoterol; Salbutamol; β-Adrenoceptors (Rabe, K.F. (231) 305)

**Restraint stress**
Analgesia; Morphine; NECA (5′-(N-ethyl)carboxamido-adenosine); Caffeine; Opioids (Woolfolk, D.R. (239) 177)

**Retina**
Dopamine; Electrooculogram; Haloperidol; Light peak; Transepithelial potential; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

GABA (γ-aminobutyric acid); GABA $\rho_2$ receptors; GABA $\rho_1$ receptors; Ligand-gated ion channel; Inhibitory amino acids (Kusama, T. (245) 83)

**Reward**
Cholecystokinin; Dopamine; Neurotensin; Ventral tegmental area (Rompré, P.-P. (232) 299)

Cocaine; *C-fos*; Psychostimulants; Nucleus accumbens (Heilig, M. (236) 339)

**Rhesus monkey**
Shock titration; Antinociception; Opioid peptides; SC-39566 (Hammond, D.L. (231) 281)

**Ricinoleic acid**
Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester); $N^G$-Monomethyl-L-arginine; L-Arginine; Tetrodotoxin; Ileum; (Rat) (Izzo, A.A. (243) 87)

**Riluzole**
Cerebral ischemia (focal); Neurological examination; Passive avoidance task; (Rat) (Wahl, F. (230) 209)

*Xenopus* oocytes (rat brain mRNA-injected); Excitatory amino acid receptors; Kainate; NMDA (N-methyl-D-aspartate) (Debono, M.-W. (235) 283)

**Rimcazole**
σ Receptor ligands; Neurogenic twitch contraction; Benzomorphan-type σ receptor; ATP transmission; Vas deferens (mouse); Brain (guinea-pig); SK&F 10,047 (N-allylnormetazocine); Haloperidol (Matsuno, K. (231) 451)

U-50,488H; DuPont Merck S-7389-4; κ-Opioid agonists; σ Receptor antagonists; EEG power spectra (Young, G.A. (231) 473)

σ Sites; Antitussive effects; Dextromethorphan; Noscapine (Kamei, J. (242) 209)

Dopamine uptake; Cocaine; Caudate-putamen; σ Receptors; [$^3$H]CFT ([$^3$H]2β-carbomethoxy-3β-(4-fluoro-phenyl)-tropane, [$^3$H]WIN 35,428) (Izenwasser, S. (243) 201)

**Risperidone**
$\alpha_{1A}$-Adrenoceptors; $\alpha_{1B}$-Adrenoceptors; Antipsychotics; Receptor binding (Sleight, A.J. (238) 407)

**mRNA**
In situ hybridisation; Cholecystokinin (CCK); Diazepam; Tolerance; Withdrawal (Rattray, M. (245) 193)

$GABA_A$ receptor $\alpha_1$-subunit; Ethanol inhalation; Alcohol dependence (Hirouchi, M. (247) 127)

Muscarinic receptors; Organophosphate pesticides; Development; Phosphoinositide hydrolysis (Balduini, W. (248) 281)

**mRNA levels**
5-$HT_2$ receptor regulation; Behavioural response; Phosphoinositide turnover; Gene transcription (Rinaldi-Carmona, M. (246) 73)

**RNA synthesis**
Thymidine; Uridine; Leucine; DNA synthesis; Protein synthesis; Thymidine kinase activity (Garg, U.C. (237) 243)

**Ro 15-4513**
Development; Ethanol; Flunitrazepam; $GABA_A$ receptors; Muscimol (Taira, T. (230) 307)

$GABA_A$ receptor; Benzodiazepine; Flunitrazepam (Duncalfe, L.L. (246) 141)

Cerebellum; $GABA_A$ receptor subtypes; Recombinant mutant receptors; (Selected rat lines) (Korpi, E.R. (247) 23)

**Ro 31-6930**
BRL 38227; Bronchoconstriction; Cholinergic; Neurotransmission (Gater, P.R. (238) 59)

**Robenidine**
Coccidiosis; D-Galactose; L-Leucine; Intestinal transport; Jejunum (rabbit); Drug-nutrient interaction; Sucrase; Aminopeptidase (Sorribas, V. (248) 137)

**Rolipram receptor**
Autoradiography; Dopamine $D_1$ receptors; Cerebral ischemia; SCH 23390; Pentobarbital; $Ca^{2+}$/calmodulin independent cyclic adenosine monophosphate selective phosphodiesterase; (Gerbil) (Kanai, Y. (248) 191)

**Rostral vasodepressive area**
Nucleus tractus solitarii; Lateral tegmental field; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Vayssettes-Courchay, C. (242) 37)

**Rostral ventrolateral medulla**
Cardiovascular neurons; Cyanide; Hydrogen ions; GABA (γ-aminobutyric acid); (Rat) (Sun, M.-K. (236) 305)

**Rostral ventromedial medulla**
Pain; Spinal cord; Morphine; Descending inhibitory controls (Bouhassira, D. (232) 207)

**Rotation**
On-off effects; Classical conditioning; Dopamine receptor agonists; 6-Hydroxydopamine (6-OHDA); Nigrostriatal lesions (Silverman, P.B. (229) 235)

**Rotational behaviour**
Ceruletide; CCK (cholecystokinin); $CCK_A$ receptors; $CCK_B$ receptors; Parkinson's disease (Fujisawa, M. (238) 127)

Parkinsonism; 6-Hydroxydopamine; Bromocriptine; SK&F-77434; Cocaine (Silverman, P.B. (242) 31)

**RP 62203**
5-$HT_2$ receptor antagonists; 5-HT (5-hydroxytryptamine, serotonin); Autoradiography; [$^{125}$I]AMIK ([$^{125}$I]7-amino-8-iodo-ketanserin); [$^3$H]Mesulergine (Malgouris, C. (233) 29)

**RP 67580**
Substance P; $NK_1$ receptors; Transfection; Second messenger (binding) (Hermans, E. (245) 43)

**[$^3$H]RP 62203 binding sites**
5-$HT_2$ receptor antagonists; Brain autoradiography (Malgouris, C. (233) 37)

**RS-15385-197**
[$^3$H]p-Aminoclonidine; [$^3$H]Idazoxan; Imidazoline binding sites; Kidney (rat) (MacKinnon, A.C. (232) 79)

**RS-42358-197**
5-$HT_3$ receptor antagonists; Aversive behaviour; (Mouse); (Rat); (Marmoset) (Costall, B. (234) 91)

**RU 24969**
5-HT (5-hydroxytryptamine, serotonin); NAN-190; TFMPP (trifluoromethylphenylpiperazine); mCPP (m-chlorophenylpiperazine); 5-HIAA (CSF levels); 5-$HT_1$ receptor binding (in vitro); (Pigeon) (Gleeson, S. (229) 109)

**RX 77368**
Gastric cytoprotection; L-Arginine; L-NAME ($N^G$-nitro-L-arginine methyl ester); Nitric oxide (NO); Vagus (Király, Á. (240) 299)

**RX 821002**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX851034 (Chan, S.L.F. (230) 375)

**[$^3$H]RX 821002**
$\alpha_2$-Adrenoceptors; Brain (rat); Vas deferens (rat); [$^3$H]UK 14304; Reserpine (Ugedo, L. (239) 149)

Zucker rat; Imidazoline $I_2$ binding sites; $\alpha_2$-Adrenoceptors; Brain; [$^3$H]Idazoxan; [$^3$H]Clonidine; Mazindol (Miralles, A. (243) 305)

**[$^3$H]RX 821002 (2-methoxy idazoxan)**
$\alpha_2$-Adrenoceptors; [$^3$H]Clonidine; [$^3$H]UK 14,304 (bromoxidine); Neostigmine; Physostigmine; Diisopropylfluorophosphate; Pilocarpine (Olmos, G. (236) 467)

**RX 851033**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851034; RX821002 (Chan, S.L.F. (230) 375)

**RX 851034**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX821002 (Chan, S.L.F. (230) 375)

**Ryanodine**
Thapsigargin; Smooth muscle (vascular); $Ca^{2+}$ mobilization (Low, A.M. (230) 53)

Cyclopiazonic acid; Smooth muscle; $Ca^{2+}$ channels; $Ca^{2+}$ stores; Whole-cell voltage clamp (Gagov, H.S. (243) 19)

**S312**
Dihydrothienopyridine; Aorta (rat); Cerebral microvessels (rat); Dihydropyridine binding site; Phenylalkylamine binding site (Dessy, C. (231) 435)

**S-1452 (calcium (1R,2S,3S,4S)-(5Z)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate)**
Thromboxane $A_2$; Lipopolysaccharide; TNF (tumor necrosis factor); Bronchial hyperresponsiveness (Arimura, A. (231) 13)

**S 15535**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; Raphe; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

**Sabeluzole**
NMDA receptors; Glutamate; Cerebellum; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

**Salbutamol**
Eosinophils; Respiratory burst; Salmeterol; Eformoterol; $\beta$-Adrenoceptors (Rabe, K.F. (231) 305)

**Salmeterol**
Eosinophils; Respiratory burst; Eformoterol; Salbutamol; $\beta$-Adrenoceptors (Rabe, K.F. (231) 305)

**Saphenous vein**
Congestive heart failure; $\alpha_1$-Adrenoceptor activation pathways; $Ca^{2+}$ channel antagonists; Dorsal pedal artery (Forster, C. (242) 119)

**Saphenous vein (dog)**
Tetrandrine; Smooth muscle (vascular); $Ca^{2+}$; Excitation-contraction (Kwan, C.-Y. (238) 431)

**Saphenous vein (human)**
Endothelin-1; Sarafotoxin S6b; BQ-123; Endothelin $ET_A$ receptor (Bax, W.A. (239) 267)

**Sarafotoxins**
FR139317; BQ-123; Endothelins; Endothelin receptors; Iliac artery (guinea-pig) (Schoeffter, P. (241) 165)

Endothelins; Endothelin receptor subtypes; Phospholipases; C6 glioma; Fibroblasts (Rat-1, Swiss 3T3) (Ambar, I. (245) 31)

**Sarafotoxin S6b**
Endothelin-1; BQ-123; Endothelin $ET_A$ receptor; Saphenous vein (human) (Bax, W.A. (239) 267)

**Sarafotoxin S6c**
Endothelin-1; Mean arterial pressure; Endothelin receptor antagonist (Bird, J.E. (240) 295)

**Sarcolemma hyperexcitability**
2,3-Butanedione monoxime; Excitation-contraction uncoupling; Dantrolene; Depolarization contractures; Caffeine contracture; Diaphragm (rat) (Røed, A. (241) 229)

**SC-39566**
Shock titration; Antinociception; Opioid peptides; Rhesus monkey (Hammond, D.L. (231) 281)

**SCH 23390**
Dopamine; Acetylcholine; Microdialysis; Cocaine; $\alpha$-Methyltyrosine + reserpine; (−)-Sulpiride (Imperato, A. (229) 265)

NMDA (N-methyl-D-aspartate); MK-801; LY274614; Clebopride; Catalepsy; Dopamine; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors; (Rat) (Moore, N.A. (237) 1)

Dopamine (renal); Fenoldopam; Quinpirole; Cis-flupentixol; LLC-$PK_1$ cells; Organic cations (renal); Dopamine receptors; Quinine (Dawson, Jr., R. (240) 277)

Dopamine $D_1$ receptors; Dihydrexidine; SKF38393; Adenylate cyclase; Parkinson's disease; (Rhesus monkey); (Rat) (Watts, V.J. (242) 165)

Dopamine; Dopamine $D_1$ receptors; Self-stimulation (Sabater, R. (242) 205)

Dopamine $D_1$ receptors; Dopamine $D_1$ receptor turnover; N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); Striatum; Substantia nigra; Brain (Rat) (Giorgi, O. (245) 139)

Autoradiography; Dopamine $D_1$ receptors; Rolipram receptor; Cerebral ischemia; Pentobarbital; $Ca^{2+}$/calmodulin independent cyclic adenosine monophosphate selective phosphodiesterase; (Gerbil) (Kanai, Y. (248) 191)

**SCH 39166**
Paw test; Raclopride; Haloperidol; Dopamine $D_1$ receptors; Dopamine $D_2$ receptors (Prinssen, E.P.M. (231) 275)

**Schizophrenia**
Affinity states; Dopamine $D_1$ receptors (Mamelak, M. (233) 175)

Dopamine $D_4$ receptors; Dopamine $D_2$ receptors; Antipsychotics; Extrapyramidal side effects; Tardive dyskinesia (Lahti, R.A. (236) 483)

Prefrontal cortex; Microdialysis; Dopamine; Amperozide; Clozapine (Pehek, E.A. (240) 107)

Phencyclidine; Glucose metabolism; Psychosis; Histopathology; Limbic system (Gao, X.-M. (241) 7)

**Scopolamine**
DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Acetylcholine; Working memory; Reference memory (Ohno, M. (238) 117)

TRH (thyrotropin-releasing hormone); Sustained release formulation; AF64A (ethylcholine aziridinium ion); Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

**Scrapie**
Cortical cells; Memantine; NMDA receptor; Neurons; Prion; Adamantanes; MK-801 (Müller, W.E.G. (246) 261)

**Scratching behaviour**
Bombesin; Gastrin-releasing peptide (GRP); Phyllolitorin; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

**SDZ 205-557**
5-$HT_4$ receptors; Atria (piglet); Papillary muscle (piglet) (Lorrain, J. (229) 105)

**SDZ 216-525**
MDL 73005; NAN 190; 5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; 5-$HT_{1B}$ receptors; 5-$HT_{1C}$ receptors; 5-$HT_{1D}$ receptors (Schoeffter, P. (244) 251)

**Secondary inward current**
OPC-8212; Action potential duration; Cardiac ventricular myocytes; $K^+$ currents; Veratrine (Lathrop, D.A. (240) 127)

**Second messenger (binding)**
RP 67580; Substance P; $NK_1$ receptors; Transfection (Hermans, E. (245) 43)

**Second messengers**
cAMP; Protein kinase C; Adenylate cyclase; Adrenal chromaffin cells; Adrenal medulla (Marley, P.D. (244) 7)

c-*fos*; *jun*-B; Pineal gland; Adrenoceptors; Protein kinase (Carter, D.A. (244) 285)

**Sedation**
Histamine $H_1$ receptors; Histamine $H_1$ receptor antagonists; [$^3$H]Mepyramine; Lung tissue; Cerebellum; Selectivity (Ter Laak, A.M. (232) 199)

$\alpha_2$-Adrenoceptors; Anaesthesia; Medetomidine; Atipamezole; (Cat) (Stenberg, D. (238) 241)

**Seizures**
VIP (vasoactive intestinal polypeptide); VIP-(22–28); Pentylenetetrazole; Brain (rat) (Romualdi, P. (229) 149)

Nitric oxide (NO); Prepiriform cortex (deep); Excitatory amino acid; L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

Electroshock (maximal); CGP 37849; CGP 39551; Valproate (Czechowska, G. (232) 59)

Ucb L059; Epilepsy; Piracetam; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

Adenosine; GABA (γ-aminobutyric acid); GABA/benzodiazepine receptor; Glutamate; Mouse (Klitgaard, H. (242) 221)

*N*-Methyl-D-aspartate receptor; Polyamines; Ethanol; c-*fos* (Matsumoto, I. (247) 289)

**Seizures (chemically induced)**
Pilocarpine; Epilepsy; Anticonvulsants; ACTH (adrenocorticotrophic hormone) (Croiset, G. (229) 211)

**Seizure tolerance**
GABA (γ-aminobutyric acid); Benzodiazepines; CNS (central nervous system) depressants; Receptor coupling; $Cl^-$ channels (Chang, Y.-F. (233) 209)

**Selective agonists**
Ileum (Guinea pig); $NK_3$ receptors; Inositol monophosphate accumulation (Petitet, F. (247) 185)

**Selective inhibitor inducible**
Nitric oxide synthase; Aminoguanidine (Misko, T.P. (233) 119)

**Selectivity**
Histamine $H_1$ receptors; Histamine $H_1$ receptor antagonists; [$^3$H]Mepyramine; Lung tissue; Cerebellum; Sedation (Ter Laak, A.M. (232) 199)

**Self-administration**
Cocaine; Cocaine dependence; Ibogaine; (Rat) (Cappendijk, S.L.T. (241) 261)

**Self-stimulation**
Neurotensin; Xenopsin; Prefrontal cortex (Ferrer, J.M.R. (231) 39)

SCH 23390; Dopamine; Dopamine $D_1$ receptors (Sabater, R. (242) 205)

**Seminal vesicle protein**
PAF (platelet-activating factor); Hypotension; Bronchoconstriction; Gastric mucosal injury (Persico, P. (241) 71)

**Sensitization**
Excitatory amino acids; Quisqualate priming; Cortical wedge; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

Locomotion; Methamphetamine; Cycloheximide; (Mouse) (Shimosato, K. (234) 67)

Amphetamine; Dopamine; Prefrontal cortex; Stress (Hamamura, T. (237) 65)

NMDA receptors; Dopamine receptor agonists; Apomorphine; MK-801 (Druhan, J.P. (243) 73)

Cocaine; Naltrindole; Locomotor activity; Opioids (Heidbreder, C. (243) 123)

**Sensitization (pharmacological)**
Oral dyskinesia; Haloperidol (intermittent); Drug holidays (rats); Amygdala kindling (Glenthøj, B. (236) 401)

**Sensory nerves**
Capsaicin; Tracheal hyperreactivity; (Guinea-pig) (Ladenius, A.R.C. (235) 127)

Adenosine $A_2$ receptors; Substance P release; Airways (Morimoto, H. (240) 121)

Levodropropizine; Capsaicin; Substance P; Neurogenic inflammation; Plasma extravasation (Yamawaki, I. (243) 1)

Toluene diisocyanate; Prostanoids (Mapp, C.E. (248) 277)

**Sensory nerves (capsaicin-sensitive)**
CGRP (calcitonin gene-related peptide); Fischer 344 rats; Aging; Mesenteric vasculature (Li, Y. (236) 373)

**Sensory neuropeptides**
Adenosine; Antinociception; Adenosine receptors; Capsaicin (Santicioli, P. (231) 139)

**Septide**
Tachykinin receptors; Tachykinin receptor subtypes; CP 96,345 (Maggi, C.A. (235) 309)

**Serotonergic mechanisms (peripheral)**
Glucose; Free fatty acids; Insulin; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

**Serotonergic neurotransmission**
Anxiolytics; Dorsal raphe nucleus; Electrophysiology; Hippocampus; Ipsapirone; Microdialysis; 5-$HT_{1A}$ receptors; Ultrasonic vocalization; (Rat) (Sommermeyer, H. (240) 29)

**Serotonin-5-O-carboxymethyl-glycyl[$^{125}$I]tyrosinamide ([$^{125}$I]GTI)**
5-$HT_{1D\alpha/\beta}$ receptors; Cerebral cortex (human) (Beer, M.S. (242) 195)

**Sexual behaviour**
Ejaculation; Castration; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Testosterone; (Wistar rat) (Haensel, S.M. (233) 187)

**Shape-change parameter**
Platelets (human); Protein kinase C; Disc-sphere change; Thrombin; 1-Oleoyl-2-acetyl-glycerol (Ozaki, Y. (235) 255)

**Shock titration**
Antinociception; Opioid peptides; Rhesus monkey; SC-39566 (Hammond, D.L. (231) 281)

κ-Opioid receptor antagonists; Morphine; U50,488; Analgesia; Squirrel monkeys (Craft, R.M. (234) 199)

**Side-effects**
Dopamine autoreceptors; Dopamine $D_2$ receptor agonists; Dopamine $D_2$ receptor antagonists; Amphetamine; (Monkey) (Peacock, L. (237) 329)

**Single-unit recording**
Reserpine; Substantia nigra pars compacta; Dopamine neurons; Dopamine receptor agonists; Firing pattern; Supersensitivity (Sun, B.-C. (231) 331)

d-Amphetamine; Dopamine; Substantia nigra; Autoreceptors; (In vitro) (Lee, T.H. (232) 125)

**Single ventricular cells**
Class III antiarrhythmics; Action potentials; Ionic currents (Lee, K.S. (234) 43)

**Sin-1 (3-morpholinosydnonimine)**
Aorta (rat); Aging; Nitrate tolerance; Nitroglycerin (Unger, P. (248) 145)

**Sinoatrial node**
Atrioventricular node; Angiotensin system; Angiotensin receptors; Losartan (Saavedra, J.M. (235) 301)

**Sinus node inhibitors**
Bradycardiac agents; Zatebradine; Pacemaker currents; Purkinje fibres; Iontophoresis; Use-dependent blockade; (Electrophysiology) (Van Bogaert, P.P. (229) 55)

**Sinusoidal plasma membrane**
Cloning; Loop diuretics; Bumetanide (transport); Organic anions; Liver (rat); Bile acid (Honscha, W. (246) 227)

**σ Sites**
Antitussive effects; Dextromethorphan; Noscapine; Rimcazole (Kamei, J. (242) 209)

Dopamine $D_3$ receptors (bovine caudate); 7-OH-DPAT (7-hydroxy-N,N-di-n-propyl-2-aminotetralin) (Schoemaker, H. (242) R1)

**Skeletal muscle**
Trifluoperazine; Calmodulin; Glucose uptake; Insulin (Guarner, V. (237) 139)

$K^+$ channels (ATP-sensitive); Fatigue (Comtois, A. (242) 65)

**Skeletal muscle contraction**
Gold ion; $Ca^{2+}$ channels (L-type); Perchlorate; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

**Skeletal muscle $K_{ATP}$ channels**
Patch clamp; Glibenclamide; $K^+$ channel openers (Allard, B. (236) 419)

**SK&F 38393**
Dopamine $D_1$ receptor agonists; Dopamine $D_2$ receptor agonists; Nucleus accumbens; Oral behaviour; Principal factor analysis; Quinpirole (Koene, P. (233) 151)

Dopamine $D_1$ receptor agonists; A68930; Grooming behaviour; REM (rapid eye movement) sleep; (Rat) (Trampus, M. (235) 83)

Autoradiography; 6-Hydroxydopamine; Quinpirole; Basal ganglia (Engber, T.M. (236) 385)

Turning behaviour; Dopamine $D_1/D_2$ receptor interaction; Nucleus accumbens; Quinpirole; Limb stepping (Saigusa, T. (237) 161)

Dopamine $D_1$ receptors; Dihydrexidine; SCH23390; Adenylate cyclase; Parkinson's disease; (Rhesus monkey); (Rat) (Watts, V.J. (242) 165)

**SK&F 77434**
Parkinsonism; Rotational behaviour; 6-Hydroxydopamine; Bromocriptine; Cocaine (Silverman, P.B. (242) 31)

**SK&F 96365**
$Ca^{2+}$ dynamics; Amylase secretion; Pancreatic acini (Busik, J. (247) 273)

**SK&F 10,047 (N-allylnormetazocine)**
$\sigma$ Receptor ligands; Neurogenic twitch contraction; Benzomorphan-type $\sigma$ receptor; ATP transmission; Vas deferens (mouse); Brain (guinea-pig); Rimcazole; Haloperidol (Matsuno, K. (231) 451)

**SK&F 104353**
Spleen (ferret); Leukotriene receptors; ICI 198615; MK571 (Gardiner, P.J. (238) 19)

**(+)-SK&F10,047**
$\sigma$ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol); Radiolabeled ligand binding; Stereotyped behaviour (Tanaka, M. (238) 89)

**Skin blood flow (rat)**
Big endothelin-1; Big endothelin-3; Phosphoramidon; Microcirculation; Cheek pouch (hamster) (Lawrence, E. (233) 243)

**Skinned fibres**
Extensor digitorum longus; Soleus; Cyclopiazonic acid; $Ca^{2+}$ sensitivity (Huchet, C. (241) 41)

**SL 84.0418**
$\alpha_2$-Adrenoceptors; (Peripheral activity) (Angel, I. (234) 137)

**Slow depolarization**
Cholecystokinin; $CCK_A$ receptors; Sympathetic neurons (mammalian); Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

**Slow wave**
Locus coeruleus; $\alpha_2$-Adrenoceptor agonists; $\alpha_2$-Adrenoceptor antagonists; High voltage spindle (Riekkinen, Jr., P. (238) 263)

High voltage spindles; Muscarinic $M_1$ receptor; Muscarinic $M_2$ receptor; Physostigmine; Tetrahydroaminoacridine; Pilocarpine; AF102B; Oxotremorine (Riekkinen, Jr., P. (240) 1)

**SM-12502**
Complement; Zymosan; PAF (platelet-activating factor, PAF-acether); WEB 2086; Plasma leakage (Damas, J. (231) 231)

**Small cell lung carcinoma cells**
$Ca^{2+}$; $Ca^{2+}$ channels; $Ca^{2+}$ channel antagonists; $\omega$-Conotoxin; $\omega$-Agatoxin IVA; Proliferation (Cattaneo, M.G. (247) 325)

**Small intestine**
Indomethacin; Morphine; Naloxone; NANC (non-adrenergic, non-cholinergic); Vagal nerve (Gustafsson, B.I. (230) 1)

**Small intestine (guinea-pig)**
GABA ($\gamma$-aminobutyric acid); Ivermectin; Lindane; Enteric $GABA_A$ receptors (Coccini, T. (248) 1)

**Smoking behaviour**
Nicotine; Antinociception; Opioid and anti-opioid interactions; (Mice) (Aceto, M.D. (248) 333)

**Smooth muscle**
$Ca^{2+}$ channel blockers; Cytosolic $Ca^{2+}$ levels; Felodipine; Nifedipine; Verapamil; Aorta (rat); (Relaxation) (Hagiwara, S. (234) 1)

Asthma; Anaesthetics; Ketamine; Propofol; Trachea (Pedersen, C.M. (238) 75)

Gamma globulin (human); Immunoglobulins; Immunoglobulin G; Spontaneous contractility (Abrahams, Z. (238) 435)

Nitric oxide (NO); Neuroeffector modulation; Cholinergic; Tachykinin; Chemiluminescence (Wiklund, C.U. (240) 235)

Cyclopiazonic acid; Ryanodine; $Ca^{2+}$ channels; $Ca^{2+}$ stores; Whole-cell voltage clamp (Gagov, H.S. (243) 19)

NPPB (5-nitro-2-(3-phenylpropylamino)-benzoic acid); Fluorescence microscopy (single cell); Vasopressin; Phosphatidylinositol metabolism; $Ca^{2+}$-activated chloride conductance (Pon, D.J. (245) 119)

Phorbol esters; Feedback inhibition (Bazan, E. (245) 173)

$Ca^{2+}$ channel antagonist; Voltage-operated channel; Heart; SR 33805 (Chatelain, P. (246) 181)

Ethanol; Gall bladder; Tolerance; $Ca^{2+}$ (Masui, H. (248) 103)

**Smooth muscle (airway)**
$K^+$ channel antagonists; $\beta_2$-Adrenoceptor agonists; Trachea (guinea-pig) (Huang, J.-C. (235) 37)

**Smooth muscle (arterial)**
5-HT (5-hydroxytryptamine, serotonin); $Ca^{2+}$ channel antagonists; Cerebral arteries (Clark, A.H. (235) 113)

**Smooth muscle cell (aorta, rat)**
27-O-Caffeoyl myricerone (50-235); Endothelin receptor antagonist; Cytosolic free $Ca^{2+}$; Mitogenesis; Girardi heart cell (human) (Mihara, S.-i. (246) 33)

**Smooth muscle cell (vascular)**
Cyclosporine A; Endothelin; (Rat) (Takeda, Y. (233) 299)

**Smooth muscle cells**
$PGE_2$; EP receptors (Botella, A. (237) 131)

Interleukin-8; Chemotaxis; Migration; Atherosclerosis (Yue, T.-L. (240) 81)

**Smooth muscle cells (ileal)**
Trimebutine; $K^+$ currents; Patch-clamp (whole cell) (Nagasaki, M. (235) 197)

**Smooth muscle cells (myometrial)**
Forskolin action; Uterus (pregnant); $K^+$ currents; cAMP; Tetraethylammonium (Inoue, Y. (240) 169)

**Smooth muscle cells (vascular)**
Esculetin; Coumarins; Antiproliferative effect; Lipoxygenase inhibitors (Huang, H.-C. (237) 39)

**Smooth muscle (human airway)**
Inositol phosphates; Cell culture; Airway receptors (Daykin, K. (246) 135)

**Smooth muscle (trachealis, guinea-pig)**
Atherosperminine; Phosphodiesterase inhibition; Cyclic nucleotides; *Fissistigma glaucescens* (Lin, C.-H. (237) 109)

**Smooth muscle (vascular)**
Thapsigargin; Ryanodine; $Ca^{2+}$ mobilization (Low, A.M. (230) 53)

Cromakalim; $Na^+$,$K^+$ ATPase pump; $K^+$ channels (Hong, K.W. (231) 1)

Endothelium (vascular); EDRF (endothelium-derived relaxing factor); Endothelins; $ET_B$ receptors; $ET_B$ receptor antagonists; IRL 1038; Aorta (rat) (Karaki, H. (231) 371)

Angiotensin II; Receptor affinity (Kuttan, S.C. (232) 173)

Interleukin-1; Interleukin-6; Interleukin receptors; Phycoerythrin (French, J.F. (233) 109)

Tetrandrine; Saphenous vein (dog); $Ca^{2+}$; Excitation-contraction (Kwan, C.-Y. (238) 431)

$K^+$ channel openers; Airways (Dumas, M. (239) 141)

Prostaglandins; $Ca^{2+}$ channels; Protein kinase C; Norepinephrine; Dihydropyridine (Rapoport, R.M. (243) 207)

Tetramethylpyrazine; Membrane fluidity; Electron spin resonance; Fluorescence polarization (Nie, S.-Q. (244) 15)

$Ca^{2+}$ influx; $A_7r_5$ cells; Lacidipine; Amlodipine; 1,4-Dihydropyridines (Spampinato, S. (244) 139)

$Ca^{2+}$ channel antagonists; Proliferation (Agrotis, A. (244) 269)

$\alpha_1$-Adrenoceptors; Prazosin binding; Contraction (Sayet, I. (246) 275)

Mesenteric artery; Cyclic AMP; Dopamine receptor; Phenoxybenzamine (Hall, A.S. (247) 249)

**Sodium nitroprusside**
Seizures; Nitric oxide (NO); Prepiriform cortex (deep); Excitatory amino acid; L-Arginine (De Sarro, G. (230) 151)

**Soleus**
Skinned fibres; Extensor digitorum longus; Cyclopiazonic acid; $Ca^{2+}$ sensitivity (Huchet, C. (241) 41)

**Soleus muscle**
Chlorpromazine; Extensor digitorum longus muscle; Myotonic depression (Liu, S.-H. (231) 23)

**Soluble guanylate cyclase**
FK409; Vasorelaxation; cGMP; Cyclic guanosine monophosphate phosphodiesterase (Isono, T. (246) 205)

**Somatostatin**
2-Deoxyglucose; Cerebral cortex; Hippocampus; Acetylcholine; Acetylcholine receptors (Shibata, S. (231) 381)

Galanin; M35; Islets of Langerhans (isolated); Insulin secretion; Clonidine (Gregersen, S. (232) 35)

Neuropeptide Y; l-DOPA (l-dihydroxyphenylalanine); Amantadine; 6-Hydroxydopamine; Bifemelane (Maeda, K. (233) 227)

Pancreas (dog); Exocrine secretion; Glucagon (Horiuchi, A. (237) 23)

CGRP (calcitonin gene-related peptide); Gastric ulcer; Reserpine (Clementi, G. (238) 101)

Hippocampus; Long-term potentiation; Cognitive enhancer; Acetylcholine; Mossy fiber-CA3 pathway; FR121196; (Guinea-pig) (Matsuoka, N. (241) 27)

**Somatostatin release**
GABA release; GABA autoreceptors; CGP 52432; $GABA_B$ receptor subtypes; Glutamate release (Lanza, M. (237) 191)

**Spantide**
Substance P; Substance P analogues (containing D-His); Formalin; Capsaicin; Nociceptive response; Intrathecal injection (Sakurada, T. (242) 47)

**Spatial learning**
Actyl-l-carnitine; Histotoxic hypoxia; Cyanide; Phosphoinositide metabolism (Blokland, A. (235) 275)

**Species differences (Guinea Pig, Pig, Rabbit, Rat)**
Heart; Adenosine receptors; $\beta$-Adrenoceptors (Musser, B. (246) 105)

**Specific serotonin transport inhibitors**
Molecular modelling; Neurotransmitter transport; Transport pharmacophore (Chang, A.S.-S. (247) 239)

**SPECT (single photon emission computed tomography)**
[$^{123}$I]Iomazenil; Benzodiazepine receptors (Laruelle, M. (230) 119)

5-HT (5-hydroxytryptamine, serotonin); Brain (primate) (Jagust, W.J. (242) 189)

**Sphincter of Oddi**
Nitric oxide (NO); Cholecystokinin; Non-adrenergic, non-cholinergic (NANC) nerves; Histamine (Pauletzki, J.G. (232) 263)

**Spinal antinociception**
F8Famide (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-$NH_2$); FMRFamide (Phe-Met-Arg-Phe-$NH_2$); Naloxone; Morphine (Gouardères, C. (237) 73)

**Spinal cord**
GABA ($\gamma$-aminobutyric acid); Baclofen; MBFG (4-amino-3-(5-methoxybenzo(b)furan-2-yl) butanoic acid); Antinociception; BFG (4-amino-3-benzo(b)furan-2-yl-butanoic acid) (Hammond, D.L. (229) 227)

Pain; Morphine; Descending inhibitory controls; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

Neurokinin receptor antagonists; $NK_1$ receptors; $NK_2$ receptors; Nociception (Picard, P. (232) 255)

Baclofen; CGP 35348; Antinociception; $GABA_B$ receptors (Hammond, D.L. (234) 255)

$GABA_B$ receptor antagonists; Monosynaptic reflex; Baclofen; (In vitro) (Brugger, F. (235) 153)

Morphine; Nociception; C-fibre reflex (Strimbu-Gozariu, M. (237) 197)

Substance P; Neurokinin A; Tachykinin receptors; Acetylcholine release; Polymerase chain reaction (Suzuki, H. (241) 105)

[Leu$^5$]enkephalin; [Met$^5$]enkephalin; Antinociception; $\delta_1$-Opioid receptors; $\delta_2$-Opioid receptors; BNTX (7-benzylidenenaltrexone); Naltriben; Brain; $\beta$-Endorphin (Takemori, A.E. (242) 145)

Tachykinins; Neurokinins; Pain; Analgesia (Fleetwood-Walker, S.M. (242) 173)

**Spinal 5-HT$_{1C}$ sites**
5-HT$_{1C}$ receptors; [$^3$H]Mesulergine; Down-regulation; (Rat) (Pranzatelli, M.R. (244) 1)

**Spinal reflexes**
Descending inhibition; $\alpha_2$-Adrenoceptors; Imidazoline binding sites; Blood pressure (Harris, J. (237) 323)

**Spinal seizures**
non-NMDA receptor antagonism; (Mouse) (McAllister, K.H. (231) 309)

**Spin traps**
Ischemia/reperfusion; Heart; Free radicals; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (234) 113)

Ischemia/reperfusion; Heart; Free radicals; DMPO (5,5-dimethyl-1-pyrroline-1-oxide) (Bradamante, S. (239) 275)

**Spiperone**
5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{1A}$ receptors; Raphe; S 15535; BMY 7378; NAN-190 (Millan, M.J. (230) 99)

5-HT (5-hydroxytryptamine, serotonin); $\alpha$-Methyl-5-hydroxytryptamine; Bronchi (rat); 5-HT$_2$ receptors; Ketanserin; Mianserin; Electrical field stimulation; Cholinergic nerves (Szarek, J.L. (231) 339)

**[$^3$H]Spiperone**
Dopamine D$_2$ receptors; Affinity state; Dorsal hippocampus; Ventral hippocampus; Striatum; $Mg^{2+}$; GTP; Iron-chelator (Bruinink, A. (245) 157)

**Spleen (ferret)**
Leukotriene receptors; ICI 198615; SK&F 104353; MK571 (Gardiner, P.J. (238) 19)

**Splicing (alternative)**
Glutamate; Glutamate receptors; Gene expression; Hippocampus (human) (McLaughlin, D.P. (244) 89)

**Spontaneous alternation performance**
Dynorphin A-(1–13); Nor-binaltorphimine; Memory; (Mouse) (Itoh, J. (236) 341)

Memory; Dynorphin A-(1–13); Dopamine D$_1$ receptors; Dopamine D$_2$ receptors; (Mouse) (Itoh, J. (241) 99)

**Spontaneous contractility**
Gamma globulin (human); Immunoglobulins; Smooth muscle; Immunoglobulin G (Abrahams, Z. (238) 435)

**Spontaneously hypertensive rat (SHR)**
Imipramine; Clonidine; Centhaquin; Blood pressure; Central nervous system (CNS); 5-HT uptake sites (Gulati, A. (231) 151)

5-Carboxamidotryptamine; 5-HT$_1$ receptor agonists; Blood pressure (systolic); Baroreflex sensitivity; (Chronic infusion) (Balasubramaniam, G. (237) 207)

Dopamine receptors; Locomotor activity; Turning behaviour; Yawning; Blood pressure; Pressor response; Body temperature (Van den Buuse, M. (243) 169)

Voltage-dependent $Ca^{2+}$ channels; Transmembrane $Ca^{2+}$ influx; Arterial myogenic tone; $Ca^{2+}$-activated $K^+$ channels; (Early hypertensive stages) (Asano, M. (247) 295)

Hyperlipidemia; Vascular reactivity; Wistar-Kyoto rats (WKY); Endothelium-derived relaxing factor (EDRF); Aortic arch; Abdominal aorta (Yu, S.-M. (248) 289)

**Squirrel monkeys**
$\kappa$-Opioid receptor antagonists; Morphine; U50,488; Analgesia; Shock titration (Craft, R.M. (234) 199)

**SR 27897**
CCK$_A$ receptors; Gastric emptying; Gall bladder emptying; Amylase secretion (Gully, D. (232) 13)

**SR 31742A**
Neurotensin; $\sigma$ Receptor ligands; Antipsychotics (Labie, C. (231) 465)

**SR 33805**
$Ca^{2+}$ channel antagonist; Voltage-operated channel; Smooth muscle; Heart (Chatelain, P. (246) 181)

**SR 47436**
Cardiomyocytes (neonatal rat); Angiotensin II; $Ca^{2+}$ (intracellular free); Angiotensin AT$_1$ receptors (Delisée, C. (247) 139)

**SR 48968**
Tachykinin NK$_2$ receptors; Opioid receptors (Martin, C.A.E. (243) 309)

**Stable transfection**
$\alpha_2$-Adrenoceptor subtype; Cell line; [$^3$H]Rauwolscine binding; (Antagonist) (Marjamäki, A. (246) 219)

**Stereoselectivity**
MPC-1304; $Ca^{2+}$ entry blocking activity; (Metabolites) (Okumura, K. (235) 69)

**Stereotyped behaviour**
$\sigma$ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl) carbazol); Radiolabeled ligand binding; (+)-SKF10,047 (Tanaka, M. (238) 89)

**Stereotypies**
Ceruletide; Amphetamine; Hyperlocomotion; Microdialysis; (Rat) (Kihara, T. (230) 271)

Dopamine receptors; Behavioral supersensitivity; Autoradiography (Marin, C. (231) 191)

**Steroid hormones**
Mineralocorticoid receptor; Glucocorticoid receptor; Receptor binding; Localization; Trans-activation (Rupprecht, R. (247) 145)

**Steroids**
Myometrium; Uterine artery; Estrogen; Progesterone; Diethylstilbestrol (Kostrzewska, A. (233) 127)

**Stimulants**
Development; Ontogeny; Distress vocalization; Ultrasonic vocalization; Tolerance; Withdrawal; Cocaine (Barr, G.A. (233) 143)

**Stimulus train length**
$\beta$-Adrenoceptors; Desensitization; Facilitation; Prejunctional (Lakhlani, P.P. (230) 107)

**Stomach**
Nitric oxide (NO); L-Arginine; Indomethacin; Prostaglandins (Konturek, S.J. (229) 155)

Interleukin-1; Tumour necrosis factor (Montuschi, P. (233) 303)

FRG-8813; Histamine $H_2$ receptor antagonists; Gastric acid secretation (Shibata, M. (235) 245)

Colon; Gastrointestinal motility; Pain; VIP (vasoactive intestinal polypeptide); VIP antiserum (Bojö, L. (236) 443)

Angiotensin II; Losartan; Angiotensin receptor (antagonism); Trachea (Liu, Yu.J. (240) 147)

**Stomach (isolated)**
Gastric acid secretion; DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid); Amiloride; $Cl^-$-$HCO_3^-$ exchanger; $Na^+$-$H^+$ exchanger; (Rat) (Horie, S. (229) 15)

**Stomach (rat)**
Non-adrenergic, non-cholinergic (NANC) transmission; Nitric oxide (NO) (Shimamura, K. (231) 103)

**Streptokinase**
Thrombolysis; Thromboxane receptor antagonists; Thromboxane synthase inhibitors; Coronary blood flow (Olson, R.W. (236) 75)

**Streptozotocin**
Diabetes; Endothelium; Mesenteric artery; Vasodilatation (Furman, B.L. (232) 29)

Diabetes mellitus; Diabetic neuropathy; Inositol phosphates; myo-Inositol; Nerve conduction (Carrington, A.L. (237) 257)

Diabetes; Dopamine; Dopamine $D_1$ receptors; Fenoldopam (Wang, Y.-X. (248) 217)

**Stress**
EGTA; EDTA; Gastric acid secretion; Ethanol; Gastric ulcer; Pepsin (Glavin, G.B. (233) 269)

Handling; 5-$HT_{1A}$ receptors; 5-$HT_3$ receptors; $GABA_B$ receptors; Anxiolytics (Andrews, N. (235) 109)

Tianeptine; Catecholamines; Frontal cortex; (Rat) (Sacchetti, G. (236) 171)

$\alpha$-Interferon; Corticosterone; Paraventricular nucleus; Opioid receptors (Saphier, D. (236) 183)

Amphetamine; Dopamine; Prefrontal cortex; Sensitization (Hamamura, T. (237) 65)

5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake; Tianeptine; Buspirone; Diazepam (Mennini, T. (241) 255)

**Stress (emotional)**
5-$HT_{1A}$ receptor agonists; 5-$HT_2$ receptor antagonists; 5-$HT_3$ receptor antagonists; Colonic motility; (Rat) (Gué, M. (233) 193)

**Striatal dopamine**
Parkinson's disease; Locus coeruleus; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); C57Bl/6 mouse (Marien, M. (236) 487)

**Striatal neurons**
Morphine exposure (chronic); Tolerance; Dependence; G-proteins; Adenylyl cyclase activity (Van Vliet, B.J. (245) 23)

**Striatum**
Dopamine release; Haloperidol; Apomorphine; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

Neuroleptics; Dopamine release; Dopamine metabolism; 3-Methoxytyramine; Nucleus accumbens; Frontal cortex; Depolarization block; (Rat) (Chrapusta, S.J. (233) 135)

Adenosine (extracellular); Brain microdialysis; Anaesthesia; Tetrodotoxin; NMDA receptors (Pazzagli, M. (234) 61)

$\sigma$ Binding sites; DTG (1,3-di-o-tolylguanidine); Imipramine; Hippocampus; 5-HT (5-hydroxytryptamine, serotonin) (Shirayama, Y. (237) 117)

AJ 76; UH 232; Dopamine receptors; Acetylcholine release; Antipsychotics (Gifford, A.N. (237) 169)

Aromatic L-amino acid decarboxylase; Dopamine receptors; Neuroleptics (Zhu, M.-Y. (238) 157)

Adenine nucleotides; Adenosine $A_2$ receptors; Adenosine deaminase; APCP (5′-O-($\alpha$,$\beta$-methylene)diphosphate) (Pirotton, S. (241) 55)

Microdialysis; Galanin receptor antagonists; M15; M35; Receptor binding (Ögren, S.O. (242) 59)

Dopamine release; Glutamate receptors; Brain, in vitro (rat); Olfactory tubercle; Frontal cortex (Jones, C.A. (242) 183)

Cocaine; Tropanes; Dopamine transporters (Davies, H.M.L. (244) 93)

NMDA receptors; Glutamate; Proenkephalin mRNA; Accumbens; MK-801 (Angulo, J.A. (244) 317)

Dopamine $D_1$ receptors; Dopamine $D_1$ receptor turnover; SCH 23390; N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); Substantia nigra; Brain (Rat) (Giorgi, O. (245) 139)

[$^3$H]Spiperone; Dopamine $D_2$ receptors; Affinity state; Dorsal hippocampus; Ventral hippocampus; $Mg^{2+}$; GTP; Iron-chelator (Bruinink, A. (245) 157)

[$^3$H]Quinpirole; Monoamine oxidase inhibitor; Receptor binding; CNS (central nervous system); (Rat) (Levant, B. (246) 171)

Cyanide; Thiocyanate; Dopamine receptors (Cassel, G.E. (248) 297)

**Striatum (dorsal)**
GABA ($\gamma$-aminobutyric acid); GABA/dopamine interaction; GABA/acetylcholine interaction; Striatum (ventral); Oral movements; (Rat) (Kikuchi de Beltrán, K. (239) 47)

**Striatum (rat)**
Phospholipase C; Phosphatidylinositol 4,5-bisphosphate; Inositol 1,4,5-trisphosphate; Dopamine; Aging (Sugawa, M. (247) 39)

Dopamine neuronal carrier; Membrane polarity; [$^3$H]GBR 12783; Binding (in vitro) (Billaud, G. (247) 333)

**Striatum (ventral)**
GABA (γ-aminobutyric acid); GABA/dopamine interaction; GABA/acetylcholine interaction; Striatum (dorsal); Oral movements; (Rat) (Kikuchi de Beltrán, K. (239) 47)

**Structure-activity relationships**
Neuropeptide Y; Neuropeptide Y receptor sub-types; Truncated analogues; Binding assays; Bioassays (Dumont, Y. (238) 37)

Bombesin; Gastrin-releasing peptide (GRP); Phyllolitorin; Scratching behaviour; (Rat) (Masui, A. (238) 297)

27-*O*-Caffeoyl myricerone (50-235); Endothelin receptor antagonist; [$^{125}$I]Endothelin-1 binding; Cytosolic free $Ca^{2+}$ (Mihara, S.-i. (247) 219)

**[$^3$H]Strychnine binding (agonist and antagonist)**
Glycine receptor; Entropy change of binding; Kinetic cooperativity of dissociation (Maksay, G. (245) 183)

**Strychnine-insensitive glycine receptors**
Nimodipine; BAY K 8644 (Nowak, G. (247) 101)

Electroconvulsive shock; Imipramine; NMDA (*N*-methyl-D-aspartate) receptor complex; 5,7-Dichlorokynurenic acid; CGP-39653 (Paul, I.A. (247) 305)

**Strychnine-insensitive glycine site**
NMDA receptor complex; (High affinity) (Lewin, A.H. (247) 1)

**Submandibular gland**
Nitric oxide (NO); Afferent nerves; Blood flow; Pulp; Oral mucosa; Lip (Kerezoudis, N.P. (241) 209)

**Substance P**
DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); Morphine; Naloxone; Naloxonazine, β-Funaltrexamine; Nor-binaltorphimine; ICI 174,864; Trigeminal nucleus caudalis (Suarez-Roca, H. (229) 1)

Tracheal epithelium; Thrombin; Endothelin; Vasopressin (Rennick, R.E. (230) 367)

Allergen; Bradykinin; CP-96,345; Airway microvascular leakage; $NK_1$ receptors (Sakamoto, T. (231) 31)

Pertussis toxin; Morphine; Quinpirole; Carbachol; U-50,488H (Bot, G. (231) 53)

Intestine; Ganglia; Enteric nervous system; Myenteric plexus; Tachykinins (Tamura, K. (232) 235)

Medial habenula; Neurokinin; Tachykinin (Norris, S.K. (234) 223)

Prostaglandins; Aqueous humor; Indomethacin; Timolol; Surgical miosis (Kieselbach, G. (235) 117)

Neurokinin A; Adrenoceptors (Luo, L. (235) 157)

Neurokinin A; Capsaicin; Airway constriction; Plasma extravasation (Murai, M. (236) 7)

Neurogenic plasma extravasation; Opiate action (peripheral); C-fibre; Inflammation (Barber, A. (236) 113)

Nitric oxide (NO); Morphine; Substance P receptor antagonists; β-Adrenoceptors (Persico, P. (238) 105)

Substance P N-terminus; Morphine withdrawal; (Intrathecal) (Kreeger, J.S. (238) 111)

$NK_1$ receptor antagonist (non-peptide); Dura mater; Neurogenic inflammation; Migraine model (Moussaoui, S.M. (238) 421)

Lower esophageal sphincter; Tachykinins; Neurokinin A; $NK_2$ receptors; (Human) (Huber, O. (239) 103)

Bradykinin; Histamine; Cromakalim; Vascular permeability; Plasma exudation; Airways (Martin, C.A.E. (239) 119)

Diabetes mellitus; Vascular permeability; Neurokinins; Nitric oxide (NO) (Mathison, R. (240) 163)

Neurokinin A; $NK_2$ receptor antagonists; $NK_1$ receptor antagonists; Capsaicin; Lung (guinea-pig) (Kudlacz, E.M. (241) 17)

Spinal cord; Neurokinin A; Tachykinin receptors; Acetylcholine release; Polymerase chain reaction (Suzuki, H. (241) 105)

Pain (chronic); Diabetes (Courteix, C. (241) 267)

Spantide; Substance P analogues (containing D-His); Formalin; Capsaicin; Nociceptive response; Intrathecal injection (Sakurada, T. (242) 47)

Levodropropizine; Capsaicin; Sensory nerves; Neurogenic inflammation; Plasma extravasation (Yamawaki, I. (243) 1)

RP 67580; $NK_1$ receptors; Transfection; Second messenger (binding) (Hermans, E. (245) 43)

**Substance P analogues (containing D-His)**
Substance P; Spantide; Formalin; Capsaicin; Nociceptive response; Intrathecal injection (Sakurada, T. (242) 47)

**Substance P N-terminus**
Substance P; Morphine withdrawal; (Intrathecal) (Kreeger, J.S. (238) 111)

**Substance P receptor antagonists**
Substance P; Nitric oxide (NO); Morphine; β-Adrenoceptors (Persico, P. (238) 105)

**Substance P release**
Adenosine $A_2$ receptors; Sensory nerves; Airways (Morimoto, H. (240) 121)

**Substantia nigra**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Motor deficits; Dopamine; Age; (Common marmoset) (Rose, S. (230) 177)

Primary neuronal cultures; Locus coeruleus; κ-Opioid receptors; μ-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

Normetazocine; σ Receptors; Movement; Naloxone; Opiates (Walker, J.M. (231) 61)

d-Amphetamine; Dopamine; Autoreceptors; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

Neurokinin receptor agonists; Intranigral infusion; Oral movements; (Rat) (Liminga, U. (235) 177)

Normetazocine; $\sigma$ Receptors; Movement; Naloxone; Opiates (Walker, J.M. (236) 495)

l-Deprenyl (selegiline); Hydroxyl radical; Dopamine; MPTP neurotoxin; $MPP^+$ (1-methyl-4-phenylpyridinium ion); Parkinson's disease (Wu, R.-M. (243) 241)

Dopamine $D_1$ receptors; Dopamine $D_1$ receptor turnover; SCH 23390; N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); Striatum; Brain (Rat) (Giorgi, O. (245) 139)

**Substantia nigra (human)**
Angiotensin II receptor subtypes; Cerebellum (human); Brain (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Substantia nigra pars compacta**
Reserpine; Dopamine neurons; Dopamine receptor agonists; Firing pattern; Single-unit recording; Supersensitivity (Sun, B.-C. (231) 331)

Benzamides (substituted); Ventral tegmental area; (Repeated treatment) (Skarsfeldt, T. (240) 269)

**Sucrase**
Robenidine; Coccidiosis; D-Galactose; L-Leucine; Intestinal transport; Jejunum (rabbit); Drug-nutrient interaction; Aminopeptidase (Sorribas, V. (248) 137)

**Sulfhydryl group**
Gold ion; $Ca^{2+}$ channels (L-type); Perchlorate; Skeletal muscle contraction; (Frog) (Nihonyanagi, K. (238) 149)

**8-(p-Sulfophenyl)theophylline**
Anococcygeus (rabbit); Nitric oxide (NO); Nitric oxide synthase inhibitors; Purinoceptors; ATP; Adenosine; Suramin (Graham, A.M. (237) 93)

**Sulphonylureas**
$Mg^{2+}$; $K_{ATP}$ channels (Lee, K. (247) 347)

**(−)-Sulpiride**
Dopamine; Acetylcholine; Microdialysis; Cocaine; $\alpha$-Methyltyrosine + reserpine; SCH 23390 (Imperato, A. (229) 265)

**Sulpiride**
Dopamine release; Striatum; Haloperidol; Apomorphine; (Chronic treatment) (Yamada, S. (232) 1)

Dopamine $D_4$ receptors; Aporphines (Seeman, P. (233) 173)

**$^{125}$I-Sulpiride**
Dopamine $D_2$ receptors; Dopamine $D_3$ receptors; Nucleus accumbens; Olfactory tubercle; Caudate nucleus; (Rat) (Parsons, B. (234) 269)

**Sumatriptan**
5-HT (5-hydroxytryptamine, serotonin); Platelets; Coronary artery (human); Ergotamine; 5-$HT_{1D}$-like receptors; 5-$HT_2$ receptors (Bax, W.A. (239) 203)

**Superfusion**
p-Chloroamphetamine; p-Methylthioamphetamine; Drug discrimination; Uptake inhibition; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain slices (Huang, X. (229) 31)

**Superoxide anion**
PAF (platelet-activating factor, PAF-acether); Alveolar macrophages; Polymorphonuclear leukocytes; Thromboxane $A_2$; (Guinea-pig) (Kato, M. (232) 7)

**Superoxide radicals**
5-HT (serotonin 5-hydroxytryptamine binding proteins); Brain; 5-HT (serotonin 5-hydroxytryptamine); Dopamine; Iron ions (Jimenez Del Rio, M. (247) 11)

**Supersensitivity**
Reserpine; Substantia nigra pars compacta; Dopamine neurons; Dopamine receptor agonists; Firing pattern; Single-unit recording (Sun, B.-C. (231) 331)

**Supraspinal $\delta$-opioid receptor**
Naltrindole; $\delta$-Opioid receptor; Naloxone-precipitated withdrawal; Butorphanol dependence (Jaw, S.P. (240) 67)

**Suramin**
Anococcygeus (rabbit); Nitric oxide (NO); Nitric oxide synthase inhibitors; Purinoceptors; ATP; Adenosine; 8-(p-Sulfophenyl)theophylline (Graham, A.M. (237) 93)

**Surgical miosis**
Substance P; Prostaglandins; Aqueous humor; Indomethacin; Timolol (Kieselbach, G. (235) 117)

**Sustained release formulation**
TRH (thyrotropin-releasing hormone); Scopolamine; AF64A (ethylcholine aziridinium ion); Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

**Sympathetic ganglia**
Dequalinium; Ganglion blockers; Muscarinic receptor antagonists; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

$Ca^{2+}$ channels; Nitric oxide (NO); Norepinephrine; Voltage-clamp; Patch-clamp (Chen, C. (243) 83)

**Sympathetic nerve activity**
8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Cardiovascular neurons; Lateral tegmental field (Vayssettes-Courchay, C. (236) 121)

**Sympathetic nervous system**
Tryptophan; 5-$HT_{1C}$/5-$HT_2$ receptors; Blood-brain barrier; Immobilization stress (Chaouloff, F. (231) 77)

Catecholamine re-uptake blockers; Cortex injury; Procholecystokinin mRNA (Mondeh, J.D. (240) 39)

**Sympathetic neurons (mammalian)**
Cholecystokinin; $CCK_A$ receptors; Slow depolarization; Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

**Synaptic excitation**
Clozapine; Haloperidol; Loxapine; Hippocampus (Baskys, A. (235) 305)

**Synaptosomes**
Calcium channels; Alcohols; Longitudinal muscle; [$^3$H]Nitrendipine; [$^{125}$I]$\omega$-Conotoxin (Hawthorn, M.H. (229) 143)

5-HT (5-hydroxytryptamine, serotonin); 5-HT release; d-Fenfluramine; $Ca^{2+}$ channels (Gobbi, M. (238) 9)

Fenfluramine; Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Neuronal uptake (Westphalen, R.I. (238) 399)

Nucleoside transport; R75231; Positive cooperativity (Jones, K.W. (246) 97)

**Synergism**
Platelet (human); 5-HT (5-hydroxytryptamine) (Roevens, P. (245) 273)

**System-L**
Gabapentin; Anticonvulsant; L-Amino acids; Transporter; Brain (Thurlow, R.J. (247) 341)

**Tachykinin**
Neurokinin A; Neurokinin receptor subtypes; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (232) 287)

$NK_2$ receptors; Radioligand binding; Neurokinin A; Neuropeptide γ; Gastric fundus (rat) (Burcher, E. (233) 201)

Medial habenula; Neurokinin; Substance P (Norris, S.K. (234) 223)

Neurokinin A; Neurokinin receptor subtypes; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (236) 496)

Nitric oxide (NO); Neuroeffector modulation; Cholinergic; Smooth muscle; Chemiluminescence (Wiklund, C.U. (240) 235)

**Tachykinin receptor antagonists**
Tachykinin; Neurokinin A; Neurokinin receptor subtypes; Bladder (rabbit, hamster) (Guard, S. (232) 287)

Tachykinins; Tachykinin $NK_2$ receptors (Maggi, C.A. (234) 83)

Amastatin; Aminopeptidases; Tachykinin receptors (Patacchini, R. (236) 31)

Tachykinin; Neurokinin A; Neurokinin receptor subtypes; Bladder (rabbit, hamster) (Guard, S. (236) 496)

**Tachykinin receptors**
Cilia; Maxillary sinus; Mucociliary activity; Phosphoramidon; Tachykinins; (Rabbit) (Lindberg, S. (231) 375)

Tachykinin receptor subtypes; Septide; CP 96,345 (Maggi, C.A. (235) 309)

Amastatin; Aminopeptidases; Tachykinin receptor antagonists (Patacchini, R. (236) 31)

Neurogenic inflammation; Plasma protein extravasation; Dura mater; CGRP (calcitonin gene-related peptide) (O'Shaughnessy, C.T. (236) 319)

Spinal cord; Substance P; Neurokinin A; Acetylcholine release; Polymerase chain reaction (Suzuki, H. (241) 105)

**Tachykinin $NK_2$ receptors**
Tachykinins; Tachykinin receptor antagonists (Maggi, C.A. (234) 83)

SR 48968; Opioid receptors (Martin, C.A.E. (243) 309)

**Tachykinin receptor subtypes**
Tachykinin receptors; Septide; CP 96,345 (Maggi, C.A. (235) 309)

**Tachykinins**
Cilia; Maxillary sinus; Mucociliary activity; Phosphoramidon; Tachykinin receptors; (Rabbit) (Lindberg, S. (231) 375)

Intestine; Ganglia; Enteric nervous system; Myenteric plexus; Substance P (Tamura, K. (232) 235)

Tachykinin $NK_2$ receptors; Tachykinin receptor antagonists (Maggi, C.A. (234) 83)

Lower esophageal sphincter; Substance P; Neurokinin A; $NK_2$ receptors; (Human) (Huber, O. (239) 103)

Ileum (guinea-pig); Circular muscle; ω-Conotoxin; Nitric oxide (NO); Apamin; NANC (non-adrenergic, non-cholinergic); NANC relaxation (Maggi, C.A. (240) 45)

Neurokinins; Pain; Analgesia; Spinal cord (Fleetwood-Walker, S.M. (242) 173)

**Tachyphylaxis**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Prostaglandins E; Temperature; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

Diabetes mellitus; Aorta (rat); $N^G$-Nitro-L-arginine; Haemoglobin; Endothelium-dependent relaxation (Sikorski, B.W. (242) 275)

**Tacrine**
Lithium chloride; Nitric oxide (NO); Epilepsy; Neurodegeneration (Bagetta, G. (237) 61)

**Taenia coli myocytes**
Aortic myocytes; Verapamil (Fan, S.-f. (229) 259)

**Tail artery (rat)**
Postjunctional $\alpha_2$-adrenoceptors; Adrenergic reactivity; $\alpha_2$-Adrenoceptor antagonists; $\alpha_2$-Adrenoceptor agonists; Aging (Tsai, H. (237) 311)

**Tail-flick inhibition**
β-Endorphin; Morphine; Tolerance; Cross-tolerance; Antinociception; Hot-plate inhibition (Tseng, L.F. (241) 63)

**Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine)**
Bromocriptine; Dopamine $D_2$ receptor agonists; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

EEDQ (*N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); Radioligand binding (in vivo); Pituitary; Prolactin; Dopamine $D_2$ receptors; NPA (*R*-(−)-*N*-*n*-propylnorapomorphine); (Receptor reserve); (+)-3-PPP ((+)-3-(3-hydroxyphenyl)-*N*-*n*-propylpiperidine) (Ekman, A. (243) 295)

**Tardive dyskinesia**
Dopamine $D_4$ receptors; Dopamine $D_2$ receptors; Schizophrenia; Antipsychotics; Extrapyramidal side effects (Lahti, R.A. (236) 483)

**Taurine**
Milacemide; Amino acids; Monoamine metabolites; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

$Ca^{2+}$ channels (L-type); $Ca^{2+}$ channels (T-type); Cardiac myocytes; Heart cells (embryonic chick); Voltage clamp (whole cell); Electrophysiology (Satoh, H. (231) 443)

**Taurine release**
Posterior hypothalamus; Blood pressure; Veratridine; Tetrodotoxin; Push-pull cannula (Singewald, N. (240) 21)

**Taxol neuropathy**
Neuroprotection; ORG 2766 (Hamers, F.P.T. (233) 177)

**[$^{35}$S]TBPS binding**
$GABA_A$ receptors; $La^{3+}$; Lanthanides; Conformational changes in $GABA_A$ receptors (Im, W.B. (245) 111)

$GABA_A$ receptor-ionophore complex; Benzodiazepine receptors; Agonists/inverse agonists (Partial and full); Allosteric regulation of efficacy (Maksay, G. (246) 255)

**TBPS binding**
$GABA_A$ receptor complex; Benzodiazepine; $Cl^-$ uptake (Finn, D.A. (247) 233)

**TEI-6720**
Allopurinol; Xanthine oxidase/xanthine dehydrogenase; Uric acid; Hyperuricemia (Osada, Y. (241) 183)

**Temelastine**
HeLa cell; Histamine $H_1$ receptor; [$^3$H]Mepyramine; Phosphoinositide; (+)-Chlorpheniramine (Arias-Montaño, J.-A. (245) 291)

**Temperature**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Prostaglandins E; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

**Temperature dependence**
MK-801; Repetitive firing (sustained); $Na^+$-dependent action potentials; Neurons (cultured) (Wamil, A.W. (230) 263)

**Terminals**
NPY receptors; Brain; [$^3$H]noradrenaline release; (Rat) (Martire, M. (230) 231)

**(−)-Tertatolol**
Dorsal raphe nucleus; WAY 100,135; Flat-body posture; Corticosterone (Lejeune, F. (240) 307)

**Testosterone**
Sexual behaviour; Ejaculation; Castration; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Wistar rat) (Haensel, S.M. (233) 187)

**Tetraethylammonium**
Forskolin action; Uterus (pregnant); Smooth muscle cells (myometrial); $K^+$ currents; cAMP (Inoue, Y. (240) 169)

CGRP (calcitonin gene-related peptide); Uterine artery (human); $K^+$ channels; Pregnancy; Glybenclamide; Pinacidil (Nelson, S.H. (242) 255)

$5\text{-}HT_3$ receptor; 5-HT (5-hydroxytryptamine, serotonin); N1E-115 neuroblastoma; Whole-cell voltage clamp; Ion channel; Desensitization (Kooyman, A.R. (246) 247)

**Tetrahydroaminoacridine (THA, tacrine)**
Alzheimer's disease; PET (positron emission tomography); Acetylcholinesterase; (Baboon); (Rat) (Tavitian, B. (236) 229)

High voltage spindles; Slow wave; Muscarinic $M_1$ receptor; Muscarinic $M_2$ receptor; Physostigmine; Pilocarpine; AF102B; Oxotremorine (Riekkinen, Jr., P. (240) 1)

Physostigmine; β-Adrenoceptors; Adenylate cyclase; Hippocampus; Cortex; cAMP (Vivas, N.M. (245) 9)

**Tetrahydrocannabinol**
Cannabinoids; Marihuana (Fride, E. (231) 313)

**Tetramethylpyrazine**
Membrane fluidity; Electron spin resonance; Fluorescence polarization; Smooth muscle (vascular) (Nie, S.-Q. (244) 15)

**Tetrandrine**
Smooth muscle (vascular); Saphenous vein (dog); $Ca^{2+}$; Excitation-contraction (Kwan, C.-Y. (238) 431)

**Tetrodotoxin**
Adenosine (extracellular); Brain microdialysis; Striatum; Anaesthesia; NMDA receptors (Pazzagli, M. (234) 61)

Taurine release; Posterior hypothalamus; Blood pressure; Veratridine; Push-pull cannula (Singewald, N. (240) 21)

Ricinoleic acid; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester); $N^G$-Monomethyl-L-arginine; L-Arginine; Ileum; (Rat) (Izzo, A.A. (243) 87)

**TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine)**
5-HT (5-hydroxytryptamine, serotonin); NAN-190; RU 24969; mCPP (m-chlorophenylpiperazine); 5-HIAA (CSF levels); $5\text{-}HT_1$ receptor binding (in vitro); (Pigeon) (Gleeson, S. (229) 109)

Feeding behaviour; Genetic obesity; Insulin; Neuropeptide Y; CRF (corticotropin-releasing factor); (Zucker rat) (Rouru, J. (234) 191)

Aggression; Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Dorsal raphe (rat) (Mos, J. (238) 411)

**TGF-α (transforming growth factor-α)**
Tryptophan; 5-HT (5-hydroxytryptamine, serotonin); Antidepressant drugs; Depression; Aggression; Transgenic mice (Hilakivi-Clarke, L.A. (237) 101)

Parietal cell rat; Acid production; Glucagon-like peptide 1-(7–36) amide; Epidermal growth factor; GTP-binding proteins (Schmidtler, J. (246) 59)

**Thalamic extracellular recording**
$NK_2$ receptor antagonists; Thermal nociception (Santucci, V. (237) 143)

**Thaliporphine**
Vasoconstrictors; $Ca^{2+}$ channel agonists; Thoracic aorta (rat) (Teng, C.-M. (233) 7)

Contraction; Ileum (guinea-pig); $Ca^{2+}$ channels (Yu, S.-M. (234) 121)

**Thapsigargin**
Ryanodine; Smooth muscle (vascular); $Ca^{2+}$ mobilization (Low, A.M. (230) 53)

**Thermal nociception**
$NK_2$ receptor antagonists; Thalamic extracellular recording (Santucci, V. (237) 143)

**Thermal stimuli**
Opioids; Parabrachial; Noxious; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**Thermodilution**
Heart failure (high-output); Laser-Doppler flowmetry; Neurohumoral factors; Renal blood flow; Wistar rat (Oka, T. (234) 55)

**Thermodynamics**
δ-Opioid receptors; Mouse vas deferens; DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin) (Raffa, R.B. (244) 231)

**Thermogenesis**
Metformin; Zucker rat; Genetic obesity; Brown adipose tissue; Uncoupling protein (Rouru, J. (246) 67)

**Thermoregulation**
Vasopressin; Ultrasonic vocalization; Anxiety; Affiliation; Vasotocin (Winslow, J.T. (233) 101)

Dopamine; Dopamine receptors; (Rat) (Salmi, P. (236) 395)

**Thiazide diuretics**
M17055; Loop diuretics; Amiloride; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

**Thiocyanate**
Cyanide; Dopamine receptors; Striatum (Cassel, G.E. (248) 297)

**Thioperamide**
Histamine $H_3$ receptors; (R)-α-Methylhistamine; Water consumption; (Rat) (Clapham, J. (232) 99)

Histamine; Histamine $H_3$ receptor antagonists; (R)-α-Methylhistamine; Convulsions (electrically induced) (Yokoyama, H. (234) 129)

**Thiorphan**
Acetylthiorphan; Acetorphan; Neutral endopeptidase; Hot-plate test; Analgesia (Lambert, D.M. (243) 129)

**Thoracic aorta (rabbit)**
Kinetics; Antagonism, functional; Adenosine $A_2$ receptors; $\alpha_1$-Adrenoceptor (Wiener, H.L. (238) 65)

**Thoracic aorta (rat)**
Thaliporphine; Vasoconstrictors; $Ca^{2+}$ channel agonists (Teng, C.-M. (233) 7)

Cardiotonic agent; Phosphodiesterase inhibitor; $Ca^{2+}$; cAMP (Itoh, H. (240) 57)

**THP-1 cells**
Human polymorphonuclear leukocytes; Leukotriene $B_4$ receptors; Leukotrienes (Slipetz, D.M. (244) 161)

**Thrombin**
Tracheal epithelium; Endothelin; Vasopressin; Substance P (Rennick, R.E. (230) 367)

Thrombosis; Thromboxane $A_2$; PAF (platelet-activating factor, PAF-acether); ADP; (Guinea-pig) (Hirata, Y. (231) 421)

Platelets (human); Shape-change parameter; Protein kinase C; Discsphere change; 1-Oleoyl-2-acetyl-glycerol (Ozaki, Y. (235) 255)

Glycosphingolipids; Lysogangliosides; Platelet aggregation; 5-HT (5-hydroxytryptamine, serotonin); Tromboxane $B_2$; Bleeding; Coagulation; Fibrinolysis (Tubaro, E. (248) 175)

**Thrombolysis**
Streptokinase; Thromboxane receptor antagonists; Thromboxane synthase inhibitors; Coronary blood flow (Olson, R.W. (236) 75)

**Thrombosis**
Thromboxane $A_2$; PAF (platelet-activating factor, PAF-acether); ADP; Thrombin; (Guinea-pig) (Hirata, Y. (231) 421)

**Thromboxane**
Carrageenan; Oedema; Ph CL28A; Pleurisy; Prostacyclin (Santana, A.C. (231) 237)

Thromboxane receptor antagonists; Inhalation injury (one lung); Toxic airway damages; Pulmonary hemodynamics; (Sheep) (Loick, H.M. (248) 75)

Nicotine; Cotinine; Prostaglandins; Leukotrienes (Saareks, V. (248) 345)

**Thromboxane $A_2$**
S-1452 (calcium (1R,2S,3S,4S)-(5Z)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate); Lipopolysaccharide; TNF (tumor necrosis factor); Bronchial hyperresponsiveness (Arimura, A. (231) 13)

Thrombosis; PAF (platelet-activating factor, PAF-acether); ADP; Thrombin; (Guinea-pig) (Hirata, Y. (231) 421)

Superoxide anion; PAF (platelet-activating factor, PAF-acether); Alveolar macrophages; Polymorphonuclear leukocytes; (Guinea-pig) (Kato, M. (232) 7)

Basilar artery (rat); Endothelium; 5-HT receptors (Descombes, J.-J. (243) 193)

Platelets; Milrinone; Phosphodiesterase (Jeremy, J.Y. (245) 67)

**Thromboxane $B_2$**
Phospholipase $A_2$; Pleurisy; Carrageenan; Zymosan; Inflammation (Tesson, F. (248) 27)

**Thromboxane $A_2$/prostaglandin endoperoxides receptor antagonists**
Antiplatelet compound; IBI P-05006; Platelets (Rotondo, S. (232) 41)

**Thromboxane receptor antagonists**
Thromboxane receptors; BAY u3405; Lung strip; I-BOP (1S-(1α,2α(Z),3β(1(E),3S),4α)-7-(3-(3-hydroxy-4-(4-iodophenoxy)-1-butenyl)-7-oxabicyclo(2,2,1)hept-2-yl-5-heptenoic acid); U46619 (Norman, P. (229) 171)

Thrombolysis; Streptokinase; Thromboxane synthase inhibitors; Coronary blood flow (Olson, R.W. (236) 75)

Inhalation injury (one lung); Toxic airway damages; Thromboxane; Pulmonary hemodynamics; (Sheep) (Loick, H.M. (248) 75)

**Thromboxane $A_2$ receptor antagonists**
Bronchial hyperresponsiveness; 9α,11β-Prostaglandin $F_2$ (Kurosawa, M. (238) 335)

**Thromboxane receptors**
Thromboxane receptor antagonists; BAY u3405; Lung strip; I-BOP (1S-(1α,2α(Z),3β(1(E),3S),4α)-7-(3-(3-hydroxy-4-(4-iodophenoxy)-1-butenyl)-7-oxabicyclo(2,2,1)hept-2-yl-5-heptenoic acid); U46619 (Norman, P. (229) 171)

**Thromboxane synthase inhibitors**
CS-518; Asthmatic model; Bronchoconstriction; Hyperresponsiveness (Yamaguchi, T. (236) 43)

Thrombolysis; Streptokinase; Thromboxane receptor antagonists; Coronary blood flow (Olson, R.W. (236) 75)

CS-518; Asthmatic model; Eicosanoid production (Itoh, K. (237) 215)

**Thromboxane $A_2$ synthase inhibitors**
CS-518; Asthmatic model; Eosinophil function (Itoh, K. (239) 159)

**Thromboxane synthesis**
1$\alpha$,25-Dihydroxyvitamin $D_3$ analogues; HL-60 cells (human); Vitamin D receptors (Honda, A. (229) 217)

**Thymidine**
Uridine; Leucine; DNA synthesis; RNA synthesis; Protein synthesis; Thymidine kinase activity (Garg, U.C. (237) 243)

**Thymidine kinase activity**
Thymidine; Uridine; Leucine; DNA synthesis; RNA synthesis; Protein synthesis (Garg, U.C. (237) 243)

**Thyroid hormone**
Adrenoreceptor; Noradrenaline; Proximal tubule; In situ hybridization (Meister, B. (247) 229)

**L-Thyroxine administration (repeated)**
Methimazole administration (repeated); Plasma endothelin concentration; Endothelin mechanisms; Cerebral cortex; Hypothalamus; Pituitary (Rebello, S. (237) 9)

**Tianeptine**
Catecholamines; Frontal cortex; Stress; (Rat) (Sacchetti, G. (236) 171)

5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake; Stress; Buspirone; Diazepam (Mennini, T. (241) 255)

Citalopram; $5\text{-HT}_{1B}$ receptors; Acetylcholine release; Antidepressants (Bolaños-Jiménez, F. (242) 1)

**Time to peak twitch tension**
Doxorubicin; Pirarubicin; Aclarubicin; Heart (guinea-pig); Antimuscarinic action; Positive inotropic effect; Potentiated postrest contraction (Temma, K. (234) 173)

**Timolol**
Substance P; Prostaglandins; Aqueous humor; Indomethacin; Surgical miosis (Kieselbach, G. (235) 117)

**T lymphocytes**
AIDS; Cytokine; Mucosa; Virus infection (Bourinbaiar, A.S. (230) 15)

**TMB-8 (8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate)**
Nifedipine; Hypertonic saline; Renal blood flow; Glomerular filtration rate (Ogasawara, A. (243) 103)

**TNF (tumor necrosis factor)**
S-1452 (calcium (1R,2S,3S,4S)-(5Z)-7-(((phenylsulfonyl)amino)bicyclo[2.2.1]hept-2-yl)hept-5-enoate dihydrate); Thromboxane $A_2$; Lipopolysaccharide; Bronchial hyperresponsiveness (Arimura, A. (231) 13)

Adenosine analogs; Endothelium; Polymorphonuclear leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291)

Interleukin-1; Stomach (Montuschi, P. (233) 303)

Fenspiride; Carrageenin; Endotoxin; Neutrophil migration (Cunha, F.Q. (238) 47)

**TNF-$\alpha$ (tumor necrosis factor-$\alpha$)**
E3330; Liver injury; Galactosamine; Leukotrienes; Prostanoids (Nagakawa, J.-i. (229) 63)

Anti-tumor necrosis factor-$\alpha$ antibodies; Ischaemia-reperfusion injury (Squadrito, F. (237) 223)

**Toad venom**
Bufadienolide; Arenobufagin; $Na^+/K^+$ pump current (Cruz, J.d.S. (239) 223)

**$\alpha$-Tocopherol analogue (MDL 73404)**
Free radical scavenger; Reperfusion injury; Myocardial ischaemia/reperfusion; Contractility; Lipid peroxidation (Lukovic, L. (233) 63)

**Tolbutamide**
Nicorandil; Cardiac arrhythmias; Atria (rabbit); Quinidine (Le Grand, B. (229) 91)

**Tolerance**
Chlordiazepoxide; Passive avoidance response; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Autoradiography (Ishihara, S.-i. (230) 313)

DADLE ([D-Ala$^2$,D-Leu$^5$]enkephalin); Opioid receptors; Autoradiography; (Rat) (Tao, P.-L. (231) 145)

(+)-MK-801; Ethanol; (Rat) (Wu, P.H. (231) 157)

Dopamine; Microdialysis; Ethanol reinforcement (Rossetti, Z.L. (231) 203)

Development; Ontogeny; Distress vocalization; Ultrasonic vocalization; Withdrawal; Cocaine; Stimulants (Barr, G.A. (233) 143)

U-50,488H; Abstinence; Dopamine $D_2$ receptors; 2-Bromo-$\alpha$-ergocryptine; Behavioural activity (Veeranna, (235) 23)

Dopamine $D_1$ receptor; c-Fos (Asin, K.E. (235) 167)

Pentobarbital; $GABA_A$ receptors; Dependence; (Intracerebroventricular) (Tseng, Y.T. (236) 23)

$\beta$-Endorphin; Morphine; Cross-tolerance; Antinociception; Tail-flick inhibition; Hot-plate inhibition (Tseng, L.F. (241) 63)

Cholinergic drugs; Adrenocortical axis; Corticosterone (Cattaneo, L. (241) 245)

Morphine exposure (chronic); Dependence; G-proteins; Adenylyl cyclase activity; Striatal neurons (Van Vliet, B.J. (245) 23)

In situ hybridisation; Cholecystokinin (CCK); Diazepam; Withdrawal; mRNA (Rattray, M. (245) 193)

Radiation inactivation; Opioid receptor; G-protein; (Uncoupling) (Tao, P.-L. (246) 233)

Benzodiazepine; $Cl^-$ flux; Flurazepam; Bretazenil; Clonazepam; Diazepam (Li, M. (247) 313)

Ethanol; Gall bladder; Smooth muscle; $Ca^{2+}$ (Masui, H. (248) 103)

**Toluene diisocyanate**
Prostanoids; Sensory nerves (Mapp, C.E. (248) 277)

**Toxic airway damages**
Thromboxane receptor antagonists; Inhalation injury (one lung); Thromboxane; Pulmonary hemodynamics; (Sheep) (Loick, H.M. (248) 75)

**Trachea**
5-Lipoxygenase; Leukotriene; Bronchoconstriction; Asthma; (Guinea-pig) (Heaslip, R.J. (234) 247)

Asthma; Anaesthetics; Ketamine; Propofol; Smooth muscle (Pedersen, C.M. (238) 75)

Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Defibrotide (Bianchi, G. (238) 327)

Bradykinin; Bradykinin receptor antagonists; Bradykinin binding; (Guinea-pig) (Trifilieff, A. (239) 227)

Angiotensin II; Losartan; Angiotensin receptor (antagonism); Stomach (Liu, Yu.J. (240) 147)

**Trachea (guinea-pig)**
Cholinergic neurotransmission; Muscarinic $M_2$ receptors; Muscarinic $M_3$ receptors; Muscarinic receptor antagonists; Electrical field stimulation (Ten Berge, R.E.J. (233) 279)

$K^+$ channel antagonists; $\beta_2$-Adrenoceptor agonists; Smooth muscle (airway) (Huang, J.-C. (235) 37)

Co-axial bioassay; EpDRF (epithelium-derived relaxing factor); Ovalbumin challenge; Anococcygeus muscle (rat); 5-HT (5-hydroxytryptamine, serotonin) (Çakici, İ. (236) 97)

**Tracheal epithelium**
Thrombin; Endothelin; Vasopressin; Substance P (Rennick, R.E. (230) 367)

**Tracheal hyperreactivity**
Sensory nerves; Capsaicin; (Guinea-pig) (Ladenius, A.R.C. (235) 127)

**Trachealis**
$Ca^{2+}$ channel antagonists; Carbachol; Histamine; Verapamil; GS 283 (Chang, K.C. (236) 51)

**Trans-activation**
Mineralocorticoid receptor; Glucocorticoid receptor; Steroid hormones; Receptor binding; Localization (Rupprecht, R. (247) 145)

**Transcription factor**
Down-regulation; $\beta$-Adrenoceptors; $\beta$-Adrenoceptor agonist; Lung; (*r*at) (Nishikawa, M. (247) 131)

**Transepithelial potential**
Dopamine; Electrooculogram; Haloperidol; Light peak; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Transfected CHO cells**
Kidney cells (opossum); $\alpha_2$-Adrenoceptors (Pleus, R.C. (244) 181)

**Transfection**
Promiscuous coupling; AMP formation; Neurotensin (Yamada, M. (244) 99)

RP 67580; Substance P; $NK_1$ receptors; Second messenger (binding) (Hermans, E. (245) 43)

**Transgenic mice**
$TGF_\alpha$ (transforming growth factor $\alpha$); Tryptophan; 5-HT (5-hydroxytryptamine, serotonin); Antidepressant drugs; Depression; Aggression (Hilakivi-Clarke, L.A. (237) 101)

**Translational activation**
Ethanol-inducible cytochrome P450; Isoniazid (Park, K.S. (248) 7)

**Transmembrane $Ca^{2+}$ influx**
Voltage-dependent $Ca^{2+}$ channels; Arterial myogenic tone; $Ca^{2+}$-activated $K^+$ channels; Spontaneously hypertensive rats (SHR); (Early hypertensive stages) (Asano, M. (247) 295)

**Transmitter interaction**
5-HT (5-hydroxytryptamine, serotonin); NMDA (N-methyl-D-aspartate); Cortex (Rahman, S. (231) 347)

5-HT (5-hydroxytryptamine, serotonin); Desensitization; Receptor internalization; Protein kinase C (Rahman, S. (238) 173)

**Transmitter release**
Neuromuscular junction; $Mg^{2+}$ (Pearson, H.A. (236) 323)

**Transporter**
Gabapentin; Anticonvulsant; L-Amino acids; System-L; Brain (Thurlow, R.J. (247) 341)

**Transport pharmacophore**
Molecular modelling; Neurotransmitter transport; Specific serotonin transport inhibitors (Chang, A.S.-S. (247) 239)

**TRH analog**
Gastric acid secretion; Xanthine; 2-Deoxy-D-glucose; Vagus; Gastric mucosal blood flow; Carbachol (Tanaka, T. (243) 221)

**TRH (thyrotropin-releasing hormone)**
JTP-2942 ($N^{\alpha}$-[(1S,2R)-2-methyl-4-oxycyclopentanecarbonyl]-L-histidyl-L-prolinamide); Acetylcholine; Choline; Frontal cortex; Hippocampus; Microdialysis (Toide, K. (233) 21)

Sustained release formulation; Scopolamine; AF64A (ethylcholine aziridinium ion); Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

**Triazolam**
GABA/benzodiazepine receptors; Patch clamp; Primary culture; cDNA (Dučić, I. (244) 29)

**Tributyltin**
Triethyltin; Trimethyltin; Intracellular $Ca^{2+}$; Brain neurons; Cytotoxicity (Oyama, Y. (248) 89)

**Tricarboxylic acid cycle**
Microsphere embolism; Naftidrofuryl oxalate; Triphenyltetrazolium chloride (Miyake, K. (235) 75)

**Tricyclic antidepressants**
G-protein; Cerebral cortex; Adenylyl cyclase; $\beta$-Adrenoceptors; F-344 rats; Down-regulation (Scarpace, P.J. (247) 65)

**Triethyltin**
Tributyltin; Trimethyltin; Intracellular $Ca^{2+}$; Brain neurons; Cytotoxicity (Oyama, Y. (248) 89)

**Trifluoperazine**
Calmodulin; Glucose uptake; Insulin; Skeletal muscle (Guarner, V. (237) 139)

$K^+$ channel (*Xenopus laevis*); $K^+$ channel opener; KRN2391; Nicorandil; Cromakalim; Glibenclamide; Phentolamine (Sakuta, H. (244) 277)

**Trifluoroacetylated proteins**
Halothane; Neoantigens (Heijink, E. (248) 15)

**Trigeminal nucleus caudalis**
DPDPE ([D-Pen$^2$,D-Pen$^5$]enkephalin); Morphine; Naloxone; Naloxonazine, $\beta$-Funaltrexamine; Nor-binaltorphimine; ICI 174,864; Substance P (Suarez-Roca, H. (229) 1)

**Triiodothyronine**
Imipramine; Desipramine; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin) (Suzuki, S. (231) 297)

**Trimebutine**
$K^+$ currents; Smooth muscle cells (ileal); Patch-clamp (whole cell) (Nagasaki, M. (235) 197)

**Trimetazidine**
Platelets; Membrane fluidity; Aggregation; cAMP (Devynck, M.-A. (245) 105)

**Trimethyltin**
Tributyltin; Triethyltin; Intracellular $Ca^{2+}$; Brain neurons; Cytotoxicity (Oyama, Y. (248) 89)

**Trimipramine**
Imipramine; Fluoxetine; 5-HIAA (5-hydroxyindole-3-acetic acid); 5-HT uptake (Dewar, K.M. (235) 137)

**$\alpha$-Trinositol**
D-myo-Inositol 1,2,6-trisphosphate; Mesenteric circulation; Neuropeptide Y; Noradrenaline-induced vasoconstriction (Donoso, M.V. (240) 93)

**Triphenyltetrazolium chloride**
Microsphere embolism; Naftidrofuryl oxalate; Tricarboxylic acid cycle (Miyake, K. (235) 75)

**Trolox conjugates**
Oxyradicals; Ventricular myocytes (human) (Zielenski, J. (248) 313)

**Tromboxane $B_2$**
Glycosphingolipids; Lysogangliosides; Platelet aggregation; Thrombin; 5-HT (5-hydroxytryptamine, serotonin); Bleeding; Coagulation; Fibrinolysis (Tubaro, E. (248) 175)

**Tropanes**
Cocaine; Dopamine transporters; Striatum (Davies, H.M.L. (244) 93)

**Trophism**
Cultured neurons; Norepinephrine release; $Ca^{2+}$ transients (Przywara, D.A. (247) 353)

**Tropisetron**
5-HT (5-hydroxytryptamine, serotonin); [$^3$H]5-HT uptake; Cortical synaptosomes (rat); Cocaine; 5-HT receptor ligands (Cheng, C.H.K. (239) 211)

Enterotoxin; Intestinal secretion; Ketanserin; Ondansetron; Granisetron (Beubler, E. (248) 157)

**Truncated analogues**
Neuropeptide Y; Neuropeptide Y receptor sub-types; Structure-activity relationships; Binding assays; Bioassays (Dumont, Y. (238) 37)

**Tryptamines**
5-$HT_2$ receptors; Ergolines; LY53857; Amesergide (Johnson, M.P. (239) 111)

**Tryptophan**
5-$HT_{1C}$/5-$HT_2$ receptors; Blood-brain barrier; Sympathetic nervous system; Immobilization stress (Chaouloff, F. (231) 77)

$TGF_\alpha$ (transforming growth factor $\alpha$); 5-HT (5-hydroxytryptamine, serotonin); Antidepressant drugs; Depression; Aggression; Transgenic mice (Hilakivi-Clarke, L.A. (237) 101)

Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin (Huether, G. (238) 249)

**Tumour promotion**
Polychlorinated biphenyls; Hepatic foci (altered) (Hemming, H. (248) 163)

**Turning behaviour**
Dopamine $D_1/D_2$ receptor interaction; Nucleus accumbens; SKF 38393; Quinpirole; Limb stepping (Saigusa, T. (237) 161)

5-$HT_3$ receptors; [$^3$H]Zacopride; [$^3$H]Granisetron; [$^{14}$C]Guanidinium; Ileum; Bezold-Jarisch reflex; Cortical firing rate; (Ex vivo binding) (Bachy, A. (237) 299)

Dopamine receptors; Locomotor activity; Yawning; Blood pressure; Pressor response; Body temperature; Spontaneously hypertensive rats (SHR) (Van den Buuse, M. (243) 169)

**Turning model**
5-$HT_{1D}$ receptors; 5-Carboxamidotryptamine; (Autoreceptor) (Moret, C. (230) 379)

**L-Tyrosine (methyl ester)**
Antinociception; $\delta$-Opioid receptors; Bulbo-spinal noradrenergic system (Kawabata, A. (233) 255)

**U937 cell line**
Leukotriene $D_4$; Leukotriene $D_4$ receptors; Leukotriene receptor antagonists (Frey, E.A. (244) 239)

**U-46619**
Thromboxane receptors; Thromboxane receptor antagonists; BAY u3405; Lung strip; I-BOP (1S-(1$\alpha$,2$\alpha$(Z),3$\beta$(1(E),3S),4$\alpha$)-7-(3-(3-hydroxy-4-(4-iodophenoxy)-1-butenyl)-7-oxabicyclo(2,2,1)hept-2-yl-5-heptenoic acid) (Norman, P. (229) 171)

**U-50,488**
$\kappa$-Opioid receptor antagonists; Morphine; Analgesia; Shock titration; Squirrel monkeys (Craft, R.M. (234) 199)

**U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide)**
Morphine; $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

Pertussis toxin; Morphine; Substance P; Quinpirole; Carbachol (Bot, G. (231) 53)

Rimcazole; DuPont Merck S-7389-4; κ-Opioid agonists; σ Receptor antagonists; EEG power spectra (Young, G.A. (231) 473)

Tolerance; Abstinence; Dopamine $D_2$ receptors; 2-Bromo-α-ergocryptine; Behavioural activity (Veeranna, (235) 23)

Nor-binaltorphimine; Naloxone; Opioid withdrawal; Locomotor activity; (Guinea-pig) (Brent, P.J. (241) 149)

**Ucb L059**
Seizures; Epilepsy; Piracetam; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

**UH-232**
AJ 76; Dopamine receptors; Striatum; Acetylcholine release; Antipsychotics (Gifford, A.N. (237) 169)

**(S)-UH-301**
5-$HT_{1A}$ receptor agonists; 5-$HT_{1A}$ receptor antagonists; 8-OH-DPAT derivatives; LY-41; 5-HT motor syndrome (Yu, H. (231) 69)

**[$^3$H]UK 14,304 (bromoxidine)**
$\alpha_2$-Adrenoceptors; [$^3$H]Clonidine; [$^3$H]RX 821002 (2-methoxy idazoxan); Neostigmine; Physostigmine; Diisopropylfluorophosphate; Pilocarpine (Olmos, G. (236) 467)

$\alpha_2$-Adrenoceptors; Brain (rat); Vas deferens (rat); [$^3$H]RX 821002; Reserpine (Ugedo, L. (239) 149)

**Ultrasonic calls**
8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Long-term treatment; Neonatal; (Rat pup) (Johansson-Wallsten, C.E. (243) 149)

**Ultrasonic vocalization**
Vasopressin; Anxiety; Thermoregulation; Affiliation; Vasotocin (Winslow, J.T. (233) 101)

Development; Ontogeny; Distress vocalization; Tolerance; Withdrawal; Cocaine; Stimulants (Barr, G.A. (233) 143)

Anxiolytics; Dorsal raphe nucleus; Electrophysiology; Hippocampus; Ipsapirone; Microdialysis; Serotonergic neurotransmission; 5-$HT_{1A}$ receptors; (Rat) (Sommermeyer, H. (240) 29)

**Umbilical artery**
Dopamine $D_1$ receptors; Radioligand binding; Autoradiography; (Human) (Ferreira-de-Almeida, J.A. (234) 209)

**Uncoupling protein**
Metformin; Zucker rat; Genetic obesity; Brown adipose tissue; Thermogenesis (Rouru, J. (246) 67)

**Uptake$_2$ (central)**
Catechol O-methyltransferase (COMT) inhibition; Dopamine; Dopamine metabolism; Brain (Törnwall, M. (239) 39)

**Uptake inhibition**
p-Chloroamphetamine; p-Methylthioamphetamine; Drug discrimination; Superfusion; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Brain slices (Huang, X. (229) 31)

**Urethane anesthesia**
$\gamma_2$-MSH ($\gamma_2$-melanocyte-stimulating hormone); ACTH-(4–10); Melanotropins; Hemodynamics; Pentobarbital anesthesia; Excitability; (Conscious rat) (De Wildt, D.J. (233) 157)

**Urethra**
Ontogeny; $Ca^{2+}$ channel antagonists; Dihydropyridine; Bladder (Yoshida, M. (232) 159)

**Urethra (dog)**
Non-adrenergic, non-cholinergic (NANC) relaxation; Nitric oxide (NO) synthase inhibitor; VIP receptor antagonists (Hashimoto, S. (231) 209)

**Uric acid**
TEI-6720; Allopurinol; Xanthine oxidase/xanthine dehydrogenase; Hyperuricemia (Osada, Y. (241) 183)

**Uridine**
Thymidine; Leucine; DNA synthesis; RNA synthesis; Protein synthesis; Thymidine kinase activity (Garg, U.C. (237) 243)

**Urinary bladder**
Purine receptors; ATP; Nucleotides (Theobald, Jr., R.J. (229) 125)

**Urine**
Poststatin; Bradykinin; Degradation pathway; Kininase (Majima, M. (232) 181)

**Use dependence**
Lidocaine; Acidosis; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (230) 167)

Lidocaine; Acidosis; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (236) 497)

**Use-dependent blockade**
Bradycardiac agents; Sinus node inhibitors; Zatebradine; Pacemaker currents; Purkinje fibres; Iontophoresis; (Electrophysiology) (Van Bogaert, P.P. (229) 55)

**Uterine artery**
Steroids; Myometrium; Estrogen; Progesterone; Diethylstilbestrol (Kostrzewska, A. (233) 127)

**Uterine artery (human)**
CGRP (calcitonin gene-related peptide); $K^+$ channels; Pregnancy; Glybenclamide; Tetraethylammonium; Pinacidil (Nelson, S.H. (242) 255)

**Uterine artery (sheep)**
LSD (d-lysergic acid diethylamide); 5-HT receptors; Dissociation constant (Zhang, L. (230) 115)

**Uterus (pregnant)**
Forskolin action; Smooth muscle cells (myometrial); $K^+$ currents; cAMP; Tetraethylammonium (Inoue, Y. (240) 169)

**Uterus (rat)**
Bradykinin; Hoe 140; G-protein activation; Functional antagonism; (Binding sites) (Liebmann, C. (235) 183)

Big-endothelin-1; Endothelin-1; Endothelin-3; Endothelin $ET_A$ receptor; BQ-123; Phosphoramidon; Endothelin-converting enzyme (Rae, G.A. (240) 113)

**Vacuous chewing**
σ Receptor ligands; Dopamine; Microdialysis; DTG (1,3-di-o-tolylguanidine); (+)-Pentazocine (Patrick, S.L. (231) 243)

Dopamine $D_1$ receptor subtypes; Grooming (Downes, R.P. (234) 135)

**Vacuous chewing movement**
Dopamine $D_1$ receptors; NNC-756; Dopamine $D_1$ receptor antagonists; Dopamine $D_1$ receptor agonists; Oral movement (Glenthøj, B. (242) 283)

**Vagal nerve**
Indomethacin; Morphine; Naloxone; NANC (non-adrenergic, non-cholinergic); Small intestine (Gustafsson, B.I. (230) 1)

**Vagus**
Gastric cytoprotection; L-Arginine; L-NAME ($N^G$-nitro-L-arginine methyl ester); Nitric oxide (NO); RX 77368 (Király, Á. (240) 299)

Gastric acid secretion; Xanthine; TRH analog; 2-Deoxy-D-glucose; Gastric mucosal blood flow; Carbachol (Tanaka, T. (243) 221)

**Vagus nerve stimulation**
Plasma exudation; Cigarette smoke; $K^+$ channel opener; Glibenclamide (Lei, Y.-H. (239) 257)

**Valproate**
Electroshock (maximal); CGP 37849; CGP 39551; Seizures (Czechowska, G. (232) 59)

Ucb L059; Seizures; Epilepsy; Piracetam; Anticonvulsant drugs (Löscher, W. (232) 147)

Epilepsy; NMDA (N-methyl-D-aspartate); MK-801; Behaviour; CGP 37849 (Löscher, W. (234) 237)

Dexamphetamine-chlordiazepoxide mixture; GABA receptor antagonists; Hyperactivity (Cao, B.-J. (237) 177)

**Vascular 5-$HT_1$-like receptors**
5-HT (5-hydroxytryptamine, serotonin); 5-Carboxamidotryptamine; (Effect of pre-contraction) (Choppin, A. (231) 469)

**Vascular neuropeptide Y receptors**
Neuropeptide Y; Neuropeptide $Y_1$ receptors; Neuropeptide $Y_2$ receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

**Vascular permeability**
Asthma; Edema; Plasma exudation; Bradykinin; Airway obstruction; OKY-046; Indomethacin (Arakawa, H. (229) 131)

Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Nitric oxide (NO); L-NAME ($N^G$-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Airway obstruction; Asthma; Development; Maturation; Plasma exudation (Yokoyama, T. (236) 427)

Bradykinin; Histamine; Substance P; Cromakalim; Plasma exudation; Airways (Martin, C.A.E. (239) 119)

Diabetes mellitus; Substance P; Neurokinins; Nitric oxide (NO) (Mathison, R. (240) 163)

Angiotensin-converting enzyme inhibition; Albuminuria; Diabetes; (Rat) (Huijberts, M. (240) 207)

**Vascular (rat aorta)**
Endothelin-3; $ET_B$ receptors; Endothelium-dependent relaxation; $Ca^{2+}$ levels (cytosolic); (Relaxation) (Sudjarwo, S.A. (229) 137)

**Vascular reactivity**
Cloricromene; Endotoxin; Murine J774 macrophages; Nitric oxide synthase (Zingarelli, B. (243) 107)

Hyperlipidemia; Wistar-Kyoto rats (WKY); Endothelium-derived relaxing factor (EDRF); Spontaneously hypertensive rats (SHR); Aortic arch; Abdominal aorta (Yu, S.-M. (248) 289)

**Vas deferens**
Neuropeptide Y; Neuropeptide $Y_1$ receptors; Neuropeptide $Y_2$ receptors; Vascular neuropeptide Y receptors; Blood vessels (Grundemar, L. (232) 271)

Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

**Vas deferens (guinea pig)**
Nitropropane analog of baclofen; Baclofen; $GABA_B$ receptor agonists; Ileum (guinea-pig, isolated); Brain slices (rat) (Kerr, D.I.B. (236) 239)

**Vas deferens (mouse)**
$\sigma$ Receptor ligands; Neurogenic twitch contraction; Benzomorphan-type $\sigma$ receptor; ATP transmission; Brain (guinea-pig); SK&F 10,047 (N-allylnormetazocine); Rimcazole; Haloperidol (Matsuno, K. (231) 451)

**Vas deferens (rabbit)**
Muscarinic $M_1$ receptors; Muscarinic $M_1$ receptor agonists; Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

**Vas deferens (rat)**
$\alpha_2$-Adrenoceptors; Brain (rat); [$^3$H]UK 14304; [$^3$H]RX 821002; Reserpine (Ugedo, L. (239) 149)

**Vasoactive intestinal contractor**
Endothelin; Acetylcholine release; Ileum (guinea-pig) (Taniyama, K. (235) 149)

**Vasoactive peptides**
Pulmonary vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasodilation (Cheng, D.Y. (243) 79)

Hindquarters vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasodilation; Vasoconstriction (Santiago, J.A. (243) 291)

**Vasoconstriction**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Prostaglandins E; Temperature; Tachyphylaxis; (Release) (Rat) (Šmíd, M. (230) 69)

Bufodienolides; $Na^+$,$K^+$-ATPase inhibition (Bagrov, A.Y. (234) 165)

Hindquarters vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasodilation (Santiago, J.A. (243) 291)

**Vasoconstrictors**
Thaliporphine; $Ca^{2+}$ channel agonists; Thoracic aorta (rat) (Teng, C.-M. (233) 7)

**Vasocortin**
Dexamethasone; Endothelial cells; GM 7373 cell line; Dextran oedema; Histamine release (Iuvone, T. (243) 163)

**Vasodilatation**
Diabetes; Streptozotocin; Endothelium; Mesenteric artery (Furman, B.L. (232) 29)

Hoe 140; Bradykinin; Mesenteric vascular bed; (Cat) (Santiago, J.A. (236) 315)

Endotoxin; Nitric oxide (NO); Interleukin-1; Neutrophils; Glucocorticoids (Pons, F. (239) 23)

Adrenomedullin; cAMP; Blood pressure (rat) (Ishiyama, Y. (241) 271)

Aprikalim; Cheek pouch arterioles; Nitric oxide (NO); L-NMMA ($N^G$-monomethyl-L-arginine); (Hamster) (Mayhan, W.G. (242) 109)

Pulmonary vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasoactive peptides (Cheng, D.Y. (243) 79)

Hindquarters vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); VIP (vasoactive intestinal polypeptide); Vasoactive peptides; Vasoconstriction (Santiago, J.A. (243) 291)

**Vasodilating action**
MPC-1304; $Ca^{2+}$ channel antagonists; 1,4-Dihydropyridines (Miyoshi, K. (238) 139)

**Vasomotion**
L-NAME ($N^G$-nitro-L-arginine methyl ester); EDRF (endothelium-derived relaxing factor); Intravascular ultrasound (Schwarzacher, S. (229) 253)

**Vasopressin**
Tracheal epithelium; Thrombin; Endothelin; Substance P (Rennick, R.E. (230) 367)

Ultrasonic vocalization; Anxiety; Thermoregulation; Affiliation; Vasotocin (Winslow, J.T. (233) 101)

NPPB (5-nitro-2-(3-phenylpropylamino)-benzoic acid); Fluorescence microscopy (single cell); Phosphatidylinositol metabolism; $Ca^{2+}$-activated chloride conductance; Smooth muscle (Pon, D.J. (245) 119)

Endothelin; Inositol phosphates; Papillary tubules (Woodcock, E.A. (247) 93)

**Vasopressin analogues**
Factor VIII; Antidiuretic activity; Monkey (Vilhardt, H. (232) 223)

**Vasopressor**
$N^G$-Nitro-L-arginine; Ethanol; Angiotensin II; Noradrenaline; Bradycardia; Baroreflex (Wang, Y.-X. (233) 275)

**Vasorelaxation**
Ethanol; Acetylcholine; Endothelium; Aorta; (Rat) (Hatake, K. (238) 441)

$Ca^{2+}$ channels; Portal hypertension; Portal vein; Mesenteric artery; (Rat) (Suga, T. (242) 129)

FK409; cGMP; Soluble guanylate cyclase; Cyclic guanosine monophosphate phosphodiesterase (Isono, T. (246) 205)

**Vasotocin**
Vasopressin; Ultrasonic vocalization; Anxiety; Thermoregulation; Affiliation (Winslow, J.T. (233) 101)

**V79 Chinese hamster cells**
Cytochrome P450 1A1 (human); Cytochrome P450 1A1 recombinant expression vector; Polycyclic aromatic hydrocarbons; Benzo[a]pyrene (Schmalix, W.A. (248) 251)

**Vecuronium**
Hepatocytes; Nicotinic receptors; $Ca^{2+}$-activated $K^+$ channels; Dequalinium; Apamin (Castle, N.A. (236) 201)

**Vein**
Endothelin; Cholinergic innervation; Atropine; Neostigmine; Embryology (Hayakawa, A. (239) 219)

**Venous stasis**
Aspirin; Fibrinolytic activity (Iacoviello, L. (229) 39)

**Ventilatory response**
Breathing; $CO_2$; Chemoreflex (central); Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

**Ventral hippocampus**
[$^3$H]Spiperone; Dopamine $D_2$ receptors; Affinity state; Dorsal hippocampus; Striatum; $Mg^{2+}$; GTP; Iron-chelator (Bruinink, A. (245) 157)

**Ventral medullary surface**
Dihydropyridines; $Ca^{2+}$ channels; $Ca^{2+}$ channel activators; Respiration; Opioids (endogenous) (Ruiz, F. (240) 155)

**Ventral tegmental area**
Cholecystokinin; Dopamine; Neurotensin; Reward (Rompré, P.-P. (232) 299)

Benzamides (substituted); Substantia nigra pars compacta; (Repeated treatment) (Skarsfeldt, T. (240) 269)

Microdialysis; Dopamine; Opioid; $\mu$-Opioid receptors; GABA ($\gamma$-aminobutyric acid); Nucleus accumbens (Devine, D.P. (243) 55)

**Ventricle**
Atrium; Contractile force; Heart; 5-HT (5-hydroxytryptamine, serotonin); (Human) (Schoemaker, R.G. (230) 103)

**Ventricular arrhythmia**
Gallopamil; (Triggered activity); (Plasma concentration) (Matsuzaki, T. (231) 363)

**Ventricular cells (single)**
Decavanadate; $K^+$ channels (ATP-sensitive); Patch clamp (Nakashima, H. (233) 219)

**Ventricular fibrillation**
$Ca^{2+}$ channel antagonists; Myocardial ischemia; Myocardial infarction; Cardiac arrhythmias (Billman, G.E. (229) 179)

$K^+$ channels; Antiarrhythmic drugs; Cardiac ischaemia (Gwilt, M. (236) 107)

**Ventricular myocytes (human)**
Trolox conjugates; Oxyradicals (Zielenski, J. (248) 313)

**Verapamil**
Aortic myocytes; Taenia coli myocytes (Fan, S.-f. (229) 259)

$Ca^{2+}$ channels; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

ANP (atrial natriuretic peptide); $Ca^{2+}$ entry blockers; Felodipine; Nifedipine; Diuretic effects (Shamiss, A. (233) 113)

$Ca^{2+}$ channel blockers; Cytosolic $Ca^{2+}$ levels; Felodipine; Nifedipine; Smooth muscle; Aorta (rat); (Relaxation) (Hagiwara, S. (234) 1)

$Ca^{2+}$ channel antagonists; Carbachol; Histamine; GS 283; Trachealis (Chang, K.C. (236) 51)

Pancreatic vessels; Insulin secretion; $\alpha$-Adrenoceptor antagonists; Pancreas (isolated); cAMP analogues; (Rat) (Skoglund, G. (236) 69)

d-Amphetamine; Reinforcement; Place preference conditioning; $Ca^{2+}$ channel inhibitors (Pucilowski, O. (240) 89)

$\alpha_1$-Adrenoceptors (cardiac); Inositol 1,4,5-trisphosphate (cardiac); Protein kinase C (cardiac); Diabetic cardiomyopathy; (Rat) (Tanaka, Y. (244) 105)

Gadolinium; Neomycin; Nimodipine; Voltage-sensitive $Ca^{2+}$ channels; Brain synaptosomes (Canzoniero, L.M.T. (245) 97)

**Veratridine**
Taurine release; Posterior hypothalamus; Blood pressure; Tetrodotoxin; Push-pull cannula (Singewald, N. (240) 21)

**Veratrine**
OPC-8212; Action potential duration; Cardiac ventricular myocytes; $K^+$ currents; Secondary inward current (Lathrop, D.A. (240) 127)

**Videomicroscopy (guinea pig)**
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens (Eltze, M. (238) 343)

**Vinblastine**
Colchicine; Blood $Ca^{2+}$; Bone cells; Microtubules (Ohya, K. (248) 111)

**Vincristine**
Cellular pharmacokinetics; Multidrug resistance (Domènech, C. (248) 49)

**γ-Vinyl GABA**
GABA release; Microdialysis (Jolkkonen, J. (229) 269)

**VIP-(22–28)**
VIP (vasoactive intestinal polypeptide); Pentylenetetrazole; Seizures; Brain (rat) (Romualdi, P. (229) 149)

**VIP antiserum**
Colon; Gastrointestinal motility; Pain; Stomach; VIP (vasoactive intestinal polypeptide) (Bojö, L. (236) 443)

**VIP receptor antagonists**
Urethra (dog); Non-adrenergic, non-cholinergic (NANC) relaxation; Nitric oxide (NO) synthase inhibitor (Hashimoto, S. (231) 209)

**VIP (vasoactive intestinal polypeptide)**
VIP-(22–28); Pentylenetetrazole; Seizures; Brain (rat) (Romualdi, P. (229) 149)

Nitric oxide (NO); Cholinergic neurotransmission; Inhibitory non-adrenergic non-cholinergic (i-NANC); Electrical field stimulation (Belvisi, M.G. (231) 97)

Colon; Gastrointestinal motility; Pain; Stomach; VIP antiserum (Bojö, L. (236) 443)

$Cl^-$ secretion; Colitis; cAMP; Inflammatory bowel disease; Prostaglandin (Goldhill, J. (238) 387)

Pulmonary vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); Vasoactive peptides; Vasodilation (Cheng, D.Y. (243) 79)

Hindquarters vascular bed; PACAP-38 (pituitary adenylate cyclase activating polypeptide 38); PACAP-27 (pituitary adenylate cyclase activating polypeptide 27); Vasoactive peptides; Vasodilation; Vasoconstriction (Santiago, J.A. (243) 291)

**Virus infection**
AIDS; Cytokine; T lymphocytes; Mucosa (Bourinbaiar, A.S. (230) 15)

**Visual cortex (human)**
Benzodiazepine receptors; Autoradiography; CL218872 (March, D. (236) 333)

**Vitamin $B_{12}$**
Cerebral cortex; Glutamate; Nitric oxide (NO); NMDA (N-methyl-D-aspartate); Methylcobalamin (Akaike, A. (241) 1)

**Vitamin $B_6$ deficiency**
Hypertension; 5-$HT_{1A}$ receptors; (Rat) (Lal, K.J. (234) 183)

**Vitamin D receptors**
1$\alpha$,25-Dihydroxyvitamin $D_3$ analogues; Thromboxane synthesis; HL-60 cells (human) (Honda, A. (229) 217)

**VLDL (very low-density lipoprotein)**
EPA-E (ethyl all-cis-5,8,11,14,17-icosapentaenoate); (Rat) (Mizuguchi, K. (235) 221)

**Voltage clamp**
Achatin-I; D-Amino acid residue; Molluscan peptide; 5-HT (5-hydroxytryptamine, serotonin); Modulatory effects; Neurons; (Snail) (Jun Liu, G. (231) 259)

Sabeluzole; NMDA receptors; Glutamate; Cerebellum; Granule cells (Van der Valk, J.B.F. (232) 131)

Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; $Ca^{2+}$ channel blocking agents; $Na^+$ channel blocking agents; Nerve cell cultures (Netzer, R. (238) 209)

Achatin-I; D-Amino acid residue; Oxytocin, APGW-amide (Ala-Pro-Gly-Trp-$NH_2$), FMRFamide (Phe-Met-Arg-Phe-$NH_2$); [$Ser^2$]MIP (Gly-Ser-Pro-Met-Phe-Val-$NH_2$); Modulatory effects; Neurons; (Snail) (Liu, G.J. (240) 139)

Sympathetic ganglion; $Ca^{2+}$ channels; Nitric oxide (NO); Norepinephrine; Patch-clamp (Chen, C. (243) 83)

Hypertension; $Ca^{2+}$ currents (heart); Phosphodiesterase inhibitors (Scamps, F. (244) 119)

**Voltage clamp (whole cell)**
Taurine; $Ca^{2+}$ channels (L-type); $Ca^{2+}$ channels (T-type); Cardiac myocytes; Heart cells (embryonic chick); Electrophysiology (Satoh, H. (231) 443)

**Voltage dependence**
Flunarizine; $Ca^{2+}$ channel antagonists; Adrenal medulla; Catecholamine secretion (De la Fuente, M.-T. (229) 189)

**Voltage-dependent $Ca^{2+}$ channels**
Transmembrane $Ca^{2+}$ influx; Arterial myogenic tone; $Ca^{2+}$-activated $K^+$ channels; Spontaneously hypertensive rats (SHR); (Early hypertensive stages) (Asano, M. (247) 295)

**Voltage-operated channel**
$Ca^{2+}$ channel antagonist; Smooth muscle; Heart; SR 33805 (Chatelain, P. (246) 181)

**Voltage-operated $Ca^{2+}$ channels**
NMDA receptors; Glutamate release; $^{45}Ca^{2+}$ uptake; $K^+$ depolarization; Cerebellar granule cells (Didier, M. (244) 57)

**Voltage-sensitive $Ca^{2+}$ channels**
Gadolinium; Neomycin; Nimodipine; Verapamil; Brain synaptosomes (Canzoniero, L.M.T. (245) 97)

**Volume expansion**
Candoxatrilat; Neutral endopeptidase inhibition; ANF (atrial natriuretic factor); cGMP (Scott, J.M. (242) 91)

**Vomiting**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; Reserpine; 6-Hydroxydopamine (6-OHDA); Area postrema (Hikasa, Y. (229) 241)

**Water consumption**
Histamine $H_3$ receptors; (R)-$\alpha$-Methylhistamine; Thioperamide; (Rat) (Clapham, J. (232) 99)

**Water maze task**
TRH (thyrotropin-releasing hormone); Sustained release formulation; Scopolamine; AF64A (ethylcholine aziridinium ion); Passive avoidance task (Miyamoto, M. (238) 181)

**WAY 100,135**
$5\text{-HT}_{1A}$ receptors; $5\text{-HT}_{1A}$ receptor antagonists (Fletcher, A. (237) 283)

$5\text{-HT}_{1A}$ receptor antagonists; Microdialysis; Hippocampal 5-HT (5-hydroxytryptamine, serotonin) release (Routledge, C. (239) 195)

Dorsal raphe nucleus; (−)-Tertatolol; Flat-body posture; Corticosterone (Lejeune, F. (240) 307)

**WEB 2086**
Complement; Zymosan; PAF (platelet-activating factor, PAF-acether); SM-12502; Plasma leakage (Damas, J. (231) 231)

**WEB 2170**
PAF receptor antagonists; Anaphylactic shock (Amorim, C.Z. (235) 17)

**Whole-cell clamping**
Myocytes (rat ventricular); Caffeine; Depolarization-activated, $Ca^{2+}$-independent outward currents (Sanchez-Chapula, J. (229) 163)

**Whole-cell voltage clamp**
Cyclopiazonic acid; Ryanodine; Smooth muscle; $Ca^{2+}$ channels; $Ca^{2+}$ stores (Gagov, H.S. (243) 19)

$5\text{-HT}_3$ receptor; 5-HT (5-hydroxytryptamine, serotonin); Tetraethylammonium; N1E-115 neuroblastoma; Ion channel; Desensitization (Kooyman, A.R. (246) 247)

**Wistar-Kyoto rat (WKY)**
Hyperlipidemia; Vascular reactivity; Endothelium-derived relaxing factor (EDRF); Spontaneously hypertensive rats (SHR); Aortic arch; Abdominal aorta (Yu, S.-M. (248) 289)

**Wistar rat**
Heart failure (high-output); Laser-Doppler flowmetry; Neurohumoral factors; Renal blood flow; Thermodilution (Oka, T. (234) 55)

**Withdrawal**
Development; Ontogeny; Distress vocalization; Ultrasonic vocalization; Tolerance; Cocaine; Stimulants (Barr, G.A. (233) 143)

In situ hybridisation; Cholecystokinin (CCK); Diazepam; Tolerance; mRNA (Rattray, M. (245) 193)

**Working memory**
Hippocampus; $5\text{-HT}_{1A}$ receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Reference memory; (Microinjection) (Ohno, M. (234) 29)

DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Scopolamine; Acetylcholine; Reference memory (Ohno, M. (238) 117)

**WY-50,295 tromethamine**
5-Lipoxygenase inhibitors; Leukotriene biosynthesis inhibitors; Anti-allergic activity (Grimes, D. (236) 217)

**Xamoterol**
$\beta$-Adrenoceptors; Adenylate cyclase; Desensitisation; Atenolol (Arnold, I.R. (245) 285)

**Xanthine**
Gastric acid secretion; TRH analog; 2-Deoxy-D-glucose; Vagus; Gastric mucosal blood flow; Carbachol (Tanaka, T. (243) 221)

**Xanthine oxidase/xanthine dehydrogenase**
TEI-6720; Allopurinol; Uric acid; Hyperuricemia (Osada, Y. (241) 183)

**Xanthurenic acid (urinary excretion)**
Noncholinergic actions; Organophosphorous insecticides; Methylcarbamate insecticides; Kynurenine formamidase inhibition; Plasma L-kynurenine; (Structural requirements) (Pewnim, T. (248) 237)

**Xenopsin**
Neurotensin; Self-stimulation; Prefrontal cortex (Ferrer, J.M.R. (231) 39)

***Xenopus laevis* oocyte**
Local anesthetics; Bupivacaine; $K^+$ channel; Glibenclamide; Calmodulin (Yoneda, I. (247) 267)

***Xenopus* oocyte expression**
Angiotensin receptor; cDNA sequence; Aorta (porcine); COS cell expression (Itazaki, K. (245) 147)

***Xenopus* oocyte expression system**
$5\text{-HT}_3$ receptor; Cloned $5\text{-HT}_3$ receptor subunit; N1E-115 neuroblastoma cell (Hope, A.G. (245) 187)

***Xenopus* oocytes (rat brain mRNA-injected)**
Excitatory amino acid receptors; Riluzole; Kainate; NMDA (N-methyl-D-aspartate) (Debono, M.-W. (235) 283)

***Xenopus* oocytes (rat cortex mRNA-injected)**
Hippocampal slices; Glutamate receptors; GABA receptor; ATP-sensitive potassium channel activators; [$^3$H]AMPA (*R,S*)-α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) binding; [$^3$H]Kainate binding (Randle, J.C.R. (247) 257)

**Yawning**
Dopamine receptors; Locomotor activity; Turning behaviour; Blood pressure; Pressor response; Body temperature; Spontaneously hypertensive rats (SHR) (Van den Buuse, M. (243) 169)

5-HT (5-hydroxytryptamine, serotonin); Male sexual behavior; Penile erection; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); m-CPP; (Primates); (Rhesus monkey) (Pomerantz, S.M. (243) 227)

**YM-060**
Emesis; 5-HT$_3$ receptor; Cisplatin; m-Chlorophenylbiguanide (Kamato, T. (238) 369)

**[$^3$H]YM-09151-2**
Dopamine D$_2$ receptors; Antipsychotics; Neuroleptics; Dopamine D$_2$ receptor binding; Biphasic displacement (Assié, M.-B. (237) 183)

**Yohimbine**
Feeding; Obese mice; Norepinephrine; Clonidine; $\alpha_2$-Adrenoceptors (Currie, P.J. (232) 227)

**YT-146 (2-(1-octynyl)-adenosine)**
Adenosine; Glibenclamide-sensitive K$^+$ channels; Levcromakalim; G-protein (pertussis toxin-sensitive) (Furukawa, S. (236) 255)

**[$^3$H]Zacopride**
5-HT$_3$ receptors; [$^3$H]Granisetron; [$^{14}$C]Guanidinium; Ileum; Bezold-Jarisch reflex; Turning behaviour; Cortical firing rate; (Ex vivo binding) (Bachy, A. (237) 299)

**[$^3$H](*R*)-Zacopride**
High-affinity 'R' sites; 5-HT$_3$ receptors; (*S*)-[$^3$H]Zacopride; Brain (rat and human); Periphery (rat) (Kidd, E.J. (247) 45)

**[$^3$H](S)-Zacopride**
5-HT$_3$ receptor agonists; [$^3$H]meta-Chlorophenylbiguanide; Brain (rat) (Steward, L.J. (243) 13)

High-affinity 'R' sites; 5-HT$_3$ receptors; (*R*)-[$^3$H]Zacopride; Brain (rat and human); Periphery (rat) (Kidd, E.J. (247) 45)

**Zaprinast**
Nitrate vasodilators; Phosphodiesterase inhibitors; N$^\omega$-Nitro-L-arginine; L-Arginine; Acetylcholine; Bradykinin; Blood pressure (De Garavilla, L. (234) 77)

Nitroglycerin tolerance; cGMP-phosphodiesterase inhibitor; cGMP (intracellular); (Reversal of tolerance) (Pagani, E.D. (243) 141)

**Zatebradine**
Bradycardiac agents; Sinus node inhibitors; Pacemaker currents; Purkinje fibres; Iontophoresis; Use-dependent blockade; (Electrophysiology) (Van Bogaert, P.P. (229) 55)

**ZG-63**
GABA$_A$ receptor; GABA (γ-aminobutyric acid); Diazepam-insensitive benzodiazepine receptor (Wong, G. (247) 57)

**Zolpidem**
GABA$_A$ receptors; ω modulatory site; [$^3$H]Flumazenil; Alpidem (Faure-Halley, C. (246) 283)

**[$^3$H]Zolpidem binding**
GABA$_A$ receptor complex (Type I and Type II benzodiazepine binding sites); [$^3$H]Flunitrazepam binding; γ-Aminobutyric acid; Aging; Cortex (Ruano, D. (246) 81)

**Zucker rat**
Nitric oxide (NO); Brain; Food intake (Squadrito, F. (230) 125)

Imidazoline I$_2$ binding sites; $\alpha_2$-Adrenoceptors; Brain; [$^3$H]Idazoxan; [$^3$H]Clonidine; [$^3$H]RX821002; Mazindol (Miralles, A. (243) 305)

Metformin; Genetic obesity; Brown adipose tissue; Thermogenesis; Uncoupling protein (Rouru, J. (246) 67)

**Zymosan**
Complement; PAF (platelet-activating factor, PAF-acether); WEB 2086; SM-12502; Plasma leakage (Damas, J. (231) 231)

Phospholipase A$_2$; Pleurisy; Carrageenan; Inflammation; Thromboxane B$_2$ (Tesson, F. (248) 27)

# Interested in Associative Learning?

**OPAL** is the answer! **O**pen **P**rograms for **A**ssociative **L**earning is an interactive system using computer technology and hypermedia principles to present a revolutionary approach to learning and teaching. **OPAL** modules provide the tools for intuitive and associative learning.

## NOW AVAILABLE: OPAL Module 2 **Calcium as a Messenger**

By **M.R. Celio**, *Department of Histology, University of Fribourg, Fribourg, Switzerland*

**Calcium as a Messenger** covers many topics including the following: 1. Calcium ions as messengers. 2. Mechanisms involved in the action of $Ca^{2+}$ as a messenger in an idealized cell. 3. How voltage-dependent $Ca^{2+}$ channels function. 4. Voltage-dependent $Ca^{2+}$ channel antagonists. 5. Calcium ionophores. 6. Calcium binding proteins have pockets with high affinity for $Ca^{2+}$. 7. Differences in the distribution of two calcium binding proteins in the cerebellum. 8. Calcium binding proteins translate the $Ca^{2+}$ information in a meaningful message to the cell. 9. The smooth endoplasmic reticulum of certain cells stores $C^{2+}$. 10. The calciosomes are intracellular membrane bound $Ca^{2+}$ storage vesicles. 11. Phospholipase C and inositol-tri-phosphate (IP3) pathway. 12. Role of calcium ions in neurotransmitters secretion. 13. Calcium-dependent ion channels. …and there's more!

**Teacher Version, MS-Windows:**
Price: Dfl 600.00 / US $ 342.75
ISBN 0-444-81728-X

**Student Version, MS-Windows:**
Price: Dfl. 120.00 / US $ 68.50
ISBN 0-444-81729-8

**Teacher Version, Macintosh**
Price: Dfl. 600.00 / US $ 342.75
ISBN 0-444-81730-1

**Student Version, Macintosh:**
Price: Dfl. 120.00 / US $ 68.50
ISBN 0-444-81731-X

Please note that Macintosh versions will not be available until Summer 1994.

**Options:** • Intermodular Links • Interactive Animations • Sensitive Zones and Words • Navigation Tools.

Seeing is believing....so ask for your own preview disk with more details on a range of electronic products. (Specify MAC or MS-Windows.)

For more information on availability and price, please contact:

**ELSEVIER SCIENCE B.V.**
P.O. Box 1527,
1000 BM Amsterdam,
The Netherlands
Fax: (31) 20-5803342
e-mail: j.hobbelink@elsevier.nl

In the USA and Canada:
**ELSEVIER SCIENCE Inc.**
P.O. Box 945,
Madison Square Station,
New York
NY 10160-0757, USA
Fax: (212) 633-3990

**Recommended equipment:**

**IBM compatible version:**
IBM 386 compatible computer, 2 Mb of free RAM, VGA screen, Microsoft Windows 3.00, 2 Mb of free space on the hard disk for each module. 3.5" disk HD. (Other formats available on request).

**Macintosh version:**
Mac SE/ 30 minimum, 2 Mb of RAM, 3 Mb of free space on the hard disk for each module.




93/BOV/143

# Methods in Behavioral Pharmacology

edited by **F. van Haaren**

Techniques in the Behavioral and Neural Sciences Volume 10

**Methods in Behavioral Pharmacology** is unique in offering a complete description and critical evaluation of most, if not all, methods available to study the effects of drugs on behavior. It stands apart in that it is not limited to the analysis of a particular class of pharmacological agents in a limited number of paradigms. **Methods in Behavioral Pharmacology** covers all paradigms without reference to specific pharmacological compounds.

The book provides a comprehensive overview of the methodology used to study the behavioral effects of legal and illegal drugs. It also provides an in-depth presentation of dependent variables, their quantification and a critical evaluation of their advantages and disadvantages. An excellent work, contributed to by well-known experts in the different fields of behavioral pharmacology.

**Contents:** *Only chapter headings are given in this listing - a full list of contents is available from the Publisher on request.*

Preface. List of Contributors. Chapter 1. The use of animal models in behavioral pharmacology (M.A. Ellenberger). 2. Psychotropic screening procedures (R.D. Porsolt, R.A. McArthur, A. Lenègre). 3. Classical conditioning (C.W. Schindler). 4. Schedule-controlled behavior: positive reinforcement (F. van Haaren). 5. Schedule-controlled behavior: negative reinforcement (S.I. Dworkin, R.C. Pitts, M. Galizio). 6. Drugs and stimulus control: generalization, discrimination and threshold procedures (M.J. Picker, S. Stevens Negus). 7. Complex and delayed discriminations: automated repeated measures techniques (M.J. Pontecorvo, D.B. Clissold). 8. Mazes: their use in delayed conditional discriminations and place discriminations (D.S. Olton, A.J. Markowska). 9. Drug discrimination (I.P. Stolerman). 10. State-dependent learning (A. Poling, J. Cross). 11. Drug self-administration (R.A. Meisch, G.A. Lemaire). 12. Schedule-induced drug self-administration (J.L. Falk). 13. Behavioral factors in drug tolerance (M.N. Branch). 14. Pavlovian drug conditioning (C.L. Cunningham). 15. Electrical brain stimulation reward: a model of drug reward and euphoria (M.J. Lewis). 16. Animal models of stress in pharmacology (W.P. Paré, G.B. Glavin). 17. Conflict behaviors as animal models for the study of anxiety (R.L. Commissaris). 18. Methods in the human behavioral pharmacology of drug abuse (S.T. Higgins, W.K. Bickel. J.R. Hughes). 19. Locomotor activity and exploration (A.E. Kelley). 20. Stereotyped behavior (B.A. Ellenbroek, A.R. Cools). 21. Methods in behavioral pharmacology: measurement of aggression (E.D. Kemble, D.C. Blanchard, R.J. Blanchard). 22. The behavioral pharmacology of ingestive behavior (N.E. Rowland). 23. The behavioral pharmacology of sleep (G. van Luijtelaar, A. Coenen). 24. Reproductive behavior in behavioral pharmacology (K. Larsson, S. Ahlenius). 25. Experimental design and data analysis in behavioral pharmacology (J. Krauth). Subject index.

1993 672 pages
Hardbound
Price: US $ 282.75 / Dfl. 495.00
ISBN 0-444-81444-2
Paperback
Price: US $ 108.50 / Dfl. 190.00
ISBN 0-444-81445-0

*Obtainable from your bookseller or:*

*in the U.S.A. and Canada:*
P.O. Box 945
Madison Square Station,
New York, NY 10160-0757
Tel: (212) 633-3650
Fax: (212) 633-3880.

rest of the world:
P.O. Box 211
1000 AE Amsterdam
The Netherlands.
Fax: +31 (20) 5803-705

*The Dutch Guilder price is definitive. The US $ price is subject to exchange rate fluctuations. Orders from individuals must be accompanied by a remittance. Customers in the European Community should add the Value Added Tax applicable in their country.*

ELSEVIER
SCIENCE PUBLISHERS

93/BO/112

# EUROPEAN JOURNAL OF PHARMACOLOGY

EJP Molecular Pharmacology Section, Volumes 244–247, and EJP Environmental Toxicology and Pharmacology Section, Volume 248, incorporated

*Cited in: Biological Abstracts – Chemical Abstracts – Current Contents/Life Sciences – Excerpta Medica (EMBASE) – Index Medicus – Pascal M – Reference Update – Unlisted Drugs – Current Awareness in Biological Sciences (CABS)*


CONTENTS


Master author index to volumes 229–248 ..... 1

Master key word index to volumes 229–248 ..... 53

0014-2999(1993)229/248*;1-1